The	O
frameshift	O
takes	O
place	O
at	O
the	O
slippery	O
sequence	O
with	O
the	O
two	O
ribosome	B-COMP
-	O
bound	O
tRNAs	O
slipping	O
back	O
simultaneously	O
by	O
one	O
nucleotide	O
from	O
the	O
zero	O
phase	O
(	O
U	O
UUA	O
AAC	O
)	O
to	O
the	O
-	O
1	O
phase	O
(	O
UUU	O
AAA	O
).	O

Over	O
ten	O
cell	B-COMP
passages	O
,	O
however	O
,	O
we	O
found	O
no	O
significant	O
difference	O
in	O
frameshift	O
efficiency	O
between	O
the	O
cell	B-COMP
types	O
,	O
arguing	O
against	O
a	O
role	O
for	O
Q	O
in	O
frameshifting	O
.	O

TITLE	O
:	O
Retargeting	O
of	O
coronavirus	O
by	O
substitution	O
of	O
the	O
spike	O
glycoprotein	O
ectodomain	O
:	O
crossing	O
the	O
host	B-COMP
cell	I-COMP
species	O
barrier	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
C57BL	O
/	O
6	O
mice	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
results	O
in	O
a	O
demyelinating	O
encephalomyelitis	O
characterized	O
by	O
mononuclear	O
cell	B-COMP
infiltration	O
and	O
white	O
matter	O
destruction	O
similar	O
to	O
the	O
pathology	O
of	O
the	O
human	O
demyelinating	O
disease	O
multiple	O
sclerosis	O
.	O

Here	O
we	O
demonstrate	O
that	O
incorporation	O
is	O
mediated	O
by	O
the	O
short	O
carboxy	O
-	O
terminal	O
segment	O
comprising	O
the	O
transmembrane	B-COMP
and	O
endodomain	O
.	O

Both	O
chimeric	O
S	O
proteins	O
appeared	O
to	O
cause	O
cell	B-COMP
fusion	O
when	O
expressed	O
individually	O
,	O
suggesting	O
that	O
they	O
were	O
biologically	O
fully	O
active	O
.	O

This	O
was	O
indeed	O
confirmed	O
by	O
incorporating	O
one	O
of	O
the	O
proteins	O
into	O
virions	B-COMP
which	O
thereby	O
acquired	O
a	O
new	O
host	B-COMP
cell	I-COMP
tropism	O
,	O
as	O
will	O
be	O
reported	O
elsewhere	O
.	O

In	O
four	O
of	O
the	O
HAD	O
mutants	O
a	O
nearby	O
antigenic	O
site	O
is	O
affected	O
in	O
addition	O
to	O
the	O
sialic	O
acid	O
binding	O
site	O
,	O
as	O
indicated	O
by	O
reactivity	O
with	O
monoclonal	O
antibodies	B-COMP
.	O

We	O
believe	O
that	O
the	O
efficacy	O
and	O
safety	O
of	O
chelation	O
therapy	O
in	O
severe	O
acute	O
iron	O
poisoning	O
may	O
be	O
improved	O
by	O
targeting	O
the	O
initial	O
high	O
levels	O
of	O
readily	O
chelatable	O
serum	B-COMP
iron	O
with	O
adequate	O
doses	O
of	O
desferrioxamine	O
without	O
prolonging	O
its	O
use	O
unnecessarily	O
.	O

Furthermore	O
,	O
MAb	O
showing	O
strong	O
neutralizing	O
activity	O
in	O
Felis	O
catus	O
whole	O
fetus	O
(	O
fcwf	O
-	O
4	O
)	O
cells	B-COMP
and	O
Crandell	O
feline	O
kidney	O
(	O
CrFK	O
)	O
cells	B-COMP
shows	O
strong	O
enhancing	O
activity	O
in	O
feline	O
macrophages	O
,	O
indicating	O
that	O
the	O
neutralizing	O
epitope	O
and	O
the	O
enhancing	O
epitope	O
are	O
closely	O
related	O
.	O

These	O
findings	O
indicated	O
that	O
the	O
FIPV	O
replication	O
mechanism	O
differs	O
between	O
feline	O
macrophages	O
and	O
CrFK	O
/	O
fcwf	O
-	O
4	O
cells	B-COMP
and	O
that	O
a	O
neutralizing	O
epitope	O
that	O
can	O
prevent	O
FIPV	O
infection	O
of	O
feline	O
macrophages	O
after	O
viral	O
absorption	O
is	O
present	O
on	O
M	O
protein	O
.	O

Accordingly	O
,	O
this	O
domain	O
of	O
the	O
protein	O
could	O
not	O
be	O
detected	O
on	O
the	O
outside	O
of	O
virions	B-COMP
but	O
appeared	O
to	O
be	O
inside	O
,	O
where	O
it	O
was	O
protected	O
from	O
proteolytic	O
degradation	O
.	O

The	O
results	O
lead	O
to	O
a	O
topological	O
model	O
in	O
which	O
the	O
polypeptide	O
is	O
buried	O
within	O
the	O
membrane	B-COMP
,	O
spanning	O
the	O
lipid	O
bilayer	O
once	O
,	O
possibly	O
twice	O
,	O
and	O
exposing	O
only	O
its	O
carboxy	O
-	O
terminal	O
domain	O
.	O

Second	O
,	O
to	O
determine	O
whether	O
the	O
volumes	O
of	O
blood	O
and	O
crystalloid	B-COMP
solutions	O
administered	O
in	O
the	O
early	O
posttrauma	O
period	O
are	O
independent	O
risk	O
factors	O
for	O
acute	O
lung	O
injury	O
in	O
severely	O
traumatized	O
patients	O
.	O

The	O
effect	O
of	O
cocaine	O
on	O
IFN	O
production	O
was	O
found	O
to	O
be	O
primarily	O
at	O
the	O
transcript	O
level	O
in	O
both	O
Mphi	O
and	O
L929	O
cells	B-COMP
.	O

Seven	O
of	O
the	O
MAbs	O
were	O
shown	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
Western	O
blot	O
assay	O
to	O
be	O
reactive	O
with	O
the	O
BRV	O
outer	B-COMP
capsid	I-COMP
protein	O
,	O
VP7	O
,	O
which	O
has	O
a	O
molecular	O
mass	O
of	O
37	O
.	O
5	O
kDa	O
.	O

Monospecific	O
antibodies	B-COMP
directed	O
against	O
the	O
four	O
distinct	O
domains	O
detected	O
proteins	O
of	O
10	O
,	O
12	O
,	O
and	O
15	O
kDa	O
(	O
p1a	O
-	O
10	O
,	O
p1a	O
-	O
12	O
,	O
and	O
p1a	O
-	O
15	O
)	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
DBT	O
cells	B-COMP
,	O
in	O
addition	O
to	O
a	O
previously	O
identified	O
22	O
-	O
kDa	O
protein	O
(	O
p1a	O
-	O
22	O
).	O

Blood	O
samples	O
were	O
taken	O
on	O
Days	O
0	O
,	O
1	O
,	O
3	O
,	O
7	O
,	O
and	O
10	O
for	O
red	O
blood	O
cell	B-COMP
(	O
RBC	O
),	O
white	O
blood	O
cell	B-COMP
(	O
WBC	O
),	O
and	O
platelet	O
counts	O
,	O
pH	O
,	O
PO	O
(	O
2	O
),	O
PCO	O
(	O
2	O
),	O
carbon	O
dioxide	O
content	O
(	O
HCO	O
(	O
3	O
)(-))	O
measurements	O
,	O
and	O
renal	O
and	O
liver	O
tests	O
.	O

Adoptive	O
transfer	O
of	O
immune	O
T	O
cells	B-COMP
to	O
chicks	O
prior	O
to	O
infection	O
demonstrated	O
that	O
IBV	O
primed	O
CD8	O
(+),	O
alphabeta	O
T	O
lymphocytes	O
could	O
protect	O
chicks	O
from	O
acute	O
infection	O
.	O

CTL	O
determinants	O
in	O
the	O
viral	B-COMP
particle	I-COMP
can	O
be	O
mapped	O
to	O
the	O
spike	O
and	O
nucleocapsid	B-COMP
proteins	O
but	O
not	O
to	O
the	O
membrane	B-COMP
protein	O
.	O

Viral	O
antigen	O
was	O
detected	O
in	O
the	O
cytoplasm	B-COMP
of	O
tracheal	O
epithelium	O
from	O
1	O
to	O
7	O
days	O
post	O
-	O
inoculation	O
(	O
d	O
.	O
p	O
.	O
i	O
.)	O
with	O
a	O
peak	O
on	O
3	O
d	O
.	O
p	O
.	O
i	O
.	O

Deletion	O
analysis	O
failed	O
to	O
identify	O
a	O
postulated	O
internal	O
ribosomal	B-COMP
entry	O
structure	O
(	O
IRES	O
)	O
within	O
ORF	O
3a	O
.	O

Bovine	O
IgA	O
and	O
IgM	O
antibodies	B-COMP
in	O
milk	O
and	O
serum	B-COMP
showed	O
high	O
stability	O
towards	O
freezing	O
and	O
thawing	O
and	O
storage	O
at	O
room	O
temperature	O
.	O

The	O
antibody	B-COMP
responses	O
to	O
BCV	O
were	O
followed	O
in	O
milk	O
and	O
serum	B-COMP
from	O
six	O
dairy	O
cows	O
and	O
in	O
serum	B-COMP
from	O
four	O
calves	O
for	O
a	O
period	O
of	O
1	O
year	O
after	O
an	O
outbreak	O
of	O
winter	O
dysentery	O
(	O
WD	O
).	O

0	O
.	O
25	O
x	O
10	O
(	O
9	O
)	O
cells	B-COMP
/	O
L	O
at	O
an	O
average	O
of	O
1	O
hour	O
after	O
delivery	O
to	O
2	O
.	O
8	O
+/-	O

TITLE	O
:	O
Contributions	O
of	O
CD8	O
+	O
T	O
cells	B-COMP
and	O
viral	O
spread	O
to	O
demyelinating	O
disease	O
.	O

We	O
have	O
explored	O
the	O
caspase	O
activation	O
events	O
that	O
are	O
initiated	O
upon	O
infection	O
of	O
the	O
human	O
rectal	O
tumor	O
cell	B-COMP
line	O
HRT18	O
with	O
TGEV	O
.	O

Cleavage	O
of	O
the	O
N	O
protein	O
was	O
inhibited	O
by	O
cell	B-COMP
-	O
permeative	O
caspase	O
inhibitors	O
,	O
suggesting	O
that	O
this	O
viral	O
structural	O
protein	O
is	O
a	O
target	O
for	O
host	B-COMP
cell	I-COMP
caspases	O
.	O

When	O
expressed	O
using	O
recombinant	O
vaccinia	O
virus	O
,	O
the	O
IBV	O
E	O
protein	O
is	O
released	O
from	O
cells	B-COMP
at	O
low	O
levels	O
in	O
sedimentable	O
particles	O
that	O
have	O
a	O
density	O
similar	O
to	O
that	O
of	O
coronavirus	O
virions	B-COMP
.	O

Electron	O
microscopy	O
of	O
cryoablation	O
-	O
treated	O
liver	O
tissue	O
demonstrated	O
disruption	O
of	O
the	O
hepatocyte	O
plasma	B-COMP
membrane	I-COMP
with	O
extension	O
of	O
intact	O
hepatocyte	O
organelles	B-COMP
into	O
the	O
space	O
of	O
Disse	O
;	O
RFA	O
-	O
treated	O
liver	O
tissue	O
demonstrated	O
coagulative	O
destruction	O
of	O
hepatocyte	O
organelles	B-COMP
within	O
an	O
intact	O
plasma	B-COMP
membrane	I-COMP
.	O

The	O
positive	O
signals	O
with	O
the	O
recombinant	O
PAS16	O
antibody	B-COMP
were	O
similar	O
to	O
those	O
with	O
the	O
monoclonal	O
antibody	B-COMP
.	O

Serum	B-COMP
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
protein	O
(	O
ELISA	O
),	O
hepatic	O
TNF	O
mRNA	O
(	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
),	O
and	O
hepatic	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
were	O
also	O
determined	O
.	O

Prevention	O
of	O
inflammatory	O
mediator	O
production	O
by	O
intrahepatic	O
leukocytes	O
attenuates	O
injury	O
and	O
supports	O
recent	O
adult	O
respiratory	O
distress	O
syndrome	O
and	O
in	O
vitro	O
data	O
suggesting	O
that	O
elastase	O
is	O
the	O
principal	O
factor	O
that	O
propagates	O
pancreatic	O
inflammation	O
into	O
a	O
systemic	O
illness	O
through	O
direct	O
activation	O
of	O
systemic	O
inflammatory	O
cells	B-COMP
.	O

Defective	O
genomes	O
with	O
shortened	O
poly	O
(	O
A	O
)	O
tails	O
consisting	O
of	O
5	O
or	O
10	O
A	O
residues	O
were	O
replicated	O
after	O
transfection	O
into	O
helper	O
virus	O
-	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Cells	B-COMP
infected	O
with	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
were	O
solubilized	O
with	O
Triton	O
X	O
-	O
100	O
to	O
yield	O
a	O
cell	B-COMP
lysate	O
(	O
CL	O
)	O
antigen	O
having	O
high	O
hemagglutinating	O
(	O
HA	O
)	O
titers	O
.	O

The	O
groups	O
immunized	O
with	O
the	O
CL	O
antigen	O
having	O
an	O
HA	O
titer	O
of	O
4000	O
or	O
16	O
000	O
produced	O
hemagglutination	O
inhibition	O
(	O
HI	O
)	O
antibody	B-COMP
titers	O
of	O
>	O
320	O
and	O
serum	B-COMP
neutralizing	O
(	O
SN	O
)	O
antibody	B-COMP
titers	O
of	O
>	O
1280	O
.	O

The	O
99	O
nt	O
overlap	O
between	O
ORF1a	O
and	O
ORF1b	O
contains	O
a	O
putative	O
AAAUUUU	O
'	O
slippery	O
'	O
sequence	O
associated	O
with	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
.	O

Protection	O
correlated	O
with	O
the	O
presence	O
of	O
sufficient	O
levels	O
of	O
specific	O
antiviral	O
antibodies	B-COMP
recognizing	O
the	O
same	O
immunodominant	O
domain	O
and	O
13	O
-	O
mer	O
peptide	O
,	O
located	O
within	O
the	O
C	O
-	O
terminal	O
S2	O
subunit	O
,	O
as	O
the	O
selecting	O
mAb	O
.	O

TITLE	O
:	O
Mucosal	O
and	O
systemic	O
immune	O
responses	O
to	O
chimeric	O
fimbriae	B-COMP
expressed	O
by	O
Salmonella	O
enterica	O
serovar	O
typhimurium	O
vaccine	O
strains	O
.	O

Accordingly	O
,	O
the	O
immune	O
response	O
of	O
mice	O
immunized	O
with	O
a	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
vaccine	O
strain	O
expressing	O
the	O
Escherichia	O
coli	O
987P	O
fimbrial	O
antigen	O
on	O
its	O
surface	O
(	O
Fas	O
(+))	O
was	O
compared	O
with	O
the	O
expression	O
in	O
the	O
periplasmic	B-COMP
compartment	O
(	O
Fas	O
(-)).	O

Further	O
studies	O
were	O
aimed	O
at	O
determining	O
whether	O
the	O
987P	O
fimbriae	B-COMP
expressed	O
by	O
serovar	O
Typhimurium	O
chi4550	O
(	O
cya	O
crp	O
asd	O
)	O
could	O
be	O
used	O
as	O
carriers	O
of	O
foreign	O
epitopes	O
.	O

We	O
report	O
the	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
to	O
rescue	O
a	O
child	O
with	O
ARDS	O
.	O

After	O
14	O
days	O
p	O
.	O
i	O
.,	O
small	O
number	O
of	O
IgG	O
+	O
and	O
IgM	O
+	O
cells	B-COMP
were	O
detected	O
in	O
the	O
germinal	O
center	O
of	O
lymph	O
follicles	O
in	O
the	O
lamina	O
propria	O
.	O

CD4	O
+	O
cells	B-COMP
were	O
dramatically	O
decreased	O
from	O
7	O
days	O
p	O
.	O
i	O
.,	O
and	O
CD3	O
+	O
and	O
CD8	O
+	O
cells	B-COMP
were	O
decreased	O
from	O
14	O
days	O
p	O
.	O
i	O
.	O

No	O
T	O
-	O
cells	B-COMP
were	O
detected	O
in	O
the	O
lymph	O
follicles	O
in	O
the	O
lamina	O
propria	O
.	O

In	O
this	O
study	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)-	O
infected	O
cells	B-COMP
were	O
fractionated	O
and	O
analyzed	O
to	O
determine	O
if	O
gene	O
1	O
proteins	O
segregated	O
to	O
more	O
than	O
one	O
membrane	B-COMP
population	O
.	O

Nine	O
patients	O
met	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
(	O
ECMO	O
)	O
criteria	O
,	O
although	O
only	O
two	O
patients	O
were	O
cannulated	O
.	O

ABSTRACT	O
:	O
The	O
acute	O
chest	O
syndrome	O
is	O
the	O
leading	O
cause	O
of	O
death	O
among	O
patients	O
with	O
sickle	O
cell	B-COMP
disease	O
.	O

Immunofluorescence	O
microscopy	O
and	O
subcellular	O
fractionation	O
studies	O
further	O
show	O
differential	O
subcellular	O
localization	O
of	O
the	O
proteinase	O
in	O
IBV	O
-	O
infected	O
cells	B-COMP
and	O
in	O
cells	B-COMP
expressing	O
the	O
3C	O
-	O
like	O
proteinase	O
alone	O
,	O
indicating	O
that	O
additional	O
roles	O
in	O
viral	O
replication	O
might	O
be	O
played	O
by	O
this	O
protein	O
.	O

The	O
putative	O
functional	O
site	O
for	O
acetylesterase	O
activity	O
was	O
present	O
in	O
the	O
HE	O
protein	O
as	O
Phe	O
-	O
Gly	O
-	O
Asp	O
-	O
Ser	B-COMP
(	O
FGDS	O
),	O
suggesting	O
that	O
the	O
SDAV	O
HE	O
protein	O
might	O
have	O
retained	O
the	O
esterase	O
activity	O
.	O

ABSTRACT	O
:	O
This	O
study	O
describes	O
the	O
clinicopathologic	O
features	O
of	O
5	O
patients	O
who	O
developed	O
a	O
fulminant	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)-	O
positive	O
clonal	O
T	O
-	O
cell	B-COMP
lymphoproliferative	O
disorder	O
(	O
LPD	O
)	O
after	O
acute	O
EBV	O
infection	O
.	O

Taken	O
together	O
,	O
our	O
results	O
confirmed	O
most	O
of	O
the	O
previously	O
proposed	O
structure	O
,	O
but	O
they	O
revealed	O
that	O
the	O
terminal	B-COMP
loop	I-COMP
and	O
an	O
internal	O
loop	O
are	O
larger	O
than	O
originally	O
thought	O
.	O

These	O
observations	O
suggest	O
that	O
inefficient	O
infections	O
in	O
BHK	O
-	O
R2	O
cells	B-COMP
by	O
srr	O
mutants	O
occur	O
in	O
the	O
absence	O
of	O
a	O
functional	O
receptor	O
MHVR1	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
srr	O
entry	O
into	O
cells	B-COMP
.	O

TITLE	O
:	O
Activation	O
of	O
glial	O
cells	B-COMP
by	O
human	O
coronavirus	O
OC43	O
infection	O
.	O

Infection	O
of	O
the	O
human	O
astrocytic	O
cell	B-COMP
line	O
U	O
-	O
373MG	O
by	O
the	O
OC43	O
strain	O
of	O
human	O
coronavirus	O
caused	O
an	O
upregulation	O
of	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
MCP	O
-	O
1	O
mRNA	O
expression	O
.	O

This	O
virus	O
also	O
modulated	O
the	O
activity	O
of	O
matrix	O
metalloproteinases	O
-	O
2	O
and	O
-	O
9	O
and	O
augmented	O
nitric	O
oxide	O
production	O
in	O
both	O
U	O
-	O
373MG	O
cells	B-COMP
and	O
the	O
human	O
microglial	O
cell	B-COMP
line	O
CHME	O
-	O
5	O
.	O

The	O
authors	O
suggest	O
that	O
high	O
PCWP	O
was	O
caused	O
by	O
high	O
intraalveolar	O
pressure	O
,	O
pneumomediastinum	O
,	O
and	O
venule	O
constriction	B-COMP
in	O
the	O
hypoxic	O
sites	O
of	O
the	O
lung	O
.	O

Numerous	O
signs	O
of	O
apoptosis	O
were	O
detected	O
in	O
TGEV	O
-	O
infected	O
ST	O
cells	B-COMP
by	O
TUNEL	O
assay	O
,	O
the	O
positive	O
(	O
dark	O
brown	O
)	O
staining	O
reaction	O
being	O
present	O
in	O
the	O
majority	O
of	O
cell	B-COMP
nuclei	I-COMP
,	O
without	O
background	O
staining	O
.	O

To	O
determine	O
whether	O
a	O
patient	O
has	O
a	O
transudative	O
or	O
exudative	O
pleural	O
effusion	O
,	O
Light	O
'	O
s	O
criteria	O
should	O
be	O
applied	O
to	O
measure	O
the	O
concentrations	O
of	O
protein	O
and	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
in	O
the	O
pleural	O
fluid	O
and	O
serum	B-COMP
.	O

In	O
these	O
diseases	O
,	O
the	O
pulmonary	O
bloodflow	O
is	O
impaired	O
by	O
a	O
pathologic	O
constriction	B-COMP
of	O
blood	O
vessels	O
that	O
may	O
lead	O
to	O
right	O
ventricular	O
overloading	O
as	O
well	O
as	O
serious	O
worsening	O
of	O
gas	O
exchange	O
mainly	O
caused	O
by	O
ventilation	O
/	O
perfusion	O
mismatch	O
.	O

We	O
studied	O
the	O
macromolecular	O
interactions	O
involved	O
in	O
coronavirus	O
assembly	O
in	O
cells	B-COMP
infected	O
with	O
a	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

However	O
,	O
the	O
M	O
protein	O
-	O
N	O
protein	O
interaction	O
did	O
not	O
occur	O
in	O
cells	B-COMP
coexpressing	O
M	O
protein	O
and	O
N	O
protein	O
alone	O
.	O

A	O
TGEV	O
strain	O
(	O
BW021898B	O
)	O
was	O
isolated	O
in	O
swine	O
testicular	O
cells	B-COMP
from	O
gut	O
contents	O
of	O
a	O
diarrheic	O
pig	O
and	O
three	O
PRCV	O
strains	O
(	O
BW126	O
,	O
BW154	O
,	O
BW155	O
)	O
were	O
isolated	O
from	O
nasal	O
swabs	O
from	O
normal	O
TGEV	O
-	O
seronegative	O
sentinel	O
pigs	O
in	O
contact	O
with	O
the	O
diarrheic	O
pigs	O
.	O

In	O
contrast	O
,	O
the	O
18	O
clinically	O
normal	O
and	O
RBCV	O
isolation	O
-	O
negative	O
cattle	O
had	O
high	O
hemagglutinin	O
inhibition	O
antibody	B-COMP
titers	O
to	O
RBCV	O
from	O
the	O
beginning	O
,	O
while	O
their	O
antibody	B-COMP
responses	O
to	O
P	O
.	O
haemolytica	O
antigens	O
were	O
delayed	O
.	O

Overexpression	O
of	O
hnRNP	O
A1	O
accelerated	O
the	O
kinetics	O
of	O
viral	O
RNA	O
synthesis	O
,	O
whereas	O
the	O
expression	O
in	O
the	O
cytoplasm	B-COMP
of	O
a	O
dominant	O
-	O
negative	O
hnRNP	O
A1	O
mutant	O
that	O
lacks	O
the	O
nuclear	O
transport	O
domain	O
significantly	O
delayed	O
it	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
-	O
type	O
hnRNP	O
A1	O
,	O
the	O
mutant	O
protein	O
failed	O
to	O
bind	O
a	O
250	O
kDa	O
cellular	B-COMP
protein	O
,	O
suggesting	O
that	O
the	O
recruitment	O
of	O
cellular	B-COMP
proteins	O
by	O
hnRNP	O
A1	O
is	O
important	O
for	O
MHV	O
RNA	O
synthesis	O
.	O

This	O
case	O
provides	O
an	O
opportunity	O
for	O
reviewing	O
the	O
main	O
causes	O
and	O
consequences	O
of	O
hypophosphataemia	O
,	O
and	O
for	O
emphasising	O
the	O
value	O
of	O
monitoring	O
serum	B-COMP
phosphate	O
levels	O
and	O
providing	O
supplemental	O
phosphate	O
in	O
ICU	O
patients	O
at	O
risk	O
for	O
phosphate	O
depletion	O
.	O

Serum	B-COMP
samples	O
were	O
obtained	O
at	O
arrival	O
and	O
again	O
28	O
days	O
after	O
arrival	O
and	O
tested	O
for	O
antibodies	B-COMP
to	O
BCV	O
,	O
using	O
an	O
antibody	B-COMP
-	O
detection	O
ELISA	O
.	O

TITLE	O
:	O
RNase	O
L	O
-	O
independent	O
specific	O
28S	O
rRNA	O
cleavage	O
in	O
murine	O
coronavirus	O
-	O
infected	O
cells	B-COMP
.	O

MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
was	O
detected	O
in	O
all	O
MHV	O
-	O
susceptible	O
cell	B-COMP
lines	O
and	O
all	O
MHV	O
strains	O
tested	O
.	O

BMV	O
1a	O
and	O
2a	O
can	O
direct	O
virus	O
-	O
specific	O
RNA	O
replication	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
which	O
reproduces	O
the	O
known	O
features	O
of	O
BMV	O
replication	O
in	O
plant	O
cells	B-COMP
.	O

The	O
envelope	B-COMP
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MHV	O
contains	O
determinants	O
of	O
properties	O
essential	O
for	O
virus	O
-	O
host	B-COMP
interactions	O
.	O

Genome	O
-	O
length	O
negative	O
-	O
strand	O
RNA	O
and	O
subgenomic	O
-	O
length	O
negative	O
-	O
strand	O
RNAs	O
,	O
each	O
of	O
which	O
corresponds	O
to	O
each	O
of	O
the	O
subgenomic	O
mRNAs	O
,	O
also	O
accumulate	O
in	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
An	O
antibody	B-COMP
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	B-COMP
to	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
utilizing	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antigen	O
was	O
developed	O
.	O

Goat	O
anti	O
-	O
turkey	O
immunoglobulin	O
G	O
(	O
light	O
plus	O
heavy	O
chains	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	O
was	O
used	O
as	O
detector	O
antibody	B-COMP
.	O

The	O
RT	O
-	O
PCR	O
,	O
MAb	O
-	O
based	O
fluorescent	O
antibody	B-COMP
(	O
FA	O
),	O
and	O
MAb	O
-	O
based	O
immunoperoxidase	O
(	O
IP	O
)	O
procedures	O
were	O
compared	O
with	O
virus	O
isolation	O
(	O
VI	O
)	O
for	O
detection	O
of	O
TCV	O
in	O
experimentally	O
infected	O
turkeys	O
.	O

The	O
pancytopenia	O
was	O
severe	O
(	O
white	O
blood	O
cell	B-COMP
count	O
,	O
0	O
.	O
9	O
x	O
10	O
(	O
9	O
)/	O
L	O
;	O
hemoglobin	O
,	O
59	O
g	O
/	O
L	O
;	O
platelets	O
,	O
36	O
x	O
10	O
(	O
9	O
)/	O
L	O
),	O
required	O
many	O
transfusions	O
,	O
and	O
resolved	O
2	O
months	O
later	O
.	O

The	O
types	O
of	O
malignant	O
cells	B-COMP
found	O
in	O
his	O
bone	O
marrow	O
were	O
also	O
seen	O
in	O
both	O
infiltrative	O
lesions	O
in	O
the	O
lung	O
parenchyma	O
and	O
the	O
pleural	O
effusion	O
.	O

Although	O
there	O
are	O
significant	O
differences	O
among	O
species	O
in	O
the	O
basal	O
rates	O
of	O
sodium	O
and	O
fluid	O
transport	O
,	O
the	O
basic	O
mechanism	O
seems	O
to	O
depend	O
on	O
sodium	O
uptake	O
by	O
channels	O
on	O
the	O
apical	O
membrane	B-COMP
of	O
alveolar	O
type	O
II	O
cells	B-COMP
,	O
followed	O
by	O
extrusion	O
of	O
sodium	O
on	O
the	O
basolateral	O
surface	O
by	O
Na	O
,	O
K	O
-	O
ATPase	O
.	O

Host	B-COMP
range	O
phenotypes	O
of	O
the	O
molecularly	O
cloned	O
and	O
wild	O
-	O
type	O
viruses	O
were	O
similar	O
in	O
cells	B-COMP
of	O
swine	O
and	O
feline	O
origin	O
.	O

Cells	B-COMP
were	O
co	O
-	O
infected	O
simultaneously	O
with	O
IBV	O
,	O
the	O
recombinant	O
FPV	O
(	O
rFPV	O
)	O
containing	O
the	O
D	O
-	O
RNA	O
sequence	O
and	O
a	O
second	O
rFPV	O
expressing	O
T7	O
RNA	O
polymerase	O
for	O
the	O
initial	O
expression	O
of	O
the	O
D	O
-	O
RNA	O
transcript	O
,	O
subsequently	O
rescued	O
by	O
helper	O
IBV	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
severe	O
acute	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
Published	O
evidence	O
of	O
pathogenetic	O
mechanisms	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
mycoplasmal	O
lung	O
infections	O
suggests	O
that	O
the	O
pulmonary	O
injury	O
is	O
related	O
to	O
a	O
cell	B-COMP
-	O
mediated	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
A	O
coronavirus	O
was	O
isolated	O
from	O
feces	O
of	O
a	O
diarrheic	O
foal	O
and	O
serially	O
propagated	O
in	O
human	O
rectal	O
adenocarcinoma	O
(	O
HRT	O
-	O
18	O
)	O
cells	B-COMP
.	O

The	O
results	O
indicate	O
that	O
IC	O
-	O
21	O
cells	B-COMP
were	O
the	O
most	O
sensitive	O
to	O
murine	O
coronaviruses	O
.	O

TITLE	O
:	O
Sialic	O
acid	O
binding	O
activity	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
affects	O
sedimentation	O
behavior	O
of	O
virions	B-COMP
and	O
solubilized	O
glycoproteins	O
.	O

The	O
mechanisms	O
that	O
ultimately	O
result	O
in	O
the	O
loss	O
of	O
CNS	O
myelin	B-COMP
appear	O
to	O
be	O
equally	O
diverse	O
as	O
the	O
etiological	O
agents	O
capable	O
of	O
causing	O
diseases	O
which	O
result	O
in	O
demyelination	O
.	O

Alternatively	O
,	O
antigenic	O
epitopes	O
derived	O
from	O
the	O
viral	O
proteins	O
may	O
exhibit	O
sufficient	O
homology	O
to	O
host	B-COMP
components	O
that	O
the	O
immune	O
response	O
to	O
the	O
virus	O
activates	O
autoreactive	O
T	O
cells	B-COMP
,	O
i	O
.	O
e	O
.	O
molecular	O
mimicry	O
.	O

TITLE	O
:	O
Expression	O
of	O
Mig	O
(	O
monokine	O
induced	O
by	O
interferon	O
-	O
gamma	O
)	O
is	O
important	O
in	O
T	O
lymphocyte	O
recruitment	O
and	O
host	B-COMP
defense	O
following	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
.	O

The	O
present	O
studies	O
demonstrate	O
a	O
role	O
for	O
the	O
T	O
cell	B-COMP
chemoattractant	O
chemokine	O
Mig	O
(	O
monokine	O
induced	O
by	O
IFN	O
-	O
gamma	O
)	O
in	O
contributing	O
to	O
a	O
Th1	O
response	O
against	O
mouse	O
hepatitis	O
virus	O
infection	O
of	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
Effects	O
of	O
liquid	O
paraffin	O
on	O
antibody	B-COMP
responses	O
and	O
local	O
adverse	O
reactions	O
after	O
intramuscular	O
injection	O
of	O
oil	O
adjuvanted	O
vaccines	O
containing	O
Newcastle	O
disease	O
(	O
ND	O
)	O
and	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
virus	O
were	O
investigated	O
in	O
chickens	O
.	O

These	O
vaccines	O
induced	O
sustained	O
antibody	B-COMP
responses	O
against	O
ND	O
and	O
IB	O
.	O

Antibodies	B-COMP
to	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
avian	O
nephritis	O
virus	O
,	O
Mycoplasma	O
gallisepticum	O
and	O
M	O
.	O
synoviae	O
were	O
detected	O
early	O
within	O
the	O
first	O
month	O
.	O

Antibody	B-COMP
titer	O
to	O
IBV	O
suggested	O
that	O
the	O
laying	O
chickens	O
were	O
infected	O
with	O
IBV	O
repeatedly	O
during	O
the	O
experiment	O
on	O
both	O
farms	O
.	O

However	O
,	O
antibodies	B-COMP
to	O
infectious	O
bursal	O
disease	O
virus	O
and	O
6	O
pathogens	O
were	O
not	O
detected	O
.	O

Viral	O
inactivation	O
is	O
all	O
the	O
more	O
easy	O
when	O
there	O
is	O
an	O
envelope	B-COMP
.	O

Cattle	O
nasally	O
shedding	O
RBCV	O
at	O
the	O
beginning	O
of	O
the	O
epizootic	O
experienced	O
characteristic	O
primary	O
immune	O
responses	O
with	O
specific	O
antibodies	B-COMP
for	O
hemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
and	O
spike	O
(	O
S	O
)	O
glycoproteins	O
.	O

Cattle	O
remaining	O
negative	O
in	O
RBCV	O
isolation	O
tests	O
entered	O
this	O
epizootic	O
with	O
antibodies	B-COMP
against	O
HE	O
and	O
S	O
.	O
Protection	O
against	O
respiratory	O
tract	O
disease	O
was	O
apparently	O
associated	O
with	O
high	O
level	O
of	O
opsonic	O
and	O
virus	O
-	O
neutralizing	O
IgG2	B-COMP
.	O

These	O
data	O
show	O
that	O
control	O
of	O
an	O
infection	O
in	O
the	O
first	O
compartment	O
in	O
which	O
bacteria	O
enter	O
the	O
host	B-COMP
is	O
a	O
critical	O
determinant	O
of	O
the	O
systemic	O
response	O
.	O

The	O
mutations	O
that	O
we	O
have	O
identified	O
therefore	O
point	O
to	O
regions	O
of	O
the	O
S	O
protein	O
that	O
specifically	O
regulate	O
the	O
membrane	B-COMP
fusion	O
reaction	O
.	O

Milk	O
from	O
these	O
transgenic	O
mice	O
contained	O
up	O
to	O
0	O
.	O
7	O
mg	O
of	O
recombinant	O
antibody	B-COMP
/	O
ml	O
.	O

ABSTRACT	O
:	O
Viruses	O
with	O
RNA	O
genomes	O
often	O
capture	O
and	O
redirect	O
host	B-COMP
cell	I-COMP
components	O
to	O
assist	O
in	O
mechanisms	O
particular	O
to	O
RNA	O
-	O
dependent	O
RNA	O
synthesis	O
.	O

Hybridization	O
signals	O
were	O
confined	O
to	O
the	O
cytoplasm	B-COMP
.	O

TITLE	O
:	O
[	O
10	O
years	O
experience	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
].	O

TITLE	O
:	O
Mitochondrial	B-COMP
aconitase	O
binds	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
genome	O
.	O

Comparison	O
of	O
the	O
three	O
groups	O
at	O
4	O
hours	O
did	O
not	O
demonstrate	O
any	O
differences	O
in	O
serum	B-COMP
concentrations	O
of	O
IL	O
-	O
6	O
.	O

Moreover	O
,	O
this	O
work	O
shows	O
that	O
IFN	O
-	O
alpha	O
released	O
in	O
serum	B-COMP
is	O
likely	O
to	O
originate	O
almost	O
exclusively	O
from	O
gut	O
IPC	O
triggered	O
locally	O
by	O
viral	O
antigens	O
to	O
produce	O
IFN	O
-	O
alpha	O
,	O
since	O
there	O
were	O
very	O
few	O
IPC	O
in	O
spleen	O
or	O
peripheral	O
lymph	O
nodes	O
.	O

The	O
prevalence	O
of	O
antibodies	B-COMP
varied	O
from	O
zero	O
to	O
76	O
%	O
in	O
kennelled	O
dogs	O
.	O

About	O
23	O
%	O
of	O
128	O
dogs	O
positive	O
for	O
IgG	O
antibodies	B-COMP
to	O
CCV	O
were	O
also	O
positive	O
for	O
IgM	O
antibodies	B-COMP
to	O
CCV	O
,	O
indicating	O
recent	O
CCV	O
infection	O
.	O

Viral	O
clearance	O
from	O
most	O
cell	B-COMP
types	O
is	O
controlled	O
by	O
a	O
perforin	O
dependent	O
mechanism	O
.	O

The	O
loss	O
of	O
cytolytic	O
activity	O
,	O
but	O
retention	O
of	O
IFN	O
-	O
gamma	O
secretion	O
during	O
viral	O
clearance	O
suggests	O
stringent	O
regulation	O
of	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
effector	O
function	O
,	O
possibly	O
as	O
a	O
means	O
to	O
minimize	O
CNS	O
damage	O
.	O

Studies	O
in	O
B	O
-	O
cell	B-COMP
-	O
deficient	O
mice	O
suggest	O
that	O
antibodies	B-COMP
are	O
required	O
to	O
prevent	O
virus	O
recrudescence	O
.	O

The	O
third	O
domain	O
of	O
E	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
virus	O
budding	O
is	O
a	O
putative	O
transmembrane	B-COMP
domain	O
present	O
at	O
the	O
N	O
-	O
terminal	O
region	O
,	O
because	O
deletion	O
of	O
the	O
domain	O
resulted	O
in	O
a	O
free	O
distribution	O
of	O
the	O
mutant	O
protein	O
and	O
in	O
dysfunctional	O
viral	O
assembly	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
immunogenicity	O
of	O
chimeric	O
987P	O
fimbriae	B-COMP
on	O
a	O
Salmonella	O
vaccine	O
strain	O
was	O
improved	O
by	O
optimizing	O
fimbrial	O
expression	O
.	O

Moreover	O
,	O
only	O
the	O
Salmonella	O
vaccine	O
strains	O
harboring	O
a	O
plasmid	O
with	O
the	O
pagC	O
promoter	O
,	O
with	O
or	O
without	O
an	O
additional	O
tetA	O
promoter	O
in	O
tandem	O
,	O
elicited	O
neutralizing	O
antibodies	B-COMP
to	O
TGEV	O
.	O

This	O
indicated	O
that	O
the	O
pagC	O
promoter	O
can	O
be	O
used	O
successfully	O
to	O
improve	O
epitope	O
-	O
display	O
by	O
chimeric	O
fimbriae	B-COMP
on	O
Salmonella	O
vaccine	O
strains	O
for	O
the	O
induction	O
of	O
a	O
desired	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
was	O
amplified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
cloned	O
,	O
and	O
expressed	O
in	O
the	O
baculovirus	O
expression	O
system	O
.	O

The	O
phagocytic	O
activity	O
of	O
macrophages	O
remained	O
unaffected	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
when	O
the	O
positive	O
-	O
control	O
serum	B-COMP
was	O
replaced	O
with	O
E	O
.	O
coli	O
antiserum	O
produced	O
in	O
chickens	O
infected	O
with	O
IBV	O
alone	O
.	O

ABSTRACT	O
:	O
Chicks	O
hatched	O
with	O
high	O
levels	O
of	O
maternal	O
antibody	B-COMP
had	O
excellent	O
protection	O
(>	O
95	O
%)	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
challenge	O
at	O
1	O
day	O
of	O
age	O
,	O
but	O
not	O
at	O
7	O
days	O
(<	O
30	O
%).	O

CONCLUSIONS	O
:	O
In	O
indicated	O
cases	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
remains	O
the	O
method	O
of	O
choice	O
in	O
critically	O
ill	O
mature	O
neonates	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
feline	O
(	O
FECV	O
and	O
FIPV	O
)	O
and	O
canine	O
(	O
CCoV	O
)	O
coronavirus	O
entry	O
into	O
and	O
release	O
from	O
polarized	O
porcine	O
epithelial	O
LLC	B-COMP
-	O
PK1	O
cells	B-COMP
,	O
stably	O
expressing	O
the	O
recombinant	O
feline	O
aminopeptidase	O
-	O
N	O
cDNA	O
,	O
were	O
investigated	O
.	O

Virus	O
entry	O
appeared	O
to	O
occur	O
preferentially	O
through	O
the	O
apical	O
membrane	B-COMP
,	O
similar	O
to	O
the	O
entry	O
of	O
the	O
related	O
porcine	O
coronavirus	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
into	O
these	O
cells	B-COMP
.	O

A	O
patient	O
was	O
treated	O
with	O
thoracic	O
radiotherapy	O
for	O
non	O
-	O
small	O
-	O
cell	B-COMP
lung	O
cancer	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
coronavirus	O
,	O
is	O
translated	O
as	O
a	O
precursor	O
protein	O
(	O
So	O
),	O
then	O
cleaved	O
into	O
two	O
subunits	O
(	O
S1	O
and	O
S2	O
)	O
by	O
host	B-COMP
cell	I-COMP
serine	O
proteases	O
.	O

Thus	O
,	O
the	O
number	O
of	O
basic	O
residues	O
around	O
the	O
cleavage	O
recognition	O
site	O
does	O
not	O
appear	O
to	O
correlate	O
with	O
increased	O
cleavability	O
,	O
host	B-COMP
cell	I-COMP
range	O
,	O
and	O
increased	O
virulence	O
as	O
it	O
does	O
with	O
envelope	B-COMP
glycoproteins	O
in	O
orthomyxoviruses	O
and	O
paramyxoviruses	O
.	O

2	O
.	O
1	O
%	O
of	O
48	O
sera	B-COMP
and	O
20	O
.	O
3	O
%	O
of	O
74	O
sera	B-COMP
,	O
which	O
were	O
all	O
negative	O
for	O
NT	O
antibody	B-COMP
,	O
were	O
positive	O
for	O
IP	O
antibody	B-COMP
in	O
the	O
dogs	O
of	O
under	O
one	O
year	O
of	O
age	O
and	O
at	O
least	O
one	O
year	O
of	O
age	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Antiviral	O
roles	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	B-COMP
subsets	O
were	O
examined	O
in	O
C57BL	O
/	O
6	O
mice	O
infected	O
with	O
murine	O
cytomegalovirus	O
(	O
MCMV	O
)	O
and	O
other	O
viruses	O
,	O
including	O
lymphocytic	O
choriomeningitis	O
virus	O
(	O
LCMV	O
),	O
vaccinia	O
virus	O
(	O
VV	O
),	O
and	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Each	O
virus	O
vigorously	O
induced	O
an	O
NK	O
cell	B-COMP
infiltrate	O
into	O
the	O
peritoneal	O
cavity	O
and	O
liver	O
,	O
causing	O
some	O
redistributions	O
of	O
NK	O
cell	B-COMP
subsets	O
defined	O
by	O
monoclonal	O
antibody	B-COMP
(	O
mAb	O
)	O
directed	O
against	O
Ly49A	O
,	O
C	O
/	O
I	O
,	O
D	O
,	O
and	O
G2	O
.	O

mAb	O
1F8	O
also	O
stains	O
Ly49	O
C	O
and	O
I	O
,	O
but	O
exclusion	O
of	O
those	O
reactivities	O
with	O
mAb	O
5E6	O
,	O
which	O
recognizes	O
Ly49	O
C	O
and	O
I	O
,	O
indicated	O
that	O
Ly49H	O
(+)	O
cells	B-COMP
infiltrated	O
the	O
peritoneal	O
cavity	O
and	O
liver	O
and	O
were	O
particularly	O
effective	O
at	O
synthesizing	O
interferon	O
gamma	O
.	O

Depletion	O
of	O
1F8	O
(+)	O
but	O
not	O
5E6	O
(+)	O
cells	B-COMP
in	O
vivo	O
by	O
mAb	O
injections	O
enhanced	O
MCMV	O
titers	O
by	O
20	O
-	O
1	O
,	O
000	O
-	O
fold	O
in	O
the	O
spleen	O
and	O
approximately	O
fivefold	O
in	O
the	O
liver	O
.	O

All	O
18	O
shipping	O
boxes	O
were	O
transported	O
to	O
a	O
facility	O
housing	O
a	O
breeding	O
colony	O
of	O
mice	O
enzootically	O
infected	O
with	O
four	O
murine	O
viruses	O
,	O
including	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
and	O
were	O
placed	O
inside	O
the	O
colony	O
for	O
15	O
h	O
.	O
The	O
boxes	O
were	O
then	O
transported	O
to	O
a	O
commercial	O
testing	O
laboratory	O
,	O
at	O
which	O
the	O
animals	O
were	O
aseptically	O
removed	O
and	O
were	O
held	O
in	O
microisolation	O
cages	O
for	O
28	O
days	O
,	O
after	O
which	O
their	O
sera	B-COMP
tested	O
for	O
antibody	B-COMP
to	O
all	O
four	O
murine	O
viruses	O
.	O

In	O
experiment	O
2	O
,	O
2	O
-	O
day	O
-	O
old	O
piglets	O
fed	O
HCC	O
containing	O
antibody	B-COMP
titers	O
of	O
1	O
:	O
512	O
,	O
1	O
:	O
128	O
and	O
1	O
:	O
32	O
,	O
and	O
UCC	O
were	O
inoculated	O
with	O
PED	O
virus	O
,	O
and	O
survival	O
rates	O
after	O
challenge	O
were	O
100	O
,	O
75	O
,	O
50	O
and	O
0	O
%,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
piglets	O
fed	O
UCC	O
,	O
villous	O
atrophy	O
and	O
PED	O
virus	O
antigen	O
were	O
observed	O
in	O
epithelial	O
cells	B-COMP
of	O
the	O
jejunum	O
and	O
ileum	O
from	O
24	O
hr	O
.	O

Although	O
overall	O
T	O
cell	B-COMP
recruitment	O
into	O
the	O
CNS	O
of	O
muMT	O
mice	O
was	O
not	O
impaired	O
,	O
discrepancies	O
in	O
frequencies	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
were	O
most	O
severe	O
during	O
acute	O
infection	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
the	O
lack	O
of	O
Ab	O
,	O
limited	O
CD8	O
(+)	O
and	O
CD4	O
(+)	O
T	O
cell	B-COMP
responses	O
in	O
muMT	O
mice	O
contribute	O
to	O
the	O
ultimate	O
loss	O
of	O
control	O
of	O
CNS	O
infection	O
.	O

Inflammatory	O
infiltration	O
was	O
generally	O
dominated	O
by	O
mononuclear	O
cells	B-COMP
and	O
was	O
moderate	O
in	O
the	O
unaltered	O
intestine	O
and	O
in	O
cats	O
with	O
PV	O
enteritis	O
and	O
marked	O
in	O
cats	O
with	O
FAE	O
,	O
CoV	O
enteritis	O
,	O
and	O
EUE	O
.	O

Serum	B-COMP
was	O
collected	O
from	O
the	O
852	O
animals	O
enrolled	O
to	O
determine	O
titers	O
to	O
H	O
.	O
somnus	O
,	O
M	O
.	O
haemolytica	O
,	O
bovine	O
coronavirus	O
and	O
bovine	O
viral	O
diarrhea	O
virus	O
.	O

Recent	O
work	O
has	O
shown	O
that	O
either	O
virus	O
-	O
specific	O
CD4	O
(+)	O
or	O
CD8	O
(+)	O
T	O
cells	B-COMP
are	O
able	O
to	O
mediate	O
demyelination	O
and	O
also	O
that	O
the	O
antibody	B-COMP
response	O
is	O
crucial	O
for	O
clearing	O
infectious	O
virus	O
.	O

However	O
,	O
Fas	O
ligation	O
can	O
also	O
lead	O
to	O
cell	B-COMP
activation	O
and	O
cytokine	O
production	O
.	O

ABSTRACT	O
:	O
Expression	O
of	O
negative	O
-	O
strand	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
transcripts	O
in	O
MHV	O
-	O
infected	O
cells	B-COMP
results	O
in	O
the	O
accumulation	O
of	O
positive	O
-	O
strand	O
DI	O
RNAs	O
(	O
M	O
.	O
Joo	O
et	O
al	O
.,	O
1996	O
,	O
J	O
.	O
Virol	O
.	O

Nucleolar	O
localization	O
signals	O
were	O
identified	O
in	O
the	O
domain	O
III	O
region	O
of	O
the	O
N	O
protein	O
from	O
all	O
three	O
coronavirus	O
groups	O
,	O
and	O
this	O
suggested	O
that	O
transport	O
of	O
N	O
protein	O
to	O
the	O
nucleus	B-COMP
might	O
be	O
an	O
active	O
process	O
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
the	O
N	O
protein	O
might	O
function	O
to	O
disrupt	O
cell	B-COMP
division	O
.	O

Thus	O
,	O
we	O
observed	O
that	O
approximately	O
30	O
%	O
of	O
cells	B-COMP
transfected	O
with	O
the	O
N	O
protein	O
appeared	O
to	O
be	O
undergoing	O
cell	B-COMP
division	O
.	O

These	O
virus	O
-	O
receptor	O
interactions	O
can	O
be	O
highly	O
species	O
specific	O
;	O
for	O
example	O
,	O
the	O
human	O
coronavirus	O
can	O
use	O
human	O
APN	O
(	O
hAPN	O
)	O
but	O
not	O
porcine	O
APN	O
(	O
pAPN	O
)	O
as	O
its	O
cellular	B-COMP
receptor	O
,	O
and	O
porcine	O
coronaviruses	O
can	O
use	O
pAPN	O
but	O
not	O
hAPN	O
.	O

Paired	O
serum	B-COMP
samples	O
obtained	O
were	O
tested	O
for	O
antibodies	B-COMP
to	O
BCV	O
,	O
using	O
antibody	B-COMP
-	O
detection	O
ELISA	O
.	O

ABSTRACT	O
:	O
Demyelination	O
in	O
multiple	O
sclerosis	O
and	O
in	O
animal	O
models	O
is	O
associated	O
with	O
infiltrating	O
CD8	O
+	O
and	O
CD4	O
+	O
T	O
cells	B-COMP
.	O

We	O
set	O
out	O
to	O
precisely	O
define	O
which	O
central	O
nervous	O
system	O
cells	B-COMP
express	O
MHC	O
molecules	O
in	O
vivo	O
during	O
infection	O
with	O
a	O
strain	O
of	O
murine	O
hepatitis	O
virus	O
that	O
causes	O
a	O
chronic	O
,	O
inflammatory	O
demyelinating	O
disease	O
.	O

Eighteen	O
showed	O
severe	O
ARF	O
(	O
Serum	B-COMP
creatinine	O
>	O
5	O
mg	O
%).	O

Collectively	O
,	O
these	O
results	O
indicate	O
an	O
important	O
role	O
for	O
CCR2	O
in	O
host	B-COMP
defense	O
and	O
disease	O
by	O
regulating	O
leukocyte	O
activation	O
and	O
trafficking	O
.	O

An	O
optimal	O
antibody	B-COMP
response	O
was	O
achieved	O
with	O
100	O
microg	O
of	O
pcDNA	O
/	O
N	O
.	O
The	O
response	O
lasted	O
at	O
least	O
11	O
weeks	O
after	O
primary	O
immunization	O
.	O

Lymphocyte	O
proliferation	O
responses	O
of	O
spleen	O
cells	B-COMP
to	O
concanavalin	O
A	O
were	O
higher	O
in	O
TCV	O
-	O
infected	O
turkeys	O
than	O
in	O
noninfected	O
control	O
turkeys	O
with	O
significant	O
differences	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
being	O
noted	O
at	O
14	O
and	O
63	O
d	O
PI	O
in	O
Experiment	O
2	O
and	O
at	O
3	O
and	O
28	O
d	O
PI	O
in	O
Experiment	O
3	O
.	O

These	O
data	O
suggest	O
that	O
clearance	O
of	O
infectious	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
from	O
the	O
CNS	O
requires	O
Ab	O
production	O
and	O
perhaps	O
B	O
cell	B-COMP
support	O
of	O
T	O
cells	B-COMP
;	O
however	O
,	O
virus	O
is	O
cleared	O
from	O
the	O
liver	O
without	O
the	O
involvement	O
of	O
Abs	O
or	O
B	O
cells	B-COMP
.	O

Infectious	O
IBV	O
RNA	O
was	O
generated	O
in	O
situ	O
after	O
the	O
transfection	O
of	O
restricted	O
recombinant	O
vaccinia	O
virus	O
DNA	O
into	O
primary	O
chick	O
kidney	O
cells	B-COMP
previously	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
RNA	O
polymerase	O
.	O

Ultrastructurally	O
,	O
morphogenesis	O
of	O
virus	O
progeny	O
was	O
detected	O
only	O
in	O
the	O
cytoplasm	B-COMP
.	O

Egress	O
of	O
mature	O
virions	B-COMP
occurs	O
primarily	O
by	O
exocytosis	O
and	O
,	O
only	O
very	O
rarely	O
,	O
by	O
budding	O
directly	O
at	O
the	O
plasma	B-COMP
membrane	I-COMP
.	O

Moreover	O
,	O
in	O
YAC	O
-	O
MHV3	O
-	O
infected	O
mice	O
,	O
the	O
percentages	O
of	O
intrahepatic	O
CD8	O
(+)	O
cells	B-COMP
slightly	O
decreased	O
at	O
24	O
h	O
pi	O
,	O
then	O
increased	O
until	O
15	O
days	O
pi	O
.	O

Intestinal	O
contents	O
or	O
intestines	O
from	O
affected	O
turkey	O
poults	O
and	O
inoculated	O
turkey	O
embryos	O
contained	O
coronaviruses	O
as	O
revealed	O
by	O
electron	O
microscopy	O
or	O
were	O
positive	O
for	O
turkey	O
coronavirus	O
by	O
immunofluorescent	O
antibody	B-COMP
assay	O
.	O

Immunity	O
was	O
assessed	O
as	O
antibody	B-COMP
production	O
to	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
SRBC	O
,	O
and	O
Brucella	O
abortus	O
(	O
BA	O
)	O
antigens	O
,	O
mitogenic	O
response	O
to	O
phytohemagglutinin	O
A	O
(	O
PHA	O
)	O
and	O
concanavalin	O
A	O
(	O
Con	O
A	O
),	O
cutaneous	O
basophil	O
hypersensitivity	O
(	O
CBH	O
)	O
to	O
PHA	O
,	O
and	O
lipopolysaccharide	O
induction	O
of	O
acute	O
-	O
phase	O
proteins	O
(	O
APP	O
)	O
and	O
heterophilia	O
.	O

ABSTRACT	O
:	O
Respiratory	O
distress	O
syndrome	O
(	O
RDS	O
)	O
and	O
development	O
of	O
bronchopulmonary	O
dysplasia	O
(	O
BPD	O
)	O
are	O
characterized	O
by	O
endothelial	O
cell	B-COMP
damage	O
.	O

TITLE	O
:	O
Nanostructured	O
materials	O
designed	O
for	O
cell	B-COMP
binding	O
and	O
transduction	O
.	O

CHO	O
cells	B-COMP
bound	O
with	O
fluorescent	O
PTD	O
-	O
nanocage	O
bioconjugates	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
and	O
fluorescence	O
activated	O
cell	B-COMP
sorting	O
(	O
FACS	O
).	O

Increases	O
in	O
cytokine	O
expression	O
and	O
cellular	B-COMP
nitration	O
can	O
lead	O
to	O
tissue	O
damage	O
and	O
are	O
consistent	O
with	O
the	O
differences	O
between	O
genotypes	O
in	O
the	O
early	O
onset	O
of	O
pathology	O
and	O
mortality	O
in	O
Ron	O
tk	O
-/-	O
mice	O
.	O

The	O
membrane	B-COMP
(	O
M	O
)	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
proteins	O
were	O
chosen	O
as	O
antigens	O
,	O
because	O
antibodies	B-COMP
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
FIP	O
virus	O
(	O
FIPV	O
)	O
are	O
known	O
to	O
precipitate	O
pathogenesis	O
.	O

Serum	B-COMP
antibody	B-COMP
prevalence	O
averaged	O
70	O
%	O
(	O
167	O
/	O
240	O
)	O
during	O
the	O
spring	O
collection	O
period	O
and	O
25	O
%	O
(	O
46	O
/	O
185	O
)	O
during	O
the	O
autumn	O
collection	O
period	O
.	O

Concomitantly	O
,	O
surfactant	O
proteins	O
and	O
Clara	O
cell	B-COMP
secretory	O
protein	O
mRNA	O
expression	O
decreased	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
severe	O
multiple	O
trauma	O
complicated	O
by	O
acute	O
lung	O
injury	O
on	O
endothelial	O
cell	B-COMP
activity	O
].	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
the	O
E	O
protein	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
localized	O
to	O
the	O
Golgi	B-COMP
complex	I-COMP
when	O
expressed	O
exogenously	O
from	O
cDNA	O
.	O

In	O
both	O
cases	O
,	O
GFP	O
expression	O
and	O
leader	O
-	O
containing	O
GFP	O
transcripts	O
were	O
detected	O
in	O
transfected	O
cells	B-COMP
.	O

Cell	B-COMP
culture	O
supernatants	O
,	O
collected	O
approximately	O
36	O
h	O
posttransfection	O
,	O
were	O
passed	O
onto	O
fresh	O
ST	O
cells	B-COMP
where	O
GFP	O
expression	O
was	O
evident	O
approximately	O
18	O
h	O
postinfection	O
.	O

TOCVs	O
also	O
did	O
not	O
cross	O
-	O
react	O
in	O
a	O
BCV	O
antigen	O
-	O
capture	O
(	O
AC	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
system	O
with	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)	O
against	O
N	O
,	O
spike	O
glycoprotein	O
,	O
and	O
hemagglutinin	O
esterase	O
glycoprotein	O
proteins	O
of	O
BCV	O
as	O
coating	O
antibodies	B-COMP
.	O

Fifty	O
-	O
four	O
commercial	O
turkey	O
flocks	O
on	O
farms	O
in	O
areas	O
with	O
and	O
without	O
a	O
history	O
of	O
TCV	O
infection	O
were	O
monitored	O
for	O
weekly	O
mortality	O
and	O
for	O
antibodies	B-COMP
to	O
TCV	O
.	O

In	O
addition	O
,	O
the	O
spleen	O
cell	B-COMP
-	O
derived	O
supernatants	O
(	O
natural	O
IFN	O
)	O
inhibited	O
tracheal	O
ring	O
ciliostasis	O
mediated	O
by	O
the	O
Gray	O
strain	O
of	O
IBV	O
.	O

In	O
contrast	O
to	O
diminished	O
T	O
cell	B-COMP
responses	O
in	O
H	O
-	O
2	O
(	O
b	O
)	O
B	O
cell	B-COMP
-	O
deficient	O
muMT	O
mice	O
,	O
the	O
absence	O
of	O
B	O
cells	B-COMP
or	O
Ab	O
in	O
the	O
H	O
-	O
2	O
(	O
d	O
)	O
mice	O
did	O
not	O
compromise	O
expansion	O
,	O
recruitment	O
into	O
the	O
CNS	O
,	O
or	O
function	O
of	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	B-COMP
.	O

These	O
data	O
conclusively	O
demonstrate	O
that	O
the	O
Ab	O
component	O
of	O
humoral	O
immunity	O
is	O
critical	O
in	O
preventing	O
virus	O
reactivation	O
within	O
CNS	O
glial	O
cells	B-COMP
.	O

MHV	O
-	O
S	O
,	O
MHV	O
-	O
JHM	O
and	O
PV	O
bound	O
to	O
horse	O
serum	B-COMP
glycoproteins	O
containing	O
Neu4	O
,	O
5Ac2	O
.	O

The	O
ideal	O
vector	O
should	O
efficiently	O
transduce	O
non	O
-	O
dividing	O
cells	B-COMP
with	O
minimal	O
toxicity	O
,	O
thus	O
endowing	O
the	O
system	O
with	O
persistent	O
transgene	O
expression	O
.	O

We	O
showed	O
previously	O
that	O
adoptive	O
transfer	O
of	O
MHV	O
-	O
immune	O
splenocytes	O
depleted	O
of	O
either	O
CD4	O
or	O
CD8	O
T	O
cells	B-COMP
to	O
infected	O
RAG1	O
(-/-)	O
recipients	O
(	O
mice	O
deficient	O
in	O
recombination	O
activation	O
gene	O
1	O
)	O
resulted	O
in	O
demyelination	O
.	O

Expression	O
of	O
the	O
reporter	O
gene	O
beta	O
-	O
glucuronidase	O
(	O
GUS	O
)	O
(	O
2	O
-	O
8	O
microg	O
per	O
10	O
(	O
6	O
)	O
cells	B-COMP
)	O
and	O
the	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
ORF5	O
(	O
1	O
-	O
2	O
microg	O
per	O
10	O
(	O
6	O
)	O
cells	B-COMP
)	O
has	O
been	O
shown	O
using	O
a	O
TGEV	O
-	O
derived	O
minigenome	O
.	O

Mp	O
-	O
associated	O
HPS	O
was	O
diagnosed	O
in	O
this	O
case	O
by	O
clinical	O
and	O
laboratory	O
findings	O
,	O
including	O
a	O
bone	O
marrow	O
aspiration	O
specimen	O
and	O
serum	B-COMP
Mp	O
antibody	B-COMP
titer	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
humoral	O
and	O
cellular	B-COMP
immunities	O
on	O
turkeys	O
infected	O
with	O
turkey	O
coronavirus	O
(	O
TCV	O
).	O

Prior	O
to	O
infection	O
,	O
treatment	O
with	O
CsA	O
selectively	O
suppressed	O
T	O
cell	B-COMP
activity	O
as	O
revealed	O
by	O
2	O
-	O
3	O
fold	O
decreased	O
(	O
p	O
<	O
0	O
.	O
1	O
)	O
lymphocyte	O
proliferation	O
responses	O
to	O
a	O
T	O
cell	B-COMP
mitogen	O
,	O
concanavalin	O
A	O
(	O
Con	O
A	O
).	O

Treatment	O
with	O
CY	O
mainly	O
induced	O
B	O
cell	B-COMP
deficiency	O
as	O
indicated	O
by	O
significant	O
reductions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
antibody	B-COMP
responses	O
to	O
sheep	O
erythrocytes	O
7	O
days	O
after	O
injection	O
.	O

TITLE	O
:	O
An	O
ELISA	O
for	O
antibodies	B-COMP
against	O
infectious	O
bronchitis	O
virus	O
using	O
an	O
S1	O
spike	O
polypeptide	O
.	O

Reliable	O
and	O
rapid	O
methods	O
as	O
immunofluorescence	O
with	O
monoclonal	O
antibodies	B-COMP
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
allow	O
new	O
researches	O
on	O
epidemiology	O
.	O

TITLE	O
:	O
Mucosal	O
and	O
systemic	O
isotype	O
-	O
specific	O
antibody	B-COMP
responses	O
and	O
protection	O
in	O
conventional	O
pigs	O
exposed	O
to	O
virulent	O
or	O
attenuated	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
.	O

ABSTRACT	O
:	O
Lead	O
,	O
a	O
ubiquitous	O
environmental	O
contaminant	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
various	O
functions	O
of	O
the	O
immune	O
system	O
and	O
decrease	O
host	B-COMP
resistance	O
to	O
infectious	O
disease	O
.	O

While	O
antibody	B-COMP
response	O
to	O
IBV	O
in	O
juvenile	O
chicks	O
was	O
unaffected	O
by	O
the	O
in	O
ovo	O
lead	O
exposure	O
,	O
IFN	O
-	O
gamma	O
-	O
like	O
cytokine	O
production	O
by	O
splenocytes	O
was	O
significantly	O
depressed	O
following	O
lead	O
exposure	O
at	O
both	O
developmental	O
stages	O
.	O

TITLE	O
:	O
Recruitment	O
kinetics	O
and	O
composition	O
of	O
antibody	B-COMP
-	O
secreting	O
cells	B-COMP
within	O
the	O
central	O
nervous	O
system	O
following	O
viral	O
encephalomyelitis	O
.	O

Following	O
elimination	O
of	O
infectious	O
virus	O
,	O
virus	O
-	O
specific	O
ASC	O
continued	O
to	O
increase	O
within	O
the	O
CNS	O
and	O
then	O
remained	O
stable	O
during	O
persistence	O
,	O
in	O
contrast	O
to	O
declining	O
T	O
cell	B-COMP
numbers	O
.	O

TITLE	O
:	O
IFN	O
-	O
gamma	O
-	O
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
;	O
CXCL10	O
)-	O
deficient	O
mice	O
reveal	O
a	O
role	O
for	O
IP	O
-	O
10	O
in	O
effector	O
T	O
cell	B-COMP
generation	O
and	O
trafficking	O
.	O

Expression	O
of	O
IP	O
-	O
10	O
is	O
seen	O
in	O
many	O
Th1	O
-	O
type	O
inflammatory	O
diseases	O
,	O
where	O
it	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
recruiting	O
activated	O
T	O
cells	B-COMP
into	O
sites	O
of	O
tissue	O
inflammation	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
IP	O
-	O
10	O
in	O
both	O
effector	O
T	O
cell	B-COMP
generation	O
and	O
trafficking	O
in	O
vivo	O
.	O

Intracellular	B-COMP
double	O
-	O
stranded	O
(	O
ds	O
)	O
RNAs	O
equivalent	O
in	O
size	O
to	O
the	O
26	O
.	O
2	O
kb	O
genomic	O
RNA	O
and	O
two	O
sgRNAs	O
were	O
also	O
identified	O
by	O
RNase	O
/	O
DNase	O
digestion	O
of	O
total	O
RNA	O
from	O
GAV	O
-	O
infected	O
prawn	O
tissue	O
.	O

TITLE	O
:	O
Differentiation	O
of	O
mouse	O
hepatitis	O
viruses	O
in	O
animal	O
facilities	O
in	O
Japan	O
by	O
use	O
of	O
nucleotide	O
analysis	O
of	O
the	O
nucleocapsid	B-COMP
gene	O
.	O

Endotoxin	O
mediated	O
chemokine	O
production	O
in	O
LMVEC	O
seems	O
not	O
to	O
involve	O
PLA	O
(	O
2	O
)	O
activity	O
,	O
since	O
LPS	O
stimulation	O
was	O
not	O
associated	O
with	O
activation	O
of	O
intracellular	B-COMP
or	O
secreted	O
PLA	O
(	O
2	O
).	O

Based	O
on	O
previously	O
identified	O
p28	B-COMP
and	O
p65	O
cleavage	O
sites	O
,	O
a	O
p50	O
cleavage	O
site	O
was	O
proposed	O
to	O
occur	O
between	O
Ala	O
-	O
1262	O
and	O
Ala	O
-	O
1263	O
.	O

As	O
his	O
clinical	O
situation	O
deteriorated	O
rapidly	O
,	O
BMT	O
was	O
performed	O
with	O
unmanipulated	O
marrow	O
stem	O
cells	B-COMP
from	O
his	O
EBV	O
-	O
positive	O
HLA	O
-	O
identical	O
sister	O
after	O
conditioning	O
with	O
dexamethasone	O
(	O
1	O
.	O
75	O
mg	O
/	O
kg	O
/	O
day	O
),	O
cyclophosphamide	O
(	O
114	O
mg	O
/	O
kg	O
)	O
and	O
etoposide	O
(	O
10	O
mg	O
/	O
kg	O
),	O
with	O
no	O
immunosuppression	O
given	O
post	O
transplant	O
.	O

Analysis	O
of	O
multiple	O
second	O
-	O
site	O
revertants	O
of	O
the	O
M	O
(	O
Delta	O
)	O
2	O
mutant	O
has	O
revealed	O
changes	O
in	O
regions	O
of	O
both	O
the	O
M	O
protein	O
and	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
that	O
can	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
last	O
two	O
residues	O
of	O
the	O
M	O
protein	O
.	O

TITLE	O
:	O
Interaction	O
of	O
the	O
coronavirus	O
nucleoprotein	O
with	O
nucleolar	O
antigens	O
and	O
the	O
host	B-COMP
cell	I-COMP
.	O

Two	O
of	O
the	O
major	O
components	O
of	O
the	O
nucleolus	B-COMP
are	O
fibrillarin	O
and	O
nucleolin	O
.	O

Both	O
N	O
protein	O
and	O
a	O
fibrillarin	O
-	O
green	O
fluorescent	O
protein	O
fusion	O
protein	O
colocalized	O
to	O
the	O
perinuclear	O
region	O
and	O
the	O
nucleolus	B-COMP
.	O

Coronaviruses	O
might	O
therefore	O
delay	O
the	O
cell	B-COMP
cycle	O
in	O
interphase	O
,	O
where	O
maximum	O
translation	O
of	O
viral	O
mRNAs	O
can	O
occur	O
.	O

This	O
article	O
will	O
review	O
these	O
studies	O
,	O
which	O
suggest	O
that	O
it	O
is	O
the	O
host	B-COMP
response	O
to	O
the	O
virus	O
and	O
not	O
the	O
virus	O
itself	O
that	O
plays	O
the	O
major	O
role	O
in	O
symptom	O
pathogenesis	O
.	O

Several	O
other	O
MHV	O
-	O
permissive	O
cell	B-COMP
lines	O
also	O
showed	O
activation	O
of	O
both	O
p38	O
MAPK	O
and	O
JNK	O
,	O
which	O
indicated	O
that	O
the	O
MHV	O
-	O
induced	O
stress	O
-	O
kinase	O
activation	O
was	O
not	O
restricted	O
to	O
any	O
particular	O
cell	B-COMP
type	I-COMP
.	O

Furthermore	O
,	O
MHV	O
production	O
was	O
suppressed	O
in	O
SB	O
203580	O
-	O
treated	O
cells	B-COMP
,	O
demonstrating	O
that	O
activated	O
p38	O
MAPK	O
played	O
a	O
role	O
in	O
MHV	O
replication	O
.	O

By	O
comparing	O
parental	O
TGEV	O
with	O
mutant	O
viruses	O
deficient	O
in	O
the	O
sialic	O
acid	O
binding	O
activity	O
,	O
we	O
determined	O
the	O
contributions	O
of	O
both	O
binding	O
activities	O
to	O
the	O
attachment	O
of	O
TGEV	O
to	O
cultured	O
cells	B-COMP
.	O

We	O
propose	O
that	O
binding	O
to	O
a	O
surface	O
sialoglycoprotein	O
is	O
required	O
for	O
TGEV	O
as	O
a	O
primary	O
attachment	O
site	O
to	O
initiate	O
infection	O
of	O
intestinal	O
cells	B-COMP
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
the	O
most	O
C	O
-	O
terminal	O
cleavage	O
product	O
of	O
the	O
1a	O
polyprotein	O
as	O
a	O
16	O
-	O
kDa	O
protein	O
in	O
infectious	O
bronchitis	O
virus	O
-	O
infected	O
Vero	O
cells	B-COMP
.	O

Peritoneal	O
fluid	O
analysis	O
revealed	O
a	O
sterile	O
plasma	O
ultrafiltrate	O
with	O
electrolyte	O
and	O
other	O
chemistries	O
reflecting	O
patient	O
serum	B-COMP
levels	O
.	O

Srr7A	O
and	O
srr7B	O
grew	O
2	O
log10	O
higher	O
than	O
srr7	O
and	O
induced	O
fusion	O
in	O
BHK	O
-	O
R2	O
cells	B-COMP
,	O
being	O
similar	O
to	O
wt	O
virus	O
.	O

Srr7A	O
and	O
srr7B	O
S	O
proteins	O
showed	O
high	O
fusogenicity	O
in	O
both	O
BHK	O
-	O
R1	O
and	O
BHK	O
-	O
R2	O
cells	B-COMP
,	O
like	O
the	O
wt	O
virus	O
,	O
while	O
srr7Aa	O
and	O
srr7Ba	O
S	O
proteins	O
,	O
which	O
had	O
mutations	O
in	O
S1N330	O
-	O
III	O
but	O
not	O
at	O
amino	O
acid	O
1114	O
,	O
exhibited	O
profoundly	O
reduced	O
fusion	O
activity	O
in	O
these	O
cell	B-COMP
lines	O
.	O

Unstable	O
spine	B-COMP
fractures	O
and	O
pelvic	O
external	O
fixators	O
were	O
the	O
only	O
contraindications	O
to	O
IPP	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
low	O
level	O
integrative	O
recombination	O
by	O
wild	O
-	O
type	O
integrase	O
is	O
stimulated	O
when	O
purified	O
integration	O
host	B-COMP
factor	O
is	O
co	O
-	O
transfected	O
.	O

This	O
corroborates	O
our	O
previous	O
conclusion	O
that	O
sufficient	O
amounts	O
of	O
eukaryotic	O
protein	O
co	O
-	O
factors	O
,	O
which	O
could	O
functionally	O
replace	O
IHF	O
,	O
are	O
not	O
present	O
in	O
human	O
cells	B-COMP
.	O

It	O
also	O
provides	O
a	O
potential	O
means	O
to	O
control	O
site	O
-	O
specific	O
recombination	O
in	O
eukaryotic	O
cells	B-COMP
.	O

In	O
infected	O
B	O
-	O
cell	B-COMP
-	O
deficient	O
mice	O
,	O
demyelination	O
not	O
only	O
occurred	O
but	O
was	O
also	O
more	O
severe	O
than	O
in	O
parental	O
C57BL	O
/	O
6	O
animals	O
.	O

In	O
mice	O
lacking	O
antibody	B-COMP
receptors	O
or	O
complement	O
pathway	O
activity	O
,	O
virus	O
did	O
not	O
persist	O
yet	O
demyelination	O
was	O
similar	O
to	O
parental	O
mice	O
.	O

Therefore	O
,	O
demyelination	O
can	O
occur	O
in	O
the	O
absence	O
of	O
B	O
and	O
T	O
cells	B-COMP
.	O

Escherichia	O
coli	O
isolates	O
were	O
characterized	O
on	O
the	O
basis	O
of	O
epithelial	O
cell	B-COMP
attachment	I-COMP
,	O
fluorescent	O
actin	O
staining	O
(	O
FAS	O
)	O
test	O
,	O
and	O
presence	O
of	O
E	O
.	O
coli	O
attaching	O
/	O
effacing	O
(	O
EAE	O
),	O
shigalike	O
toxin	O
(	O
SLT	O
)	O
type	O
I	O
,	O
SLT	O
II	O
,	O
and	O
bundle	O
-	O
forming	O
pilus	B-COMP
(	O
BFP	O
)	O
genes	O
by	O
polymerase	O
chain	O
reaction	O
procedures	O
.	O

The	O
remaining	O
two	O
isolates	O
,	O
N	O
-	O
M24	O
and	O
N	O
-	O
M39	O
,	O
that	O
did	O
not	O
react	O
with	O
Mass	O
-	O
specific	O
Mab	O
,	O
resisted	O
neutralization	O
by	O
Mass	O
-	O
specific	O
chicken	O
serum	B-COMP
,	O
and	O
were	O
neutralized	O
only	O
by	O
homologous	O
chicken	O
antibody	B-COMP
were	O
identified	O
as	O
non	O
-	O
Mass	O
IBV	O
.	O

Intestinal	O
sections	O
were	O
prepared	O
from	O
turkey	O
embryos	O
infected	O
with	O
different	O
TCV	O
isolates	O
and	O
reacted	O
with	O
polyclonal	O
or	O
monoclonal	O
antibodies	B-COMP
to	O
TCV	O
,	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
reovirus	O
,	O
rotavirus	O
,	O
adenovirus	O
,	O
or	O
enterovirus	O
in	O
immunofluorescent	O
antibody	B-COMP
staining	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
,	O
in	O
contrast	O
,	O
that	O
demyelination	O
and	O
lymphocyte	O
infiltration	O
were	O
increased	O
in	O
recipients	O
of	O
IFN	O
-	O
gamma	O
(-/-)	O
CD4	O
T	O
cells	B-COMP
when	O
compared	O
to	O
levels	O
in	O
mice	O
receiving	O
C57BL	O
/	O
6	O
CD4	O
T	O
cells	B-COMP
.	O

These	O
results	O
show	O
that	O
dietary	O
arginine	O
influences	O
the	O
character	O
of	O
the	O
chicken	O
cellular	B-COMP
response	O
to	O
IBV	O
and	O
the	O
distribution	O
of	O
responding	O
leukocyte	O
subpopulations	O
in	O
a	O
target	O
tissue	O
for	O
the	O
infection	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
:	O
chemokine	O
-	O
mediated	O
regulation	O
of	O
host	B-COMP
defense	O
and	O
disease	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
kinetics	O
and	O
magnitudes	O
of	O
specific	O
IgA	B-COMP
antibody	I-COMP
responses	O
in	O
intestines	O
of	O
turkey	O
poults	O
infected	O
with	O
turkey	O
coronavirus	O
(	O
TCV	O
).	O

Infection	O
of	O
immunosuppressed	O
mice	O
suggested	O
that	O
expression	O
of	O
most	O
MMP	O
,	O
TIMP	O
,	O
and	O
chemokine	O
mRNA	O
was	O
induced	O
primarily	O
in	O
CNS	O
-	O
resident	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
OBJECTIVE	O
To	O
investigate	O
the	O
expression	O
and	O
pathogenic	O
role	O
of	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
in	O
human	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
METHODS	O
The	O
serum	B-COMP
level	O
of	O
MIF	O
in	O
ARDS	O
patients	O
and	O
normal	O
persons	O
were	O
measured	O
by	O
ELISA	O
method	O
.	O

One	O
possibility	O
is	O
that	O
T	O
cells	B-COMP
specific	O
for	O
the	O
inciting	O
microbial	O
pathogen	O
are	O
able	O
to	O
effect	O
demyelination	O
at	O
a	O
site	O
of	O
ongoing	O
inflammation	O
within	O
the	O
CNS	O
.	O

Eleven	O
percent	O
of	O
cattle	O
had	O
antibody	B-COMP
titers	O
against	O
BCV	O
at	O
0	O
DPA	O
and	O
91	O
%	O
of	O
cattle	O
seroconverted	O
to	O
BCV	O
by	O
21	O
DPA	O
.	O

Twenty	O
-	O
eight	O
respiratory	O
and	O
7	O
enteric	O
BCV	O
strains	O
were	O
isolated	O
from	O
nasal	O
and	O
fetal	O
samples	O
of	O
32	O
cattle	O
in	O
HRT	O
-	O
18	O
cell	B-COMP
cultures	O
.	O

Lung	O
injury	O
,	O
quantitated	O
by	O
measuring	O
lung	O
myeloperoxidase	O
activity	O
(	O
an	O
indicator	O
of	O
neutrophil	O
sequestration	O
),	O
alveolar	O
-	O
capillary	O
permeability	O
,	O
and	O
alveolar	O
membrane	B-COMP
thickness	O
was	O
less	O
severe	O
in	O
GM	O
-	O
CSF	O
-/-	O
than	O
in	O
GM	O
-	O
CSF	O
+/+	O
mice	O
.	O

Administration	O
of	O
anti	O
-	O
MIP	O
-	O
2	O
antibodies	B-COMP
was	O
found	O
to	O
reduce	O
the	O
severity	O
of	O
pancreatitis	O
-	O
associated	O
ALI	O
.	O

The	O
results	O
confirm	O
that	O
T	O
-	O
cell	B-COMP
-	O
helper	O
function	O
,	O
assessed	O
by	O
lymphocyte	O
proliferation	O
responses	O
,	O
contributes	O
to	O
establishing	O
a	O
protective	O
immune	O
response	O
against	O
PEDV	O
infections	O
.	O

AMPhi	O
were	O
harvested	O
,	O
and	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	O
)-	O
2	O
release	O
and	O
serum	B-COMP
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
levels	O
were	O
measured	O
at	O
5	O
h	O
after	O
HCLP	O
.	O

Extensive	O
antigen	O
staining	O
in	O
the	O
cytoplasm	B-COMP
of	O
epithelial	O
cells	B-COMP
in	O
the	O
trachea	O
,	O
lung	O
,	O
bursa	O
,	O
and	O
intestine	O
was	O
detected	O
at	O
2	O
dpi	O
with	O
all	O
8	O
strains	O
of	O
IBV	O
.	O

The	O
cuprizone	O
neurotoxicant	O
model	O
causes	O
extensive	O
corpus	O
callosum	O
demyelination	O
without	O
a	O
lymphocytic	O
cell	B-COMP
response	O
.	O

Lung	O
myeloperoxidase	O
activity	O
,	O
18FDG	O
,	O
and	O
peripheral	O
white	O
blood	O
cells	B-COMP
all	O
significantly	O
increased	O
in	O
both	O
mild	O
and	O
severe	O
pancreatitis	O
,	O
but	O
lung	O
fMLFK	O
only	O
increased	O
in	O
severe	O
pancreatitis	O
.	O

ABSTRACT	O
:	O
Ischemic	O
optic	O
neuropathy	O
is	O
a	O
rare	O
cause	O
of	O
blindness	O
reported	O
most	O
commonly	O
in	O
association	O
with	O
collagen	B-COMP
-	O
vascular	O
diseases	O
,	O
infectious	O
processes	O
,	O
and	O
systemic	O
hypotension	O
related	O
to	O
massive	O
exsanguinating	O
hemorrhage	O
.	O

Our	O
findings	O
suggest	O
that	O
PSAGN	O
complicating	O
pre	O
-	O
existing	O
IgA	O
-	O
N	O
activates	O
cellular	B-COMP
immunity	O
and	O
augments	O
renal	O
tissue	O
injury	O
.	O

These	O
cells	B-COMP
,	O
but	O
not	O
conventional	O
CD4	O
or	O
CD8	O
alpha	O
beta	O
T	O
cells	B-COMP
,	O
were	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
of	O
MHV	O
-	O
infected	O
nude	O
mice	O
and	O
their	O
depletion	O
with	O
neutralizing	O
antibody	B-COMP
resulted	O
in	O
an	O
80	O
%	O
reduction	O
in	O
demyelination	O
.	O

Postmortem	O
tissues	O
were	O
stained	O
using	O
the	O
Verhoeff	O
-	O
Van	O
Gieson	O
procedure	O
for	O
elastic	B-COMP
fibers	I-COMP
,	O
and	O
with	O
Congo	O
red	O
for	O
examination	O
under	O
a	O
polarizing	O
microscope	O
.	O

MVM	O
virions	B-COMP
were	O
strongly	O
retained	O
by	O
the	O
20	O
-	O
nm	O
filters	O
;	O
however	O
,	O
the	O
virus	O
was	O
still	O
detectable	O
in	O
the	O
filtrate	O
.	O

The	O
PCR	O
products	O
were	O
cloned	O
and	O
sequenced	O
and	O
their	O
nucleic	B-COMP
acid	O
structure	O
and	O
similarity	O
to	O
the	O
published	O
sequences	O
of	O
IBV	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
Replication	O
-	O
competent	O
propagation	O
-	O
deficient	O
virus	O
vectors	O
based	O
on	O
the	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
genome	O
that	O
are	O
deficient	O
in	O
the	O
essential	O
E	O
gene	O
have	O
been	O
developed	O
by	O
complementation	O
within	O
E	O
(+)	O
packaging	O
cell	B-COMP
lines	O
.	O

In	O
addition	O
,	O
cell	B-COMP
lines	O
stably	O
expressing	O
the	O
E	O
gene	O
under	O
the	O
CMV	O
promoter	O
have	O
been	O
developed	O
.	O

The	O
kinetics	O
and	O
distribution	O
of	O
TUNEL	O
staining	O
correlated	O
with	O
the	O
pathologic	O
damage	O
and	O
colocalized	O
with	O
viral	O
antigen	O
in	O
some	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
The	O
most	O
frequent	O
manifestations	O
of	O
heteroplasmic	O
mitochondrial	B-COMP
DNA	I-COMP
(	O
mtDNA	B-COMP
)	O
mutation	O
8993	O
T	O
>	O
G	O
are	O
Leigh	O
syndrome	O
or	O
NARP	O
syndrome	O
(	O
Neurogenic	O
Muscle	O
Weakness	O
,	O
Ataxia	O
,	O
and	O
Retinitis	O
Pigmentosa	O
).	O

A	O
cl	O
-	O
2	O
mutant	O
,	O
srr7	O
,	O
of	O
the	O
MHV	O
JHM	O
virus	O
(	O
JHMV	O
)	O
was	O
digested	O
with	O
proteinase	O
K	O
after	O
treatment	O
with	O
soMHVR	O
,	O
and	O
the	O
resultant	O
S	O
protein	O
was	O
analyzed	O
by	O
Western	O
blotting	O
using	O
monoclonal	O
antibody	B-COMP
(	O
MAb	O
)	O
10G	O
,	O
specific	O
for	O
the	O
membrane	B-COMP
-	O
anchored	O
S2	O
subunit	O
.	O

In	O
our	O
country	O
diagnosis	O
is	O
made	O
using	O
the	O
complement	O
fixation	O
test	O
(	O
CFT	O
),	O
which	O
detects	O
antibodies	B-COMP
due	O
to	O
soluble	O
group	O
specific	O
antigen	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
-	O
induced	O
apoptosis	O
in	O
17Cl	O
-	O
1	O
cells	B-COMP
involves	O
a	O
mitochondria	B-COMP
-	O
mediated	O
pathway	O
and	O
its	O
downstream	O
caspase	O
-	O
8	O
activation	O
and	O
bid	O
cleavage	O
.	O

Activation	O
of	O
the	O
mitochondria	B-COMP
-	O
mediated	O
apoptotic	O
pathway	O
was	O
indicated	O
by	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
delay	O
of	O
apoptosis	O
by	O
Bcl	O
-	O
2	O
overexpression	O
.	O

Collectively	O
these	O
results	O
demonstrate	O
that	O
CCR5	O
signaling	O
is	O
important	O
to	O
migration	O
of	O
CD4	O
(+)	O
T	O
cells	B-COMP
to	O
the	O
CNS	O
following	O
MHV	O
infection	O
.	O

To	O
further	O
characterize	O
the	O
function	O
of	O
PTB	O
in	O
MHV	O
replication	O
,	O
we	O
generated	O
dominant	O
-	O
negative	O
mutant	O
cell	B-COMP
lines	O
that	O
express	O
a	O
full	O
-	O
length	O
PTB	O
or	O
a	O
truncated	O
form	O
of	O
PTB	O
,	O
which	O
includes	O
only	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
,	O
retaining	O
its	O
protein	O
-	O
dimerization	O
domain	O
.	O

To	O
clarify	O
the	O
precise	O
function	O
of	O
PTB	O
in	O
MHV	O
replication	O
,	O
we	O
dissociated	O
the	O
processes	O
of	O
viral	O
transcription	O
from	O
translation	O
by	O
transfecting	O
different	O
types	O
of	O
MHV	O
defective	O
-	O
interfering	O
(	O
DI	O
)	O
RNA	O
that	O
contain	O
various	O
reporter	O
genes	O
into	O
these	O
stable	O
cell	B-COMP
lines	O
.	O

In	O
contrast	O
,	O
translation	O
of	O
the	O
DI	O
RNA	O
was	O
not	O
affected	O
by	O
PTB	O
depletion	O
in	O
in	O
vitro	O
translation	O
in	O
rabbit	O
reticulocyte	O
lysate	O
or	O
by	O
PTB	O
overexpression	O
in	O
in	O
vivo	O
translation	O
experiments	O
in	O
MHV	O
-	O
infected	O
cells	B-COMP
.	O

We	O
have	O
previously	O
characterized	O
a	O
novel	O
transgenic	O
(	O
Tg	O
)	O
mouse	O
on	O
the	O
IL	O
-	O
2Rbeta	O
-/-	O
genetic	O
background	O
(	O
Tg	O
-/-	O
mice	O
)	O
that	O
lacks	O
autoimmune	O
disease	O
but	O
still	O
contains	O
peripheral	O
T	O
cells	B-COMP
that	O
are	O
nonresponsive	O
to	O
IL	O
-	O
2	O
and	O
IL	O
-	O
15	O
.	O

Receptor	O
binding	O
induced	O
a	O
profound	O
,	O
apparently	O
irreversible	O
conformational	O
change	O
in	O
S	O
on	O
the	O
viral	B-COMP
envelope	I-COMP
that	O
allowed	O
S2	O
,	O
but	O
not	O
S1	O
,	O
to	O
be	O
degraded	O
by	O
trypsin	O
at	O
4	O
degrees	O
C	O
.	O
Various	O
murine	O
CEACAM	O
proteins	O
triggered	O
conformational	O
changes	O
in	O
S	O
on	O
recombinant	O
MHV	O
strains	O
expressing	O
S	O
glycoproteins	O
of	O
MHV	O
-	O
A59	O
or	O
MHV	O
-	O
4	O
(	O
MHV	O
-	O
JHM	O
)	O
with	O
the	O
same	O
specificities	O
as	O
seen	O
for	O
virus	O
neutralization	O
and	O
virus	O
-	O
receptor	O
activities	O
.	O

In	O
the	O
second	O
assay	O
,	O
which	O
requires	O
virus	O
entry	O
and	O
replication	O
,	O
all	O
recombinant	O
viruses	O
replicated	O
efficiently	O
in	O
BHK	O
cells	B-COMP
expressing	O
mCEACAM1	O
(	O
a	O
).	O

In	O
this	O
instance	O
,	O
lesions	O
develop	O
from	O
the	O
axon	B-COMP
(	O
inside	O
)	O
to	O
the	O
myelin	B-COMP
(	O
outside	O
)	O
(	O
Inside	O
-	O
Out	O
model	O
).	O

TITLE	O
:	O
STAT1	O
and	O
STAT3	O
alpha	O
/	O
beta	O
splice	O
form	O
activation	O
predicts	O
host	B-COMP
responses	O
in	O
mouse	O
hepatitis	O
virus	O
type	O
3	O
infection	O
.	O

Treatment	O
of	O
sensitive	O
Balb	O
/	O
cJ	O
mice	O
with	O
neutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
antibody	B-COMP
could	O
increase	O
the	O
STAT1	O
alpha	O
/	O
beta	O
ratio	O
to	O
<	O
1	O
.	O
0	O
in	O
spleens	O
,	O
predicting	O
enhanced	O
rates	O
of	O
survival	O
.	O

TITLE	O
:	O
Role	O
of	O
viruses	O
and	O
atypical	O
bacteria	O
in	O
exacerbations	O
of	O
asthma	O
in	O
hospitalized	O
children	O
:	O
a	O
prospective	O
study	O
in	O
the	O
Nord	O
-	O
Pas	B-COMP
de	O
Calais	O
region	O
(	O
France	O
).	O

A	O
51Cr	O
-	O
cytolytic	O
release	O
assay	O
was	O
used	O
to	O
determine	O
the	O
activity	O
of	O
the	O
NK	O
cells	B-COMP
harvested	O
via	O
lung	O
lavage	O
from	O
the	O
respiratory	O
tracts	O
of	O
infected	O
chickens	O
.	O

Neonatally	O
thymectomized	O
CBA	O
/	O
J	O
mice	O
infected	O
with	O
1	O
x	O
10	O
(	O
7	O
)	O
pfu	O
(	O
ARDS	O
)	O
reovirus	O
1	O
/	O
L	O
still	O
develop	O
the	O
hallmark	O
characteristics	O
of	O
ARDS	O
,	O
including	O
a	O
severe	O
viral	O
pneumonia	O
with	O
cellular	B-COMP
infiltrates	O
comprised	O
mainly	O
of	O
macrophages	O
and	O
neutrophils	O
,	O
hyaline	O
membrane	B-COMP
formation	O
,	O
and	O
hemorrhage	O
during	O
the	O
acute	O
phase	O
of	O
the	O
disease	O
and	O
persistent	O
intra	O
-	O
alveolar	O
fibrosis	O
during	O
the	O
chronic	O
phase	O
of	O
the	O
disease	O
.	O

S	O
proteins	O
that	O
contain	O
the	O
N	O
-	O
terminal	O
268	O
or	O
417	O
amino	O
acids	O
did	O
not	O
bind	O
to	O
hAPN	O
-	O
3T3	O
cells	B-COMP
.	O

These	O
data	O
not	O
only	O
confirm	O
direct	O
antiviral	O
activity	O
of	O
IFN	O
-	O
gamma	O
within	O
the	O
CNS	O
but	O
also	O
demonstrate	O
IFN	O
-	O
gamma	O
-	O
dependent	O
MHC	O
surface	O
expression	O
to	O
guarantee	O
local	O
T	O
cell	B-COMP
effector	O
function	O
in	O
tissues	O
inherently	O
low	O
in	O
MHC	O
expression	O
.	O

ABSTRACT	O
:	O
Neutrophils	O
are	O
the	O
first	O
infiltrating	O
cell	B-COMP
population	O
to	O
appear	O
within	O
the	O
CNS	O
during	O
infection	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
).	O

This	O
happened	O
at	O
a	O
younger	O
age	O
among	O
the	O
more	O
heavily	O
infected	O
sculpins	O
at	O
Torbjørnskjaer	O
than	O
at	O
Vega	O
,	O
and	O
we	O
interpret	O
this	O
as	O
density	O
dependence	O
in	O
the	O
fish	O
host	B-COMP
.	O

TITLE	O
:	O
CC	O
chemokine	O
ligand	O
3	O
(	O
CCL3	O
)	O
regulates	O
CD8	O
(+)-	O
T	O
-	O
cell	B-COMP
effector	O
function	O
and	O
migration	O
following	O
viral	O
infection	O
.	O

Moreover	O
,	O
these	O
molecules	O
also	O
regulate	O
T	O
-	O
cell	B-COMP
activation	O
and	O
differentiation	O
following	O
antigenic	O
stimulation	O
.	O

CCL3	O
(-/-)	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
exhibited	O
a	O
significant	O
reduction	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
within	O
the	O
CNS	O
,	O
correlating	O
with	O
delayed	O
viral	O
clearance	O
.	O

We	O
could	O
not	O
detect	O
serum	B-COMP
antibodies	B-COMP
to	O
MHV	O
and	O
isolate	O
Pasteurella	O
pneumotropica	O
in	O
the	O
progeny	O
mice	O
,	O
suggesting	O
that	O
cross	O
-	O
contamination	O
between	O
tubes	O
in	O
a	O
liquid	O
nitrogen	O
tank	O
scarcely	O
occurs	O
.	O

Memory	O
immune	O
T	O
cells	B-COMP
collected	O
at	O
3	O
to	O
6	O
weeks	O
p	O
.	O
i	O
.	O

The	O
greatest	O
protection	O
was	O
observed	O
after	O
the	O
transfer	O
of	O
10	O
(	O
7	O
)	O
T	O
cells	B-COMP
collected	O
at	O
6	O
weeks	O
p	O
.	O
i	O
.,	O
whereas	O
T	O
cells	B-COMP
collected	O
at	O
2	O
weeks	O
p	O
.	O
i	O
.	O

Observation	O
with	O
electron	O
microscope	O
revealed	O
injuries	O
to	O
type	O
II	O
alveolar	O
epithelial	O
cells	B-COMP
,	O
broadened	O
respiratory	O
mucosa	O
,	O
and	O
platelet	O
adherence	O
.	O

In	O
a	O
second	O
,	O
reverse	O
process	O
,	O
mFIPV	O
was	O
used	O
as	O
the	O
recipient	O
,	O
and	O
the	O
reintroduction	O
of	O
the	O
FIPV	O
spike	O
now	O
allowed	O
for	O
selection	O
of	O
candidate	O
recombinants	O
by	O
their	O
regained	O
ability	O
to	O
grow	O
in	O
feline	O
cells	B-COMP
.	O

While	O
its	O
precise	O
function	O
is	O
not	O
clearly	O
defined	O
,	O
E	O
is	O
a	O
pivotal	O
player	O
in	O
the	O
morphogenesis	O
of	O
the	O
virion	B-COMP
envelope	B-COMP
.	O

TITLE	O
:	O
Control	O
of	O
central	O
nervous	O
system	O
viral	O
persistence	O
by	O
neutralizing	O
antibody	B-COMP
.	O

These	O
data	O
indicate	O
that	O
following	O
acute	O
viral	O
clearance	O
cellular	B-COMP
immunity	O
is	O
ineffective	O
in	O
controlling	O
virus	O
recrudescence	O
and	O
suggest	O
that	O
the	O
continued	O
presence	O
of	O
neutralizing	O
Ab	O
is	O
the	O
essential	O
effector	O
in	O
maintaining	O
viral	O
persistence	O
within	O
the	O
central	O
nervous	O
system	O
.	O

By	O
using	O
animal	O
models	O
of	O
chronic	O
ethanol	O
ingestion	O
,	O
researchers	O
have	O
identified	O
alcohol	O
-	O
mediated	O
alterations	O
in	O
epithelial	O
and	O
endothelial	O
cell	B-COMP
function	O
,	O
surfactant	O
synthesis	O
and	O
secretion	O
,	O
alveolar	O
-	O
capillary	O
barrier	O
function	O
,	O
and	O
lung	O
matrix	O
content	O
and	O
composition	O
.	O

Clinical	O
specimens	O
from	O
patients	O
with	O
SARS	O
were	O
searched	O
for	O
unknown	O
viruses	O
with	O
the	O
use	O
of	O
cell	B-COMP
cultures	O
and	O
molecular	O
techniques	O
.	O

The	O
virus	O
was	O
isolated	O
in	O
cell	B-COMP
culture	O
,	O
and	O
a	O
sequence	O
300	O
nucleotides	O
in	O
length	O
was	O
obtained	O
by	O
a	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
PCR	O
)-	O
based	O
random	O
-	O
amplification	O
procedure	O
.	O

Paired	O
serum	B-COMP
samples	O
obtained	O
from	O
blood	O
collected	O
on	O
days	O
0	O
and	O
35	O
were	O
analyzed	O
for	O
BoTV	O
antibodies	B-COMP
with	O
a	O
hemagglutination	O
inhibition	O
assay	O
.	O

Though	O
acute	O
graft	O
-	O
versus	O
-	O
host	B-COMP
disease	O
(	O
GVHD	O
)	O
of	O
systemic	O
skin	O
(	O
grade	O
II	O
)	O
and	O
pneumonia	O
were	O
observed	O
during	O
neutropenia	O
due	O
to	O
the	O
post	O
-	O
conditioning	O
regimen	O
,	O
he	O
could	O
be	O
discharged	O
from	O
our	O
hospital	O
on	O
the	O
135th	O
day	O
after	O
BMT	O
.	O

ABSTRACT	O
:	O
The	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
of	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
was	O
cloned	O
and	O
expressed	O
in	O
E	O
.	O
coli	O
.	O

Morphological	O
changes	O
identified	O
were	O
bronchial	O
epithelial	O
denudation	O
,	O
loss	O
of	O
cilia	B-COMP
,	O
and	O
squamous	O
metaplasia	O
.	O

The	O
transmembrane	B-COMP
(	O
TM	O
)	O
segment	O
of	O
the	O
SARS	O
E	O
protein	O
is	O
relatively	O
more	O
conserved	O
in	O
the	O
whole	O
protein	O
than	O
other	O
regions	O
.	O

FAV	O
antibody	B-COMP
ELISA	O
confirmed	O
that	O
maternal	O
antibody	B-COMP
directed	O
against	O
inclusion	B-COMP
body	I-COMP
hepatitis	O
(	O
serotype	O
8	O
)	O
had	O
decayed	O
in	O
control	O
birds	O
and	O
that	O
FAV	O
specific	O
serum	B-COMP
IgG	O
responses	O
were	O
produced	O
in	O
vaccinated	O
birds	O
at	O
the	O
time	O
of	O
challenge	O
.	O

In	O
this	O
study	O
,	O
the	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
of	O
the	O
amino	O
terminal	O
half	O
of	O
the	O
S	O
glycoprotein	O
gene	O
of	O
one	O
Korean	O
field	O
TGEV	O
strain	O
(	O
133	O
)	O
isolated	O
in	O
1997	O
and	O
three	O
Korean	O
field	O
TGEV	O
strains	O
(	O
KT2	O
,	O
KT3	O
and	O
KT4	O
)	O
isolated	O
in	O
2000	O
and	O
HKT2	O
strain	O
,	O
KT2	O
passaged	O
104	O
times	O
in	O
ST	O
cells	B-COMP
,	O
were	O
determined	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
an	O
antioxidant	O
,	O
such	O
as	O
N	O
-	O
acetylcysteine	O
(	O
NAC	B-COMP
),	O
has	O
any	O
protective	O
effect	O
.	O

Feeding	O
of	O
single	O
dose	O
of	O
NAC	B-COMP
(	O
0	O
.	O
5	O
g	O
)	O
by	O
gavage	O
just	O
before	O
the	O
CEES	O
infusion	O
was	O
ineffective	O
to	O
counteract	O
these	O
effects	O
.	O

Low	O
counts	O
of	O
CD4	O
and	O
CD8	O
cells	B-COMP
at	O
presentation	O
were	O
associated	O
with	O
adverse	O
outcomes	O
.	O

The	O
following	O
factors	O
were	O
associated	O
with	O
a	O
significantly	O
higher	O
mortality	O
rate	O
in	O
the	O
SARS	O
with	O
ARDS	O
patients	O
,	O
including	O
age	O
increase	O
(	O
OR	O
=	O
1	O
.	O
203	O
,	O
CI	O
=	O
1	O
.	O
036	O
to	O
1	O
.	O
396	O
,	O
P	O
=	O
0	O
.	O
016	O
),	O
long	O
-	O
time	O
hypoxia	O
(	O
OR	O
=	O
1	O
.	O
067	O
,	O
CI	O
=	O
1	O
.	O
014	O
to	O
1	O
.	O
122	O
,	O
P	O
=	O
0	O
.	O
013	O
),	O
thrombocytopenia	O
(	O
OR	O
=	O
111	O
.	O
932	O
,	O
CI	O
=	O
6	O
.	O
096	O
to	O
2	O
055	O
.	O
252	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
hypernatremia	O
(	O
OR	O
=	O
26	O
.	O
667	O
,	O
CI	O
=	O
2	O
.	O
242	O
to	O
317	O
.	O
147	O
,	O
P	O
=	O
0	O
.	O
009	O
),	O
and	O
elevation	O
of	O
serum	B-COMP
creatinine	O
levels	O
(	O
OR	O
=	O
111	O
.	O
932	O
,	O
CI	O
=	O
6	O
.	O
096	O
to	O
2	O
055	O
.	O
252	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

Electron	O
microscopy	O
demonstrated	O
clusters	O
of	O
viral	B-COMP
particles	I-COMP
,	O
consistent	O
with	O
coronavirus	O
,	O
in	O
lung	O
tissue	O
.	O

TITLE	O
:	O
Identification	O
of	O
an	O
epitope	O
of	O
SARS	O
-	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
.	O

After	O
immunization	O
with	O
two	O
peptides	O
,	O
the	O
peptides	O
-	O
specific	O
antibodies	B-COMP
were	O
isolated	O
from	O
the	O
immunized	O
rabbits	O
.	O

The	O
serum	B-COMP
levels	O
of	O
IgM	O
and	O
IgG	O
antibodies	B-COMP
to	O
N	O
antigen	O
were	O
measured	O
in	O
200	O
healthy	O
blood	O
donors	O
and	O
13	O
SARS	O
patients	O
at	O
different	O
time	O
points	O
of	O
acute	O
and	O
convalescent	O
phases	O
using	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
N	O
fusion	O
proteins	O
of	O
SARS	O
-	O
associated	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
rapid	O
and	O
efficient	O
method	O
for	O
preparing	O
monoclonal	O
antibodies	B-COMP
(	O
mAb	O
)	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
Cov	O
)	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
.	O

The	O
identification	O
of	O
the	O
mAb	O
against	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
Cov	O
was	O
performed	O
using	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
indirect	O
fluorescent	O
-	O
antibody	B-COMP
assay	O
(	O
IFA	O
),	O
and	O
Western	O
immunoblotting	O
.	O

The	O
Salmonella	O
spiC	O
promoter	O
construct	O
induced	O
the	O
highest	O
level	O
of	O
chimeric	O
fimbriae	B-COMP
after	O
being	O
taken	O
up	O
by	O
the	O
J774A	O
.	O
1	O
macrophagelike	O
cells	B-COMP
.	O

In	O
contrast	O
,	O
its	O
isogenic	O
pgtE	O
mutant	O
produced	O
fimbriae	B-COMP
consisting	O
exclusively	O
of	O
intact	O
chimeric	O
subunits	O
.	O

Mice	O
immunized	O
orally	O
with	O
the	O
Salmonella	O
pgtE	O
vaccine	O
expressing	O
chimeric	O
fimbriae	B-COMP
from	O
the	O
spiC	O
promoter	O
elicited	O
significantly	O
higher	O
systemic	O
and	O
mucosal	O
antibody	B-COMP
titers	O
against	O
the	O
TGEV	O
epitopes	O
compared	O
to	O
the	O
parental	O
vaccine	O
.	O

The	O
damage	O
of	O
cellular	B-COMP
immunity	O
is	O
probably	O
an	O
important	O
mechanism	O
of	O
pathogenesis	O
of	O
SARS	O
.	O

TITLE	O
:	O
Acute	O
Chest	O
Syndrome	O
:	O
the	O
role	O
of	O
erythro	O
-	O
exchange	O
in	O
patients	O
with	O
sickle	O
cell	B-COMP
disease	O
in	O
Sicily	O
.	O

ABSTRACT	O
:	O
Gefitinib	O
is	O
a	O
potent	O
drug	O
used	O
in	O
the	O
treatment	O
of	O
nonsmall	O
-	O
cell	B-COMP
lung	O
cancer	O
(	O
NSCLC	O
).	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
early	O
and	O
long	O
-	O
term	O
results	O
after	O
mitral	O
valve	O
replacement	O
for	O
rheumatic	O
valvular	O
disease	O
by	O
using	O
home	O
-	O
made	O
tilting	O
disc	B-COMP
valve	O
,	O
and	O
the	O
determinant	O
factors	O
involved	O
and	O
subsequent	O
therapies	O
.	O

One	O
hundred	O
and	O
five	O
patients	O
,	O
including	O
31	O
patients	O
with	O
rheumatic	O
mitral	O
stenosis	O
,	O
92	O
patients	O
with	O
mixed	O
mitral	O
stenosis	O
and	O
regurgitation	O
,	O
and	O
2	O
patients	O
with	O
bacterial	O
endocarditis	O
,	O
underwent	O
prosthetic	O
mitral	O
valve	O
replacement	O
with	O
home	O
-	O
made	O
tilting	O
disc	B-COMP
valve	O
from	O
September	O
1978	O
to	O
June	O
1982	O
.	O

Infectious	O
virons	O
entered	O
cells	B-COMP
by	O
endocytosis	O
or	O
membrane	B-COMP
fusion	O
and	O
released	O
through	O
a	O
budding	O
process	O
.	O

BeauR	O
-	O
M41	O
(	O
S	O
)	O
acquired	O
the	O
same	O
cell	B-COMP
tropism	O
phenotype	O
as	O
IBV	O
M41	O
-	O
CK	O
in	O
four	O
different	O
cell	B-COMP
types	O
,	O
demonstrating	O
that	O
the	O
IBV	O
spike	O
glycoprotein	O
is	O
a	O
determinant	O
of	O
cell	B-COMP
tropism	O
.	O

The	O
agents	O
in	O
the	O
organs	O
and	O
cell	B-COMP
cultures	O
were	O
revealed	O
by	O
immunoassay	O
.	O

Common	O
laboratory	O
findings	O
were	O
lymphopenia	O
,	O
and	O
elevated	O
serum	B-COMP
levels	O
of	O
lactate	O
dehydrogenase	O
and	O
C	O
-	O
reactive	O
protein	O
.	O

Both	O
serum	B-COMP
IL	O
and	O
CD	O
are	O
associated	O
with	O
injury	O
of	O
immune	O
function	O
,	O
and	O
thus	O
they	O
could	O
be	O
regarded	O
as	O
a	O
monitoring	O
index	O
for	O
judging	O
the	O
condition	O
of	O
SARS	O
patients	O
and	O
prescribing	O
immune	O
therapy	O
.	O

Published	O
experience	O
in	O
adults	O
suggests	O
that	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
successfully	O
support	O
trauma	O
victims	O
with	O
pulmonary	O
failure	O
.	O

63	O
,	O
78	O
,	O
98	O
,	O
160	O
and	O
164	O
kD	O
fusion	O
proteins	O
were	O
successfully	O
expressed	O
with	O
amounts	O
of	O
35	O
%,	O
34	O
%,	O
24	O
%,	O
17	O
%	O
and	O
5	O
%	O
of	O
total	O
cell	B-COMP
protein	O
.	O

TITLE	O
:	O
[	O
Serum	B-COMP
antibodies	B-COMP
detection	O
for	O
serological	O
diagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

The	O
results	O
show	O
that	O
the	O
presence	O
of	O
a	O
host	B-COMP
response	O
to	O
this	O
second	O
epitope	O
protected	O
mice	O
against	O
CTL	O
escape	O
at	O
the	O
immunodominant	O
JHM	O
-	O
specific	O
CD8	O
T	O
cell	B-COMP
epitope	O
,	O
the	O
persistence	O
of	O
infectious	O
virus	O
,	O
and	O
the	O
development	O
of	O
clinical	O
disease	O
.	O

Serum	B-COMP
antibody	B-COMP
was	O
not	O
detected	O
until	O
on	O
the	O
9th	O
day	O
of	O
the	O
course	O
of	O
illness	O
;	O
CT	O
is	O
a	O
more	O
sensitive	O
method	O
for	O
detection	O
of	O
the	O
abnormal	O
chest	O
radiographs	O
than	O
regular	O
X	O
-	O
ray	O
test	O
.	O

The	O
plasma	O
levels	O
of	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	B-COMP
antibody	I-COMP
of	O
57	O
normal	O
subjects	O
,	O
127	O
physicians	O
and	O
nurses	O
worked	O
in	O
SARS	O
wards	O
for	O
one	O
month	O
and	O
73	O
SARS	O
patients	O
with	O
different	O
course	O
of	O
SARS	O
were	O
measured	O
by	O
enzyme	O
linked	O
immunosorbent	O
assay	O
.	O

CONCLUSIONS	O
:	O
The	O
specificity	O
and	O
sensitivity	O
of	O
ELISA	O
to	O
detect	O
plasma	O
anti	O
-	O
SARS	O
IgG	B-COMP
antibody	I-COMP
were	O
satisfactory	O
.	O

Limitin	O
inhibited	O
not	O
only	O
cytopathic	O
effects	O
in	O
encephalomyocarditis	O
virus	O
-	O
or	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
type	O
1	O
-	O
infected	O
L929	O
cells	B-COMP
,	O
but	O
also	O
plaque	O
formation	O
in	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
type	O
2	O
-	O
infected	O
DBT	O
cells	B-COMP
.	O

The	O
clinical	O
presentation	O
,	O
chest	O
radiographs	O
,	O
white	O
blood	O
cell	B-COMP
count	O
and	O
outcome	O
of	O
45	O
SARS	O
patients	O
from	O
April	O
5	O
to	O
20	O
2003	O
were	O
compared	O
,	O
with	O
those	O
of	O
80	O
CAP	O
patients	O
from	O
October	O
1	O
2002	O
to	O
April	O
1	O
2003	O
in	O
our	O
hospital	O
,	O
and	O
the	O
clinical	O
features	O
of	O
SARS	O
were	O
summarized	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
M	O
protein	O
,	O
the	O
most	O
abundant	O
coronaviral	O
envelope	B-COMP
component	O
,	O
is	O
invariably	O
glycosylated	O
,	O
which	O
provides	O
the	O
virion	B-COMP
with	O
a	O
diffuse	O
,	O
hydrophilic	O
cover	O
on	O
its	O
outer	O
surface	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
the	O
M	O
protein	O
glycosylation	O
in	O
the	O
host	B-COMP
,	O
two	O
genetically	O
modified	O
MHVs	O
were	O
generated	O
by	O
using	O
targeted	O
RNA	O
recombination	O
.	O

However	O
,	O
it	O
affected	O
their	O
interferogenic	O
capacity	O
as	O
measured	O
using	O
fixed	O
,	O
virus	O
-	O
infected	O
cells	B-COMP
.	O

T	O
cells	B-COMP
participate	O
in	O
both	O
defense	O
and	O
disease	O
progression	O
following	O
MHV	O
infection	O
.	O

The	O
apoptotic	O
cells	B-COMP
included	O
pneumocytes	O
,	O
lymphocytes	O
and	O
monocytes	O
,	O
and	O
CD68	O
+	O
monocytes	O
were	O
observed	O
in	O
abundance	O
in	O
the	O
lung	O
,	O
spleen	O
and	O
lymph	O
nodes	O
of	O
SARS	O
patients	O
.	O

Specimens	O
of	O
the	O
lungs	O
,	O
spleens	O
and	O
lymph	O
nodes	O
were	O
obtained	O
from	O
autopsy	O
of	O
3	O
SARS	O
cases	O
to	O
investigate	O
the	O
expression	O
of	O
the	O
immune	O
cells	B-COMP
and	O
their	O
activities	O
with	O
double	O
immunohistochemical	O
staining	O
(	O
DAB	O
and	O
AP	O
)	O
by	O
using	O
14	O
immune	O
cell	B-COMP
markers	O
and	O
their	O
active	O
antigens	O
.	O

Six	O
hours	O
after	O
CVVH	O
,	O
serum	B-COMP
concentration	O
of	O
endotoxin	O
was	O
decreased	O
significantly	O
.	O

Nsp9	O
crystals	O
diffract	O
to	O
2	O
.	O
8	O
A	O
resolution	O
and	O
belong	O
to	O
space	O
group	O
P6	O
(	O
1	O
/	O
5	O
)	O
22	O
,	O
with	O
unit	O
-	O
cell	B-COMP
parameters	O
a	O
=	O
b	O
=	O
89	O
.	O
7	O
,	O
c	O
=	O
136	O
.	O
7	O
A	O
.	O
With	O
two	O
molecules	O
in	O
the	O
asymmetric	O
unit	O
,	O
the	O
solvent	O
content	O
is	O
60	O
%	O
(	O
V	O
(	O
M	O
)	O
=	O
3	O
.	O
1	O
A	O
(	O
3	O
)	O
Da	O
(-	O
1	O
)).	O

Vero	O
-	O
E6	O
cells	B-COMP
was	O
transfected	O
with	O
siRNA	O
before	O
SARS	O
virus	O
infection	O
,	O
and	O
the	O
effectiveness	O
of	O
siRNA	O
interference	O
was	O
evaluated	O
by	O
observing	O
the	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
on	O
Vero	O
-	O
E6	O
cells	B-COMP
.	O

When	O
being	O
admitted	O
to	O
hospital	O
,	O
serum	B-COMP
ALT	O
and	O
(	O
or	O
)	O
AST	O
levels	O
were	O
elevated	O
in	O
37	O
.	O
7	O
%	O
SARS	O
patients	O
.	O

RESULTS	O
:	O
When	O
being	O
admitted	O
to	O
hospital	O
,	O
serum	B-COMP
ALT	O
and	O
(	O
or	O
)	O
AST	O
levels	O
were	O
elevated	O
in	O
37	O
.	O
7	O
%	O
SARS	O
patients	O
.	O

Immunohistochemical	O
examination	O
demonstrated	O
a	O
marked	O
increase	O
in	O
immunoreactivity	O
for	O
intracellular	B-COMP
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
P	O
-	O
selectin	O
and	O
E	O
-	O
selectin	O
in	O
the	O
pancreas	O
and	O
lung	O
of	O
cerulein	O
-	O
treated	O
mice	O
.	O

In	O
summary	O
,	O
we	O
describe	O
a	O
new	O
class	O
of	O
eukaryotic	O
,	O
multigene	O
expression	O
vectors	O
that	O
are	O
based	O
on	O
the	O
human	O
coronavirus	O
229E	O
and	O
have	O
the	O
ability	O
to	O
transduce	O
human	O
dendritic	B-COMP
cells	B-COMP
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
expression	O
,	O
intracellular	B-COMP
localization	O
,	O
and	O
replication	O
complex	O
association	O
of	O
the	O
putative	O
mouse	O
hepatitis	O
virus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

Factors	O
that	O
influence	O
whether	O
FCoV	O
establishes	O
lifelong	O
infection	O
in	O
some	O
cats	O
and	O
not	O
others	O
are	O
determined	O
mainly	O
by	O
the	O
host	B-COMP
response	O
to	O
infection	O
.	O

These	O
include	O
(	O
1	O
)	O
an	O
N	O
-	O
terminal	O
leucine	O
/	O
isoleucine	O
zipper	O
-	O
like	O
sequence	O
,	O
and	O
(	O
2	O
)	O
a	O
C	O
-	O
terminal	O
heptad	O
repeat	O
located	O
upstream	O
of	O
(	O
3	O
)	O
an	O
aromatic	O
residue	O
-	O
rich	O
region	O
juxtaposed	O
to	O
the	O
(	O
4	O
)	O
transmembrane	B-COMP
segment	O
.	O

A	O
decrease	O
in	O
LVEF	O
correlated	O
moderately	O
with	O
an	O
elevated	O
lactate	O
dehydrogenase	O
level	O
(	O
r	O
=-	O
0	O
.	O
605	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
whereas	O
a	O
higher	O
IMP	B-COMP
correlated	O
weakly	O
with	O
an	O
increase	O
in	O
creatine	O
kinase	O
level	O
(	O
r	O
=	O
0	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
016	O
).	O

Multinucleated	O
cells	B-COMP
were	O
shown	O
to	O
be	O
both	O
type	O
II	O
pneumocytes	O
and	O
macrophages	O
by	O
pancytokeratin	O
,	O
thyroid	O
transcription	O
factor	O
-	O
1	O
,	O
and	O
CD68	O
staining	O
.	O

TITLE	O
:	O
SARS	O
associated	O
coronavirus	O
has	O
a	O
recombinant	O
polymerase	O
and	O
coronaviruses	O
have	O
a	O
history	O
of	O
host	B-COMP
-	O
shifting	O
.	O

The	O
N	O
protein	O
produced	O
in	O
Sf9	O
cells	B-COMP
was	O
phosphorylated	O
whereas	O
N	O
protein	O
from	O
E	O
.	O
coli	O
was	O
not	O
.	O

Sixty	O
-	O
one	O
cases	O
of	O
SARS	O
with	O
positive	O
antibodies	B-COMP
to	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
classified	O
into	O
the	O
following	O
categories	O
:	O
initial	O
stage	O
(	O
3	O
-	O
7	O
days	O
),	O
peak	O
stage	O
(	O
8	O
-	O
14	O
days	O
),	O
and	O
remission	O
and	O
recovery	O
stage	O
(	O
15	O
-	O
27	O
days	O
).	O

The	O
mean	O
concentration	O
of	O
serum	B-COMP
IL	O
-	O
6	O
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
that	O
in	O
the	O
control	O
group	O
in	O
initial	O
and	O
peak	O
stages	O
,	O
but	O
became	O
significantly	O
higher	O
in	O
remission	O
and	O
recovery	O
stage	O
compared	O
with	O
the	O
control	O
group	O
,	O
initial	O
and	O
peak	O
stages	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Moreover	O
,	O
acute	O
pancreatitis	O
increased	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
-	O
biotin	O
nick	O
end	O
labeling	O
-	O
positive	O
alveolar	O
and	O
bronchiolar	O
cells	B-COMP
in	O
the	O
lung	O
.	O

Realistic	O
hope	O
for	O
the	O
future	O
,	O
or	O
false	O
dawn	O
in	O
the	O
promised	O
land	B-COMP
?	O

TITLE	O
:	O
[	O
Dynamic	O
observation	O
IgG	O
and	O
IgM	O
antibodies	B-COMP
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

Recombinant	O
viruses	O
were	O
generated	O
by	O
using	O
a	O
convenient	O
method	O
based	O
on	O
targeted	O
recombination	O
and	O
host	B-COMP
cell	I-COMP
switching	O
.	O

CONCLUSIONS	O
:	O
No	O
SARS	O
coronavirus	O
-	O
specific	O
antibody	B-COMP
are	O
present	O
in	O
the	O
sera	B-COMP
of	O
non	O
-	O
SARS	O
children	O
.	O

The	O
ELISA	O
kit	O
coated	O
by	O
non	O
-	O
purification	O
antigen	O
may	O
induce	O
the	O
false	O
-	O
positive	O
of	O
SARS	O
-	O
CoV	O
antibody	B-COMP
in	O
patients	O
with	O
SLE	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
the	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
specific	O
antibody	B-COMP
levels	O
in	O
156	O
SARS	O
patients	O
].	O

TITLE	O
:	O
[	O
Genomic	O
variations	O
in	O
the	O
locus	O
for	O
aminopeptidase	O
N	O
:	O
a	O
putative	O
cellular	B-COMP
receptor	O
for	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
].	O

TITLE	O
:	O
Antibody	B-COMP
-	O
mediated	O
protection	O
against	O
cytotoxic	O
T	O
-	O
cell	B-COMP
escape	O
in	O
coronavirus	O
-	O
induced	O
demyelination	O
.	O

Prior	O
treatment	O
of	O
cells	B-COMP
with	O
the	O
lysosomotropic	O
agents	O
NH	O
(	O
4	O
)	O
Cl	O
and	O
chloroquine	O
as	O
well	O
as	O
the	O
vacuolar	B-COMP
proton	B-COMP
pump	I-COMP
-	O
ATPase	O
inhibitor	O
bafilomycin	O
A1	O
,	O
all	O
of	O
which	O
block	O
the	O
acidification	O
of	O
the	O
endosome	B-COMP
,	O
prevented	O
oligodendrocytes	O
from	O
succumbing	O
to	O
apoptosis	O
induced	O
by	O
MHV	O
mutant	O
OBLV60	O
,	O
which	O
enters	O
cells	B-COMP
via	O
endocytosis	O
,	O
indicating	O
that	O
fusion	O
between	O
the	O
viral	B-COMP
envelope	I-COMP
and	O
cell	B-COMP
membranes	I-COMP
triggers	O
the	O
apoptotic	O
cascade	O
.	O

Moreover	O
,	O
during	O
FIP	O
many	O
lymphocytes	O
do	O
not	O
express	O
any	O
membrane	B-COMP
antigen	O
,	O
most	O
likely	O
due	O
to	O
early	O
apoptosis	O
.	O

Here	O
,	O
a	O
reporter	O
-	O
containing	O
BCoV	O
DI	O
RNA	O
was	O
shown	O
to	O
be	O
replicated	O
by	O
all	O
five	O
BCoV	O
-	O
like	O
helper	O
viruses	O
and	O
by	O
MHV	O
-	O
H2	O
(	O
a	O
human	O
cell	B-COMP
-	O
adapted	O
MHV	O
strain	O
),	O
a	O
representative	O
of	O
the	O
MHV	O
-	O
like	O
subgroup	O
,	O
demonstrating	O
group	O
2	O
common	O
5	O
'	O
and	O
3	O
'	O
replication	O
signaling	O
elements	O
.	O

These	O
results	O
may	O
provide	O
insights	O
into	O
the	O
mechanisms	O
by	O
which	O
MHV	O
evades	O
host	B-COMP
antiviral	O
defense	O
and	O
promotes	O
cell	B-COMP
survival	O
,	O
thereby	O
allowing	O
its	O
persistence	O
in	O
the	O
host	B-COMP
astrocytes	O
.	O

The	O
antibody	B-COMP
titers	O
of	O
pigs	O
experimentally	O
immunized	O
with	O
commercial	O
live	O
vaccine	O
and	O
two	O
types	O
of	O
inactivated	O
vaccines	O
clearly	O
increased	O
after	O
immunization	O
,	O
and	O
all	O
pigs	O
were	O
completely	O
protected	O
against	O
challenge	O
with	O
virulent	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
the	O
SpaA416	O
ELISA	O
is	O
an	O
effective	O
method	O
not	O
only	O
for	O
evaluating	O
pigs	O
for	O
the	O
presence	O
of	O
protective	O
antibody	B-COMP
levels	O
resulting	O
from	O
vaccination	O
or	O
maternal	O
antibody	B-COMP
but	O
also	O
for	O
detecting	O
antibody	B-COMP
produced	O
by	O
natural	O
infection	O
.	O

A	O
neurosurgical	O
patient	O
with	O
sickle	O
cell	B-COMP
disease	O
received	O
two	O
units	O
of	O
packed	O
red	O
blood	O
cells	B-COMP
postoperatively	O
.	O

Central	O
to	O
this	O
approach	O
was	O
a	O
DNA	O
microarray	O
designed	O
to	O
detect	O
a	O
wide	O
range	O
of	O
known	O
viruses	O
as	O
well	O
as	O
novel	O
members	O
of	O
existing	O
viral	O
families	O
;	O
this	O
microarray	O
contained	O
the	O
most	O
highly	O
conserved	O
70mer	O
sequences	O
from	O
every	O
fully	O
sequenced	O
reference	O
viral	B-COMP
genome	I-COMP
in	O
GenBank	O
.	O

Immunohistochemistry	O
identified	O
positive	O
monoclonal	O
antibody	B-COMP
against	O
SARS	O
-	O
CoV	O
nuceeocapsid	O
(	O
N	O
)	O
protein	O
in	O
the	O
alveolar	O
epithelium	O
and	O
the	O
infiltrating	O
monocytes	O
or	O
macrophages	O
in	O
the	O
lung	O
,	O
spleen	O
and	O
lymph	O
nodes	O
;	O
the	O
presence	O
of	O
the	O
antibody	B-COMP
was	O
also	O
detected	O
in	O
the	O
serous	O
gland	O
epithelium	O
of	O
the	O
trachea	O
/	O
bronchus	O
,	O
squamous	O
epithelium	O
of	O
the	O
esophagus	O
,	O
the	O
gastric	O
parietal	O
cells	B-COMP
,	O
the	O
epithelium	O
of	O
the	O
intestinal	O
tract	O
,	O
acidophilic	O
cells	B-COMP
in	O
the	O
parathyroids	O
and	O
pituitary	O
,	O
acinus	O
cells	B-COMP
in	O
the	O
pancreas	O
,	O
adrenal	O
cortical	O
cells	B-COMP
,	O
sweat	O
gland	O
cells	B-COMP
,	O
small	O
vessel	O
endothelium	O
,	O
bone	O
marrow	O
promyelocytes	O
,	O
epithelial	O
cells	B-COMP
of	O
the	O
distal	O
convoluted	O
tubule	O
of	O
the	O
kidney	O
,	O
brain	O
neurons	O
,	O
and	O
the	O
hepatocytes	O
near	O
the	O
central	O
vein	O
.	O

A	O
total	O
of	O
10	O
(	O
6	O
)	O
TCID50	O
viruses	O
were	O
placed	O
in	O
each	O
tested	O
condition	O
,	O
and	O
changes	O
of	O
the	O
viral	O
infectivity	O
in	O
samples	O
after	O
treatments	O
were	O
measured	O
by	O
evaluating	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
in	O
cell	B-COMP
line	O
Vero	O
-	O
E6	O
at	O
48	O
h	O
after	O
infection	O
.	O

The	O
serum	B-COMP
anti	O
-	O
coronavirus	O
IgG	B-COMP
antibody	I-COMP
titer	O
in	O
medical	O
personnel	O
who	O
had	O
closely	O
contacted	O
with	O
SARS	O
patients	O
,	O
healthy	O
individuals	O
,	O
patients	O
with	O
community	O
acquired	O
pneumonia	O
and	O
patients	O
recovered	O
from	O
SARS	O
was	O
detected	O
by	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
.	O

The	O
antibody	B-COMP
titer	O
was	O
expressed	O
as	O
the	O
value	O
of	O
absorbency	O
(	O
A	O
)	O
with	O
common	O
logarithm	O
conversion	O
.	O

Serum	B-COMP
levels	O
of	O
ILs	O
,	O
TNF	O
-	O
alpha	O
and	O
TGF	O
-	O
beta1	O
were	O
measured	O
in	O
all	O
cases	O
.	O

The	O
mean	O
concentration	O
of	O
serum	B-COMP
IL	O
-	O
6	O
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
the	O
control	O
group	O
in	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
,	O
but	O
became	O
significantly	O
higher	O
in	O
over	O
14	O
day	O
group	O
as	O
compared	O
to	O
the	O
control	O
group	O
,	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
[	O
B	O
cell	B-COMP
subsets	O
and	O
the	O
expression	O
of	O
CD40	O
in	O
peripheral	O
blood	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

The	O
B	O
cell	B-COMP
count	O
correlated	O
with	O
the	O
severity	O
of	O
SARS	O
.	O

We	O
investigated	O
whether	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
can	O
be	O
detected	O
in	O
serum	B-COMP
and	O
plasma	O
samples	O
during	O
the	O
early	O
stages	O
of	O
SARS	O
and	O
studied	O
the	O
potential	O
prognostic	O
implications	O
of	O
such	O
an	O
approach	O
.	O

The	O
RT	O
-	O
PCR	O
system	O
for	O
the	O
polymerase	O
region	O
detected	O
SARS	O
-	O
CoV	O
RNA	O
in	O
50	O
%	O
of	O
plasma	O
and	O
78	O
%	O
of	O
serum	B-COMP
samples	O
from	O
SARS	O
patients	O
during	O
the	O
first	O
week	O
of	O
illness	O
.	O

The	O
median	O
serum	B-COMP
SARS	O
-	O
CoV	O
concentrations	O
in	O
patients	O
who	O
required	O
and	O
did	O
not	O
require	O
intensive	O
care	O
unit	O
admission	O
during	O
the	O
course	O
of	O
hospitalization	O
were	O
5800	O
and	O
140	O
copies	O
/	O
mL	O
,	O
respectively	O
(	O
Mann	O
-	O
Whitney	O
test	O
,	O
P	O
<	O
0	O
.	O
005	O
).	O

Notably	O
,	O
N371	O
and	O
N385	O
,	O
located	O
at	O
the	O
COOH	O
terminus	O
of	O
the	O
N	O
protein	O
,	O
inhibited	O
binding	O
of	O
antibodies	B-COMP
to	O
SARS	O
-	O
coronavirus	O
lysate	O
and	O
bound	O
to	O
antibodies	B-COMP
in	O
>	O
94	O
%	O
of	O
samples	O
from	O
SARS	O
study	O
patients	O
.	O

N385	O
had	O
the	O
highest	O
affinity	O
for	O
forming	O
peptide	O
-	O
antibody	B-COMP
complexes	O
with	O
SARS	O
serum	B-COMP
.	O

In	O
this	O
study	O
,	O
we	O
immunized	O
cats	O
with	O
cell	B-COMP
lysate	O
with	O
recombinant	O
baculovirus	O
-	O
expressed	O
N	O
protein	O
of	O
the	O
Type	O
I	O
FIPV	O
strain	O
KU	O
-	O
2	O
with	O
an	O
adjuvant	O
and	O
investigated	O
its	O
preventive	O
effect	O
on	O
the	O
progression	O
of	O
FIP	O
.	O

Extracellular	B-COMP
virus	B-COMP
particles	I-COMP
were	O
present	O
by	O
5	O
h	O
p	O
.	O
i	O
.	O

ABSTRACT	O
:	O
To	O
clone	O
,	O
express	O
and	O
purify	O
nucleocapsid	B-COMP
protein	O
from	O
SARS	O
coronavirus	O
PUMC2	O
strain	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
reliability	O
of	O
SARS	O
-	O
CoV	O
antibody	B-COMP
detection	O
for	O
SARS	O
diagnosis	O
.	O

The	O
virus	O
gains	O
access	O
to	O
host	B-COMP
through	O
the	O
mucosa	O
of	O
the	O
respiratory	O
tract	O
and	O
the	O
eyes	O
.	O

presence	O
of	O
immune	O
complexes	O
measured	O
by	O
a	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
were	O
0	O
.	O
67	O
and	O
0	O
.	O
84	O
,	O
and	O
detection	O
of	O
viral	O
RNA	O
by	O
serum	B-COMP
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
0	O
.	O
90	O
and	O
0	O
.	O
47	O
.	O

Serum	B-COMP
tests	O
can	O
only	O
be	O
used	O
to	O
facilitate	O
the	O
decision	O
for	O
more	O
invasive	O
diagnostic	O
methods	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
mediates	O
infection	O
of	O
receptor	O
-	O
expressing	O
host	B-COMP
cells	B-COMP
and	O
is	O
a	O
critical	O
target	O
for	O
antiviral	O
neutralizing	O
antibodies	B-COMP
.	O

The	O
analyses	O
support	O
a	O
mammalian	O
-	O
like	O
origin	O
for	O
the	O
replicase	O
protein	O
,	O
an	O
avian	O
-	O
like	O
origin	O
for	O
the	O
matrix	O
and	O
nucleocapsid	B-COMP
proteins	O
,	O
and	O
a	O
mammalian	O
-	O
avian	O
mosaic	O
origin	O
for	O
the	O
host	B-COMP
-	O
determining	O
spike	O
protein	O
.	O

To	O
more	O
globally	O
and	O
systematically	O
identify	O
such	O
host	B-COMP
factors	O
,	O
we	O
used	O
engineered	O
BMV	O
derivatives	O
to	O
assay	O
viral	O
RNA	O
replication	O
in	O
each	O
strain	O
of	O
an	O
ordered	O
,	O
genome	O
-	O
wide	O
set	O
of	O
yeast	O
single	O
-	O
gene	O
deletion	O
mutants	O
.	O

TITLE	O
:	O
Total	O
pancreatectomy	O
and	O
autologous	O
islet	O
cell	B-COMP
transplantation	O
as	O
a	O
means	O
to	O
treat	O
severe	O
chronic	O
pancreatitis	O
.	O

This	O
increases	O
protection	O
of	O
the	O
laying	O
birds	O
against	O
egg	O
production	O
losses	O
and	O
induces	O
a	O
sustained	O
level	O
of	O
serum	B-COMP
antibody	B-COMP
,	O
which	O
is	O
passed	O
to	O
progeny	O
.	O

We	O
believe	O
it	O
is	O
likely	O
that	O
MHV	O
RNA	O
interacts	O
with	O
m	O
-	O
aconitase	O
prior	O
to	O
its	O
import	O
into	O
mitochondria	B-COMP
in	O
cooperation	O
with	O
extra	O
-	O
mitochondrial	B-COMP
mtHSP70	O
,	O
HSP60	O
,	O
and	O
HSP40	O
.	O

Serum	B-COMP
calcium	O
,	O
magnesium	O
and	O
phosphorus	O
(	O
but	O
not	O
sodium	O
,	O
potassium	O
and	O
chloride	O
)	O
were	O
abnormal	O
in	O
most	O
patients	O
.	O

TITLE	O
:	O
Neurotropism	O
of	O
swine	O
haemagglutinating	O
encephalomyelitis	O
virus	O
(	O
coronavirus	O
)	O
in	O
mice	O
depending	O
upon	O
host	B-COMP
age	O
and	O
route	O
of	O
infection	O
.	O

We	O
recently	O
reported	O
that	O
certain	O
N	O
-	O
methylthio	O
-	O
substituted	O
beta	O
-	O
lactam	O
antibiotics	O
had	O
DNA	O
-	O
damaging	O
and	O
apoptosis	O
-	O
inducing	O
activities	O
in	O
various	O
tumor	O
cells	B-COMP
.	O

Serum	B-COMP
IgG	O
to	O
SARS	O
virus	O
was	O
positive	O
in	O
69	O
.	O
9	O
%	O
of	O
the	O
patients	O
at	O
recovery	O
stage	O
.	O

By	O
biotinylated	O
ELISA	O
and	O
Western	O
blot	O
using	O
biotin	O
-	O
labeled	O
S	O
protein	O
as	O
the	O
probe	O
,	O
we	O
identified	O
130	O
-	O
kDa	O
and	O
140	O
-	O
kDa	O
proteins	O
in	O
Vero	O
cells	B-COMP
that	O
might	O
be	O
the	O
cellular	B-COMP
receptors	O
responsible	O
for	O
SARS	O
-	O
CoV	O
infection	O
.	O

RESULTS	O
:	O
Infliximab	O
treatment	O
significantly	O
decreased	O
serum	B-COMP
amylase	O
activity	O
(	O
11939	O
+/-	O

TITLE	O
:	O
Hericium	O
erinaceum	O
(	O
yamabushitake	O
)	O
extract	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
monitored	O
by	O
serum	B-COMP
surfactant	O
proteins	O
.	O

ABSTRACT	O
:	O
Fecal	O
secretory	O
immunoglobulin	O
A	O
(	O
IgA	O
)	O
antibodies	B-COMP
in	O
dogs	O
infected	O
or	O
vaccinated	O
with	O
canine	O
coronavirus	O
(	O
CCV	O
)	O
were	O
evaluated	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Mice	O
with	O
CD8	O
(+)	O
T	O
cells	B-COMP
specific	O
for	O
gp33	O
-	O
41	O
(	O
an	O
H	O
-	O
2D	O
(	O
b	O
)-	O
restricted	O
CD8	O
(+)	O
T	O
-	O
cell	B-COMP
epitope	O
derived	O
from	O
lymphocytic	O
choriomeningitis	O
glycoprotein	O
)	O
were	O
infected	O
with	O
a	O
recombinant	O
MHV	O
-	O
A59	O
,	O
also	O
expressing	O
gp33	O
-	O
41	O
,	O
as	O
a	O
fusion	O
protein	O
with	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
).	O

Two	O
of	O
the	O
mAbs	O
were	O
IgG2a	B-COMP
isotype	O
,	O
and	O
the	O
other	O
was	O
IgG1	B-COMP
.	O

The	O
results	O
indicated	O
that	O
N	O
was	O
recognized	O
in	O
most	O
of	O
the	O
sera	B-COMP
.	O

The	O
mouse	O
serum	B-COMP
IgG	B-COMP
antibody	I-COMP
against	O
SARS	O
-	O
CoV	O
was	O
measured	O
by	O
ELISA	O
with	O
E	O
.	O
coli	O
expressed	O
truncated	O
S	O
protein	O
or	O
SARS	O
-	O
CoV	O
lysate	O
as	O
diagnostic	O
antigen	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
mentioned	O
above	O
suggest	O
that	O
SARS	O
-	O
CoV	O
is	O
responding	O
to	O
host	B-COMP
immunological	O
pressures	O
and	O
experiencing	O
variation	O
which	O
provide	O
clues	O
,	O
information	O
and	O
evidence	O
of	O
molecular	O
biology	O
for	O
the	O
clinical	O
pathology	O
,	O
vaccine	O
developing	O
and	O
epidemic	O
investigation	O
.	O

ABSTRACT	O
:	O
Purification	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
,	O
expressed	O
in	O
a	O
prokaryotic	O
expression	O
system	O
as	O
histidine	O
-	O
tagged	O
fusion	O
protein	O
is	O
demonstrated	O
in	O
the	O
present	O
study	O
.	O

The	O
purified	O
N	O
protein	O
was	O
recognized	O
by	O
antibody	B-COMP
to	O
TCoV	O
in	O
Western	O
blotting	O
assay	O
.	O

These	O
results	O
indicated	O
that	O
the	O
expressed	O
N	O
protein	O
is	O
a	O
superior	O
source	O
of	O
TCoV	O
antigen	O
for	O
development	O
of	O
antibody	B-COMP
-	O
capture	O
ELISA	O
for	O
detection	O
of	O
antibodies	B-COMP
to	O
TCoV	O
.	O

Based	O
on	O
seroconversion	O
to	O
BRSV	O
and	O
clinical	O
picture	O
,	O
67	O
pairs	O
of	O
sera	B-COMP
were	O
selected	O
from	O
calves	O
with	O
a	O
BRSV	O
-	O
associated	O
PRDS	O
for	O
circulating	O
MC	O
tryptase	O
determination	O
.	O

We	O
previously	O
demonstrated	O
that	O
JHM	O
-	O
infected	O
mice	O
that	O
only	O
have	O
CD8	O
T	O
cells	B-COMP
specific	O
for	O
an	O
epitope	O
not	O
in	O
the	O
virus	O
develop	O
demyelination	O
on	O
specific	O
activation	O
of	O
these	O
cells	B-COMP
.	O

In	O
this	O
study	O
,	O
six	O
fatal	O
cases	O
of	O
SARS	O
were	O
investigated	O
for	O
the	O
tissue	O
and	O
cellular	B-COMP
tropism	O
of	O
SARS	O
-	O
CoV	O
using	O
an	O
in	O
-	O
situ	O
hybridization	O
(	O
ISH	O
)	O
technique	O
.	O

TITLE	O
:	O
Perforin	O
and	O
gamma	O
interferon	O
-	O
mediated	O
control	O
of	O
coronavirus	O
central	O
nervous	O
system	O
infection	O
by	O
CD8	O
T	O
cells	B-COMP
in	O
the	O
absence	O
of	O
CD4	O
T	O
cells	B-COMP
.	O

The	O
contributions	O
of	O
perforin	O
-	O
mediated	O
cytolysis	O
and	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
secretion	O
by	O
CD8	O
(+)	O
T	O
cells	B-COMP
to	O
the	O
control	O
of	O
infection	O
and	O
the	O
induction	O
of	O
demyelination	O
were	O
examined	O
by	O
adoptive	O
transfer	O
into	O
infected	O
SCID	O
recipients	O
.	O

Untreated	O
SCID	O
mice	O
exhibited	O
uncontrolled	O
virus	O
replication	O
in	O
all	O
CNS	O
cell	B-COMP
types	O
but	O
had	O
little	O
or	O
no	O
demyelination	O
.	O

The	O
initial	O
blood	O
cells	B-COMP
count	O
showed	O
that	O
total	O
white	O
blood	O
cell	B-COMP
(	O
WBC	O
)	O
count	O
was	O
(	O
2	O
.	O
5	O
-	O
9	O
.	O
7	O
)	O
x	O
10	O
(	O
9	O
)/	O
L	O
.	O
In	O
22	O
(	O
67	O
%)	O
cases	O
the	O
WBC	O
count	O
was	O
<	O
5	O
.	O
0	O
x	O
10	O
(	O
9	O
)/	O
L	O
,	O
and	O
in	O
10	O
(	O
30	O
%)	O
WBC	O
was	O
(	O
5	O
.	O
0	O
-	O
7	O
.	O
0	O
)	O
x	O
10	O
(	O
9	O
)/	O
L	O
,	O
in	O
18	O
cases	O
most	O
of	O
the	O
WBC	O
were	O
lymphocyte	O
count	O
.	O

For	O
this	O
reason	O
,	O
we	O
raised	O
peptide	O
-	O
induced	O
polyclonal	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
spike	O
protein	O
and	O
polyclonal	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
using	O
6x	O
His	O
nucleocapsid	B-COMP
recombinant	O
protein	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
-	O
mass	O
spectrometry	O
determination	O
showed	O
that	O
relative	O
molecular	O
weight	O
of	O
intact	O
N	O
protein	O
is	O
45	O
929	O
Da	O
,	O
which	O
is	O
very	O
close	O
to	O
its	O
theoretically	O
calculated	O
molecular	O
weight	O
45	O
935	O
Da	O
based	O
on	O
the	O
amino	O
acid	O
sequence	O
deduced	O
from	O
the	O
genome	O
with	O
the	O
first	O
amino	O
acid	O
methionine	O
at	O
the	O
N	O
-	O
terminus	O
depleted	O
and	O
second	O
,	O
serine	O
,	O
acetylated	O
,	O
indicating	O
that	O
phosphorylation	O
does	O
not	O
happen	O
at	O
all	O
in	O
the	O
predicted	O
phosphorylation	O
sites	O
within	O
infected	O
cells	B-COMP
nor	O
in	O
virus	B-COMP
particles	I-COMP
.	O

ABSTRACT	O
:	O
We	O
have	O
expressed	O
a	O
series	O
of	O
truncated	O
spike	O
(	O
S	O
)	O
glycoproteins	O
of	O
SARS	O
-	O
CoV	O
and	O
found	O
that	O
the	O
N	O
-	O
terminus	O
14	O
-	O
502	O
residuals	O
were	O
sufficient	O
to	O
bind	O
to	O
SARS	O
-	O
CoV	O
susceptible	O
Vero	O
E6	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
This	O
report	O
demonstrates	O
that	O
a	O
rapid	O
decrease	O
of	O
peripheral	O
T	O
cell	B-COMP
subsets	O
is	O
a	O
unique	O
characteristic	O
in	O
patients	O
with	O
SARS	O
during	O
acute	O
infection	O
,	O
although	O
total	O
white	O
blood	O
cell	B-COMP
counts	O
,	O
red	O
blood	O
cell	B-COMP
counts	O
,	O
and	O
platelet	O
counts	O
remain	O
relatively	O
normal	O
.	O

In	O
recovering	O
patients	O
,	O
a	O
rapid	O
and	O
dramatic	O
restoration	O
of	O
peripheral	O
T	O
cell	B-COMP
subsets	O
was	O
seen	O
in	O
the	O
periphery	O
.	O

We	O
determined	O
the	O
relation	O
of	O
endogenous	O
G	O
-	O
CSF	O
to	O
proinflammatory	O
and	O
anti	O
-	O
inflammatory	O
mediators	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
serum	B-COMP
of	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

It	O
will	O
contribute	O
to	O
vaccine	O
development	O
against	O
feline	O
viruses	O
by	O
facilitating	O
the	O
identification	O
of	O
T	O
cell	B-COMP
antigens	O
and	O
epitopes	O
,	O
and	O
by	O
allowing	O
the	O
quantitative	O
detection	O
of	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
after	O
vaccination	O
.	O

TITLE	O
:	O
Detection	O
of	O
feline	O
coronavirus	O
antibody	B-COMP
,	O
feline	O
immunodeficiency	O
virus	O
antibody	B-COMP
,	O
and	O
feline	O
leukemia	O
virus	O
antigen	O
in	O
ascites	O
from	O
cats	O
with	O
effusive	O
feline	O
infectious	O
peritonitis	O
.	O

After	O
purification	O
,	O
the	O
recombinant	O
protein	O
was	O
identified	O
by	O
anti	O
-	O
SARS	O
positive	O
sera	B-COMP
from	O
recovered	O
SARS	O
patients	O
.	O

The	O
mode	O
of	O
action	O
of	O
chloroquine	O
in	O
prevention	O
of	O
malaria	O
is	O
not	O
known	O
,	O
but	O
it	O
may	O
be	O
to	O
minimize	O
replication	O
of	O
the	O
parasite	O
in	O
the	O
liver	O
cells	B-COMP
,	O
which	O
occurs	O
before	O
invasion	O
of	O
the	O
erythrocytes	O
,	O
by	O
facilitating	O
premature	O
apoptosis	O
of	O
the	O
infected	O
host	B-COMP
cells	B-COMP
.	O

ABSTRACT	O
:	O
We	O
measured	O
CD8	O
T	O
cell	B-COMP
clonotypic	O
diversity	O
to	O
three	O
epitopes	O
recognized	O
in	O
C57BL	O
/	O
6	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
,	O
strain	O
JHM	O
,	O
or	O
lymphocytic	O
choriomeningitis	O
virus	O
.	O

We	O
have	O
identified	O
eight	O
recombinant	O
human	O
single	O
-	O
chain	O
variable	O
region	O
fragments	O
(	O
scFvs	O
)	O
against	O
the	O
S1	O
domain	O
of	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
SARS	O
-	O
CoV	O
from	O
two	O
nonimmune	O
human	O
antibody	B-COMP
libraries	O
.	O

A	O
human	O
IgG1	B-COMP
form	O
of	O
80R	O
bound	O
S1	O
with	O
a	O
20	O
-	O
fold	O
higher	O
affinity	O
of	O
1	O
.	O
59	O
nM	O
comparable	O
to	O
that	O
of	O
ACE2	O
(	O
Kd	O
=	O
1	O
.	O
70	O
nM	O
),	O
and	O
neutralized	O
virus	O
20	O
-	O
fold	O
more	O
efficiently	O
than	O
the	O
80R	O
scFv	O
.	O

These	O
data	O
suggest	O
that	O
the	O
80R	O
human	O
monoclonal	O
antibody	B-COMP
may	O
be	O
a	O
useful	O
viral	O
entry	O
inhibitor	O
for	O
the	O
emergency	O
prophylaxis	O
and	O
treatment	O
of	O
SARS	O
,	O
and	O
that	O
the	O
ACE2	O
-	O
binding	O
site	O
of	O
S1	O
could	O
be	O
an	O
attractive	O
target	O
for	O
subunit	O
vaccine	O
and	O
drug	O
development	O
.	O

The	O
RNAi	O
methodology	O
has	O
been	O
used	O
as	O
a	O
tool	O
to	O
silence	O
genes	O
in	O
cultured	O
cells	B-COMP
and	O
in	O
animals	O
.	O

These	O
macrophages	O
frequently	O
showed	O
morphological	O
changes	O
,	O
such	O
as	O
cytoplasmic	B-COMP
foaminess	O
,	O
vacuole	B-COMP
formation	O
,	O
and	O
nuclear	O
changes	O
(	O
including	O
multinucleation	O
and	O
a	O
ground	O
glass	O
appearance	O
)	O
when	O
compared	O
with	O
the	O
control	O
samples	O
.	O

TITLE	O
:	O
Requirements	O
for	O
CEACAMs	O
and	O
cholesterol	O
during	O
murine	O
coronavirus	O
cell	B-COMP
entry	O
.	O

ABSTRACT	O
:	O
After	O
various	O
observational	O
studies	O
demonstrated	O
a	O
benefit	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
the	O
therapy	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
ECMO	O
now	O
represents	O
an	O
important	O
contribution	O
for	O
ARDS	O
therapy	O
using	O
clinical	O
algorithms	O
despite	O
a	O
lack	O
of	O
positive	O
controlled	O
studies	O
.	O

Our	O
objective	O
was	O
to	O
assess	O
exposure	O
to	O
morphine	O
as	O
an	O
etiologic	O
factor	O
for	O
acute	O
chest	O
syndrome	O
in	O
sickle	O
cell	B-COMP
disease	O
.	O

We	O
then	O
compared	O
it	O
to	O
a	O
novel	O
nucleocapsid	B-COMP
gene	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
with	O
genomic	O
RNA	O
.	O

Staphylococcus	O
aureus	O
Cowan	O
1	O
(	O
SAC	B-COMP
)-	O
stimulated	O
IL	O
-	O
10	O
secreting	O
cells	B-COMP
were	O
increased	O
in	O
early	O
SARS	O
but	O
fell	O
during	O
treatment	O
.	O

The	O
ELISA	O
detected	O
IgG	O
antibodies	B-COMP
to	O
SARS	O
-	O
CoV	O
in	O
all	O
74	O
convalescent	O
-	O
phase	O
samples	O
from	O
SARS	O
patients	O
while	O
weakly	O
cross	O
-	O
reacting	O
to	O
only	O
1	O
of	O
the	O
210	O
control	O
sera	B-COMP
from	O
healthy	O
donors	O
.	O

Sera	B-COMP
from	O
some	O
of	O
the	O
patients	O
also	O
showed	O
immunoreactivity	O
to	O
U274	O
(	O
59	O
of	O
81	O
[	O
73	O
%]),	O
a	O
protein	O
that	O
is	O
unique	O
to	O
SARS	O
-	O
CoV	O
.	O
In	O
addition	O
,	O
all	O
of	O
the	O
convalescent	O
-	O
phase	O
sera	B-COMP
showed	O
immunoreactivity	O
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
when	O
analyzed	O
by	O
an	O
immunofluorescence	O
method	O
utilizing	O
mammalian	O
cells	B-COMP
stably	O
expressing	O
S	O
.	O
However	O
,	O
samples	O
from	O
the	O
acute	O
phase	O
(	O
2	O
to	O
9	O
days	O
after	O
the	O
onset	O
of	O
illness	O
)	O
did	O
not	O
react	O
with	O
S	O
,	O
suggesting	O
that	O
antibodies	B-COMP
to	O
N	O
may	O
appear	O
earlier	O
than	O
antibodies	B-COMP
to	O
S	O
.	O
Alternatively	O
,	O
this	O
could	O
be	O
due	O
to	O
the	O
difference	O
in	O
the	O
sensitivities	O
of	O
the	O
two	O
methods	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
Western	O
blot	O
assay	O
for	O
detection	O
of	O
antibodies	B-COMP
against	O
coronavirus	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

SARS	O
-	O
CoV	O
protein	O
-	O
derived	O
peptide	O
-	O
1	O
(	O
SSp	O
-	O
1	O
RLNEVAKNL	O
),	O
induced	O
peptide	O
-	O
specific	O
CTLs	O
both	O
in	O
vivo	O
(	O
transgenic	O
mice	O
)	O
and	O
in	O
vitro	O
(	O
human	O
PBLs	O
),	O
which	O
specifically	O
released	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
upon	O
stimulation	O
with	O
SSp	O
-	O
1	O
-	O
pulsed	O
autologous	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
)	O
or	O
T2	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
The	O
molecular	O
and	O
cellular	B-COMP
basis	O
of	O
coronavirus	O
neurovirulence	O
is	O
poorly	O
understood	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
studied	O
the	O
interaction	O
between	O
coronaviruses	O
(	O
mouse	O
hepatitis	O
virus	O
)	O
of	O
different	O
neurovirulences	O
with	O
primary	O
cell	B-COMP
cultures	O
of	O
brain	O
immune	O
cells	B-COMP
(	O
astrocytes	O
and	O
microglia	O
)	O
and	O
mouse	O
tissues	O
.	O

Seroconversion	O
for	O
SARS	O
-	O
CoV	O
using	O
immunofluorescence	O
on	O
infected	O
cells	B-COMP
is	O
an	O
excellent	O
method	O
of	O
confirming	O
the	O
diagnosis	O
,	O
but	O
antibody	B-COMP
responses	O
only	O
appear	O
around	O
day	O
10	O
of	O
the	O
illness	O
.	O

After	O
10	O
days	O
of	O
illness	O
the	O
picture	O
changes	O
to	O
one	O
of	O
organizing	O
DAD	O
with	O
increased	O
fibrosis	O
,	O
squamous	O
metaplasia	O
and	O
multinucleated	O
giant	O
cells	B-COMP
.	O

Several	O
adverse	O
prognostic	O
factors	O
have	O
been	O
identified	O
,	O
including	O
advanced	O
age	O
,	O
presence	O
of	O
comorbidity	O
,	O
higher	O
lactose	O
dehydrogenase	O
levels	O
and	O
initial	O
neutrophil	O
count	O
,	O
but	O
the	O
impact	O
of	O
viral	O
and	O
other	O
host	B-COMP
factors	O
on	O
outcome	O
is	O
unknown	O
.	O

Four	O
canine	O
sera	B-COMP
-	O
positive	O
for	O
CCoV	O
type	O
II	O
,	O
four	O
sera	B-COMP
-	O
positive	O
for	O
CCoV	O
type	O
I	O
and	O
10	O
negative	O
control	O
sera	B-COMP
were	O
examined	O
.	O

Only	O
the	O
sera	B-COMP
-	O
positive	O
for	O
CCoV	O
type	O
I	O
strongly	O
reacted	O
with	O
both	O
the	O
proteins	O
,	O
whereas	O
the	O
sera	B-COMP
-	O
positive	O
for	O
CCoV	O
type	O
II	O
showed	O
low	O
reactivity	O
in	O
the	O
ELISA	O
test	O
.	O

These	O
expression	O
vectors	O
induced	O
robust	O
immune	O
responses	O
mediated	O
by	O
CD4	O
and	O
CD8	O
cells	B-COMP
,	O
as	O
well	O
as	O
significant	O
antibody	B-COMP
titres	O
,	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Experiments	O
were	O
performed	O
to	O
elucidate	O
the	O
duration	O
of	O
enterotropic	O
MHV	O
-	O
Y	O
shedding	O
by	O
immunocompetent	O
BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	O
and	O
immunocompromised	O
B	O
and	O
T	O
cell	B-COMP
-	O
deficient	O
mice	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2003	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
,	O
a	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
which	O
targets	O
the	O
nucleocapsid	B-COMP
gene	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
viral	B-COMP
genome	I-COMP
,	O
was	O
established	O
to	O
detect	O
and	O
identify	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

We	O
focused	O
on	O
using	O
synthetic	O
peptides	O
for	O
developing	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
,	O
which	O
aimed	O
to	O
block	O
viral	O
invasion	O
by	O
eliciting	O
an	O
immune	O
response	O
specific	O
to	O
the	O
native	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

Less	O
commonly	O
,	O
the	O
recipient	O
may	O
have	O
antibodies	B-COMP
which	O
interact	O
with	O
white	O
cells	B-COMP
in	O
the	O
donor	O
products	O
.	O

ABSTRACT	O
:	O
The	O
pathophysiology	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
at	O
present	O
poorly	O
understood	O
,	O
but	O
advanced	O
age	O
and	O
serum	B-COMP
total	O
lactate	O
dehydrogenase	O
(	O
LD	O
)	O
activity	O
>	O
300	O
U	O
L	O
(-	O
1	O
)	O
have	O
been	O
associated	O
with	O
adverse	O
clinical	O
outcomes	O
.	O

CD3	O
+,	O
CD4	O
+,	O
CD8	O
+	O
and	O
natural	O
killer	O
cell	B-COMP
counts	O
were	O
promising	O
immunological	O
prognostic	O
indicators	O
for	O
predicting	O
admission	O
to	O
ICU	O
with	O
AUC	O
of	O
0	O
.	O
94	O
(	O
CI	O
=	O
0	O
.	O
86	O
-	O
0	O
.	O
98	O
),	O
0	O
.	O
91	O
(	O
CI	O
=	O
0	O
.	O
81	O
-	O
0	O
.	O
96	O
),	O
0	O
.	O
93	O
(	O
CI	O
=	O
0	O
.	O
85	O
-	O
0	O
.	O
98	O
),	O
and	O
0	O
.	O
87	O
(	O
CI	O
=	O
0	O
.	O
76	O
-	O
0	O
.	O
94	O
),	O
respectively	O
.	O

The	O
N	O
protein	O
is	O
a	O
potential	O
diagnostic	O
antigen	O
and	O
vaccine	O
candidate	O
for	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
The	O
full	O
-	O
length	O
protein	O
and	O
two	O
other	O
fragments	O
reacted	O
with	O
all	O
52	O
sera	B-COMP
tested	O
.	O

TITLE	O
:	O
[	O
Serum	B-COMP
levels	O
of	O
luteinizing	O
hormone	O
,	O
testosterone	O
and	O
prolactin	O
in	O
patients	O
with	O
septic	O
shock	O
].	O

We	O
studied	O
serum	B-COMP
level	O
of	O
luteinizing	O
hormone	O
(	O
LH	O
),	O
testosterone	O
(	O
T	O
)	O
and	O
prolactin	O
(	O
PRL	O
)	O
in	O
20	O
patients	O
with	O
septic	O
shock	O
and	O
in	O
healthy	O
male	O
volunteers	O
(	O
n	O
=	O
20	O
).	O

There	O
was	O
no	O
significant	O
difference	O
in	O
serum	B-COMP
level	O
of	O
C3	O
between	O
the	O
three	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Generation	O
and	O
characterization	O
of	O
DNA	O
vaccines	O
targeting	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

These	O
results	O
show	O
that	O
a	O
DNA	O
vaccine	O
encoding	O
CRT	O
linked	O
to	O
a	O
SARS	O
-	O
CoV	O
antigen	O
is	O
capable	O
of	O
generating	O
strong	O
N	O
-	O
specific	O
humoral	O
and	O
cellular	B-COMP
immunity	O
and	O
may	O
potentially	O
be	O
useful	O
for	O
control	O
of	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O

The	O
total	O
number	O
of	O
NK	O
and	O
CD158b	O
+	O
NK	O
cells	B-COMP
and	O
the	O
percentage	O
of	O
CD158b	O
+	O
NK	O
cells	B-COMP
were	O
significantly	O
lower	O
in	O
patients	O
with	O
SARS	O
than	O
in	O
those	O
with	O
M	O
.	O
pneumoniae	O
infection	O
(	O
P	O
<	O
.	O
05	O
for	O
all	O
)	O
and	O
healthy	O
subjects	O
(	O
P	O
<	O
.	O
01	O
,	O
P	O
<	O
.	O
01	O
,	O
P	O
<	O
.	O
05	O
,	O
respectively	O
);	O
in	O
72	O
patients	O
with	O
severe	O
SARS	O
than	O
in	O
149	O
with	O
mild	O
SARS	O
(	O
P	O
<	O
.	O
05	O
for	O
all	O
);	O
and	O
in	O
174	O
cases	O
of	O
SARS	O
with	O
anti	O
-	O
SARS	O
coronavirus	O
-	O
specific	O
IgG	O
and	O
/	O
or	O
IgM	O
antibodies	B-COMP
than	O
in	O
47	O
without	O
antibodies	B-COMP
(	O
P	O
<	O
.	O
05	O
,	O
P	O
<	O
.	O
01	O
,	O
P	O
<	O
.	O
01	O
,	O
respectively	O
).	O

Monitoring	O
the	O
total	O
number	O
of	O
NK	O
and	O
CD158b	O
+	O
NK	O
cells	B-COMP
and	O
the	O
percentage	O
of	O
CDD158b	O
+	O
NK	O
cells	B-COMP
might	O
aid	O
in	O
differentiating	O
SARS	O
from	O
M	O
.	O
pneumoniae	O
infection	O
.	O

However	O
,	O
the	O
target	O
cells	B-COMP
of	O
SARS	O
viral	O
infection	O
have	O
not	O
been	O
characterized	O
in	O
detail	O
.	O

The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
together	O
with	O
the	O
viral	O
RNA	O
genome	O
presumably	O
form	O
a	O
helical	O
core	O
located	O
within	O
the	O
viral	B-COMP
envelope	I-COMP
.	O

ABSTRACT	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
male	O
with	O
a	O
known	O
history	O
of	O
sickle	O
cell	B-COMP
disease	O
(	O
SCD	O
)	O
and	O
acute	O
chest	O
syndrome	O
(	O
ACS	O
)	O
was	O
treated	O
in	O
our	O
hospital	O
.	O

ABSTRACT	O
:	O
A	O
commercially	O
available	O
in	O
-	O
practice	O
test	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibodies	B-COMP
(	O
FCoV	O
Immunocomb	O
,	O
Biogal	O
Galed	O
Laboratories	O
)	O
was	O
evaluated	O
by	O
comparison	O
with	O
the	O
gold	O
standard	O
FCoV	O
immunofluorescent	O
antibody	B-COMP
(	O
IFA	O
)	O
test	O
.	O

One	O
hundred	O
and	O
three	O
serum	B-COMP
or	O
plasma	O
samples	O
were	O
selected	O
and	O
tested	O
:	O
70	O
were	O
positive	O
by	O
both	O
tests	O
,	O
24	O
were	O
negative	O
by	O
both	O
tests	O
.	O

A	O
strong	O
positive	O
result	O
would	O
be	O
useful	O
in	O
the	O
diagnosis	O
of	O
FIP	O
(	O
in	O
conjunction	O
with	O
other	O
biochemical	O
and	O
cytological	O
testing	O
),	O
but	O
positive	O
results	O
would	O
be	O
of	O
limited	O
value	O
in	O
monitoring	O
FCoV	O
infection	O
in	O
healthy	O
cats	O
as	O
the	O
antibody	B-COMP
titre	O
could	O
not	O
be	O
reliably	O
compared	O
with	O
those	O
obtained	O
with	O
IFA	O
.	O

Tissues	O
from	O
five	O
control	O
cats	O
and	O
from	O
15	O
cats	O
with	O
FIP	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
monoclonal	O
antibodies	B-COMP
against	O
human	O
AGP	O
,	O
FCoV	O
and	O
myeloid	O
antigens	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
coronavirus	O
-	O
mediated	O
membrane	B-COMP
fusion	O
.	O

ABSTRACT	O
:	O
The	O
surface	O
transmembrane	B-COMP
glycoprotein	O
is	O
responsible	O
for	O
mediating	O
virion	B-COMP
attachment	O
to	O
cell	B-COMP
and	O
subsequent	O
virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusion	O
.	O

The	O
serum	B-COMP
creatinine	O
level	O
increased	O
to	O
6	O
.	O
6	O
mg	O
/	O
dl	O
.	O

Medical	O
examination	O
was	O
also	O
carried	O
out	O
for	O
313	O
people	O
who	O
had	O
close	O
contact	O
with	O
the	O
29	O
antibody	B-COMP
positive	O
health	O
care	O
professionals	O
,	O
but	O
no	O
clinical	O
SARS	O
was	O
found	O
.	O

Here	O
we	O
report	O
a	O
method	O
for	O
eliminating	O
false	O
-	O
negative	O
results	O
and	O
increasing	O
test	O
sensitivity	O
,	O
based	O
on	O
the	O
hypothesis	O
that	O
the	O
message	O
encoded	O
by	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
is	O
the	O
most	O
abundant	O
during	O
viral	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
nucleocapsid	B-COMP
gene	O
represents	O
an	O
additional	O
sensitive	O
molecular	O
marker	O
for	O
the	O
diagnosis	O
of	O
the	O
SARS	O
coronavirus	O
and	O
can	O
be	O
further	O
adapted	O
for	O
use	O
in	O
a	O
high	O
-	O
throughput	O
platform	O
assay	O
.	O

Dilutions	O
of	O
gamma	O
-	O
irradiated	O
cell	B-COMP
culture	O
supernatants	O
of	O
SARS	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
were	O
prepared	O
to	O
determine	O
the	O
precisions	O
,	O
linear	O
ranges	O
,	O
and	O
accuracies	O
of	O
the	O
assays	O
.	O

We	O
generated	O
specific	O
antibodies	B-COMP
against	O
SARS	O
protein	O
3a	O
by	O
using	O
a	O
synthetic	O
peptide	O
(	O
P2	O
)	O
corresponding	O
to	O
amino	O
acids	O
261	O
-	O
274	O
of	O
the	O
putative	O
protein	O
.	O

To	O
detect	O
false	O
negative	O
results	O
due	O
to	O
PCR	O
inhibitors	O
or	O
faulty	O
RNA	O
extraction	O
,	O
we	O
have	O
further	O
modified	O
this	O
one	O
step	O
RT	O
-	O
PCR	O
assay	O
for	O
simultaneous	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
and	O
18S	O
ribosomal	B-COMP
RNA	I-COMP
(	O
rRNA	O
)	O
as	O
an	O
internal	O
positive	O
control	O
.	O

Antibodies	B-COMP
against	O
red	O
cells	B-COMP
,	O
platelets	O
,	O
lymphocytes	O
and	O
granulocytes	O
were	O
detected	O
in	O
extremely	O
high	O
titers	O
.	O

The	O
lower	O
prevalence	O
of	O
CDV	O
antibody	B-COMP
-	O
positive	O
hyenas	O
near	O
human	O
habitation	O
suggests	O
that	O
reservoirs	O
for	O
CDV	O
other	O
than	O
domestic	O
dogs	O
are	O
present	O
in	O
the	O
Serengeti	O
ecosystem	O
.	O

Although	O
myeloid	O
dendritic	B-COMP
cells	B-COMP
were	O
able	O
to	O
interact	O
with	O
S	O
and	O
to	O
bind	O
virus	O
,	O
these	O
cells	B-COMP
could	O
not	O
be	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
these	O
cells	B-COMP
were	O
able	O
to	O
transfer	O
the	O
virus	O
to	O
susceptible	O
target	O
cells	B-COMP
through	O
a	O
synapse	B-COMP
-	O
like	O
structure	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
replication	O
induces	O
cell	B-COMP
cycle	O
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
.	O

MHV	O
infection	O
in	O
quiescent	O
17Cl	O
-	O
1	O
cells	B-COMP
prevented	O
normal	O
increases	O
in	O
Cdk4	O
,	O
Cdk6	O
,	O
cyclin	O
D1	O
,	O
and	O
cyclin	O
D3	O
levels	O
after	O
serum	B-COMP
stimulation	O
.	O

This	O
dibasic	O
motif	O
also	O
retained	O
a	O
reporter	O
protein	O
in	O
the	O
ERGIC	B-COMP
,	O
similar	O
to	O
the	O
dilysine	O
motif	O
in	O
IBV	O
S	O
.	O
The	O
cytoplasmic	B-COMP
tails	O
of	O
S	O
proteins	O
from	O
group	O
2	O
coronaviruses	O
lack	O
an	O
intracellular	B-COMP
localization	O
signal	O
.	O

TITLE	O
:	O
Cleavage	O
between	O
replicase	O
proteins	O
p28	B-COMP
and	O
p65	O
of	O
mouse	O
hepatitis	O
virus	O
is	O
not	O
required	O
for	O
virus	O
replication	O
.	O

The	O
most	O
remarkable	O
finding	O
was	O
the	O
surface	O
expression	O
of	O
ACE2	O
protein	O
on	O
lung	O
alveolar	O
epithelial	O
cells	B-COMP
and	O
enterocytes	O
of	O
the	O
small	O
intestine	O
.	O

ABSTRACT	O
:	O
The	O
behavior	O
and	O
myelinogenic	O
properties	O
of	O
glial	O
cells	B-COMP
have	O
been	O
well	O
documented	O
following	O
transplantation	O
into	O
regions	O
of	O
focal	O
experimental	O
demyelination	O
in	O
animal	O
models	O
.	O

This	O
protocol	O
relies	O
on	O
virion	B-COMP
capture	O
by	O
monoclonal	O
antibodies	B-COMP
specific	O
for	O
a	O
virion	B-COMP
membrane	I-COMP
protein	O
.	O

TITLE	O
:	O
Experimental	O
human	O
metapneumovirus	O
infection	O
of	O
cynomolgus	O
macaques	O
(	O
Macaca	O
fascicularis	O
)	O
results	O
in	O
virus	O
replication	O
in	O
ciliated	O
epithelial	O
cells	B-COMP
and	O
pneumocytes	O
with	O
associated	O
lesions	O
throughout	O
the	O
respiratory	O
tract	O
.	O

This	O
observation	O
provides	O
important	O
clues	O
for	O
the	O
selection	O
of	O
specific	O
immunologic	O
probes	O
to	O
examine	O
whether	O
SARS	O
-	O
CoV	O
expresses	O
antigenic	O
structures	O
that	O
mimic	O
the	O
host	B-COMP
glycan	O
.	O

Fusion	O
of	O
coronaviruses	O
with	O
the	O
host	B-COMP
cell	I-COMP
is	O
mediated	O
by	O
the	O
envelope	B-COMP
spike	O
protein	O
.	O

TITLE	O
:	O
Serum	B-COMP
hepatic	O
enzyme	O
manifestations	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
retrospective	O
analysis	O
.	O

Inhibition	O
of	O
vacuolar	B-COMP
acidification	O
impaired	O
infection	O
by	O
SARS	O
-	O
CoV	O
S	O
-	O
bearing	O
pseudotypes	O
,	O
indicating	O
that	O
S	O
-	O
mediated	O
entry	O
requires	O
low	O
pH	O
.	O
Finally	O
,	O
infection	O
by	O
SARS	O
-	O
CoV	O
S	O
pseudotypes	O
but	O
not	O
by	O
vesicular	O
stomatitis	O
virus	O
G	O
pseudotypes	O
was	O
efficiently	O
inhibited	O
by	O
a	O
rabbit	O
serum	B-COMP
raised	O
against	O
SARS	O
-	O
CoV	O
particles	O
and	O
by	O
sera	B-COMP
from	O
SARS	O
patients	O
,	O
demonstrating	O
that	O
SARS	O
-	O
CoV	O
S	O
is	O
a	O
target	O
for	O
neutralizing	O
antibodies	B-COMP
and	O
that	O
such	O
antibodies	B-COMP
are	O
generated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

ABSTRACT	O
:	O
For	O
a	O
long	O
time	O
fibrinopeptide	O
A	O
(	O
FPA	O
),	O
fibrinopeptide	O
B	O
(	O
FPB	O
),	O
D	O
-	O
dimer	O
,	O
FM	O
test	O
,	O
serum	B-COMP
FDP	O
,	O
and	O
thrombin	O
anti	O
-	O
thrombin	O
complex	O
(	O
TAT	O
)	O
are	O
being	O
used	O
as	O
molecular	O
markers	O
to	O
for	O
sure	O
diagnose	O
hypercoagulable	O
state	O
and	O
thrombus	O
formation	O
.	O

The	O
soluble	O
fibrin	O
monomer	O
-	O
fibrinogen	B-COMP
complex	I-COMP
(	O
SF	O
)	O
is	O
a	O
complex	O
coupling	O
fibrin	O
monomer	O
and	O
fibrinogen	B-COMP
molecules	O
to	O
be	O
formed	O
in	O
the	O
early	O
-	O
activated	O
state	O
of	O
blood	O
coagulation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
make	O
differential	O
diagnosis	O
between	O
Pneumoniae	O
associated	O
with	O
SIRS	O
and	O
Coagulopathy	O
(	O
PASC	O
)	O
and	O
Simple	O
Pneumoniae	O
(	O
SP	O
)	O
by	O
using	O
a	O
newly	O
developed	O
SF	O
test	O
utilizing	O
an	O
SF	O
specific	O
monoclonal	O
antibody	B-COMP
(	O
IF	O
-	O
43	O
).	O

Indeed	O
,	O
the	O
results	O
do	O
show	O
that	O
the	O
CPE	O
was	O
induced	O
by	O
apoptosis	O
rather	O
than	O
necrosis	O
,	O
shown	O
by	O
typical	O
DNA	O
fragmentation	O
,	O
through	O
the	O
existence	O
of	O
apoptotic	O
bodies	O
and	O
swollen	O
mitochondria	B-COMP
.	O

TITLE	O
:	O
The	O
life	O
cycle	O
of	O
SARS	O
coronavirus	O
in	O
Vero	O
E6	O
cells	B-COMP
.	O

The	O
smooth	O
vesicles	B-COMP
fused	O
with	O
the	O
cell	B-COMP
membrane	I-COMP
,	O
and	O
the	O
mature	O
particles	O
were	O
released	O
.	O

Canine	O
coronavirus	O
BGF	O
revealed	O
a	O
full	O
length	O
non	O
-	O
structural	O
protein	O
3b	O
(	O
nsp	O
3b	O
),	O
associated	O
with	O
virulence	O
in	O
other	O
coronaviruses	O
,	O
and	O
a	O
highly	O
divergent	O
region	O
at	O
the	O
amino	O
terminal	O
domain	O
of	O
the	O
membrane	B-COMP
protein	O
that	O
may	O
be	O
implicated	O
in	O
avoiding	O
the	O
host	B-COMP
immune	O
reaction	O
.	O

The	O
definition	O
of	O
these	O
axes	O
facilitates	O
proteomic	O
analysis	O
of	O
diverse	O
biological	O
samples	O
,	O
for	O
example	O
,	O
mixtures	O
of	O
proteins	O
such	O
as	O
serum	B-COMP
samples	O
or	O
T	O
cell	B-COMP
extracts	O
.	O

Among	O
six	O
fusion	O
peptides	O
,	O
S5	O
reacted	O
with	O
monoclonal	O
antibody	B-COMP
D3C5	O
and	O
S2	O
reacted	O
with	O
monoclonal	O
antibody	B-COMP
D3D1	O
against	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
epitopes	O
recognized	O
by	O
monoclonal	O
antibodies	B-COMP
D3C5	O
and	O
D3D1	O
are	O
linear	O
,	O
and	O
correspond	O
to	O
447	O
-	O
458	O
and	O
789	O
-	O
799	O
amino	O
acids	O
of	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
respectively	O
.	O

The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
abundantly	O
expressed	O
in	O
infected	O
-	O
cell	B-COMP
culture	O
filtrate	O
as	O
demonstrable	O
by	O
Western	O
blotting	O
using	O
convalescent	O
-	O
phase	O
sera	B-COMP
from	O
patients	O
with	O
SARS	O
.	O

Using	O
a	O
panel	O
of	O
sera	B-COMP
collected	O
at	O
different	O
points	O
in	O
time	O
,	O
the	O
amount	O
of	O
circulating	O
N	O
antigen	O
was	O
found	O
to	O
peak	O
6	O
to	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

CONCLUSIONS	O
:	O
The	O
Trx	O
-	O
S2	O
fusion	O
protein	O
provides	O
a	O
basis	O
for	O
the	O
research	O
on	O
its	O
role	O
in	O
the	O
course	O
of	O
SARS	O
virus	O
infection	O
of	O
host	B-COMP
cells	B-COMP
and	O
preparation	O
of	O
recombinant	O
vaccine	O
against	O
SARS	O
virus	O
.	O

The	O
convalescent	O
SARS	O
patients	O
'	O
immune	O
function	O
gradually	O
recovers	O
,	O
and	O
the	O
effect	O
of	O
SARS	O
virus	O
on	O
activation	O
of	O
T	O
cells	B-COMP
gradually	O
disappears	O
.	O

The	O
p38	O
MAPK	O
inhibitor	O
,	O
SB203580	O
,	O
inhibited	O
effectively	O
phosphorylation	O
of	O
HSP	O
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	B-COMP
.	O

By	O
indirect	O
immunofluorescence	O
,	O
U274	O
was	O
localized	O
to	O
the	O
perinuclear	O
region	O
,	O
as	O
well	O
as	O
to	O
the	O
plasma	B-COMP
membrane	I-COMP
,	O
in	O
both	O
transfected	O
and	O
infected	O
cells	B-COMP
.	O

Using	O
an	O
N	O
terminus	O
myc	O
-	O
tagged	O
U274	O
,	O
the	O
topology	O
of	O
U274	O
and	O
its	O
expression	O
on	O
the	O
cell	B-COMP
surface	I-COMP
were	O
confirmed	O
.	O

To	O
determine	O
whether	O
neutralizing	O
antibodies	B-COMP
can	O
be	O
elicited	O
by	O
these	O
two	O
determinants	O
,	O
we	O
immunized	O
animals	O
and	O
found	O
that	O
both	O
of	O
them	O
could	O
induce	O
the	O
S2	O
-	O
specific	O
antisera	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
the	O
reaction	O
of	O
GST	O
-	O
N	O
to	O
anti	O
-	O
SARS	O
-	O
CoV	O
sera	B-COMP
was	O
positive	O
.	O

To	O
minimize	O
the	O
effects	O
of	O
sequencing	O
errors	O
and	O
additional	O
mutations	O
during	O
the	O
cell	B-COMP
culture	O
,	O
three	O
strategies	O
were	O
applied	O
to	O
estimate	O
the	O
mutation	O
rate	O
by	O
1	O
)	O
using	O
the	O
closely	O
related	O
sequences	O
as	O
background	O
controls	O
;	O
2	O
)	O
adjusting	O
the	O
divergence	O
time	O
for	O
cell	B-COMP
culture	O
;	O
or	O
3	O
)	O
using	O
the	O
common	O
variants	O
only	O
.	O

Microwave	O
treatment	O
appears	O
to	O
be	O
a	O
satisfactory	O
method	O
of	O
inactivating	O
virus	O
while	O
preserving	O
nucleic	B-COMP
acid	O
for	O
PCR	O
identification	O
.	O

Horse	O
polyclonal	O
antibody	B-COMP
against	O
SARS	O
-	O
CoV	O
was	O
bound	O
onto	O
the	O
PZ	O
crystal	O
surface	O
in	O
an	O
ordered	O
orientation	O
through	O
protein	O
A	O
.	O
The	O
antigen	O
sample	O
was	O
atomized	O
into	O
aerosol	O
by	O
an	O
ultrasonator	O
,	O
by	O
which	O
the	O
antibody	B-COMP
on	O
the	O
crystal	O
could	O
specifically	O
adsorb	O
SARS	O
antigen	O
and	O
the	O
changed	O
mass	O
of	O
crystal	O
would	O
lead	O
a	O
frequency	O
shift	O
.	O

Self	O
-	O
designed	O
questionnaires	O
were	O
used	O
and	O
serum	B-COMP
samples	O
were	O
tested	O
.	O

The	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
was	O
first	O
determined	O
in	O
sera	B-COMP
on	O
the	O
9th	O
day	O
by	O
Euroimmun	O
IFA	O
,	O
12th	O
day	O
by	O
EIA	O
No	O
.	O
B	O
,	O
13th	O
day	O
by	O
Australian	O
IFA	O
,	O
and	O
16th	O
day	O
by	O
EIA	O
No	O
.	O
A	O
.	O
The	O
positive	O
rates	O
of	O
antibody	B-COMP
on	O
the	O
3rd	O
week	O
after	O
onset	O
were	O
84	O
.	O
2	O
%	O
(	O
16	O
/	O
19	O
),	O
94	O
.	O
7	O
%	O
(	O
18	O
/	O
19	O
),	O
78	O
.	O
9	O
%	O
(	O
15	O
/	O
19	O
)	O
and	O
52	O
.	O
6	O
%	O
(	O
10	O
/	O
19	O
)	O
respectively	O
.	O

Antiviral	O
activity	O
was	O
estimated	O
by	O
the	O
inhibition	O
of	O
the	O
SARS	O
-	O
CoV	O
cytopathic	O
effect	O
in	O
Vero	O
E6	O
cells	B-COMP
,	O
determined	O
by	O
a	O
tetrazolium	O
-	O
based	O
colorimetric	O
method	O
.	O

The	O
survival	O
rate	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	B-COMP
was	O
greatly	O
increased	O
by	O
the	O
treatment	O
with	O
SNAP	O
,	O
and	O
the	O
concentration	O
of	O
this	O
compound	O
needed	O
to	O
inhibit	O
the	O
viral	O
cytopathic	O
effect	O
to	O
50	O
%	O
was	O
222	O
microM	O
,	O
with	O
a	O
selectivity	O
index	O
of	O
3	O
.	O

Twelve	O
serum	B-COMP
samples	O
from	O
convalescent	O
patients	O
,	O
diluted	O
by	O
1	O
:	O
8	O
with	O
maintenance	O
medium	O
,	O
were	O
mixed	O
with	O
the	O
three	O
dilution	O
supernatants	O
of	O
SARS	O
-	O
CoV	O
.	O
SARS	O
-	O
CoV	O
were	O
isolated	O
,	O
cultured	O
and	O
identified	O
by	O
the	O
Guangzhou	O
Institute	O
of	O
Respiratory	O
Disease	O
,	O
and	O
cultured	O
with	O
Vero	O
E6	O
cell	B-COMP
suspension	O
.	O

RESULTS	O
:	O
The	O
absorbance	O
(	O
A	O
)	O
value	O
of	O
SARS	O
-	O
CoV	O
IgG	B-COMP
antibody	I-COMP
ranged	O
from	O
0	O
.	O
81	O
to	O
2	O
.	O
06	O
in	O
patients	O
after	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
,	O
and	O
form	O
0	O
.	O
79	O
to	O
2	O
.	O
01	O
in	O
patients	O
before	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
.	O

TITLE	O
:	O
Longitudinal	O
profile	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
),	O
IgM	O
,	O
and	O
IgA	O
antibodies	B-COMP
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
in	O
patients	O
with	O
pneumonia	O
due	O
to	O
the	O
SARS	O
coronavirus	O
.	O

At	O
day	O
240	O
,	O
36	O
%	O
of	O
the	O
patients	O
were	O
still	O
positive	O
for	O
anti	O
-	O
nucleocapsid	B-COMP
protein	O
IgM	B-COMP
antibody	I-COMP
.	O

TITLE	O
:	O
Discovery	O
of	O
novel	O
human	O
and	O
animal	O
cells	B-COMP
infected	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
by	O
replication	O
-	O
specific	O
multiplex	O
reverse	O
transcription	O
-	O
PCR	O
.	O

VeroE6	O
cells	B-COMP
,	O
fetal	O
rhesus	O
monkey	O
kidney	O
cells	B-COMP
,	O
and	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
were	O
the	O
only	O
cells	B-COMP
known	O
to	O
be	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
.	O
We	O
developed	O
a	O
multiplex	O
reverse	O
transcription	O
-	O
PCR	O
assay	O
to	O
analyze	O
the	O
susceptibility	O
of	O
cells	B-COMP
derived	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
species	O
to	O
SARS	O
-	O
CoV	O
.	O
Additionally	O
,	O
productive	O
infection	O
was	O
determined	O
by	O
titration	O
of	O
cellular	B-COMP
supernatants	O
.	O

Mink	O
lung	O
epithelial	O
cells	B-COMP
(	O
Mv1Lu	O
)	O
and	O
R	O
-	O
Mix	O
,	O
a	O
mixed	O
monolayer	O
of	O
human	O
lung	O
-	O
derived	O
cells	B-COMP
(	O
A549	O
)	O
and	O
mink	O
lung	O
-	O
derived	O
cells	B-COMP
(	O
Mv1Lu	O
),	O
are	O
used	O
by	O
diagnostic	O
laboratories	O
to	O
detect	O
respiratory	O
viruses	O
(	O
e	O
.	O
g	O
.,	O
influenza	O
virus	O
);	O
they	O
were	O
also	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
indicating	O
that	O
the	O
practices	O
of	O
diagnostic	O
laboratories	O
should	O
be	O
examined	O
to	O
ensure	O
appropriate	O
biosafety	O
precautions	O
.	O

The	O
development	O
of	O
auto	O
-	O
immune	O
antibodies	B-COMP
or	O
immune	O
complexes	O
triggered	O
by	O
viral	O
infection	O
may	O
play	O
a	O
major	O
role	O
in	O
inducing	O
lymphopenia	O
and	O
thrombocytopenia	O
.	O

The	O
optical	O
density	O
value	O
of	O
the	O
immunological	O
reaction	O
of	O
synthesized	O
8	O
peptides	O
with	O
SARS	O
patient	O
serum	B-COMP
was	O
1	O
.	O
5	O
-	O
2	O
.	O
6	O
times	O
higher	O
than	O
that	O
with	O
normal	O
serum	B-COMP
.	O

The	O
8	O
peptides	O
from	O
S1	O
domain	O
of	O
S	O
protein	O
appear	O
to	O
have	O
low	O
immunogenicity	O
to	O
the	O
serum	B-COMP
of	O
SARS	O
patients	O
,	O
indicating	O
that	O
these	O
peptides	O
may	O
not	O
be	O
the	O
epitope	O
of	O
the	O
SARS	O
-	O
Cov	O
.	O

CONCLUSIONS	O
:	O
The	O
8	O
peptides	O
from	O
S1	O
domain	O
of	O
S	O
protein	O
appear	O
to	O
have	O
low	O
immunogenicity	O
to	O
the	O
serum	B-COMP
of	O
SARS	O
patients	O
,	O
indicating	O
that	O
these	O
peptides	O
may	O
not	O
be	O
the	O
epitope	O
of	O
the	O
SARS	O
-	O
Cov	O
.	O

TITLE	O
:	O
Persistent	O
infection	O
of	O
SARS	O
coronavirus	O
in	O
colonic	O
cells	B-COMP
in	O
vitro	O
.	O

In	O
contrast	O
to	O
Vero	O
cells	B-COMP
,	O
SARS	O
-	O
CoV	O
did	O
not	O
produce	O
cytopathic	O
effects	O
on	O
LoVo	O
cells	B-COMP
.	O

Chemically	O
synthesized	O
siRNA	O
duplexes	O
were	O
transfected	O
into	O
foetal	O
rhesus	O
kidney	O
(	O
FRhK	O
-	O
4	O
)	O
cells	B-COMP
prior	O
to	O
or	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
inhibitory	O
effects	O
of	O
the	O
siRNAs	O
were	O
evaluated	O
for	O
reductions	O
of	O
intracellular	B-COMP
viral	B-COMP
genome	I-COMP
copy	O
number	O
and	O
viral	O
titres	O
in	O
the	O
cell	B-COMP
culture	O
medium	O
measured	O
by	O
Q	O
-	O
RT	O
-	O
PCR	O
and	O
CPE	O
-	O
based	O
titration	O
,	O
respectively	O
.	O

Combination	O
of	O
active	O
siRNA	O
duplexes	O
targeting	O
different	O
regions	O
of	O
the	O
viral	B-COMP
genome	I-COMP
resulted	O
in	O
therapeutic	O
activity	O
of	O
up	O
to	O
80	O
%	O
inhibition	O
.	O

Accordingly	O
,	O
S	O
-	O
protein	O
plays	O
an	O
important	O
role	O
in	O
virus	O
infection	O
cycle	O
and	O
is	O
the	O
primary	O
target	O
of	O
neutralizing	O
antibodies	B-COMP
.	O

The	O
detection	O
of	O
S	O
-	O
protein	O
by	O
immunoassays	O
was	O
difficult	O
using	O
human	O
convalescent	O
sera	B-COMP
,	O
suggesting	O
that	O
the	O
protein	O
may	O
not	O
elicit	O
strong	O
humoral	O
immune	O
response	O
in	O
virus	O
-	O
infected	O
patients	O
.	O

Our	O
predictions	O
against	O
experimental	O
data	O
from	O
four	O
melanoma	O
-	O
related	O
proteins	O
showed	O
that	O
MULTIPRED	O
ANN	O
and	O
HMM	O
models	O
could	O
predict	O
T	O
-	O
cell	B-COMP
epitopes	O
with	O
high	O
accuracy	O
.	O

Squamous	O
metaplasia	O
and	O
scattered	O
multinucleate	O
giant	O
cells	B-COMP
were	O
present	O
in	O
most	O
cases	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
229E	O
binds	O
to	O
CD13	O
in	O
rafts	O
and	O
enters	O
the	O
cell	B-COMP
through	O
caveolae	B-COMP
.	O

The	O
incubation	O
of	O
living	O
fibroblasts	O
with	O
an	O
anti	O
-	O
CD13	O
antibody	B-COMP
on	O
ice	O
gave	O
punctate	O
labeling	O
that	O
was	O
evenly	O
distributed	O
on	O
the	O
cell	B-COMP
surface	I-COMP
,	O
but	O
raising	O
the	O
temperature	O
to	O
37	O
degrees	O
C	O
before	O
fixation	O
caused	O
aggregation	O
of	O
the	O
labeling	O
.	O

The	O
HCoV	O
-	O
229E	O
virus	B-COMP
particle	I-COMP
showed	O
a	O
binding	O
and	O
redistribution	O
pattern	O
that	O
was	O
similar	O
to	O
that	O
caused	O
by	O
the	O
anti	O
-	O
CD13	O
antibody	B-COMP
:	O
the	O
virus	O
bound	O
to	O
the	O
cell	B-COMP
evenly	O
when	O
incubated	O
on	O
ice	O
but	O
became	O
colocalized	O
with	O
caveolin	O
-	O
1	O
at	O
37	O
degrees	O
C	O
;	O
importantly	O
,	O
the	O
virus	O
also	O
caused	O
sequestration	O
of	O
CD13	O
to	O
the	O
caveolin	O
-	O
1	O
-	O
positive	O
area	O
.	O

TITLE	O
:	O
Antibody	B-COMP
responses	O
against	O
SARS	O
-	O
coronavirus	O
and	O
its	O
nucleocaspid	O
in	O
SARS	O
patients	O
.	O

Serial	O
serum	B-COMP
samples	O
from	O
14	O
SARS	O
patients	O
were	O
isolated	O
from	O
7	O
to	O
210	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
,	O
and	O
were	O
tested	O
for	O
anti	O
-	O
viral	O
IgG	O
and	O
IgM	O
by	O
indirect	O
immunofluorescence	O
tests	O
(	O
IFA	O
),	O
anti	O
-	O
nucleocaspid	O
antibody	B-COMP
by	O
ELISA	O
tests	O
and	O
viral	O
neutralization	O
.	O

Neutralizing	O
viral	O
antibodies	B-COMP
were	O
demonstrated	O
in	O
the	O
sera	B-COMP
from	O
all	O
of	O
the	O
patients	O
with	O
SARS	O
symptoms	O
.	O

Here	O
we	O
describe	O
the	O
molecular	O
characterization	O
of	O
SCoV	O
E	O
protein	O
,	O
a	O
critical	O
component	O
of	O
the	O
virus	O
responsible	O
for	O
virion	B-COMP
envelope	B-COMP
morphogenesis	O
.	O

An	O
immunofluorescence	O
assay	O
indicated	O
high	O
levels	O
of	O
exposure	O
to	O
coronavirus	O
among	O
Serengeti	O
hyenas	O
:	O
95	O
%	O
when	O
considering	O
sera	B-COMP
with	O
titer	O
levels	O
of	O
>	O
or	O
=	O
1	O
:	O
10	O
and	O
74	O
%	O
when	O
considering	O
sera	B-COMP
with	O
titer	O
levels	O
of	O
>	O
or	O
=	O
1	O
:	O
40	O
.	O

Exposure	O
among	O
Serengeti	O
hyenas	O
to	O
coronavirus	O
was	O
also	O
confirmed	O
by	O
a	O
serum	B-COMP
neutralisation	O
assay	O
and	O
an	O
ELISA	O
.	O

TITLE	O
:	O
Mouse	O
antibody	B-COMP
production	O
test	O
:	O
can	O
we	O
do	O
without	O
it	O
?	O

In	O
this	O
report	O
,	O
the	O
sensitivity	O
of	O
the	O
viral	O
plaque	O
assay	O
,	O
mouse	O
antibody	B-COMP
production	O
test	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
detection	O
of	O
MHV	O
-	O
A59	O
and	O
MMVp	O
,	O
two	O
of	O
the	O
most	O
prevalent	O
pathogenic	O
viruses	O
in	O
experimental	O
mouse	O
facilities	O
,	O
was	O
compared	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
N	O
is	O
capable	O
of	O
inducing	O
apoptosis	O
of	O
COS	O
-	O
1	O
monkey	O
kidney	O
cells	B-COMP
in	O
the	O
absence	O
of	O
growth	O
factors	O
by	O
down	O
-	O
regulating	O
ERK	O
(	O
extracellular	B-COMP
-	O
signal	O
-	O
regulated	O
kinase	O
),	O
up	O
-	O
regulating	O
JNK	O
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
and	O
p38	O
MAPK	O
(	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
)	O
pathways	O
,	O
and	O
affecting	O
their	O
downstream	O
effectors	O
.	O

TITLE	O
:	O
Recombinant	O
scFv	O
antibodies	B-COMP
against	O
E	O
protein	O
and	O
N	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
virus	O
.	O

ABSTRACT	O
:	O
Three	O
single	O
chain	O
antibodies	B-COMP
(	O
scFv	O
)	O
against	O
the	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
isolated	O
by	O
phage	O
display	O
from	O
an	O
scFv	O
antibody	B-COMP
library	O
.	O

TITLE	O
:	O
A	O
novel	O
sorting	O
signal	O
for	O
intracellular	B-COMP
localization	O
is	O
present	O
in	O
the	O
S	O
protein	O
of	O
a	O
porcine	O
coronavirus	O
but	O
absent	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
moved	O
into	O
humans	O
from	O
a	O
reservoir	O
species	O
and	O
subsequently	O
caused	O
an	O
epidemic	O
in	O
its	O
new	O
host	B-COMP
.	O

Efficient	O
gene	O
transfer	O
could	O
be	O
detected	O
in	O
Vero	O
and	O
CaCo2	O
cells	B-COMP
,	O
whereas	O
the	O
level	O
of	O
gene	O
marking	O
of	O
293T	O
,	O
HeLa	O
,	O
and	O
HepG2	O
cells	B-COMP
was	O
only	O
slightly	O
above	O
background	O
levels	O
.	O

Interestingly	O
,	O
PK	O
-	O
15	O
,	O
a	O
porcine	O
kidney	O
cell	B-COMP
line	O
,	O
and	O
primary	O
porcine	O
kidney	O
cells	B-COMP
were	O
also	O
highly	O
permissive	O
for	O
SARS	O
S	O
pseudotypes	O
and	O
wild	O
-	O
type	O
SARS	O
CoV	O
.	O
This	O
finding	O
suggests	O
that	O
swine	O
may	O
be	O
susceptible	O
to	O
SARS	O
infection	O
and	O
may	O
be	O
a	O
source	O
for	O
infection	O
of	O
humans	O
.	O

ELISA	O
indicated	O
that	O
sera	B-COMP
from	O
SARS	O
patients	O
have	O
significant	O
positive	O
reactions	O
with	O
synthesized	O
peptides	O
derived	O
from	O
the	O
3a	O
protein	O
.	O

The	O
serum	B-COMP
samples	O
could	O
neutralize	O
the	O
pseudotype	O
particles	O
bearing	O
the	O
spike	O
glycoproteins	O
from	O
different	O
SARS	O
-	O
CoV	O
strains	O
,	O
suggesting	O
that	O
the	O
NAbs	O
to	O
SARS	O
-	O
CoV	O
were	O
broadly	O
reactive	O
.	O

Furthermore	O
,	O
APC	B-COMP
reduces	O
the	O
ischemia	O
/	O
reperfusion	O
-	O
induced	O
renal	O
injury	O
and	O
the	O
stress	O
-	O
induced	O
gastric	O
mucosal	O
injury	O
in	O
rats	O
.	O

Inhibition	O
by	O
APC	B-COMP
of	O
the	O
endothelial	O
cell	B-COMP
damage	O
inhibited	O
the	O
decrease	O
in	O
the	O
endothelial	O
production	O
of	O
prostacyclin	O
in	O
vivo	O
.	O

All	O
sera	B-COMP
tested	O
contained	O
Ab	O
to	O
cryptic	O
FAH	O
epitopes	O
according	O
with	O
results	O
from	O
western	O
-	O
blot	O
tests	O
,	O
whereas	O
ELISA	O
data	O
indicated	O
that	O
some	O
of	O
these	O
same	O
sera	B-COMP
did	O
recognize	O
native	O
epitopes	O
of	O
the	O
autoantigen	O
(	O
autoAg	O
).	O

The	O
results	O
indicate	O
that	O
CCL3	O
participates	O
in	O
an	O
effective	O
host	B-COMP
response	O
to	O
MHV	O
infection	O
by	O
contributing	O
to	O
CD11c	O
+	O
CD11b	O
+	O
CD8alpha	O
-	O
DC	O
maturation	O
,	O
activation	O
,	O
and	O
migration	O
to	O
cervical	O
lymph	O
nodes	O
(	O
CLN	O
).	O

Diminished	O
CD8alpha	O
-	O
DC	O
activation	O
correlated	O
with	O
reduced	O
IFN	O
-	O
gamma	O
expression	O
by	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
accompanied	O
by	O
increased	O
IL	O
-	O
10	O
production	O
suggesting	O
that	O
CCL3	O
contributes	O
to	O
an	O
effective	O
host	B-COMP
response	O
to	O
viral	O
infection	O
by	O
enhancing	O
the	O
T	O
cell	B-COMP
activation	O
potential	O
of	O
DC	O
.	O

For	O
the	O
prototype	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
it	O
has	O
previously	O
been	O
established	O
that	O
S	O
protein	O
assembly	O
into	O
virions	B-COMP
is	O
specified	O
by	O
the	O
carboxy	O
-	O
terminal	O
segment	O
,	O
which	O
comprises	O
the	O
transmembrane	B-COMP
domain	O
and	O
the	O
endodomain	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
the	O
adjacent	O
cysteine	O
-	O
rich	O
region	O
of	O
the	O
endodomain	O
is	O
critical	O
for	O
fusion	O
of	O
infected	O
cells	B-COMP
,	O
confirming	O
results	O
previously	O
obtained	O
with	O
S	O
protein	O
expression	O
systems	O
.	O

Immunoblot	O
analysis	O
of	O
infected	O
-	O
cell	B-COMP
lysates	O
identified	O
proteins	O
of	O
the	O
predicted	O
sizes	O
.	O

More	O
than	O
94	O
%	O
of	O
cases	O
with	O
SARS	O
could	O
produce	O
IgG	B-COMP
antibody	I-COMP
when	O
they	O
were	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Detecting	O
SARS	O
-	O
CoV	O
IgG	O
could	O
provide	O
a	O
diagnostic	O
evidence	O
for	O
case	O
confirmation	O
.	O

Then	O
the	O
high	O
rate	O
of	O
antibody	B-COMP
was	O
maintained	O
for	O
more	O
than	O
6	O
months	O
.	O

The	O
major	O
pathological	O
changes	O
of	O
2	O
autopsy	O
cases	O
of	O
SARS	O
in	O
lung	O
tissues	O
were	O
acute	O
pulmonary	O
interstitial	O
and	O
alveolar	O
exudative	O
inflammation	O
,	O
and	O
2	O
autopsy	O
and	O
one	O
biopsy	O
lung	O
tissues	O
showed	O
alveolar	O
hyaline	O
membrane	B-COMP
formation	O
.	O

RESULTS	O
:	O
In	O
total	O
of	O
6	O
cases	O
,	O
diffuse	O
alveolar	O
damage	O
and	O
alveolar	O
cell	B-COMP
proliferation	O
were	O
common	O
.	O

TITLE	O
:	O
Importance	O
of	O
Akt	O
signaling	O
pathway	O
for	O
apoptosis	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

The	O
results	O
of	O
the	O
present	O
study	O
indicated	O
that	O
before	O
cell	B-COMP
death	O
,	O
Akt	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
apoptosis	O
,	O
was	O
also	O
activated	O
in	O
response	O
to	O
viral	O
replication	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
highly	O
immunogenic	O
during	O
infection	O
and	O
immunizations	O
,	O
and	O
contains	O
five	O
linear	O
immunodominant	O
sites	O
(	O
sites	O
I	O
to	O
V	O
)	O
as	O
determined	O
by	O
Pepscan	O
analysis	O
with	O
a	O
set	O
of	O
synthetic	O
peptides	O
overlapping	O
the	O
entire	O
S	O
protein	O
sequence	O
against	O
the	O
convalescent	O
sera	B-COMP
from	O
SARS	O
patients	O
and	O
antisera	O
from	O
small	O
animals	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
Site	O
IV	O
located	O
in	O
the	O
middle	O
region	O
of	O
the	O
S	O
protein	O
(	O
residues	O
528	O
-	O
635	O
)	O
is	O
a	O
major	O
immunodominant	O
epitope	O
.	O

ABSTRACT	O
:	O
Ampligen	O
[	O
polyI	O
:	O
polyC12U	O
]	O
is	O
a	O
mismatched	O
double	O
-	O
stranded	O
RNA	O
that	O
acts	O
by	O
inducing	O
interferon	O
production	O
(	O
immunomodulator	O
)	O
and	O
by	O
activating	O
an	O
intracellular	B-COMP
enzyme	O
(	O
RNase	O
-	O
L	O
)	O
against	O
viral	O
RNA	O
transcripts	O
(	O
antiviral	O
).	O

SARS	O
-	O
CoV	O
antibody	B-COMP
binding	O
assays	O
indicated	O
that	O
SARS	O
specific	O
antibodies	B-COMP
inhibited	O
SARS	O
-	O
CoV	O
viral	O
replication	O
.	O

Nucleocapsid	B-COMP
protein	O
(	O
NP	O
)	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS_NP	O
)	O
functions	O
in	O
enveloping	O
the	O
entire	O
genomic	O
RNA	O
and	O
interacts	O
with	O
viron	O
structural	O
proteins	O
,	O
thus	O
playing	O
important	O
roles	O
in	O
the	O
process	O
of	O
virus	B-COMP
particle	I-COMP
assembly	O
and	O
release	O
.	O

The	O
acute	O
exudative	O
protein	O
was	O
PAS	B-COMP
-	O
positive	O
.	O

Immunohistochemistry	O
showed	O
mainly	O
types	O
I	O
and	O
IV	O
collagen	B-COMP
fibers	O
.	O

The	O
primitive	O
mesenchymal	O
cells	B-COMP
,	O
hyperplastic	O
alveolar	O
epithelial	O
cells	B-COMP
and	O
macrophages	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
.	O

TITLE	O
:	O
Protein	O
chip	O
array	O
profiling	O
analysis	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
identified	O
serum	B-COMP
amyloid	O
a	O
protein	O
as	O
a	O
biomarker	O
potentially	O
useful	O
in	O
monitoring	O
the	O
extent	O
of	O
pneumonia	O
.	O

When	O
we	O
monitored	O
the	O
SAA	O
concentrations	O
longitudinally	O
in	O
45	O
sera	B-COMP
from	O
four	O
SARS	O
patients	O
,	O
we	O
found	O
a	O
good	O
correlation	O
of	O
SAA	O
concentration	O
with	O
the	O
extent	O
of	O
pneumonia	O
as	O
assessed	O
by	O
a	O
serial	O
chest	O
x	O
-	O
ray	O
opacity	O
score	O
.	O

The	O
results	O
of	O
serum	B-COMP
immunological	O
examination	O
showed	O
that	O
after	O
administration	O
of	O
KBD	O
,	O
the	O
immunity	O
of	O
organism	O
was	O
improved	O
and	O
elevated	O
.	O

While	O
the	O
expressed	O
full	O
-	O
length	O
S	O
glycoprotein	O
was	O
exclusively	O
cell	B-COMP
associated	I-COMP
,	O
a	O
truncation	O
of	O
S	O
by	O
excluding	O
the	O
C	O
-	O
terminal	O
transmembrane	B-COMP
and	O
cytoplasmic	B-COMP
tail	O
domains	O
resulted	O
in	O
the	O
expression	O
of	O
an	O
endoplasmic	B-COMP
reticulum	I-COMP
-	O
localized	O
glycoprotein	O
(	O
gp160	O
)	O
as	O
well	O
as	O
a	O
Golgi	B-COMP
-	O
specific	O
form	O
(	O
gp170	O
)	O
which	O
was	O
ultimately	O
secreted	O
into	O
the	O
cell	B-COMP
culture	O
medium	O
.	O

Three	O
months	O
after	O
the	O
discharge	O
ELISA	O
and	O
indirect	O
immunofluorescent	O
antibody	B-COMP
(	O
IFA	O
)	O
assay	O
were	O
used	O
to	O
detect	O
the	O
serum	B-COMP
IgG	O
.	O
Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
was	O
used	O
to	O
detect	O
the	O
damage	O
of	O
the	O
head	O
of	O
femur	O
and	O
quantitative	O
ultrasound	O
(	O
QUS	O
)	O
was	O
used	O
to	O
detect	O
osteoporosis	O
at	O
the	O
left	O
heel	O
.	O

ELISPOT	O
detection	O
of	O
primary	O
B	O
cells	B-COMP
could	O
be	O
useful	O
in	O
the	O
early	O
detection	O
of	O
infection	O
following	O
infection	O
with	O
respiratory	O
coronaviruses	O
.	O

TITLE	O
:	O
Efficient	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
mouse	O
cells	B-COMP
is	O
limited	O
by	O
murine	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

Univariate	O
analysis	O
revealed	O
that	O
control	O
calves	O
with	O
intranasal	O
BRD	O
on	O
entry	O
to	O
the	O
feedlot	O
and	O
those	O
with	O
antibody	B-COMP
titer	O
<	O
20	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
treated	O
for	O
BRD	O
.	O

This	O
includes	O
individual	O
health	O
and	O
safety	O
issues	O
,	O
travel	O
and	O
lodging	O
,	O
and	O
the	O
nature	O
of	O
the	O
host	B-COMP
country	O
culture	O
,	O
health	O
care	O
system	O
,	O
and	O
assignment	O
site	O
.	O

In	O
addition	O
,	O
immunofluorescence	O
and	O
FACS	O
analysis	O
confirmed	O
the	O
cell	B-COMP
surface	I-COMP
expression	O
of	O
the	O
S	O
protein	O
.	O

In	O
addition	O
,	O
we	O
introduced	O
a	O
31	O
-	O
mer	O
peptide	O
containing	O
an	O
auto	O
-	O
cleavage	O
site	O
to	O
the	O
N	O
-	O
terminal	O
of	O
the	O
proteases	O
and	O
found	O
the	O
peptide	O
could	O
be	O
cleaved	O
efficiently	O
by	O
3CLsc	O
itself	O
,	O
but	O
,	O
among	O
the	O
four	O
mutants	O
,	O
only	O
the	O
mutant	O
Cys145	O
-->	O
Ser	B-COMP
showed	O
residual	O
activity	O
as	O
detected	O
by	O
the	O
auto	O
-	O
cleavage	O
assay	O
.	O

Here	O
we	O
show	O
that	O
a	O
recombinant	O
fusion	O
protein	O
(	O
designated	O
RBD	O
-	O
Fc	O
)	O
containing	O
193	O
-	O
amino	O
acid	O
RBD	O
(	O
residues	O
318	O
-	O
510	O
)	O
and	O
a	O
human	O
IgG1	B-COMP
Fc	O
fragment	O
can	O
induce	O
highly	O
potent	O
antibody	B-COMP
responses	O
in	O
the	O
immunized	O
rabbits	O
.	O

The	O
term	O
is	O
strictly	O
related	O
to	O
plague	O
and	O
dates	O
back	O
to	O
1377	O
,	O
when	O
the	O
Rector	O
of	O
the	O
seaport	O
of	O
Ragusa	O
(	O
then	O
belonging	O
to	O
the	O
Venetian	O
Republic	O
)	O
officially	O
issued	O
a	O
30	O
-	O
day	O
isolation	O
period	O
for	O
ships	O
,	O
that	O
became	O
40	O
days	O
for	O
land	B-COMP
travellers	O
.	O

For	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
the	O
first	O
proteolytic	O
processing	O
event	O
of	O
the	O
replicase	O
polyprotein	O
liberates	O
an	O
amino	O
-	O
terminal	O
28	O
-	O
kDa	O
product	O
(	O
p28	B-COMP
).	O

While	O
previous	O
biochemical	O
studies	O
have	O
suggested	O
that	O
p28	B-COMP
is	O
associated	O
with	O
viral	O
replication	O
complexes	O
,	O
the	O
intracellular	B-COMP
localization	O
and	O
interactions	O
of	O
p28	B-COMP
with	O
other	O
proteins	O
during	O
the	O
course	O
of	O
MHV	O
replication	O
have	O
not	O
been	O
defined	O
.	O

To	O
express	O
the	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
at	O
high	O
-	O
level	O
in	O
vitro	O
,	O
the	O
M	O
gene	O
fragment	O
was	O
amplified	O
and	O
cloned	O
it	O
into	O
the	O
Pichia	O
Pastoris	O
expression	O
vector	O
pPICZalphaA	O
.	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
analysis	O
of	O
the	O
induced	O
products	O
of	O
recombinant	O
yeast	O
transformant	O
indicated	O
that	O
successful	O
high	O
-	O
level	O
expression	O
of	O
M	O
protein	O
was	O
achieved	O
,	O
and	O
that	O
the	O
expression	O
product	O
was	O
similar	O
antigenically	O
to	O
the	O
natural	O
protein	O
.	O

A	O
molecular	O
characterization	O
of	O
nine	O
monoclonal	O
antibodies	B-COMP
raised	O
in	O
immune	O
mice	O
,	O
using	O
highly	O
purified	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
as	O
the	O
inoculating	O
antigen	O
,	O
is	O
presented	O
in	O
this	O
report	O
.	O

Serum	B-COMP
potassium	O
reached	O
its	O
nadir	O
in	O
the	O
first	O
week	O
of	O
GCS	O
treatment	O
and	O
then	O
grew	O
up	O
in	O
the	O
second	O
week	O
.	O

Appropriate	O
low	O
dosage	O
of	O
GCS	O
(	O
MP	O
(	O
Initial	O
)	O
and	O
MP	O
(	O
Maximal	O
)	O
<	O
159	O
mg	O
/	O
d	O
,	O
MP	O
(	O
Cumulative	O
)<	O
2999	O
mg	O
)	O
causes	O
few	O
changes	O
of	O
blood	O
glucose	O
,	O
serum	B-COMP
potassium	O
,	O
and	O
blood	O
calcium	O
.	O

Recently	O
solved	O
high	O
-	O
resolution	O
crystal	O
structures	O
of	O
the	O
apo	O
-	O
bound	O
and	O
inhibitor	O
-	O
bound	O
forms	O
of	O
ACE2	O
have	O
provided	O
the	O
basis	O
for	O
a	O
novel	O
molecular	O
docking	O
approach	O
in	O
an	O
attempt	O
to	O
identify	O
ACE2	O
inhibitors	O
and	O
compounds	O
that	O
block	O
SARS	O
coronavirus	O
spike	O
protein	O
-	O
mediated	O
cell	B-COMP
fusion	O
.	O

In	O
this	O
structure	O
-	O
activity	O
relation	O
study	O
,	O
the	O
molecules	O
with	O
the	O
highest	O
predicted	O
binding	O
scores	O
were	O
identified	O
and	O
assayed	O
for	O
ACE2	O
enzymatic	O
inhibitory	O
activity	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	O
coronavirus	O
spike	O
protein	O
-	O
mediated	O
cell	B-COMP
fusion	O
.	O

One	O
mechanism	O
involves	O
the	O
presence	O
of	O
antibodies	B-COMP
to	O
white	O
blood	O
cells	B-COMP
,	O
usually	O
in	O
a	O
transfused	O
blood	O
component	O
.	O

Serum	B-COMP
viral	O
load	O
(	O
n	O
=	O
53	O
)	O
was	O
associated	O
with	O
oxygen	O
desaturation	O
,	O
mechanical	O
ventilation	O
,	O
and	O
death	O
.	O

The	O
plasmid	O
pEGFP	O
-	O
optS	O
,	O
which	O
contains	O
the	O
codon	O
-	O
optimized	O
SARS	O
-	O
CoV	O
S	O
gene	O
and	O
expresses	O
spike	O
-	O
EGFP	O
fusion	O
protein	O
(	O
S	O
-	O
EGFP	O
)	O
as	O
silencing	O
target	O
and	O
expressing	O
reporter	O
,	O
was	O
transfected	O
with	O
siRNAs	O
into	O
HEK	O
293T	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Programmed	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
is	O
an	O
alternate	O
mechanism	O
of	O
translation	O
used	O
by	O
coronavirus	O
to	O
synthesize	O
replication	O
proteins	O
encoded	O
by	O
two	O
overlapping	O
open	O
reading	O
frames	O
.	O

We	O
found	O
that	O
the	O
more	O
virulent	O
field	O
isolates	O
grew	O
to	O
significantly	O
higher	O
levels	O
in	O
pigs	O
than	O
did	O
cell	B-COMP
-	O
culture	O
adapted	O
isolates	O
.	O

ABSTRACT	O
:	O
The	O
construction	O
of	O
a	O
set	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)-	O
derived	O
replicons	O
as	O
bacterial	O
artificial	O
chromosomes	B-COMP
is	O
reported	O
.	O

Recombinant	O
hexa	O
-	O
histidine	O
-	O
tagged	O
N	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
47	O
kD	O
was	O
produced	O
in	O
insect	O
cells	B-COMP
.	O

The	O
paucity	O
in	O
T	O
cell	B-COMP
accumulation	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
MHV	O
-	O
infected	O
CCR2	O
(-/-)	O
mice	O
was	O
not	O
the	O
result	O
of	O
either	O
a	O
deficiency	O
in	O
antigen	O
-	O
presenting	O
cell	B-COMP
(	O
APC	B-COMP
)	O
accumulation	O
within	O
draining	O
cervical	O
lymph	O
nodes	O
(	O
CLN	O
)	O
or	O
the	O
generation	O
of	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
within	O
this	O
compartment	O
.	O

ABSTRACT	O
:	O
To	O
promote	O
viral	O
entry	O
,	O
replication	O
,	O
release	O
,	O
and	O
spread	O
to	O
neighboring	O
cells	B-COMP
,	O
many	O
cytolytic	O
animal	O
viruses	O
encode	O
proteins	O
responsible	O
for	O
modification	O
of	O
host	B-COMP
cell	I-COMP
membrane	I-COMP
permeability	O
and	O
for	O
formation	O
of	O
ion	O
channels	O
in	O
host	O
cell	B-COMP
membranes	I-COMP
during	O
their	O
life	O
cycles	O
.	O

TITLE	O
:	O
Tyrosine	O
dephosphorylation	O
of	O
STAT3	O
in	O
SARS	O
coronavirus	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
its	O
downstream	O
targets	O
are	O
activated	O
in	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
infected	O
Vero	O
E6	O
cells	B-COMP
and	O
activation	O
of	O
p38	O
MAPK	O
enhances	O
the	O
cytopathic	O
effects	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Coronaviruses	O
including	O
SARS	O
-	O
CoV	O
encode	O
an	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
,	O
a	O
small	O
,	O
hydrophobic	O
membrane	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
Antigenic	O
sites	O
on	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
mapped	O
by	O
Pepscan	O
analysis	O
with	O
overlapping	O
peptides	O
that	O
span	O
the	O
N	O
protein	O
sequence	O
.	O

Two	O
major	O
immunodominant	O
epitopes	O
located	O
in	O
the	O
C	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
[	O
aa	O
]	O
362	O
to	O
412	O
)	O
and	O
middle	O
region	O
(	O
aa	O
153	O
to	O
178	O
)	O
reacted	O
with	O
more	O
than	O
75	O
%	O
of	O
sera	B-COMP
from	O
SARS	O
patients	O
.	O

Based	O
on	O
their	O
phylogenetic	O
tree	O
,	O
13	O
strains	O
were	O
selected	O
for	O
sequencing	O
the	O
entire	O
S1	O
and	O
partial	O
nucleocapsid	B-COMP
(	O
N	O
)	O
genes	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
SARS	O
-	O
CoV	O
inactivated	O
by	O
beta	O
-	O
propiolactone	O
elicited	O
high	O
titers	O
of	O
antibodies	B-COMP
in	O
the	O
immunized	O
mice	O
and	O
rabbits	O
that	O
recognize	O
the	O
spike	O
(	O
S	O
)	O
protein	O
,	O
especially	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
S1	O
region	O
.	O

The	O
antisera	O
from	O
the	O
immunized	O
animals	O
efficiently	O
bound	O
to	O
the	O
RBD	O
and	O
blocked	O
binding	O
of	O
RBD	O
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
the	O
functional	O
receptor	O
on	O
the	O
susceptible	O
cells	B-COMP
for	O
SARS	O
-	O
CoV	O
.	O
With	O
a	O
sensitive	O
and	O
quantitative	O
single	O
-	O
cycle	O
infection	O
assay	O
using	O
pseudovirus	O
bearing	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
,	O
we	O
demonstrated	O
that	O
mouse	O
and	O
rabbit	O
antisera	O
significantly	O
inhibited	O
S	O
protein	O
-	O
mediated	O
virus	O
entry	O
with	O
mean	O
50	O
%	O
inhibitory	O
titers	O
of	O
1	O
:	O
7393	O
and	O
1	O
:	O
2060	O
,	O
respectively	O
.	O

Above	O
90	O
.	O
00	O
%	O
patients	O
had	O
normal	O
or	O
low	O
white	O
blood	O
cell	B-COMP
(	O
WBC	O
)	O
count	O
on	O
the	O
first	O
day	O
.	O

The	O
changes	O
in	O
serum	B-COMP
biochemistry	O
are	O
more	O
marked	O
in	O
SARS	O
patients	O
compared	O
with	O
patients	O
suffering	O
from	O
other	O
viral	O
pneumonias	O
,	O
the	O
decrease	O
of	O
Fe	O
as	O
well	O
as	O
the	O
inhibition	O
of	O
TC	O
may	O
be	O
caused	O
by	O
the	O
treatment	O
of	O
anti	O
-	O
virus	O
.	O

ABSTRACT	O
:	O
A	O
Western	O
immunoblot	O
assay	O
for	O
confirmatory	O
serodiagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
was	O
developed	O
utilizing	O
viral	O
lysate	O
antigens	O
combined	O
with	O
a	O
recombinant	O
nucleocapsid	B-COMP
protein	O
,	O
GST	O
-	O
N	O
(	O
glutathione	O
S	O
-	O
transferase	O
-	O
nucleocapsid	B-COMP
)	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

In	O
Vero	O
E6	O
cells	B-COMP
,	O
the	O
antisense	O
effect	O
was	O
dependent	O
on	O
the	O
concentrations	O
of	O
the	O
antisense	O
PS	O
-	O
ODNs	O
in	O
a	O
range	O
of	O
0	O
-	O
10	O
microM	O
or	O
0	O
-	O
30	O
microM	O
.	O

The	O
clinical	O
picture	O
of	O
our	O
patients	O
presenting	O
with	O
hospital	O
-	O
acquired	O
SARS	O
revealed	O
atypical	O
pneumonia	O
associated	O
with	O
lymphopenia	O
,	O
elevated	O
serum	B-COMP
levels	O
of	O
LDH	O
,	O
rapid	O
clinical	O
deterioration	O
,	O
and	O
lack	O
of	O
response	O
to	O
empirical	O
antibiotic	O
therapy	O
.	O

TITLE	O
:	O
Nucleocapsid	B-COMP
protein	O
as	O
early	O
diagnostic	O
marker	O
for	O
SARS	O
.	O

Exploring	O
the	O
types	O
of	O
interactions	O
responsible	O
for	O
structural	O
stabilities	O
of	O
its	O
component	O
protein	O
molecules	O
constitutes	O
one	O
of	O
the	O
approaches	O
to	O
find	O
a	O
destabilization	O
method	O
for	O
the	O
virion	B-COMP
particle	O
.	O

The	O
number	O
of	O
NK	O
cells	B-COMP
was	O
in	O
the	O
low	O
level	O
at	O
onset	O
,	O
and	O
keep	O
decreasing	O
at	O
the	O
2nd	O
week	O
.	O

Specimens	O
from	O
the	O
first	O
day	O
of	O
his	O
admission	O
were	O
among	O
the	O
first	O
to	O
demonstrate	O
the	O
novel	O
coronavirus	O
,	O
by	O
culture	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
rising	O
of	O
specific	O
antibody	B-COMP
,	O
but	O
proper	O
protective	O
measures	O
remained	O
unknown	O
.	O

Serum	B-COMP
samples	O
from	O
35	O
close	O
contacts	O
obtained	O
after	O
day	O
28	O
had	O
a	O
negative	O
result	O
for	O
SARS	O
coronavirus	O
antibody	B-COMP
.	O

Site	O
-	O
specific	O
proteolysis	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
a	O
number	O
of	O
cellular	B-COMP
and	O
viral	O
processes	O
.	O

BALF	O
from	O
ARDS	O
patients	O
induced	O
41	O
%	O
greater	O
procollagen	O
I	O
promoter	O
activation	O
than	O
that	O
from	O
negative	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
a	O
TGF	O
-	O
beta1	O
blocking	O
antibody	B-COMP
significantly	O
reduced	O
this	O
activation	O
in	O
ARDS	O
patients	O
.	O

However	O
,	O
the	O
antibody	B-COMP
level	O
gradually	O
decline	O
with	O
the	O
lapse	O
of	O
time	O
during	O
the	O
convalescence	O
.	O

Titers	O
of	O
both	O
specific	O
IgG	B-COMP
antibody	I-COMP
and	O
neutralizing	O
antibody	B-COMP
peaked	O
at	O
about	O
six	O
weeks	O
after	O
first	O
vaccination	O
,	O
with	O
the	O
maximum	O
value	O
of	O
1	O
:	O
81	O
920	O
and	O
1	O
:	O
20	O
480	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
the	O
level	O
of	O
plasma	O
peroxiredoxin	O
II	O
in	O
patients	O
with	O
SARS	O
is	O
significantly	O
high	O
and	O
could	O
be	O
secreted	O
by	O
T	O
cells	B-COMP
.	O

Although	O
cell	B-COMP
cycle	O
control	O
is	O
fairly	O
well	O
characterized	O
in	O
terms	O
of	O
checkpoints	O
and	O
control	O
molecules	O
(	O
e	O
.	O
g	O
.,	O
cyclins	O
),	O
in	O
recent	O
years	O
several	O
researchers	O
have	O
demonstrated	O
that	O
the	O
nucleolus	B-COMP
is	O
also	O
involved	O
in	O
cell	B-COMP
cycle	O
control	O
.	O

The	O
nucleolus	B-COMP
and	O
associated	O
subnuclear	O
structures	O
can	O
sequester	O
cell	B-COMP
cycle	O
regulatory	O
complexes	O
,	O
and	O
nucleolar	O
proteins	O
also	O
have	O
a	O
direct	O
and	O
indirect	O
effect	O
on	O
the	O
cycling	O
cell	B-COMP
.	O

Numerous	O
approaches	O
to	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
vaccines	O
have	O
been	O
undertaken	O
,	O
and	O
there	O
is	O
evidence	O
that	O
antibodies	B-COMP
to	O
the	O
spike	O
protein	O
may	O
be	O
protective	O
from	O
replication	O
and	O
pathology	O
in	O
animal	O
models	O
.	O

This	O
paper	O
describes	O
an	O
easy	O
and	O
safe	O
cell	B-COMP
-	O
based	O
assay	O
suitable	O
for	O
studying	O
the	O
binding	O
between	O
SARS	O
-	O
CoV	O
S	O
protein	O
and	O
its	O
receptor	O
.	O

ABSTRACT	O
:	O
Using	O
paired	O
serum	B-COMP
samples	O
obtained	O
from	O
patients	O
with	O
illness	O
associated	O
with	O
increases	O
in	O
anti	O
-	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
or	O
anti	O
-	O
HCoV	O
-	O
229E	O
antibodies	B-COMP
,	O
we	O
examined	O
the	O
possibility	O
of	O
false	O
-	O
positive	O
results	O
detected	O
in	O
a	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	B-COMP
protein	O
immunoglobulin	O
G	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

TITLE	O
:	O
Induction	O
of	O
IL	O
-	O
8	O
release	O
in	O
lung	O
cells	B-COMP
via	O
activator	O
protein	O
-	O
1	O
by	O
recombinant	O
baculovirus	O
displaying	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
spike	O
proteins	O
:	O
identification	O
of	O
two	O
functional	O
regions	O
.	O

The	O
membrane	B-COMP
-	O
bound	O
proprotein	O
convertases	O
(	O
PCs	O
)	O
furin	O
,	O
PC7	O
or	O
PC5B	O
enhanced	O
the	O
production	O
of	O
the	O
approximately	O
80	O
kDa	O
protein	O
.	O

Significantly	O
,	O
overexpression	O
of	O
Bcl	O
-	O
xL	O
alone	O
was	O
sufficient	O
to	O
convert	O
acute	O
to	O
persistent	O
,	O
nonproductive	O
infection	O
in	O
CG	O
-	O
4	O
cells	B-COMP
.	O

TITLE	O
:	O
Monoclonal	O
antibodies	B-COMP
versus	O
reverse	O
transcription	O
-	O
PCR	O
for	O
detection	O
of	O
respiratory	O
viruses	O
in	O
a	O
patient	O
population	O
with	O
respiratory	O
tract	O
infections	O
admitted	O
to	O
hospital	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
recombinant	O
nucleocapsid	B-COMP
protein	O
-	O
based	O
assay	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
detection	O
.	O

The	O
titer	O
of	O
serum	B-COMP
neutralizing	O
antibodies	B-COMP
was	O
up	O
to	O
1	O
:	O
640	O
.	O

TITLE	O
:	O
Ribavirin	O
and	O
interferon	O
-	O
beta	O
synergistically	O
inhibit	O
SARS	O
-	O
associated	O
coronavirus	O
replication	O
in	O
animal	O
and	O
human	O
cell	B-COMP
lines	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
genome	O
replication	O
and	O
transcription	O
take	O
place	O
at	O
cytoplasmic	B-COMP
membranes	I-COMP
and	O
involve	O
coordinated	O
processes	O
of	O
both	O
continuous	O
and	O
discontinuous	O
RNA	O
synthesis	O
that	O
are	O
mediated	O
by	O
the	O
viral	O
replicase	O
,	O
a	O
huge	O
protein	B-COMP
complex	I-COMP
encoded	O
by	O
the	O
20	O
-	O
kb	O
replicase	O
gene	O
.	O

ABSTRACT	O
:	O
As	O
the	O
largest	O
RNA	O
virus	O
,	O
coronavirus	O
replication	O
employs	O
complex	O
mechanisms	O
and	O
involves	O
various	O
viral	O
and	O
cellular	B-COMP
proteins	O
.	O

Like	O
many	O
other	O
RNA	O
viruses	O
,	O
coronavirus	O
may	O
subvert	O
these	O
cellular	B-COMP
proteins	O
from	O
cellular	B-COMP
RNA	O
processing	O
or	O
translation	O
machineries	O
to	O
play	O
a	O
role	O
in	O
viral	O
replication	O
.	O

Isolation	O
of	O
the	O
virus	O
by	O
using	O
various	O
cell	B-COMP
lines	O
,	O
mixed	O
neuron	O
-	O
glia	O
culture	O
,	O
and	O
intracerebral	O
inoculation	O
of	O
suckling	O
mice	O
was	O
unsuccessful	O
.	O

A	O
severe	O
recurrent	O
infection	O
developed	O
,	O
typified	O
by	O
viral	O
persistence	O
and	O
acute	O
lymphopenia	O
,	O
with	O
waves	O
of	O
enhanced	O
viral	O
replication	O
coinciding	O
with	O
fever	O
,	O
weight	O
loss	O
,	O
and	O
depletion	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	B-COMP
.	O

The	O
pathogenic	O
phenomena	O
described	O
here	O
likely	O
bear	O
relevance	O
to	O
other	O
severe	O
coronavirus	O
infections	O
,	O
in	O
particular	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
for	O
which	O
multiphasic	O
disease	O
progression	O
and	O
acute	O
T	O
-	O
cell	B-COMP
lymphopenia	O
have	O
also	O
been	O
reported	O
.	O

TITLE	O
:	O
Effect	O
of	O
soluble	O
porcine	O
aminopeptidase	O
N	O
on	O
antibody	B-COMP
production	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Antibody	B-COMP
production	O
against	O
PEDV	O
was	O
compared	O
among	O
groups	O
at	O
regular	O
intervals	O
.	O

Its	O
structure	O
can	O
be	O
divided	O
into	O
three	O
regions	O
:	O
a	O
long	O
N	O
-	O
terminal	O
region	O
in	O
the	O
exterior	O
,	O
a	O
characteristic	O
transmembrane	B-COMP
(	O
TM	O
)	O
region	O
,	O
and	O
a	O
short	O
C	O
-	O
terminus	O
in	O
the	O
interior	O
of	O
a	O
virion	B-COMP
.	O

TITLE	O
:	O
The	O
E	O
protein	O
is	O
a	O
multifunctional	O
membrane	B-COMP
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
E	O
(	O
envelope	B-COMP
)	O
protein	O
is	O
the	O
smallest	O
structural	O
protein	O
in	O
all	O
coronaviruses	O
and	O
is	O
the	O
only	O
viral	O
structural	O
protein	O
in	O
which	O
no	O
variation	O
has	O
been	O
detected	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
develop	O
clinical	O
diagnostic	O
tools	O
for	O
rapid	O
detection	O
of	O
the	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
)	O
and	O
to	O
identify	O
candidate	O
proteins	O
for	O
vaccine	O
development	O
,	O
the	O
C	O
-	O
terminal	O
portion	O
of	O
the	O
nucleocapsid	B-COMP
(	O
NC	O
)	O
gene	O
was	O
amplified	O
using	O
RT	O
-	O
PCR	O
from	O
the	O
SARS	O
-	O
CoV	O
genome	O
,	O
cloned	O
into	O
a	O
yeast	O
expression	O
vector	O
(	O
pEGH	O
),	O
and	O
expressed	O
as	O
a	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
and	O
Hisx6	O
double	O
-	O
tagged	O
fusion	O
protein	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Using	O
Western	O
blot	O
and	O
Enzyme	O
-	O
linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
),	O
the	O
recombinant	O
N	O
proteins	O
and	O
the	O
synthesized	O
peptides	O
derived	O
from	O
the	O
N	O
protein	O
were	O
screened	O
in	O
sera	B-COMP
from	O
SARS	O
patients	O
.	O

These	O
recombinant	O
S	O
fragments	O
were	O
confirmed	O
to	O
have	O
positive	O
cross	O
-	O
reactions	O
with	O
SARS	O
sera	B-COMP
,	O
either	O
by	O
Western	O
blot	O
or	O
by	O
ELISA	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
human	O
phage	O
antibody	B-COMP
library	O
against	O
SARS	O
virus	O
.	O

Human	O
phage	O
antibody	B-COMP
library	O
against	O
SARS	O
virus	O
has	O
been	O
constructed	O
successfully	O
,	O
from	O
which	O
10	O
anti	O
-	O
SARS	O
virus	O
antibodies	B-COMP
were	O
obtained	O
.	O

The	O
percentage	O
of	O
activated	O
T	O
cells	B-COMP
(	O
Ta	O
,	O
CD3	O
(+)/	O
HLA	O
-	O
DR	O
(+))	O
in	O
36	O
convalescent	O
SARS	O
patients	O
and	O
the	O
percentage	O
of	O
activated	O
B	O
cells	B-COMP
(	O
Ba	O
,	O
CD3	O
(-)/	O
HLA	O
-	O
DR	O
(+))	O
in	O
30	O
convalescent	O
SARS	O
patients	O
were	O
higher	O
than	O
normal	O
references	O
.	O

The	O
increased	O
Ta	O
and	O
Ba	O
expressions	O
may	O
be	O
associated	O
with	O
activation	O
of	O
T	O
and	O
B	O
cells	B-COMP
.	O

Results	O
show	O
that	O
cellular	B-COMP
and	O
humoral	O
immune	O
responses	O
can	O
be	O
detected	O
after	O
immunization	O
with	O
pcDNAM	O
,	O
pcDNAN	O
or	O
pcDNASa	O
-	O
pcDNASb	O
plasmids	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

These	O
unusual	O
features	O
likely	O
form	O
interaction	O
surfaces	O
with	O
conserved	O
host	B-COMP
cell	I-COMP
components	O
or	O
other	O
reactive	O
sites	O
required	O
for	O
virus	O
function	O
.	O

Fixation	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
with	O
a	O
fixative	O
including	O
formalin	O
,	O
glutaraldehyde	O
,	O
methanol	O
,	O
and	O
acetone	O
for	O
5	O
min	O
or	O
longer	O
eliminated	O
all	O
infectivity	O
.	O

(	O
2	O
)	O
Specific	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
were	O
assayed	O
with	O
two	O
methods	O
,	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
for	O
detecting	O
IgG	O
antibodies	B-COMP
and	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
mixed	O
antibodies	B-COMP
.	O

(	O
4	O
)	O
Among	O
23	O
parents	O
of	O
children	O
with	O
SARS	O
,	O
one	O
was	O
positive	O
for	O
IgG	O
and	O
the	O
mixed	O
antibodies	B-COMP
,	O
whose	O
grandson	O
and	O
husband	O
suffered	O
from	O
SARS	O
;	O
The	O
IgG	B-COMP
antibody	I-COMP
and	O
the	O
mixed	O
antibodies	B-COMP
were	O
also	O
positive	O
in	O
another	O
adult	O
who	O
had	O
close	O
contact	O
with	O
adult	O
SARS	O
cases	O
(	O
3	O
%).	O

Of	O
70	O
sera	B-COMP
from	O
hepatitis	O
A	O
patients	O
,	O
2	O
showed	O
false	O
positive	O
results	O
,	O
while	O
127	O
sera	B-COMP
from	O
other	O
patients	O
were	O
all	O
negative	O
,	O
detected	O
by	O
the	O
3	O
methods	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
evidence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infection	O
among	O
close	O
contacts	O
to	O
SARS	O
patients	O
and	O
the	O
level	O
of	O
sera	B-COMP
IgG	B-COMP
antibody	I-COMP
in	O
SARS	O
cases	O
.	O

The	O
neutralized	O
antibody	B-COMP
levels	O
were	O
from	O
1	O
:	O
16	O
to	O
1	O
:	O
203	O
,	O
with	O
medium	O
level	O
of	O
1	O
:	O
43	O
.	O

Six	O
strains	O
of	O
hybridomas	O
that	O
produced	O
the	O
monoclonal	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
were	O
obtained	O
.	O

Spleen	O
cells	B-COMP
were	O
collected	O
and	O
infused	O
with	O
SP2	O
/	O
0	O
cell	B-COMP
.	O

The	O
positive	O
cells	B-COMP
were	O
cloned	O
and	O
injected	O
into	O
abdominal	O
cavity	O
.	O

Three	O
of	O
the	O
11	O
purified	O
monoclonal	O
antibodies	B-COMP
had	O
very	O
high	O
affinity	O
to	O
N	O
protein	O
,	O
while	O
4	O
purified	O
McAbs	O
showed	O
very	O
weak	O
reaction	O
to	O
N	O
protein	O
,	O
the	O
affinities	O
of	O
remaining	O
4	O
McAbs	O
were	O
in	O
between	O
.	O

RESULTS	O
:	O
Eleven	O
monoclonal	O
cells	B-COMP
secreting	O
antibody	B-COMP
have	O
been	O
developed	O
.	O

This	O
result	O
suggested	O
that	O
S1	O
domain	O
could	O
be	O
an	O
effective	O
subunit	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
,	O
which	O
has	O
been	O
demonstrated	O
harboring	O
the	O
receptor	O
binding	O
domain	O
,	O
successfully	O
elicited	O
SARS	O
-	O
CoV	O
specific	O
IgG	B-COMP
antibody	I-COMP
in	O
mouse	O
after	O
combined	O
immunization	O
with	O
DNA	O
and	O
purified	O
S1	O
protein	O
;	O
the	O
antibody	B-COMP
elicited	O
solely	O
by	O
S1	O
could	O
potently	O
neutralize	O
SARS	O
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
)	O
in	O
vitro	O
,	O
50	O
%	O
of	O
1	O
000	O
TCID50	O
SARS	O
-	O
CoV	O
challenged	O
cells	B-COMP
were	O
protected	O
from	O
viral	O
infection	O
by	O
a	O
1	O
:	O
1499	O
.	O
68	O
dilution	O
of	O
mice	O
sera	B-COMP
immunized	O
with	O
S1	O
protein	O
,	O
but	O
negative	O
control	O
sera	B-COMP
showed	O
no	O
protection	O
.	O

They	O
were	O
subjected	O
to	O
influenza	O
virus	O
detection	O
by	O
fluorescent	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
,	O
MDCK	O
cell	B-COMP
culture	O
,	O
and	O
hemagglutinin	O
inhibition	O
assay	O
.	O

From	O
104	O
cases	O
in	O
9	O
collections	O
dual	O
serum	B-COMP
samples	O
were	O
obtainable	O
.	O

RESULTS	O
:	O
Out	O
of	O
207	O
samples	O
,	O
79	O
(	O
38	O
.	O
16	O
%)	O
were	O
positive	O
for	O
influenza	O
viruses	O
when	O
tested	O
by	O
fluorescent	O
real	O
-	O
time	O
PCR	O
,	O
and	O
62	O
(	O
29	O
.	O
95	O
%)	O
positive	O
when	O
tested	O
by	O
MDCK	O
cell	B-COMP
culture	O
.	O

TITLE	O
:	O
Expression	O
and	O
purification	O
of	O
SARS	O
coronavirus	O
membrane	B-COMP
protein	O
.	O

Results	O
of	O
Western	O
-	O
blot	O
showed	O
that	O
this	O
expressed	O
protein	O
could	O
react	O
with	O
antibodies	B-COMP
in	O
sera	B-COMP
of	O
SARS	O
patients	O
during	O
convalescence	O
.	O

Furthermore	O
,	O
of	O
16	O
sera	B-COMP
collected	O
from	O
four	O
patients	O
during	O
the	O
SARS	O
recurrence	O
in	O
Guangzhou	O
,	O
5	O
sera	B-COMP
collected	O
from	O
7	O
to	O
9	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
were	O
positive	O
for	O
the	O
N	O
protein	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
define	O
and	O
characterize	O
target	O
cells	B-COMP
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
we	O
studied	O
the	O
susceptibility	O
of	O
23	O
different	O
permanent	O
and	O
primary	O
eukaryotic	O
cell	B-COMP
lines	O
to	O
SARS	O
-	O
coronavirus	O
.	O

TITLE	O
:	O
High	O
-	O
dose	O
hydrocortisone	O
reduces	O
expression	O
of	O
the	O
pro	O
-	O
inflammatory	O
chemokines	O
CXCL8	O
and	O
CXCL10	O
in	O
SARS	O
coronavirus	O
-	O
infected	O
intestinal	O
cells	B-COMP
.	O

TITLE	O
:	O
Molecular	O
and	O
biological	O
characterization	O
of	O
human	O
monoclonal	O
antibodies	B-COMP
binding	O
to	O
the	O
spike	O
and	O
nucleocapsid	B-COMP
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

CONCLUSIONS	O
:	O
The	O
anti	O
-	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
McAbs	O
were	O
developed	O
and	O
these	O
McAbs	O
may	O
be	O
useful	O
in	O
the	O
development	O
of	O
diagnosis	O
assays	O
and	O
basic	O
research	O
of	O
SARS	O
.	O

The	O
positive	O
rate	O
of	O
SARS	O
coronavirus	O
IgG	B-COMP
antibody	I-COMP
of	O
patients	O
was	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
.	O

RESULTS	O
:	O
SARS	O
coronavirus	O
IgG	B-COMP
antibody	I-COMP
was	O
detected	O
positive	O
in	O
6	O
of	O
the	O
9	O
patients	O
,	O
it	O
was	O
still	O
positive	O
in	O
the	O
sera	B-COMP
twelve	O
months	O
after	O
recovery	O
;	O
1	O
of	O
the	O
closely	O
contacted	O
persons	O
and	O
3	O
normal	O
subjects	O
were	O
found	O
positive	O
.	O

Serological	O
examination	O
using	O
blood	O
samples	O
collected	O
on	O
the	O
12th	O
and	O
28th	O
hospital	O
days	O
revealed	O
elevation	O
of	O
anti	O
-	O
L	O
.	O
pneumophila	O
serogroup	O
I	O
antibody	B-COMP
.	O

TITLE	O
:	O
A	O
molecular	O
beacon	O
,	O
bead	O
-	O
based	O
assay	O
for	O
the	O
detection	O
of	O
nucleic	B-COMP
acids	O
by	O
flow	O
cytometry	O
.	O

TITLE	O
:	O
Intragastric	O
administration	O
of	O
Lactobacillus	O
casei	O
expressing	O
transmissible	O
gastroentritis	O
coronavirus	O
spike	O
glycoprotein	O
induced	O
specific	O
antibody	B-COMP
production	O
.	O

About	O
one	O
third	O
of	O
the	O
samples	O
were	O
also	O
tested	O
for	O
antibodies	B-COMP
to	O
bovine	O
virus	O
diarrhoea	O
virus	O
(	O
BVDV	O
)	O
with	O
negative	O
results	O
.	O

The	O
test	O
was	O
applied	O
to	O
1075	O
feline	O
blood	O
samples	O
(	O
424	O
from	O
healthy	O
,	O
651	O
from	O
sick	O
cats	O
suspected	O
of	O
FIP	O
)	O
and	O
returned	O
46	O
%	O
of	O
the	O
diseased	O
cats	O
as	O
positive	O
for	O
feline	O
coronavirus	O
mRNA	O
in	O
their	O
peripheral	O
blood	O
cells	B-COMP
;	O
of	O
the	O
healthy	O
cats	O
,	O
5	O
%	O
tested	O
positive	O
.	O

Of	O
633	O
consecutively	O
enrolled	O
febrile	O
patients	O
,	O
321	O
(	O
50	O
.	O
7	O
%)	O
had	O
antileptospiral	O
IgM	O
antibodies	B-COMP
or	O
high	O
titers	O
of	O
antileptospiral	O
antibodies	B-COMP
.	O

This	O
recombinant	O
baculovirus	O
expressing	O
protein	O
C	O
was	O
first	O
characterized	O
using	O
five	O
SARS	O
convalescent	O
human	O
sera	B-COMP
and	O
five	O
normal	O
human	O
sera	B-COMP
.	O

The	O
results	O
showed	O
that	O
protein	O
C	O
is	O
an	O
authentic	O
antigen	O
against	O
SARS	O
-	O
CoV	O
antibody	B-COMP
.	O

No	O
cross	O
-	O
reactivity	O
with	O
serum	B-COMP
samples	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
detected	O
in	O
our	O
assays	O
.	O

TITLE	O
:	O
Programmed	O
ribosomal	B-COMP
frameshifting	O
in	O
decoding	O
the	O
SARS	O
-	O
CoV	O
genome	O
.	O

Frameshifting	O
in	O
SARS	O
-	O
CoV	O
has	O
been	O
characterized	O
in	O
cultured	O
mammalian	O
cells	B-COMP
using	O
a	O
dual	O
luciferase	O
reporter	O
system	O
and	O
mass	O
spectrometry	O
.	O

Both	O
the	O
truncated	O
recombinant	O
proteins	O
were	O
expressed	O
in	O
soluble	O
forms	O
and	O
reacted	O
specifically	O
with	O
the	O
sera	B-COMP
from	O
immunized	O
pSecS	O
mice	O
and	O
clinically	O
diagnosed	O
SARS	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
recombinant	O
protein	O
could	O
be	O
used	O
as	O
an	O
antigen	O
for	O
detecting	O
the	O
serum	B-COMP
of	O
SARS	O
CoV	O
-	O
infected	O
patients	O
.	O

They	O
both	O
have	O
the	O
potential	O
to	O
become	O
pandemics	O
because	O
human	O
beings	O
lack	O
antibodies	B-COMP
to	O
the	O
animal	O
-	O
derived	O
antigens	O
present	O
on	O
the	O
viral	O
surface	O
and	O
rapid	O
dissemination	O
can	O
occur	O
from	O
the	O
relative	O
ease	O
and	O
availability	O
of	O
high	O
speed	O
and	O
far	O
-	O
reaching	O
transportation	O
methods	O
.	O

Patients	O
were	O
identified	O
as	O
hypouricemic	O
when	O
their	O
serum	B-COMP
uric	O
acid	O
(	O
UA	O
)	O
level	O
was	O
less	O
than	O
2	O
.	O
5	O
mg	O
/	O
dL	O
(<	O
149	O
micromol	O
/	O
L	O
)	O
within	O
15	O
days	O
after	O
fever	O
onset	O
.	O

One	O
fourth	O
of	O
patients	O
with	O
SARS	O
developed	O
hypouricemia	O
,	O
which	O
might	O
result	O
from	O
a	O
defect	O
in	O
renal	O
UA	O
handling	O
and	O
was	O
associated	O
with	O
a	O
high	O
serum	B-COMP
IL	O
-	O
8	O
level	O
.	O

TITLE	O
:	O
Using	O
cellular	B-COMP
automata	O
to	O
generate	O
image	O
representation	O
for	O
biological	O
sequences	O
.	O

TITLE	O
:	O
Reference	O
gene	O
selection	O
for	O
quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
in	O
virus	O
infected	O
cells	B-COMP
:	O
SARS	O
corona	O
virus	O
,	O
Yellow	O
fever	O
virus	O
,	O
Human	O
Herpesvirus	O
-	O
6	O
,	O
Camelpox	O
virus	O
and	O
Cytomegalovirus	O
infections	O
.	O

However	O
,	O
over	O
all	O
,	O
beta	O
-	O
actin	O
is	O
an	O
unsuitable	O
as	O
reference	O
gene	O
,	O
whereas	O
TATA	O
-	O
Box	O
binding	O
protein	O
and	O
peptidyl	O
-	O
prolyl	O
-	O
isomerase	O
A	O
are	O
stable	O
reference	O
genes	O
for	O
expression	O
studies	O
in	O
virus	O
infected	O
cells	B-COMP
.	O

Two	O
main	O
assumptions	O
were	O
considered	O
;	O
the	O
first	O
is	O
that	O
protein	O
E	O
contains	O
one	O
transmembrane	B-COMP
alpha	O
-	O
helical	O
domain	O
,	O
with	O
its	O
N	O
-	O
and	O
C	O
-	O
termini	O
located	O
in	O
opposite	O
faces	O
of	O
the	O
lipid	O
bilayer	O
.	O

In	O
addition	O
,	O
these	O
results	O
strongly	O
support	O
a	O
general	O
model	O
where	O
transmembrane	B-COMP
domains	O
transiently	O
adopt	O
many	O
aggregation	O
states	O
necessary	O
for	O
function	O
.	O

The	O
cerebrospinal	O
fluid	O
contained	O
1	O
white	O
cell	B-COMP
per	O
cubic	O
millimeter	O
,	O
normal	O
glucose	O
levels	O
,	O
and	O
increased	O
levels	O
of	O
protein	O
(	O
0	O
.	O
81	O
g	O
per	O
liter	O
).	O

The	O
numbers	O
of	O
peripheral	O
white	O
blood	O
cells	B-COMP
and	O
lymphocytes	O
were	O
in	O
the	O
normal	O
range	O
without	O
any	O
specific	O
changes	O
typical	O
of	O
SARS	O
.	O

The	O
average	O
levels	O
of	O
ALT	O
of	O
the	O
patients	O
were	O
56	O
.	O
07	O
+/-	O
51	O
.	O
57	O
U	O
/	O
L	O
,	O
86	O
.	O
46	O
+/-	O
69	O
.	O
93	O
U	O
/	O
L	O
,	O
106	O
.	O
69	O
+/-	O
102	O
.	O
50	O
U	O
/	O
L	O
and	O
111	O
.	O
32	O
+/-	O
160	O
.	O
24	O
U	O
/	O
L	O
,	O
and	O
the	O
average	O
levels	O
of	O
serum	B-COMP
albumin	O
were	O
37	O
.	O
25	O
+/-	O
5	O
.	O
37	O
g	O
/	O
L	O
,	O
35	O
.	O
82	O
+/-	O
4	O
.	O
74	O
g	O
/	O
L	O
,	O
34	O
.	O
49	O
+/-	O
5	O
.	O
04	O
g	O
/	O
L	O
,	O
and	O
34	O
.	O
26	O
+/-	O
4	O
.	O
70	O
g	O
/	O
L	O
,	O
at	O
the	O
day	O
of	O
admission	O
,	O
the	O
first	O
week	O
,	O
second	O
week	O
,	O
and	O
third	O
week	O
after	O
hospitalization	O
,	O
respectively	O
.	O

All	O
the	O
antibodies	B-COMP
were	O
also	O
able	O
to	O
detect	O
the	O
maturation	O
of	O
the	O
200	O
-	O
kDa	O
form	O
of	O
S	O
to	O
the	O
210	O
-	O
kDa	O
form	O
by	O
pulse	O
-	O
chase	O
experiments	O
.	O

When	O
the	O
antibodies	B-COMP
were	O
tested	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	O
-	O
CoV	O
propagation	O
in	O
Vero	O
E6	O
culture	O
,	O
it	O
was	O
found	O
that	O
the	O
anti	O
-	O
SDelta10	O
antibody	B-COMP
,	O
which	O
was	O
targeted	O
to	O
amino	O
acid	O
residues	O
1029	O
to	O
1192	O
of	O
S	O
,	O
which	O
include	O
heptad	O
repeat	O
2	O
,	O
has	O
strong	O
neutralizing	O
activities	O
,	O
suggesting	O
that	O
this	O
region	O
of	O
S	O
carries	O
neutralizing	O
epitopes	O
and	O
is	O
very	O
important	O
for	O
virus	O
entry	O
into	O
cells	B-COMP
.	O

Immunoassays	O
found	O
that	O
most	O
of	O
the	O
patients	O
who	O
had	O
recovered	O
from	O
SARS	O
developed	O
complementary	O
antibodies	B-COMP
to	O
the	O
epitope	O
-	O
rich	O
region	O
on	O
the	O
spike	O
S2	O
protein	O
,	O
indicating	O
that	O
this	O
is	O
an	O
immunodominant	O
site	O
on	O
the	O
viral	B-COMP
envelope	I-COMP
comprising	O
the	O
spike	O
,	O
matrix	O
,	O
and	O
small	O
envelope	B-COMP
glycoproteins	O
.	O

Bone	O
marrow	O
was	O
collected	O
from	O
the	O
anterior	O
crista	O
of	O
iliac	O
in	O
both	O
sides	O
in	O
13	O
cases	O
while	O
peripheral	O
mononuclear	O
cell	B-COMP
was	O
harvested	O
with	O
CS	O
-	O
3000	O
cell	B-COMP
separator	O
in	O
other	O
15	O
patients	O
after	O
G	O
-	O
CSF	O
mobilization	O
.	O

We	O
were	O
also	O
able	O
to	O
detect	O
heterogeneous	O
viral	O
sequences	O
in	O
primary	O
lung	O
tissues	O
,	O
suggesting	O
a	O
possible	O
coevolution	O
of	O
quasispecies	O
of	O
virus	O
within	O
a	O
single	O
host	B-COMP
.	O

The	O
purified	O
SA59B	O
scFv	O
-	O
antibody	B-COMP
was	O
labeled	O
with	O
HRP	O
by	O
the	O
glutaraldehyde	O
method	O
,	O
and	O
the	O
concentration	O
of	O
HRP	O
and	O
SA59B	O
scFv	O
-	O
antibody	B-COMP
in	O
the	O
SA59B	O
-	O
HRP	O
solution	O
reached	O
2	O
.	O
4	O
and	O
2	O
.	O
28mg	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
expression	O
of	O
protein	O
X4	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	B-COMP
and	O
lung	O
tissues	O
from	O
patients	O
with	O
SARS	O
was	O
performed	O
using	O
immunofluorescence	O
assay	O
and	O
immunohistochemistry	O
technique	O
.	O

RESULTS	O
:	O
We	O
expressed	O
and	O
purified	O
soluble	O
recombinant	O
protein	O
X4	O
from	O
E	O
.	O
coli	O
,	O
and	O
generated	O
specific	O
antibodies	B-COMP
against	O
protein	O
X4	O
.	O

Although	O
less	O
is	O
known	O
about	O
the	O
ability	O
of	O
antibodies	B-COMP
to	O
mediate	O
demyelination	O
,	O
the	O
presence	O
of	O
oligoclonally	O
expanded	O
B	O
cells	B-COMP
and	O
high	O
concentrations	O
of	O
antibodies	B-COMP
(	O
against	O
self	O
or	O
infectious	O
agents	O
)	O
in	O
the	O
central	O
nervous	O
system	O
of	O
many	O
multiple	O
sclerosis	O
patients	O
suggests	O
that	O
antibodies	B-COMP
may	O
also	O
contribute	O
to	O
myelin	B-COMP
destruction	O
.	O

Anti	O
-	O
JHM	O
antibody	B-COMP
was	O
detected	O
adjacent	O
to	O
areas	O
of	O
demyelination	O
,	O
consistent	O
with	O
a	O
direct	O
interaction	O
between	O
antibody	B-COMP
and	O
infected	O
cells	B-COMP
.	O

At	O
12h	O
post	O
-	O
infection	O
,	O
the	O
intracellular	B-COMP
viral	O
RNA	O
load	O
was	O
3x10	O
(	O
2	O
)-	O
fold	O
higher	O
than	O
at	O
the	O
time	O
of	O
infection	O
,	O
and	O
the	O
extracellular	B-COMP
viral	O
RNA	O
load	O
was	O
increased	O
with	O
a	O
factor	O
of	O
2	O
x	O
10	O
(	O
3	O
).	O

Here	O
,	O
we	O
describe	O
a	O
healthy	O
donor	O
for	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
who	O
developed	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
after	O
4	O
days	O
of	O
G	O
-	O
CSF	O
administration	O
.	O

In	O
the	O
absence	O
of	O
effective	O
vaccines	O
,	O
nucleic	B-COMP
acid	O
-	O
based	O
immunomodulators	O
have	O
the	O
potential	O
to	O
offer	O
effective	O
,	O
broad	O
-	O
spectrum	O
protection	O
against	O
these	O
deadly	O
pathogens	O
.	O

Toward	O
this	O
goal	O
,	O
we	O
have	O
prepared	O
and	O
characterized	O
soluble	O
full	O
-	O
length	O
nucleocapsid	B-COMP
proteins	O
(	O
N	O
protein	O
)	O
from	O
SARS	O
and	O
229E	O
human	O
coronaviruses	O
.	O

We	O
have	O
predicted	O
several	O
antigenic	O
sites	O
(	O
15	O
-	O
20	O
amino	O
acids	O
)	O
of	O
S	O
,	O
M	O
and	O
N	O
proteins	O
and	O
produced	O
antibodies	B-COMP
against	O
those	O
peptides	O
,	O
some	O
of	O
which	O
could	O
be	O
recognized	O
by	O
sera	B-COMP
obtained	O
from	O
SARS	O
patients	O
.	O

Morphological	O
findings	O
showed	O
that	O
the	O
oleic	O
acid	O
group	O
demonstrated	O
a	O
marked	O
lung	O
injury	O
represented	O
by	O
prominent	O
atelectasis	O
,	O
intraalveolar	O
and	O
interstitial	O
patchy	O
hemorrhage	O
,	O
edema	O
,	O
thickened	O
alveolar	O
septum	B-COMP
,	O
formation	O
of	O
hyaline	O
membranes	O
and	O
the	O
existence	O
of	O
inflammatory	O
cells	B-COMP
in	O
alveolar	O
spaces	O
.	O

Few	O
CD68	O
-	O
positive	O
syncytial	O
multinucleated	O
giant	O
cells	B-COMP
were	O
also	O
seen	O
in	O
the	O
specimens	O
but	O
no	O
viral	O
inclusion	B-COMP
body	I-COMP
could	O
be	O
identified	O
in	O
these	O
cells	B-COMP
.	O

Among	O
the	O
clinic	O
diagnosed	O
SARS	O
patients	O
,	O
the	O
positive	O
antibody	B-COMP
detective	O
rate	O
was	O
90	O
.	O
4	O
%	O
for	O
those	O
which	O
had	O
specific	O
contact	O
history	O
or	O
infectivity	O
,	O
which	O
was	O
higher	O
than	O
that	O
for	O
other	O
population	O
.	O

An	O
indirect	O
antibody	B-COMP
ELISA	O
method	O
was	O
developed	O
and	O
clinical	O
positive	O
and	O
negative	O
sera	B-COMP
for	O
their	O
antibodies	B-COMP
against	O
GST	O
-	O
N2	O
fusion	O
protein	O
were	O
assayed	O
.	O

Serum	B-COMP
TAC	O
and	O
lung	O
tissue	O
Na	O
+-	O
K	O
+	O
ATPase	O
activity	O
levels	O
were	O
found	O
to	O
be	O
increased	O
in	O
ILO	O
group	O
compared	O
to	O
IR	O
group	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
).	O

Characteristically	O
,	O
ca	O
-	O
PEDV	O
syncytia	O
with	O
one	O
or	O
more	O
chlamydial	O
inclusions	O
were	O
detected	O
but	O
dually	O
infected	O
single	O
cells	B-COMP
were	O
absent	O
.	O

The	O
important	O
role	O
of	O
the	O
about	O
38	O
-	O
residues	O
cytoplasmic	B-COMP
domain	O
in	O
the	O
assembly	O
of	O
and	O
membrane	B-COMP
fusion	O
by	O
this	O
approximately	O
1300	O
amino	O
acids	O
long	O
protein	O
is	O
discussed	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
first	O
proteomic	O
analysis	O
on	O
the	O
cellular	B-COMP
response	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
.	O

Two	O
methods	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
indirect	O
immunofluorescent	O
assay	O
(	O
IFA	O
),	O
were	O
used	O
to	O
detect	O
specific	O
serum	B-COMP
IgG	O
and	O
IgM	O
against	O
SARS	O
-	O
CoV	O
in	O
98	O
SARS	O
patients	O
and	O
250	O
controls	O
consisting	O
of	O
patients	O
with	O
pneumonia	O
,	O
health	O
-	O
care	O
professionals	O
and	O
healthy	O
subjects	O
.	O

The	O
detection	O
of	O
antibodies	B-COMP
against	O
SARS	O
virus	O
is	O
helpful	O
in	O
the	O
clinical	O
diagnosis	O
of	O
SARS	O
.	O

The	O
presence	O
of	O
viral	B-COMP
particles	I-COMP
in	O
passage	O
11	O
cells	B-COMP
was	O
assessed	O
by	O
electron	O
microscopy	O
.	O

Two	O
-	O
hundred	O
and	O
seventy	O
-	O
six	O
serum	B-COMP
samples	O
were	O
collected	O
from	O
health	O
care	O
workers	O
in	O
a	O
hospital	O
in	O
which	O
a	O
nosocomial	O
SARS	O
outbreak	O
took	O
place	O
and	O
used	O
for	O
evaluation	O
.	O

By	O
contrast	O
,	O
bystander	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
numbers	O
declined	O
to	O
background	O
numbers	O
following	O
control	O
of	O
CNS	O
virus	O
replication	O
.	O

Whereas	O
virus	O
-	O
induced	O
MMP	O
-	O
3	O
expression	O
was	O
restricted	O
to	O
CNS	O
resident	O
astrocytes	O
,	O
MMP	O
-	O
12	O
mRNA	O
was	O
expressed	O
by	O
both	O
inflammatory	O
cells	B-COMP
and	O
CNS	O
resident	O
cells	B-COMP
.	O

During	O
inflammation	O
TIMP	O
-	O
1	O
mRNA	O
was	O
most	O
prominently	O
expressed	O
by	O
infiltrating	O
cells	B-COMP
.	O

By	O
contrast	O
,	O
in	O
the	O
immunosuppressed	O
host	B-COMP
TIMP	O
-	O
1	O
mRNA	O
was	O
expressed	O
by	O
CNS	O
resident	O
cells	B-COMP
.	O

None	O
of	O
the	O
serum	B-COMP
samples	O
from	O
100	O
healthy	O
blood	O
donors	O
was	O
positive	O
in	O
the	O
S450	O
-	O
650	O
-	O
based	O
assay	O
.	O

RESULTS	O
:	O
The	O
S450	O
-	O
650	O
-	O
based	O
ELISA	O
detected	O
IgG	O
Abs	O
in	O
41	O
out	O
of	O
51	O
serum	B-COMP
samples	O
from	O
22	O
hospitalized	O
patients	O
with	O
probable	O
SARS	O
,	O
a	O
result	O
closely	O
correlated	O
with	O
that	O
obtained	O
with	O
a	O
virus	O
-	O
based	O
ELISA	O
(	O
r	O
=	O
0	O
.	O
75	O
,	O
k	O
=	O
0	O
.	O
8	O
).	O

Specimens	O
from	O
clinically	O
suspected	O
SARS	O
patients	O
collected	O
during	O
outbreak	O
and	O
post	O
-	O
epidemic	O
periods	O
were	O
tested	O
by	O
an	O
automatic	O
nucleic	B-COMP
acid	O
extraction	O
system	O
followed	O
by	O
our	O
first	O
generation	O
conventional	O
RT	O
-	O
PCR	O
and	O
two	O
standardized	O
real	O
-	O
time	O
PCR	O
assays	O
(	O
Artus	O
GmbH	O
,	O
Germany	O
and	O
Roche	O
Diagnostics	O
,	O
Germany	O
).	O

To	O
determine	O
the	O
in	O
vivo	O
role	O
of	O
IL	O
-	O
2	O
during	O
CNS	O
infection	O
,	O
IL	O
-	O
2	O
signaling	O
was	O
inhibited	O
via	O
administration	O
of	O
a	O
neutralizing	O
IL	O
-	O
2	O
-	O
specific	O
monoclonal	O
antibody	B-COMP
(	O
mAb	O
).	O

Serial	O
assay	O
of	O
serum	B-COMP
ALT	O
was	O
followed	O
in	O
patients	O
who	O
fulfilled	O
the	O
WHO	O
criteria	O
of	O
SARS	O
.	O

By	O
using	O
a	O
syncytia	O
formation	O
model	O
,	O
we	O
tested	O
the	O
neutralization	O
ability	O
of	O
all	O
10	O
peptides	O
and	O
their	O
corresponding	O
antibodies	B-COMP
.	O

The	O
Y	O
-	O
N	O
-	O
ELISA	O
was	O
rapid	O
,	O
sensitive	O
,	O
and	O
specific	O
for	O
detecting	O
chicken	O
serum	B-COMP
antibodies	B-COMP
to	O
IBV	O
,	O
and	O
it	O
compared	O
favorably	O
with	O
a	O
commercial	O
ELISA	O
.	O

New	O
techniques	O
such	O
as	O
new	O
generations	O
of	O
Polymerase	O
Chain	O
Reaction	O
(	O
PCR	O
),	O
rapid	O
methods	O
for	O
nucleic	B-COMP
acid	O
sequence	O
analyses	O
and	O
microarrays	O
have	O
enabled	O
more	O
rapid	O
identification	O
of	O
organisms	O
and	O
provide	O
powerful	O
tools	O
in	O
the	O
epidemiological	O
analysis	O
of	O
an	O
outbreak	O
.	O

We	O
constructed	O
96	O
hexanucleotides	O
(	O
non	O
-	O
ribosomal	B-COMP
hexanucleotides	O
)	O
and	O
used	O
them	O
as	O
mixed	O
primers	O
for	O
reverse	O
transcription	O
of	O
cDNA	O
RDA	O
.	O

A	O
synchronous	O
analysis	O
of	O
hexanucleotide	O
patterns	O
in	O
known	O
viral	O
sequences	O
showed	O
that	O
all	O
the	O
known	O
genomic	O
-	O
size	O
viral	O
sequences	O
include	O
non	O
-	O
ribosomal	B-COMP
hexanucleotides	O
.	O

In	O
some	O
of	O
these	O
heritable	O
forms	O
of	O
primary	O
iron	O
overload	O
,	O
stainable	O
iron	O
is	O
present	O
in	O
both	O
hepatocytes	O
and	O
Kupffer	O
cells	B-COMP
.	O

Occasional	O
intra	O
-	O
alveolar	O
macrophages	O
were	O
also	O
weakly	O
reactive	O
to	O
SARS	O
-	O
CoV	O
antibody	B-COMP
.	O

Log	O
reduction	O
of	O
enveloped	O
viruses	O
for	O
cell	B-COMP
-	O
free	O
HIV	O
-	O
1	O
was	O
>	O
6	O
.	O
2	O
;	O
for	O
cell	B-COMP
-	O
associated	O
HIV	O
-	O
1	O
,	O
>	O
6	O
.	O
1	O
;	O
for	O
clinical	O
isolate	O
HIV	O
-	O
1	O
,	O
>	O
3	O
.	O
4	O
;	O
for	O
clinical	O
isolate	O
HIV	O
-	O
2	O
,	O
>	O
2	O
.	O
5	O
;	O
for	O
HBV	O
,	O
>	O
5	O
.	O
5	O
;	O
for	O
HCV	O
,	O
>	O
4	O
.	O
5	O
;	O
for	O
DHBV	O
,	O
>	O
6	O
.	O
2	O
;	O
for	O
BVDV	O
,	O
>	O
6	O
.	O
0	O
;	O
for	O
HTLV	O
-	O
I	O
,	O
4	O
.	O
2	O
;	O
for	O
HTLV	O
-	O
II	O
,	O
4	O
.	O
6	O
;	O
for	O
CMV	O
,	O
>	O
5	O
.	O
9	O
;	O
for	O
WNV	O
,	O
>	O
5	O
.	O
5	O
;	O
for	O
SARS	O
-	O
HCoV	O
,	O
>	O
5	O
.	O
8	O
;	O
and	O
for	O
vaccinia	O
virus	O
,	O
>	O
4	O
.	O
7	O
.	O

There	O
was	O
,	O
however	O
,	O
no	O
association	O
between	O
MBL	O
genotypes	O
,	O
which	O
are	O
associated	O
with	O
low	O
or	O
deficient	O
serum	B-COMP
levels	O
of	O
MBL	O
,	O
and	O
mortality	O
related	O
to	O
SARS	O
.	O

FTA	O
paper	O
is	O
a	O
cotton	O
-	O
based	O
cellulose	O
membrane	B-COMP
containing	O
lyophilized	O
chemicals	O
that	O
lyses	O
many	O
types	O
of	O
bacteria	O
and	O
viruses	O
.	O

TITLE	O
:	O
Cells	B-COMP
of	O
human	O
aminopeptidase	O
N	O
(	O
CD13	O
)	O
transgenic	O
mice	O
are	O
infected	O
by	O
human	O
coronavirus	O
-	O
229E	O
in	O
vitro	O
,	O
but	O
not	O
in	O
vivo	O
.	O

Although	O
hAPN	O
-	O
transgenic	O
mice	O
were	O
resistant	O
to	O
HCoV	O
-	O
229E	O
in	O
vivo	O
,	O
primary	O
embryonic	O
cells	B-COMP
and	O
bone	O
marrow	O
dendritic	B-COMP
cells	B-COMP
were	O
infected	O
in	O
vitro	O
.	O

Tonsillar	O
swabs	O
and	O
serum	B-COMP
were	O
obtained	O
from	O
dogs	O
on	O
entry	O
into	O
the	O
kennels	O
and	O
in	O
regular	O
intervals	O
thereafter	O
.	O

TITLE	O
:	O
Sumoylation	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Although	O
neurovirulent	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
JHMV	O
multiplies	O
in	O
a	O
variety	O
of	O
brain	O
cells	B-COMP
,	O
expression	O
of	O
its	O
receptor	O
carcinoembryonic	O
antigen	O
cell	B-COMP
adhesion	O
molecule	O
1	O
(	O
CEACAM	O
1	O
)	O
(	O
MHVR	O
)	O
is	O
restricted	O
only	O
in	O
microglia	O
.	O

Pretreatment	O
of	O
those	O
cells	B-COMP
with	O
CC1	O
prevented	O
virus	O
attachment	O
to	O
the	O
cell	B-COMP
surface	I-COMP
and	O
also	O
blocked	O
virus	O
infection	O
.	O

Our	O
results	O
suggest	O
that	O
IBV	O
3a	O
is	O
partially	O
targeted	O
to	O
a	O
novel	O
domain	O
of	O
the	O
smooth	B-COMP
ER	I-COMP
.	O

The	O
early	O
transcriptional	O
profiles	O
of	O
host	B-COMP
cell	I-COMP
response	O
to	O
both	O
types	O
of	O
infection	O
at	O
2	O
and	O
4	O
h	O
postinoculation	O
were	O
determined	O
by	O
using	O
the	O
Affymetrix	O
HG	O
-	O
U133A	O
microarray	O
(	O
about	O
22	O
,	O
000	O
genes	O
).	O

Much	O
more	O
perturbation	O
of	O
cellular	B-COMP
gene	O
transcription	O
was	O
observed	O
after	O
infection	O
by	O
SARS	O
-	O
CoV	O
than	O
after	O
infection	O
by	O
HCoV	O
-	O
229E	O
.	O

Besides	O
the	O
upregulation	O
of	O
genes	O
associated	O
with	O
apoptosis	O
,	O
which	O
was	O
exactly	O
opposite	O
to	O
the	O
previously	O
reported	O
effect	O
of	O
SARS	O
-	O
CoV	O
in	O
a	O
colonic	O
carcinoma	O
cell	B-COMP
line	O
,	O
genes	O
related	O
to	O
inflammation	O
,	O
stress	O
response	O
,	O
and	O
procoagulation	O
were	O
also	O
upregulated	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
(	O
SARS_CoV	O
)	O
is	O
a	O
major	O
structural	O
component	O
of	O
virions	B-COMP
,	O
which	O
appears	O
to	O
be	O
a	O
multifunctional	O
protein	O
involved	O
in	O
viral	O
RNA	O
replication	O
and	O
translation	O
.	O

The	O
quantification	O
results	O
for	O
SARS	O
-	O
CoV	O
from	O
cell	B-COMP
culture	O
correlated	O
well	O
with	O
those	O
of	O
the	O
RT	O
-	O
PCR	O
by	O
using	O
any	O
two	O
of	O
the	O
three	O
sets	O
of	O
primer	O
and	O
probe	O
used	O
in	O
this	O
assay	O
.	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	B-COMP
(	O
mAb	O
)	O
to	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
nucleoprotein	O
(	O
N	O
)	O
and	O
membrane	B-COMP
protein	O
(	O
M	O
)	O
were	O
prepared	O
and	O
used	O
for	O
the	O
comparative	O
assessment	O
of	O
three	O
blocking	O
ELISA	O
variants	O
to	O
detect	O
TGEV	O
.	O

In	O
this	O
study	O
,	O
13	O
recombinant	O
proteins	O
associated	O
with	O
four	O
structural	O
proteins	O
(	O
S	O
,	O
E	O
,	O
M	O
and	O
N	O
)	O
and	O
five	O
putative	O
uncharacterized	O
proteins	O
(	O
3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
and	O
9b	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
were	O
prepared	O
and	O
used	O
for	O
screening	O
and	O
monitoring	O
their	O
specific	O
IgG	O
antibodies	B-COMP
in	O
SARS	O
patient	O
sera	B-COMP
by	O
protein	O
microarray	O
.	O

In	O
the	O
detectable	O
specific	O
antibodies	B-COMP
,	O
anti	O
-	O
S	O
and	O
anti	O
-	O
N	O
were	O
dominant	O
and	O
could	O
persist	O
in	O
the	O
sera	B-COMP
of	O
SARS	O
patients	O
until	O
week	O
30	O
.	O

The	O
results	O
suggest	O
(	O
1	O
)	O
that	O
anti	O
-	O
S	O
and	O
anti	O
-	O
N	O
antibodies	B-COMP
are	O
diagnostic	O
markers	O
and	O
in	O
particular	O
that	O
S3	O
is	O
immunogenic	O
and	O
therefore	O
is	O
a	O
good	O
candidate	O
as	O
a	O
subunit	O
vaccine	O
antigen	O
;	O
and	O
(	O
2	O
)	O
that	O
,	O
from	O
a	O
virus	O
structure	O
viewpoint	O
,	O
the	O
presence	O
in	O
some	O
human	O
sera	B-COMP
of	O
antibodies	B-COMP
reacting	O
with	O
two	O
recombinant	O
polypeptides	O
,	O
3a	O
and	O
9b	O
,	O
supports	O
the	O
hypothesis	O
that	O
they	O
are	O
synthesized	O
during	O
the	O
virus	O
cycle	O
.	O

Many	O
years	O
ago	O
,	O
it	O
was	O
noted	O
that	O
the	O
elderly	O
possessed	O
oligoclonal	O
expansions	O
of	O
T	O
cells	B-COMP
,	O
especially	O
of	O
CD8	O
(+)	O
cells	B-COMP
.	O

It	O
was	O
discovered	O
that	O
CMV	O
was	O
the	O
prime	O
driving	O
force	O
behind	O
most	O
of	O
the	O
oligoclonal	O
expansions	O
and	O
altered	O
phenotypes	O
and	O
functions	O
of	O
CD8	O
cells	B-COMP
.	O

Inspection	O
of	O
the	O
overlap	O
regions	O
between	O
ORF1a	O
and	O
ORF1b	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
revealed	O
that	O
,	O
similar	O
to	O
all	O
coronaviruses	O
,	O
a	O
programmed	O
-	O
1	O
ribosomal	B-COMP
frameshift	O
could	O
be	O
used	O
by	O
the	O
virus	O
to	O
produce	O
a	O
fusion	O
protein	O
.	O

ABSTRACT	O
:	O
During	O
the	O
acute	O
phase	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
mononuclear	O
cells	B-COMP
infiltration	O
,	O
alveolar	O
cell	B-COMP
desquamation	O
and	O
hyaline	O
membrane	B-COMP
formation	O
have	O
been	O
described	O
,	O
together	O
with	O
dysregulation	O
of	O
plasma	O
cytokine	O
levels	O
.	O

Electron	O
microscopy	O
of	O
purified	O
influenza	O
A	O
virus	O
showed	O
extensive	O
clumping	O
and	O
morphological	O
changes	O
in	O
spike	O
configuration	O
after	O
contact	O
with	O
the	O
virucidal	O
mixture	O
,	O
but	O
no	O
overt	O
destruction	O
of	O
the	O
viral	B-COMP
membrane	I-COMP
.	O

Development	O
of	O
a	O
Western	O
blot	O
assay	O
for	O
detection	O
of	O
antibodies	B-COMP
against	O
coronavirus	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

In	O
this	O
report	O
,	O
we	O
described	O
the	O
utility	O
of	O
these	O
two	O
new	O
neutralization	O
assays	O
in	O
measuring	O
the	O
neutralizing	O
activities	O
against	O
SCV	O
infection	O
from	O
rabbit	O
sera	B-COMP
immunized	O
with	O
various	O
forms	O
of	O
spike	O
protein	O
of	O
SCV	O
.	O

Potent	O
neutralizing	O
activity	O
directed	O
against	O
NL63	O
-	O
but	O
not	O
229E	O
-	O
S	O
protein	O
was	O
detected	O
in	O
virtually	O
all	O
sera	B-COMP
from	O
patients	O
8	O
years	O
of	O
age	O
or	O
older	O
,	O
suggesting	O
that	O
HCoV	O
-	O
NL63	O
infection	O
of	O
humans	O
is	O
common	O
and	O
usually	O
acquired	O
during	O
childhood	O
.	O

By	O
use	O
of	O
Western	O
blot	O
analysis	O
,	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
antigenic	O
cross	O
-	O
reactivity	O
between	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
2	O
HCoVs	O
(	O
229E	O
and	O
OC43	O
)	O
was	O
demonstrated	O
in	O
immunized	O
animals	O
and	O
human	O
serum	B-COMP
.	O

The	O
eukaryotic	O
expression	O
plasmid	O
pEGFP	O
-	O
C1	O
-	O
N	O
,	O
containing	O
SARS	O
-	O
CoV	O
N	O
gene	O
,	O
was	O
co	O
-	O
transfected	O
into	O
293	O
cells	B-COMP
with	O
either	O
the	O
RNAi	O
plasmid	O
pshRNA	O
-	O
N	O
or	O
unrelated	O
control	O
plasmid	O
pshRNA	O
-	O
HBV	O
-	O
C4	O
.	O

They	O
reproduce	O
rapidly	O
,	O
mutate	O
frequently	O
,	O
breach	O
species	O
barriers	O
,	O
adapt	O
with	O
relative	O
ease	O
to	O
new	O
hosts	B-COMP
and	O
new	O
environments	O
,	O
and	O
develop	O
resistance	O
to	O
the	O
drugs	O
used	O
to	O
treat	O
them	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
furosemide	O
infusion	O
on	O
serum	B-COMP
epidermal	O
growth	O
factor	O
concentration	O
after	O
acute	O
lung	O
injury	O
.	O

These	O
results	O
indicated	O
that	O
two	O
signaling	O
pathways	O
of	O
JNK	O
and	O
PI3K	O
/	O
Akt	O
were	O
important	O
for	O
the	O
establishment	O
of	O
persistence	O
in	O
Vero	O
E6	O
cells	B-COMP
.	O

We	O
have	O
previously	O
shown	O
that	O
mutants	O
of	O
A59	O
,	O
unable	O
to	O
induce	O
hepatitis	O
,	O
may	O
be	O
selected	O
by	O
persistent	O
infection	O
of	O
primary	O
glial	O
cells	B-COMP
in	O
vitro	O
.	O

Immunohistochemical	O
studies	O
on	O
different	O
human	O
tissues	O
,	O
including	O
a	O
cohort	O
of	O
nine	O
autopsies	O
,	O
two	O
liver	O
biopsies	O
and	O
intestinal	O
biopsies	O
of	O
SARS	O
patients	O
,	O
further	O
confirmed	O
the	O
existence	O
of	O
coronaviral	O
hypothetical	O
and	O
structural	O
proteins	O
in	O
the	O
cytoplasm	B-COMP
of	O
pneumocytes	O
and	O
small	O
intestinal	O
surface	O
enterocytes	O
in	O
SARS	O
patients	O
.	O

With	O
this	O
vast	O
array	O
of	O
antibodies	B-COMP
,	O
no	O
signal	O
was	O
observed	O
in	O
other	O
cell	B-COMP
types	O
including	O
those	O
organs	O
in	O
which	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reactions	O
were	O
reported	O
to	O
be	O
positive	O
.	O

The	O
mean	O
neopterin	O
concentrations	O
were	O
34	O
.	O
2	O
nmol	O
/	O
L	O
in	O
acute	O
sera	B-COMP
of	O
SARS	O
patients	O
,	O
5	O
.	O
1	O
nmol	O
/	O
L	O
in	O
convalescent	O
sera	B-COMP
,	O
and	O
6	O
.	O
7	O
nmol	O
/	O
L	O
in	O
healthy	O
controls	O
.	O

In	O
contrast	O
,	O
the	O
mean	O
CRP	O
concentrations	O
in	O
both	O
acute	O
and	O
convalescent	O
sera	B-COMP
of	O
SARS	O
patients	O
were	O
in	O
the	O
normal	O
range	O
(<	O
10	O
mg	O
/	O
L	O
).	O

TITLE	O
:	O
Serum	B-COMP
C	O
-	O
reactive	O
protein	O
elevation	O
predicts	O
poor	O
clinical	O
outcome	O
in	O
patients	O
with	O
distal	O
type	O
acute	O
aortic	O
dissection	O
:	O
association	O
with	O
the	O
occurrence	O
of	O
oxygenation	O
impairment	O
.	O

These	O
purified	O
proteins	O
have	O
been	O
used	O
to	O
generate	O
highly	O
specific	O
polyclonal	O
antibodies	B-COMP
.	O

ABSTRACT	O
:	O
An	O
immune	O
antibody	B-COMP
phage	O
-	O
display	O
library	O
was	O
constructed	O
from	O
B	O
cells	B-COMP
of	O
SARS	O
convalescent	O
patients	O
.	O

The	O
B1	O
recognized	O
SARS	O
pseudovirus	O
in	O
vivo	O
and	O
competed	O
with	O
SARS	O
sera	B-COMP
for	O
binding	O
to	O
SARS	O
-	O
CoV	O
with	O
high	O
affinity	O
(	O
equilibrium	O
dissociation	O
constant	O
,	O
K	O
(	O
d	O
)	O
=	O
105	O
nM	O
).	O

This	O
study	O
not	O
only	O
first	O
made	O
a	O
human	O
neutralizing	O
antibody	B-COMP
,	O
which	O
recognized	O
an	O
epitope	O
on	O
S2	O
protein	O
like	O
natural	O
antibody	B-COMP
in	O
sera	B-COMP
,	O
but	O
also	O
may	O
help	O
us	O
to	O
better	O
understand	O
the	O
immunological	O
characteristics	O
of	O
SARS	O
protein	O
and	O
SARS	O
vaccine	O
design	O
.	O

IgG	B-COMP
antibody	I-COMP
against	O
coronavirus	O
was	O
detected	O
by	O
ELISA	O
in	O
the	O
blood	O
of	O
311	O
convalescent	O
SARS	O
patients	O
for	O
every	O
2	O
-	O
4	O
weeks	O
.	O

Data	O
showed	O
that	O
all	O
the	O
SARS	O
convalescent	O
patients	O
had	O
generated	O
high	O
level	O
of	O
specific	O
IgG	B-COMP
antibody	I-COMP
against	O
coronavirus	O
in	O
the	O
early	O
stage	O
of	O
recovery	O
,	O
but	O
the	O
antibody	B-COMP
level	O
declined	O
along	O
with	O
the	O
progress	O
of	O
convalescence	O
,	O
suggesting	O
that	O
the	O
detection	O
of	O
the	O
IgG	B-COMP
antibody	I-COMP
should	O
go	O
on	O
until	O
it	O
disappeared	O
.	O

Using	O
paired	O
ELISA	O
assay	O
,	O
three	O
mAbs	O
N1E8	O
,	O
N8E1	O
and	O
N10E4	O
were	O
selected	O
as	O
capturing	O
antibody	B-COMP
and	O
rabbit	O
polyclonal	O
antibodies	B-COMP
as	O
detecting	O
antibody	B-COMP
then	O
triple	O
antibodies	B-COMP
-	O
based	O
sandwich	O
ELISA	O
was	O
established	O
following	O
horseradish	O
peroxidase	O
(	O
HRP	O
)-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
immunoglobulin	O
G	O
.	O
The	O
recombinant	O
N	O
protein	O
was	O
used	O
as	O
a	O
standard	O
to	O
establish	O
a	O
detection	O
sensitivity	O
of	O
approximated	O
50	O
pg	O
/	O
ml	O
with	O
this	O
assay	O
.	O

The	O
cytokine	O
release	O
of	O
cultured	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
,	O
peritoneal	O
macrophages	O
,	O
splenocytes	O
,	O
and	O
splenic	O
macrophages	O
and	O
plasma	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
from	O
those	O
animals	O
were	O
quantified	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
and	O
the	O
innate	O
immune	O
responses	O
:	O
modulation	O
of	O
effector	O
cell	B-COMP
function	O
without	O
productive	O
infection	O
.	O

We	O
investigated	O
the	O
interaction	O
of	O
SARS	O
-	O
CoV	O
with	O
human	O
macrophages	O
(	O
Mphi	O
)	O
and	O
dendritic	B-COMP
cells	B-COMP
(	O
DC	O
),	O
two	O
key	O
innate	O
immune	O
cells	B-COMP
of	O
the	O
host	B-COMP
immune	O
system	O
,	O
by	O
focusing	O
on	O
their	O
susceptibility	O
to	O
viral	O
infection	O
and	O
subsequent	O
responses	O
(	O
e	O
.	O
g	O
.,	O
phenotypic	O
maturation	O
,	O
T	O
cell	B-COMP
-	O
priming	O
activity	O
,	O
phagocytosis	O
,	O
and	O
cytokine	O
production	O
).	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
laws	O
of	O
the	O
appearance	O
of	O
the	O
specific	O
serum	B-COMP
antibodies	B-COMP
against	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
and	O
the	O
S1	O
domain	O
of	O
spike	O
(	O
S	O
)	O
glycoprotein	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
evaluate	O
the	O
value	O
of	O
these	O
two	O
proteins	O
to	O
be	O
used	O
as	O
diagnostic	O
makers	O
for	O
SARS	O
.	O

TITLE	O
:	O
[	O
An	O
immunofluorescence	O
assay	O
for	O
the	O
detection	O
of	O
SARS	O
associated	O
coronavirus	O
antibody	B-COMP
based	O
on	O
recombinant	O
nucleocapsid	B-COMP
antigen	O
and	O
its	O
application	O
].	O

SARS	O
antibody	B-COMP
could	O
be	O
detected	O
since	O
the	O
sixth	O
day	O
after	O
onset	O
,	O
and	O
the	O
titer	O
increased	O
from	O
1	O
:	O
40	O
to	O
1	O
:	O
600	O
on	O
the	O
ninth	O
day	O
.	O

Initially	O
,	O
the	O
MHV	O
E	O
gene	O
was	O
inducibly	O
expressed	O
in	O
Escherichia	O
coli	O
cells	B-COMP
,	O
leading	O
to	O
the	O
arrest	O
of	O
bacterial	O
growth	O
,	O
cell	B-COMP
lysis	O
and	O
permeabilization	O
to	O
different	O
compounds	O
.	O

Thus	O
,	O
exit	O
of	O
labeled	O
nucleotides	O
from	O
E	O
.	O
coli	O
cells	B-COMP
to	O
the	O
cytoplasm	B-COMP
was	O
apparent	O
upon	O
expression	O
of	O
MHV	O
E	O
.	O
In	O
addition	O
,	O
enhanced	O
entry	O
of	O
the	O
antibiotic	O
hygromycin	O
B	O
occurred	O
at	O
levels	O
comparable	O
to	O
those	O
observed	O
with	O
the	O
viroporin	O
6K	O
from	O
Sindbis	O
virus	O
.	O

Mammalian	O
cells	B-COMP
are	O
also	O
readily	O
permeabilized	O
by	O
the	O
expression	O
of	O
MHV	O
E	O
protein	O
.	O

A	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
numbers	O
of	O
DC	O
and	O
T	O
-	O
cell	B-COMP
subsets	O
and	O
high	O
-	O
dose	O
steroid	O
treatment	O
.	O

RNA	O
interference	O
(	O
RNAi	O
)	O
is	O
a	O
process	O
in	O
cell	B-COMP
to	O
degradation	O
specific	O
target	O
mRNA	O
by	O
double	O
-	O
stranded	O
RNA	O
.	O

RdRp	O
,	O
spike	O
and	O
nucleocapsid	B-COMP
DNA	O
fragments	O
were	O
inserted	O
into	O
the	O
plasmid	O
pGL3	O
-	O
Control	O
,	O
obtained	O
plasmids	O
pGL	O
-	O
R	O
,	O
pGL	O
-	O
S	O
and	O
pGL	O
-	O
N	O
can	O
express	O
hybrid	O
mRNAs	O
luciferase	O
-	O
RdRp	O
,	O
spike	O
and	O
-	O
nucleocapsid	B-COMP
in	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Genes	O
encoding	O
nucleocaspid	O
(	O
N	O
)	O
and	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
were	O
obtained	O
by	O
RT	O
-	O
PCR	O
and	O
were	O
cloned	O
into	O
expression	O
vector	O
pET22b	O
and	O
pBV222	O
.	O

The	O
genes	O
were	O
over	O
-	O
expressed	O
in	O
E	O
.	O
coli	O
either	O
as	O
inclusion	B-COMP
body	I-COMP
or	O
as	O
soluble	O
form	O
.	O

ABSTRACT	O
:	O
Four	O
clinical	O
isolates	O
of	O
SARS	O
coronavirus	O
were	O
serially	O
passaged	O
in	O
two	O
primate	O
cell	B-COMP
lines	O
(	O
FRhK4	O
and	O
Vero	O
E6	O
).	O

Seven	O
of	O
these	O
mutations	O
were	O
recurrent	O
mutation	O
and	O
all	O
located	O
at	O
the	O
spike	O
,	O
membrane	B-COMP
,	O
and	O
Orf	O
8a	O
protein	O
encoding	O
sequences	O
.	O

ABSTRACT	O
:	O
We	O
recently	O
published	O
experimental	O
results	O
that	O
indicated	O
Aurintricarboxylic	O
Acid	O
(	O
ATA	O
)	O
could	O
selectively	O
inhibit	O
SARS	O
-	O
CoV	O
replication	O
inside	O
host	B-COMP
cells	B-COMP
by	O
greater	O
than	O
1000	O
times	O
.	O

On	O
the	O
contrary	O
,	O
substitution	O
of	O
these	O
two	O
amino	O
acid	O
residues	O
of	O
pcSARS	O
-	O
CoV	O
for	O
those	O
of	O
huSRAS	O
-	O
CoV	O
made	O
pcSARS	O
-	O
CoV	O
capable	O
of	O
infecting	O
human	O
ACE2	O
-	O
expressing	O
cells	B-COMP
.	O

A	O
soluble	O
form	O
of	O
ACE2	O
,	O
lacking	O
its	O
cytosolic	B-COMP
and	O
transmembrane	B-COMP
domains	O
,	O
has	O
been	O
shown	O
to	O
block	O
binding	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
to	O
its	O
receptor	O
.	O

Information	O
about	O
virion	B-COMP
morphology	O
and	O
architecture	O
,	O
antigenic	O
and	O
biological	O
properties	O
,	O
viral	B-COMP
genome	I-COMP
,	O
protein	O
composition	O
,	O
thermal	O
and	O
chemical	O
stability	O
,	O
and	O
pH	O
and	O
proteolytic	O
enzymes	O
resistance	O
is	O
also	O
summarized	O
.	O

Tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
concentrations	O
were	O
measured	O
in	O
portal	O
and	O
systemic	O
serum	B-COMP
,	O
and	O
in	O
the	O
perfusate	O
30	O
and	O
90	O
min	O
after	O
the	O
'	O
second	O
hit	O
'.	O

TITLE	O
:	O
Susceptibility	O
of	O
human	O
and	O
rat	O
neural	O
cell	B-COMP
lines	O
to	O
infection	O
by	O
SARS	O
-	O
coronavirus	O
.	O

Here	O
,	O
we	O
examined	O
the	O
susceptibility	O
of	O
neural	O
cell	B-COMP
lines	O
of	O
human	O
(	O
OL	O
)	O
and	O
rat	O
(	O
C6	O
)	O
origins	O
to	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

Nucleocapsid	B-COMP
(	O
N	O
)	O
proteins	O
of	O
the	O
Coronaviridae	O
family	O
have	O
no	O
discernable	O
homology	O
,	O
but	O
they	O
share	O
a	O
common	O
nucleolar	O
-	O
cytoplasmic	B-COMP
distribution	O
pattern	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
wild	O
type	O
N	O
was	O
distributed	O
mainly	O
in	O
the	O
cytoplasm	B-COMP
.	O

The	O
cell	B-COMP
-	O
based	O
assays	O
also	O
indicate	O
that	O
18c	O
is	O
a	O
nontoxic	O
anti	O
-	O
SARS	O
agent	O
with	O
an	O
EC50	O
value	O
of	O
0	O
.	O
18	O
microM	O
.	O

TITLE	O
:	O
Contributions	O
of	O
the	O
viral	O
genetic	O
background	O
and	O
a	O
single	O
amino	O
acid	O
substitution	O
in	O
an	O
immunodominant	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
epitope	O
to	O
murine	O
coronavirus	O
neurovirulence	O
.	O

Serum	B-COMP
samples	O
collected	O
from	O
healthy	O
volunteers	O
and	O
SARS	O
patients	O
in	O
Vietnam	O
were	O
used	O
to	O
evaluate	O
the	O
newly	O
developed	O
methods	O
.	O

The	O
DNA	O
vaccine	O
contained	O
a	O
plasmid	O
encoding	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S	O
protein	O
under	O
the	O
control	O
of	O
the	O
human	O
CMV	O
promoter	O
and	O
intron	O
A	O
.	O
The	O
whole	O
killed	O
virus	O
vaccine	O
was	O
comprised	O
of	O
SARS	O
-	O
CoV	O
,	O
propagated	O
in	O
Vero	O
-	O
E6	O
cells	B-COMP
,	O
with	O
subsequent	O
beta	O
-	O
propilactone	O
inactivation	O
and	O
formulated	O
with	O
aluminum	O
hydroxide	O
adjuvant	O
.	O

Giardia	O
lamblia	O
was	O
significantly	O
underestimated	O
by	O
fecal	O
flotation	O
,	O
compared	O
with	O
a	O
direct	O
fluorescent	O
antibody	B-COMP
technique	O
.	O

The	O
introduction	O
of	O
the	O
nucleic	B-COMP
acid	O
amplification	O
can	O
avoid	O
the	O
window	O
period	O
of	O
these	O
viral	O
infections	O
.	O

Light	O
chains	O
of	O
all	O
monoclonal	O
antibodies	B-COMP
are	O
kappa	O
.	O

TITLE	O
:	O
Important	O
roles	O
for	O
gamma	O
interferon	O
and	O
NKG2D	O
in	O
gammadelta	O
T	O
-	O
cell	B-COMP
-	O
induced	O
demyelination	O
in	O
T	O
-	O
cell	B-COMP
receptor	O
beta	O
-	O
deficient	O
mice	O
infected	O
with	O
a	O
coronavirus	O
.	O

These	O
results	O
indicate	O
that	O
MHV	O
release	O
does	O
not	O
involve	O
lipid	B-COMP
rafts	I-COMP
.	O

These	O
findings	O
suggest	O
that	O
MHV	O
entry	O
requires	O
specific	O
interactions	O
between	O
the	O
spike	O
protein	O
and	O
lipid	B-COMP
rafts	I-COMP
,	O
probably	O
during	O
the	O
virus	O
internalization	O
step	O
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3a	O
protein	O
up	O
-	O
regulates	O
expression	O
of	O
fibrinogen	B-COMP
in	O
lung	O
epithelial	O
cells	B-COMP
.	O

Although	O
the	O
development	O
of	O
autoimmune	O
antibodies	B-COMP
or	O
immune	O
complexes	O
triggered	O
by	O
viral	O
infection	O
may	O
play	O
a	O
significant	O
role	O
in	O
inducing	O
thrombocytopenia	O
,	O
SARS	O
-	O
CoV	O
may	O
also	O
directly	O
infect	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	B-COMP
,	O
megakaryocytes	O
and	O
platelets	O
inducing	O
their	O
growth	O
inhibition	O
and	O
apoptosis	O
.	O

Thermal	O
aggregation	O
of	O
SARS	O
-	O
CoV	O
membrane	B-COMP
protein	O
may	O
be	O
one	O
of	O
the	O
reasons	O
for	O
the	O
inactivation	O
of	O
this	O
virus	O
by	O
heat	O
.	O

Extrapolated	O
to	O
clinical	O
samples	O
,	O
this	O
novel	O
assay	O
has	O
a	O
detection	O
range	O
of	O
10	O
(	O
4	O
)	O
to	O
10	O
(	O
10	O
)	O
copies	O
of	O
viral	B-COMP
genome	I-COMP
equivalents	O
per	O
millilitre	O
.	O

During	O
the	O
first	O
10	O
days	O
after	O
onset	O
,	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
,	O
SARS	O
-	O
CoV	O
RNA	O
and	O
the	O
N	O
protein	O
were	O
detected	O
in	O
21	O
.	O
4	O
,	O
42	O
.	O
9	O
,	O
and	O
90	O
%	O
of	O
the	O
patients	O
'	O
sera	B-COMP
,	O
respectively	O
.	O

The	O
detection	O
of	O
both	O
antigens	O
and	O
antibodies	B-COMP
in	O
SARS	O
-	O
CoV	O
from	O
human	O
specimens	O
with	O
suspected	O
SARS	O
plays	O
an	O
important	O
role	O
in	O
preventing	O
infection	O
.	O

We	O
developed	O
a	O
novel	O
rapid	O
immunochromatographic	O
test	O
(	O
RICT	O
)	O
based	O
on	O
the	O
sandwich	O
format	O
enzyme	O
immunoassay	O
(	O
EIA	O
)	O
with	O
an	O
all	O
-	O
in	O
-	O
one	O
device	O
for	O
detecting	O
the	O
native	O
nucleocapsid	B-COMP
antigen	O
(	O
N	O
-	O
Ag	O
)	O
of	O
SARS	O
-	O
CoV	O
using	O
monoclonal	O
antibodies	B-COMP
(	O
MoAbs	O
),	O
which	O
we	O
produced	O
by	O
immunizing	O
recombinant	O
N	O
-	O
Ag	O
to	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
human	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
protein	O
)	O
is	O
its	O
most	O
antigenic	O
structural	O
protein	O
.	O

The	O
toxicity	O
of	O
beta	O
-	O
propiolactone	O
was	O
hydrolyzed	O
completely	O
when	O
the	O
inactivated	O
virus	O
was	O
cultured	O
for	O
16	O
hours	O
at	O
2	O
degrees	O
C	O
,	O
8	O
degrees	O
C	O
and	O
in	O
water	O
bath	O
for	O
2	O
hours	O
at	O
37	O
degrees	O
C	O
.	O
The	O
titer	O
of	O
SARS	O
-	O
CoV	O
was	O
the	O
highest	O
when	O
it	O
was	O
cultured	O
in	O
Vero	O
or	O
Vero	O
-	O
E6	O
cells	B-COMP
for	O
72	O
hours	O
at	O
37	O
degrees	O
C	O
in	O
5	O
percent	O
CO2	O
incubator	O
.	O

The	O
toxicity	O
of	O
beta	O
-	O
propiolactone	O
was	O
hydrolyzed	O
completely	O
when	O
the	O
inactivated	O
virus	O
was	O
cultured	O
for	O
16	O
hours	O
at	O
2	O
degrees	O
C	O
,	O
8	O
degrees	O
C	O
and	O
in	O
water	O
bath	O
for	O
2	O
hours	O
at	O
37	O
degrees	O
C	O
.	O
CONCLUSIONS	O
:	O
The	O
titer	O
of	O
SARS	O
-	O
CoV	O
was	O
the	O
highest	O
when	O
it	O
was	O
cultured	O
in	O
Vero	O
or	O
Vero	O
-	O
E6	O
cells	B-COMP
for	O
72	O
hours	O
at	O
37	O
degrees	O
C	O
in	O
5	O
percent	O
CO2	O
incubator	O
.	O

Sera	B-COMP
from	O
SARS	O
patients	O
at	O
phase	O
II	O
/	O
phase	O
III	O
could	O
mediate	O
complement	O
dependent	O
cytotoxicity	O
against	O
some	O
A549	O
cells	B-COMP
and	O
HPEC	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
is	O
the	O
only	O
phosphorylated	O
structural	O
protein	O
of	O
the	O
coronavirus	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

Green	O
fluorescent	O
protein	O
expression	O
was	O
demonstrated	O
as	O
early	O
as	O
7	O
h	O
after	O
infection	O
of	O
Vero	O
E6	O
cells	B-COMP
with	O
VSV	O
-	O
SARS	O
-	O
St19	O
.	O

VSV	O
-	O
SARS	O
-	O
St19	O
will	O
be	O
useful	O
for	O
analysing	O
the	O
function	O
of	O
SARS	O
-	O
CoV	O
-	O
S	O
protein	O
and	O
for	O
developing	O
rapid	O
methods	O
of	O
detecting	O
neutralizing	O
antibodies	B-COMP
specific	O
for	O
SARS	O
-	O
CoV	O
infection	O
.	O

All	O
residues	O
except	O
Thr2p	O
and	O
Lys9p	O
are	O
accessible	O
for	O
T	O
-	O
cell	B-COMP
recognition	O
.	O

TITLE	O
:	O
Antibody	B-COMP
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
spike	O
protein	O
domain	O
2	O
cross	O
-	O
reacts	O
with	O
lung	O
epithelial	O
cells	B-COMP
and	O
causes	O
cytotoxicity	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
in	O
SARS	O
patient	O
sera	B-COMP
there	O
were	O
autoantibodies	O
(	O
autoAbs	O
)	O
that	O
reacted	O
with	O
A549	O
cells	B-COMP
,	O
the	O
type	O
-	O
2	O
pneumocytes	O
,	O
and	O
that	O
these	O
autoAbs	O
were	O
mainly	O
IgG	O
.	O
The	O
autoAbs	O
were	O
detectable	O
20	O
days	O
after	O
fever	O
onset	O
.	O

Furthermore	O
,	O
immunohistochemistry	O
of	O
frozen	O
HG	O
sections	O
showed	O
positive	O
stained	O
cells	B-COMP
for	O
both	O
H	O
-	O
PGDS	O
and	O
mast	O
cell	B-COMP
tryptase	O
in	O
the	O
sub	O
-	O
epithelial	O
cell	B-COMP
layers	O
of	O
the	O
HG	O
ducts	O
.	O

Co	O
-	O
transfection	O
of	O
p3b	O
-	O
EGFP	O
with	O
pC23	O
-	O
DsRed	O
,	O
pB23	O
-	O
DsRed	O
and	O
pfibrillarin	O
-	O
DsRed	O
further	O
confirmed	O
3b	O
'	O
s	O
nucleolus	B-COMP
localization	O
.	O

All	O
animals	O
developed	O
a	O
multifocal	O
mononuclear	O
cell	B-COMP
interstitial	O
pneumonitis	O
,	O
accompanied	O
by	O
multinucleated	O
syncytial	O
cells	B-COMP
,	O
edema	O
,	O
and	O
bronchiolitis	O
in	O
most	O
animals	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
LSECtin	O
is	O
N	O
-	O
linked	O
glycosylated	O
and	O
that	O
glycosylation	O
is	O
required	O
for	O
cell	B-COMP
surface	I-COMP
expression	O
.	O

TITLE	O
:	O
Peptide	O
domain	O
involved	O
in	O
the	O
interaction	O
between	O
membrane	B-COMP
protein	O
and	O
nucleocapsid	B-COMP
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

TITLE	O
:	O
Membrane	B-COMP
-	O
associated	O
zinc	O
peptidase	O
families	O
:	O
comparing	O
ACE	O
and	O
ACE2	O
.	O

It	O
has	O
been	O
established	O
that	O
the	O
function	O
of	O
the	O
alveolar	O
-	O
capillary	O
membrane	B-COMP
is	O
not	O
impaired	O
with	O
the	O
PaO2	O
/	O
FiO2	O
ratio	O
of	O
more	O
than	O
1	O
.	O
5	O
and	O
the	O
ratio	O
of	O
less	O
than	O
1	O
.	O
0	O
is	O
typical	O
of	O
the	O
severe	O
course	O
of	O
the	O
severe	O
course	O
of	O
ARDS	O
and	O
suggests	O
both	O
alveolar	O
-	O
capillary	O
membrane	B-COMP
damage	O
and	O
energy	O
deficiency	O
.	O

Synthetic	O
peptides	O
M1	O
-	O
31	O
derived	O
from	O
the	O
N	O
-	O
terminal	O
epitope	O
and	O
M132	O
-	O
161	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
epitope	O
were	O
highly	O
reactive	O
with	O
all	O
of	O
the	O
convalescent	O
-	O
phase	O
sera	B-COMP
from	O
40	O
SARS	O
patients	O
but	O
not	O
with	O
30	O
control	O
serum	B-COMP
samples	O
from	O
healthy	O
blood	O
donors	O
,	O
suggesting	O
their	O
potential	O
application	O
for	O
serologic	O
diagnosis	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
Histidine	O
-	O
tagged	O
N	O
(	O
rNH	O
)	O
and	O
E	O
(	O
rEH	O
)	O
proteins	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)-	O
coronovirus	O
were	O
expressed	O
in	O
the	O
baculovirus	O
/	O
insect	O
cell	B-COMP
system	O
and	O
purified	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
.	O

TITLE	O
:	O
Apoptosis	O
induced	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
Vero	O
cells	B-COMP
is	O
replication	O
-	O
dependent	O
and	O
involves	O
caspase	O
.	O

It	O
plays	O
an	O
important	O
role	O
in	O
the	O
interaction	O
with	O
receptors	O
and	O
neutralizing	O
antibodies	B-COMP
.	O

The	O
selection	O
of	O
25	O
test	O
materials	O
includes	O
eleven	O
trioxa	O
-	O
adamantane	O
-	O
triols	O
(	O
TATs	O
)	O
[	O
BN	O
,	O
IBNCA	O
,	O
ABNCA	O
,	O
VANBA	O
,	O
ethylVANBA	O
,	O
euBN	O
,	O
euVANBA	O
,	O
ansaBN	O
,	O
Ehrlich	O
BN	O
,	O
[	O
6	O
]	O
prismaneBN	O
,	O
nitrodiBN	O
],	O
trivially	O
termed	O
bananins	O
,	O
one	O
trioxa	O
-	O
adamantan	O
-	O
ol	O
(	O
TAO	O
)	O
THYMOBA	O
,	O
one	O
bis	O
-	O
bananin	O
pi	O
-	O
bananin	O
(	O
piBN	O
),	O
one	O
triazaadamantane	O
delta	O
-	O
bananin	O
(	O
deltaBN	O
),	O
seven	O
potential	O
nucleic	B-COMP
acid	O
-	O
binding	O
drugs	O
(	O
XBQC	O
,	O
INDO	O
,	O
PivINDO	O
,	O
AZTRION	O
,	O
AZADO	O
,	O
AZOCYS	O
,	O
AZOGALL	O
),	O
one	O
potential	O
antiviral	O
interferon	O
-	O
inducer	O
and	O
distant	O
nucleoside	O
analog	O
diazon	O
,	O
one	O
potential	O
HIV	O
protein	O
Vif	O
antagonist	O
AZODIAZON	O
,	O
one	O
folic	O
acid	O
-	O
diazon	O
condensate	O
DIAZONOFOL	O
,	O
and	O
one	O
special	O
nucleoside	O
analog	O
(	O
fructoinosine	O
/	O
fructovir	O
).	O

One	O
protein	O
,	O
the	O
product	O
of	O
SARS	O
-	O
CoV	O
ORF6	O
,	O
converted	O
a	O
sublethal	O
infection	O
to	O
a	O
uniformly	O
lethal	O
encephalitis	O
and	O
enhanced	O
virus	O
growth	O
in	O
tissue	O
culture	O
cells	B-COMP
,	O
indicating	O
that	O
SARS	O
-	O
CoV	O
proteins	O
function	O
in	O
the	O
context	O
of	O
a	O
heterologous	O
coronavirus	O
infection	O
.	O

Experimentally	O
,	O
we	O
have	O
shown	O
in	O
this	O
report	O
that	O
the	O
N	O
protein	O
of	O
the	O
SARS	O
-	O
CoV	O
gets	O
serine	O
-	O
phosphorylated	O
by	O
multiple	O
kinases	O
,	O
in	O
both	O
the	O
cytoplasm	B-COMP
and	O
the	O
nucleus	B-COMP
.	O

However	O
,	O
confocal	O
microscopy	O
of	O
N	O
protein	O
localization	O
in	O
Vero	O
cells	B-COMP
infected	O
with	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
or	O
transfected	O
with	O
the	O
SARS	O
-	O
CoV	O
N	O
gene	O
failed	O
to	O
show	O
the	O
presence	O
of	O
N	O
in	O
the	O
nucleoplasm	B-COMP
or	O
nucleolus	B-COMP
.	O

RESULTS	O
:	O
A	O
total	O
of	O
325	O
laboratory	O
-	O
confirmed	O
SARS	O
cases	O
were	O
analyzed	O
;	O
of	O
which	O
301	O
(	O
92	O
.	O
6	O
%)	O
had	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
detected	O
in	O
their	O
sera	B-COMP
at	O
the	O
time	O
of	O
sampling	O
.	O

TITLE	O
:	O
Characterization	O
and	O
application	O
of	O
monoclonal	O
antibodies	B-COMP
against	O
N	O
protein	O
of	O
SARS	O
-	O
coronavirus	O
.	O

Chloroquine	O
is	O
effective	O
in	O
preventing	O
the	O
spread	O
of	O
SARS	O
CoV	O
in	O
cell	B-COMP
culture	O
.	O

Favorable	O
inhibition	O
of	O
virus	O
spread	O
was	O
observed	O
when	O
the	O
cells	B-COMP
were	O
either	O
treated	O
with	O
chloroquine	O
prior	O
to	O
or	O
after	O
SARS	O
CoV	O
infection	O
.	O

RESULTS	O
:	O
We	O
report	O
,	O
however	O
,	O
that	O
chloroquine	O
has	O
strong	O
antiviral	O
effects	O
on	O
SARS	O
-	O
CoV	O
infection	O
of	O
primate	O
cells	B-COMP
.	O

CONCLUSIONS	O
:	O
Chloroquine	O
is	O
effective	O
in	O
preventing	O
the	O
spread	O
of	O
SARS	O
CoV	O
in	O
cell	B-COMP
culture	O
.	O

In	O
this	O
study	O
,	O
Isatis	O
indigotica	O
root	O
extract	O
,	O
five	O
major	O
compounds	O
of	O
I	O
.	O
indigotica	O
root	O
,	O
and	O
seven	O
plant	O
-	O
derived	O
phenolic	O
compounds	O
were	O
tested	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
3CLpro	O
effects	O
using	O
cell	B-COMP
-	O
free	O
and	O
cell	B-COMP
-	O
based	O
cleavage	O
assays	O
.	O

We	O
found	O
that	O
proteases	O
such	O
as	O
trypsin	O
and	O
thermolysin	O
enabled	O
SARS	O
-	O
CoV	O
adsorbed	O
onto	O
the	O
cell	B-COMP
surface	I-COMP
to	O
enter	O
cells	B-COMP
directly	O
from	O
that	O
site	O
.	O

We	O
developed	O
a	O
system	O
for	O
large	O
-	O
scale	O
molecular	O
virus	O
screening	O
of	O
clinical	O
samples	O
based	O
on	O
host	B-COMP
DNA	O
depletion	O
,	O
random	O
PCR	O
amplification	O
,	O
large	O
-	O
scale	O
sequencing	O
,	O
and	O
bioinformatics	O
.	O

TITLE	O
:	O
A	O
serological	O
survey	O
on	O
neutralizing	O
antibody	B-COMP
titer	O
of	O
SARS	O
convalescent	O
sera	B-COMP
.	O

The	O
geometric	O
mean	O
titer	O
(	O
GMT	O
)	O
of	O
the	O
87	O
convalescent	O
sera	B-COMP
was	O
1	O
:	O
61	O
.	O

The	O
Kolmogorov	O
-	O
Smirnov	O
test	O
showed	O
that	O
the	O
neutralizing	O
antibody	B-COMP
titers	O
conform	O
to	O
normal	O
distribution	O
,	O
which	O
suggests	O
that	O
the	O
average	O
anti	O
-	O
SARS	O
antibody	B-COMP
level	O
in	O
this	O
study	O
was	O
representative	O
of	O
the	O
convalescent	O
antibody	B-COMP
level	O
of	O
the	O
SARS	O
population	O
.	O

The	O
kinetic	O
study	O
of	O
the	O
replication	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
showed	O
that	O
there	O
were	O
infected	O
cells	B-COMP
in	O
HuH7	O
and	O
MDCK	O
lines	O
as	O
early	O
as	O
24	O
hr	O
post	O
-	O
infection	O
.	O

Different	O
host	B-COMP
receptors	O
for	O
cellular	B-COMP
entry	O
,	O
poorly	O
conserved	O
structural	O
proteins	O
(	O
antigens	O
),	O
and	O
the	O
high	O
mutation	O
and	O
recombination	O
rates	O
of	O
CoVs	O
pose	O
a	O
significant	O
problem	O
in	O
the	O
development	O
of	O
wide	O
-	O
spectrum	O
anti	O
-	O
CoV	O
drugs	O
and	O
vaccines	O
.	O

ABSTRACT	O
:	O
Many	O
factors	O
influence	O
the	O
choice	O
of	O
methods	O
used	O
to	O
develop	O
antibody	B-COMP
to	O
infectious	O
agents	O
.	O

Bacterial	O
membranes	O
seemed	O
to	O
be	O
cracked	O
and	O
the	O
cytoplasm	B-COMP
seemed	O
to	O
be	O
effluent	O
from	O
cell	B-COMP
bodies	O
.	O

A	O
total	O
of	O
2892	O
clinical	O
serum	B-COMP
samples	O
were	O
tested	O
with	O
the	O
ELISA	O
kit	O
,	O
which	O
positively	O
identified	O
25	O
of	O
35	O
(	O
71	O
.	O
4	O
%)	O
samples	O
of	O
patients	O
with	O
confirmed	O
SARS	O
infection	O
,	O
286	O
of	O
407	O
(	O
70	O
%)	O
samples	O
of	O
patients	O
suspected	O
of	O
having	O
SARS	O
,	O
229	O
of	O
302	O
(	O
75	O
.	O
8	O
%)	O
samples	O
of	O
convalescent	O
SARS	O
patients	O
,	O
and	O
0	O
of	O
544	O
samples	O
obtained	O
from	O
healthcare	O
workers	O
;	O
only	O
1	O
of	O
1604	O
clinical	O
samples	O
obtained	O
from	O
patients	O
with	O
other	O
diseases	O
demonstrated	O
a	O
weakly	O
positive	O
result	O
.	O

In	O
this	O
report	O
,	O
we	O
study	O
the	O
chronological	O
order	O
of	O
genotypic	O
changes	O
in	O
the	O
spike	O
protein	O
of	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
during	O
its	O
adaptation	O
to	O
a	O
primate	O
cell	B-COMP
line	O
.	O

Primers	O
were	O
designed	O
from	O
conserved	O
or	O
variable	O
regions	O
of	O
nucleocapsid	B-COMP
(	O
N	O
)	O
or	O
spike	O
(	O
S	O
)	O
protein	O
gene	O
among	O
TCoV	O
,	O
IBV	O
,	O
and	O
BCoV	O
and	O
used	O
in	O
the	O
same	O
PCR	O
reaction	O
.	O

Obstructive	O
apnea	O
is	O
associated	O
with	O
endothelial	O
dysfunction	O
,	O
increased	O
C	O
-	O
reactive	O
protein	O
and	O
cytokine	O
expression	O
,	O
elevated	O
fibrinogen	B-COMP
levels	O
and	O
decreased	O
fibrinolytic	O
activity	O
.	O

TITLE	O
:	O
Protection	O
of	O
mammalian	O
cells	B-COMP
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
by	O
equine	O
neutralizing	O
antibody	B-COMP
.	O

The	O
protective	O
effect	O
of	O
the	O
F	O
(	O
ab	O
')	O
2	O
fragments	O
against	O
SARS	O
-	O
CoV	O
infection	O
was	O
determined	O
in	O
cultured	O
Vero	O
E6	O
cells	B-COMP
by	O
cytopathic	O
effect	O
(	O
CPE	O
),	O
MTT	O
and	O
plaque	O
-	O
forming	O
assays	O
and	O
in	O
a	O
Balb	O
/	O
c	O
mouse	O
model	O
by	O
CPE	O
and	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Five	O
of	O
these	O
peptides	O
showed	O
high	O
cross	O
-	O
immunoreactivities	O
(	O
approximately	O
66	O
.	O
7	O
to	O
90	O
.	O
5	O
%)	O
to	O
SARS	O
convalescent	O
patients	O
'	O
sera	B-COMP
from	O
the	O
severest	O
epidemic	O
regions	O
of	O
the	O
China	O
mainland	O
.	O

The	O
TEM	B-COMP
image	O
for	O
our	O
purposes	O
is	O
defined	O
on	O
2	O
-	O
D	O
information	O
,	O
such	O
as	O
the	O
membrane	B-COMP
having	O
undergone	O
proliferation	O
and	O
from	O
pattern	O
recognition	O
suggesting	O
that	O
the	O
membrane	B-COMP
-	O
described	O
pattern	O
is	O
possibly	O
a	O
gyroid	O
type	O
of	O
membrane	B-COMP
.	O

Rather	O
than	O
focusing	O
on	O
the	O
detection	O
of	O
an	O
individual	O
pathogen	O
component	O
,	O
we	O
have	O
developed	O
a	O
T	O
cell	B-COMP
profiling	O
system	O
to	O
monitor	O
responses	O
to	O
the	O
pathogens	O
in	O
an	O
array	O
format	O
.	O

Using	O
a	O
matrix	O
of	O
antigens	O
specific	O
for	O
different	O
pathogens	O
,	O
a	O
specific	O
T	O
cell	B-COMP
profile	O
was	O
generated	O
for	O
each	O
individual	O
by	O
monitoring	O
the	O
intracellular	B-COMP
production	O
of	O
interferon	O
-	O
gamma	O
by	O
flow	O
cytometry	O
.	O

Passive	O
transfer	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-COMP
from	O
the	O
mother	O
was	O
considered	O
as	O
a	O
possibility	O
.	O

Bacterially	O
expressed	O
forms	O
of	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
X	O
domains	O
were	O
shown	O
to	O
dephosphorylate	O
Appr	O
-	O
1	O
"""-"	O
p	O
,	O
a	O
side	O
product	O
of	O
cellular	B-COMP
tRNA	O
splicing	O
,	O
to	O
ADP	O
-	O
ribose	O
in	O
a	O
highly	O
specific	O
manner	O
.	O

TITLE	O
:	O
Influence	O
of	O
intron	O
and	O
exon	O
splicing	O
enhancers	O
on	O
mammalian	O
cell	B-COMP
expression	O
of	O
a	O
truncated	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
and	O
its	O
implication	O
for	O
subunit	O
vaccine	O
development	O
.	O

In	O
the	O
ethanol	O
group	O
,	O
serum	B-COMP
and	O
tissue	O
MDA	O
levels	O
and	O
MPO	O
activities	O
were	O
increased	O
(	O
p	O
=	O
0	O
.	O
007	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
),	O
and	O
lung	O
tissue	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	O
activities	O
and	O
erythrocyte	O
GSH	O
were	O
decreased	O
(	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
)	O
compared	O
to	O
the	O
controls	O
.	O

Screening	O
for	O
viral	O
contamination	O
is	O
done	O
by	O
the	O
mouse	O
antibody	B-COMP
production	O
(	O
MAP	O
)	O
test	O
,	O
by	O
cell	B-COMP
culture	O
,	O
or	O
alternatively	O
by	O
direct	O
detection	O
of	O
the	O
viral	O
agents	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

TITLE	O
:	O
[	O
Molecular	O
cloning	O
and	O
expression	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
and	O
its	O
clinical	O
application	O
].	O

Novel	O
findings	O
included	O
hyaline	O
membrane	B-COMP
formation	O
in	O
respiratory	O
system	O
cases	O
that	O
is	O
similar	O
to	O
acute	O
(	O
adult	O
)	O
respiratory	O
distress	O
syndrome	O
and	O
evidence	O
of	O
primary	O
gastrointestinal	O
involvement	O
,	O
showing	O
the	O
ability	O
of	O
the	O
organism	O
to	O
pass	O
the	O
gastric	O
barrier	O
.	O

There	O
is	O
also	O
evidence	O
suggesting	O
that	O
SARS	O
-	O
CoV	O
might	O
be	O
able	O
to	O
directly	O
invade	O
cells	B-COMP
of	O
the	O
immune	O
system	O
.	O

The	O
peak	O
inflammatory	O
response	O
was	O
obtained	O
at	O
24	O
h	O
when	O
the	O
fluid	O
volume	O
,	O
protein	O
concentration	O
,	O
C	O
-	O
reactive	O
protein	O
and	O
cell	B-COMP
infiltration	O
were	O
maximums	O
.	O

Moreover	O
,	O
the	O
vaccine	O
confers	O
protective	O
immunity	O
as	O
demonstrated	O
by	O
prevention	O
of	O
SARS	O
-	O
CoV	O
replication	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
after	O
intranasal	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
Protection	O
of	O
mice	O
was	O
correlated	O
to	O
antibody	B-COMP
titre	O
against	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
and	O
neutralising	O
antibody	B-COMP
titre	O
.	O

expression	O
dramatically	O
,	O
and	O
T	O
lymphocytes	O
and	O
their	O
subsets	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	B-COMP
are	O
decreased	O
after	O
onset	O
of	O
the	O
disease	O
.	O

Balb	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
recombinant	O
Protein	O
X4	O
,	O
hybridoma	O
cell	B-COMP
lines	O
secreting	O
monoclonal	O
antibodies	B-COMP
against	O
protein	O
X4	O
were	O
screened	O
by	O
regular	O
cell	B-COMP
fusion	O
and	O
subcloning	O
approach	O
.	O

Three	O
hybridoma	O
cell	B-COMP
lines	O
(	O
8A5	O
,	O
8H6	O
and	O
4A2	O
)	O
stable	O
in	O
secreting	O
specific	O
monoclonal	O
antibodies	B-COMP
were	O
successfully	O
obtained	O
.	O

CONCLUSIONS	O
:	O
Monoclonal	O
antibodies	B-COMP
of	O
high	O
specificity	O
against	O
protein	O
X4	O
have	O
been	O
successfully	O
prepared	O
,	O
which	O
laid	O
the	O
foundation	O
for	O
the	O
further	O
study	O
of	O
protein	O
X4	O
.	O

Infectious	O
MHVDeltansp2	O
and	O
SARSDeltansp2	O
viruses	O
recovered	O
from	O
electroporated	O
cells	B-COMP
had	O
0	O
.	O
5	O
to	O
1	O
log10	O
reductions	O
in	O
peak	O
titers	O
in	O
single	O
-	O
cycle	O
growth	O
assays	O
,	O
as	O
well	O
as	O
a	O
reduction	O
in	O
viral	O
RNA	O
synthesis	O
that	O
was	O
not	O
specific	O
for	O
any	O
positive	O
-	O
stranded	O
RNA	O
species	O
.	O

In	O
all	O
cell	B-COMP
types	O
,	O
SCV	O
-	O
specific	O
subgenomic	O
mRNAs	O
were	O
seen	O
,	O
whereas	O
no	O
expression	O
of	O
SCV	O
proteins	O
was	O
found	O
.	O

Furthermore	O
,	O
SARS	O
virus	O
RNA	O
was	O
detected	O
in	O
feces	O
and	O
in	O
serum	B-COMP
during	O
the	O
acute	O
phase	O
.	O

Taken	O
together	O
,	O
TGEV	O
spiker	O
protein	O
belongs	O
to	O
the	O
class	O
I	O
fusion	O
protein	O
,	O
characterized	O
by	O
the	O
existence	O
of	O
two	O
heptad	O
-	O
repeat	O
(	O
HR	O
)	O
regions	O
,	O
HR1	O
and	O
HR2	O
,	O
and	O
the	O
present	O
knowledge	O
about	O
the	O
truncated	O
TGEV	O
fusion	O
protein	O
core	O
may	O
facilitate	O
in	O
the	O
design	O
of	O
the	O
small	O
molecule	O
or	O
polypeptide	O
drugs	O
targeting	O
the	O
membrane	B-COMP
fusion	O
between	O
TGEV	O
and	O
its	O
host	B-COMP
.	O

Recent	O
data	O
have	O
shown	O
stable	O
patterns	O
of	O
activation	O
among	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
and	O
neutrophils	O
in	O
healthy	O
human	O
subjects	O
.	O

The	O
results	O
demonstrate	O
that	O
,	O
compared	O
with	O
other	O
compounds	O
reported	O
so	O
far	O
,	O
AVLQSGFR	O
is	O
the	O
most	O
active	O
in	O
inhibiting	O
replication	O
of	O
the	O
SARS	O
coronavirus	O
,	O
and	O
that	O
no	O
detectable	O
toxicity	O
is	O
observed	O
on	O
Vero	O
cells	B-COMP
under	O
the	O
condition	O
of	O
experimental	O
concentration	O
.	O

ABSTRACT	O
:	O
The	O
mannose	O
binding	O
proteins	O
on	O
the	O
surface	O
of	O
the	O
dendritic	B-COMP
cells	B-COMP
are	O
responsible	O
for	O
capture	O
of	O
pathogens	O
in	O
the	O
early	O
stages	O
of	O
immune	O
response	O
.	O

The	O
resultant	O
plasmids	O
were	O
expressed	O
in	O
the	O
E	O
.	O
coil	O
cells	B-COMP
and	O
purified	O
by	O
glutathione	O
-	O
Sepharose	O
affinity	O
chromatography	O
.	O

The	O
adaptation	O
of	O
the	O
virus	O
through	O
the	O
use	O
of	O
heparan	O
sulfate	O
as	O
an	O
attachment	O
/	O
entry	O
receptor	O
was	O
demonstrated	O
by	O
increased	O
heparin	O
binding	O
as	O
well	O
as	O
by	O
inhibition	O
of	O
infection	O
through	O
treatment	O
of	O
cells	B-COMP
and	O
the	O
virus	O
with	O
heparinase	O
and	O
heparin	O
,	O
respectively	O
.	O

We	O
therefore	O
developed	O
a	O
real	O
-	O
time	O
nucleic	B-COMP
acid	O
sequence	O
-	O
based	O
amplification	O
(	O
NASBA	O
)	O
test	O
for	O
SARS	O
-	O
CoV	O
.	O
A	O
number	O
of	O
primer	O
/	O
beacon	O
sets	O
were	O
designed	O
to	O
target	O
different	O
regions	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
,	O
and	O
were	O
tested	O
for	O
sensitivity	O
and	O
specificity	O
.	O

RESULTS	O
:	O
Recombinant	O
N	O
protein	O
reacted	O
strongly	O
and	O
specifically	O
with	O
the	O
sera	B-COMP
from	O
immunized	O
mice	O
and	O
SARS	O
patients	O
.	O

Intravaginal	O
or	O
intranasal	O
immunization	O
by	O
HIV	O
-	O
NS	O
with	O
diameters	O
ranging	O
360	O
to	O
1230	O
nm	O
significantly	O
induced	O
vaginal	O
antibody	B-COMP
responses	O
.	O

After	O
virus	O
attack	O
,	O
the	O
level	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-COMP
were	O
induced	O
by	O
SARS	O
-	O
CoV	O
in	O
the	O
interferon	O
group	O
was	O
weaker	O
than	O
in	O
control	O
group	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
preventive	O
effect	O
of	O
recombinant	O
human	O
interferon	O
alpha	O
-	O
2b	O
for	O
nasal	O
spray	O
against	O
SARS	O
and	O
other	O
common	O
respiratory	O
viral	O
infections	O
by	O
serum	B-COMP
-	O
epidemiological	O
method	O
.	O

No	O
statistically	O
significant	O
difference	O
in	O
serum	B-COMP
SARS	O
IgG	B-COMP
antibody	I-COMP
positive	O
rate	O
was	O
found	O
between	O
the	O
interferon	O
and	O
control	O
groups	O
among	O
2	O
,	O
757	O
serum	B-COMP
samples	O
.	O

This	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
assay	O
could	O
be	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-COMP
.	O

Our	O
results	O
suggest	O
that	O
pulmonary	O
vascular	O
occlusion	O
occurs	O
in	O
both	O
patients	O
with	O
uncomplicated	O
malaria	O
and	O
those	O
with	O
severe	O
malaria	O
,	O
likely	O
from	O
sequestration	O
of	O
both	O
red	O
blood	O
cells	B-COMP
(	O
RBCs	O
)	O
and	O
white	O
blood	O
cells	B-COMP
.	O

Convalescent	O
serum	B-COMP
was	O
collected	O
from	O
clinical	O
confirmed	O
patient	O
.	O

Upon	O
subsequent	O
culturing	O
of	O
the	O
remaining	O
adherent	O
cells	B-COMP
,	O
the	O
cells	B-COMP
gradually	O
proliferated	O
and	O
recovered	O
normal	O
morphology	O
similar	O
to	O
that	O
of	O
the	O
parental	O
cells	B-COMP
,	O
and	O
continued	O
to	O
produce	O
large	O
numbers	O
of	O
infectious	O
viral	B-COMP
particles	I-COMP
during	O
the	O
observation	O
period	O
of	O
5	O
months	O
.	O

Western	O
blot	O
analysis	O
as	O
well	O
as	O
electron	O
microscopy	O
indicated	O
that	O
the	O
ratios	O
of	O
spike	O
to	O
nucleocapsid	B-COMP
protein	O
in	O
clone	O
#	O
21	O
as	O
well	O
as	O
its	O
parental	O
persistently	O
infected	O
cells	B-COMP
were	O
lower	O
than	O
that	O
in	O
the	O
cells	B-COMP
in	O
the	O
acute	O
phase	O
of	O
infection	O
.	O

These	O
Vero	O
E6	O
cells	B-COMP
persistently	O
infected	O
with	O
SARS	O
-	O
CoV	O
may	O
be	O
useful	O
for	O
clarifying	O
the	O
mechanism	O
of	O
the	O
persistent	O
infection	O
and	O
also	O
for	O
elucidating	O
the	O
possible	O
pathophysiologic	O
significance	O
of	O
such	O
long	O
-	O
term	O
maintenance	O
of	O
this	O
virus	O
.	O

When	O
this	O
is	O
extrapolated	O
to	O
clinical	O
samples	O
,	O
this	O
corresponds	O
to	O
a	O
detection	O
range	O
of	O
10	O
(	O
3	O
)	O
to	O
10	O
(	O
10	O
)	O
viral	B-COMP
genome	I-COMP
equivalents	O
per	O
ml	O
.	O

TITLE	O
:	O
Transfer	O
of	O
the	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
patient	O
to	O
the	O
intensive	O
care	O
unit	O
:	O
does	O
it	O
really	O
matter	O
?	O

Further	O
flow	O
cytometry	O
assay	O
demonstrated	O
the	O
high	O
efficiency	O
of	O
RBD	O
'	O
s	O
binding	O
ability	O
to	O
ACE2	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
)	O
positive	O
Vero	O
E6	O
cell	B-COMP
.	O

And	O
ACE2	O
was	O
proved	O
as	O
a	O
cellular	B-COMP
receptor	O
that	O
meditated	O
an	O
initial	O
-	O
affinity	O
interaction	O
with	O
SARS	O
-	O
Cov	O
spike	O
protein	O
.	O

As	O
assessed	O
by	O
immunofluorescence	O
staining	O
and	O
membrane	B-COMP
biotinylation	O
,	O
ACE2	O
protein	O
was	O
more	O
abundantly	O
expressed	O
on	O
the	O
apical	O
than	O
the	O
basolateral	O
surface	O
of	O
polarized	O
airway	O
epithelia	O
.	O

Undifferentiated	O
cells	B-COMP
expressing	O
little	O
ACE2	O
were	O
poorly	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
while	O
well	O
-	O
differentiated	O
cells	B-COMP
expressing	O
more	O
ACE2	O
were	O
readily	O
infected	O
.	O

Viral	O
proteins	O
as	O
a	O
coating	O
antigen	O
of	O
PEDV	O
ELISA	O
were	O
extracted	O
from	O
the	O
cytoplasm	B-COMP
of	O
PEDV	O
-	O
infected	O
Vero	O
cells	B-COMP
using	O
a	O
non	O
-	O
ionic	O
detergent	O
,	O
Triton	O
X	O
-	O
100	O
,	O
and	O
a	O
simple	O
protocol	O
of	O
PEDV	O
ELISA	O
was	O
followed	O
.	O

TITLE	O
:	O
Transplantation	O
of	O
glial	O
-	O
committed	O
progenitor	O
cells	B-COMP
into	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
induces	O
remyelination	O
in	O
the	O
absence	O
of	O
an	O
attenuated	O
inflammatory	O
response	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
BW001	O
could	O
activate	O
CD19	O
+	O
B	O
cells	B-COMP
and	O
CD56	O
+	O
NK	O
cells	B-COMP
in	O
human	O
PBMCs	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
using	O
cells	B-COMP
derived	O
from	O
the	O
natural	O
host	B-COMP
when	O
studying	O
coronavirus	O
non	O
-	O
structural	O
proteins	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
is	O
a	O
viral	O
RNA	O
-	O
binding	O
protein	O
with	O
multiple	O
functions	O
in	O
terms	O
of	O
virus	O
replication	O
and	O
modulating	O
cell	B-COMP
signalling	O
pathways	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
COS	O
-	O
7	O
and	O
Vero	O
cells	B-COMP
.	O

It	O
rapidly	O
adapted	O
to	O
the	O
new	O
host	B-COMP
and	O
not	O
only	O
became	O
readily	O
transmissible	O
between	O
humans	O
but	O
also	O
more	O
pathogenic	O
.	O

Here	O
we	O
analyzed	O
whether	O
these	O
characteristics	O
can	O
be	O
used	O
to	O
redirect	O
MHV	O
to	O
human	O
cancer	O
cells	B-COMP
.	O

The	O
soR	O
and	O
soR	O
-	O
425	O
proteins	O
,	O
both	O
produced	O
with	O
the	O
vaccinia	O
virus	O
system	O
,	O
were	O
able	O
to	O
neutralize	O
MHV	O
infection	O
of	O
murine	O
LR7	O
cells	B-COMP
.	O

We	O
conclude	O
that	O
the	O
specific	O
spike	O
-	O
binding	O
property	O
of	O
the	O
CEACAM1a	O
N	O
-	O
terminal	O
fragment	O
can	O
be	O
exploited	O
to	O
direct	O
the	O
virus	O
to	O
selected	O
cells	B-COMP
by	O
linking	O
it	O
to	O
a	O
moiety	O
able	O
to	O
bind	O
a	O
receptor	O
on	O
those	O
cells	B-COMP
.	O

SARS	O
-	O
CoV	O
structural	O
proteins	O
and	O
virions	B-COMP
localized	O
to	O
ciliated	O
epithelial	O
cells	B-COMP
.	O

The	O
caveolae	B-COMP
engulfed	O
SV40	O
virions	B-COMP
begin	O
budding	O
from	O
plasma	B-COMP
membrane	I-COMP
depending	O
on	O
dynamin	O
.	O

A	O
corona	O
of	O
large	O
,	O
distinctive	O
spikes	O
in	O
the	O
envelope	B-COMP
was	O
measured	O
after	O
treatment	O
with	O
hydroxyoctanoic	O
acid	O
.	O

By	O
monitoring	O
apoptosis	O
indicators	O
including	O
chromatin	B-COMP
condensation	O
,	O
cellular	B-COMP
DNA	O
fragmentation	O
and	O
cell	B-COMP
membrane	I-COMP
asymmetry	O
,	O
we	O
demonstrated	O
that	O
the	O
adenovirus	O
-	O
mediated	O
over	O
-	O
expression	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
and	O
its	O
C	O
-	O
terminal	O
domain	O
(	O
S2	O
)	O
induce	O
apoptosis	O
in	O
Vero	O
E6	O
cells	B-COMP
in	O
a	O
time	O
-	O
and	O
dosage	O
-	O
dependent	O
manner	O
,	O
whereas	O
the	O
expression	O
of	O
its	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
)	O
and	O
other	O
structural	O
proteins	O
,	O
including	O
envelope	B-COMP
(	O
E	O
),	O
membrane	B-COMP
(	O
M	O
)	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
do	O
not	O
.	O

Familial	O
occurrence	O
and	O
consanguinity	O
suggest	O
autosomal	B-COMP
recessive	O
inheritance	O
of	O
this	O
distinct	O
entity	O
.	O

ABSTRACT	O
:	O
Using	O
the	O
Taiwan	O
nationwide	O
laboratory	O
-	O
confirmed	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
database	O
,	O
we	O
analyzed	O
neutralizing	O
antibody	B-COMP
in	O
relation	O
to	O
clinical	O
outcomes	O
.	O

TITLE	O
:	O
Multiorgan	O
failure	O
and	O
antiphospholipid	O
antibodies	B-COMP
:	O
the	O
catastrophic	O
antiphospholipid	O
(	O
Asherson	O
'	O
s	O
)	O
syndrome	O
.	O

ABSTRACT	O
:	O
Viruses	O
require	O
specific	O
cellular	B-COMP
receptors	O
to	O
infect	O
their	O
target	O
cells	B-COMP
.	O

Finally	O
,	O
our	O
analysis	O
of	O
viral	O
RNA	O
synthesis	O
in	O
ts	O
mutant	O
virus	O
-	O
infected	O
cells	B-COMP
allows	O
us	O
to	O
discriminate	O
three	O
phenotypes	O
with	O
regard	O
to	O
the	O
inability	O
of	O
specific	O
mutants	O
to	O
synthesize	O
viral	O
RNA	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
a	O
model	O
that	O
describes	O
a	O
pathway	O
for	O
viral	O
RNA	O
synthesis	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	B-COMP
.	O

These	O
results	O
might	O
facilitate	O
therapeutic	O
strategies	O
aiming	O
at	O
the	O
disruption	O
of	O
the	O
association	O
between	O
SARS	O
-	O
CoV	O
membrane	B-COMP
and	O
nucleocapsid	B-COMP
proteins	O
.	O

The	O
presence	O
of	O
the	O
YxxPhi	O
and	O
diacidic	O
motifs	O
,	O
located	O
within	O
the	O
cytoplasmic	B-COMP
tail	O
of	O
the	O
3a	O
protein	O
,	O
was	O
not	O
required	O
for	O
its	O
efficient	O
release	O
.	O

Replication	O
in	O
primary	O
chick	O
kidney	O
(	O
CK	O
)	O
cells	B-COMP
and	O
in	O
chicken	O
embryos	O
was	O
not	O
affected	O
.	O

Pretreatment	O
of	O
cells	B-COMP
with	O
a	O
caspase	O
-	O
9	O
inhibitor	O
completely	O
blocked	O
caspase	O
-	O
9	O
activation	O
and	O
partially	O
inhibited	O
the	O
apoptosis	O
mediated	O
by	O
MHV	O
infection	O
.	O

However	O
,	O
treatment	O
with	O
a	O
caspase	O
-	O
8	O
inhibitor	O
only	O
slightly	O
blocked	O
cytochrome	O
c	O
release	O
from	O
the	O
mitochondria	B-COMP
.	O

Both	O
pathogen	O
and	O
host	B-COMP
factors	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
SARS	O
.	O

Western	O
blot	O
analysis	O
using	O
phosphospecific	O
antibodies	B-COMP
indicated	O
that	O
7a	O
protein	O
activated	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
),	O
but	O
not	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
protein	O
kinase	O
/	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O

Serial	O
plasma	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
(	O
IL	O
-	O
1beta	O
),	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
of	O
preserved	O
serum	B-COMP
were	O
measured	O
by	O
enzyme	O
immunoassay	O
.	O

The	O
strongest	O
T	O
-	O
cell	B-COMP
IFN	O
-	O
gamma	O
and	O
CTL	O
responses	O
were	O
to	O
the	O
LAMP	O
-	O
N	O
chimera	O
followed	O
by	O
the	O
pN	O
immunogen	O
.	O

Nevertheless	O
,	O
the	O
profiles	O
of	O
T	O
-	O
cell	B-COMP
responses	O
were	O
distinctly	O
different	O
.	O

TITLE	O
:	O
Immunogenicity	O
and	O
protective	O
efficacy	O
in	O
monkeys	O
of	O
purified	O
inactivated	O
Vero	O
-	O
cell	B-COMP
SARS	O
vaccine	O
.	O

Although	O
today	O
'	O
s	O
immunoglobulins	O
are	O
safer	O
than	O
ever	O
,	O
in	O
preparation	O
for	O
future	O
challenges	O
it	O
is	O
a	O
high	O
priority	O
for	O
the	O
plasma	O
industry	O
to	O
proactively	O
investigate	O
such	O
viruses	O
on	O
a	O
molecular	O
and	O
cellular	B-COMP
level	O
to	O
identify	O
their	O
vulnerabilities	O
.	O

(	O
4	O
)	O
Compared	O
with	O
Nc	O
group	O
,	O
the	O
levels	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
,	O
TGF	O
-	O
beta1	O
in	O
both	O
serum	B-COMP
and	O
BALF	O
of	O
P1	O
group	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
the	O
levels	O
of	O
these	O
cytokines	O
in	O
P2	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
P1	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
significantly	O
lower	O
in	O
P	O
+	O
D	O
group	O
compared	O
with	O
P2	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Infection	O
is	O
usually	O
initiated	O
after	O
inhalation	O
of	O
rodent	O
excreta	O
containing	O
virus	B-COMP
particles	I-COMP
,	O
but	O
human	O
-	O
to	O
-	O
human	O
transmission	O
has	O
been	O
documented	O
.	O

We	O
have	O
utilized	O
Andes	O
virus	O
infection	O
of	O
primary	O
,	O
differentiated	O
airway	O
epithelial	O
cells	B-COMP
to	O
investigate	O
the	O
ability	O
of	O
the	O
virus	O
to	O
interact	O
with	O
and	O
cross	O
the	O
respiratory	O
epithelium	O
.	O

Furthermore	O
,	O
inoculation	O
of	O
human	O
target	O
cells	B-COMP
with	O
the	O
virus	O
resulted	O
in	O
a	O
His	O
receptor	O
-	O
specific	O
infection	O
that	O
was	O
multiround	O
.	O

Notably	O
,	O
some	O
mutations	O
(	O
C1347F	O
and	O
C1348S	O
)	O
did	O
not	O
interfere	O
with	O
S	O
incorporation	O
into	O
virions	B-COMP
,	O
indicating	O
that	O
only	O
a	O
subset	O
of	O
the	O
cysteine	O
-	O
rich	O
region	O
provides	O
the	O
essential	O
S	O
-	O
assembly	O
functions	O
.	O

The	O
cytoplasmic	B-COMP
tail	O
of	O
S	O
has	O
previously	O
been	O
shown	O
to	O
be	O
required	O
for	O
assembly	O
.	O

Here	O
,	O
the	O
roles	O
of	O
the	O
transmembrane	B-COMP
and	O
cytoplasmic	B-COMP
domains	O
of	O
S	O
in	O
the	O
infectivity	O
and	O
membrane	B-COMP
fusion	O
activity	O
of	O
SARS	O
-	O
CoV	O
have	O
been	O
studied	O
.	O

TITLE	O
:	O
Coronavirus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
:	O
host	B-COMP
-	O
virus	O
stand	O
-	O
off	O
.	O

The	O
two	O
recombinant	O
proteins	O
were	O
separately	O
verified	O
by	O
Western	O
blot	O
,	O
purified	O
by	O
nickel	O
-	O
affinity	O
chromatography	O
,	O
and	O
incubated	O
with	O
Vero	O
cells	B-COMP
,	O
a	O
susceptible	O
cell	B-COMP
line	O
of	O
SARS	O
-	O
CoV	O
infection	O
,	O
for	O
cell	B-COMP
binding	O
assay	O
.	O

Severely	O
elevated	O
serum	B-COMP
lithium	O
levels	O
were	O
found	O
.	O

ABSTRACT	O
:	O
The	O
capacity	O
of	O
the	O
surface	O
glycoproteins	O
of	O
enveloped	O
viruses	O
to	O
mediate	O
virus	O
/	O
cell	B-COMP
binding	O
and	O
membrane	B-COMP
fusion	O
requires	O
a	O
proper	O
thiol	O
/	O
disulfide	O
balance	O
.	O

Chemical	O
manipulation	O
of	O
their	O
redox	O
state	O
using	O
reducing	O
agents	O
or	O
free	O
sulfhydryl	O
reagents	O
affects	O
virus	O
/	O
cell	B-COMP
interaction	O
.	O

Conversely	O
,	O
natural	O
thiol	O
/	O
disulfide	O
rearrangements	O
often	O
occur	O
during	O
the	O
cell	B-COMP
interaction	O
to	O
trigger	O
fusogenicity	O
,	O
hence	O
the	O
virus	O
entry	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
there	O
exists	O
an	O
interaction	O
between	O
nucleocapsid	B-COMP
(	O
N	O
)	O
and	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
an	O
emerging	O
infectious	O
disease	O
caused	O
by	O
a	O
new	O
coronavirus	O
strain	O
,	O
SARS	O
-	O
CoV	O
.	O
Specific	O
proteomic	O
patterns	O
might	O
be	O
present	O
in	O
serum	B-COMP
in	O
response	O
to	O
the	O
infection	O
and	O
could	O
be	O
useful	O
for	O
early	O
detection	O
of	O
the	O
disease	O
.	O

Using	O
surface	O
-	O
enhanced	O
laser	O
desorption	O
/	O
ionization	O
(	O
SELDI	O
)	O
ProteinChip	O
technology	O
,	O
we	O
profiled	O
and	O
compared	O
serum	B-COMP
proteins	O
of	O
39	O
patients	O
with	O
early	O
-	O
stage	O
SARS	O
infection	O
and	O
39	O
non	O
-	O
SARS	O
patients	O
who	O
were	O
suspected	O
cases	O
during	O
the	O
SARS	O
outbreak	O
period	O
.	O

ABSTRACT	O
:	O
Deregulation	O
of	O
the	O
cell	B-COMP
cycle	O
is	O
a	O
common	O
strategy	O
employed	O
by	O
many	O
DNA	O
and	O
RNA	O
viruses	O
to	O
trap	O
and	O
exploit	O
the	O
host	B-COMP
cell	I-COMP
machinery	O
toward	O
their	O
own	O
benefit	O
.	O

The	O
ectodomain	O
-	O
specific	O
antibodies	B-COMP
from	O
the	O
convalescent	O
-	O
phase	O
plasma	O
readily	O
recognized	O
and	O
induced	O
destruction	O
of	O
3a	O
-	O
expressing	O
cells	B-COMP
in	O
the	O
presence	O
of	O
the	O
human	O
complement	O
system	O
,	O
demonstrating	O
their	O
potential	O
ability	O
to	O
provide	O
immune	O
protection	O
by	O
recognizing	O
and	O
eliminating	O
SARS	O
coronavirus	O
-	O
infected	O
cells	B-COMP
that	O
express	O
the	O
target	O
protein	O
.	O

In	O
addition	O
,	O
when	O
coupled	O
to	O
a	O
carrier	O
protein	O
,	O
the	O
ectodomain	O
peptide	O
elicited	O
3a	O
-	O
specific	O
antibodies	B-COMP
in	O
mice	O
and	O
rabbit	O
at	O
high	O
titres	O
.	O

Although	O
virus	O
-	O
specific	O
ASC	O
declined	O
in	O
cervical	O
lymph	O
node	O
and	O
spleen	O
after	O
infectious	O
virus	O
clearance	O
,	O
virus	O
-	O
specific	O
serum	B-COMP
Ab	O
was	O
sustained	O
at	O
steady	O
levels	O
,	O
with	O
a	O
delay	O
in	O
neutralizing	O
Ab	O
.	O

By	O
electron	O
spin	O
resonance	O
(	O
ESR	O
)	O
detection	O
,	O
we	O
found	O
that	O
the	O
prescription	O
I	O
,	O
Herba	O
Patriniae	O
and	O
other	O
main	O
herbs	O
in	O
that	O
recipe	O
,	O
could	O
quench	O
effectively	O
the	O
free	O
radicals	O
generated	O
in	O
the	O
process	O
of	O
lambda	O
-	O
lysogenic	O
cells	B-COMP
by	O
UV	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
membrane	B-COMP
protein	O
(	O
M	O
)	O
is	O
the	O
key	O
player	O
in	O
the	O
assembly	O
of	O
virions	B-COMP
at	O
intracellular	B-COMP
membranes	O
between	O
endoplasmic	O
-	O
reticulum	O
and	O
Golgi	B-COMP
-	O
complex	O
.	O

SARS	O
-	O
CoV	O
infections	O
were	O
detected	O
by	O
using	O
enzyme	O
immunoassays	O
and	O
confirmed	O
by	O
a	O
combination	O
of	O
Western	O
blot	O
assays	O
,	O
neutralizing	O
antibody	B-COMP
tests	O
,	O
and	O
commercial	O
SARS	O
tests	O
.	O

Antibodies	B-COMP
are	O
captured	O
in	O
a	O
sandwich	O
manner	O
between	O
surface	O
immobilized	O
peptide	O
probes	O
and	O
fluorescence	O
-	O
labeled	O
secondary	O
antibodies	B-COMP
.	O

Potential	O
antigenic	O
epitopes	O
were	O
identified	O
in	O
the	O
structural	O
proteins	O
(	O
nucleocapsid	B-COMP
,	O
membrane	B-COMP
,	O
spike	O
,	O
and	O
small	O
envelope	B-COMP
proteins	O
)	O
and	O
hypothetical	O
proteins	O
(	O
SARS3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
,	O
and	O
9b	O
)	O
that	O
are	O
specific	O
for	O
SARS	O
-	O
CoV	O
.	O
A	O
peptide	O
chip	O
platform	O
was	O
created	O
and	O
the	O
profiles	O
of	O
antibodies	B-COMP
to	O
these	O
epitopes	O
were	O
investigated	O
in	O
59	O
different	O
SARS	O
patients	O
'	O
sera	B-COMP
obtained	O
6	O
-	O
103	O
days	O
after	O
the	O
onset	O
of	O
the	O
illness	O
.	O

Epitopes	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
membrane	B-COMP
protein	O
and	O
the	O
C	O
-	O
terminus	O
of	O
nucleocapsid	B-COMP
protein	O
elicited	O
strong	O
antibody	B-COMP
responses	O
.	O

Antibodies	B-COMP
were	O
also	O
detected	O
for	O
some	O
putative	O
proteins	O
,	O
noticeably	O
the	O
C	O
-	O
termini	O
of	O
SARS3a	O
and	O
SARS6	O
.	O

RESULTS	O
:	O
Epitopes	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
membrane	B-COMP
protein	O
and	O
the	O
C	O
-	O
terminus	O
of	O
nucleocapsid	B-COMP
protein	O
elicited	O
strong	O
antibody	B-COMP
responses	O
.	O

A	O
set	O
of	O
deletion	O
mutant	O
plasmids	O
,	O
of	O
which	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
1	O
,	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
2	O
,	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
3	O
and	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
4	O
are	O
with	O
3	O
,	O
2	O
,	O
1	O
,	O
and	O
0	O
residual	O
stem	O
-	O
loops	O
of	O
3	O
'	O
termini	O
respectively	O
,	O
were	O
constructed	O
from	O
pGL3	O
-	O
5	O
'	O
UTR	O
and	O
were	O
transfected	O
into	O
HepG2	O
cells	B-COMP
to	O
express	O
reporter	O
gene	O
luc	O
+,	O
with	O
pGL3	O
-	O
5	O
'	O
UTR	O
containing	O
full	O
sequence	O
as	O
control	O
.	O

All	O
nucleic	B-COMP
acid	O
diagnostic	O
assays	O
were	O
negative	O
for	O
C	O
pneumoniae	O
and	O
M	O
pneumoniae	O
in	O
respiratory	O
samples	O
from	O
patients	O
with	O
SARS	O
having	O
serological	O
evidence	O
for	O
these	O
atypical	O
pathogens	O
.	O

TITLE	O
:	O
Glycosylation	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
triple	O
-	O
spanning	O
membrane	B-COMP
proteins	O
3a	O
and	O
M	O
.	O
ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
open	O
reading	O
frame	O
3a	O
protein	O
has	O
recently	O
been	O
shown	O
to	O
be	O
a	O
structural	O
protein	O
.	O

To	O
identify	O
potential	O
target	O
genes	O
that	O
are	O
activated	O
downstream	O
of	O
the	O
IFN	O
-	O
inducible	O
signaling	O
effectors	O
we	O
identified	O
,	O
and	O
that	O
mediate	O
protection	O
from	O
coronavirus	O
infection	O
,	O
we	O
examined	O
the	O
gene	O
expression	O
profiles	O
in	O
the	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
of	O
SARS	O
patients	O
who	O
received	O
IFN	O
treatment	O
.	O

ABSTRACT	O
:	O
Serum	B-COMP
samples	O
from	O
214	O
Swedish	O
cats	O
with	O
no	O
signs	O
of	O
infectious	O
disease	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
antibodies	B-COMP
against	O
Chlamydophila	O
felis	O
(	O
Cp	O
felis	O
),	O
while	O
209	O
of	O
these	O
were	O
also	O
analysed	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibodies	B-COMP
.	O

Finally	O
,	O
the	O
sera	B-COMP
of	O
vaccinated	O
mice	O
contained	O
antibodies	B-COMP
to	O
S	O
,	O
further	O
suggesting	O
a	O
role	O
for	O
this	O
protein	O
in	O
conferring	O
protective	O
immunity	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
Lymphocyte	O
infiltration	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
following	O
viral	O
infection	O
represents	O
an	O
important	O
component	O
of	O
host	B-COMP
defense	O
and	O
is	O
required	O
for	O
control	O
of	O
viral	O
replication	O
.	O

Therefore	O
,	O
CXCR3	O
signaling	O
has	O
a	O
non	O
-	O
redundant	O
role	O
in	O
T	O
cell	B-COMP
subset	O
trafficking	O
in	O
response	O
to	O
viral	O
infection	O
.	O

TITLE	O
:	O
Vaccine	O
-	O
induced	O
memory	O
CD8	O
+	O
T	O
cells	B-COMP
cannot	O
prevent	O
central	O
nervous	O
system	O
virus	O
reactivation	O
.	O

Recrudescence	O
of	O
neurotropic	O
coronavirus	O
due	O
to	O
loss	O
of	O
T	O
cell	B-COMP
-	O
mediated	O
immune	O
control	O
provided	O
an	O
experimental	O
model	O
to	O
test	O
T	O
cell	B-COMP
vaccination	O
efficacy	O
in	O
the	O
absence	O
of	O
Ab	O
.	O

ABSTRACT	O
:	O
Given	O
the	O
potential	O
for	O
laboratory	O
-	O
associated	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infections	O
,	O
we	O
must	O
know	O
which	O
cell	B-COMP
lines	O
are	O
susceptible	O
to	O
the	O
virus	O
.	O

We	O
investigated	O
21	O
cell	B-COMP
lines	O
routinely	O
used	O
for	O
virus	O
isolation	O
or	O
research	O
.	O

To	O
identify	O
the	O
B	O
-	O
cell	B-COMP
immunodominant	O
epitopes	O
of	O
the	O
rN	O
protein	O
in	O
the	O
mouse	O
and	O
monkey	O
,	O
the	O
reactivities	O
of	O
antisera	O
raised	O
against	O
purified	O
rN	O
proteins	O
formulated	O
in	O
ISA	O
-	O
51	O
/	O
CpG	O
were	O
tested	O
with	O
a	O
panel	O
of	O
overlapping	O
synthetic	O
peptides	O
covering	O
the	O
entire	O
N	O
protein	O
sequence	O
.	O

Three	O
immunodominant	O
linear	O
B	O
-	O
cell	B-COMP
epitope	O
regions	O
were	O
mapped	O
to	O
residues	O
166	O
-	O
180	O
,	O
356	O
-	O
375	O
,	O
and	O
396	O
-	O
410	O
of	O
the	O
rN	O
protein	O
.	O

Significantly	O
enhanced	O
immune	O
responses	O
,	O
manifested	O
by	O
higher	O
titers	O
of	O
serum	B-COMP
ELISA	O
and	O
viral	O
neutralizing	O
antibodies	B-COMP
,	O
were	O
achieved	O
in	O
adjuvanted	O
groups	O
with	O
fewer	O
doses	O
and	O
lower	O
concentration	O
of	O
S	O
glycoprotein	O
.	O

Initially	O
,	O
partial	O
sequences	O
of	O
the	O
polymerase	O
,	O
spike	O
,	O
membrane	B-COMP
protein	O
,	O
and	O
nucleocapsid	B-COMP
genes	O
were	O
generated	O
using	O
coronavirus	O
consensus	O
PCR	O
assays	O
.	O

TITLE	O
:	O
Acute	O
lung	O
infections	O
in	O
normal	O
and	O
immunocompromised	O
hosts	B-COMP
.	O

TITLE	O
:	O
[	O
Some	O
medical	O
staff	O
positive	O
for	O
serum	B-COMP
SARS	O
coronavirus	O
antibody	B-COMP
IgG	O
have	O
only	O
mild	O
symptoms	O
].	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
expression	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
in	O
mammalian	O
cells	B-COMP
alters	O
the	O
membrane	B-COMP
permeability	O
of	O
these	O
cells	B-COMP
.	O

Immunofluorescent	O
staining	O
and	O
cell	B-COMP
fractionation	O
studies	O
demonstrate	O
that	O
this	O
protein	O
is	O
an	O
integral	O
membrane	B-COMP
protein	O
.	O

However	O
,	O
the	O
CNS	O
inflammatory	O
cell	B-COMP
composition	O
and	O
CD8	O
(+)	O
T	O
-	O
cell	B-COMP
effector	O
functions	O
were	O
similar	O
between	O
transgenic	O
and	O
wild	O
-	O
type	O
mice	O
,	O
supporting	O
unimpaired	O
peripheral	O
and	O
CNS	O
immune	O
responses	O
in	O
transgenic	O
mice	O
.	O

In	O
addition	O
,	O
the	O
absence	O
of	O
a	O
correlation	O
between	O
increased	O
oligodendroglial	O
infection	O
and	O
the	O
extent	O
of	O
demyelination	O
suggests	O
a	O
complex	O
pathobiology	O
of	O
myelin	B-COMP
loss	O
in	O
which	O
infection	O
of	O
oligodendroglia	O
is	O
required	O
but	O
not	O
sufficient	O
.	O

Studies	O
of	O
the	O
1918	O
pandemic	O
virus	O
have	O
shown	O
the	O
potential	O
for	O
direct	O
interspecies	O
transmission	O
from	O
an	O
avian	O
host	B-COMP
.	O

scFv	O
H12	O
bound	O
to	O
SARS	O
-	O
CoV	O
with	O
high	O
affinity	O
(	O
equilibrium	O
dissociation	O
constant	O
,	O
Kd	O
=	O
73	O
.	O
5	O
nM	O
),	O
and	O
neutralized	O
SARS	O
virions	B-COMP
in	O
vitro	O
.	O

We	O
show	O
that	O
furin	O
cleavage	O
at	O
the	O
modified	O
R667	O
position	O
generates	O
discrete	O
S1	O
and	O
S2	O
subunits	O
and	O
potentiates	O
membrane	B-COMP
fusion	O
activity	O
.	O

As	O
antigen	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
,	O
the	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
)	O
showed	O
high	O
sensitivity	O
and	O
strong	O
reactivity	O
with	O
all	O
samples	O
from	O
SARS	O
-	O
CoV	O
patients	O
and	O
cross	O
-	O
reacted	O
with	O
all	O
serum	B-COMP
samples	O
from	O
healthy	O
subjects	O
,	O
with	O
either	O
those	O
obtained	O
from	O
China	O
(	O
10	O
samples	O
)	O
or	O
those	O
obtained	O
from	O
France	O
(	O
38	O
serum	B-COMP
samples	O
),	O
giving	O
then	O
a	O
significant	O
rate	O
of	O
false	O
positives	O
.	O

ABSTRACT	O
:	O
Acute	O
polyradiuloneuritis	O
is	O
acute	O
inflammatory	O
demyelinizing	O
polyneuropathy	O
,	O
with	O
still	O
unknown	O
cause	O
,	O
and	O
which	O
main	O
pathophysiological	O
disorder	O
is	O
degeneration	O
of	O
axons	B-COMP
which	O
affects	O
peripheral	O
nerves	O
.	O

Therefore	O
,	O
the	O
molecular	O
basis	O
of	O
coronavirus	O
fusion	O
during	O
entry	O
into	O
host	B-COMP
cells	B-COMP
remains	O
incompletely	O
defined	O
.	O

ABSTRACT	O
:	O
This	O
study	O
describes	O
the	O
assembly	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
clone	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
)-	O
OC43	O
in	O
a	O
bacterial	O
artificial	O
chromosome	B-COMP
(	O
BAC	O
).	O

However	O
,	O
the	O
N	O
protein	O
-	O
targeted	O
Fab	O
or	O
IgG	O
antibodies	B-COMP
failed	O
to	O
neutralize	O
the	O
virus	O
.	O

Combined	O
with	O
phylogenetic	O
analyses	O
to	O
predict	O
mutations	O
associated	O
with	O
a	O
1992	O
-	O
1993	O
epidemic	O
,	O
we	O
used	O
reverse	O
genetic	O
studies	O
to	O
identify	O
an	O
envelope	B-COMP
glycoprotein	O
gene	O
mutation	O
that	O
mediated	O
emergence	O
.	O

The	O
prevalence	O
of	O
serum	B-COMP
antibodies	B-COMP
to	O
CRCoV	O
,	O
in	O
a	O
population	O
of	O
dogs	O
in	O
the	O
south	O
east	O
of	O
England	O
,	O
has	O
been	O
shown	O
previously	O
to	O
be	O
30	O
.	O
1	O
%	O
on	O
the	O
first	O
day	O
of	O
entry	O
to	O
a	O
rehoming	O
kennel	O
[	O
Erles	O
,	O
K	O
.,	O
Toomey	O
,	O
C	O
.,	O
Brooks	O
,	O
H	O
.	O
W	O
.,	O
Brownlie	O
,	O
J	O
.,	O
2003	O
.	O

An	O
ELISA	O
,	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
antibodies	B-COMP
to	O
CRCoV	O
in	O
canine	O
serum	B-COMP
samples	O
,	O
identified	O
seropositive	O
dogs	O
in	O
UK	O
,	O
USA	O
,	O
Canada	O
,	O
Republic	O
of	O
Ireland	O
and	O
Greece	O
.	O

ABSTRACT	O
:	O
The	O
advantages	O
of	O
nucleic	B-COMP
acid	O
amplification	O
tests	O
(	O
NAT	O
)	O
over	O
conventional	O
methods	O
for	O
the	O
detection	O
of	O
pathogens	O
in	O
lower	O
respiratory	O
tract	O
samples	O
have	O
not	O
been	O
established	O
.	O

We	O
found	O
that	O
exposure	O
of	O
naïve	O
cells	B-COMP
to	O
longitudinal	O
plasma	O
samples	O
led	O
to	O
divergent	O
directions	O
in	O
NF	O
-	O
kappaB	O
and	O
GRalpha	O
activation	O
that	O
reflected	O
the	O
severity	O
of	O
systemic	O
inflammation	O
.	O

Transmission	O
electron	O
microscopy	O
revealed	O
selective	O
injury	O
to	O
superficial	O
epithelial	O
cells	B-COMP
with	O
disruption	O
of	O
cell	B-COMP
attachments	O
and	O
cell	B-COMP
shedding	O
.	O

Together	O
,	O
these	O
findings	O
indicate	O
that	O
injured	O
bronchial	O
epithelial	O
cells	B-COMP
up	O
-	O
regulate	O
ALX	O
in	O
a	O
COX	O
-	O
2	O
-	O
dependent	O
manner	O
to	O
promote	O
LXA	O
(	O
4	O
)-	O
mediated	O
resolution	O
of	O
airway	O
inflammation	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
cytokine	O
response	O
of	O
two	O
human	O
non	O
-	O
lymphatic	O
cell	B-COMP
lines	O
,	O
Caco	O
-	O
2	O
and	O
HEK	O
293	O
,	O
which	O
are	O
fully	O
permissive	O
for	O
SARS	O
-	O
CoV	O
.	O
A	O
comparison	O
with	O
established	O
cytokine	O
-	O
inducing	O
viruses	O
revealed	O
that	O
SARS	O
-	O
CoV	O
only	O
weakly	O
triggered	O
a	O
cytokine	O
response	O
.	O

Interestingly	O
,	O
however	O
,	O
SARS	O
-	O
CoV	O
strongly	O
induced	O
the	O
chemokines	O
IP	O
-	O
10	O
and	O
IL	O
-	O
8	O
in	O
the	O
colon	O
carcinoma	O
cell	B-COMP
line	O
Caco	O
-	O
2	O
,	O
but	O
not	O
in	O
the	O
embryonic	O
kidney	O
cell	B-COMP
line	O
293	O
.	O

This	O
poses	O
a	O
hazard	O
,	O
as	O
high	O
-	O
affinity	O
virion	B-COMP
binding	O
to	O
any	O
of	O
such	O
""""	O
false	O
''	O
receptors	O
would	O
result	O
in	O
loss	O
of	O
infectivity	O
.	O

The	O
ensuing	O
targeted	O
destruction	O
of	O
viral	O
RNA	O
should	O
interfere	O
with	O
viral	O
replication	O
without	O
entailing	O
negative	O
effects	O
on	O
ongoing	O
cellular	B-COMP
processes	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
,	O
or	O
SCV	O
),	O
which	O
caused	O
a	O
world	O
-	O
wide	O
epidemic	O
in	O
2002	O
and	O
2003	O
,	O
binds	O
to	O
a	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
through	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
its	O
envelope	B-COMP
(	O
spike	O
,	O
S	O
)	O
glycoprotein	O
.	O

The	O
antibody	B-COMP
-	O
bound	O
RBD	O
structure	O
is	O
completely	O
defined	O
,	O
revealing	O
two	O
previously	O
unresolved	O
segments	O
(	O
residues	O
376	O
-	O
381	O
and	O
503	O
-	O
512	O
)	O
and	O
a	O
new	O
disulfide	O
bond	O
(	O
between	O
residues	O
378	O
and	O
511	O
).	O

These	O
results	O
provide	O
a	O
structural	O
rationale	O
for	O
the	O
function	O
of	O
a	O
major	O
determinant	O
of	O
SCV	O
immunogenicity	O
and	O
neutralization	O
,	O
the	O
development	O
of	O
SCV	O
therapeutics	O
based	O
on	O
the	O
antibody	B-COMP
paratope	O
and	O
epitope	O
,	O
and	O
a	O
retrovaccinology	O
approach	O
for	O
the	O
design	O
of	O
anti	O
-	O
SCV	O
vaccines	O
.	O

Here	O
,	O
it	O
is	O
discussed	O
that	O
binding	O
to	O
sialic	O
acid	O
may	O
be	O
used	O
by	O
IBV	O
for	O
primary	O
attachment	O
to	O
the	O
cell	B-COMP
surface	I-COMP
;	O
tighter	O
binding	O
and	O
subsequent	O
fusion	O
between	O
the	O
viral	O
and	O
the	O
cellular	B-COMP
membrane	I-COMP
may	O
require	O
interaction	O
with	O
a	O
second	O
receptor	O
.	O

In	O
the	O
majority	O
of	O
naturally	O
infected	O
animals	O
,	O
FCoV	O
infection	O
remains	O
subclinical	O
and	O
is	O
associated	O
with	O
generalised	O
B	O
and	O
T	O
cell	B-COMP
hyperplasia	O
,	O
but	O
no	O
other	O
pathological	O
findings	O
.	O

The	O
spleen	O
,	O
mesenteric	O
lymph	O
nodes	O
and	O
bone	O
marrow	O
from	O
naturally	O
FCoV	O
-	O
infected	O
cats	O
with	O
and	O
without	O
FIP	O
and	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
control	O
cats	O
were	O
examined	O
for	O
the	O
quantity	O
and	O
activation	O
state	O
of	O
monocytes	O
/	O
macrophages	O
both	O
by	O
immunohistology	O
and	O
by	O
quantitative	O
real	O
time	O
PCR	O
for	O
the	O
transcription	O
of	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
12	O
p40	B-COMP
,	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
),	O
granulocyte	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
),	O
macrophage	O
-	O
CSF	O
(	O
M	O
-	O
CSF	O
)	O
and	O
GM	O
-	O
CSF	O
.	O

In	O
cats	O
with	O
FIP	O
,	O
however	O
,	O
IL	O
-	O
12	O
p40	B-COMP
levels	O
were	O
significantly	O
lower	O
in	O
lymphatic	O
tissues	O
in	O
comparison	O
to	O
both	O
SPF	O
cats	O
and	O
FCoV	O
-	O
infected	O
cats	O
without	O
FIP	O
.	O

ABSTRACT	O
:	O
Because	O
of	O
the	O
conflicting	O
data	O
concerning	O
the	O
SARS	O
-	O
CoV	O
inhibitory	O
efficacy	O
of	O
ribavirin	O
,	O
an	O
inosine	O
monophosphate	O
(	O
IMP	B-COMP
)	O
dehydrogenase	O
inhibitor	O
,	O
studies	O
were	O
done	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ribavirin	O
and	O
other	O
IMP	B-COMP
dehydrogenase	O
inhibitors	O
(	O
5	O
-	O
ethynyl	O
-	O
1	O
-	O
beta	O
-	O
D	O
-	O
ribofuranosylimidazole	O
-	O
4	O
-	O
carboxamide	O
(	O
EICAR	O
),	O
mizoribine	O
,	O
and	O
mycophenolic	O
acid	O
)	O
in	O
preventing	O
viral	O
replication	O
in	O
the	O
lungs	O
of	O
BALB	O
/	O
c	O
mice	O
,	O
a	O
replication	O
model	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
(	O
Subbarao	O
,	O
K	O
.,	O
McAuliffe	O
,	O
J	O
.,	O
Vogel	O
,	O
L	O
.,	O
Fahle	O
,	O
G	O
.,	O
Fischer	O
,	O
S	O
.,	O
Tatti	O
,	O
K	O
.,	O
Packard	O
,	O
M	O
.,	O
Shieh	O
,	O
W	O
.	O
J	O
.,	O
Zaki	O
,	O
S	O
.,	O
Murphy	O
,	O
B	O
.,	O
2004	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
immunization	O
with	O
SARS	O
-	O
CoV	O
S	O
DNA	O
vaccine	O
can	O
generate	O
antigen	O
-	O
specific	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
that	O
may	O
contribute	O
to	O
long	O
-	O
term	O
protection	O
.	O

Immunohistochemical	O
stains	O
showed	O
a	O
strong	O
positivity	O
of	O
X4	O
protein	O
in	O
denudation	O
cells	B-COMP
,	O
vascular	O
endothelial	O
cells	B-COMP
and	O
also	O
erythrocytes	O
and	O
neutrophils	O
in	O
the	O
alveoli	O
of	O
the	O
lung	O
tissues	O
from	O
the	O
4	O
cases	O
.	O

Torovirus	O
-	O
specific	O
nucleic	B-COMP
acid	O
confirmed	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
was	O
found	O
in	O
12	O
of	O
230	O
calves	O
(	O
5	O
.	O
2	O
%).	O

These	O
matured	O
MoDCs	O
displayed	O
an	O
enhanced	O
ability	O
to	O
present	O
antigen	O
to	O
and	O
thus	O
stimulate	O
T	O
cells	B-COMP
.	O

Coronavirus	O
assembly	O
also	O
takes	O
place	O
at	O
pre	O
-	O
Golgi	B-COMP
membranes	O
.	O

TITLE	O
:	O
Cross	O
-	O
neutralization	O
of	O
human	O
and	O
palm	O
civet	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
by	O
antibodies	B-COMP
targeting	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
spike	O
protein	O
.	O

As	O
a	O
result	O
of	O
testing	O
1524	O
serum	B-COMP
samples	O
the	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
rNpIBV	O
-	O
ELISA	O
when	O
comparing	O
those	O
of	O
the	O
routine	O
whole	O
IBV	O
ELISA	O
have	O
been	O
shown	O
to	O
be	O
93	O
.	O
81	O
%	O
and	O
87	O
.	O
36	O
%,	O
respectively	O
.	O

RESULTS	O
:	O
2	O
positive	O
clones	O
that	O
having	O
specific	O
affinity	O
to	O
SARS	O
sera	B-COMP
were	O
obtained	O
.	O

TITLE	O
:	O
Production	O
of	O
an	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
human	O
monoclonal	O
antibody	B-COMP
Fab	O
fragment	O
by	O
using	O
a	O
combinatorial	O
immunoglobulin	O
gene	O
library	O
derived	O
from	O
patients	O
who	O
recovered	O
from	O
SARS	O
.	O

TITLE	O
:	O
Mitochondrial	B-COMP
location	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3b	O
protein	O
.	O

Extracorporeal	O
lung	O
assist	O
(	O
ECLA	O
)	O
or	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
using	O
capillary	O
membrane	B-COMP
oxygenators	O
can	O
provide	O
sufficient	O
gas	O
exchange	O
and	O
lung	O
rest	O
.	O

TITLE	O
:	O
Biochemical	O
evidence	O
for	O
the	O
presence	O
of	O
mixed	O
membrane	B-COMP
topologies	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	B-COMP
protein	O
expressed	O
in	O
mammalian	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
The	O
triplet	O
-	O
based	O
genetic	O
code	O
requires	O
that	O
translating	O
ribosomes	B-COMP
maintain	O
the	O
reading	O
frame	O
of	O
a	O
messenger	O
RNA	O
faithfully	O
to	O
ensure	O
correct	O
protein	O
synthesis	O
.	O

Together	O
,	O
the	O
structural	O
changes	O
provide	O
a	O
mechanical	O
explanation	O
of	O
how	O
the	O
pseudoknot	O
manipulates	O
the	O
ribosome	B-COMP
into	O
a	O
different	O
reading	O
frame	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
virus	O
-	O
host	B-COMP
interactions	O
and	O
comparative	O
etiologies	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
as	O
determined	O
by	O
transcriptional	O
and	O
cytokine	O
profiling	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
.	O

ABSTRACT	O
:	O
These	O
studies	O
attempt	O
to	O
understand	O
more	O
fully	O
the	O
host	B-COMP
response	O
and	O
pathogenesis	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
monitoring	O
gene	O
expression	O
using	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
pulmonary	O
autopsy	O
tissues	O
.	O

Many	O
factors	O
detected	O
during	O
pulmonary	O
damage	O
and	O
repair	O
,	O
such	O
as	O
extracellular	B-COMP
matrix	I-COMP
(	O
ECM	B-COMP
)	O
components	O
,	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
enhancers	O
,	O
acute	O
-	O
phase	O
proteins	O
,	O
and	O
antioxidants	O
,	O
were	O
included	O
in	O
the	O
molecular	O
profiles	O
of	O
these	O
ARDS	O
lung	O
tissues	O
.	O

Epitope	O
mapping	O
study	O
indicated	O
that	O
a	O
cluster	O
of	O
overlapping	O
peptides	O
located	O
in	O
the	O
C	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
[	O
aa	O
]	O
331	O
to	O
362	O
)	O
of	O
N	O
protein	O
contained	O
at	O
least	O
two	O
different	O
T	O
-	O
cell	B-COMP
epitopes	O
.	O

Antibodies	B-COMP
seem	O
unable	O
to	O
identify	O
infected	O
cells	B-COMP
and	O
mediate	O
antibody	B-COMP
-	O
dependent	O
cell	B-COMP
lysis	O
.	O

Eighteen	O
surface	O
residues	O
from	O
two	O
regions	O
of	O
HRN	O
and	O
HRC	O
were	O
incorporated	O
into	O
the	O
template	O
and	O
used	O
to	O
generate	O
four	O
anti	O
-	O
sera	B-COMP
,	O
HRN1	O
,	O
HRN2	O
,	O
HRC1	O
,	O
and	O
HRC2	O
.	O

TITLE	O
:	O
Model	O
of	O
a	O
putative	O
pore	B-COMP
:	O
the	O
pentameric	O
alpha	O
-	O
helical	O
bundle	O
of	O
SARS	O
coronavirus	O
E	O
protein	O
in	O
lipid	O
bilayers	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
contains	O
a	O
small	O
envelope	B-COMP
protein	O
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	B-COMP
apoptosis	O
and	O
virus	O
morphogenesis	O
.	O

TITLE	O
:	O
Phase	O
I	O
trial	O
of	O
the	O
trifunctional	O
anti	O
-	O
HER2	O
x	O
anti	O
-	O
CD3	O
antibody	B-COMP
ertumaxomab	O
in	O
metastatic	O
breast	O
cancer	O
.	O

ABSTRACT	O
:	O
Ertumaxomab	O
is	O
an	O
intact	O
bispecific	O
antibody	B-COMP
targeting	O
HER2	O
/	O
neu	O
and	O
CD3	O
with	O
selective	O
binding	O
to	O
activatory	O
Fcgamma	O
type	O
I	O
/	O
III	O
receptors	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
a	O
tri	O
-	O
cell	B-COMP
complex	O
between	O
tumor	O
cells	B-COMP
,	O
T	O
cells	B-COMP
,	O
and	O
accessory	O
cells	B-COMP
.	O

The	O
induction	O
of	O
human	O
anti	O
-	O
mouse	O
/	O
anti	O
-	O
rat	O
antibodies	B-COMP
was	O
detected	O
in	O
5	O
out	O
of	O
16	O
(	O
31	O
%)	O
patients	O
.	O

We	O
have	O
showed	O
that	O
a	O
monoclonal	O
antibody	B-COMP
targeting	O
HK	O
decreases	O
angiogenesis	O
and	O
arrests	O
tumor	O
growth	O
in	O
a	O
syngeneic	O
animal	O
model	O
.	O

Because	O
27	O
%	O
of	O
human	O
serum	B-COMP
samples	O
from	O
the	O
United	O
States	O
tested	O
so	O
far	O
have	O
an	O
anti	O
-	O
AdH5	O
NAb	O
titer	O
higher	O
than	O
40	O
,	O
our	O
results	O
suggested	O
that	O
a	O
significant	O
percentage	O
of	O
humans	O
with	O
preexisting	O
anti	O
-	O
AdH5	O
immunity	O
would	O
not	O
be	O
candidates	O
for	O
vaccination	O
with	O
an	O
AdH5	O
-	O
based	O
genetic	O
vaccine	O
.	O

The	O
biosensor	O
technique	O
based	O
on	O
imaging	O
ellipsometry	O
was	O
employed	O
directly	O
to	O
detect	O
two	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
and	O
serial	O
serum	B-COMP
samples	O
from	O
10	O
SARS	O
patients	O
and	O
12	O
volunteers	O
who	O
had	O
not	O
SARS	O
.	O

ABSTRACT	O
:	O
Most	O
strains	O
of	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
express	O
a	O
cleavable	O
spike	O
glycoprotein	O
that	O
mediates	O
viral	O
entry	O
and	O
pH	O
-	O
independent	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
.	O

Electron	O
microscopy	O
revealed	O
the	O
early	O
formation	O
and	O
accumulation	O
of	O
typical	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
,	O
which	O
probably	O
carry	O
the	O
viral	B-COMP
replication	I-COMP
complex	I-COMP
.	O

Additionally	O
,	O
a	O
classical	O
nuclear	O
export	O
signal	O
(	O
NES	O
)	O
functioned	O
to	O
direct	O
N	O
protein	O
to	O
the	O
cytoplasm	B-COMP
.	O

Biochemical	O
markers	O
of	O
bone	O
metabolism	O
showed	O
significant	O
bone	O
resorption	O
as	O
evidenced	O
by	O
a	O
marked	O
increase	O
in	O
serum	B-COMP
C	O
-	O
terminal	O
telopeptide	O
concentration	O
(	O
CTx	O
)	O
from	O
Day	O
28	O
-	O
44	O
after	O
the	O
onset	O
of	O
fever	O
.	O

The	O
siRNA	O
or	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
expression	O
cassettes	O
were	O
co	O
-	O
transfected	O
with	O
the	O
SARS	O
viral	O
RDRP	O
or	O
envelope	B-COMP
E	O
expression	O
vectors	O
into	O
NIH	O
3T3	O
cells	B-COMP
.	O

Interferon	O
responses	O
are	O
not	O
triggered	O
during	O
infection	O
,	O
although	O
the	O
L	O
cells	B-COMP
can	O
be	O
readily	O
stimulated	O
to	O
produce	O
interferon	O
by	O
dsRNA	O
,	O
a	O
known	O
potent	O
inducer	O
of	O
interferon	O
.	O

In	O
addition	O
to	O
Oct	O
-	O
4	O
,	O
these	O
cells	B-COMP
also	O
express	O
other	O
stem	O
cell	B-COMP
markers	O
such	O
as	O
stage	O
-	O
specific	O
embryonic	O
antigen	O
1	O
(	O
SSEA	O
-	O
1	O
),	O
stem	O
cell	B-COMP
antigen	O
1	O
(	O
Sca	O
-	O
1	O
),	O
and	O
Clara	O
cell	B-COMP
secretion	O
protein	O
(	O
CCSP	O
)	O
but	O
not	O
c	O
-	O
Kit	O
,	O
CD34	O
,	O
and	O
p63	O
,	O
indicating	O
that	O
they	O
represent	O
a	O
subpopulation	O
of	O
Clara	O
cells	B-COMP
that	O
have	O
been	O
implicated	O
as	O
lung	O
stem	O
/	O
progenitor	O
cells	B-COMP
in	O
lung	O
injury	O
models	O
.	O

These	O
colony	O
cells	B-COMP
can	O
be	O
kept	O
for	O
weeks	O
in	O
primary	O
cultures	O
and	O
undergo	O
terminal	O
differentiation	O
to	O
alveolar	O
type	O
-	O
2	O
-	O
and	O
type	O
-	O
1	O
-	O
like	O
pneumocytes	O
sequentially	O
when	O
removed	O
from	O
the	O
stroma	O
.	O

These	O
observations	O
imply	O
the	O
possible	O
involvement	O
of	O
lung	O
stem	O
/	O
progenitor	O
cells	B-COMP
,	O
in	O
addition	O
to	O
pneumocytes	O
,	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
,	O
accounting	O
for	O
the	O
continued	O
deterioration	O
of	O
lung	O
tissues	O
and	O
apparent	O
loss	O
of	O
capacity	O
for	O
lung	O
repair	O
.	O

A	O
dose	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
mfgl2	O
expression	O
by	O
mfgl2	O
antisense	O
plasmid	O
was	O
observed	O
in	O
interferon	O
-	O
gamma	O
-	O
treated	O
RAW	O
264	O
.	O
7	O
cells	B-COMP
.	O

None	O
of	O
the	O
serum	B-COMP
specimens	O
collected	O
from	O
healthy	O
children	O
before	O
and	O
during	O
epidemic	O
in	O
Beijing	O
and	O
children	O
from	O
non	O
-	O
epidemic	O
region	O
was	O
positive	O
when	O
IFA	O
methods	O
and	O
ELISA	O
with	O
Beier	O
kits	O
were	O
used	O
for	O
detection	O
,	O
but	O
some	O
were	O
positive	O
when	O
ELISA	O
with	O
the	O
diagnostic	O
kit	O
from	O
other	O
source	O
was	O
applied	O
.	O

TITLE	O
:	O
Accelerated	O
induction	O
of	O
apoptosis	O
in	O
insect	O
cells	B-COMP
by	O
baculovirus	O
-	O
expressed	O
SARS	O
-	O
CoV	O
membrane	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
shown	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3a	O
and	O
7a	O
proteins	O
,	O
but	O
not	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
,	O
induce	O
apoptosis	O
in	O
mammalian	O
cells	B-COMP
.	O

TITLE	O
:	O
Mechanisms	O
of	O
establishment	O
of	O
persistent	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	B-COMP
.	O

The	O
states	O
and	O
transitions	O
of	O
S	O
suggest	O
conformational	O
changes	O
that	O
mediate	O
viral	O
entry	O
into	O
cells	B-COMP
.	O

The	O
present	O
results	O
suggest	O
that	O
DNA	O
immunization	O
followed	O
by	O
recombinant	O
adenovirus	O
boosting	O
could	O
be	O
used	O
as	O
a	O
potential	O
SARS	O
-	O
CoV	O
vaccine	O
in	O
the	O
induction	O
of	O
an	O
enhanced	O
humoral	O
and	O
cellular	B-COMP
immune	O
response	O
.	O

We	O
engineered	O
a	O
recombinant	O
JHMV	O
with	O
mutations	O
in	O
the	O
immunodominant	O
CD4	O
T	O
-	O
cell	B-COMP
epitope	O
(	O
rJ	O
.	O
M	O
(	O
Y135Q	O
)).	O

The	O
decrease	O
in	O
disease	O
severity	O
was	O
not	O
due	O
to	O
a	O
switch	O
from	O
Th1	O
to	O
Th2	O
predominance	O
in	O
rJ	O
.	O
M	O
(	O
Y135Q	O
)-	O
infected	O
mice	O
,	O
an	O
effect	O
on	O
CD8	O
T	O
-	O
cell	B-COMP
function	O
,	O
or	O
differential	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
by	O
JHMV	O
-	O
specific	O
CD4	O
T	O
cells	B-COMP
.	O

No	O
positive	O
results	O
for	O
antibody	B-COMP
to	O
SARS	O
-	O
CoV	O
were	O
detected	O
in	O
the	O
25	O
healthy	O
persons	O
.	O

ABSTRACT	O
:	O
The	O
nucleolus	B-COMP
is	O
a	O
dynamic	O
subnuclear	O
structure	O
involved	O
in	O
ribosome	B-COMP
subunit	I-COMP
biogenesis	O
,	O
cell	B-COMP
cycle	O
control	O
and	O
mediating	O
responses	O
to	O
cell	B-COMP
stress	O
,	O
among	O
other	O
functions	O
.	O

We	O
found	O
that	O
the	O
tumour	O
suppressor	O
protein	O
,	O
p53	O
,	O
which	O
localizes	O
normally	O
to	O
the	O
nucleus	B-COMP
and	O
nucleolus	B-COMP
,	O
was	O
redistributed	O
predominately	O
to	O
the	O
cytoplasm	B-COMP
.	O

SNPs	O
in	O
the	O
OAS1	O
3	O
'-	O
UTR	O
and	O
MxA	O
promoter	O
region	O
appear	O
associated	O
with	O
host	B-COMP
susceptibility	O
to	O
SARS	O
in	O
Chinese	O
Han	O
population	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
inactivation	O
expressed	O
as	O
log	O
-	O
reduction	O
were	O
as	O
follows	O
:	O
cell	B-COMP
-	O
free	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
),	O
greater	O
than	O
6	O
.	O
8	O
;	O
cell	B-COMP
-	O
associated	O
HIV	O
-	O
1	O
,	O
greater	O
than	O
6	O
.	O
4	O
;	O
human	O
T	O
-	O
lymphotropic	O
virus	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
),	O
4	O
.	O
5	O
;	O
HTLV	O
-	O
II	O
,	O
greater	O
than	O
5	O
.	O
7	O
;	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
hepatitis	O
C	O
virus	O
,	O
greater	O
than	O
4	O
.	O
5	O
;	O
duck	O
HBV	O
,	O
4	O
.	O
4	O
to	O
4	O
.	O
5	O
;	O
bovine	O
viral	O
diarrhea	O
virus	O
,	O
6	O
.	O
0	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
5	O
.	O
5	O
;	O
West	O
Nile	O
virus	O
,	O
6	O
.	O
8	O
;	O
bluetongue	O
virus	O
,	O
5	O
.	O
1	O
;	O
human	O
adenovirus	O
5	O
,	O
6	O
.	O
8	O
;	O
Klebsiella	O
pneumoniae	O
,	O
greater	O
than	O
7	O
.	O
4	O
;	O
Staphylococcus	O
epidermidis	O
and	O
Yersinia	O
enterocolitica	O
,	O
greater	O
than	O
7	O
.	O
3	O
;	O
Treponema	O
pallidum	O
,	O
greater	O
than	O
5	O
.	O
9	O
;	O
Borrelia	O
burgdorferi	O
,	O
greater	O
than	O
10	O
.	O
6	O
;	O
Plasmodium	O
falciparum	O
,	O
6	O
.	O
9	O
;	O
Trypanosoma	O
cruzi	O
,	O
greater	O
than	O
5	O
.	O
0	O
;	O
and	O
Babesia	O
microti	O
,	O
greater	O
than	O
5	O
.	O
3	O
.	O

The	O
interspecies	O
transmissions	O
of	O
coronaviruses	O
between	O
different	O
hosts	B-COMP
form	O
a	O
complex	O
ecosystem	O
of	O
which	O
little	O
is	O
known	O
.	O

There	O
was	O
a	O
statistical	O
significance	O
between	O
M	O
-	O
transfected	O
cells	B-COMP
and	O
co	O
-	O
transfected	O
cells	B-COMP
(	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
a	O
remarkable	O
difference	O
between	O
N	O
-	O
transfected	O
cells	B-COMP
and	O
co	O
-	O
transfected	O
cells	B-COMP
(	O
p	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
The	O
early	O
release	O
of	O
cytokines	O
by	O
cells	B-COMP
involved	O
in	O
innate	O
immunity	O
is	O
an	O
important	O
host	B-COMP
response	O
to	O
intracellular	B-COMP
pathogens	O
.	O

Serum	B-COMP
concentrations	O
of	O
IFN	O
-	O
gamma	O
peaked	O
at	O
about	O
10	O
d	O
after	O
inoculation	O
and	O
returned	O
to	O
approximately	O
baseline	O
levels	O
by	O
day	O
22	O
.	O

Trimeric	O
glycoprotein	O
spikes	O
were	O
in	O
register	O
with	O
four	O
underlying	O
ribonucleoprotein	B-COMP
densities	O
.	O

NM	O
calves	O
had	O
a	O
high	O
geometric	O
mean	O
titer	O
for	O
BCV	O
antibody	B-COMP
at	O
arrival	O
(	O
GMT	O
,	O
1	O
,	O
928	O
);	O
only	O
2	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
1	O
%	O
in	O
feces	O
.	O

Engineering	O
regulatory	O
transcription	O
circuits	O
of	O
intercommunicating	O
alleles	O
successfully	O
introduces	O
genetic	O
traps	O
into	O
a	O
viral	B-COMP
genome	I-COMP
that	O
are	O
lethal	O
in	O
RNA	O
recombinant	O
progeny	O
viruses	O
.	O

TITLE	O
:	O
Multicenter	O
comparison	O
of	O
nucleic	B-COMP
acid	O
extraction	O
methods	O
for	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
RNA	O
in	O
stool	O
specimens	O
.	O

The	O
microneutralizing	O
test	O
showed	O
that	O
one	O
clone	O
,	O
designated	O
M1A	O
,	O
had	O
neutralizing	O
activity	O
on	O
Vero	O
E6	O
cells	B-COMP
against	O
SARS	O
-	O
CoV	O
.	O
DNA	O
sequence	O
analysis	O
indicated	O
that	O
the	O
light	O
-	O
and	O
heavy	O
-	O
chain	O
genes	O
of	O
M1A	O
Fab	O
belong	O
to	O
the	O
kappa2a	O
and	O
4f	O
families	O
,	O
respectively	O
.	O

In	O
this	O
study	O
we	O
confirmed	O
the	O
3a	O
protein	O
expression	O
and	O
investigated	O
its	O
localization	O
at	O
the	O
surface	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
or	O
3a	O
-	O
cDNA	O
-	O
transfected	O
cells	B-COMP
.	O

Our	O
experiments	O
showed	O
that	O
recombinant	O
3a	O
protein	O
can	O
form	O
a	O
homotetramer	O
complex	O
through	O
interprotein	O
disulfide	O
bridges	O
in	O
3a	O
-	O
cDNA	O
-	O
transfected	O
cells	B-COMP
,	O
providing	O
a	O
clue	O
to	O
ion	O
channel	O
function	O
.	O

TITLE	O
:	O
Copious	O
production	O
of	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
employing	O
codon	O
optimized	O
synthetic	O
gene	O
.	O

Moreover	O
,	O
we	O
observed	O
that	O
NL63	O
-	O
S	O
-	O
driven	O
entry	O
was	O
less	O
dependent	O
on	O
a	O
low	O
-	O
pH	O
environment	O
and	O
activity	O
of	O
endosomal	O
proteases	O
compared	O
to	O
infection	O
mediated	O
by	O
SARS	O
-	O
S	O
,	O
further	O
suggesting	O
differences	O
in	O
hCoV	O
-	O
NL63	O
and	O
SARS	O
-	O
CoV	O
cellular	B-COMP
entry	O
.	O

Although	O
antibody	B-COMP
-	O
based	O
diagnosis	O
of	O
SARS	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
reliable	O
proof	O
of	O
SARS	O
infection	O
,	O
it	O
is	O
not	O
sensitive	O
enough	O
for	O
detection	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
-	O
mediated	O
cell	B-COMP
fusion	O
is	O
important	O
for	O
the	O
viral	O
entry	O
mechanism	O
and	O
identification	O
of	O
SARS	O
-	O
CoV	O
entry	O
inhibitors	O
.	O

Our	O
data	O
showed	O
that	O
H5N1	O
viral	O
infection	O
in	O
mice	O
resulted	O
in	O
typical	O
ARDS	O
,	O
which	O
was	O
characterized	O
by	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
about	O
80	O
%	O
of	O
mice	O
(	O
13	O
of	O
16	O
)	O
dead	O
on	O
Days	O
6	O
to	O
8	O
postinoculation	O
;	O
(	O
2	O
)	O
highly	O
edematous	O
lungs	O
and	O
dramatically	O
increased	O
lung	O
wet	O
:	O
dry	O
weight	O
ratios	O
and	O
lung	O
wet	O
weight	O
:	O
body	O
weight	O
ratios	O
;	O
(	O
3	O
)	O
inflammatory	O
cellular	B-COMP
infiltration	O
,	O
alveolar	O
and	O
interstitial	O
edema	O
,	O
and	O
hemorrhage	O
in	O
lungs	O
;	O
(	O
4	O
)	O
progressive	O
and	O
severe	O
hypoxemia	O
;	O
and	O
(	O
5	O
)	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

TITLE	O
:	O
Antigenic	O
and	O
cellular	B-COMP
localisation	O
analysis	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
using	O
monoclonal	O
antibodies	B-COMP
.	O

Confocal	O
microscopic	O
analysis	O
identified	O
nucleocapsids	O
packaged	O
in	O
vesicles	B-COMP
in	O
the	O
perinuclear	O
area	O
indicating	O
viral	O
synthesis	O
at	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
and	O
Golgi	B-COMP
apparatus	I-COMP
.	O

In	O
this	O
system	O
,	O
the	O
viral	O
RNA	O
was	O
expressed	O
in	O
the	O
cell	B-COMP
nucleus	I-COMP
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
and	O
further	O
amplified	O
in	O
the	O
cytoplasm	B-COMP
by	O
the	O
viral	O
replicase	O
.	O

Unusually	O
,	O
group	O
2	O
antibodies	B-COMP
appeared	O
to	O
recognize	O
cross	O
-	O
reactive	O
bacterial	O
epitopes	O
that	O
presumably	O
were	O
posttranslationally	O
modified	O
in	O
eukaryotes	O
and	O
hence	O
were	O
probably	O
not	O
induced	O
by	O
SARS	O
-	O
CoV	O
or	O
related	O
coronaviruses	O
but	O
rather	O
by	O
bacteria	O
.	O

Our	O
results	O
demonstrate	O
the	O
feasibility	O
of	O
producing	O
S1	O
in	O
nuclear	O
-	O
and	O
chloroplast	B-COMP
-	O
transformed	O
plants	O
,	O
indicating	O
its	O
potential	O
in	O
subsequent	O
development	O
of	O
a	O
plant	O
-	O
derived	O
and	O
safe	O
oral	O
recombinant	O
subunit	O
vaccine	O
against	O
the	O
SARS	O
-	O
CoV	O
in	O
edible	O
plants	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
S1	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
a	O
neutralizing	O
antibody	B-COMP
,	O
80R	O
,	O
at	O
2	O
.	O
3	O
A	O
resolution	O
,	O
as	O
well	O
as	O
the	O
structure	O
of	O
the	O
uncomplexed	O
S1	O
RBD	O
at	O
2	O
.	O
2	O
A	O
resolution	O
.	O

In	O
Rhabdomyosarcoma	O
cells	B-COMP
,	O
Madin	O
-	O
Darby	O
-	O
Canine	O
-	O
kidney	O
cells	B-COMP
and	O
in	O
an	O
undefined	O
monkey	O
kidney	O
cell	B-COMP
line	O
some	O
replication	O
was	O
observed	O
but	O
massive	O
exponential	O
rise	O
in	O
virus	O
yield	O
lacked	O
The	O
results	O
will	O
lead	O
to	O
an	O
improved	O
routine	O
diagnostic	O
algorithm	O
for	O
the	O
detection	O
of	O
the	O
human	O
coronavirus	O
NL63	O
.	O

TITLE	O
:	O
Over	O
-	O
expression	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3b	O
protein	O
induces	O
both	O
apoptosis	O
and	O
necrosis	O
in	O
Vero	O
E6	O
cells	B-COMP
.	O

N	O
protein	O
chaperone	O
activity	O
was	O
blocked	O
by	O
specific	O
monoclonal	O
antibodies	B-COMP
.	O

CD4	O
+	O
and	O
CD8	O
+	O
spleen	O
T	O
lymphocytes	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
to	O
evaluate	O
T	O
cell	B-COMP
-	O
mediated	O
immune	O
responses	O
,	O
the	O
antigen	O
-	O
specific	O
responses	O
of	O
T	O
cells	B-COMP
were	O
evaluated	O
by	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
assay	O
,	O
and	O
the	O
level	O
of	O
IgG	O
in	O
antisera	O
from	O
immunized	O
mice	O
was	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Moreover	O
,	O
both	O
anti	O
-	O
S1	O
and	O
anti	O
-	O
S2	O
IgGs	O
were	O
able	O
to	O
abolish	O
the	O
binding	O
between	O
S	O
protein	O
and	O
its	O
cellular	B-COMP
receptor	O
(	O
s	O
),	O
although	O
anti	O
-	O
S1	O
IgG	O
showed	O
a	O
significantly	O
higher	O
blocking	O
efficiency	O
.	O

Patients	O
with	O
ARDS	O
required	O
more	O
colloids	O
(	O
P	O
=	O
.	O
005	O
)	O
and	O
red	O
blood	O
cell	B-COMP
units	O
(	O
P	O
=	O
.	O
02	O
)	O
than	O
patients	O
without	O
ARDS	O
during	O
the	O
first	O
24	O
hours	O
.	O

ELISA	O
and	O
Western	O
blot	O
demonstrated	O
that	O
the	O
S1	O
could	O
react	O
with	O
the	O
convalescent	O
sera	B-COMP
of	O
people	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
ligand	O
blot	O
assay	O
showed	O
that	O
the	O
recombinant	O
S1	O
could	O
react	O
with	O
ACE2	O
,	O
the	O
receptor	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
molecular	O
mass	O
of	O
expressed	O
S1	O
was	O
about	O
70	O
kDa	O
,	O
which	O
was	O
higher	O
than	O
that	O
of	O
the	O
30	O
kDa	O
expected	O
.	O

ABSTRACT	O
:	O
The	O
performances	O
of	O
four	O
multiplex	O
PCR	O
(	O
m	O
-	O
PCR	O
)	O
were	O
compared	O
to	O
direct	O
immunofluorescence	O
assay	O
(	O
DFA	O
)	O
and	O
HuH7	O
cell	B-COMP
culture	O
for	O
the	O
detection	O
of	O
viruses	O
in	O
263	O
children	O
admitted	O
to	O
hospital	O
with	O
an	O
acute	O
respiratory	O
illness	O
.	O

Based	O
on	O
S	O
.	O
Wolfram	O
'	O
s	O
cellular	B-COMP
automation	O
theory	O
,	O
the	O
method	O
transfers	O
one	O
-	O
dimensional	O
DNA	O
sequence	O
into	O
two	O
-	O
demensional	O
visual	O
image	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
envelops	O
the	O
genomic	O
RNA	O
to	O
form	O
long	O
helical	O
nucleocapsid	B-COMP
during	O
virion	B-COMP
assembly	O
.	O

Gel	O
shift	O
assay	O
results	O
revealed	O
that	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
C	O
-	O
terminus	O
is	O
also	O
able	O
to	O
associate	O
with	O
nucleic	B-COMP
acids	O
and	O
residues	O
363	O
-	O
382	O
are	O
the	O
responsible	O
interaction	O
partner	O
,	O
demonstrating	O
that	O
this	O
fragment	O
might	O
involve	O
genomic	O
RNA	O
binding	O
sites	O
.	O

The	O
fact	O
that	O
nucleic	B-COMP
acid	O
binding	O
could	O
promote	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
C	O
-	O
terminus	O
to	O
form	O
high	O
-	O
order	O
oligomers	O
implies	O
that	O
the	O
oligomeric	O
SARS	O
-	O
CoV	O
N	O
protein	O
probably	O
combines	O
with	O
the	O
viral	O
genomic	O
RNA	O
in	O
triggering	O
long	O
nucleocapsid	B-COMP
formation	O
.	O

ABSTRACT	O
:	O
To	O
extend	O
the	O
potential	O
of	O
antibodies	B-COMP
and	O
their	O
derivatives	O
to	O
provide	O
passive	O
protection	O
against	O
enteric	O
infections	O
when	O
supplied	O
orally	O
in	O
crude	O
plant	O
extracts	O
,	O
we	O
have	O
expressed	O
both	O
a	O
small	O
immune	O
protein	O
(	O
SIP	O
)	O
and	O
a	O
full	O
-	O
length	O
antibody	B-COMP
in	O
plants	O
using	O
two	O
different	O
plant	O
virus	O
vectors	O
based	O
on	O
potato	O
virus	O
X	O
(	O
PVX	O
)	O
and	O
cowpea	O
mosaic	O
virus	O
(	O
CPMV	O
).	O

Intradermal	O
administration	O
of	O
RVV	O
-	O
S	O
into	O
rabbits	O
induced	O
neutralizing	O
(	O
NT	O
)	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
1	O
week	O
after	O
administration	O
and	O
the	O
NT	O
titer	O
reached	O
1	O
:	O
1000	O
after	O
boost	O
immunization	O
with	O
RVV	O
-	O
S	O
.	O
Significantly	O
,	O
NT	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
were	O
induced	O
by	O
administration	O
of	O
RVV	O
-	O
S	O
to	O
rabbits	O
that	O
had	O
been	O
pre	O
-	O
immunized	O
with	O
LC16m8	O
.	O

ABSTRACT	O
:	O
Safety	O
and	O
efficacy	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
pregnancy	O
is	O
unknown	O
.	O

In	O
addition	O
,	O
three	O
specific	O
replacements	O
(	O
F360S	O
,	O
T487S	O
and	O
L665S	O
)	O
were	O
only	O
found	O
between	O
03	O
-	O
human	O
SARS	O
-	O
CoVs	O
and	O
strains	O
from	O
02	O
-	O
04	O
interspecies	O
epidemic	O
group	O
,	O
which	O
reveals	O
that	O
selective	O
sweep	O
may	O
also	O
force	O
the	O
evolution	O
of	O
S	O
genes	O
before	O
the	O
jump	O
of	O
SARS	O
-	O
CoVs	O
into	O
human	O
hosts	B-COMP
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
investigated	O
the	O
presence	O
and	O
location	O
of	O
fluorescent	O
microspheres	O
having	O
the	O
size	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
of	O
mouse	O
minute	O
virus	O
(	O
MMV	O
)	O
in	O
the	O
zona	B-COMP
pellucida	I-COMP
(	O
ZP	O
)	O
of	O
in	O
vivo	O
-	O
produced	O
murine	O
embryos	O
,	O
the	O
transmission	O
of	O
these	O
viruses	O
by	O
embryos	O
during	O
embryo	O
transfer	O
,	O
and	O
the	O
time	O
of	O
seroconversion	O
of	O
recipients	O
and	O
pups	O
.	O

TITLE	O
:	O
Upregulation	O
of	O
mitochondrial	B-COMP
gene	O
expression	O
in	O
PBMC	O
from	O
convalescent	O
SARS	O
patients	O
.	O

We	O
found	O
that	O
genes	O
encoded	O
by	O
mitochondrial	B-COMP
DNA	I-COMP
(	O
mtDNA	B-COMP
)	O
were	O
obviously	O
upregulated	O
,	O
while	O
mitochondria	B-COMP
were	O
now	O
found	O
to	O
be	O
closely	O
connected	O
with	O
antiviral	O
immunity	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
was	O
carried	O
out	O
with	O
two	O
primer	O
sets	O
designed	O
to	O
amplify	O
either	O
a	O
156	O
bp	O
region	O
of	O
the	O
BVDV	O
5	O
'-	O
UTR	O
or	O
a	O
280	O
bp	O
region	O
of	O
the	O
CECov	O
nucleocapsid	B-COMP
protein	O
gene	O
.	O

In	O
fact	O
,	O
the	O
size	O
and	O
amino	O
acid	O
sequence	O
variability	O
of	O
nsp2	O
across	O
the	O
different	O
coronaviruses	O
has	O
led	O
some	O
investigators	O
to	O
speculate	O
that	O
the	O
nsp2	O
protein	O
,	O
along	O
with	O
the	O
nsp1	O
and	O
nsp3	O
proteins	O
,	O
may	O
play	O
host	B-COMP
-	O
and	O
/	O
or	O
cell	B-COMP
-	O
specific	O
roles	O
in	O
the	O
virus	O
life	O
cycle	O
.	O

Mice	O
vaccinated	O
with	O
SARS	O
CoV	O
(	O
N	O
)	O
DNA	O
or	O
(	O
M	O
)	O
DNA	O
using	O
pcDNA	O
3	O
.	O
1	O
(+)	O
plasmid	O
vector	O
showed	O
T	O
-	O
cell	B-COMP
immune	O
responses	O
(	O
CTL	O
induction	O
and	O
proliferation	O
)	O
against	O
type	O
II	O
alveolar	O
epithelial	O
cells	B-COMP
(	O
T7	O
)	O
transfected	O
with	O
SARS	O
(	O
N	O
)	O
or	O
(	O
M	O
)	O
DNA	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
SARS	O
N	O
DNA	O
vaccine	O
induced	O
CTL	O
activity	O
(	O
IFN	O
-	O
gamma	O
production	O
by	O
recombinant	O
N	O
protein	O
or	O
N	O
protein	O
-	O
pulsed	O
autologous	O
B	O
blast	O
cells	B-COMP
)	O
and	O
proliferation	O
of	O
spleen	O
cells	B-COMP
in	O
SCID	O
-	O
PBL	O
/	O
hu	O
mice	O
.	O

Specific	O
immobilization	O
of	O
GBP	O
-	O
EGFP	O
fusion	O
protein	O
and	O
its	O
interaction	O
with	O
the	O
antibody	B-COMP
in	O
the	O
microchannels	O
could	O
be	O
demonstrated	O
.	O

Lessons	O
learned	O
from	O
current	O
vaccine	O
studies	O
,	O
coupled	O
with	O
our	O
increasing	O
knowledge	O
of	O
the	O
host	B-COMP
and	O
viral	O
factors	O
involved	O
in	O
viral	O
pathogenesis	O
,	O
will	O
help	O
to	O
increase	O
the	O
speed	O
with	O
which	O
efficacious	O
vaccines	O
targeting	O
newly	O
emerging	O
viral	O
pathogens	O
can	O
be	O
developed	O
.	O

TITLE	O
:	O
Characterisation	O
of	O
the	O
RNA	O
binding	O
properties	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	B-COMP
protein	O
amino	O
-	O
terminal	O
region	O
.	O

TITLE	O
:	O
Selection	O
of	O
SARS	O
-	O
coronavirus	O
-	O
specific	O
B	O
cell	B-COMP
epitopes	O
by	O
phage	O
peptide	O
library	O
screening	O
and	O
evaluation	O
of	O
the	O
immunological	O
effect	O
of	O
epitope	O
-	O
based	O
peptides	O
on	O
mice	O
.	O

Here	O
proposes	O
a	O
strategy	O
--	O
sequence	O
the	O
whole	O
genome	O
(	O
chromosomal	B-COMP
as	O
well	O
as	O
other	O
genetic	O
systems	O
)	O
of	O
infected	O
human	O
cells	B-COMP
obtained	O
from	O
diseased	O
patients	O
.	O

Analysis	O
of	O
the	O
innate	O
immune	O
response	O
in	O
the	O
DNA	O
-	O
PKcs	O
-	O
deficient	O
mice	O
with	O
short	O
dysfunctional	O
telomeres	B-COMP
revealed	O
high	O
basal	O
serum	B-COMP
levels	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
and	O
hyper	O
-	O
active	O
cytokine	O
responses	O
upon	O
challenge	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
poly	O
-	O
IC	O
).	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
immune	O
injury	O
in	O
the	O
spleen	O
,	O
we	O
investigated	O
the	O
number	O
and	O
distribution	O
of	O
various	O
immune	O
cell	B-COMP
types	O
in	O
the	O
spleens	O
of	O
SARS	O
patients	O
.	O

The	O
SARS	O
spleens	O
all	O
had	O
severe	O
damage	O
to	O
the	O
white	O
pulp	O
and	O
showed	O
an	O
alteration	O
of	O
the	O
normal	O
distribution	O
of	O
various	O
cell	B-COMP
types	O
.	O

Sera	B-COMP
from	O
100	O
healthcare	O
workers	O
and	O
five	O
2	O
-	O
3	O
-	O
year	O
-	O
old	O
children	O
were	O
tested	O
in	O
a	O
Western	O
blot	O
assay	O
using	O
the	O
purified	O
recombinant	O
N	O
protein	O
.	O

Further	O
,	O
MHV	O
infection	O
did	O
not	O
inhibit	O
IFN	O
-	O
beta	O
production	O
mediated	O
by	O
known	O
host	B-COMP
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
(	O
RIG	O
-	O
I	O
,	O
Mda	O
-	O
5	O
,	O
and	O
TLR3	O
).	O

We	O
therefore	O
conclude	O
that	O
the	O
ORF7b	O
protein	O
is	O
not	O
only	O
an	O
accessory	O
protein	O
but	O
a	O
structural	O
component	O
of	O
the	O
SARS	O
-	O
CoV	O
virion	B-COMP
.	O

The	O
inhibitory	O
effect	O
of	O
UO126	O
on	O
MHV	O
production	O
appeared	O
to	O
be	O
a	O
general	O
phenomenon	O
since	O
the	O
effect	O
was	O
consistently	O
observed	O
in	O
all	O
six	O
different	O
MHV	O
strains	O
and	O
in	O
three	O
different	O
cell	B-COMP
types	O
tested	O
;	O
it	O
was	O
likely	O
exerted	O
at	O
the	O
postentry	O
steps	O
of	O
the	O
virus	O
life	O
cycle	O
because	O
the	O
virus	O
titers	O
were	O
similarly	O
inhibited	O
from	O
infected	O
cells	B-COMP
treated	O
at	O
1	O
h	O
prior	O
to	O
,	O
during	O
,	O
or	O
after	O
infection	O
.	O

Cox	O
regression	O
analysis	O
demonstrated	O
that	O
a	O
>	O
or	O
=	O
85	O
%	O
increase	O
in	O
baseline	O
serum	B-COMP
creatinine	O
(	O
hazard	O
rate	O
,	O
2	O
.	O
30	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
30	O
-	O
4	O
.	O
08	O
),	O
oliguria	O
(	O
hazard	O
rate	O
,	O
2	O
.	O
51	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
24	O
-	O
5	O
.	O
08	O
),	O
and	O
the	O
number	O
of	O
antibiotics	O
(	O
hazard	O
rate	O
,	O
2	O
.	O
64	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
51	O
-	O
4	O
.	O
63	O
)	O
predicted	O
longer	O
duration	O
of	O
weaning	O
.	O

The	O
histopathological	O
features	O
of	O
ReoV	O
infected	O
animals	O
consisted	O
of	O
diffuse	O
alveolar	O
damage	O
,	O
with	O
scattered	O
hemorrhage	O
,	O
hyaline	O
membrane	B-COMP
formation	O
and	O
interstitial	O
pneumonia	O
.	O

The	O
isolate	O
CRCoV	O
-	O
4182	O
was	O
cultured	O
in	O
HRT	O
-	O
18	O
cells	B-COMP
but	O
failed	O
to	O
replicate	O
in	O
a	O
number	O
of	O
other	O
cell	B-COMP
lines	O
.	O

Using	O
mouse	O
-	O
feline	O
APN	O
chimeras	O
,	O
we	O
identified	O
three	O
small	O
,	O
discontinuous	O
regions	O
,	O
amino	O
acids	O
(	O
aa	O
)	O
288	O
to	O
290	O
,	O
aa	O
732	O
to	O
746	O
(	O
called	O
R1	O
),	O
and	O
aa	O
764	O
to	O
788	O
(	O
called	O
R2	O
)	O
in	O
fAPN	O
that	O
determined	O
the	O
host	B-COMP
ranges	O
of	O
these	O
coronaviruses	O
.	O

Blockade	O
of	O
infection	O
with	O
anti	O
-	O
fAPN	O
monoclonal	O
antibody	B-COMP
RG4	O
suggested	O
that	O
these	O
three	O
regions	O
lie	O
close	O
together	O
on	O
the	O
fAPN	O
surface	O
.	O

Here	O
,	O
the	O
generation	O
and	O
characterization	O
of	O
the	O
first	O
selectable	O
,	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
based	O
replicon	O
cell	B-COMP
line	O
which	O
can	O
be	O
used	O
for	O
screening	O
is	O
described	O
.	O

ABSTRACT	O
:	O
We	O
reported	O
the	O
analytical	O
interference	O
of	O
anti	O
-	O
Escherichia	O
coli	O
protein	O
(	O
EP	O
)	O
antibodies	B-COMP
in	O
human	O
sera	B-COMP
and	O
residual	O
EP	O
in	O
a	O
recombinant	O
nucleocapsid	B-COMP
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
as	O
a	O
possible	O
source	O
of	O
false	O
positives	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
serodiagnosis	O
.	O

Indirect	O
immunofluorescence	O
assays	O
showed	O
that	O
in	O
the	O
infected	O
cells	B-COMP
expressing	O
each	O
of	O
the	O
siRNAs	O
,	O
there	O
was	O
aspecific	O
silencing	O
of	O
S	O
,	O
3a	O
and	O
7a	O
,	O
respectively	O
,	O
but	O
the	O
expression	O
of	O
nucleocapsid	B-COMP
protein	O
was	O
not	O
affected	O
.	O

Unique	O
genomic	O
features	O
distinguishing	O
between	O
these	O
four	O
subgroups	O
,	O
including	O
the	O
number	O
of	O
papain	O
-	O
like	O
proteases	O
,	O
the	O
presence	O
or	O
absence	O
of	O
hemagglutinin	O
esterase	O
,	O
small	O
ORFs	O
between	O
the	O
membrane	B-COMP
and	O
nucleocapsid	B-COMP
genes	O
and	O
ORFs	O
(	O
NS7a	O
and	O
NS7b	O
),	O
bulged	O
stem	O
-	O
loop	O
and	O
pseudoknot	O
structures	O
downstream	O
of	O
the	O
nucleocapsid	B-COMP
gene	O
,	O
transcription	O
regulatory	O
sequence	O
,	O
and	O
ribosomal	B-COMP
recognition	O
signal	O
for	O
the	O
envelope	B-COMP
gene	O
,	O
were	O
also	O
observed	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
role	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
the	O
induction	O
of	O
acute	O
lung	O
injury	O
by	O
promoting	O
the	O
synthesis	O
of	O
chemokine	O
/	O
cytokines	O
in	O
human	O
endothelial	O
cells	B-COMP
.	O

Spike	O
glycoprotein	O
of	O
SARS	O
-	O
CoV	O
was	O
recombined	O
by	O
using	O
insect	O
-	O
baculovirus	O
expression	O
system	O
and	O
Nickel	O
affinity	O
Magnet	O
Beads	O
,	O
and	O
then	O
used	O
to	O
stimulate	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	B-COMP
(	O
HUVEC	O
).	O

Levels	O
of	O
chemokines	O
/	O
cytokines	O
involved	O
in	O
immunoreaction	O
in	O
response	O
to	O
virus	O
infection	O
were	O
detected	O
in	O
the	O
supernatants	O
of	O
those	O
cells	B-COMP
cultured	O
with	O
the	O
Spike	O
glycoprotein	O
by	O
liquid	O
chip	O
system	O
.	O

(	O
2	O
)	O
The	O
Spike	O
glycoprotein	O
of	O
SARS	O
-	O
CoV	O
induced	O
a	O
high	O
level	O
of	O
IP	O
-	O
10	O
in	O
endothelial	O
cells	B-COMP
,	O
which	O
in	O
turn	O
damaged	O
endothelial	O
cells	B-COMP
.	O

TITLE	O
:	O
Palmitoylation	O
of	O
the	O
cysteine	O
-	O
rich	O
endodomain	O
of	O
the	O
SARS	O
-	O
coronavirus	O
spike	O
glycoprotein	O
is	O
important	O
for	O
spike	O
-	O
mediated	O
cell	B-COMP
fusion	O
.	O

The	O
cytoplasmic	B-COMP
portion	O
of	O
the	O
S	O
glycoprotein	O
contains	O
four	O
cysteine	O
-	O
rich	O
amino	O
acid	O
clusters	O
.	O

Studies	O
on	O
both	O
innate	O
and	O
adaptative	O
immune	O
responses	O
of	O
pigs	O
to	O
influenza	O
virus	O
and	O
coronaviruses	O
contribute	O
,	O
therefore	O
,	O
to	O
a	O
better	O
control	O
of	O
these	O
infections	O
in	O
their	O
natural	O
hosts	B-COMP
and	O
will	O
be	O
briefly	O
reviewed	O
in	O
this	O
article	O
.	O

Thus	O
,	O
nasal	O
and	O
pulmonary	O
antibody	B-COMP
responses	O
were	O
analyzed	O
in	O
influenza	O
virus	O
infected	O
or	O
vaccinated	O
pigs	O
showing	O
short	O
-	O
lived	O
,	O
but	O
potentially	O
protective	O
local	O
IgA	O
and	O
IgG	B-COMP
antibody	I-COMP
(	O
Ab	O
)	O
responses	O
.	O

ABSTRACT	O
:	O
This	O
study	O
examined	O
flock	O
size	O
and	O
management	O
,	O
level	O
of	O
internal	O
and	O
external	O
parasite	O
burden	O
and	O
seroprevalence	O
of	O
antibodies	B-COMP
to	O
poultry	O
pathogens	O
in	O
indigenous	O
chickens	O
in	O
Bokaa	O
village	O
,	O
Kgatleng	O
district	O
,	O
Botswana	O
.	O

We	O
constructed	O
recombinant	O
adenoviral	O
vectors	O
that	O
can	O
express	O
shRNAs	O
,	O
which	O
inhibited	O
the	O
expression	O
of	O
SARS	O
-	O
CoV	O
genes	O
effectively	O
in	O
mammalian	O
cells	B-COMP
.	O

In	O
this	O
study	O
,	O
we	O
designed	O
several	O
plasmids	O
that	O
express	O
small	O
hairpin	O
RNA	O
molecules	O
(	O
shRNA	O
)	O
specifically	O
targeting	O
to	O
the	O
genes	O
encoding	O
for	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
and	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
,	O
respectively	O
.	O

Since	O
many	O
cell	B-COMP
types	O
can	O
be	O
efficiently	O
infected	O
by	O
adenovirus	O
,	O
recombinant	O
adenoviruses	O
could	O
serve	O
as	O
an	O
alternative	O
powerful	O
tool	O
for	O
shRNA	O
delivery	O
and	O
for	O
gene	O
suppression	O
,	O
especially	O
when	O
the	O
targeted	O
cells	B-COMP
are	O
resistant	O
to	O
transfection	O
by	O
DNA	O
or	O
RNA	O
.	O

Furthermore	O
,	O
3a	O
/	O
X1	O
and	O
7a	O
/	O
X4	O
expression	O
in	O
A549	O
cells	B-COMP
enhanced	O
production	O
of	O
inflammatory	O
chemokines	O
that	O
were	O
known	O
to	O
be	O
up	O
-	O
regulated	O
in	O
SARS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
infection	O
of	O
rat	O
oligodendrocytes	O
by	O
ultraviolet	O
light	O
-	O
inactivated	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
apoptosis	O
,	O
suggesting	O
that	O
the	O
apoptosis	O
is	O
triggered	O
during	O
cell	B-COMP
entry	O
.	O

Utilizing	O
the	O
human	O
immunoglobulin	O
transgenic	O
mouse	O
,	O
XenoMouse	O
,	O
we	O
produced	O
fully	O
human	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
specific	O
antibodies	B-COMP
.	O

Additionally	O
,	O
57	O
neutralizing	O
antibodies	B-COMP
were	O
found	O
that	O
are	O
likely	O
specific	O
to	O
S2	O
.	O

The	O
KxHxx	O
motif	O
also	O
partially	O
retained	O
two	O
different	O
reporter	O
proteins	O
in	O
the	O
ERGIC	B-COMP
region	O
and	O
reduced	O
their	O
rates	O
of	O
trafficking	O
,	O
although	O
the	O
motif	O
was	O
less	O
potent	O
than	O
the	O
canonical	O
dilysine	O
signal	O
.	O

We	O
have	O
previously	O
developed	O
an	O
efficient	O
surface	O
-	O
display	O
system	O
by	O
genetically	O
engineering	O
987P	O
fimbriae	B-COMP
to	O
present	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
C	O
and	O
A	O
epitopes	O
for	O
the	O
induction	O
of	O
anti	O
-	O
TGEV	O
antibodies	B-COMP
with	O
a	O
Salmonella	O
vaccine	O
vector	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
coronavirus	O
A59	O
nucleocapsid	B-COMP
protein	O
is	O
a	O
type	O
I	O
interferon	O
antagonist	O
.	O

TITLE	O
:	O
Exceptional	O
flexibility	O
in	O
the	O
sequence	O
requirements	O
for	O
coronavirus	O
small	O
envelope	B-COMP
protein	O
function	O
.	O

ABSTRACT	O
:	O
The	O
small	O
envelope	B-COMP
protein	O
(	O
E	O
)	O
plays	O
a	O
role	O
of	O
central	O
importance	O
in	O
the	O
assembly	O
of	O
coronaviruses	O
.	O

These	O
cells	B-COMP
belong	O
mainly	O
to	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

All	O
group	O
1b	O
coronaviruses	O
encode	O
a	O
single	O
accessory	O
protein	O
between	O
the	O
spike	O
and	O
envelope	B-COMP
genes	O
,	O
except	O
for	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
nuclear	O
export	O
signal	O
in	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
localizes	O
to	O
the	O
cytoplasm	B-COMP
and	O
nucleolus	B-COMP
and	O
contains	O
an	O
eight	O
-	O
amino	O
-	O
acid	O
nucleolar	O
retention	O
motif	O
.	O

Dynamic	O
monitorings	O
of	O
metabolic	O
status	O
of	O
tissue	O
and	O
cell	B-COMP
are	O
valuable	O
in	O
predicting	O
the	O
development	O
of	O
MODS	O
after	O
severe	O
trauma	O
.	O

Later	O
on	O
,	O
viral	O
nucleocapsids	O
have	O
to	O
be	O
transported	O
to	O
the	O
budding	O
sites	O
in	O
the	O
Golgi	B-COMP
region	O
where	O
the	O
viral	O
glycoproteins	O
accumulate	O
and	O
particle	O
formation	O
occurs	O
.	O

Severe	O
falciparum	O
malaria	O
,	O
or	O
infections	O
complicated	O
by	O
a	O
relatively	O
high	O
parasite	O
count	O
(	O
more	O
than	O
2	O
%	O
of	O
red	O
blood	O
cells	B-COMP
parasitized	O
),	O
should	O
be	O
treated	O
with	O
intravenous	O
therapy	O
until	O
the	O
patient	O
is	O
well	O
enough	O
to	O
continue	O
with	O
oral	O
treatment	O
.	O

Anti	O
-	O
coronavirus	O
IgG	O
was	O
measured	O
in	O
CSF	O
and	O
serum	B-COMP
by	O
indirect	O
immunofluorescence	O
assay	O
.	O

The	O
identification	O
of	O
cytoplasmic	B-COMP
inclusion	I-COMP
bodies	O
in	O
acute	O
Kawasaki	O
disease	O
ciliated	O
bronchial	O
epithelium	O
has	O
provided	O
direction	O
for	O
future	O
Kawasaki	O
disease	O
etiology	O
studies	O
.	O

The	O
protein	O
is	O
a	O
minor	O
virion	B-COMP
structural	O
component	O
that	O
plays	O
an	O
important	O
,	O
not	O
fully	O
understood	O
role	O
in	O
virus	O
production	O
.	O

These	O
assays	O
will	O
be	O
useful	O
not	O
only	O
for	O
routine	O
SARS	O
coronavirus	O
diagnostics	O
but	O
also	O
for	O
epidemiological	O
and	O
antibody	B-COMP
kinetic	O
studies	O
.	O

These	O
asymmetries	O
in	O
nucleotide	O
composition	O
have	O
been	O
extensively	O
analyzed	O
in	O
prokaryotic	O
and	O
eukaryotic	O
genomes	O
and	O
related	O
to	O
chromosome	B-COMP
organization	I-COMP
,	O
transcription	O
orientation	O
and	O
other	O
processes	O
in	O
certain	O
organisms	O
.	O

Following	O
CCoV	O
infection	O
A	O
-	O
72	O
cell	B-COMP
line	O
,	O
which	O
is	O
permissive	O
to	O
CCoV	O
,	O
showed	O
reduced	O
growth	O
rate	O
,	O
as	O
detected	O
by	O
MTT	O
assay	O
,	O
a	O
standard	O
colorimetric	O
assay	O
for	O
measuring	O
cellular	B-COMP
proliferation	O
,	O
and	O
underwent	O
to	O
apoptotic	O
death	O
.	O

Commonly	O
to	O
other	O
animal	O
coronavirus	O
infection	O
caspase	O
-	O
3	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
execution	O
phase	O
of	O
apoptosis	O
induced	O
by	O
CCoV	O
in	O
A	O
-	O
72	O
cells	B-COMP
since	O
we	O
found	O
activation	O
of	O
enzymatic	O
activity	O
as	O
well	O
as	O
procaspase	O
-	O
3	O
activating	O
cleavage	O
.	O

Previous	O
studies	O
have	O
described	O
the	O
general	O
pathology	O
in	O
the	O
lungs	O
of	O
SARS	O
patients	O
and	O
have	O
identified	O
some	O
of	O
the	O
cell	B-COMP
types	O
infected	O
by	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Exosomal	O
vaccines	O
containing	O
the	O
S	O
protein	O
of	O
the	O
SARS	O
coronavirus	O
induce	O
high	O
levels	O
of	O
neutralizing	O
antibodies	B-COMP
.	O

After	O
priming	O
with	O
the	O
SARS	O
-	O
S	O
exosomal	O
vaccine	O
and	O
boosting	O
with	O
the	O
adenoviral	O
vector	O
the	O
neutralizing	O
antibody	B-COMP
titers	O
exceeded	O
those	O
observed	O
in	O
the	O
convalescent	O
serum	B-COMP
of	O
a	O
SARS	O
patient	O
.	O

These	O
assays	O
were	O
used	O
to	O
screen	O
58	O
samples	O
from	O
SARS	O
convalescent	O
patients	O
,	O
40	O
serial	O
serum	B-COMP
specimens	O
from	O
patients	O
at	O
different	O
phases	O
of	O
SARS	O
infection	O
,	O
and	O
88	O
plasma	O
specimens	O
from	O
normal	O
blood	O
donors	O
.	O

The	O
most	O
promising	O
newly	O
developed	O
technology	O
for	O
intervention	O
in	O
SARS	O
may	O
be	O
RNA	O
interference	O
,	O
an	O
endogenous	O
cellular	B-COMP
process	I-COMP
for	O
the	O
inhibition	O
of	O
gene	O
expression	O
mediated	O
by	O
sequence	O
-	O
specific	O
double	O
-	O
stranded	O
RNAs	O
.	O

The	O
average	O
anodic	O
currents	O
of	O
9	O
(	O
Cp	O
),	O
5	O
(	O
Hb	O
),	O
8	O
(	O
Hh	O
)	O
and	O
7	O
(	O
MHV	O
)	O
PCR	O
positive	O
samples	O
derived	O
from	O
feces	O
of	O
spontaneously	O
infected	O
mice	O
(	O
Cp	O
,	O
Hb	O
and	O
Hh	O
)	O
and	O
MHV	O
-	O
contaminated	O
tumor	O
cells	B-COMP
were	O
27	O
.	O
9	O
+/-	O
7	O
.	O
2	O
,	O
31	O
.	O
9	O
+/-	O
8	O
.	O
1	O
,	O
29	O
.	O
3	O
+/-	O
10	O
.	O
1	O
,	O
and	O
27	O
.	O
6	O
+/-	O
3	O
.	O
0	O
nA	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
activated	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
expression	O
.	O

Analysis	O
of	O
population	O
dynamics	O
revealed	O
that	O
coronavirus	O
populations	O
in	O
bats	O
have	O
constant	O
population	O
growth	O
,	O
while	O
viruses	O
from	O
all	O
other	O
hosts	B-COMP
show	O
epidemic	O
-	O
like	O
increases	O
in	O
population	O
.	O

It	O
is	O
also	O
essential	O
to	O
further	O
determine	O
how	O
PTX3	O
binds	O
to	O
pathogens	O
,	O
complement	O
,	O
and	O
apoptotic	O
cells	B-COMP
,	O
and	O
to	O
determine	O
whether	O
PTX3	O
has	O
a	O
specific	O
receptor	O
in	O
targeted	O
cells	B-COMP
.	O

As	O
in	O
SAP	O
-	O
S	O
group	O
,	O
the	O
injection	O
was	O
repeated	O
at	O
12	O
h	O
.	O
Serum	B-COMP
IL	O
-	O
1beta	O
was	O
measured	O
by	O
ELISA	O
.	O

We	O
have	O
investigated	O
innate	O
immune	O
responses	O
to	O
both	O
viruses	O
using	O
primary	O
human	O
macrophages	O
and	O
respiratory	O
epithelial	O
cells	B-COMP
as	O
in	O
vitro	O
models	O
.	O

In	O
vitro	O
experiments	O
of	O
chromatin	B-COMP
condensation	O
and	O
DNA	O
fragmentation	O
suggest	O
that	O
the	O
3a	O
protein	O
may	O
trigger	O
apoptosis	O
.	O

TITLE	O
:	O
Effective	O
inhibition	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
replication	O
in	O
ST	O
cells	B-COMP
by	O
shRNAs	O
targeting	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
.	O

Antibody	B-COMP
prophylaxis	O
as	O
supplemental	O
measure	O
generally	O
allows	O
for	O
containment	O
of	O
higher	O
R	O
(	O
0	O
)	O
values	O
and	O
restricts	O
both	O
the	O
size	O
and	O
duration	O
of	O
an	O
outbreak	O
.	O

362	O
serum	B-COMP
samples	O
were	O
collected	O
from	O
the	O
onset	O
of	O
the	O
disease	O
to	O
660	O
days	O
afterward	O
.	O

Convalescence	O
-	O
phase	O
sera	B-COMP
from	O
humans	O
were	O
similarly	O
ineffective	O
against	O
the	O
dominant	O
civet	O
pseudovirus	O
.	O

TITLE	O
:	O
Group	O
2	O
coronaviruses	O
prevent	O
immediate	O
early	O
interferon	O
induction	O
by	O
protection	O
of	O
viral	O
RNA	O
from	O
host	B-COMP
cell	I-COMP
recognition	O
.	O

,	O
there	O
was	O
no	O
cilia	B-COMP
loss	O
and	O
lymphoid	O
nodules	O
were	O
observed	O
in	O
the	O
muscularis	O
layer	O
of	O
the	O
infundibulum	O
and	O
magnum	O
of	O
some	O
hens	O
from	O
both	O
infected	O
groups	O
.	O

There	O
was	O
an	O
increase	O
in	O
RER	B-COMP
deposits	O
in	O
infected	O
cells	B-COMP
,	O
irrespective	O
of	O
egg	O
position	O
in	O
the	O
oviduct	O
.	O

Eggs	O
with	O
watery	O
whites	O
which	O
were	O
laid	O
by	O
infected	O
hens	O
could	O
be	O
attributed	O
to	O
cytopathological	O
changes	O
in	O
the	O
granular	O
epithelial	O
cells	B-COMP
and	O
tubular	O
gland	O
epithelial	O
cells	B-COMP
of	O
the	O
magnum	O
resulting	O
in	O
reduced	O
synthesis	O
of	O
albumen	O
proteins	O
.	O

It	O
represents	O
the	O
first	O
successful	O
isolation	O
,	O
purification	O
and	O
characterisation	O
of	O
the	O
oocytic	O
/	O
early	O
embryonic	O
factor	O
that	O
is	O
capable	O
of	O
controlling	O
cell	B-COMP
growth	O
activities	O
of	O
the	O
early	O
embryonic	O
tissues	O
.	O

Here	O
we	O
show	O
that	O
,	O
whereas	O
both	O
transient	O
transfection	O
and	O
constitutive	O
expression	O
of	O
fAPN	O
on	O
BHK	O
-	O
21	O
cells	B-COMP
can	O
rescue	O
FIPV	O
and	O
TGEV	O
infection	O
in	O
non	O
-	O
permissive	O
BHK	O
cells	B-COMP
,	O
fAPN	O
expression	O
does	O
not	O
rescue	O
infection	O
by	O
the	O
prototype	O
IBV	O
strain	O
Mass41	O
.	O

To	O
account	O
for	O
the	O
previous	O
suggestion	O
that	O
fAPN	O
could	O
serve	O
as	O
an	O
IBV	O
receptor	O
,	O
we	O
show	O
that	O
feline	O
cells	B-COMP
can	O
be	O
infected	O
with	O
the	O
prototype	O
strain	O
of	O
IBV	O
(	O
Mass	O
41	O
),	O
but	O
with	O
low	O
susceptibility	O
compared	O
to	O
primary	O
chick	O
kidney	O
cells	B-COMP
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
two	O
terminal	O
residues	O
are	O
important	O
,	O
and	O
the	O
charged	O
residue	O
(	O
R227	O
)	O
in	O
the	O
penultimate	O
position	O
in	O
the	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
A59	O
M	O
protein	O
was	O
suggested	O
to	O
participate	O
in	O
intermolecular	O
interactions	O
with	O
negative	O
charges	O
in	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
.	O

In	O
MHV	O
lesions	O
,	O
Myt1	O
was	O
not	O
expressed	O
in	O
astrocytes	O
,	O
lymphocytes	O
,	O
or	O
macrophage	O
/	O
microglial	O
cells	B-COMP
.	O

Western	O
blot	O
analysis	O
of	O
transfected	O
CHO	O
homogenates	O
showed	O
the	O
same	O
band	O
using	O
both	O
patient	O
purified	O
IgG	O
and	O
anti	O
-	O
GABA	O
(	O
B	O
)	O
R1	O
antibody	B-COMP
.	O

After	O
incubation	O
with	O
anti	O
-	O
GABA	O
(	O
B	O
)	O
R	O
antibody	B-COMP
,	O
a	O
marked	O
reduction	O
of	O
receptor	O
immunostaining	O
was	O
found	O
with	O
relative	O
sparing	O
of	O
neuronal	O
architecture	O
.	O

Serum	B-COMP
AGP	O
concentrations	O
fluctuated	O
over	O
time	O
in	O
clinically	O
healthy	O
cats	O
from	O
the	O
cattery	O
with	O
the	O
highest	O
prevalence	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
significantly	O
increased	O
just	O
before	O
an	O
outbreak	O
of	O
FIP	O
.	O

ABSTRACT	O
:	O
Analysis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
by	O
either	O
sucrose	O
gradient	O
equilibrium	O
centrifugation	O
or	O
a	O
virus	O
capture	O
assay	O
using	O
an	O
anti	O
-	O
SCoV	O
S	O
protein	O
antibody	B-COMP
demonstrated	O
that	O
the	O
SCoV	O
6	O
protein	O
,	O
which	O
is	O
one	O
of	O
the	O
accessory	O
proteins	O
of	O
SCoV	O
,	O
was	O
incorporated	O
into	O
virus	B-COMP
particles	I-COMP
.	O

Ten	O
P	O
-	O
PMOs	O
directed	O
against	O
various	O
target	O
sites	O
in	O
the	O
viral	B-COMP
genome	I-COMP
were	O
tested	O
in	O
cell	B-COMP
culture	O
,	O
and	O
one	O
of	O
these	O
(	O
5TERM	O
),	O
which	O
was	O
complementary	O
to	O
the	O
5	O
'	O
terminus	O
of	O
the	O
genomic	O
RNA	O
,	O
was	O
effective	O
against	O
six	O
strains	O
of	O
MHV	O
.	O

Examples	O
of	O
CBAs	O
include	O
the	O
procaryotic	O
cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
),	O
plant	O
lectins	O
such	O
as	O
HHA	O
,	O
GNA	O
,	O
NPA	O
,	O
CA	O
and	O
UDA	O
,	O
the	O
monoclonal	O
antibody	B-COMP
2G12	O
directed	O
against	O
a	O
glycan	O
-	O
containing	O
epitope	O
on	O
HIV	O
envelope	B-COMP
gp120	O
,	O
and	O
the	O
mannose	O
-	O
specific	O
non	O
-	O
peptidic	O
antibiotic	O
Pradimicin	O
A	O
,	O
which	O
inhibits	O
the	O
entry	O
of	O
HIV	O
-	O
1	O
into	O
its	O
target	O
cells	B-COMP
.	O

Specifically	O
,	O
the	O
unmethylated	O
CpG	O
ODN	O
(	O
and	O
/	O
or	O
the	O
phosphorothioate	O
group	O
)	O
activates	O
the	O
immune	O
system	O
,	O
but	O
this	O
potentially	O
important	O
anti	O
-	O
cancer	O
effect	O
is	O
lost	O
when	O
the	O
immune	O
cells	B-COMP
undergo	O
premature	O
apoptosis	O
apparently	O
because	O
their	O
Bcl	O
-	O
2	O
levels	O
have	O
been	O
lowered	O
by	O
the	O
antisense	O
effect	O
of	O
G3139	O
.	O

Although	O
chemokine	O
signaling	O
is	O
critical	O
in	O
promoting	O
T	O
cell	B-COMP
infiltration	O
into	O
the	O
CNS	O
and	O
control	O
of	O
viral	O
replication	O
,	O
additional	O
signaling	O
pathways	O
have	O
not	O
been	O
completely	O
explored	O
.	O

DRAK2	O
,	O
a	O
lymphoid	O
-	O
restricted	O
serine	O
/	O
threonine	O
kinase	O
,	O
prevents	O
spurious	O
T	O
cell	B-COMP
activation	O
.	O

TITLE	O
:	O
Positive	O
rate	O
of	O
serum	B-COMP
SARS	O
-	O
CoV	O
immunoglobulin	O
G	O
antibody	B-COMP
among	O
healthcare	O
workers	O
.	O

The	O
same	O
six	O
sites	O
were	O
also	O
phosphorylated	O
on	O
the	O
extracellular	B-COMP
mature	O
virion	B-COMP
N	O
protein	O
.	O

TITLE	O
:	O
Computational	O
simulation	O
of	O
interactions	O
between	O
SARS	O
coronavirus	O
spike	O
mutants	O
and	O
host	B-COMP
species	O
-	O
specific	O
receptors	O
.	O

And	O
the	O
calculations	O
predict	O
a	O
number	O
of	O
single	O
substitutions	O
on	O
RBD	O
,	O
receptor	O
or	O
antibody	B-COMP
that	O
could	O
remarkably	O
elevate	O
the	O
binding	O
affinities	O
of	O
those	O
complexes	O
.	O

Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
to	O
detect	O
and	O
quantify	O
SARS	O
-	O
CoV	O
in	O
934	O
sera	B-COMP
and	O
self	O
-	O
collected	O
throat	O
washes	O
and	O
fecal	O
samples	O
from	O
271	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
managed	O
at	O
a	O
single	O
institution	O
.	O

SARS	O
-	O
CoV	O
detection	O
rates	O
in	O
sera	B-COMP
were	O
highest	O
in	O
the	O
first	O
9	O
days	O
of	O
illness	O
,	O
whereas	O
detection	O
was	O
highest	O
in	O
throat	O
washes	O
5	O
-	O
14	O
days	O
after	O
onset	O
of	O
symptoms	O
.	O

Volunteers	O
from	O
employees	O
of	O
the	O
animal	O
market	O
were	O
recruited	O
and	O
their	O
serum	B-COMP
specific	O
antibody	B-COMP
against	O
SARS	O
-	O
CoV	O
were	O
determined	O
by	O
enzyme	O
linked	O
immunesorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
.	O

No	O
specific	O
IgM	B-COMP
antibody	I-COMP
was	O
found	O
in	O
all	O
of	O
those	O
samples	O
.	O

RESULTS	O
:	O
Positive	O
SARS	O
-	O
CoV	O
specific	O
IgG	B-COMP
antibody	I-COMP
was	O
found	O
25	O
.	O
61	O
%	O
(	O
n	O
=	O
328	O
),	O
13	O
.	O
03	O
%	O
(	O
n	O
=	O
238	O
),	O
12	O
.	O
59	O
%	O
(	O
n	O
=	O
135	O
),	O
5	O
.	O
04	O
%	O
(	O
n	O
=	O
139	O
)	O
and	O
9	O
.	O
43	O
%	O
(	O
n	O
=	O
53	O
)	O
among	O
volunteers	O
,	O
which	O
were	O
sampled	O
in	O
May	O
2003	O
,	O
Dec	O
.	O
2003	O
,	O
Jan	O
.	O
2004	O
,	O
July	O
2004	O
and	O
June	O
2005	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Unlike	O
SARS	O
,	O
direct	O
contact	O
with	O
patient	O
contracted	O
with	O
avian	O
influenza	O
at	O
the	O
end	O
of	O
incubation	O
period	O
and	O
in	O
the	O
stage	O
of	O
illness	O
through	O
flying	O
droplets	O
,	O
saliva	O
,	O
mucous	O
membrane	B-COMP
and	O
skin	O
injuries	O
will	O
not	O
lead	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
,	O
indicating	O
the	O
virus	O
'	O
ability	O
to	O
pass	O
from	O
human	O
to	O
human	O
is	O
limited	O
.	O

These	O
results	O
indicate	O
that	O
macrophages	O
play	O
a	O
protective	O
role	O
in	O
noninflammatory	O
lung	O
injury	O
caused	O
by	O
the	O
selective	O
ablation	O
of	O
AE2	O
cells	B-COMP
.	O

TITLE	O
:	O
Proteomic	O
analysis	O
of	O
up	O
-	O
regulated	O
proteins	O
in	O
human	O
promonocyte	O
cells	B-COMP
expressing	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	O
-	O
like	O
protease	O
.	O

In	O
this	O
study	O
,	O
proteome	O
analysis	O
of	O
the	O
human	O
promonocyte	O
HL	O
-	O
CZ	O
cells	B-COMP
expressing	O
SARS	O
CoV	O
3CLpro	O
was	O
performed	O
using	O
2	O
-	O
DE	O
and	O
nanoscale	O
capillary	O
LC	O
/	O
ESI	O
quadrupole	O
-	O
TOF	O
MS	O
.	O

In	O
addition	O
,	O
confocal	O
image	O
analysis	O
has	O
shown	O
release	O
of	O
mitochondrial	B-COMP
apoptogenic	O
apoptosis	O
-	O
inducing	O
factor	O
and	O
cytochrome	O
c	O
into	O
the	O
cytosol	B-COMP
.	O

The	O
study	O
provides	O
system	O
-	O
level	O
insights	O
into	O
the	O
interaction	O
of	O
SARS	O
CoV	O
3CLpro	O
with	O
host	B-COMP
cells	B-COMP
,	O
which	O
will	O
be	O
helpful	O
in	O
elucidating	O
the	O
molecular	O
basis	O
of	O
SARS	O
CoV	O
pathogenesis	O
.	O

Here	O
we	O
observed	O
that	O
transient	O
expression	O
of	O
3a	O
inhibited	O
cell	B-COMP
growth	O
and	O
prevented	O
5	O
-	O
bromodeoxyuridine	O
incorporation	O
,	O
suggesting	O
that	O
3a	O
deregulated	O
cell	B-COMP
cycle	O
progression	O
.	O

Viral	O
proteins	O
can	O
localise	O
to	O
the	O
nucleolus	B-COMP
and	O
using	O
the	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
as	O
a	O
model	O
,	O
the	O
cell	B-COMP
cycle	O
dependent	O
trafficking	O
of	O
viral	O
proteins	O
to	O
the	O
nucleolus	B-COMP
was	O
investigated	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
9b	O
protein	O
is	O
exported	O
outside	O
of	O
a	O
cell	B-COMP
nucleus	I-COMP
and	O
localizes	O
to	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
.	O

ABSTRACT	O
:	O
Some	O
patients	O
with	O
severe	O
primary	O
graft	O
dysfunction	O
(	O
PGD	O
)	O
after	O
lung	O
transplantation	O
(	O
LTx	O
)	O
require	O
gas	O
exchange	O
support	O
using	O
an	O
extracorporeal	O
membrane	B-COMP
oxygenator	O
(	O
ECMO	O
)	O
as	O
a	O
life	O
-	O
saving	O
therapy	O
.	O

An	O
emerging	O
theme	O
in	O
coronavirus	O
pathogenesis	O
is	O
that	O
the	O
interaction	O
between	O
specific	O
viral	O
genes	O
and	O
the	O
host	B-COMP
immune	O
system	O
,	O
specifically	O
the	O
innate	O
immune	O
system	O
,	O
functions	O
as	O
a	O
key	O
determinant	O
in	O
regulating	O
virulence	O
and	O
disease	O
outcomes	O
.	O

Using	O
SARS	O
-	O
CoV	O
as	O
a	O
model	O
,	O
we	O
will	O
review	O
the	O
current	O
knowledge	O
of	O
the	O
interplay	O
between	O
coronavirus	O
infection	O
and	O
the	O
host	B-COMP
innate	O
immune	O
system	O
in	O
vivo	O
,	O
and	O
then	O
discuss	O
the	O
mechanisms	O
by	O
which	O
specific	O
gene	O
products	O
antagonize	O
the	O
host	B-COMP
innate	O
immune	O
response	O
in	O
cell	B-COMP
culture	O
models	O
.	O

SARS	O
-	O
CoV	O
GFP	O
replicated	O
to	O
similar	O
titers	O
as	O
wild	O
type	O
viruses	O
in	O
Vero	O
E6	O
,	O
MA104	O
,	O
and	O
CaCo2	O
cells	B-COMP
.	O

In	O
2005	O
,	O
horseshoe	O
bats	O
were	O
identified	O
as	O
the	O
natural	O
reservoir	O
of	O
a	O
group	O
of	O
coronaviruses	O
that	O
are	O
distantly	O
related	O
to	O
SARS	O
-	O
CoV	O
.	O
The	O
genome	O
sequences	O
of	O
bat	O
SARS	O
-	O
like	O
coronavirus	O
had	O
about	O
88	O
-	O
92	O
%	O
nt	O
identity	O
with	O
that	O
of	O
the	O
SARS	O
-	O
CoV	O
.	O
The	O
prevalence	O
of	O
antibodies	B-COMP
and	O
viral	O
RNA	O
in	O
different	O
bat	O
species	O
and	O
the	O
characteristics	O
of	O
the	O
bat	O
SARS	O
-	O
like	O
coronavirus	O
were	O
elucidated	O
.	O

ABSTRACT	O
:	O
The	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strain	O
Beaudette	O
is	O
an	O
embryo	O
-	O
adapted	O
virus	O
that	O
has	O
extended	O
species	O
tropism	O
in	O
cell	B-COMP
culture	O
.	O

To	O
ascertain	O
the	O
requirements	O
of	O
cell	B-COMP
-	O
surface	O
HS	O
for	O
Beaudette	O
infectivity	O
,	O
we	O
assayed	O
for	O
infectivity	O
in	O
the	O
presence	O
of	O
soluble	O
heparin	O
as	O
a	O
competitor	O
and	O
determined	O
infectivity	O
in	O
mutant	O
cell	B-COMP
lines	O
with	O
no	O
HS	O
or	O
glycosaminoglycan	O
expression	O
.	O

Our	O
results	O
indicate	O
that	O
HS	O
plays	O
a	O
role	O
as	O
an	O
attachment	O
factor	O
for	O
IBV	O
,	O
working	O
in	O
concert	O
with	O
other	O
factors	O
like	O
sialic	O
acid	O
to	O
mediate	O
virus	O
binding	O
to	O
cells	B-COMP
,	O
and	O
may	O
explain	O
in	O
part	O
the	O
extended	O
tropism	O
of	O
IBV	O
Beaudette	O
.	O

It	O
was	O
also	O
confirmed	O
previously	O
that	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
can	O
bind	O
to	O
PEDV	O
,	O
and	O
anti	O
-	O
pAPN	O
antibodies	B-COMP
may	O
inhibit	O
the	O
combination	O
.	O

In	O
the	O
seven	O
unvaccinated	O
groups	O
,	O
CDV	O
titers	O
were	O
low	O
and	O
occurred	O
in	O
20	O
-	O
100	O
%	O
of	O
the	O
animals	O
;	O
antibody	B-COMP
titers	O
against	O
CPV	O
were	O
found	O
in	O
seven	O
of	O
eight	O
areas	O
.	O

Its	O
surface	O
glycoprotein	O
(	O
spike	O
protein	O
)	O
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
prime	O
targets	O
for	O
SARS	O
therapeutics	O
and	O
intervention	O
because	O
its	O
proteolytic	O
maturation	O
by	O
a	O
host	B-COMP
protease	O
is	O
crucial	O
for	O
host	B-COMP
-	O
virus	O
fusion	O
.	O

We	O
present	O
a	O
male	O
adolescent	O
in	O
whom	O
hemoptysis	O
was	O
mistaken	O
to	O
be	O
a	O
sign	O
of	O
airway	O
infection	O
for	O
several	O
months	O
and	O
who	O
later	O
on	O
underwent	O
an	O
unusual	O
antibody	B-COMP
-	O
negative	O
relapse	O
.	O

Renal	O
biopsy	O
revealed	O
linear	O
IgG	O
deposits	O
along	O
the	O
glomerular	O
basement	B-COMP
membrane	I-COMP
(	O
GBM	B-COMP
)	O
and	O
cellular	B-COMP
crescents	O
in	O
13	O
/	O
16	O
glomeruli	O
,	O
simultaneously	O
increased	O
anti	O
-	O
GBM	B-COMP
antibodies	B-COMP
were	O
detected	O
.	O

It	O
is	O
important	O
to	O
consider	O
that	O
in	O
patients	O
with	O
anti	O
-	O
GBM	O
disease	O
antibody	B-COMP
-	O
negative	O
relapses	O
are	O
possible	O
.	O

Host	B-COMP
cell	I-COMP
protein	O
synthesis	O
still	O
took	O
place	O
in	O
LiCl	O
-	O
treated	O
cells	B-COMP
and	O
the	O
level	O
of	O
a	O
standard	O
cellular	B-COMP
housekeeping	O
protein	O
remained	O
unchanged	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
LiCl	O
was	O
specifically	O
against	O
IBV	O
.	O

The	O
comparison	O
between	O
the	O
three	O
vaccination	O
routes	O
indicated	O
that	O
oral	O
vaccination	O
evoked	O
a	O
vigorous	O
T	O
-	O
cell	B-COMP
response	O
and	O
a	O
weak	O
response	O
predominantly	O
with	O
subclass	O
immunoglobulin	O
G2a	O
(	O
IgG2a	B-COMP
)	O
antibody	B-COMP
.	O

TITLE	O
:	O
Antigenic	O
characterization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
expressed	O
in	O
insect	O
cells	B-COMP
:	O
The	O
effect	O
of	O
phosphorylation	O
on	O
immunoreactivity	O
and	O
specificity	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
involved	O
in	O
the	O
pathological	O
reaction	O
to	O
SARS	O
and	O
is	O
a	O
key	O
antigen	O
for	O
the	O
development	O
of	O
a	O
sensitive	O
diagnostic	O
assay	O
.	O

We	O
also	O
provide	O
new	O
comparative	O
data	O
on	O
viral	O
replication	O
and	O
associated	O
pathology	O
following	O
infection	O
of	O
golden	O
Syrian	O
hamsters	O
with	O
various	O
SARS	O
-	O
CoV	O
strains	O
and	O
report	O
the	O
levels	O
of	O
neutralizing	O
antibody	B-COMP
titers	O
following	O
these	O
infections	O
and	O
the	O
cross	O
-	O
protective	O
efficacy	O
of	O
infection	O
with	O
these	O
strains	O
in	O
protecting	O
against	O
heterologous	O
challenge	O
.	O

TITLE	O
:	O
GxxxG	O
motif	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
glycoprotein	O
transmembrane	B-COMP
domain	O
is	O
not	O
involved	O
in	O
trimerization	O
and	O
is	O
not	O
important	O
for	O
entry	O
.	O

The	O
recombinant	O
viruses	O
replicated	O
efficiently	O
in	O
cell	B-COMP
culture	O
and	O
demonstrated	O
variable	O
sensitivities	O
to	O
neutralization	O
with	O
antibodies	B-COMP
.	O

Analysis	O
of	O
the	O
immunogenicity	O
of	O
the	O
UV	O
-	O
F	O
-	O
V	O
+	O
alum	O
vaccine	O
in	O
mice	O
revealed	O
that	O
it	O
generated	O
comparable	O
neutralizing	O
serum	B-COMP
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	B-COMP
antibody	I-COMP
levels	O
as	O
the	O
UV	O
-	O
V	O
+	O
alum	O
vaccine	O
.	O

TITLE	O
:	O
Clathrin	O
-	O
dependent	O
entry	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
into	O
target	O
cells	B-COMP
expressing	O
ACE2	O
with	O
the	O
cytoplasmic	B-COMP
tail	O
deleted	O
.	O

The	O
SARS	O
-	O
CoV	O
entered	O
caveolin	O
-	O
1	O
-	O
negative	O
HepG2	O
cells	B-COMP
,	O
and	O
the	O
entry	O
was	O
significantly	O
inhibited	O
by	O
treatment	O
with	O
chlorpromazine	O
,	O
an	O
inhibitor	O
for	O
clathrin	O
-	O
dependent	O
endocytosis	O
,	O
and	O
by	O
small	O
interfering	O
RNA	O
-	O
mediated	O
gene	O
silencing	O
for	O
the	O
clathrin	O
heavy	O
chain	O
.	O

Furthermore	O
,	O
the	O
SARS	O
-	O
CoV	O
entered	O
COS7	O
cells	B-COMP
transfected	O
with	O
the	O
mutant	O
of	O
ACE2	O
with	O
the	O
cytoplasmic	B-COMP
tail	O
deleted	O
,	O
SARS	O
-	O
CoV	O
receptor	O
,	O
as	O
well	O
as	O
the	O
wild	O
-	O
type	O
ACE2	O
,	O
and	O
their	O
entries	O
were	O
significantly	O
inhibited	O
by	O
treatment	O
with	O
chlorpromazine	O
.	O

TITLE	O
:	O
Trafficking	O
motifs	O
in	O
the	O
SARS	O
-	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
.	O

TITLE	O
:	O
Coronavirus	O
envelope	B-COMP
protein	O
:	O
a	O
small	O
membrane	B-COMP
protein	O
with	O
multiple	O
functions	O
.	O

African	O
green	O
monkeys	O
immunized	O
through	O
the	O
respiratory	O
tract	O
with	O
two	O
doses	O
of	O
the	O
vaccine	O
developed	O
a	O
titer	O
of	O
SARS	O
-	O
CoV	O
-	O
neutralizing	O
antibodies	B-COMP
comparable	O
with	O
the	O
robust	O
secondary	O
response	O
observed	O
in	O
animals	O
that	O
have	O
been	O
immunized	O
with	O
a	O
different	O
experimental	O
SARS	O
-	O
CoV	O
vaccine	O
and	O
challenged	O
with	O
SARS	O
-	O
CoV	O
.	O
When	O
animals	O
immunized	O
with	O
NDV	O
expressing	O
S	O
were	O
challenged	O
with	O
a	O
high	O
dose	O
of	O
SARS	O
-	O
CoV	O
,	O
direct	O
viral	O
assay	O
of	O
lung	O
tissues	O
taken	O
by	O
necropsy	O
at	O
the	O
peak	O
of	O
viral	O
replication	O
demonstrated	O
a	O
236	O
-	O
or	O
1	O
,	O
102	O
-	O
fold	O
(	O
depending	O
on	O
the	O
NDV	O
vector	O
construct	O
)	O
mean	O
reduction	O
in	O
pulmonary	O
SARS	O
-	O
CoV	O
titer	O
compared	O
with	O
control	O
animals	O
.	O

RESULTS	O
:	O
13	O
patients	O
were	O
considered	O
immunocompetent	O
and	O
10	O
were	O
immunocompromised	O
when	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
was	O
started	O
.	O

A	O
single	O
chain	O
variable	O
fragment	O
antibody	B-COMP
(	O
N18	O
)	O
with	O
high	O
affinity	O
against	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
isolated	O
.	O

Blocking	O
COX	O
activity	O
by	O
different	O
inhibitors	O
or	O
by	O
RNA	O
interference	O
affected	O
MHV	O
infection	O
in	O
different	O
cells	B-COMP
.	O

TITLE	O
:	O
Interstitial	O
lung	O
disease	O
and	O
anti	O
-	O
Jo	O
-	O
1	O
antibodies	B-COMP
:	O
difference	O
between	O
acute	O
and	O
gradual	O
onset	O
.	O

In	O
addition	O
,	O
AM	O
significantly	O
suppressed	O
apoptosis	O
of	O
alveolar	O
wall	O
cells	B-COMP
as	O
indicated	O
by	O
cleaved	O
caspase	O
-	O
3	O
staining	O
.	O

Bronchoalveolar	O
lavage	O
studies	O
have	O
shown	O
an	O
increase	O
in	O
total	O
cellular	B-COMP
inflammation	O
in	O
the	O
youngest	O
,	O
symptomatic	O
children	O
,	O
and	O
that	O
in	O
older	O
preschool	O
children	O
the	O
neutrophil	O
is	O
the	O
predominant	O
inflammatory	O
cell	B-COMP
in	O
the	O
airway	O
.	O

Serum	B-COMP
interleukin	O
(	O
IL	O
)-	O
8	O
and	O
IL	O
-	O
6	O
concentrations	O
were	O
measured	O
in	O
20	O
of	O
these	O
patients	O
.	O

Both	O
SARS	O
-	O
CoV	O
receptors	O
of	O
ACE2	O
and	O
CD209L	O
were	O
expressed	O
in	O
the	O
8	O
organ	O
/	O
tissue	O
-	O
derived	O
endothelial	O
cells	B-COMP
.	O

The	O
expression	O
of	O
ACE2	O
receptor	O
was	O
the	O
highest	O
in	O
the	O
human	O
lung	O
microvascular	O
endothelial	O
cells	B-COMP
,	O
and	O
lowest	O
in	O
the	O
lymphatic	O
endothelial	O
cells	B-COMP
.	O

CONCLUSIONS	O
:	O
The	O
organ	O
derived	O
microvascular	O
endothelial	O
cells	B-COMP
are	O
the	O
important	O
target	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
pathological	O
injury	O
of	O
lung	O
and	O
lymph	O
system	O
induced	O
by	O
SARS	O
-	O
CoV	O
may	O
be	O
mediated	O
respectively	O
by	O
different	O
receptors	O
of	O
SARS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
A	O
cytopathogenic	O
virus	O
(	O
designated	O
the	O
Aichi	O
/	O
2004	O
strain	O
)	O
was	O
isolated	O
in	O
a	O
human	O
rectal	O
adenocarcinoma	O
cell	B-COMP
line	O
(	O
HRT	O
-	O
18	O
)	O
from	O
the	O
ileum	O
contents	O
of	O
a	O
calf	O
with	O
diarrhea	O
.	O

In	O
a	O
serological	O
survey	O
of	O
serum	B-COMP
samples	O
from	O
355	O
calves	O
at	O
33	O
farms	O
,	O
92	O
%	O
of	O
calves	O
were	O
positive	O
for	O
neutralizing	O
antibodies	B-COMP
to	O
the	O
isolate	O
.	O

ABSTRACT	O
:	O
Epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
promotes	O
gastrointestinal	O
mucosal	O
recovery	O
by	O
stimulating	O
the	O
mitogenic	O
activity	O
of	O
intestinal	O
crypt	O
epithelial	O
cells	B-COMP
.	O

Recent	O
studies	O
revealed	O
that	O
M	O
protein	O
could	O
interact	O
with	O
N	O
protein	O
in	O
the	O
Golgi	B-COMP
complex	I-COMP
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
SCoV	O
M	O
protein	O
co	O
-	O
localized	O
in	O
the	O
Golgi	B-COMP
apparatus	I-COMP
with	O
a	O
Golgi	B-COMP
vector	O
marker	O
.	O

The	O
plasmid	O
,	O
pEGFP	O
-	O
M	O
,	O
encoding	O
SCoV	O
M	O
protein	O
as	O
a	O
fusion	O
protein	O
with	O
EGFP	O
,	O
was	O
used	O
for	O
silencing	O
and	O
for	O
reporter	O
gene	O
detection	O
in	O
HEK	O
293T	O
cells	B-COMP
transfected	O
with	O
siRNA	O
constructs	O
.	O

Recombinant	O
SARS	O
-	O
CoV	O
lacking	O
ORF6	O
did	O
not	O
tether	O
karyopherin	O
alpha	O
2	O
to	O
the	O
ER	O
/	O
Golgi	B-COMP
membrane	I-COMP
and	O
allowed	O
the	O
import	O
of	O
the	O
STAT1	O
complex	O
into	O
the	O
nucleus	B-COMP
.	O

Moreover	O
,	O
CXCL10	O
(-/-)	O
mice	O
infected	O
with	O
MHV	O
-	O
CXCL10	O
were	O
protected	O
from	O
severe	O
hepatitis	O
as	O
evidenced	O
by	O
reduced	O
pathology	O
and	O
serum	B-COMP
alanine	O
aminotransferase	O
levels	O
compared	O
with	O
MHV	O
-	O
infected	O
mice	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
CXCL10	O
(-/-)	O
mice	O
with	O
anti	O
-	O
CXCL10	O
Ab	O
resulted	O
in	O
increased	O
clinical	O
disease	O
correlating	O
with	O
enhanced	O
viral	O
recovery	O
from	O
the	O
brain	O
and	O
liver	O
as	O
well	O
as	O
increased	O
serum	B-COMP
alanine	O
aminotransferase	O
levels	O
.	O

TITLE	O
:	O
Intratracheally	O
administered	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
affect	O
antibody	B-COMP
responses	O
of	O
poultry	O
.	O

TITLE	O
:	O
Intranasal	O
Protollin	O
-	O
formulated	O
recombinant	O
SARS	O
S	O
-	O
protein	O
elicits	O
respiratory	O
and	O
serum	B-COMP
neutralizing	O
antibodies	B-COMP
and	O
protection	O
in	O
mice	O
.	O

Ten	O
truncated	O
spike	O
protein	O
gene	O
fragments	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
cells	B-COMP
.	O

Protein	O
6	O
consists	O
of	O
an	O
N	O
-	O
terminal	O
hydrophobic	O
peptide	O
and	O
a	O
C	O
-	O
terminal	O
region	O
containing	O
intracellular	B-COMP
protein	O
sorting	O
motifs	O
.	O

These	O
cytokines	O
induce	O
fever	O
,	O
leucocytosis	O
and	O
release	O
of	O
serum	B-COMP
acute	O
phase	O
proteins	O
(	O
APPs	O
).	O

In	O
cats	O
with	O
inflammatory	O
conditions	O
,	O
fever	O
is	O
a	O
common	O
finding	O
,	O
with	O
leucocytosis	O
due	O
to	O
the	O
release	O
of	O
cells	B-COMP
from	O
the	O
marginal	O
pool	O
,	O
followed	O
by	O
activation	O
of	O
myelopoiesis	O
.	O

The	O
major	O
APPs	O
are	O
serum	B-COMP
amyloid	O
A	O
and	O
alpha	O
(	O
1	O
)-	O
acid	O
glycoprotein	O
(	O
AGP	O
),	O
which	O
both	O
increase	O
a	O
few	O
hours	O
after	O
the	O
inflammatory	O
stimulus	O
and	O
remain	O
elevated	O
for	O
as	O
long	O
as	O
the	O
inflammation	O
persists	O
.	O

This	O
report	O
expands	O
our	O
understanding	O
of	O
the	O
specificity	O
and	O
duration	O
of	O
anti	O
-	O
SARS	O
coronavirus	O
CD4	O
(+)	O
T	O
-	O
cell	B-COMP
immune	O
responses	O
.	O

Electron	O
microscopy	O
studies	O
of	O
rTGEV	O
-	O
DeltaE	O
infected	O
BHK	O
-	O
pAPN	O
-	O
E	O
(-)	O
cells	B-COMP
showed	O
that	O
only	O
immature	O
intracellular	B-COMP
virions	B-COMP
were	O
assembled	O
.	O

Importantly	O
,	O
replication	O
of	O
nsp1	O
mutant	O
virus	O
in	O
professional	O
antigen	O
-	O
presenting	O
cells	B-COMP
such	O
as	O
conventional	O
dendritic	B-COMP
cells	B-COMP
and	O
macrophages	O
,	O
and	O
induction	O
of	O
type	O
I	O
IFN	O
in	O
plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
,	O
was	O
not	O
impaired	O
.	O

Multiplex	O
real	O
-	O
time	O
reverse	O
transcriptase	O
(	O
RT	O
)-	O
PCR	O
was	O
developed	O
for	O
simultaneous	O
differential	O
quantification	O
of	O
each	O
virus	O
in	O
a	O
single	O
reaction	O
tube	O
,	O
using	O
Cy5	O
-	O
and	O
FAM	O
-	O
labeled	O
TaqMan	O
-	O
probes	O
based	O
on	O
sequences	O
from	O
the	O
TGEV	O
and	O
PEDV	O
nucleocapsid	B-COMP
genes	O
.	O

Within	O
1	O
h	O
,	O
17	O
particles	O
were	O
bound	O
per	O
cell	B-COMP
and	O
,	O
within	O
1	O
min	O
,	O
89	O
%	O
of	O
the	O
bound	O
particles	O
were	O
internalized	O
.	O

These	O
glycoproteins	O
are	O
key	O
to	O
the	O
infection	O
process	O
as	O
they	O
are	O
mediators	O
of	O
the	O
receptor	O
binding	O
and	O
membrane	B-COMP
fusion	O
of	O
the	O
virion	B-COMP
with	O
the	O
host	B-COMP
cell	I-COMP
.	O

In	O
this	O
work	O
,	O
we	O
found	O
that	O
the	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
physically	O
interacted	O
with	O
IKKbeta	O
using	O
a	O
co	O
-	O
immunoprecipitation	O
assay	O
(	O
IPA	O
).	O

Two	O
H	O
-	O
2	O
(	O
d	O
)	O
restricted	O
CD4	O
(+)	O
T	O
epitopes	O
,	O
N60	O
(	O
S435	O
-	O
444	O
)	O
and	O
P152	O
(	O
S1111	O
-	O
1127	O
),	O
and	O
two	O
H	O
-	O
2	O
(	O
d	O
)	O
restricted	O
CD8	O
(+)	O
T	O
cell	B-COMP
epitopes	O
,	O
N50	O
(	O
S365	O
-	O
374	O
)	O
and	O
P141	O
(	O
S1031	O
-	O
1047	O
)	O
were	O
identified	O
by	O
three	O
different	O
methods	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
enzyme	O
linked	O
immunospot	O
assay	O
(	O
ELISPOT	O
)	O
and	O
fluorescence	O
activated	O
cell	B-COMP
sorter	O
(	O
FACS	O
).	O

TITLE	O
:	O
Severe	O
depletion	O
of	O
mucosal	O
CD4	O
+	O
T	O
cells	B-COMP
in	O
AIDS	O
-	O
free	O
simian	O
immunodeficiency	O
virus	O
-	O
infected	O
sooty	O
mangabeys	O
.	O

However	O
,	O
mutant	O
virus	O
replication	O
was	O
strongly	O
attenuated	O
in	O
cells	B-COMP
with	O
an	O
intact	O
IFN	O
response	O
.	O

The	O
possibility	O
of	O
obtaining	O
the	O
double	O
yield	O
of	O
bovine	O
coronavirus	O
was	O
demonstrated	O
in	O
MDBK	O
and	O
Vero	O
cell	B-COMP
cultures	O
at	O
34	O
degrees	O
C	O
.	O

TITLE	O
:	O
Genetic	O
differentiation	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
Korean	O
isolates	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
by	O
RT	O
-	O
PCR	O
based	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O

However	O
,	O
it	O
is	O
uncertain	O
whether	O
SARS	O
-	O
CoV	O
evades	O
host	B-COMP
detection	O
or	O
has	O
evolved	O
mechanisms	O
to	O
counteract	O
innate	O
host	B-COMP
defenses	O
.	O

TITLE	O
:	O
Conductance	O
and	O
amantadine	O
binding	O
of	O
a	O
pore	B-COMP
formed	O
by	O
a	O
lysine	O
-	O
flanked	O
transmembrane	B-COMP
domain	O
of	O
SARS	O
coronavirus	O
envelope	B-COMP
protein	O
.	O

TITLE	O
:	O
Impaired	O
plasmacytoid	O
dendritic	B-COMP
cell	B-COMP
innate	O
immune	O
responses	O
in	O
patients	O
with	O
herpes	O
virus	O
-	O
associated	O
acute	O
retinal	O
necrosis	O
.	O

ABSTRACT	O
:	O
Plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
(	O
PDC	O
),	O
the	O
main	O
producers	O
of	O
type	O
I	O
IFNs	O
in	O
the	O
blood	O
,	O
are	O
important	O
for	O
the	O
recognition	O
and	O
control	O
of	O
viral	O
and	O
bacterial	O
infections	O
.	O

CD8	O
+	O
cell	B-COMP
responses	O
were	O
significantly	O
lower	O
in	O
patients	O
vs	O
controls	O
(	O
p	O
=	O
0	O
.	O
04	O
).	O

ABSTRACT	O
:	O
We	O
analyzed	O
the	O
ability	O
of	O
two	O
rat	O
coronavirus	O
(	O
RCoV	O
)	O
strains	O
,	O
sialodacryoadenitis	O
virus	O
(	O
SDAV	O
)	O
and	O
Parker	O
'	O
s	O
RCoV	O
(	O
RCoV	O
-	O
P	O
),	O
to	O
infect	O
rat	O
alveolar	O
type	O
I	O
cells	B-COMP
and	O
induce	O
chemokine	O
expression	O
.	O

Dual	O
immunolabeling	O
of	O
type	O
I	O
cells	B-COMP
for	O
viral	O
antigen	O
and	O
CXC	O
chemokines	O
showed	O
that	O
chemokines	O
were	O
expressed	O
primarily	O
by	O
uninfected	O
cells	B-COMP
.	O

Other	O
cell	B-COMP
types	O
infected	O
include	O
the	O
epithelial	O
cells	B-COMP
of	O
renal	O
tubules	O
,	O
cerebral	O
neurons	O
,	O
and	O
immune	O
cells	B-COMP
.	O

Complexes	O
containing	O
the	O
mRNA	O
pseudoknot	O
exhibited	O
a	O
higher	O
efficiency	O
of	O
affinity	O
selection	O
than	O
that	O
those	O
without	O
,	O
indicating	O
that	O
the	O
pseudoknot	O
improves	O
stability	O
of	O
the	O
mRNA	O
-	O
ribosome	B-COMP
-	O
antibody	B-COMP
complex	O
in	O
a	O
eukaryotic	O
translation	O
system	O
.	O

On	O
the	O
35th	O
month	O
after	O
the	O
onset	O
,	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
were	O
still	O
having	O
the	O
neutralizing	O
antibody	B-COMP
level	O
of	O
above	O
1	O
:	O
36	O
,	O
but	O
the	O
neutralizing	O
antibody	B-COMP
level	O
in	O
another	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
had	O
decreased	O
to	O
as	O
low	O
as	O
1	O
:	O
10	O
,	O
when	O
the	O
cut	O
-	O
off	O
level	O
was	O
set	O
as	O
1	O
:	O
8	O
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
the	O
study	O
indicated	O
that	O
the	O
neutralizing	O
antibody	B-COMP
of	O
SARS	O
cases	O
could	O
last	O
for	O
at	O
least	O
three	O
years	O
,	O
but	O
the	O
sera	B-COMP
specific	O
antibody	B-COMP
in	O
SARS	O
cases	O
decreased	O
gradually	O
when	O
time	O
went	O
by	O
.	O

Incorporation	O
of	O
Boc	O
-	O
Ser	B-COMP
as	O
the	O
P	O
(	O
4	O
)-	O
ligand	O
resulted	O
in	O
enhanced	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitory	O
activity	O
.	O

Both	O
nsp4	O
proteins	O
became	O
N	O
glycosylated	O
,	O
while	O
their	O
amino	O
and	O
carboxy	O
termini	O
were	O
localized	O
to	O
the	O
cytoplasm	B-COMP
.	O

TITLE	O
:	O
Immunosuppressive	O
total	O
lymphoid	O
irradiation	O
-	O
based	O
reconditioning	O
regimens	O
enable	O
engraftment	O
after	O
graft	O
rejection	O
or	O
graft	O
failure	O
in	O
patients	O
treated	O
with	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
.	O

All	O
four	O
immunodominant	O
peptides	O
could	O
elicit	O
cellular	B-COMP
immunity	O
with	O
a	O
predominance	O
of	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
response	O
.	O

Although	O
airway	O
cells	B-COMP
secrete	O
TNF	O
-	O
alpha	O
in	O
response	O
to	O
ricin	O
,	O
blocking	O
TNF	O
-	O
alpha	O
did	O
not	O
prevent	O
ricin	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Decreased	O
levels	O
of	O
IkappaB	O
-	O
alpha	O
in	O
airway	O
cells	B-COMP
exposed	O
to	O
ricin	O
suggest	O
that	O
translational	O
suppression	O
may	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Inhibition	O
of	O
p38	O
MAPK	O
by	O
a	O
chemical	O
inhibitor	O
or	O
NF	O
-	O
kappaB	O
by	O
short	O
interfering	O
RNA	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
,	O
demonstrating	O
the	O
importance	O
of	O
these	O
two	O
pathways	O
in	O
ricin	O
intoxication	O
.	O

ABSTRACT	O
:	O
An	O
indirect	O
immunofluorescent	O
assay	O
(	O
Euroimmun	O
AG	O
,	O
Luebeck	O
,	O
Germany	O
)	O
was	O
used	O
to	O
investigate	O
the	O
avidity	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
),	O
IgM	O
,	O
IgA	O
,	O
and	O
total	O
Ig	O
(	O
IgGAM	O
)	O
antibody	B-COMP
responses	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
infections	O
.	O

Serial	O
serum	B-COMP
samples	O
from	O
eight	O
patients	O
collected	O
during	O
the	O
first	O
,	O
third	O
,	O
and	O
ninth	O
months	O
after	O
the	O
onset	O
of	O
infection	O
were	O
evaluated	O
.	O

The	O
expression	O
of	O
full	O
length	O
recombinant	O
SARS	O
spike	O
protein	O
(	O
rSS	O
)	O
in	O
HeLa	O
cells	B-COMP
possessing	O
specific	O
reaction	O
ability	O
to	O
chicken	O
anti	O
-	O
sera	B-COMP
was	O
confirmed	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
(	O
190	O
kD	O
).	O

The	O
causative	O
antibody	B-COMP
is	O
of	O
the	O
IgG	O
immunoglobulin	O
class	O
and	O
is	O
a	O
biphasic	O
hemolysin	O
that	O
is	O
demonstrated	O
by	O
incubation	O
in	O
the	O
cold	O
followed	O
by	O
incubation	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
complement	O
.	O

Mice	O
were	O
subcutaneously	O
and	O
intraperitoneally	O
injected	O
with	O
recombinant	O
baculovirus	O
,	O
and	O
both	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
were	O
induced	O
in	O
the	O
vaccinated	O
groups	O
.	O

We	O
analyzed	O
this	O
cross	O
-	O
reactivity	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
Western	O
blot	O
analysis	O
using	O
specific	O
antisera	O
to	O
animal	O
CoVs	O
and	O
SARS	O
-	O
CoV	O
and	O
SARS	O
patient	O
convalescent	O
-	O
phase	O
or	O
negative	O
sera	B-COMP
.	O

TITLE	O
:	O
Antiviral	O
antibodies	B-COMP
are	O
necessary	O
to	O
prevent	O
cytotoxic	O
T	O
-	O
lymphocyte	O
escape	O
in	O
mice	O
infected	O
with	O
a	O
coronavirus	O
.	O

Herein	O
,	O
we	O
tested	O
whether	O
antiviral	O
antibody	B-COMP
-	O
mediated	O
suppression	O
of	O
virus	O
replication	O
and	O
subsequent	O
virus	O
clearance	O
were	O
necessary	O
for	O
preventing	O
CTL	O
escape	O
in	O
coronavirus	O
-	O
infected	O
mice	O
.	O

Partially	O
protective	O
anti	O
-	O
viral	O
immune	O
responses	O
may	O
result	O
in	O
persistent	O
infection	O
and	O
chronic	O
demyelinating	O
disease	O
characterized	O
by	O
myelin	B-COMP
removal	O
from	O
axons	B-COMP
of	O
the	O
CNS	O
and	O
associated	O
with	O
dense	O
macrophage	O
/	O
microglial	O
infiltration	O
.	O

Virus	B-COMP
particles	I-COMP
were	O
found	O
in	O
the	O
necrotic	O
epithelial	O
cells	B-COMP
of	O
the	O
large	O
intestine	O
.	O

Previous	O
vaccine	O
reports	O
have	O
noted	O
robust	O
neutralizing	O
antibody	B-COMP
and	O
inflammatory	O
responses	O
in	O
ferrets	O
,	O
resulting	O
in	O
enhanced	O
hepatitis	O
.	O

Using	O
multicolor	O
colocalization	O
techniques	O
,	O
we	O
previously	O
reported	O
that	O
SARS	O
(+)	O
cells	B-COMP
in	O
the	O
lung	O
of	O
fatally	O
infected	O
patients	O
expressed	O
the	O
only	O
known	O
functional	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
and	O
also	O
a	O
binding	O
receptor	O
,	O
liver	O
/	O
lymph	O
node	O
-	O
specific	O
ICAM	O
-	O
3	O
-	O
grabbing	O
non	O
-	O
integrin	O
(	O
CD209L	O
).	O

Infection	O
of	O
these	O
cells	B-COMP
may	O
contribute	O
to	O
the	O
loss	O
of	O
lung	O
repair	O
capacity	O
that	O
leads	O
to	O
respiratory	O
failure	O
as	O
clinically	O
observed	O
.	O

TITLE	O
:	O
Type	O
I	O
interferons	O
are	O
essential	O
in	O
controlling	O
neurotropic	O
coronavirus	O
infection	O
irrespective	O
of	O
functional	O
CD8	O
T	O
cells	B-COMP
.	O

These	O
data	O
demonstrate	O
a	O
critical	O
direct	O
antiviral	O
role	O
of	O
IFN	O
-	O
I	O
in	O
controlling	O
virus	O
dissemination	O
within	O
the	O
CNS	O
,	O
even	O
in	O
the	O
presence	O
of	O
potent	O
cellular	B-COMP
immune	O
responses	O
.	O

CD11c	O
(+)	O
macrophages	O
in	O
the	O
infected	O
CNS	O
exhibit	O
variable	O
properties	O
of	O
immature	O
antigen	O
-	O
presenting	O
cells	B-COMP
(	O
APCs	O
),	O
with	O
modestly	O
increased	O
CD40	O
and	O
MHC	O
expression	O
,	O
and	O
equivalent	O
potent	O
antigen	O
uptake	O
when	O
compared	O
with	O
CD11c	O
(-)	O
macrophages	O
.	O

This	O
is	O
the	O
first	O
observation	O
that	O
HRP	O
exhibits	O
different	O
effects	O
on	O
virus	O
that	O
takes	O
the	O
endosomal	O
pathway	O
and	O
virus	O
that	O
enters	O
directly	O
from	O
the	O
cell	B-COMP
surface	I-COMP
.	O

Acrosome	B-COMP
damage	O
was	O
increased	O
in	O
vaccinated	O
cockerels	O
in	O
week	O
22	O
,	O
and	O
decreased	O
in	O
weeks	O
25	O
and	O
27	O
when	O
compared	O
to	O
controls	O
,	O
which	O
correlate	O
to	O
the	O
period	O
of	O
epididymal	O
stone	O
development	O
.	O

To	O
this	O
end	O
,	O
we	O
compared	O
a	O
productive	O
,	O
noncytopathic	O
infection	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
in	O
the	O
fibroblastlike	O
cell	B-COMP
line	O
NIH	O
3T3	O
with	O
cytopathic	O
MHV	O
infections	O
.	O

It	O
seems	O
clear	O
that	O
calves	O
serve	O
as	O
multiplying	O
hosts	B-COMP
for	O
this	O
organism	O
.	O

Transfer	O
of	O
Drak2	O
(-/-)	O
memory	O
T	O
cells	B-COMP
into	O
Rag1	O
(-/-)	O
mice	O
infected	O
intracerebrally	O
with	O
MHV	O
resulted	O
in	O
accelerated	O
clearance	O
of	O
virus	O
from	O
the	O
brain	O
.	O

theses	O
results	O
suggested	O
that	O
elevation	O
of	O
peripheral	O
blood	O
fibrinogen	B-COMP
in	O
SARS	O
patients	O
may	O
play	O
an	O
important	O
role	O
in	O
development	O
and	O
progress	O
of	O
the	O
disease	O
and	O
its	O
treatment	O
.	O

CONCLUSIONS	O
:	O
theses	O
results	O
suggested	O
that	O
elevation	O
of	O
peripheral	O
blood	O
fibrinogen	B-COMP
in	O
SARS	O
patients	O
may	O
play	O
an	O
important	O
role	O
in	O
development	O
and	O
progress	O
of	O
the	O
disease	O
and	O
its	O
treatment	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
decrease	O
of	O
Na	O
,	O
K	O
-	O
ATPase	O
function	O
seen	O
during	O
lung	O
injury	O
is	O
due	O
to	O
its	O
endocytosis	O
from	O
the	O
cell	B-COMP
plasma	B-COMP
membrane	I-COMP
into	O
intracellular	B-COMP
pools	O
.	O

Cells	B-COMP
exposed	O
to	O
hypoxia	O
generate	O
reactive	O
oxygen	O
species	O
which	O
activate	O
PKC	O
zeta	O
which	O
in	O
turn	O
phosphorylates	O
the	O
Na	O
,	O
K	O
-	O
ATPase	O
at	O
the	O
Ser18	O
residue	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
alpha1	O
-	O
subunit	O
leading	O
the	O
ubiquitination	O
of	O
any	O
of	O
the	O
four	O
lysines	O
(	O
K16	O
,	O
K17	O
,	O
K19	O
,	O
K20	O
)	O
adjacent	O
to	O
the	O
Ser18	O
residue	O
.	O

Finally	O
,	O
the	O
ubiquitinated	O
Na	O
,	O
K	O
-	O
ATPase	O
undergoes	O
degradation	O
via	O
a	O
lysosome	B-COMP
/	O
proteasome	O
dependent	O
mechanism	O
.	O

In	O
addition	O
,	O
transgenic	O
mice	O
had	O
more	O
severe	O
pulmonary	O
lesions	O
,	O
including	O
interstitial	O
hyperemia	O
and	O
hemorrhage	O
,	O
monocytic	O
and	O
lymphocytic	O
infiltration	O
,	O
protein	O
exudation	O
,	O
and	O
alveolar	O
epithelial	O
cell	B-COMP
proliferation	O
and	O
desquamation	O
.	O

Dot	O
blot	O
analysis	O
showed	O
that	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
which	O
was	O
expressed	O
and	O
purified	O
from	O
mammal	O
cells	B-COMP
,	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	B-COMP
from	O
rabbit	O
.	O

The	O
predicted	O
epitopes	O
of	O
Z	O
protein	O
can	O
induce	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
antibody	B-COMP
in	O
rabbits	O
,	O
which	O
provides	O
a	O
new	O
protein	O
for	O
developing	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Z	O
gene	O
was	O
successfully	O
designed	O
and	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
).	O

ELISA	O
analysis	O
indicated	O
the	O
SARS	O
-	O
CoV	O
antigen	O
prepared	O
from	O
SARS	O
-	O
CoV	O
lysates	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	B-COMP
.	O

CONCLUSIONS	O
:	O
The	O
predicted	O
epitopes	O
of	O
Z	O
protein	O
can	O
induce	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
antibody	B-COMP
in	O
rabbits	O
,	O
which	O
provides	O
a	O
new	O
protein	O
for	O
developing	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
pharmacokinetics	O
,	O
tolerance	O
and	O
immunity	O
of	O
this	O
kind	O
of	O
antibody	B-COMP
in	O
macaques	O
and	O
rats	O
.	O

However	O
,	O
a	O
mild	O
inflammatory	O
response	O
in	O
local	O
injection	O
site	O
and	O
a	O
moderate	O
immune	O
response	O
against	O
this	O
antibody	B-COMP
in	O
the	O
successively	O
injected	O
animals	O
were	O
observed	O
,	O
which	O
however	O
recovered	O
3	O
weeks	O
after	O
the	O
last	O
injection	O
.	O

ABSTRACT	O
:	O
The	O
MHV	O
-	O
JHM	O
strain	O
of	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
is	O
much	O
more	O
neurovirulent	O
than	O
the	O
MHV	O
-	O
A59	O
strain	O
,	O
although	O
both	O
strains	O
use	O
murine	O
CEACAM1a	O
(	O
mCEACAM1a	O
)	O
as	O
the	O
receptor	O
to	O
infect	O
murine	O
cells	B-COMP
.	O

While	O
CXCL9	O
,	O
CXCL10	O
and	O
CXCL11	O
share	O
the	O
same	O
receptor	O
and	O
have	O
overlapping	O
functions	O
,	O
each	O
can	O
also	O
have	O
unique	O
activity	O
in	O
host	B-COMP
defense	O
.	O

The	O
geometric	O
mean	O
titre	O
of	O
neutralizing	O
antibody	B-COMP
peaked	O
2	O
weeks	O
after	O
the	O
second	O
vaccination	O
,	O
but	O
decreased	O
4	O
weeks	O
later	O
.	O

The	O
inactivated	O
vaccine	O
was	O
safe	O
and	O
well	O
tolerated	O
and	O
can	O
elicit	O
SARS	O
-	O
CoV	O
-	O
specific	O
neutralizing	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Interaction	O
of	O
a	O
peptide	O
from	O
the	O
pre	O
-	O
transmembrane	B-COMP
domain	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
with	O
phospholipid	O
membranes	O
.	O

In	O
order	O
to	O
gain	O
new	O
insight	O
into	O
the	O
protein	O
membrane	B-COMP
alteration	O
leading	O
to	O
the	O
viral	O
fusion	O
mechanism	O
,	O
a	O
peptide	O
pertaining	O
to	O
the	O
putative	O
pre	O
-	O
transmembrane	B-COMP
domain	O
(	O
PTM	O
)	O
of	O
the	O
S	O
glycoprotein	O
has	O
been	O
studied	O
by	O
infrared	O
and	O
fluorescence	O
spectroscopies	O
regarding	O
its	O
structure	O
,	O
its	O
ability	O
to	O
induce	O
membrane	B-COMP
leakage	O
,	O
aggregation	O
,	O
and	O
fusion	O
,	O
as	O
well	O
as	O
its	O
affinity	O
toward	O
specific	O
phospholipids	O
.	O

All	O
four	O
pseudoknots	O
cause	O
-	O
1	O
programmed	O
ribosomal	B-COMP
frameshifting	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
replicates	O
in	O
primary	O
human	O
alveolar	O
type	O
II	O
cell	B-COMP
cultures	O
but	O
not	O
in	O
type	O
I	O
-	O
like	O
cells	B-COMP
.	O

Type	O
II	O
cell	B-COMP
cultures	O
supported	O
SARS	O
-	O
CoV	O
replication	O
as	O
evidenced	O
by	O
RT	O
-	O
PCR	O
detection	O
of	O
viral	O
subgenomic	O
RNA	O
and	O
an	O
increase	O
in	O
virus	O
titer	O
.	O

Virus	O
titers	O
were	O
maximal	O
by	O
24	O
h	O
and	O
peaked	O
at	O
approximately	O
10	O
(	O
5	O
)	O
pfu	O
/	O
mL	O
.	O
Two	O
cell	B-COMP
types	O
within	O
the	O
cultures	O
were	O
infected	O
.	O

Viral	O
replication	O
was	O
not	O
detected	O
in	O
type	O
I	O
-	O
like	O
cells	B-COMP
or	O
macrophages	O
.	O

Nuclear	B-COMP
inclusion	I-COMP
protein	O
a	O
(	O
NIa	O
)	O
proteases	O
obtained	O
from	O
the	O
family	O
Potyviridae	O
have	O
become	O
promising	O
due	O
to	O
their	O
high	O
activities	O
and	O
stringencies	O
of	O
sequences	O
recognition	O
.	O

The	O
patient	O
'	O
s	O
serum	B-COMP
creatinine	O
level	O
was	O
301	O
micromol	O
/	O
l	O
and	O
her	O
liver	O
function	O
tests	O
were	O
normal	O
.	O

A	O
mildly	O
elevated	O
white	O
cell	B-COMP
count	O
was	O
present	O
.	O

The	O
results	O
showed	O
that	O
astragalus	O
polysaccharide	O
and	O
isatis	O
root	O
polysaccharide	O
at	O
low	O
dosages	O
,	O
and	O
achyranthes	O
root	O
polysaccharide	O
and	O
Chinese	O
yam	O
polysaccharide	O
at	O
high	O
dosages	O
significantly	O
enhanced	O
the	O
ND	O
antibody	B-COMP
titers	O
,	O
concanavalin	O
A	O
-	O
induced	O
proliferation	O
of	O
peripheral	O
blood	O
lymphocytes	O
,	O
and	O
ratio	O
of	O
CD4	O
(+)	O
to	O
CD8	O
(+)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
to	O
an	O
altered	O
host	B-COMP
range	O
,	O
V51	O
displayed	O
altered	O
utilization	O
of	O
CEACAM1a	O
,	O
the	O
high	O
-	O
affinity	O
receptor	O
for	O
A59	O
.	O

Mounting	O
evidence	O
also	O
suggests	O
that	O
the	O
class	O
I	O
fusion	O
mechanism	O
may	O
possess	O
some	O
innate	O
plasticity	O
that	O
regulates	O
viral	O
host	B-COMP
range	O
.	O

Cimicifuga	O
rhizoma	O
,	O
Meliae	O
cortex	O
,	O
Coptidis	O
rhizoma	O
,	O
Phellodendron	O
cortex	O
and	O
Sophora	O
subprostrata	O
radix	O
decreased	O
the	O
MHV	O
production	O
and	O
the	O
intracellular	B-COMP
viral	O
RNA	O
and	O
protein	O
expression	O
with	O
EC50	O
values	O
ranging	O
from	O
2	O
.	O
0	O
to	O
27	O
.	O
5	O
microg	O
/	O
ml	O
.	O

After	O
intravenous	O
inoculation	O
,	O
infectious	O
virus	O
was	O
isolated	O
from	O
rectal	O
swabs	O
,	O
and	O
virus	O
antigen	O
was	O
detected	O
in	O
intestinal	O
cells	B-COMP
on	O
day	O
14	O
p	O
.	O
i	O
.	O

In	O
2001	O
,	O
the	O
Structural	O
Proteomics	O
In	O
Europe	O
(	O
SPINE	B-COMP
)	O
project	O
prototyped	O
the	O
pan	B-COMP
-	O
viral	O
structural	O
genomic	O
approach	O
,	O
and	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
outbreak	O
in	O
2003	O
accelerated	O
the	O
concept	O
of	O
structural	O
characterization	O
of	O
all	O
proteins	O
from	O
a	O
viral	O
proteome	O
and	O
the	O
interaction	O
with	O
their	O
host	B-COMP
partners	O
.	O

RESULTS	O
:	O
Key	O
recommendations	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
prior	O
to	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
potential	O
source	O
of	O
infection	O
(	O
1C	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	O
therapy	O
within	O
1	O
hr	O
of	O
diagnosis	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1D	O
);	O
reassessment	O
of	O
antibiotic	O
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
(	O
1C	O
);	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	O
therapy	O
guided	O
by	O
clinical	O
response	O
(	O
1D	O
);	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
(	O
1C	O
);	O
administration	O
of	O
either	O
crystalloid	B-COMP
or	O
colloid	O
fluid	O
resuscitation	O
(	O
1B	O
);	O
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
(	O
1C	O
);	O
reduction	O
in	O
rate	O
of	O
fluid	O
administration	O
with	O
rising	O
filing	O
pressures	O
and	O
no	O
improvement	O
in	O
tissue	O
perfusion	O
(	O
1D	O
);	O
vasopressor	O
preference	O
for	O
norepinephrine	O
or	O
dopamine	O
to	O
maintain	O
an	O
initial	O
target	O
of	O
mean	O
arterial	O
pressure	O
>	O
or	O
=	O
65	O
mm	O
Hg	O
(	O
1C	O
);	O
dobutamine	O
inotropic	O
therapy	O
when	O
cardiac	O
output	O
remains	O
low	O
despite	O
fluid	O
resuscitation	O
and	O
combined	O
inotropic	O
/	O
vasopressor	O
therapy	O
(	O
1C	O
);	O
stress	O
-	O
dose	O
steroid	O
therapy	O
given	O
only	O
in	O
septic	O
shock	O
after	O
blood	O
pressure	O
is	O
identified	O
to	O
be	O
poorly	O
responsive	O
to	O
fluid	O
and	O
vasopressor	O
therapy	O
(	O
2C	O
);	O
recombinant	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
clinical	O
assessment	O
of	O
high	O
risk	O
for	O
death	O
(	O
2B	O
except	O
2C	O
for	O
post	O
-	O
operative	O
patients	O
).	O

It	O
was	O
suggested	O
that	O
AHFC	O
can	O
balance	O
the	O
immune	O
state	O
of	O
mouse	O
model	O
of	O
acute	O
hepatic	O
failure	O
infected	O
with	O
MHV	O
-	O
3	O
virus	O
mainly	O
through	O
regulating	O
the	O
expression	O
of	O
immune	O
related	O
genes	O
,	O
decrease	O
the	O
immune	O
damage	O
and	O
inhibit	O
liver	O
cell	B-COMP
apoptosis	O
of	O
mouse	O
acute	O
hepatic	O
failure	O
model	O
obviously	O
so	O
as	O
to	O
increase	O
the	O
survival	O
rate	O
of	O
mouse	O
models	O
of	O
acute	O
hepatic	O
failure	O
.	O

This	O
method	O
,	O
which	O
has	O
been	O
successfully	O
applied	O
to	O
isolate	O
broadly	O
neutralizing	O
antibodies	B-COMP
against	O
SARS	O
and	O
H5N1	O
influenza	O
viruses	O
,	O
is	O
expected	O
to	O
accelerate	O
the	O
development	O
of	O
therapeutics	O
in	O
the	O
field	O
of	O
infectious	O
diseases	O
not	O
only	O
by	O
providing	O
neutralizing	O
antibodies	B-COMP
for	O
passive	O
serotherapy	O
,	O
but	O
also	O
by	O
generating	O
relevant	O
information	O
for	O
vaccine	O
design	O
.	O

Although	O
IMS	O
is	O
well	O
recognized	O
as	O
a	O
disorder	O
of	O
neuromuscular	B-COMP
junctions	I-COMP
,	O
its	O
exact	O
etiology	O
,	O
incidence	O
,	O
and	O
risk	O
factors	O
are	O
not	O
clearly	O
defined	O
because	O
existing	O
studies	O
are	O
largely	O
small	O
-	O
scale	O
case	O
series	O
and	O
do	O
not	O
employ	O
a	O
consistent	O
and	O
rigorous	O
definition	O
of	O
IMS	O
.	O

The	O
frequency	O
of	O
the	O
anti	O
-	O
HLA	O
antibodies	B-COMP
,	O
but	O
not	O
that	O
of	O
the	O
non	O
-	O
HLA	O
antibodies	B-COMP
,	O
was	O
significantly	O
higher	O
in	O
females	O
.	O

carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
spike	O
protein	O
(	O
S	O
-	O
CT24	O
)	O
elicited	O
a	O
strong	O
antibody	B-COMP
response	O
in	O
BALB	O
/	O
c	O
mice	O
that	O
had	O
specific	O
reactivity	O
against	O
the	O
S	O
-	O
CT24	O
and	O
PEDV	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
receptor	O
usage	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
by	O
combining	O
a	O
human	O
immunodeficiency	O
virus	O
-	O
based	O
pseudovirus	O
system	O
with	O
cell	B-COMP
lines	O
expressing	O
the	O
ACE2	O
molecules	O
of	O
human	O
,	O
civet	O
,	O
or	O
horseshoe	O
bat	O
.	O

Prevention	O
includes	O
epidemiological	O
control	O
of	O
donor	O
populations	O
;	O
checks	O
on	O
each	O
donor	O
'	O
s	O
health	O
condition	O
;	O
analysis	O
of	O
each	O
donation	O
for	O
the	O
main	O
pathogens	O
using	O
serological	O
methods	O
;	O
additional	O
analysis	O
of	O
all	O
plasma	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
and	O
the	O
B19	O
virus	O
,	O
using	O
nucleic	B-COMP
acid	O
amplification	O
techniques	O
(	O
NAT	O
).	O

IFN	O
-	O
gammaR1	O
(-/-)	O
CD8	O
T	O
cells	B-COMP
retain	O
virus	O
-	O
specific	O
effector	O
function	O
regardless	O
of	O
IFN	O
-	O
gammaR1	O
expression	O
.	O

Faecal	O
samples	O
were	O
collected	O
from	O
200	O
healthy	O
dogs	O
and	O
examined	O
by	O
electron	O
microscopy	O
for	O
presence	O
of	O
viral	B-COMP
particles	I-COMP
.	O

Deletion	O
of	O
a	O
dilysine	O
motif	O
that	O
has	O
previously	O
been	O
suggested	O
to	O
function	O
as	O
a	O
retrieval	O
signal	O
did	O
not	O
abolish	O
intracellular	B-COMP
retention	O
.	O

Both	O
wild	O
-	O
type	O
donor	O
CD90	O
.	O
1	O
and	O
recipient	O
CD90	O
.	O
2	O
CD4	O
(+)	O
T	O
cells	B-COMP
trafficked	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
parenchyma	O
and	O
localized	O
to	O
infected	O
white	O
matter	O
,	O
correlating	O
with	O
decreased	O
numbers	O
of	O
virus	O
-	O
infected	O
oligodendrocytes	O
in	O
the	O
CNS	O
.	O

After	O
introducing	O
a	O
K479N	O
mutation	O
within	O
the	O
S	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SZ16	O
,	O
the	O
recombinant	O
virus	O
(	O
icSZ16	O
-	O
S	O
K479N	O
)	O
replicated	O
in	O
Vero	O
cells	B-COMP
but	O
was	O
severely	O
debilitated	O
in	O
growth	O
.	O

It	O
was	O
thought	O
that	O
neutrophil	O
immune	O
-	O
phagocytosis	O
would	O
be	O
inhibited	O
by	O
antibodies	B-COMP
binding	O
with	O
FcgammaRIII	O
,	O
and	O
that	O
HNA	O
-	O
2a	O
was	O
not	O
related	O
to	O
immune	O
phagocytosis	O
.	O

3	O
days	O
after	O
removal	O
of	O
the	O
interventional	O
lung	O
-	O
assist	O
membrane	B-COMP
ventilator	O
,	O
and	O
all	O
of	O
them	O
were	O
discharged	O
from	O
the	O
hospital	O
.	O

In	O
Caco	O
-	O
2	O
and	O
N2a	O
cells	B-COMP
,	O
almost	O
no	O
N	O
-	O
processing	O
was	O
detectable	O
.	O

Increased	O
mortality	O
in	O
CCR1	O
-/-	O
mice	O
was	O
not	O
associated	O
with	O
increased	O
viral	O
recovery	O
from	O
the	O
CNS	O
,	O
although	O
CCR1	O
deficiency	O
correlated	O
with	O
reduced	O
T	O
-	O
cell	B-COMP
accumulation	O
within	O
the	O
CNS	O
during	O
acute	O
,	O
but	O
not	O
chronic	O
,	O
disease	O
.	O

ABSTRACT	O
:	O
Gemcitabine	O
is	O
a	O
new	O
important	O
drug	O
used	O
to	O
treat	O
solid	O
tumors	O
including	O
non	O
-	O
small	O
cell	B-COMP
lung	O
cancer	O
,	O
pancreatic	O
,	O
bladder	O
and	O
breast	O
cancers	O
.	O

Severe	O
pneumonitis	O
and	O
potentially	O
fatal	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
have	O
been	O
described	O
in	O
patients	O
treated	O
for	O
a	O
non	O
-	O
small	O
cell	B-COMP
lung	O
cancer	O
.	O

Differences	O
in	O
growth	O
rate	O
and	O
CPE	O
between	O
the	O
KT2	O
-	O
L	O
and	O
KT2	O
-	O
H	O
strains	O
were	O
discovered	O
in	O
swine	O
testicular	O
cells	B-COMP
(	O
STCs	O
).	O

ABSTRACT	O
:	O
Steady	O
-	O
state	O
mild	O
pulmonary	O
hypertension	O
is	O
a	O
risk	O
factor	O
for	O
death	O
in	O
adults	O
with	O
sickle	O
cell	B-COMP
disease	O
.	O

A	O
comparison	O
of	O
intracellular	B-COMP
and	O
extracellular	B-COMP
virus	O
yields	O
suggested	O
that	O
release	O
is	O
only	O
slightly	O
impaired	O
.	O

Coexpression	O
of	O
SCoV	O
S	O
protein	O
and	O
E	O
,	O
M	O
and	O
N	O
proteins	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
293T	O
or	O
CHO	O
cells	B-COMP
resulted	O
in	O
the	O
efficient	O
production	O
of	O
chimeric	O
VLPs	O
carrying	O
SCoV	O
S	O
protein	O
.	O

Based	O
on	O
these	O
findings	O
,	O
one	O
-	O
step	O
competition	O
ELISAs	O
were	O
established	O
which	O
were	O
able	O
to	O
detect	O
SARS	O
-	O
CoV	O
antibodies	B-COMP
from	O
human	O
and	O
at	O
least	O
seven	O
different	O
animal	O
species	O
.	O

TITLE	O
:	O
A	O
line	O
immunoassay	O
utilizing	O
recombinant	O
nucleocapsid	B-COMP
proteins	O
for	O
detection	O
of	O
antibodies	B-COMP
to	O
human	O
coronaviruses	O
.	O

Screening	O
for	O
nucleocapsid	B-COMP
(	O
N	O
)-	O
specific	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
in	O
convalescent	O
sera	B-COMP
reached	O
100	O
%	O
sensitivity	O
.	O

Possibly	O
,	O
cross	O
-	O
reactive	O
antibody	B-COMP
responses	O
were	O
observed	O
using	O
229E	O
and	O
OC43	O
serum	B-COMP
pairs	O
.	O

Elevation	O
of	O
serum	B-COMP
tumor	O
necrosis	O
factor	O
-	O
alpha	O
was	O
observed	O
before	O
treatment	O
with	O
antibiotics	O
and	O
glucocorticoids	O
,	O
but	O
the	O
elevation	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
1	O
)	O
was	O
delayed	O
for	O
2	O
to	O
4	O
weeks	O
after	O
the	O
accident	O
.	O

Ultimately	O
mRNAs	O
reached	O
similar	O
levels	O
in	O
both	O
cell	B-COMP
types	O
at	O
their	O
respective	O
time	O
points	O
of	O
maximal	O
Class	O
I	O
expression	O
.	O

TITLE	O
:	O
Application	O
of	O
ProteinChip	O
array	O
profiling	O
in	O
serum	B-COMP
biomarker	O
discovery	O
for	O
patients	O
suffering	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

By	O
protein	O
chip	O
array	O
profiling	O
technology	O
,	O
a	O
number	O
of	O
serum	B-COMP
biomarkers	O
that	O
might	O
be	O
useful	O
in	O
monitoring	O
the	O
clinical	O
course	O
of	O
SARS	O
patients	O
were	O
identified	O
.	O

Briefly	O
,	O
SARS	O
patients	O
'	O
serum	B-COMP
samples	O
were	O
first	O
fractionated	O
in	O
Q	O
Ceramic	O
HyperD	O
ion	O
exchange	O
sorbent	O
beads	O
by	O
buffers	O
at	O
different	O
pH	O
.	O
Serum	B-COMP
protein	O
fractions	O
thus	O
obtained	O
were	O
then	O
bound	O
onto	O
a	O
copper	O
(	O
II	O
)	O
immobilized	O
metal	O
affinity	O
capture	O
(	O
IMAC30	O
Cu	O
[	O
II	O
])	O
ProteinChip	O
Array	O
or	O
a	O
weak	O
cation	O
-	O
exchange	O
(	O
CM10	O
)	O
ProteinChip	O
Array	O
.	O

ABSTRACT	O
:	O
While	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
initially	O
thought	O
to	O
enter	O
cells	B-COMP
through	O
direct	O
fusion	O
with	O
the	O
plasma	B-COMP
membrane	I-COMP
,	O
more	O
recent	O
evidence	O
suggests	O
that	O
virus	O
entry	O
may	O
also	O
involve	O
endocytosis	O
.	O

In	O
addition	O
,	O
the	O
spike	O
-	O
bearing	O
pseudoviruses	O
and	O
early	B-COMP
endosome	I-COMP
antigen	O
1	O
were	O
found	O
to	O
colocalize	O
in	O
endosomes	O
.	O

Moreover	O
,	O
cholesterol	O
-	O
and	O
sphingolipid	O
-	O
rich	O
lipid	B-COMP
raft	I-COMP
microdomains	O
in	O
the	O
plasma	B-COMP
membrane	I-COMP
,	O
which	O
have	O
been	O
shown	O
to	O
act	O
as	O
platforms	O
for	O
many	O
physiological	O
signaling	O
pathways	O
,	O
were	O
shown	O
to	O
be	O
involved	O
in	O
virus	O
entry	O
.	O

Others	O
were	O
6	O
cases	O
of	O
acute	O
membrane	B-COMP
laryngotracheobronchitis	O
,	O
3	O
cases	O
of	O
congenital	O
main	O
respiratory	O
tract	O
stenosis	O
,	O
2	O
cases	O
of	O
congenital	O
laryngeal	O
webs	O
,	O
2	O
cases	O
of	O
vocal	O
cord	O
paralysis	O
,	O
3	O
cases	O
of	O
Pierre	O
Robin	O
syndrome	O
,	O
2	O
cases	O
of	O
Cri	O
-	O
du	O
-	O
chat	O
syndrome	O
.	O

ABSTRACT	O
:	O
In	O
response	O
to	O
viral	O
infection	O
,	O
the	O
expression	O
of	O
numerous	O
host	B-COMP
genes	O
,	O
including	O
predominantly	O
a	O
number	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
is	O
usually	O
up	O
-	O
regulated	O
at	O
both	O
transcriptional	O
and	O
translational	O
levels	O
.	O

Interestingly	O
,	O
IBV	O
-	O
infected	O
cells	B-COMP
stably	O
expressing	O
a	O
Flag	O
-	O
tagged	O
eIF3f	O
showed	O
much	O
higher	O
translation	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
coronavirus	O
S	O
protein	O
and	O
eIF3f	O
plays	O
a	O
functional	O
role	O
in	O
controlling	O
the	O
expression	O
of	O
host	B-COMP
genes	O
,	O
especially	O
genes	O
that	O
are	O
induced	O
during	O
coronavirus	O
infection	O
cycles	O
.	O

Therefore	O
,	O
it	O
is	O
time	O
to	O
explore	O
broad	O
spectrum	O
agents	O
that	O
can	O
target	O
either	O
the	O
lipid	O
portion	O
of	O
the	O
envelope	B-COMP
or	O
the	O
sugar	O
moieties	O
of	O
the	O
glycoproteins	O
or	O
the	O
rafts	O
(	O
regions	O
within	O
viral	O
and	O
cell	B-COMP
envelopes	O
where	O
a	O
higher	O
concentration	O
of	O
the	O
glycoproteins	O
exist	O
).	O

Combination	O
vaccinations	O
using	O
B1	O
and	O
VG	O
/	O
GA	O
did	O
not	O
interfere	O
with	O
IBV	O
immunity	O
based	O
on	O
challenge	O
or	O
serum	B-COMP
antibody	B-COMP
production	O
.	O

ABSTRACT	O
:	O
The	O
host	B-COMP
cellular	B-COMP
environment	O
is	O
a	O
key	O
determinant	O
of	O
pathogen	O
infectivity	O
.	O

We	O
postulated	O
that	O
additional	O
factors	O
should	O
regulate	O
transcription	O
of	O
sg	O
mRNA	O
N	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
described	O
a	O
novel	O
transcription	O
regulation	O
mechanism	O
operating	O
in	O
CoV	O
by	O
which	O
a	O
9	O
-	O
nucleotide	O
(	O
nt	O
)	O
sequence	O
located	O
449	O
nt	O
upstream	O
of	O
the	O
N	O
gene	O
TRS	O
core	O
sequence	O
(	O
CS	O
-	O
N	O
)	O
interacts	O
with	O
a	O
complementary	O
sequence	O
just	O
upstream	O
of	O
CS	O
-	O
N	O
,	O
specifically	O
increasing	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
Alteration	O
of	O
this	O
complementarity	O
in	O
mutant	O
replicon	O
genomes	O
showed	O
a	O
correlation	O
between	O
the	O
predicted	O
stability	O
of	O
the	O
base	O
pairing	O
between	O
9	O
-	O
nt	O
sequences	O
and	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
This	O
interaction	O
is	O
exclusively	O
conserved	O
in	O
group	O
1a	O
CoVs	O
,	O
the	O
only	O
CoV	O
subgroup	O
in	O
which	O
the	O
N	O
gene	O
is	O
not	O
the	O
most	O
3	O
'	O
gene	O
in	O
the	O
viral	B-COMP
genome	I-COMP
.	O

Since	O
T	O
cell	B-COMP
epitopes	O
are	O
highly	O
conserved	O
and	O
boosting	O
with	O
peptides	O
may	O
induce	O
the	O
production	O
of	O
effector	O
memory	O
T	O
cells	B-COMP
,	O
which	O
may	O
be	O
effective	O
against	O
viruses	O
with	O
mutations	O
in	O
the	O
neutralizing	O
epitopes	O
,	O
our	O
results	O
suggest	O
that	O
the	O
vaccination	O
protocol	O
used	O
may	O
be	O
ideal	O
for	O
providing	O
effective	O
,	O
broad	O
and	O
long	O
-	O
term	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
replicase	O
complex	O
assembles	O
on	O
double	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
).	O

To	O
determine	O
if	O
chemokine	O
expression	O
corresponds	O
with	O
the	O
cellular	B-COMP
infiltrate	O
,	O
chemokine	O
protein	O
and	O
RNA	O
levels	O
from	O
the	O
brains	O
of	O
infected	O
mice	O
were	O
quantified	O
.	O

These	O
data	O
revealed	O
that	O
nsp1	O
indeed	O
promoted	O
host	B-COMP
mRNA	O
degradation	O
and	O
contributed	O
to	O
host	B-COMP
protein	O
translation	O
inhibition	O
in	O
infected	O
cells	B-COMP
.	O

With	O
regard	O
to	O
Ang	O
(	O
1	O
-	O
7	O
),	O
the	O
identification	O
of	O
ACE2	O
and	O
of	O
Mas	B-COMP
as	O
a	O
receptor	O
implicated	O
in	O
its	O
actions	O
contributed	O
to	O
decisively	O
establish	O
this	O
heptapeptide	O
as	O
a	O
biologically	O
active	O
member	O
of	O
the	O
RAS	O
cascade	O
.	O

ABSTRACT	O
:	O
Molecular	O
mimicry	O
,	O
defined	O
as	O
similar	O
structures	O
shared	O
by	O
molecules	O
from	O
dissimilar	O
genes	O
or	O
proteins	O
,	O
is	O
a	O
general	O
strategy	O
used	O
by	O
pathogens	O
to	O
infect	O
host	B-COMP
cells	B-COMP
.	O

Its	O
leading	O
methods	O
are	O
infusion	O
therapy	O
with	O
colloid	O
-	O
crystalloid	B-COMP
solutions	O
and	O
anticoagulant	O
therapy	O
.	O

The	O
nucleic	B-COMP
acid	O
of	O
IBV	O
was	O
detected	O
in	O
105	O
out	O
174	O
(	O
60	O
%)	O
broiler	O
flocks	O
by	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Although	O
multiple	O
viruses	O
utilize	O
host	B-COMP
cell	I-COMP
cyclophilins	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
),	O
their	O
role	O
in	O
infection	O
is	O
poorly	O
understood	O
.	O

TITLE	O
:	O
Analysis	O
of	O
the	O
mechanism	O
of	O
antibody	B-COMP
-	O
dependent	O
enhancement	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
infection	O
:	O
aminopeptidase	O
N	O
is	O
not	O
important	O
and	O
a	O
process	O
of	O
acidification	O
of	O
the	O
endosome	B-COMP
is	O
necessary	O
.	O

Thus	O
,	O
these	O
two	O
amino	O
acid	O
substitutions	O
might	O
lead	O
to	O
a	O
conformational	O
change	O
in	O
the	O
S	O
protein	O
,	O
resulting	O
in	O
reduced	O
incorporation	O
into	O
viral	B-COMP
particles	I-COMP
.	O

In	O
order	O
to	O
investigate	O
the	O
potential	O
SARS	O
-	O
CoV	O
kidney	O
tropism	O
,	O
we	O
have	O
evaluated	O
the	O
susceptibility	O
of	O
human	O
renal	O
cells	B-COMP
of	O
tubular	O
and	O
glomerular	O
origin	O
to	O
in	O
vitro	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
contrast	O
to	O
the	O
cytopathic	O
infection	O
of	O
the	O
Vero	O
E6	O
cell	B-COMP
line	O
,	O
SARS	O
-	O
CoV	O
did	O
not	O
cause	O
overt	O
cytopathic	O
effects	O
in	O
PTEC	O
or	O
MC	O
.	O

Every	O
infectious	O
agent	O
spreads	O
easier	O
when	O
its	O
hosts	B-COMP
are	O
closer	O
together	O
.	O

TITLE	O
:	O
Characterization	O
and	O
epitope	O
mapping	O
of	O
monoclonal	O
antibodies	B-COMP
to	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

To	O
determine	O
the	O
region	O
on	O
the	O
NP	O
molecule	O
where	O
the	O
monoclonal	O
antibodies	B-COMP
bind	O
,	O
we	O
generated	O
four	O
truncated	O
recombinant	O
NPs	O
and	O
analyzed	O
the	O
reactivity	O
between	O
monoclonal	O
antibodies	B-COMP
and	O
truncated	O
NPs	O
.	O

The	O
information	O
about	O
binding	O
sites	O
and	O
epitopes	O
of	O
monoclonal	O
antibodies	B-COMP
may	O
be	O
useful	O
for	O
the	O
development	O
of	O
new	O
diagnostic	O
methods	O
for	O
SARS	O
and	O
for	O
analyzing	O
the	O
function	O
of	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Demyelinating	O
and	O
nondemyelinating	O
strains	O
of	O
mouse	O
hepatitis	O
virus	O
differ	O
in	O
their	O
neural	O
cell	B-COMP
tropism	O
.	O

We	O
have	O
examined	O
neural	O
cell	B-COMP
tropism	O
of	O
demyelinating	O
and	O
nondemyelinating	O
strains	O
of	O
MHV	O
in	O
order	O
to	O
determine	O
whether	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
cell	B-COMP
tropism	O
plays	O
a	O
role	O
in	O
demyelination	O
.	O

Overall	O
,	O
these	O
observations	O
suggest	O
that	O
isogenic	O
demyelinating	O
and	O
nondemyelinating	O
strains	O
of	O
MHV	O
,	O
differing	O
in	O
the	O
spike	O
protein	O
expressed	O
,	O
infect	O
neurons	O
and	O
glial	O
cells	B-COMP
in	O
different	O
proportions	O
and	O
that	O
differential	O
tropism	O
to	O
a	O
particular	O
CNS	O
cell	B-COMP
type	I-COMP
may	O
play	O
a	O
significant	O
role	O
in	O
mediating	O
the	O
onset	O
and	O
mechanisms	O
of	O
demyelination	O
.	O

Further	O
assays	O
demonstrated	O
that	O
expression	O
of	O
hfgl2	O
gene	O
was	O
related	O
with	O
N	O
protein	O
,	O
but	O
not	O
with	O
M	O
or	O
S2	O
protein	O
in	O
THP	O
-	O
1	O
cells	B-COMP
and	O
Vero	O
cells	B-COMP
.	O

We	O
found	O
that	O
the	O
vaccine	O
given	O
intramuscularly	O
induced	O
a	O
neutralizing	O
antibody	B-COMP
response	O
to	O
SARS	O
-	O
CoV	O
that	O
was	O
approximately	O
ten	O
-	O
fold	O
greater	O
than	O
that	O
required	O
for	O
the	O
protection	O
from	O
SARS	O
-	O
CoV	O
infection	O
,	O
and	O
significantly	O
greater	O
than	O
that	O
generated	O
by	O
the	O
replication	O
-	O
competent	O
vector	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	O
given	O
by	O
the	O
same	O
route	O
.	O

Our	O
results	O
,	O
along	O
with	O
earlier	O
studies	O
showing	O
potent	O
induction	O
of	O
T	O
-	O
cell	B-COMP
responses	O
by	O
single	O
-	O
cycle	O
vectors	O
,	O
indicate	O
that	O
these	O
vectors	O
are	O
excellent	O
alternatives	O
to	O
live	O
-	O
attenuated	O
VSV	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
CoV	O
M	O
gene	O
fragment	O
was	O
cloned	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
fused	O
with	O
a	O
V5	O
tag	O
at	O
the	O
C	O
-	O
terminus	O
in	O
Vero	O
E6	O
cells	B-COMP
.	O

The	O
SARS	O
-	O
CoV	O
M	O
protein	O
is	O
predicted	O
as	O
a	O
triple	O
-	O
spanning	O
membrane	B-COMP
protein	O
lack	O
of	O
a	O
conventional	O
signal	O
peptide	O
.	O

14	O
-	O
36	O
)	O
is	O
predicted	O
to	O
be	O
the	O
secondary	O
type	O
helix	O
,	O
which	O
is	O
considered	O
to	O
be	O
stabilized	O
by	O
the	O
interaction	O
with	O
other	O
trans	O
-	O
membrane	B-COMP
segments	O
.	O

TITLE	O
:	O
Priming	O
of	O
CD8	O
+	O
T	O
cells	B-COMP
during	O
central	O
nervous	O
system	O
infection	O
with	O
a	O
murine	O
coronavirus	O
is	O
strain	O
dependent	O
.	O

While	O
all	O
three	O
viruses	O
replicated	O
efficiently	O
in	O
the	O
brain	O
,	O
only	O
RA59	O
and	O
SJHM	O
/	O
RA59	O
replicated	O
to	O
appreciable	O
levels	O
in	O
the	O
cervical	O
lymph	O
nodes	O
(	O
CLN	O
),	O
the	O
site	O
of	O
T	O
-	O
cell	B-COMP
priming	O
during	O
acute	O
CNS	O
infection	O
.	O

Notably	O
,	O
the	O
weak	O
CD8	O
(+)	O
T	O
-	O
cell	B-COMP
response	O
elicited	O
by	O
RJHM	O
was	O
unique	O
to	O
CNS	O
infection	O
,	O
since	O
peripheral	O
inoculation	O
induced	O
a	O
robust	O
CD8	O
(+)	O
T	O
-	O
cell	B-COMP
response	O
in	O
the	O
spleen	O
.	O

A	O
myeloid	O
-	O
histiocytic	O
marker	O
,	O
MAC	B-COMP
387	O
,	O
was	O
also	O
used	O
to	O
identify	O
FIP	O
virus	O
-	O
infected	O
cells	B-COMP
.	O

Over	O
the	O
past	O
few	O
years	O
,	O
research	O
work	O
has	O
looked	O
into	O
factors	O
that	O
may	O
lead	O
to	O
super	O
-	O
spreading	O
events	O
,	O
clinical	O
/	O
laboratory	O
parameters	O
that	O
may	O
differentiate	O
severe	O
acute	O
respiratory	O
syndrome	O
from	O
other	O
causes	O
of	O
community	O
-	O
acquired	O
pneumonia	O
,	O
the	O
origin	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
reservoir	O
host	B-COMP
distribution	O
and	O
transmission	O
routes	O
.	O

Microscopic	O
examination	O
revealed	O
diffuse	O
alveolar	O
damage	O
with	O
hyaline	O
membrane	B-COMP
formation	O
and	O
interstitial	O
pneumonitis	O
with	O
infiltration	O
of	O
inflammatory	O
cells	B-COMP
.	O

Nuclei	O
of	O
the	O
medulla	O
,	O
including	O
the	O
vagus	O
/	O
solitarius	O
complex	O
and	O
the	O
region	O
of	O
the	O
nucleus	B-COMP
ambiguous	O
were	O
especially	O
rich	O
in	O
tau	O
positive	O
inclusions	O
.	O

Results	O
showed	O
that	O
N1	O
and	O
N3	O
fragments	O
of	O
N	O
protein	O
expressed	O
by	O
E	O
.	O
coli	O
were	O
able	O
to	O
react	O
with	O
sera	B-COMP
of	O
SARS	O
patients	O
but	O
N2	O
could	O
not	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	B-COMP
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
inhibits	O
cell	B-COMP
cytokinesis	O
and	O
proliferation	O
by	O
interacting	O
with	O
translation	O
elongation	O
factor	O
1alpha	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
cellular	B-COMP
receptor	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

TITLE	O
:	O
SARS	O
-	O
coronavirus	O
replication	O
/	O
transcription	O
complexes	O
are	O
membrane	B-COMP
-	O
protected	O
and	O
need	O
a	O
host	B-COMP
factor	O
for	O
activity	O
in	O
vitro	O
.	O

In	O
our	O
study	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
a	O
high	O
binding	O
affinity	O
for	O
the	O
leader	O
sequence	O
of	O
SARS	O
-	O
CoV	O
genome	O
.	O

TITLE	O
:	O
Improved	O
microarray	O
gene	O
expression	O
profiling	O
of	O
virus	O
-	O
infected	O
cells	B-COMP
after	O
removal	O
of	O
viral	O
RNA	O
.	O

In	O
the	O
field	O
of	O
virology	O
,	O
when	O
analyzing	O
the	O
host	B-COMP
cell	I-COMP
'	O
s	O
reaction	O
to	O
infection	O
,	O
the	O
often	O
high	O
representation	O
of	O
viral	O
RNA	O
(	O
vRNA	O
)	O
within	O
total	O
RNA	O
preparations	O
from	O
infected	O
cells	B-COMP
is	O
likely	O
to	O
interfere	O
with	O
microarray	O
analysis	O
.	O

TITLE	O
:	O
Rapid	O
discovery	O
and	O
optimization	O
of	O
therapeutic	O
antibodies	B-COMP
against	O
emerging	O
infectious	O
diseases	O
.	O

These	O
anti	O
-	O
SARS	O
antibodies	B-COMP
were	O
discovered	O
using	O
a	O
novel	O
DNA	O
display	O
method	O
,	O
which	O
can	O
identify	O
new	O
antibodies	B-COMP
within	O
days	O
.	O

BAL	O
fluid	O
of	O
PbA	O
-	O
infected	O
C57BL	O
/	O
6	O
mice	O
revealed	O
a	O
significant	O
increase	O
in	O
IgM	O
and	O
total	O
protein	O
prior	O
to	O
the	O
development	O
of	O
CM	O
,	O
indicating	O
disruption	O
of	O
the	O
alveolar	O
-	O
capillary	O
membrane	B-COMP
barrier	O
-	O
the	O
physiological	O
hallmark	O
of	O
ALI	O
.	O

Histopathology	O
showed	O
septal	O
inflammation	O
without	O
cellular	B-COMP
transmigration	O
into	O
the	O
alveolar	O
spaces	O
.	O

In	O
contrast	O
,	O
the	O
spike	O
protein	O
of	O
HNL63	O
-	O
CoV	O
(	O
NL63	O
-	O
S	O
),	O
a	O
CoV	O
that	O
uses	O
ACE2	O
as	O
a	O
receptor	O
and	O
mainly	O
induces	O
the	O
common	O
cold	O
,	O
caused	O
neither	O
of	O
these	O
cellular	B-COMP
responses	O
.	O

Intriguingly	O
,	O
viral	O
infection	O
,	O
judged	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
SARS	O
-	O
CoV	O
mRNA	O
expression	O
,	O
was	O
significantly	O
attenuated	O
by	O
deletion	O
of	O
the	O
cytoplasmic	B-COMP
tail	O
of	O
ACE2	O
or	O
knock	O
-	O
down	O
of	O
TACE	O
expression	O
by	O
siRNA	O
.	O

We	O
designed	O
a	O
recombinant	O
HCoV	O
-	O
229E	O
and	O
a	O
recombinant	O
HCoV	O
-	O
NL63	O
nucleocapsid	B-COMP
protein	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
performed	O
a	O
seroepidemiology	O
survey	O
on	O
longitudinal	O
and	O
cross	O
-	O
sectional	O
serum	B-COMP
samples	O
.	O

The	O
longitudinal	O
serum	B-COMP
samples	O
were	O
collected	O
from	O
13	O
newborns	O
,	O
and	O
data	O
for	O
those	O
newborns	O
were	O
available	O
from	O
multiple	O
time	O
points	O
spanning	O
a	O
period	O
of	O
at	O
least	O
18	O
months	O
.	O

In	O
examinations	O
of	O
the	O
longitudinal	O
serum	B-COMP
samples	O
we	O
observed	O
that	O
all	O
of	O
the	O
children	O
had	O
maternal	O
anti	O
-	O
NL63	O
and	O
anti	O
-	O
229E	O
antibodies	B-COMP
at	O
birth	O
that	O
disappeared	O
within	O
3	O
months	O
.	O

Analysis	O
of	O
the	O
data	O
sets	O
used	O
and	O
the	O
results	O
of	O
this	O
comparison	O
show	O
that	O
conclusions	O
about	O
the	O
relative	O
performance	O
of	O
different	O
B	O
-	O
cell	B-COMP
epitope	O
prediction	O
methods	O
drawn	O
on	O
the	O
basis	O
of	O
experiments	O
using	O
data	O
sets	O
of	O
unique	O
B	O
-	O
cell	B-COMP
epitopes	O
are	O
likely	O
to	O
yield	O
overly	O
optimistic	O
estimates	O
of	O
performance	O
of	O
evaluated	O
methods	O
.	O

Chickens	O
immunized	O
with	O
the	O
H5N1	O
/	O
PR8	O
-	O
5B19	O
inactivated	O
vaccine	O
produced	O
high	O
levels	O
of	O
HI	O
antibody	B-COMP
and	O
a	O
measurable	O
antibody	B-COMP
response	O
against	O
the	O
MHV	O
5B19	O
epitope	O
,	O
and	O
were	O
fully	O
protected	O
against	O
subsequent	O
challenge	O
with	O
different	O
highly	O
pathogenic	O
H5N1	O
avian	O
influenza	O
viruses	O
.	O

The	O
level	O
of	O
APQ	O
-	O
4	O
whole	O
-	O
cell	B-COMP
currents	O
was	O
decreased	O
in	O
AT	O
II	O
cell	B-COMP
membrane	I-COMP
and	O
increased	O
in	O
cytoplasm	B-COMP
in	O
ALI	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
test	O
results	O
of	O
the	O
positive	O
and	O
negative	O
controls	O
in	O
the	O
kit	O
and	O
the	O
serum	B-COMP
samples	O
from	O
convalescent	O
;	O
patient	O
were	O
consistent	O
with	O
expectation	O
.	O

This	O
SPA	O
-	O
ELISA	O
method	O
is	O
applicable	O
for	O
detecting	O
coronavirus	O
antibody	B-COMP
in	O
bat	O
sera	B-COMP
.	O

CONCLUSIONS	O
:	O
This	O
SPA	O
-	O
ELISA	O
method	O
is	O
applicable	O
for	O
detecting	O
coronavirus	O
antibody	B-COMP
in	O
bat	O
sera	B-COMP
.	O

TITLE	O
:	O
The	O
role	O
of	O
programmed	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
in	O
coronavirus	O
propagation	O
.	O

ABSTRACT	O
:	O
Stable	O
E1	O
transformed	O
cells	B-COMP
,	O
like	O
PER	O
.	O
C6	O
,	O
are	O
able	O
to	O
grow	O
at	O
scale	O
and	O
to	O
high	O
cell	B-COMP
densities	O
.	O

To	O
evaluate	O
the	O
utility	O
of	O
this	O
system	O
we	O
constructed	O
DeltaE1	O
/	O
DeltaE2	O
vector	O
carrying	O
different	O
classes	O
of	O
protein	O
,	O
that	O
is	O
,	O
the	O
gene	O
coding	O
for	O
spike	O
protein	O
derived	O
from	O
the	O
Coronavirus	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
gene	O
coding	O
for	O
the	O
SARS	O
-	O
CoV	O
receptor	O
or	O
the	O
genes	O
coding	O
for	O
an	O
antibody	B-COMP
shown	O
to	O
bind	O
and	O
neutralize	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
AB	O
).	O

Exposure	O
of	O
PER	O
.	O
C6	O
cells	B-COMP
to	O
low	O
amounts	O
(	O
30	O
vp	O
/	O
cell	B-COMP
)	O
of	O
DeltaE1	O
/	O
DeltaE2	O
vectors	O
resulted	O
in	O
highly	O
efficient	O
(>	O
80	O
%)	O
transduction	O
of	O
PER	O
.	O
C6	O
cells	B-COMP
growing	O
in	O
suspension	O
.	O

In	O
the	O
case	O
of	O
SARS	O
-	O
CoV	O
,	O
heptad	O
repeat	O
domains	O
of	O
the	O
envelope	B-COMP
glycoprotein	O
,	O
termed	O
S2	O
-	O
HR1	O
and	O
S2	O
-	O
HR2	O
,	O
are	O
thought	O
to	O
undergo	O
structural	O
changes	O
from	O
a	O
prefusion	O
state	O
,	O
in	O
which	O
S2	O
-	O
HR1	O
and	O
S2	O
-	O
HR2	O
do	O
not	O
interact	O
,	O
to	O
a	O
postfusion	O
state	O
in	O
which	O
S2	O
-	O
HR1	O
and	O
S2	O
-	O
HR2	O
associate	O
to	O
form	O
a	O
six	O
-	O
helix	O
bundle	O
.	O

The	O
pumpless	O
extracorporeal	O
lung	O
membrane	B-COMP
and	O
near	O
-	O
static	O
ventilation	O
achieved	O
a	O
significantly	O
better	O
outcome	O
than	O
conventional	O
treatment	O
in	O
this	O
pig	O
model	O
of	O
severe	O
postpneumonectomy	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
probably	O
because	O
the	O
injured	O
lungs	O
were	O
not	O
forced	O
to	O
work	O
and	O
this	O
""""	O
rest	O
""""	O
gave	O
them	O
more	O
time	O
to	O
heal	O
.	O

MHV	O
RNA	O
replication	O
was	O
not	O
sensitive	O
to	O
BFA	O
in	O
MDCK	O
cells	B-COMP
,	O
which	O
are	O
known	O
to	O
express	O
the	O
BFA	O
-	O
resistant	O
guanine	O
nucleotide	O
exchange	O
factor	O
GBF1	O
.	O

The	O
GBP	O
-	O
fusion	O
method	O
allows	O
immobilization	O
of	O
proteins	O
in	O
bioactive	O
forms	O
onto	O
the	O
gold	O
surface	O
without	O
surface	O
modification	O
suitable	O
for	O
studying	O
antigen	O
-	O
antibody	B-COMP
interaction	O
.	O

We	O
demonstrated	O
that	O
the	O
RBD	O
spike	O
protein	O
alone	O
could	O
be	O
internalized	O
into	O
SARS	O
-	O
CoV	O
susceptible	O
cells	B-COMP
together	O
with	O
ACE2	O
.	O

Of	O
these	O
,	O
382	O
(	O
62	O
%)	O
had	O
sera	B-COMP
available	O
for	O
viral	O
analysis	O
.	O

ABSTRACT	O
:	O
Unlike	O
other	O
class	O
I	O
viral	O
fusion	O
proteins	O
,	O
spike	O
proteins	O
on	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
virions	B-COMP
are	O
uncleaved	O
.	O

Early	O
alterations	O
in	O
serum	B-COMP
levels	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
7	O
and	O
IL	O
-	O
10	O
may	O
constitute	O
useful	O
predictive	O
markers	O
for	O
identifying	O
patients	O
those	O
who	O
have	O
sustained	O
a	O
burn	O
with	O
concomitant	O
inhalation	O
injury	O
and	O
who	O
have	O
high	O
mortality	O
.	O

The	O
data	O
show	O
recognition	O
of	O
prokaryotically	O
expressed	O
HIV	O
-	O
1	O
Gag	O
/	O
p24	O
fusion	O
protein	O
by	O
Western	O
blot	O
and	O
efficient	O
affinity	O
purification	O
using	O
monoclonal	O
antibodies	B-COMP
against	O
the	O
tags	O
.	O

Participants	O
were	O
randomized	O
to	O
receive	O
APC	B-COMP
(	O
24	O
microg	O
/	O
kg	O
/	O
h	O
for	O
96	O
h	O
)	O
or	O
placebo	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
within	O
72	O
hours	O
of	O
the	O
onset	O
of	O
ALI	O
.	O

The	O
results	O
of	O
this	O
trial	O
do	O
not	O
support	O
a	O
large	O
clinical	O
trial	O
of	O
APC	B-COMP
for	O
ALI	O
in	O
the	O
absence	O
of	O
severe	O
sepsis	O
and	O
high	O
disease	O
severity	O
.	O

Reports	O
using	O
historical	O
matched	O
controls	O
have	O
suggested	O
that	O
treatment	O
with	O
interferon	O
alfacon	O
-	O
1	O
(	O
a	O
synthetic	O
interferon	O
)	O
combined	O
with	O
steroid	O
,	O
protease	O
inhibitors	O
together	O
with	O
ribavirin	O
,	O
or	O
convalescent	O
plasma	O
containing	O
neutralizing	O
antibody	B-COMP
,	O
could	O
be	O
useful	O
.	O

Other	O
non	O
-	O
SARS	O
-	O
CoV	O
infections	O
are	O
generally	O
milder	O
in	O
immunocompetent	O
hosts	B-COMP
,	O
and	O
scientific	O
data	O
on	O
antiviral	O
treatment	O
of	O
these	O
viruses	O
are	O
scarce	O
.	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
IL	O
-	O
12	O
and	O
IL	O
-	O
23	O
signaling	O
are	O
dispensable	O
in	O
generating	O
a	O
protective	O
T	O
-	O
cell	B-COMP
response	O
following	O
CNS	O
infection	O
with	O
MHV	O
,	O
and	O
(	O
2	O
)	O
IL	O
-	O
12	O
and	O
IL	O
-	O
23	O
do	O
not	O
contribute	O
to	O
demyelination	O
in	O
a	O
model	O
independent	O
of	O
autoimmune	O
T	O
-	O
cell	B-COMP
-	O
mediated	O
pathology	O
.	O

RESULTS	O
:	O
In	O
vitro	O
,	O
distinct	O
signature	O
profiles	O
of	O
SeV	O
and	O
MHV	O
-	O
1	O
-	O
inducible	O
gene	O
expression	O
for	O
IFN	O
-	O
alpha2	O
,	O
IFN	O
-	O
alpha4	O
and	O
IFN	O
-	O
alpha5	O
subtypes	O
in	O
L2	O
and	O
L929	O
mouse	O
fibroblast	O
cells	B-COMP
,	O
in	O
relation	O
to	O
the	O
extent	O
and	O
kinetics	O
of	O
their	O
induction	O
,	O
were	O
identified	O
.	O

We	O
demonstrate	O
that	O
MHV	O
-	O
A59	O
,	O
a	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
that	O
causes	O
brain	O
and	O
spinal	O
cord	O
inflammation	O
and	O
demyelination	O
,	O
induces	O
ON	O
by	O
promoting	O
mixed	O
inflammatory	O
cell	B-COMP
infiltration	O
.	O

Furthermore	O
,	O
zoonotic	O
SARS	O
-	O
CoV	O
was	O
variably	O
neutralized	O
by	O
antibodies	B-COMP
that	O
were	O
effective	O
against	O
the	O
epidemic	O
strain	O
,	O
highlighting	O
their	O
utility	O
for	O
evaluating	O
passive	O
immunization	O
efficacy	O
.	O

ABSTRACT	O
:	O
Complement	O
staining	O
as	O
a	O
predictor	O
of	O
antibody	B-COMP
-	O
mediated	O
rejection	O
(	O
AMR	O
)	O
after	O
lung	O
transplantation	O
continues	O
to	O
be	O
debated	O
.	O

In	O
a	O
sub	O
-	O
group	O
analysis	O
we	O
identified	O
9	O
LTRs	O
who	O
developed	O
early	O
bronchiolitis	O
obliterans	O
syndrome	O
(	O
BOS	O
)	O
in	O
the	O
absence	O
of	O
acute	O
cellular	B-COMP
rejection	O
or	O
cytomegalovirus	O
reactivation	O
,	O
but	O
they	O
had	O
significant	O
lung	O
allograft	O
C3d	O
/	O
C4d	O
deposition	O
along	O
with	O
corroborative	O
light	O
-	O
microscopic	O
features	O
suggestive	O
of	O
AMR	O
.	O

Fibrin	O
deposits	O
,	O
which	O
are	O
the	O
hallmark	O
of	O
early	O
phase	O
acute	O
lung	O
injury	O
,	O
stimulate	O
fibroblast	O
aggregation	O
and	O
collagen	B-COMP
secretion	O
,	O
participating	O
to	O
the	O
constitution	O
of	O
pulmonary	O
fibrosis	O
.	O

We	O
immunized	O
mice	O
with	O
UV	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
to	O
generate	O
three	O
anti	O
-	O
S	O
monoclonal	O
antibodies	B-COMP
,	O
and	O
established	O
several	O
neutralization	O
escape	O
mutants	O
with	O
S	O
protein	O
.	O

Therefore	O
,	O
we	O
have	O
carried	O
out	O
a	O
study	O
of	O
the	O
binding	O
and	O
interaction	O
with	O
model	O
membranes	O
of	O
a	O
peptide	O
corresponding	O
to	O
segment	O
873	O
-	O
888	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
,	O
peptide	O
SARS	O
IFP	O
,	O
as	O
well	O
as	O
the	O
structural	O
changes	O
taking	O
place	O
in	O
both	O
the	O
phospholipid	O
and	O
the	O
peptide	O
induced	O
by	O
the	O
binding	O
of	O
the	O
peptide	O
to	O
the	O
membrane	B-COMP
.	O

Employing	O
the	O
MAb	O
-	O
based	O
immunoswab	O
,	O
an	O
NP	O
concentration	O
of	O
200	O
pg	O
/	O
mL	O
in	O
saline	O
and	O
pig	O
nasopharyngeal	O
aspirate	O
,	O
and	O
500	O
pg	O
/	O
mL	O
in	O
rabbit	O
serum	B-COMP
were	O
detected	O
.	O

These	O
two	O
elements	O
are	O
separated	O
by	O
six	O
to	O
eight	O
nucleotides	O
,	O
a	O
distance	O
that	O
places	O
the	O
5	O
'	O
edge	O
of	O
the	O
downstream	O
stimulatory	O
element	O
in	O
direct	O
contact	O
with	O
the	O
mRNA	O
entry	O
channel	O
of	O
the	O
30S	B-COMP
ribosomal	I-COMP
subunit	I-COMP
.	O

Deletion	O
or	O
mutations	O
of	O
the	O
RS	O
motif	O
enhanced	O
stress	B-COMP
granule	I-COMP
localization	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
,	O
whereas	O
overexpression	O
of	O
SR	O
protein	O
kinase	O
1	O
inhibited	O
nucleocapsid	B-COMP
protein	O
localization	O
to	O
stress	O
granules	O
.	O

Taken	O
together	O
,	O
phosphorylation	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
modulates	O
its	O
activity	O
in	O
translation	O
control	O
and	O
also	O
interferes	O
with	O
its	O
oligomerization	O
and	O
aggregation	O
in	O
stress	O
granules	O
.	O

ABSTRACT	O
:	O
The	O
relationship	O
between	O
immunosenescence	O
and	O
the	O
host	B-COMP
response	O
to	O
virus	O
infection	O
is	O
poorly	O
understood	O
at	O
the	O
molecular	O
level	O
.	O

In	O
the	O
intrinsic	O
pathway	O
,	O
there	O
was	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
cytochrome	O
c	O
release	O
from	O
the	O
mitochondria	B-COMP
.	O

This	O
was	O
the	O
result	O
of	O
increased	O
Bax	O
oligomerization	O
and	O
higher	O
levels	O
of	O
p53	O
in	O
3a	O
protein	O
-	O
expressing	O
cells	B-COMP
,	O
which	O
depended	O
on	O
the	O
activation	O
of	O
p38	O
MAP	O
kinase	O
(	O
MAPK	O
)	O
in	O
these	O
cells	B-COMP
.	O

The	O
reinforced	O
epidemiological	O
surveillance	O
on	O
CoVs	O
has	O
led	O
to	O
the	O
identification	O
of	O
new	O
viruses	O
,	O
genotypes	O
,	O
pathotypes	O
and	O
host	B-COMP
variants	O
in	O
animals	O
and	O
humans	O
.	O

ABSTRACT	O
:	O
Macrophage	O
activation	O
syndrome	O
(	O
MAS	B-COMP
)	O
is	O
a	O
severe	O
,	O
potentially	O
life	O
-	O
threatening	O
condition	O
induced	O
by	O
chronic	O
rheumatic	O
diseases	O
,	O
especially	O
systemic	O
-	O
onset	O
juvenile	O
idiopathic	O
arthritis	O
(	O
SoJIA	O
)	O
in	O
childhood	O
.	O

The	O
corresponding	O
mutations	O
in	O
SARS	O
-	O
CoV	O
Nsp9	O
do	O
not	O
hamper	O
nucleic	B-COMP
acid	O
binding	O
.	O

We	O
propose	O
that	O
both	O
forms	O
of	O
the	O
Nsp9	O
dimer	O
are	O
biologically	O
relevant	O
;	O
the	O
occurrence	O
of	O
the	O
disulfide	O
-	O
bonded	O
form	O
may	O
be	O
correlated	O
with	O
oxidative	O
stress	O
induced	O
in	O
the	O
host	B-COMP
cell	I-COMP
by	O
the	O
viral	O
infection	O
.	O

TITLE	O
:	O
Association	O
between	O
faecal	O
shedding	O
of	O
feline	O
coronavirus	O
and	O
serum	B-COMP
alpha1	O
-	O
acid	O
glycoprotein	O
sialylation	O
.	O

ABSTRACT	O
:	O
The	O
sialylation	O
pattern	O
of	O
serum	B-COMP
alpha1	O
-	O
acid	O
glycoprotein	O
(	O
AGP	O
)	O
in	O
non	O
-	O
symptomatic	O
cats	O
infected	O
by	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
its	O
possible	O
relationship	O
with	O
the	O
amount	O
of	O
FCoVs	O
shed	O
in	O
faeces	O
were	O
investigated	O
.	O

Cockayne	O
syndrome	O
A	O
(	O
CSA	O
)	O
and	O
B	O
(	O
CSB	O
)	O
play	O
essential	O
roles	O
in	O
integrating	O
the	O
recognition	O
of	O
damage	O
,	O
chromatin	B-COMP
remodeling	O
,	O
and	O
the	O
core	O
nucleotide	O
excision	O
repair	O
proteins	O
.	O

2	O
.	O
RBD	O
-	O
Fc	O
(	O
protein	O
-	O
based	O
vaccine	O
)	O
is	O
able	O
to	O
induce	O
effective	O
neutralising	O
antibodies	B-COMP
able	O
to	O
provide	O
protection	O
from	O
SARS	O
-	O
CoV	O
infection	O
in	O
animal	O
models	O
.	O

When	O
compared	O
with	O
the	O
RBD	O
-	O
rAAV	O
prime	O
/	O
boost	O
vaccination	O
,	O
RBD	O
-	O
rAAV	O
prime	O
/	O
RBD	O
-	O
peptide	O
boost	O
induced	O
similar	O
levels	O
of	O
Th1	O
and	O
neutralising	O
antibody	B-COMP
responses	O
that	O
protected	O
vaccinated	O
mice	O
from	O
subsequent	O
SARS	O
-	O
CoV	O
challenges	O
,	O
but	O
stronger	O
Th2	O
and	O
CTL	O
responses	O
.	O

Research	O
on	O
this	O
virus	O
/	O
host	B-COMP
-	O
interaction	O
will	O
broaden	O
our	O
understanding	O
of	O
its	O
relevance	O
in	O
viral	O
replication	O
.	O

This	O
important	O
control	O
center	O
of	O
cellular	B-COMP
responses	O
is	O
differently	O
employed	O
to	O
support	O
the	O
replication	O
of	O
several	O
important	O
human	O
pathogenic	O
RNA	O
viruses	O
including	O
influenza	O
,	O
Ebola	O
,	O
hepatitis	O
C	O
and	O
SARS	O
corona	O
viruses	O
.	O

TITLE	O
:	O
Membrane	B-COMP
insertion	O
of	O
the	O
three	O
main	O
membranotropic	O
sequences	O
from	O
SARS	O
-	O
CoV	O
S2	O
glycoprotein	O
.	O

Several	O
antibodies	B-COMP
against	O
the	O
S1	O
domain	O
have	O
been	O
generated	O
and	O
all	O
of	O
them	O
are	O
able	O
to	O
neutralize	O
the	O
virus	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
animal	O
models	O
.	O

Infectivity	O
was	O
also	O
reduced	O
after	O
depleting	O
cholesterol	O
from	O
the	O
viral	B-COMP
envelope	I-COMP
.	O

ABSTRACT	O
:	O
Localisation	O
of	O
both	O
viral	O
and	O
cellular	B-COMP
proteins	O
to	O
the	O
nucleolus	B-COMP
is	O
determined	O
by	O
a	O
variety	O
of	O
factors	O
including	O
nucleolar	O
localisation	O
signals	O
(	O
NoLSs	O
),	O
but	O
how	O
these	O
signals	O
operate	O
is	O
not	O
clearly	O
understood	O
.	O

In	O
conclusion	O
,	O
SARS	O
-	O
CoV	O
induces	O
IFNs	O
to	O
a	O
less	O
extent	O
compared	O
to	O
VSV	O
and	O
NDV	O
,	O
thus	O
suggesting	O
that	O
the	O
IFN	O
system	O
does	O
play	O
a	O
limited	O
role	O
in	O
early	O
host	B-COMP
defense	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

grubii	O
yeast	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Isolation	O
of	O
human	O
antibodies	B-COMP
using	O
current	O
display	O
technologies	O
can	O
be	O
limited	O
by	O
constraints	O
on	O
protein	O
expression	O
,	O
folding	O
and	O
post	O
-	O
translational	O
modifications	O
.	O

Both	O
antibody	B-COMP
-	O
displaying	O
human	O
cells	B-COMP
and	O
virus	B-COMP
particles	I-COMP
bound	O
antigen	O
specifically	O
.	O

Up	O
to	O
10	O
(	O
6	O
)-	O
fold	O
enrichment	O
of	O
antibody	B-COMP
expressing	O
cells	B-COMP
was	O
achieved	O
with	O
one	O
round	O
of	O
antigen	O
coupled	O
magnetic	O
bead	O
pre	O
-	O
selection	O
followed	O
by	O
FACS	O
sorting	O
.	O

TITLE	O
:	O
Characterization	O
and	O
membrane	B-COMP
gene	O
-	O
based	O
phylogenetic	O
analysis	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
Chinese	O
strain	O
HH06	O
.	O

Membrane	B-COMP
structures	O
supporting	O
viral	O
RNA	O
synthesis	O
range	O
from	O
distinct	O
spherular	O
membrane	B-COMP
invaginations	O
to	O
more	O
elaborate	O
webs	O
of	O
packed	O
membranes	O
and	O
vesicles	B-COMP
.	O

ABSTRACT	O
:	O
Cholesterol	O
present	O
in	O
the	O
plasma	B-COMP
membrane	I-COMP
of	O
target	O
cells	B-COMP
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
infection	O
by	O
SARS	O
-	O
CoV	O
.	O
We	O
show	O
that	O
cholesterol	O
depletion	O
by	O
treatment	O
with	O
methyl	O
-	O
beta	O
-	O
cyclodextrin	O
(	O
m	O
beta	O
CD	O
)	O
affects	O
infection	O
by	O
SARS	O
-	O
CoV	O
to	O
the	O
same	O
extent	O
as	O
infection	O
by	O
vesicular	O
stomatitis	O
virus	O
-	O
based	O
pseudotypes	O
containing	O
the	O
surface	O
glycoprotein	O
S	O
of	O
SARS	O
-	O
CoV	O
(	O
VSV	O
-	O
Delta	O
G	O
-	O
S	O
).	O

Depletion	O
of	O
cholesterol	O
from	O
the	O
ACE2	O
-	O
expressing	O
cells	B-COMP
reduced	O
the	O
binding	O
of	O
S	O
-	O
expressing	O
cells	B-COMP
by	O
50	O
%	O
whereas	O
the	O
binding	O
of	O
soluble	O
S	O
protein	O
was	O
not	O
affected	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
the	O
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
and	O
its	O
cellular	B-COMP
receptor	O
by	O
anti	O
-	O
histo	O
-	O
blood	O
group	O
antibodies	B-COMP
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
cellular	B-COMP
model	O
of	O
adhesion	O
to	O
investigate	O
whether	O
natural	O
antibodies	B-COMP
of	O
the	O
ABO	O
system	O
could	O
block	O
the	O
S	O
protein	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
interaction	O
.	O

To	O
this	O
aim	O
,	O
a	O
C	O
-	O
terminally	O
EGFP	O
-	O
tagged	O
S	O
protein	O
was	O
expressed	O
in	O
chinese	O
hamster	O
ovary	O
cells	B-COMP
cotransfected	O
with	O
an	O
alpha1	O
,	O
2	O
-	O
fucosyltransferase	O
and	O
an	O
A	O
-	O
transferase	O
in	O
order	O
to	O
coexpress	O
the	O
S	O
glycoprotein	O
ectodomain	O
and	O
the	O
A	O
antigen	O
at	O
the	O
cell	B-COMP
surface	I-COMP
.	O

TITLE	O
:	O
[	O
The	O
functions	O
of	O
liver	O
natural	O
killer	O
cells	B-COMP
in	O
murine	O
fulminant	O
hepatitis	O
induced	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
3	O
].	O

SARS	O
-	O
CoV	O
-	O
specific	O
CD4	O
+	O
T	O
-	O
cell	B-COMP
responses	O
were	O
detected	O
in	O
all	O
vaccinees	O
,	O
and	O
CD8	O
+	O
T	O
-	O
cell	B-COMP
responses	O
in	O
approximately	O
20	O
%	O
of	O
individuals	O
.	O

This	O
paper	O
proposes	O
that	O
should	O
such	O
occur	O
before	O
effective	O
vaccines	O
and	O
antiviral	O
drugs	O
are	O
available	O
,	O
the	O
outbreak	O
could	O
be	O
significantly	O
slowed	O
by	O
consumption	O
of	O
raw	O
milk	O
produced	O
by	O
herds	O
of	O
pathogen	O
-	O
free	O
lactating	O
cows	O
intranasally	O
inoculated	O
with	O
heat	O
-	O
sterilized	O
sputa	O
pooled	O
from	O
avian	O
influenza	O
patients	O
,	O
supplemented	O
by	O
parenteral	O
serum	B-COMP
immune	O
globulin	O
from	O
the	O
same	O
cows	O
.	O

Fifty	O
-	O
five	O
novel	O
T	O
cell	B-COMP
epitopes	O
were	O
identified	O
,	O
with	O
spike	O
protein	O
dominating	O
total	O
T	O
cell	B-COMP
responses	O
.	O

CD8	O
(+)	O
T	O
cell	B-COMP
responses	O
were	O
more	O
frequent	O
and	O
of	O
a	O
greater	O
magnitude	O
than	O
CD4	O
(+)	O
T	O
cell	B-COMP
responses	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Accompanying	O
data	O
relating	O
to	O
the	O
sampled	O
animals	O
were	O
collected	O
in	O
order	O
to	O
identify	O
potential	O
factors	O
associated	O
with	O
increased	O
antibody	B-COMP
prevalence	O
.	O

Using	O
a	O
commercial	O
ELISA	O
kit	O
,	O
it	O
was	O
found	O
that	O
the	O
antibodies	B-COMP
detected	O
in	O
pigs	O
of	O
all	O
the	O
raising	O
stages	O
and	O
sows	O
were	O
raised	O
against	O
PRCV	O
but	O
not	O
TGEV	O
.	O

Previously	O
we	O
showed	O
that	O
,	O
consistent	O
with	O
predictions	O
,	O
nsp4	O
occurs	O
in	O
membranes	O
with	O
both	O
of	O
its	O
termini	O
exposed	O
in	O
the	O
cytoplasm	B-COMP
(	O
M	O
.	O
Oostra	O
et	O
al	O
.,	O
J	O
.	O
Virol	O
.	O

Control	O
of	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
requires	O
the	O
collaboration	O
of	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	B-COMP
,	O
with	O
CD8	O
(+)	O
T	O
cells	B-COMP
providing	O
direct	O
perforin	O
and	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)-	O
mediated	O
antiviral	O
activity	O
.	O

To	O
distinguish	O
bystander	O
from	O
direct	O
antiviral	O
contributions	O
of	O
CD4	O
(+)	O
T	O
cells	B-COMP
in	O
virus	O
clearance	O
and	O
pathology	O
,	O
memory	O
CD4	O
(+)	O
T	O
cells	B-COMP
purified	O
from	O
wild	O
type	O
(	O
wt	O
),	O
perforin	O
-	O
deficient	O
(	O
PKO	O
),	O
and	O
IFN	O
-	O
gamma	O
-	O
deficient	O
(	O
GKO	O
)	O
immune	O
donors	O
were	O
transferred	O
to	O
immunodeficient	O
SCID	O
mice	O
prior	O
to	O
CNS	O
challenge	O
.	O

All	O
three	O
donor	O
CD4	O
(+)	O
T	O
-	O
cell	B-COMP
populations	O
controlled	O
CNS	O
virus	O
replication	O
at	O
8	O
days	O
postinfection	O
,	O
indicating	O
IFN	O
-	O
gamma	O
-	O
and	O
perforin	O
-	O
independent	O
antiviral	O
function	O
.	O

The	O
results	O
of	O
this	O
study	O
confirm	O
prior	O
reports	O
of	O
biologic	O
and	O
antigenic	O
similarities	O
between	O
bovine	O
and	O
wild	O
-	O
ruminant	O
CoVs	O
and	O
suggest	O
that	O
cattle	O
may	O
be	O
reservoirs	O
for	O
CoVs	O
that	O
infect	O
captive	O
wild	O
ruminants	O
or	O
vice	O
versa	O
and	O
that	O
these	O
CoVs	O
may	O
represent	O
host	B-COMP
range	O
variants	O
of	O
an	O
ancestral	O
CoV	O
.	O

The	O
resulting	O
compound	O
,	O
GRL0617	O
,	O
inhibited	O
SARS	O
-	O
CoV	O
viral	O
replication	O
in	O
Vero	O
E6	O
cells	B-COMP
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
15	O
microM	O
and	O
had	O
no	O
associated	O
cytotoxicity	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
:	O
unusual	O
lability	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
.	O

The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
the	O
coronavirus	O
responsible	O
for	O
this	O
disease	O
plays	O
a	O
critical	O
role	O
in	O
viral	O
assembly	O
and	O
maturation	O
and	O
is	O
of	O
particular	O
interest	O
because	O
of	O
its	O
potential	O
as	O
an	O
antiviral	O
target	O
or	O
vaccine	O
candidate	O
.	O

Internalization	O
occurred	O
through	O
a	O
clathrin	O
-	O
and	O
caveolae	B-COMP
-	O
independent	O
pathway	O
that	O
did	O
not	O
require	O
dynamin	O
,	O
rafts	O
,	O
actin	O
or	O
rho	O
-	O
GTPases	O
.	O

After	O
internalization	O
,	O
the	O
viral	O
antigen	O
-	O
antibody	B-COMP
complexes	O
passed	O
through	O
the	O
early	O
endosomes	O
,	O
where	O
they	O
resided	O
only	O
briefly	O
,	O
and	O
accumulated	O
in	O
the	O
late	O
endosomes	O
.	O

Nasal	O
discharge	O
was	O
recorded	O
,	O
and	O
antibody	B-COMP
response	O
and	O
virus	O
shedding	O
were	O
measured	O
.	O

TITLE	O
:	O
Prevention	O
of	O
cytotoxic	O
T	O
cell	B-COMP
escape	O
using	O
a	O
heteroclitic	O
subdominant	O
viral	O
T	O
cell	B-COMP
determinant	O
.	O

None	O
of	O
50	O
healthy	O
sera	B-COMP
gave	O
positive	O
results	O
in	O
either	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
the	O
middle	O
or	O
C	O
-	O
terminal	O
region	O
of	O
the	O
SARS	O
N	O
protein	O
is	O
important	O
for	O
eliciting	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
during	O
the	O
immune	O
response	O
,	O
and	O
ELISA	O
reactions	O
using	O
N1	O
or	O
N3	O
may	O
be	O
a	O
valuable	O
tool	O
for	O
SARS	O
diagnosis	O
.	O

Furthermore	O
,	O
229E	O
infection	O
was	O
inhibited	O
in	O
CPL	O
knockdown	O
cells	B-COMP
by	O
small	O
interfering	O
RNA	O
,	O
compared	O
with	O
what	O
was	O
seen	O
for	O
a	O
normal	O
counterpart	O
producing	O
CPL	O
.	O

We	O
also	O
found	O
229E	O
virion	B-COMP
S	O
protein	O
to	O
be	O
cleaved	O
by	O
CPL	O
.	O

Macro	O
domains	O
are	O
also	O
encoded	O
by	O
a	O
set	O
of	O
positive	O
-	O
strand	O
RNA	O
viruses	O
that	O
replicate	O
in	O
the	O
cytoplasm	B-COMP
of	O
animal	O
cells	B-COMP
,	O
including	O
coronaviruses	O
and	O
alphaviruses	O
.	O

Furthermore	O
,	O
a	O
strong	O
Th1	O
-	O
based	O
cellular	B-COMP
immune	O
response	O
was	O
stimulated	O
by	O
both	O
DNA	O
vaccines	O
.	O

Although	O
SARS	O
likely	O
stems	O
from	O
overexuberant	O
host	B-COMP
inflammatory	O
responses	O
,	O
the	O
exact	O
mechanism	O
leading	O
to	O
the	O
detrimental	O
outcome	O
in	O
patients	O
remains	O
unknown	O
.	O

Pulmonary	O
macrophages	O
(	O
Mphi	O
),	O
airway	O
epithelium	O
,	O
and	O
dendritic	B-COMP
cells	B-COMP
(	O
DC	O
)	O
are	O
key	O
cellular	B-COMP
elements	O
of	O
the	O
host	B-COMP
innate	O
defenses	O
against	O
respiratory	O
infections	O
.	O

In	O
the	O
beginning	O
of	O
such	O
a	O
strategy	O
a	O
roller	O
-	O
pump	O
-	O
driven	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
was	O
used	O
,	O
which	O
was	O
characterized	O
by	O
high	O
complication	O
rate	O
.	O

The	O
TCoV	O
nsp15	O
did	O
not	O
cleave	O
DNA	O
but	O
degraded	O
total	O
cellular	B-COMP
RNA	O
.	O

ABSTRACT	O
:	O
Propagation	O
of	O
new	O
human	O
respiratory	O
virus	O
pathogens	O
in	O
established	O
cell	B-COMP
lines	O
is	O
hampered	O
by	O
a	O
lack	O
of	O
predictability	O
regarding	O
cell	B-COMP
line	O
permissivity	O
and	O
by	O
availability	O
of	O
suitable	O
antibody	B-COMP
reagents	O
to	O
detect	O
infection	O
in	O
cell	B-COMP
lines	O
that	O
do	O
not	O
exhibit	O
significant	O
cytopathic	O
effect	O
.	O

ABSTRACT	O
:	O
Bioline	O
-	O
coated	O
polymethylpentene	O
(	O
PMP	O
)	O
membrane	B-COMP
oxygenators	O
(	O
MO	O
)	O
are	O
used	O
for	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
to	O
improve	O
gas	O
exchange	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

However	O
,	O
in	O
some	O
patients	O
,	O
long	O
-	O
term	O
durability	O
is	O
limited	O
due	O
to	O
fibrous	O
and	O
cellular	B-COMP
accumulations	O
on	O
the	O
gas	O
exchange	O
surface	O
which	O
can	O
increase	O
resistance	O
to	O
blood	O
flow	O
and	O
diffusion	O
path	O
.	O

The	O
membrane	B-COMP
surface	O
of	O
the	O
MO	O
was	O
covered	O
with	O
a	O
fibrous	O
network	O
with	O
imbedded	O
platelets	O
and	O
red	O
blood	O
cells	B-COMP
.	O

ELISA	O
method	O
was	O
used	O
to	O
detect	O
serum	B-COMP
amyloid	O
P	O
component	O
in	O
individual	O
serum	B-COMP
;	O
specificity	O
and	O
sensitivity	O
of	O
serum	B-COMP
amyloid	O
P	O
component	O
were	O
analyzed	O
.	O

42	O
respectively	O
,	O
and	O
the	O
matching	O
rate	O
of	O
protein	O
points	O
was	O
ranged	O
from	O
85	O
%	O
to	O
95	O
%;	O
eighteen	O
differentially	O
expressed	O
proteins	O
were	O
discovered	O
including	O
transthyretin	O
,	O
serpin	O
peptidase	O
inhibitor	O
,	O
alpha	O
-	O
1	O
-	O
antitrypsin	O
precursor	O
,	O
serum	B-COMP
amyloid	O
P	O
components	O
,	O
etc	O
.	O

The	O
serum	B-COMP
amyloid	O
P	O
component	O
in	O
3	O
groups	O
were	O
0	O
.	O
54	O
+/-	O

Serum	B-COMP
amyloid	O
P	O
components	O
might	O
be	O
one	O
of	O
the	O
potential	O
biomarkers	O
in	O
serum	B-COMP
of	O
recovered	O
SARS	O
patients	O
complicating	O
avascular	O
necrosis	O
of	O
femoral	O
head	O
.	O

The	O
areas	O
under	O
the	O
ROC	O
curve	O
on	O
serum	B-COMP
amyloid	O
P	O
component	O
was	O
0	O
.	O
854	O
,	O
the	O
specificity	O
was	O
77	O
.	O
8	O
%	O
and	O
the	O
sensitivity	O
was	O
85	O
.	O
2	O
%.	O

CONCLUSIONS	O
:	O
There	O
were	O
differentially	O
expressed	O
serum	B-COMP
proteins	O
in	O
three	O
groups	O
.	O

ABSTRACT	O
:	O
A	O
new	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
immunoglobulin	O
G	O
(	O
IgG	O
)-	O
plus	O
-	O
IgM	B-COMP
antibody	I-COMP
detection	O
test	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
developed	O
by	O
using	O
a	O
cocktail	O
of	O
four	O
recombinant	O
polypeptides	O
as	O
the	O
antigen	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
suggested	O
that	O
antibody	B-COMP
overproduction	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

ABSTRACT	O
:	O
Identification	O
of	O
dominant	O
T	O
cell	B-COMP
epitopes	O
within	O
newly	O
emerging	O
and	O
re	O
-	O
emerging	O
infectious	O
organisms	O
is	O
valuable	O
in	O
understanding	O
pathogenic	O
immune	O
responses	O
and	O
potential	O
vaccine	O
designs	O
.	O

Several	O
such	O
compounds	O
exhibited	O
significant	O
activity	O
specifically	O
against	O
influenza	O
A	O
virus	O
in	O
cell	B-COMP
culture	O
but	O
had	O
no	O
effect	O
on	O
the	O
replication	O
of	O
another	O
RNA	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
.	O

This	O
technique	O
is	O
a	O
reliable	O
method	O
for	O
the	O
titration	O
of	O
HCoV	O
in	O
biological	O
samples	O
(	O
cells	B-COMP
,	O
tissues	O
,	O
or	O
fluids	O
).	O

Virus	O
isolation	O
and	O
detection	O
of	O
antibody	B-COMP
,	O
antigen	O
,	O
and	O
nucleic	B-COMP
acid	O
.	O

Neutralization	O
assay	O
with	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-COMP
revealed	O
that	O
VSV	O
-	O
SARS	O
-	O
St19	O
/	O
GFP	O
pseudotype	O
infection	O
is	O
mediated	O
by	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

Thus	O
,	O
VSV	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
S	O
protein	O
is	O
useful	O
for	O
developing	O
a	O
rapid	O
detection	O
system	O
for	O
neutralizing	O
antibody	B-COMP
specific	O
for	O
SARS	O
-	O
CoV	O
infection	O
as	O
well	O
as	O
studying	O
the	O
S	O
-	O
mediated	O
cell	B-COMP
entry	O
of	O
SARS	O
-	O
CoV	O
.	O

Piglets	O
up	O
to	O
the	O
age	O
of	O
3	O
weeks	O
die	O
from	O
diarrhea	O
caused	O
by	O
the	O
viral	O
gastroenteritis	O
unless	O
they	O
are	O
protected	O
by	O
antibodies	B-COMP
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
into	O
cells	B-COMP
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

Recombinant	O
viruses	O
are	O
then	O
isolated	O
on	O
the	O
basis	O
of	O
their	O
regained	O
natural	O
(	O
e	O
.	O
g	O
.,	O
murine	O
or	O
feline	O
)	O
cell	B-COMP
tropism	O
.	O

TITLE	O
:	O
Establishment	O
and	O
characterization	O
of	O
monoclonal	O
antibodies	B-COMP
against	O
SARS	O
coronavirus	O
.	O

TITLE	O
:	O
Large	O
-	O
scale	O
preparation	O
of	O
UV	O
-	O
inactivated	O
SARS	O
coronavirus	O
virions	B-COMP
for	O
vaccine	O
antigen	O
.	O

The	O
developing	O
embryo	O
and	O
its	O
membranes	O
provide	O
the	O
diversity	O
of	O
cell	B-COMP
types	O
that	O
are	O
needed	O
for	O
successful	O
replication	O
of	O
a	O
wide	O
variety	O
of	O
different	O
viruses	O
.	O

The	O
lethal	O
pathology	O
associated	O
with	O
FIP	O
(	O
granulomatous	O
inflammation	O
and	O
T	O
-	O
cell	B-COMP
lymphopenia	O
)	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
aberrant	O
modulation	O
of	O
the	O
immune	O
system	O
due	O
to	O
infection	O
of	O
cells	B-COMP
such	O
as	O
monocytes	O
and	O
macrophages	O
.	O

These	O
data	O
suggest	O
that	O
MyD88	O
-	O
mediated	O
innate	O
immune	O
signaling	O
and	O
inflammatory	O
cell	B-COMP
recruitment	O
to	O
the	O
lung	O
are	O
required	O
for	O
protection	O
from	O
lethal	O
rMA15	O
infection	O
.	O

Here	O
,	O
we	O
reconcile	O
these	O
apparently	O
conflicting	O
results	O
by	O
showing	O
that	O
p6	O
enhances	O
SARS	O
-	O
CoV	O
replication	O
to	O
nearly	O
the	O
same	O
extent	O
as	O
when	O
expressed	O
in	O
the	O
context	O
of	O
MHV	O
if	O
cells	B-COMP
are	O
infected	O
at	O
a	O
low	O
MOI	O
and	O
accelerates	O
disease	O
in	O
mice	O
transgenic	O
for	O
the	O
human	O
SARS	O
-	O
CoV	O
receptor	O
.	O

IL	O
-	O
15	O
deficiency	O
also	O
had	O
no	O
affect	O
on	O
IL	O
-	O
7	O
receptor	O
(	O
CD127	O
)	O
expression	O
,	O
Bcl	O
-	O
2	O
upregulation	O
,	O
granzyme	O
B	O
expression	O
,	O
or	O
IFN	O
-	O
gamma	O
secretion	O
in	O
CNS	O
persisting	O
CD8	O
(+)	O
T	O
cells	B-COMP
.	O

Moreover	O
,	O
knockdown	O
of	O
PU	O
.	O
1	O
through	O
the	O
use	O
of	O
small	O
interfering	O
RNA	O
led	O
to	O
a	O
decrease	O
in	O
LSECtin	O
mRNA	O
levels	O
in	O
THP	O
-	O
1	O
and	O
monocyte	O
-	O
derived	O
dendritic	B-COMP
cells	B-COMP
,	O
thus	O
confirming	O
the	O
involvement	O
of	O
PU	O
.	O
1	O
in	O
the	O
myeloid	O
expression	O
of	O
the	O
lectin	O
.	O

We	O
hypothesized	O
that	O
two	O
of	O
the	O
hydrophilic	O
structural	O
coronoviral	O
proteins	O
(	O
S	O
and	O
E	O
)	O
would	O
regulate	O
alveolar	O
fluid	O
clearance	O
by	O
decreasing	O
the	O
cell	B-COMP
surface	I-COMP
expression	O
and	O
activity	O
of	O
amiloride	O
-	O
sensitive	O
epithelial	O
sodium	O
(	O
Na	O
(+))	O
channels	O
(	O
ENaC	O
),	O
the	O
rate	O
-	O
limiting	O
protein	O
in	O
transepithelial	O
Na	O
(+)	O
vectorial	O
transport	O
across	O
distal	O
lung	O
epithelial	O
cells	B-COMP
.	O

Plasmacytoid	O
dendritic	B-COMP
cell	B-COMP
-	O
derived	O
type	O
I	O
IFNs	O
are	O
of	O
prime	O
importance	O
for	O
the	O
initial	O
control	O
of	O
highly	O
cytopathic	O
viruses	O
such	O
as	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

This	O
genetic	O
analysis	O
revealed	O
that	O
IFNAR	O
expression	O
on	O
LysM	O
+	O
macrophages	O
and	O
CD11c	O
+	O
dendritic	B-COMP
cells	B-COMP
was	O
most	O
important	O
for	O
the	O
early	O
containment	O
of	O
MHV	O
within	O
secondary	O
lymphoid	O
organs	O
and	O
to	O
prevent	O
lethal	O
liver	O
disease	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
clinical	O
disease	O
in	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	O
results	O
from	O
a	O
balance	O
between	O
factors	O
critical	O
for	O
virus	O
clearance	O
,	O
such	O
as	O
virus	O
-	O
specific	O
effector	O
T	O
cells	B-COMP
and	O
anti	O
-	O
inflammatory	O
elements	O
,	O
such	O
as	O
Tregs	O
.	O

An	O
investigation	O
of	O
the	O
binding	O
properties	O
of	O
the	O
elicited	O
antibodies	B-COMP
showed	O
that	O
they	O
were	O
highly	O
conformation	O
specific	O
for	O
the	O
coiled	O
-	O
coil	O
epitope	O
because	O
they	O
specifically	O
recognized	O
the	O
native	O
trimeric	O
conformation	O
of	O
C	O
-	O
terminal	O
heptad	O
repeat	O
region	O
.	O

Their	O
aptitude	O
to	O
evolve	O
by	O
genetic	O
recombination	O
and	O
/	O
or	O
point	O
mutation	O
is	O
recognized	O
,	O
thus	O
giving	O
rise	O
to	O
new	O
viral	O
genotypes	O
and	O
mutants	O
with	O
different	O
tissues	O
or	O
host	B-COMP
tropism	O
.	O

Although	O
not	O
yet	O
formally	O
published	O
,	O
the	O
results	O
of	O
this	O
study	O
,	O
if	O
confirmed	O
,	O
represent	O
the	O
first	O
positive	O
randomized	O
clinical	O
trial	O
on	O
adult	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
application	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
.	O

ABSTRACT	O
:	O
Pumpless	O
interventional	O
lung	O
assist	O
(	O
iLA	O
)	O
is	O
used	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
aimed	O
at	O
improving	O
extracorporeal	O
gas	O
exchange	O
with	O
a	O
membrane	B-COMP
integrated	O
in	O
a	O
passive	O
arteriovenous	O
shunt	O
.	O

Additionally	O
,	O
experimental	O
studies	O
have	O
indicated	O
that	O
the	O
host	B-COMP
range	O
of	O
TCoV	O
,	O
once	O
thought	O
to	O
be	O
restricted	O
to	O
turkeys	O
,	O
includes	O
chickens	O
.	O

It	O
is	O
desirable	O
to	O
have	O
a	O
nomenclature	O
for	O
avian	O
coronaviruses	O
that	O
indicates	O
the	O
host	B-COMP
species	O
of	O
origin	O
.	O

Twenty	O
-	O
one	O
rabbits	O
were	O
operatively	O
prepared	O
and	O
randomly	O
divided	O
into	O
sham	O
,	O
control	O
,	O
or	O
APC	B-COMP
groups	O
(	O
n	O
=	O
7	O
in	O
each	O
group	O
).	O

In	O
comparison	O
with	O
nontreatment	O
in	O
the	O
control	O
group	O
,	O
the	O
infusion	O
of	O
APC	B-COMP
significantly	O
reduced	O
the	O
increase	O
of	O
thrombomodulin	O
level	O
(	O
TM	O
;	O
control	O
group	O
was	O
(	O
0	O
.	O
68	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
,	O
vs	O
APC	B-COMP
group	O
of	O
(	O
0	O
.	O
62	O
+/-	O

0	O
.	O
6	O
in	O
APC	B-COMP
group	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

We	O
describe	O
this	O
exceptional	O
large	O
intrapulmonary	O
germ	O
cell	B-COMP
tumor	O
and	O
discuss	O
the	O
spectrum	O
of	O
such	O
rare	O
tumors	O
.	O

Most	O
eukaryotic	O
viruses	O
that	O
replicate	O
in	O
the	O
cytoplasm	B-COMP
,	O
including	O
coronaviruses	O
,	O
have	O
evolved	O
strategies	O
to	O
cap	O
their	O
RNAs	O
.	O

Interestingly	O
,	O
coronavirus	O
nsp14	O
was	O
previously	O
characterized	O
as	O
a	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
,	O
and	O
by	O
mutational	O
analysis	O
,	O
we	O
mapped	O
the	O
N7	O
-	O
MTase	O
domain	O
to	O
the	O
carboxy	O
-	O
terminal	O
part	O
of	O
nsp14	O
that	O
shows	O
features	O
conserved	O
with	O
cellular	B-COMP
N7	O
-	O
MTase	O
in	O
structure	O
-	O
based	O
sequence	O
alignment	O
.	O

In	O
addition	O
,	O
the	O
S	O
proteins	O
were	O
recognized	O
specifically	O
by	O
the	O
sera	B-COMP
of	O
convalescent	O
patients	O
with	O
SARS	O
,	O
and	O
that	O
of	O
mice	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
,	O
but	O
did	O
not	O
react	O
with	O
anti	O
-	O
sera	B-COMP
of	O
HCoV	O
-	O
OC43	O
or	O
HCoV	O
-	O
229E	O
,	O
or	O
sera	B-COMP
from	O
healthy	O
donors	O
(	O
although	O
RBD	O
showed	O
a	O
false	O
-	O
positive	O
in	O
1	O
of	O
55	O
control	O
samples	O
of	O
human	O
sera	B-COMP
).	O

ABSTRACT	O
:	O
Recently	O
,	O
several	O
potently	O
neutralizing	O
fully	O
human	O
monoclonal	O
antibodies	B-COMP
(	O
hmAbs	O
)	O
targeting	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
S	O
glycoprotein	O
,	O
and	O
the	O
G	O
glycoprotein	O
of	O
the	O
paramyxoviruses	O
Hendra	O
virus	O
(	O
HeV	O
)	O
and	O
Nipah	O
virus	O
(	O
NiV	O
)	O
have	O
been	O
discovered	O
[	O
corrected	O
].	O

TITLE	O
:	O
Interaction	O
between	O
SARS	O
-	O
CoV	O
helicase	O
and	O
a	O
multifunctional	O
cellular	B-COMP
protein	O
(	O
Ddx5	O
)	O
revealed	O
by	O
yeast	O
and	O
mammalian	O
cell	B-COMP
two	O
-	O
hybrid	O
systems	O
.	O

ABSTRACT	O
:	O
A	O
high	O
survival	O
rate	O
can	O
be	O
achieved	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
using	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

Histopathological	O
analysis	O
of	O
adult	O
male	O
BALB	O
/	O
C	O
mice	O
after	O
N	O
-	O
protein	O
infection	O
showed	O
progressive	O
inflammatory	O
reactions	O
,	O
especially	O
pulmonary	O
edema	O
,	O
in	O
accordance	O
with	O
a	O
moderately	O
(	O
approximately	O
13	O
%)	O
elevated	O
level	O
of	O
W	O
/	O
D	O
ratio	O
at	O
24	O
h	O
.	O
Although	O
adult	O
groups	O
underwent	O
a	O
progressive	O
lung	O
inflammation	O
in	O
the	O
acute	O
phase	O
accompanied	O
by	O
raised	O
levels	O
of	O
TNF	O
-	O
alpha	O
in	O
serum	B-COMP
,	O
no	O
significant	O
changes	O
in	O
lung	O
TNF	O
-	O
alpha	O
level	O
were	O
reported	O
simultaneously	O
.	O

HCoV	O
infection	O
was	O
determined	O
on	O
the	O
basis	O
of	O
a	O
4	O
-	O
fold	O
increase	O
in	O
serum	B-COMP
antibody	B-COMP
and	O
the	O
detection	O
of	O
HCoV	O
by	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
Fatal	O
outcome	O
after	O
insufficient	O
spine	B-COMP
fixation	O
for	O
pyogenic	O
thoracic	O
spondylodiscitis	O
:	O
an	O
imperative	O
for	O
360	O
degrees	O
fusion	O
of	O
the	O
infected	O
spine	B-COMP
.	O

This	O
catastrophic	O
example	O
of	O
a	O
lethal	O
outcome	O
secondary	O
to	O
failure	O
of	O
anterior	O
column	O
fixation	O
for	O
pyogenic	O
thoracic	O
spondylodiscitis	O
underlines	O
the	O
notion	O
that	O
surgical	O
strategies	O
for	O
the	O
infected	O
spine	B-COMP
must	O
be	O
aimed	O
at	O
achieving	O
absolute	O
stability	O
by	O
a	O
360	O
degrees	O
fusion	O
.	O

ABSTRACT	O
:	O
Differential	O
scanning	O
calorimetry	O
,	O
circular	O
dichroism	O
spectroscopy	O
,	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
,	O
and	O
numerical	O
simulations	O
were	O
used	O
to	O
study	O
the	O
thermostability	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
.	O

This	O
extensive	O
evolutionary	O
analysis	O
revealed	O
the	O
stepwise	O
evolution	O
of	O
different	O
functional	O
proteins	O
of	O
SARS	O
-	O
CoVs	O
at	O
different	O
epidemic	O
stages	O
and	O
different	O
hosts	B-COMP
.	O

Rm1	O
nsp1	O
expression	O
in	O
trans	O
strongly	O
inhibited	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
and	O
IFN	O
-	O
stimulated	O
genes	O
in	O
cells	B-COMP
infected	O
with	O
an	O
IFN	O
-	O
inducing	O
SARS	O
-	O
CoV	O
mutant	O
,	O
while	O
133	O
and	O
HKU9	O
-	O
1	O
nsp1	O
proteins	O
had	O
relatively	O
moderate	O
IFN	O
-	O
inhibitory	O
activities	O
.	O

The	O
high	O
mortality	O
of	O
SARS	O
,	O
the	O
identification	O
of	O
a	O
natural	O
reservoir	O
,	O
and	O
the	O
well	O
-	O
founded	O
fear	O
of	O
provoking	O
antibody	B-COMP
-	O
enhanced	O
disease	O
as	O
a	O
result	O
of	O
vaccination	O
fueled	O
the	O
ongoing	O
efforts	O
in	O
anti	O
-	O
coronavirus	O
drug	O
discovery	O
.	O

One	O
case	O
with	O
transitional	O
cell	B-COMP
carcinoma	O
of	O
the	O
urinary	O
bladder	O
developed	O
acute	O
episode	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

To	O
understand	O
the	O
cellular	B-COMP
factors	O
that	O
may	O
be	O
involved	O
in	O
virion	B-COMP
assembly	O
,	O
budding	O
and	O
maturation	O
processes	O
,	O
IBV	O
M	O
was	O
used	O
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
resulting	O
in	O
the	O
identification	O
of	O
beta	O
-	O
actin	O
as	O
a	O
potentially	O
interacting	O
partner	O
.	O

This	O
interaction	O
was	O
subsequently	O
confirmed	O
by	O
coimmunoprecipitation	O
and	O
immunofluorescence	O
microscopy	O
in	O
mammalian	O
cells	B-COMP
,	O
and	O
mutation	O
of	O
amino	O
acids	O
A159	O
and	O
K160	O
on	O
the	O
M	O
protein	O
abolished	O
the	O
interaction	O
.	O

TITLE	O
:	O
Neutralizing	O
antibody	B-COMP
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
spike	O
is	O
highly	O
effective	O
for	O
the	O
protection	O
of	O
mice	O
in	O
the	O
murine	O
SARS	O
model	O
.	O

Aside	O
from	O
targeted	O
regions	O
,	O
other	O
brain	O
structures	O
also	O
showed	O
GFP	O
signal	O
(	O
internal	O
and	O
external	O
globus	O
pallidus	O
,	O
subthalamic	O
nucleus	B-COMP
),	O
supporting	O
the	O
idea	O
that	O
AAV1	O
is	O
actively	O
trafficked	O
to	O
regions	O
distal	O
from	O
the	O
infusion	O
site	O
.	O

We	O
observed	O
a	O
strong	O
humoral	O
and	O
cell	B-COMP
-	O
mediated	O
response	O
against	O
AAV1	O
-	O
hrGFP	O
in	O
transduced	O
monkeys	O
irrespective	O
of	O
the	O
anatomic	O
location	O
of	O
the	O
infusion	O
,	O
as	O
evidenced	O
by	O
induction	O
of	O
circulating	O
anti	O
-	O
AAV1	O
and	O
anti	O
-	O
hrGFP	O
antibodies	B-COMP
,	O
as	O
well	O
as	O
infiltration	O
of	O
CD4	O
(+)	O
lymphocytes	O
and	O
upregulation	O
of	O
MHC	O
-	O
II	O
in	O
regions	O
infused	O
with	O
vector	O
.	O

He	O
was	O
diagnosed	O
with	O
subclinical	O
measles	O
infection	O
since	O
no	O
anthema	O
was	O
observed	O
despite	O
the	O
fact	O
that	O
his	O
serum	B-COMP
and	O
cerebrospinal	O
fluid	O
samples	O
were	O
positive	O
for	O
measles	O
IgM	O
antibodies	B-COMP
.	O

We	O
also	O
found	O
that	O
CD8	O
(+)	O
T	O
cells	B-COMP
were	O
partially	O
effective	O
in	O
attenuating	O
the	O
pathogenesis	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
lethality	O
-	O
resistant	O
AC22	O
mice	O
.	O

TITLE	O
:	O
The	O
8ab	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
a	O
luminal	O
ER	B-COMP
membrane	I-COMP
-	O
associated	O
protein	O
and	O
induces	O
the	O
activation	O
of	O
ATF6	O
.	O

Here	O
we	O
found	O
that	O
8ab	O
protein	O
is	O
associated	O
with	O
ER	B-COMP
membrane	I-COMP
at	O
luminal	O
surface	O
.	O

When	O
incubated	O
with	O
Hela	O
cells	B-COMP
,	O
the	O
purified	O
protein	O
could	O
not	O
internalize	O
through	O
membrane	B-COMP
fusion	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
a	O
novel	O
priming	O
mechanism	O
for	O
a	O
viral	O
fusion	O
protein	O
,	O
with	O
a	O
critical	O
proteolytic	O
cleavage	O
event	O
on	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
at	O
position	O
797	O
(	O
S2	O
'),	O
acting	O
in	O
concert	O
with	O
the	O
S1	O
-	O
S2	O
cleavage	O
site	O
to	O
mediate	O
membrane	B-COMP
fusion	O
and	O
virus	O
infectivity	O
.	O

Two	O
-	O
day	O
-	O
old	O
and	O
28	O
-	O
day	O
-	O
old	O
poults	O
were	O
inoculated	O
orally	O
with	O
TCoV	O
-	O
MG10	O
to	O
examine	O
the	O
effect	O
of	O
age	O
on	O
viral	O
shedding	O
and	O
serum	B-COMP
antibody	B-COMP
responses	O
to	O
the	O
virus	O
.	O

Both	O
S	O
and	O
the	O
RBD	O
are	O
highly	O
immunogenic	O
and	O
both	O
have	O
been	O
found	O
to	O
elicit	O
neutralizing	O
antibodies	B-COMP
.	O

Significant	O
elevations	O
in	O
oxygen	O
saturation	O
,	O
serum	B-COMP
creatinine	O
,	O
lactate	O
dehydrogenase	O
,	O
creatine	O
kinase	O
MB	O
isoenzyme	O
,	O
and	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
),	O
but	O
not	O
in	O
alanine	O
transaminase	O
were	O
predictors	O
for	O
death	O
.	O

The	O
cytotoxic	O
effects	O
of	O
CD4	O
-	O
CD8	O
-	O
T	O
cells	B-COMP
on	O
normal	O
and	O
infected	O
hepatocytes	O
,	O
CD8	O
+	O
T	O
cells	B-COMP
and	O
unrelated	O
-	O
virus	O
(	O
murine	O
cytomegalovirus	O
,	O
MCMV	O
)	O
infected	O
CD8	O
+	O
T	O
cells	B-COMP
were	O
examined	O
by	O
non	O
-	O
radioactive	O
cytotoxicity	O
assay	O
.	O

The	O
phenotype	O
of	O
these	O
CD4	O
-	O
CD8	O
-	O
T	O
cells	B-COMP
detected	O
by	O
flow	O
cytometry	O
is	O
TCR	B-COMP
alpha	O
beta	O
+	O
CD3	O
+	O
CD4	O
-	O
CD8	O
-	O
CD25	O
-	O
CD28	O
-	O
CD30	O
-	O
CD44	O
+.	O

Overall	O
,	O
92	O
.	O
9	O
%	O
of	O
the	O
flocks	O
free	O
from	O
respiratory	O
disease	O
were	O
seropositive	O
for	O
antibodies	B-COMP
to	O
the	O
M	O
-	O
41	O
strain	O
,	O
whereas	O
90	O
%	O
and	O
61	O
.	O
4	O
%	O
of	O
the	O
flocks	O
were	O
seropositive	O
for	O
antibodies	B-COMP
to	O
the	O
4	O
/	O
91	O
and	O
D274	O
strains	O
,	O
respectively	O
.	O

The	O
extent	O
of	O
the	O
sustained	O
injury	O
and	O
the	O
subsequent	O
cellular	B-COMP
innate	O
immune	O
response	O
is	O
reflected	O
by	O
changes	O
in	O
a	O
functional	O
PMN	O
phenotype	O
of	O
fMLP	O
-	O
induced	O
active	O
FcgammaRII	O
in	O
the	O
peripheral	O
blood	O
.	O

Transcription	O
of	O
the	O
proinflammatory	O
cytokines	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
6	O
,	O
but	O
not	O
tumor	O
necrosis	O
factor	O
,	O
were	O
initially	O
reduced	O
in	O
infected	O
p35	B-COMP
(-/-)	O
mice	O
but	O
increased	O
to	O
wild	O
-	O
type	O
levels	O
during	O
peak	O
inflammation	O
.	O

TITLE	O
:	O
Motor	O
performance	O
in	O
five	O
-	O
year	O
-	O
old	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
survivors	O
:	O
a	O
population	O
-	O
based	O
study	O
.	O

After	O
treatment	O
of	O
A549	O
cells	B-COMP
with	O
EtP	O
,	O
a	O
substantial	O
reduction	O
in	O
the	O
cytokine	O
-	O
induced	O
adhesion	O
of	O
neutrophils	O
to	O
monolayers	O
was	O
noted	O
,	O
whereas	O
sodium	O
pyruvate	O
(	O
NaP	O
)	O
conferred	O
no	O
reduction	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
reported	O
that	O
replacing	O
HIV	O
-	O
1	O
nucleocapsid	B-COMP
(	O
NC	O
)	O
domain	O
with	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
residues	O
2	O
-	O
213	O
,	O
215	O
-	O
421	O
,	O
or	O
234	O
-	O
421	O
results	O
in	O
efficient	O
virus	B-COMP
-	I-COMP
like	I-COMP
particle	I-COMP
(	O
VLP	B-COMP
)	O
production	O
at	O
a	O
level	O
comparable	O
to	O
that	O
of	O
wild	O
-	O
type	O
HIV	O
-	O
1	O
.	O

We	O
attempted	O
to	O
isolate	O
viruses	O
from	O
fresh	O
tissue	O
samples	O
taken	O
from	O
trapped	O
bats	O
in	O
cultured	O
cells	B-COMP
of	O
bat	O
,	O
primate	O
,	O
rodent	O
,	O
porcine	O
,	O
ovine	O
and	O
avian	O
origin	O
.	O

Development	O
and	O
optimization	O
of	O
6MP	O
and	O
6TG	O
will	O
not	O
only	O
be	O
important	O
for	O
antiviral	O
studies	O
,	O
but	O
also	O
for	O
further	O
elucidating	O
the	O
biological	O
functions	O
of	O
cellular	B-COMP
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
and	O
deISGylating	O
enzymes	O
.	O

So	O
far	O
,	O
several	O
crystal	O
structures	O
of	O
cellular	B-COMP
DUBs	O
have	O
been	O
solved	O
.	O

ABSTRACT	O
:	O
The	O
neurotropic	O
coronavirus	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
persists	O
in	O
oligodendroglia	O
despite	O
the	O
presence	O
of	O
virus	O
-	O
specific	O
CD8	O
T	O
cells	B-COMP
.	O

Moreover	O
,	O
despite	O
control	O
of	O
infectious	O
virus	O
,	O
CD8	O
T	O
cells	B-COMP
within	O
the	O
CNS	O
of	O
persistently	O
infected	O
mice	O
maintained	O
high	O
PD	O
-	O
1	O
expression	O
.	O

Ab	O
blockade	O
of	O
B7	O
-	O
H1	O
on	O
oligodendroglia	O
in	O
vitro	O
enhanced	O
IFN	O
-	O
gamma	O
secretion	O
by	O
virus	O
-	O
specific	O
CD8	O
T	O
cells	B-COMP
.	O

More	O
efficient	O
virus	O
control	O
within	O
the	O
CNS	O
of	O
B7	O
-	O
H1	O
-	O
deficient	O
mice	O
confirmed	O
inhibition	O
of	O
CD8	O
T	O
cell	B-COMP
function	O
in	O
vivo	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
demonstrate	O
glia	O
cell	B-COMP
type	I-COMP
-	O
dependent	O
B7	O
-	O
H1	O
regulation	O
in	O
vivo	O
,	O
resulting	O
in	O
adverse	O
effects	O
on	O
antiviral	O
CD8	O
T	O
cell	B-COMP
function	O
.	O

TITLE	O
:	O
Detection	O
of	O
nonstructural	O
protein	O
6	O
in	O
murine	O
coronavirus	O
-	O
infected	O
cells	B-COMP
and	O
analysis	O
of	O
the	O
transmembrane	B-COMP
topology	O
by	O
using	O
bioinformatics	O
and	O
molecular	O
approaches	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
encode	O
large	O
replicase	O
polyproteins	O
which	O
are	O
proteolytically	O
processed	O
by	O
viral	O
proteases	O
to	O
generate	O
mature	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
that	O
form	O
the	O
viral	B-COMP
replication	I-COMP
complex	I-COMP
.	O

We	O
report	O
the	O
first	O
antibody	B-COMP
-	O
mediated	O
Western	O
blot	O
detection	O
of	O
nsp6	O
from	O
MHV	O
-	O
infected	O
cells	B-COMP
.	O

Analysis	O
of	O
nsp6	O
transmembrane	B-COMP
topology	O
revealed	O
six	O
membrane	B-COMP
-	O
spanning	O
segments	O
and	O
a	O
conserved	O
hydrophobic	O
domain	O
in	O
the	O
C	O
-	O
terminal	O
cytosolic	B-COMP
tail	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
9b	O
protein	O
is	O
translated	O
from	O
bicistronic	O
mRNA9	O
via	O
leaky	O
ribosome	B-COMP
scanning	O
and	O
it	O
is	O
incorporated	O
into	O
both	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
and	O
purified	O
SARS	O
-	O
CoV	O
virions	B-COMP
.	O

Our	O
data	O
indicate	O
that	O
9b	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
another	O
virion	B-COMP
-	O
associated	O
accessory	O
protein	O
.	O

The	O
ELISA	O
test	O
of	O
IgG	B-COMP
antibody	I-COMP
was	O
negative	O
in	O
200	O
community	O
controls	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
),	O
together	O
with	O
the	O
large	O
,	O
positive	O
-	O
strand	O
RNA	B-COMP
viral	I-COMP
genome	I-COMP
,	O
forms	O
a	O
helically	O
symmetric	O
nucleocapsid	B-COMP
.	O

Although	O
the	O
molecular	O
mechanisms	O
governing	O
ARDS	O
pathophysiology	O
remain	O
unknown	O
in	O
aged	O
animals	O
,	O
these	O
studies	O
reveal	O
a	O
strategy	O
for	O
dissecting	O
the	O
genetic	O
pathways	O
by	O
which	O
SARS	O
-	O
CoV	O
infection	O
induces	O
changes	O
in	O
the	O
host	B-COMP
response	O
,	O
leading	O
to	O
death	O
.	O

ABSTRACT	O
:	O
Eleven	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)	O
that	O
were	O
reactive	O
against	O
the	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
HEV	O
),	O
as	O
seen	O
in	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
were	O
obtained	O
.	O

These	O
MAbs	O
would	O
be	O
a	O
useful	O
tool	O
for	O
rapid	O
and	O
specific	O
diagnosis	O
of	O
HEV	O
and	O
also	O
for	O
antibody	B-COMP
-	O
based	O
treatment	O
of	O
the	O
disease	O
.	O

Immunization	O
of	O
mice	O
with	O
RBD193	O
-	O
CHO	O
resulted	O
in	O
induction	O
of	O
high	O
titers	O
of	O
RBD	O
-	O
specific	O
neutralizing	O
antibodies	B-COMP
and	O
potent	O
IL	O
-	O
4	O
-	O
expressing	O
T	O
cell	B-COMP
responses	O
.	O

N	O
protein	O
is	O
thought	O
to	O
dysregulate	O
cell	B-COMP
signalling	O
and	O
the	O
transcription	O
of	O
cellular	B-COMP
genes	O
,	O
including	O
FGL2	O
,	O
which	O
encodes	O
a	O
prothrombinase	O
implicated	O
in	O
vascular	O
thrombosis	O
,	O
fibrin	O
deposition	O
and	O
pneumocyte	O
necrosis	O
.	O

Here	O
,	O
we	O
showed	O
that	O
N	O
protein	O
expressed	O
in	O
cultured	O
human	O
cells	B-COMP
was	O
predominantly	O
found	O
in	O
the	O
cytoplasm	B-COMP
and	O
was	O
competent	O
in	O
repressing	O
the	O
transcriptional	O
activity	O
driven	O
by	O
interferon	O
-	O
stimulated	O
response	O
elements	O
.	O

More	O
importantly	O
,	O
N	O
protein	O
did	O
not	O
modulate	O
the	O
expression	O
of	O
FGL2	O
mRNA	O
or	O
protein	O
in	O
transfected	O
or	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	B-COMP
.	O

Bacterial	O
and	O
viral	O
infections	O
can	O
directly	O
promote	O
pulmonary	O
endothelial	O
hyperpermeability	O
and	O
indirectly	O
decrease	O
the	O
function	O
and	O
/	O
or	O
expression	O
of	O
ion	O
transporters	O
regulating	O
ALC	O
in	O
type	O
II	O
alveolar	O
epithelial	O
cells	B-COMP
,	O
by	O
means	O
of	O
inducing	O
a	O
strong	O
inflammatory	O
and	O
oxidative	O
stress	O
response	O
in	O
the	O
infected	O
lungs	O
.	O

The	O
inhibition	O
on	O
pseudovirus	O
was	O
also	O
seen	O
in	O
cells	B-COMP
pretreated	O
with	O
the	O
CC	O
and	O
CC	O
/	O
Fr	O
.	O
2	O
(	O
IC	O
(	O
50S	O
),	O
283	O
.	O
4	O
+/-	O
16	O
.	O
3	O
and	O
149	O
.	O
5	O
+/-	O
13	O
.	O
5	O
microg	O
/	O
ml	O
,	O
respectively	O
),	O
however	O
the	O
highest	O
activities	O
on	O
wtSARS	O
-	O
CoV	O
were	O
observed	O
when	O
the	O
viruses	O
were	O
treated	O
by	O
the	O
extracts	O
before	O
challenging	O
(	O
IC	O
(	O
50S	O
),	O
43	O
.	O
1	O
+/-	O
2	O
.	O
8	O
and	O
7	O
.	O
8	O
+/-	O
0	O
.	O
3	O
microg	O
/	O
ml	O
;	O
SIs	O
,	O
8	O
.	O
4	O
and	O
23	O
.	O
1	O
,	O
respectively	O
).	O

Indirubin	O
,	O
one	O
of	O
the	O
biological	O
active	O
compounds	O
of	O
Isatis	O
indigotica	O
,	O
had	O
the	O
most	O
significant	O
cytotoxicity	O
on	O
HL	O
-	O
60	O
cells	B-COMP
and	O
inhibitory	O
effect	O
on	O
PrV	O
replication	O
.	O

The	O
SARS	O
-	O
CoV	O
genome	O
is	O
devoid	O
of	O
G	O
-	O
stretches	O
longer	O
than	O
5	O
-	O
6	O
nucleotides	O
,	O
but	O
more	O
extended	O
G	O
-	O
stretches	O
are	O
found	O
in	O
the	O
3	O
'-	O
nontranslated	O
regions	O
of	O
mRNAs	O
coding	O
for	O
certain	O
host	B-COMP
-	O
cell	B-COMP
proteins	O
involved	O
in	O
apoptosis	O
or	O
signal	O
transduction	O
,	O
and	O
have	O
been	O
shown	O
to	O
bind	O
to	O
SUD	O
in	O
vitro	O
.	O

Infection	O
of	O
malignant	O
human	O
glioblastoma	O
U87DeltaEGFR	O
cells	B-COMP
gave	O
rise	O
to	O
release	O
of	O
progeny	O
virus	O
and	O
efficient	O
cell	B-COMP
killing	O
in	O
vitro	O
.	O

Part	O
2	O
:	O
Inhibitors	O
of	O
intracellular	B-COMP
life	O
cycle	O
.	O

In	O
this	O
study	O
in	O
healthy	O
Chinese	O
male	O
volunteers	O
,	O
the	O
dispersible	O
tablet	O
formulation	O
and	O
the	O
200	O
-	O
mg	O
capsule	B-COMP
formulation	O
of	O
arbidol	O
met	O
the	O
SFDA	O
'	O
s	O
regulatory	O
definition	O
of	O
bioequivalence	O
based	O
on	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
.	O

Moreover	O
,	O
combinations	O
of	O
monoclonal	O
antibodies	B-COMP
have	O
been	O
shown	O
to	O
have	O
a	O
broader	O
spectrum	O
of	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
protein	O
C	O
system	O
is	O
an	O
important	O
natural	O
anticoagulant	O
mechanism	O
mediated	O
by	O
activated	O
protein	O
C	O
(	O
APC	B-COMP
)	O
that	O
regulates	O
the	O
activity	O
of	O
factors	O
VIIIa	O
and	O
Va	O
.	O
Besides	O
well	O
-	O
defined	O
anticoagulant	O
properties	O
,	O
APC	B-COMP
also	O
demonstrates	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
apoptotic	O
and	O
endothelial	O
barrier	O
-	O
stabilizing	O
effects	O
that	O
are	O
collectively	O
referred	O
to	O
as	O
the	O
cytoprotective	O
effects	O
of	O
APC	B-COMP
.	O

Increased	O
insight	O
into	O
the	O
structure	O
-	O
function	O
relationships	O
of	O
APC	B-COMP
facilitated	O
design	O
of	O
APC	B-COMP
variants	O
that	O
conserve	O
cytoprotective	O
effects	O
and	O
reduce	O
anticoagulant	O
features	O
,	O
thereby	O
attenuating	O
the	O
risk	O
of	O
severe	O
bleeding	O
with	O
APC	B-COMP
therapy	O
.	O

The	O
integrin	O
-	O
binding	O
motif	O
Arg	O
-	O
Gly	O
-	O
Asp	O
(	O
RGD	O
)	O
was	O
incorporated	O
into	O
the	O
pcDNA	O
3	O
.	O
1	O
mammalian	O
expression	O
vector	O
expressing	O
the	O
codon	O
-	O
optimized	O
extracellular	B-COMP
domain	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
,	O
and	O
tested	O
by	O
immunizing	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
background	O
of	O
the	O
cat	O
,	O
its	O
history	O
,	O
the	O
clinical	O
signs	O
,	O
laboratory	O
changes	O
,	O
antibody	B-COMP
titres	O
and	O
effusion	O
analysis	O
should	O
all	O
be	O
used	O
to	O
help	O
in	O
decision	O
-	O
making	O
about	O
further	O
diagnostic	O
procedures	O
.	O

TITLE	O
:	O
Propagation	O
of	O
swine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
and	O
pseudorabies	O
virus	O
in	O
dorsal	O
root	O
ganglia	O
cells	B-COMP
.	O

HEV	O
infected	O
nerve	O
cells	B-COMP
but	O
did	O
not	O
infect	O
non	O
-	O
neuronal	O
cells	B-COMP
,	O
whereas	O
PRV	O
infected	O
both	O
cell	B-COMP
types	O
.	O

SARS	O
-	O
CoV	O
protein	O
eukaryotic	O
expression	O
plasmids	O
were	O
transfected	O
respectively	O
into	O
CHO	O
cells	B-COMP
.	O

Lung	O
injury	O
and	O
inflammation	O
were	O
assessed	O
by	O
arterial	O
blood	O
gases	O
and	O
levels	O
of	O
albumin	O
,	O
cells	B-COMP
,	O
and	O
cytokines	O
/	O
chemokines	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
at	O
5	O
and	O
24	O
h	O
.	O
Rats	O
with	O
LC	O
+	O
CASP	O
had	O
lower	O
mean	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratios	O
compared	O
with	O
LC	O
alone	O
at	O
24	O
h	O
,	O
and	O
higher	O
BAL	O
albumin	O
concentrations	O
compared	O
with	O
either	O
LC	O
or	O
CASP	O
alone	O
.	O

TITLE	O
:	O
Boosted	O
expression	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
in	O
tobacco	O
and	O
its	O
immunogenicity	O
in	O
mice	O
.	O

Antibodies	B-COMP
of	O
the	O
subclasses	O
IgG1	B-COMP
and	O
IgG2a	B-COMP
were	O
abundantly	O
present	O
in	O
the	O
mouse	O
sera	B-COMP
.	O

However	O
,	O
it	O
is	O
critical	O
to	O
determine	O
whether	O
SARS	O
-	O
CoV	O
-	O
specific	O
memory	O
T	O
cells	B-COMP
can	O
persist	O
for	O
long	O
periods	O
of	O
time	O
.	O

Our	O
results	O
demonstrated	O
that	O
low	O
levels	O
of	O
specific	O
memory	O
T	O
cell	B-COMP
responses	O
to	O
SARS	O
-	O
CoV	O
S	O
,	O
M	O
,	O
E	O
and	O
N	O
peptides	O
were	O
detected	O
in	O
a	O
proportion	O
of	O
SARS	O
-	O
recovered	O
patients	O
,	O
and	O
IFN	O
-	O
gamma	O
was	O
the	O
predominant	O
cytokine	O
produced	O
by	O
T	O
cells	B-COMP
after	O
stimulation	O
with	O
peptides	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
cleaved	O
into	O
S1	O
and	O
S2	O
subunits	O
at	O
the	O
furin	O
consensus	O
motif	O
RRFRR	O
(	O
537	O
)/	O
S	O
in	O
virus	O
-	O
infected	O
cells	B-COMP
.	O

Our	O
findings	O
contribute	O
to	O
developing	O
the	O
codon	O
-	O
optimization	O
method	O
in	O
DNA	O
vaccines	O
,	O
and	O
further	O
study	O
is	O
needed	O
to	O
determine	O
a	O
specific	O
correlation	O
between	O
the	O
codon	O
usage	O
patterns	O
and	O
the	O
chromosomal	B-COMP
locations	O
in	O
higher	O
organisms	O
.	O

To	O
determine	O
whether	O
the	O
spike	O
protein	O
is	O
responsible	O
for	O
the	O
difference	O
,	O
a	O
recombinant	O
virus	O
,	O
Penn	O
-	O
98	O
-	O
1	O
,	O
that	O
contains	O
the	O
A59	O
genome	O
with	O
a	O
spike	O
from	O
MHV	O
-	O
2	O
was	O
used	O
to	O
infect	O
DBT	O
cells	B-COMP
.	O

However	O
,	O
morbidity	O
in	O
A	O
/	O
J	O
and	O
C3H	O
/	O
HeJ	O
mice	O
can	O
be	O
minimized	O
by	O
treating	O
them	O
with	O
immune	O
serum	B-COMP
prior	O
to	O
MHV	O
-	O
1	O
infection	O
.	O

This	O
study	O
demonstrates	O
that	O
acquisition	O
of	O
the	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
activity	O
in	O
S	O
protein	O
determines	O
the	O
selection	O
and	O
/	O
or	O
adaptation	O
of	O
a	O
coronavirus	O
from	O
chicken	O
embryo	O
to	O
cultured	O
cells	B-COMP
of	O
human	O
and	O
animal	O
origins	O
.	O

The	O
nucleocapsid	B-COMP
DNA	O
vaccine	O
had	O
good	O
immunogenicity	O
and	O
can	O
induce	O
specific	O
humoral	O
and	O
cellular	B-COMP
immunity	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
IL	O
-	O
2	O
plays	O
an	O
immunoadjuvant	O
role	O
and	O
enhances	O
specific	O
immune	O
responses	O
.	O

Nine	O
of	O
them	O
,	O
including	O
members	O
of	O
the	O
heterogeneous	O
ribonucleoprotein	B-COMP
family	O
of	O
proteins	O
(	O
hnRNPs	O
),	O
the	O
poly	O
(	O
A	O
)-	O
binding	O
protein	O
(	O
PABP	O
),	O
the	O
p100	O
transcriptional	O
co	O
-	O
activator	O
protein	O
and	O
two	O
aminoacyl	O
-	O
tRNA	O
synthetases	O
,	O
showed	O
a	O
preferential	O
binding	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
,	O
whereas	O
only	O
the	O
polypyrimidine	O
tract	O
-	O
binding	O
protein	O
(	O
PTB	O
)	O
was	O
preferentially	O
pulled	O
down	O
with	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
.	O

During	O
the	O
vaccination	O
course	O
,	O
the	O
candidate	O
peptide	O
vaccines	O
induced	O
strong	O
humoral	O
and	O
cellular	B-COMP
response	O
,	O
and	O
provided	O
up	O
to	O
80	O
.	O
0	O
%	O
immune	O
protection	O
,	O
while	O
all	O
non	O
-	O
immunized	O
chickens	O
in	O
the	O
negative	O
control	O
group	O
manifested	O
obvious	O
typical	O
symptoms	O
and	O
died	O
after	O
virus	O
challenge	O
.	O

Serum	B-COMP
and	O
BAL	O
fluid	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
TNF	O
-	O
alpha	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
endotoxins	O
on	O
the	O
first	O
day	O
of	O
ICU	O
admission	O
were	O
obtained	O
.	O

ABSTRACT	O
:	O
The	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
from	O
coronaviruses	O
is	O
a	O
small	O
polypeptide	O
that	O
contains	O
at	O
least	O
one	O
alpha	O
-	O
helical	O
transmembrane	B-COMP
domain	O
.	O

We	O
have	O
previously	O
shown	O
for	O
the	O
coronavirus	O
species	O
responsible	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
that	O
the	O
transmembrane	B-COMP
domain	O
of	O
E	O
protein	O
(	O
ETM	O
)	O
forms	O
pentameric	O
alpha	O
-	O
helical	O
bundles	O
that	O
are	O
likely	O
responsible	O
for	O
the	O
observed	O
channel	O
activity	O
.	O

Such	O
persistent	O
infections	O
can	O
have	O
large	O
effects	O
on	O
relative	O
reproductive	O
fitness	O
of	O
competing	O
host	B-COMP
populations	O
.	O

In	O
this	O
report	O
,	O
a	O
conserved	O
C	O
-	O
terminal	O
domain	O
(	O
approximately	O
100	O
amino	O
-	O
acid	O
residues	O
)	O
has	O
been	O
delineated	O
that	O
is	O
predicted	O
to	O
face	O
the	O
cytoplasm	B-COMP
and	O
has	O
been	O
isolated	O
as	O
a	O
soluble	O
domain	O
using	O
library	O
-	O
based	O
construct	O
screening	O
.	O

Plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
,	O
in	O
contrast	O
,	O
respond	O
to	O
infection	O
with	O
production	O
of	O
high	O
levels	O
of	O
IFNs	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
(	O
i	O
)	O
IFN	O
,	O
as	O
it	O
is	O
produced	O
by	O
plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
,	O
could	O
enable	O
tissue	O
cells	B-COMP
to	O
launch	O
a	O
host	B-COMP
response	O
to	O
SARS	O
-	O
CoV	O
,	O
(	O
ii	O
)	O
IRF	O
-	O
3	O
and	O
IRF	O
-	O
7	O
may	O
be	O
active	O
at	O
subdetectable	O
levels	O
,	O
and	O
(	O
iii	O
)	O
SARS	O
-	O
CoV	O
does	O
not	O
activate	O
IRF	O
-	O
7	O
.	O

The	O
viral	B-COMP
genome	I-COMP
copies	O
in	O
the	O
tracheal	O
swabs	O
,	O
as	O
determined	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
,	O
ranged	O
from	O
1	O
x	O
10	O
(	O
2	O
.	O
6	O
)/	O
ml	O
to	O
1	O
x	O
10	O
(	O
5	O
.	O
2	O
)/	O
ml	O
and	O
,	O
in	O
most	O
studies	O
,	O
had	O
a	O
positive	O
correlation	O
with	O
the	O
number	O
of	O
birds	O
positive	O
for	O
vaccine	O
virus	O
in	O
the	O
flock	O
.	O

RCE	O
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
patients	O
with	O
sickle	O
cell	B-COMP
disease	O
and	O
ACS	O
.	O

Alveolar	O
epithelial	O
cells	B-COMP
are	O
an	O
important	O
target	O
for	O
coronavirus	O
infection	O
in	O
the	O
lung	O
,	O
and	O
infected	O
cells	B-COMP
can	O
initiate	O
innate	O
immune	O
responses	O
to	O
viral	O
infection	O
.	O

We	O
have	O
shown	O
that	O
rat	O
coronavirus	O
infection	O
of	O
rat	O
alveolar	O
type	O
I	O
epithelial	O
cells	B-COMP
in	O
vitro	O
induces	O
expression	O
of	O
CXC	O
chemokines	O
,	O
which	O
may	O
recruit	O
and	O
activate	O
neutrophils	O
.	O

With	O
each	O
declamping	O
,	O
the	O
gas	O
flow	O
through	O
the	O
membrane	B-COMP
lung	O
was	O
set	O
to	O
10	O
l	O
of	O
oxygen	O
/	O
min	O
.	O

The	O
pathology	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
involves	O
diffuse	O
alveolar	O
damage	O
,	O
which	O
comprises	O
severe	O
alveolar	O
epithelial	O
cell	B-COMP
damage	O
,	O
hyaline	O
membrane	B-COMP
formation	O
,	O
and	O
festinate	O
myofibroblast	O
proliferation	O
and	O
fibrosis	O
in	O
the	O
intra	O
-	O
alveolar	O
spaces	O
.	O

ABSTRACT	O
:	O
The	O
innate	O
immune	O
response	O
is	O
critical	O
for	O
host	B-COMP
defence	O
against	O
respiratory	O
coronaviruses	O
(	O
CoVs	O
).	O

ABSTRACT	O
:	O
In	O
order	O
to	O
enhance	O
the	O
sensitivity	O
of	O
conventional	O
immunoassay	O
technology	O
for	O
the	O
detection	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
protein	O
),	O
we	O
developed	O
a	O
localized	O
surface	O
plasmon	O
coupled	O
fluorescence	O
(	O
LSPCF	O
)	O
fiber	O
-	O
optic	O
biosensor	O
that	O
combines	O
sandwich	O
immunoassay	O
with	O
the	O
LSP	O
technique	O
.	O

Furthermore	O
,	O
human	O
epithelial	O
A549	O
cells	B-COMP
expressed	O
ACE2	O
,	O
and	O
expression	O
of	O
3a	O
/	O
X1	O
in	O
these	O
cells	B-COMP
up	O
-	O
regulated	O
TNF	O
-	O
alpha	O
,	O
which	O
is	O
known	O
to	O
accelerate	O
osteoclastogenesis	O
.	O

Given	O
the	O
fact	O
that	O
VASP	O
expression	O
is	O
reduced	O
during	O
periods	O
of	O
cellular	B-COMP
hypoxia	O
,	O
we	O
investigated	O
the	O
role	O
of	O
VASP	O
during	O
ALI	O
.	O

The	O
primary	O
function	O
of	O
the	O
HCoV	O
-	O
OC43	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
protein	O
)	O
is	O
to	O
recognize	O
viral	O
genomic	O
RNA	O
,	O
which	O
leads	O
to	O
ribonucleocapsid	O
formation	O
.	O

To	O
study	O
the	O
role	O
of	O
ORF	O
7b	O
in	O
the	O
context	O
of	O
virus	O
replication	O
,	O
we	O
cloned	O
a	O
full	O
genome	O
cDNA	O
copy	O
of	O
Frankfurt	O
-	O
1	O
in	O
a	O
bacterial	O
artificial	O
chromosome	B-COMP
downstream	O
of	O
a	O
T7	O
RNA	O
polymerase	O
promoter	O
.	O

Serial	O
LBP	O
serum	B-COMP
measurements	O
may	O
offer	O
a	O
clinically	O
useful	O
biomarker	O
for	O
identification	O
of	O
patients	O
with	O
severe	O
sepsis	O
having	O
the	O
worst	O
outcomes	O
and	O
the	O
highest	O
probability	O
of	O
developing	O
sepsis	O
-	O
induced	O
ARDS	O
.	O

ADCML	O
consists	O
of	O
virus	O
-	O
specific	O
antibodies	B-COMP
that	O
bind	O
to	O
cell	B-COMP
surface	I-COMP
expressed	O
viral	O
proteins	O
which	O
result	O
in	O
complement	O
activation	O
and	O
cell	B-COMP
lysis	O
.	O

Surprisingly	O
,	O
no	O
lysis	O
was	O
observed	O
in	O
the	O
CrFK	O
cells	B-COMP
and	O
the	O
monocytes	O
that	O
do	O
show	O
surface	O
-	O
expressed	O
viral	O
proteins	O
,	O
while	O
controls	O
showed	O
that	O
the	O
ADCML	O
assay	O
was	O
functional	O
.	O

The	O
incidence	O
of	O
CMV	O
pneumonia	O
(	O
27	O
.	O
8	O
%,	O
10	O
/	O
36	O
)	O
in	O
the	O
low	O
-	O
CD4	O
(+)	O
T	O
cell	B-COMP
recipients	O
was	O
significantly	O
higher	O
than	O
that	O
(	O
2	O
.	O
1	O
%,	O
2	O
/	O
97	O
)	O
in	O
patients	O
with	O
normal	O
T	O
cell	B-COMP
level	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

But	O
in	O
4	O
non	O
-	O
survival	O
patients	O
,	O
the	O
number	O
of	O
CD4	O
(+)	O
T	O
cell	B-COMP
kept	O
continuously	O
in	O
lower	O
level	O
.	O

ABSTRACT	O
:	O
In	O
our	O
previous	O
study	O
by	O
Gupta	O
et	O
al	O
,	O
dominant	O
T	O
-	O
cell	B-COMP
epitopes	O
of	O
SARS	O
CoV	O
-	O
N	O
(	O
N	O
)	O
protein	O
were	O
predicted	O
by	O
software	O
.	O

Carcinoembryonic	O
cell	B-COMP
adhesion	O
antigen	O
1a	O
(	O
CEACAM1a	O
)	O
is	O
the	O
specific	O
receptor	O
for	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
coronavirus	O
known	O
to	O
induce	O
acute	O
viral	O
hepatitis	O
in	O
mice	O
.	O

TITLE	O
:	O
A	O
synergistic	O
interferon	O
-	O
gamma	O
production	O
is	O
induced	O
by	O
mouse	O
hepatitis	O
virus	O
in	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)/	O
IL	O
-	O
18	O
-	O
activated	O
natural	O
killer	O
cells	B-COMP
and	O
modulated	O
by	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-COMP
adhesion	O
molecules	O
(	O
CEACAM	O
)	O
1a	O
receptor	O
.	O

ABSTRACT	O
:	O
The	O
rat	O
coronavirus	O
sialodacryoadenitis	O
virus	O
(	O
SDAV	O
)	O
causes	O
respiratory	O
infection	O
and	O
provides	O
a	O
system	O
for	O
investigating	O
respiratory	O
coronaviruses	O
in	O
a	O
natural	O
host	B-COMP
.	O

Blood	O
samples	O
(	O
n	O
=	O
1	O
,	O
348	O
)	O
were	O
analyzed	O
for	O
antibodies	B-COMP
against	O
BCoV	O
and	O
rotavirus	O
.	O

To	O
decrease	O
the	O
interference	O
of	O
the	O
host	B-COMP
genome	O
in	O
hybridization	O
,	O
the	O
consensus	O
genus	O
primers	O
were	O
designed	O
and	O
used	O
to	O
reverse	O
transcribe	O
only	O
virus	O
genome	O
.	O

Using	O
inhibitors	O
specific	O
for	O
three	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
,	O
we	O
showed	O
that	O
induction	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
by	O
MHV	O
-	O
A59	O
infection	O
was	O
mediated	O
through	O
activation	O
of	O
the	O
Janus	O
N	O
-	O
terminal	O
kinase	O
signaling	O
pathway	O
,	O
but	O
not	O
through	O
the	O
extracellular	B-COMP
signal	O
-	O
regulated	O
kinase	O
or	O
p38	O
signaling	O
pathway	O
.	O

ABSTRACT	O
:	O
A	O
previous	O
study	O
demonstrated	O
that	O
infection	O
of	O
a	O
canine	O
fibrosarcoma	O
cell	B-COMP
line	O
(	O
A	O
-	O
72	O
cells	B-COMP
)	O
by	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
resulted	O
in	O
apoptosis	O
(	O
Ruggieri	O
et	O
al	O
.,	O
2007	O
).	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
(	O
CoVs	O
),	O
including	O
the	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
encode	O
a	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
that	O
harbors	O
two	O
independent	O
RNA	O
binding	O
domains	O
of	O
known	O
structure	O
,	O
but	O
poorly	O
characterized	O
RNA	O
binding	O
properties	O
.	O

TITLE	O
:	O
De	O
novo	O
recruitment	O
of	O
antigen	O
-	O
experienced	O
and	O
naive	O
T	O
cells	B-COMP
contributes	O
to	O
the	O
long	O
-	O
term	O
maintenance	O
of	O
antiviral	O
T	O
cell	B-COMP
populations	O
in	O
the	O
persistently	O
infected	O
central	O
nervous	O
system	O
.	O

Further	O
,	O
virus	O
-	O
specific	O
T	O
cell	B-COMP
numbers	O
at	O
this	O
site	O
of	O
infection	O
are	O
maintained	O
by	O
recruitment	O
from	O
peripheral	O
Ag	O
-	O
experienced	O
and	O
naive	O
T	O
cell	B-COMP
pools	O
.	O

The	O
serum	B-COMP
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
level	O
recovered	O
more	O
quickly	O
in	O
patients	O
in	O
the	O
PCD	O
group	O
compared	O
to	O
those	O
in	O
the	O
surgery	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
addition	O
,	O
5	O
membrane	B-COMP
protein	O
amino	O
acid	O
residues	O
with	O
functional	O
potential	O
differentiated	O
healthy	O
cats	O
from	O
cats	O
with	O
FIP	O
.	O

Non	O
-	O
epithelial	O
cells	B-COMP
make	O
up	O
less	O
than	O
10	O
%	O
of	O
the	O
total	O
population	O
.	O

Furthermore	O
,	O
increased	O
morbidity	O
and	O
mortality	O
could	O
not	O
be	O
attributed	O
to	O
altered	O
proinflammatory	O
signals	O
or	O
composition	O
of	O
cells	B-COMP
infiltrating	O
the	O
CNS	O
.	O

A	O
/	O
H5N1	O
nucleic	B-COMP
acid	O
was	O
detected	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
a	O
nasopharyngeal	O
aspirate	O
.	O

Hantavirus	O
IgM	B-COMP
antibody	I-COMP
-	O
capture	O
ELISA	O
was	O
positive	O
,	O
while	O
tests	O
for	O
dengue	O
,	O
leptospirosis	O
and	O
yellow	O
fever	O
were	O
negative	O
.	O

Then	O
the	O
resulting	O
articles	O
were	O
further	O
read	O
through	O
to	O
select	O
the	O
SARS	O
detection	O
results	O
using	O
ELISA	O
methods	O
of	O
serum	B-COMP
samples	O
collected	O
at	O
least	O
1	O
month	O
after	O
disease	O
onset	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
2009	O
Influenza	O
A	O
(	O
H1N1	O
)	O

Testing	O
by	O
direct	O
fluorescent	O
antigen	O
detection	O
(	O
DFA	O
)	O
and	O
various	O
in	O
-	O
house	O
nucleic	B-COMP
acid	O
amplification	O
tests	O
(	O
NATs	O
)	O
for	O
common	O
respiratory	O
viruses	O
provided	O
an	O
etiological	O
diagnosis	O
in	O
177	O
outbreaks	O
(	O
72	O
.	O
5	O
%),	O
with	O
524	O
samples	O
testing	O
positive	O
(	O
47	O
.	O
3	O
%)	O
for	O
a	O
respiratory	O
virus	O
.	O

Current	O
concepts	O
of	O
MAS	B-COMP
pathophysiology	O
.	O

TITLE	O
:	O
A	O
two	O
-	O
pronged	O
strategy	O
to	O
suppress	O
host	B-COMP
protein	O
synthesis	O
by	O
SARS	O
coronavirus	O
Nsp1	O
protein	O
.	O

TITLE	O
:	O
Morphogenesis	O
of	O
Coronavirus	O
HCoV	O
-	O
NL63	O
in	O
Cell	B-COMP
Culture	O
:	O
A	O
Transmission	O
Electron	O
Microscopic	O
Study	O
.	O

NL63	O
productively	O
infects	O
LLCMK2	O
cells	B-COMP
and	O
ciliated	O
epithelial	O
cells	B-COMP
of	O
human	O
airway	O
cell	B-COMP
cultures	O
.	O

Virus	O
replication	O
predominantly	O
occurs	O
on	O
the	O
rough	B-COMP
endoplasmic	I-COMP
reticulum	I-COMP
(	O
RER	B-COMP
),	O
both	O
perinuclear	O
and	O
cytoplasmic	B-COMP
,	O
and	O
the	O
Golgi	B-COMP
.	O

TITLE	O
:	O
Murine	O
hepatitis	O
virus	O
nonstructural	O
protein	O
4	O
regulates	O
virus	O
-	O
induced	O
membrane	B-COMP
modifications	O
and	O
replication	O
complex	O
function	O
.	O

One	O
of	O
the	O
169	O
peptides	O
screened	O
,	O
peptide	O
9626	O
(	O
S	O
residues	O
217	O
-	O
234	O
),	O
inhibited	O
SARS	O
-	O
CoV	O
S	O
-	O
mediated	O
entry	O
of	O
the	O
pseudotyped	O
virions	B-COMP
in	O
293T	O
cells	B-COMP
expressing	O
a	O
functional	O
SARS	O
-	O
CoV	O
receptor	O
(	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
approximately	O
11	O
microM	O
).	O

These	O
findings	O
indicate	O
that	O
the	O
epitope	O
cluster	O
on	O
the	O
spike	O
protein	O
may	O
serve	O
as	O
an	O
evolutionarily	O
conserved	O
platform	O
at	O
which	O
a	O
dynamic	O
interplay	O
between	O
neutralizing	O
and	O
non	O
-	O
neutralizing	O
antibodies	B-COMP
occurs	O
,	O
thereby	O
determining	O
the	O
outcome	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Four	O
canine	O
sera	B-COMP
positive	O
for	O
TGEV	O
-	O
like	O
CCoV	O
,	O
six	O
sera	B-COMP
positive	O
to	O
classical	O
CCoV	O
-	O
II	O
strains	O
and	O
10	O
negative	O
control	O
sera	B-COMP
were	O
examined	O
.	O

TITLE	O
:	O
The	O
open	O
reading	O
frame	O
3a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
promotes	O
membrane	B-COMP
rearrangement	O
and	O
cell	B-COMP
death	O
.	O

Electron	O
microscopy	O
of	O
infected	O
cells	B-COMP
revealed	O
a	O
role	O
for	O
ORF	O
3a	O
in	O
SARS	O
-	O
CoV	O
induced	O
vesicle	B-COMP
formation	O
,	O
a	O
prominent	O
feature	O
of	O
cells	B-COMP
from	O
SARS	O
patients	O
.	O

Finally	O
,	O
overexpression	O
of	O
ADP	O
-	O
ribosylation	O
factor	O
1	O
(	O
Arf1	O
),	O
a	O
small	O
GTPase	O
essential	O
for	O
the	O
maintenance	O
of	O
the	O
Golgi	B-COMP
apparatus	I-COMP
,	O
restored	O
Golgi	B-COMP
morphology	O
during	O
infection	O
.	O

Confocal	O
microscopy	O
studies	O
showed	O
that	O
early	O
secretory	O
pathway	O
components	O
are	O
not	O
associated	O
with	O
SARS	O
-	O
CoV	O
-	O
induced	O
replication	O
sites	O
,	O
although	O
our	O
studies	O
revealed	O
that	O
infection	O
induces	O
a	O
remarkable	O
redistribution	O
of	O
the	O
translocon	B-COMP
subunit	O
Sec61alpha	O
.	O

The	O
BFA	O
-	O
induced	O
disruption	O
of	O
ER	O
integrity	O
and	O
functionality	O
probably	O
affects	O
the	O
overall	O
quality	O
of	O
the	O
membrane	B-COMP
scaffold	O
that	O
is	O
needed	O
to	O
support	O
the	O
viral	O
RTC	O
and	O
/	O
or	O
the	O
availability	O
of	O
specific	O
host	B-COMP
factors	O
,	O
which	O
in	O
turn	O
compromises	O
viral	O
RNA	O
synthesis	O
.	O

This	O
article	O
focuses	O
on	O
the	O
characteristics	O
of	O
the	O
five	O
HCoVs	O
that	O
are	O
known	O
,	O
and	O
summarizes	O
current	O
knowledge	O
of	O
their	O
pathogenic	O
potential	O
in	O
people	O
,	O
with	O
an	O
emphasis	O
on	O
the	O
interactions	O
between	O
these	O
viruses	O
and	O
their	O
cognate	O
receptors	O
on	O
susceptible	O
target	O
cells	B-COMP
.	O

Treatment	O
of	O
JHMV	O
-	O
infected	O
CXCR2	O
-/-	O
mice	O
with	O
anti	O
-	O
CXCR2	O
antibody	B-COMP
did	O
not	O
modulate	O
PMN	O
migration	O
nor	O
alter	O
viral	O
clearance	O
or	O
mortality	O
,	O
indicating	O
the	O
existence	O
of	O
compensatory	O
mechanisms	O
that	O
facilitate	O
sufficient	O
migration	O
of	O
PMNs	O
into	O
the	O
CNS	O
in	O
the	O
absence	O
of	O
CXCR2	O
.	O

One	O
clear	O
approach	O
to	O
this	O
problem	O
is	O
to	O
target	O
processes	O
of	O
the	O
host	B-COMP
organism	I-COMP
rather	O
than	O
the	O
microbe	O
.	O

Anti	O
-	O
CD134	O
binding	O
caused	O
displacement	O
of	O
SU	O
from	O
the	O
surface	O
of	O
the	O
cell	B-COMP
and	O
inhibition	O
of	O
infection	O
.	O

Depletion	O
of	O
CD8	O
(+)	O
T	O
cells	B-COMP
at	O
the	O
time	O
of	O
infection	O
did	O
not	O
affect	O
viral	O
replication	O
or	O
clearance	O
.	O

The	O
dramatically	O
elevated	O
hydroxyproline	O
levels	O
in	O
H5N1	O
-	O
infected	O
mice	O
showed	O
deposition	O
of	O
collagen	B-COMP
in	O
lungs	O
,	O
and	O
confirmed	O
fibrosis	O
of	O
lungs	O
.	O

Treatment	O
of	O
the	O
rabbits	O
with	O
a	O
humanized	O
anti	O
-	O
CXCL8	O
antibody	B-COMP
prevented	O
neutrophil	O
infiltration	O
in	O
the	O
lung	O
in	O
association	O
with	O
alleviated	O
ALI	O
syndrome	O
.	O

ABSTRACT	O
:	O
Serum	B-COMP
samples	O
from	O
92	O
giant	O
pandas	O
in	O
three	O
captive	O
facilities	O
were	O
tested	O
for	O
antibodies	B-COMP
against	O
five	O
viruses	O
of	O
carnivores	O
.	O

The	O
rapidly	O
changing	O
viral	B-COMP
genome	I-COMP
adds	O
another	O
variable	O
to	O
this	O
equation	O
.	O

We	O
have	O
focused	O
on	O
a	O
novel	O
concept	O
of	O
microRNA	O
(	O
miRNA	O
)-	O
mediated	O
host	B-COMP
-	O
virus	O
interactions	O
in	O
bronchoalveolar	O
stem	O
cells	B-COMP
(	O
BASCs	O
)	O
at	O
the	O
onset	O
of	O
infection	O
by	O
correlating	O
the	O
""""	O
BASC	O
-	O
microRNome	O
""""	O
with	O
their	O
targets	O
within	O
BASCs	O
and	O
viral	B-COMP
genome	I-COMP
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
support	O
may	O
successfully	O
rescue	O
these	O
severely	O
ill	O
patients	O
.	O

The	O
Chinese	O
isolate	O
of	O
QX	O
-	O
like	O
virus	O
caused	O
the	O
most	O
severe	O
lesions	O
and	O
induced	O
the	O
highest	O
antibody	B-COMP
titres	O
.	O

ABSTRACT	O
:	O
Plausible	O
representatives	O
of	O
plasmacytoid	O
dendritic	B-COMP
cells	B-COMP
(	O
pDCs	O
)	O
in	O
pigs	O
have	O
been	O
characterized	O
as	O
being	O
CD4	O
(	O
hi	O
)	O
CD172	O
(	O
lo	O
).	O

In	O
this	O
study	O
,	O
three	O
hybridoma	O
cell	B-COMP
lines	O
secreting	O
specific	O
monoclonal	O
antibodies	B-COMP
against	O
the	O
RBD	O
of	O
the	O
S	O
protein	O
were	O
generated	O
and	O
their	O
exact	O
binding	O
sites	O
were	O
identified	O
.	O

The	O
S	O
protein	O
is	O
a	O
potent	O
target	O
for	O
SARS	O
-	O
specific	O
cell	B-COMP
-	O
mediated	O
immune	O
responses	O
.	O

The	O
immunized	O
mice	O
released	O
IFN	O
-	O
gamma	O
and	O
lysed	O
target	O
cells	B-COMP
upon	O
stimulation	O
with	O
Sp8	O
peptide	O
-	O
pulsed	O
autologous	O
dendritic	B-COMP
cells	B-COMP
in	O
comparison	O
to	O
other	O
candidates	O
.	O

Progress	O
in	O
understanding	O
and	O
combating	O
zoonoses	O
requires	O
a	O
new	O
generation	O
of	O
models	O
that	O
addresses	O
a	O
broader	O
set	O
of	O
pathogen	O
life	O
histories	O
and	O
integrates	O
across	O
host	B-COMP
species	O
and	O
scientific	O
disciplines	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
cellular	B-COMP
factor	O
TNF	O
-	O
alpha	O
converting	O
enzyme	O
(	O
TACE	O
),	O
activated	O
by	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
S	O
protein	O
),	O
was	O
positively	O
involved	O
in	O
viral	O
entry	O
,	O
implying	O
that	O
TACE	O
is	O
a	O
possible	O
target	O
for	O
developing	O
antiviral	O
compounds	O
.	O

This	O
result	O
was	O
confirmed	O
by	O
the	O
observation	O
that	O
preexisting	O
RTCs	O
did	O
not	O
exchange	O
fluorescence	O
after	O
fusion	O
of	O
cells	B-COMP
expressing	O
either	O
a	O
green	O
or	O
a	O
red	O
fluorescent	O
nsp2	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encodes	O
3	O
major	O
envelope	B-COMP
proteins	O
:	O
spike	O
(	O
S	O
),	O
membrane	B-COMP
(	O
M	O
),	O
and	O
envelope	B-COMP
(	O
E	O
).	O

TITLE	O
:	O
The	O
murine	O
coronavirus	O
nucleocapsid	B-COMP
gene	O
is	O
a	O
determinant	O
of	O
virulence	O
.	O

A	O
pair	O
of	O
chimeric	O
recombinant	O
viruses	O
in	O
which	O
the	O
nucleocapsid	B-COMP
gene	O
was	O
exchanged	O
between	O
JHM	O
and	O
A59	O
was	O
selected	O
and	O
compared	O
to	O
wild	O
-	O
type	O
parental	O
strains	O
in	O
terms	O
of	O
virulence	O
.	O

We	O
are	O
in	O
the	O
process	O
of	O
generating	O
further	O
cell	B-COMP
lines	O
from	O
a	O
number	O
of	O
different	O
bat	O
species	O
using	O
the	O
methodology	O
established	O
in	O
this	O
study	O
.	O

We	O
previously	O
showed	O
that	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
spike	O
domain	O
2	O
(	O
S2	O
)	O
in	O
the	O
patient	O
sera	B-COMP
can	O
cross	O
-	O
react	O
with	O
human	O
lung	O
epithelial	O
cells	B-COMP
;	O
however	O
,	O
the	O
autoantigen	O
is	O
not	O
yet	O
identified	O
.	O

By	O
confocal	O
microscopic	O
observation	O
,	O
SARS	O
patient	O
sera	B-COMP
and	O
anti	O
-	O
S2	O
antibodies	B-COMP
were	O
co	O
-	O
localized	O
on	O
A549	O
cells	B-COMP
and	O
both	O
of	O
them	O
were	O
co	O
-	O
localized	O
with	O
anti	O
-	O
annexin	O
A2	O
antibodies	B-COMP
.	O

Since	O
the	O
3a	O
protein	O
localizes	O
to	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	B-COMP
)-	O
Golgi	B-COMP
compartment	O
,	O
its	O
role	O
in	O
causing	O
ER	B-COMP
stress	O
was	O
investigated	O
in	O
transiently	O
transfected	O
cells	B-COMP
.	O

Confocal	O
microscopic	O
analysis	O
showed	O
increased	O
translocation	O
of	O
IFNAR1	O
into	O
the	O
lysosomal	O
compartment	O
and	O
flow	O
cytometry	O
showed	O
reduced	O
levels	O
of	O
IFNAR1	O
in	O
3a	O
-	O
expressing	O
cells	B-COMP
.	O

Since	O
the	O
publicized	O
outbreaks	O
of	O
SARS	O
in	O
China	O
and	O
Canada	O
in	O
2002	O
-	O
2003	O
,	O
significant	O
efforts	O
successfully	O
identified	O
the	O
causative	O
agent	O
,	O
host	B-COMP
cell	I-COMP
receptor	O
(	O
s	O
),	O
and	O
many	O
of	O
the	O
pathogenic	O
mechanisms	O
underlying	O
SARS	O
.	O

Mutagenesis	O
showed	O
that	O
the	O
aromatic	O
domain	O
was	O
crucial	O
for	O
SARSpp	O
entry	O
into	O
cells	B-COMP
,	O
with	O
a	O
likely	O
role	O
in	O
pore	B-COMP
enlargement	O
.	O

RESULTS	O
:	O
Mutagenesis	O
showed	O
that	O
the	O
aromatic	O
domain	O
was	O
crucial	O
for	O
SARSpp	O
entry	O
into	O
cells	B-COMP
,	O
with	O
a	O
likely	O
role	O
in	O
pore	B-COMP
enlargement	O
.	O

These	O
data	O
indicate	O
that	O
IFN	O
-	O
gamma	O
signaling	O
by	O
oligodendroglia	O
reduces	O
viral	O
replication	O
but	O
affects	O
both	O
demyelination	O
and	O
tissue	O
destruction	O
in	O
a	O
host	B-COMP
-	O
specific	O
manner	O
.	O

Three	O
expression	O
plasmids	O
each	O
targeting	O
spike	O
protein	O
(	O
S1	O
),	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
),	O
and	O
membrane	B-COMP
protein	O
(	O
M	O
)	O
of	O
IBV	O
were	O
prepared	O
.	O

Initial	O
viral	O
antigens	O
were	O
detected	O
between	O
12	O
and	O
24	O
h	O
post	O
-	O
inoculation	O
(	O
p	O
.	O
i	O
)	O
in	O
the	O
infiltrating	O
cells	B-COMP
that	O
appeared	O
in	O
the	O
subarachnoidal	O
space	O
of	O
mouse	O
brains	O
infected	O
with	O
viruses	O
.	O

At	O
SHC	O
,	O
if	O
ATR	O
>	O
or	O
=	O
5	O
degrees	O
,	O
postero	O
-	O
anterior	O
radiograph	O
of	O
the	O
spine	B-COMP
was	O
done	O
.	O

RESULTS	O
:	O
In	O
-	O
silico	O
analysis	O
of	O
the	O
225	O
amino	O
acid	O
sequence	O
of	O
hCoV	O
-	O
NL63	O
ORF	O
3	O
predicted	O
a	O
triple	O
membrane	B-COMP
-	O
spanning	O
protein	O
.	O

By	O
combining	O
these	O
data	O
with	O
quantitative	O
analyses	O
on	O
viral	O
RNA	O
,	O
protein	O
synthesis	O
and	O
virion	B-COMP
release	O
,	O
this	O
study	O
generates	O
an	O
integrated	O
molecular	O
and	O
ultrastructural	O
overview	O
of	O
CoV	O
infection	O
.	O

Statistical	O
analysis	O
calculating	O
a	O
serologic	O
association	O
between	O
the	O
serum	B-COMP
virus	O
neutralization	O
antibody	B-COMP
titer	O
and	O
coronavirus	O
,	O
the	O
presence	O
of	O
exposure	O
history	O
on	O
40	O
animals	O
with	O
a	O
history	O
of	O
ARS	O
,	O
and	O
167	O
controls	O
provided	O
an	O
odds	O
ratio	O
of	O
121	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
36	O
.	O
54	O
and	O
402	O
.	O
84	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
examine	O
the	O
potential	O
antiviral	O
activity	O
of	O
lactic	O
acid	O
bacteria	O
(	O
LAB	O
)	O
using	O
animal	O
and	O
human	O
intestinal	O
and	O
macrophage	O
cell	B-COMP
line	O
models	O
of	O
non	O
tumor	O
origin	O
.	O

A	O
variable	O
increase	O
(	O
of	O
up	O
to	O
50	O
%)	O
on	O
the	O
release	O
of	O
NO	O
(-)	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
(	O
ROS	O
)	O
was	O
obtained	O
when	O
LAB	O
strains	O
were	O
co	O
-	O
incubated	O
with	O
the	O
cell	B-COMP
lines	O
,	O
but	O
the	O
results	O
were	O
found	O
to	O
be	O
LAB	O
strain	O
and	O
cell	B-COMP
line	O
specific	O
,	O
apart	O
from	O
a	O
small	O
number	O
of	O
strains	O
which	O
were	O
able	O
to	O
induce	O
strong	O
ROS	O
release	O
in	O
more	O
than	O
one	O
cell	B-COMP
line	O
.	O

TITLE	O
:	O
The	O
N	O
-	O
terminal	O
region	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	O
6	O
induces	O
membrane	B-COMP
rearrangement	O
and	O
enhances	O
virus	O
replication	O
.	O

Deletion	O
of	O
the	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
modestly	O
diminished	O
virus	O
growth	O
in	O
tissue	O
culture	O
but	O
abrogated	O
virulence	O
in	O
animals	O
.	O

ABSTRACT	O
:	O
Precise	O
determination	O
of	O
conformational	O
epitopes	O
of	O
neutralizing	O
antibodies	B-COMP
represents	O
a	O
key	O
step	O
in	O
the	O
rational	O
design	O
of	O
novel	O
vaccines	O
.	O

TITLE	O
:	O
Exacerbated	O
innate	O
host	B-COMP
response	O
to	O
SARS	O
-	O
CoV	O
in	O
aged	O
non	O
-	O
human	O
primates	O
.	O

ABSTRACT	O
:	O
In	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
negative	O
Hodgkin	O
'	O
s	O
cell	B-COMP
lines	O
and	O
classical	O
EBV	O
-	O
negative	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
HL	O
),	O
Reed	O
-	O
Sternberg	O
cells	B-COMP
(	O
RS	O
cells	B-COMP
)	O
represent	O
end	O
-	O
stage	O
tumor	O
cells	B-COMP
,	O
in	O
which	O
further	O
nuclear	O
division	O
becomes	O
impossible	O
because	O
of	O
sustained	O
telomere	B-COMP
loss	O
,	O
shortening	O
and	O
aggregation	O
.	O

We	O
have	O
found	O
that	O
increasing	O
mitochondrial	B-COMP
hexokinase	O
II	O
activity	O
can	O
prevent	O
cell	B-COMP
death	O
in	O
neuronal	O
cultures	O
treated	O
with	O
rotenone	O
.	O

Overexpression	O
of	O
hexokinase	O
II	O
prevented	O
both	O
rotenone	O
and	O
MPTP	O
-	O
induced	O
dopaminergic	O
neuronal	O
cell	B-COMP
death	O
,	O
as	O
well	O
as	O
reducing	O
the	O
associated	O
motor	O
defects	O
.	O

Ap4A	O
-	O
hydrolase	O
is	O
responsible	O
for	O
metabolizing	O
the	O
""""	O
allarmone	O
""""	O
nucleotide	O
Ap4A	O
and	O
therefore	O
likely	O
involved	O
in	O
regulation	O
of	O
cell	B-COMP
proliferation	O
,	O
DNA	O
replication	O
,	O
RNA	O
processing	O
,	O
apoptosis	O
and	O
DNA	O
repair	O
.	O

Human	O
tissue	O
culture	O
cells	B-COMP
transiently	O
expressing	O
7a	O
and	O
Ap4A	O
-	O
hydrolase	O
tagged	O
with	O
EGFP	O
and	O
Ds	O
-	O
Red2	O
respectively	O
show	O
these	O
proteins	O
co	O
-	O
localize	O
in	O
the	O
cytoplasm	B-COMP
.	O

C	O
jejuni	O
infection	O
was	O
significantly	O
associated	O
with	O
serum	B-COMP
antibodies	B-COMP
to	O
the	O
gangliosides	O
GM1	O
and	O
GD1a	O
,	O
axonal	O
neuropathy	O
,	O
and	O
greater	O
disability	O
.	O

Immunoblotting	O
of	O
lysates	O
from	O
cells	B-COMP
ectopically	O
expressing	O
active	O
MLK3	O
revealed	O
an	O
additional	O
immunoreactive	O
band	O
corresponding	O
to	O
a	O
CTF	O
(	O
C	O
-	O
terminal	O
fragment	O
)	O
of	O
MLK3	O
.	O

Plasma	O
levels	O
of	O
surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
),	O
Clara	O
Cell	B-COMP
protein	O
(	O
CC16	O
),	O
KL	O
-	O
6	O
and	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
sRAGE	O
)	O
were	O
measured	O
in	O
plasma	O
samples	O
obtained	O
from	O
36	O
patients	O
-	O
16	O
patients	O
who	O
were	O
intubated	O
and	O
mechanically	O
ventilated	O
because	O
of	O
ALI	O
/	O
ARDS	O
and	O
20	O
patients	O
without	O
lung	O
injury	O
at	O
the	O
onset	O
of	O
mechanical	O
ventilation	O
and	O
during	O
conduct	O
of	O
the	O
study	O
.	O

ABSTRACT	O
:	O
In	O
retroviruses	O
and	O
the	O
double	O
-	O
stranded	O
RNA	O
totiviruses	O
,	O
the	O
efficiency	O
of	O
programmed	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
is	O
critical	O
for	O
ensuring	O
the	O
proper	O
ratios	O
of	O
upstream	O
-	O
encoded	O
capsid	O
proteins	O
to	O
downstream	O
-	O
encoded	O
replicase	O
enzymes	O
.	O

Quantum	O
dots	O
(	O
QDs	O
)	O
posses	O
unique	O
fluorescence	O
properties	O
that	O
have	O
also	O
been	O
explored	O
for	O
their	O
application	O
to	O
virus	O
detection	O
when	O
combined	O
with	O
direct	O
antibody	B-COMP
conjugation	O
or	O
streptavidin	O
-	O
biotin	O
binding	O
systems	O
.	O

Given	O
that	O
regulatory	O
T	O
cells	B-COMP
(	O
Tregs	O
)	O
have	O
potent	O
anti	O
-	O
inflammatory	O
effects	O
,	O
we	O
adoptively	O
transferred	O
Tregs	O
into	O
infected	O
C57BL	O
/	O
6	O
and	O
RAG1	O
(-/-)	O
mice	O
.	O

TITLE	O
:	O
A	O
simple	O
and	O
rapid	O
strip	O
test	O
for	O
detection	O
of	O
antibodies	B-COMP
to	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
A	O
simple	O
gold	O
-	O
immunochromatographic	O
assay	O
(	O
GICA	O
)	O
based	O
on	O
indirect	O
reaction	O
format	O
was	O
developed	O
for	O
rapid	O
detection	O
of	O
antibodies	B-COMP
against	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
A	O
total	O
of	O
2	O
,	O
703	O
pig	O
sera	B-COMP
from	O
171	O
farms	O
in	O
six	O
regions	O
in	O
Japan	O
were	O
screened	O
for	O
virus	O
-	O
neutralizing	O
(	O
VN	O
)	O
antibody	B-COMP
against	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

ABSTRACT	O
:	O
This	O
study	O
examined	O
the	O
anticardiolipin	O
antibodies	B-COMP
in	O
post	O
-	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
osteonecrosis	O
patients	O
to	O
investigate	O
the	O
etiology	O
of	O
post	O
-	O
SARS	O
osteonecrosis	O
,	O
and	O
to	O
eventually	O
provide	O
valuable	O
information	O
for	O
the	O
early	O
diagnosis	O
of	O
nontraumatic	O
osteonecrosis	O
and	O
for	O
the	O
susceptible	O
population	O
screening	O
.	O

The	O
latter	O
viruses	O
entered	O
directly	O
from	O
cell	B-COMP
surface	I-COMP
,	O
when	O
receptor	O
-	O
bound	O
viruses	O
were	O
treated	O
with	O
proteases	O
that	O
activate	O
fusion	O
activity	O
of	O
their	O
S	O
proteins	O
.	O

ABSTRACT	O
:	O
Our	O
studies	O
and	O
those	O
of	O
many	O
others	O
have	O
implicated	O
hepatocyte	O
necrosis	O
and	O
apoptosis	O
mediated	O
by	O
fibrinogen	B-COMP
-	O
like	O
protein	O
-	O
2	O
(	O
fgl2	O
)	O
prothrombinase	O
and	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
rate	O
greater	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

While	O
the	O
type	O
I	O
IFN	O
response	O
is	O
a	O
crucial	O
aspect	O
of	O
host	B-COMP
defense	O
against	O
MHV	O
in	O
its	O
natural	O
host	B-COMP
,	O
there	O
is	O
little	O
if	O
any	O
induction	O
of	O
IFN	O
following	O
infection	O
of	O
mouse	O
fibroblast	O
cell	B-COMP
lines	O
in	O
vitro	O
.	O

The	O
nucleocapsid	B-COMP
protein	O
as	O
well	O
as	O
the	O
nsp1	O
and	O
nsp3	O
proteins	O
of	O
MHV	O
has	O
been	O
reported	O
to	O
have	O
IFN	O
antagonist	O
activity	O
.	O

TITLE	O
:	O
Indirect	O
ELISA	O
and	O
indirect	O
immunofluorescent	O
antibody	B-COMP
assay	O
for	O
detecting	O
the	O
antibody	B-COMP
against	O
murine	O
norovirus	O
S7	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
murine	O
norovirus	O
(	O
MNV	O
)	O
infection	O
in	O
laboratory	O
mice	O
,	O
we	O
attempted	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
system	O
and	O
an	O
indirect	O
immunofluorescent	O
antibody	B-COMP
(	O
IFA	O
)	O
assay	O
for	O
detecting	O
the	O
anti	O
-	O
MNV	O
-	O
S7	O
antibody	B-COMP
in	O
mice	O
.	O

IFA	O
against	O
infected	O
RAW	O
264	O
cells	B-COMP
was	O
able	O
to	O
discriminate	O
positive	O
sera	B-COMP
from	O
negative	O
sera	B-COMP
.	O

In	O
this	O
ELISA	O
system	O
,	O
mouse	O
sera	B-COMP
obtained	O
2	O
weeks	O
after	O
infection	O
or	O
later	O
showed	O
significantly	O
high	O
OD	O
values	O
and	O
were	O
judged	O
positive	O
.	O

An	O
equal	O
level	O
of	O
anti	O
-	O
MNV	O
-	O
S7	O
antibody	B-COMP
response	O
was	O
observed	O
in	O
BALB	O
/	O
cAJcl	O
,	O
C57BL	O
/	O
6JJcl	O
,	O
DBA	O
/	O
2JJcl	O
,	O
and	O
Jcl	O
:	O
ICR	O
mice	O
;	O
whereas	O
,	O
C3H	O
/	O
HeJJcl	O
mice	O
demonstrated	O
slightly	O
lower	O
antibody	B-COMP
production	O
4	O
weeks	O
after	O
infection	O
.	O

The	O
diagnosis	O
of	O
mtDNA	B-COMP
-	O
associated	O
Leigh	O
syndrome	O
is	O
established	O
clinically	O
in	O
a	O
proband	O
with	O
progressive	O
neurologic	O
disease	O
with	O
motor	O
and	O
intellectual	O
developmental	O
delay	O
,	O
signs	O
and	O
symptoms	O
of	O
brain	O
stem	O
and	O
/	O
or	O
basal	O
ganglia	O
disease	O
,	O
raised	O
lactate	O
concentration	O
in	O
blood	O
and	O
/	O
or	O
cerebrospinal	O
fluid	O
,	O
and	O
any	O
one	O
of	O
the	O
following	O
:	O
Characteristic	O
features	O
on	O
brain	O
imaging	O
.	O

The	O
mother	O
of	O
a	O
proband	O
usually	O
has	O
the	O
mtDNA	B-COMP
pathogenic	O
variant	O
and	O
may	O
or	O
may	O
not	O
have	O
symptoms	O
.	O

The	O
results	O
demonstrated	O
that	O
priming	O
with	O
a	O
DNA	O
vaccine	O
encoding	O
nucleocapsid	B-COMP
protein	O
(	O
pVAX1	O
-	O
N	O
)	O
and	O
boosting	O
with	O
the	O
inactivated	O
IBV	O
vaccine	O
led	O
to	O
the	O
dramatic	O
augmentation	O
of	O
humoral	O
and	O
cellular	B-COMP
responses	O
,	O
and	O
provided	O
up	O
to	O
86	O
.	O
7	O
%	O
rate	O
of	O
immune	O
protection	O
,	O
providing	O
an	O
effective	O
approach	O
to	O
protect	O
chickens	O
from	O
IBV	O
.	O

Translation	O
in	O
mammalian	O
cells	B-COMP
expressing	O
2B	O
protein	O
is	O
inhibited	O
by	O
hygromycin	O
B	O
(	O
HB	O
)	O
but	O
remains	O
unaffected	O
in	O
mock	O
cells	B-COMP
,	O
which	O
are	O
not	O
permeable	O
to	O
the	O
inhibitor	O
.	O

We	O
found	O
that	O
gap	B-COMP
junctions	I-COMP
are	O
responsible	O
mediating	O
the	O
observed	O
bystander	O
permeabilization	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
support	O
a	O
mechanism	O
involving	O
gap	O
junctional	O
intercellular	O
communication	O
in	O
the	O
bystander	O
permeabilization	O
effect	O
observed	O
in	O
healthy	O
cells	B-COMP
co	O
-	O
cultured	O
with	O
poliovirus	O
2B	O
-	O
expressing	O
cells	B-COMP
.	O

The	O
data	O
presented	O
herein	O
show	O
that	O
(	O
1	O
)	O
ligand	O
presentation	O
does	O
not	O
disrupt	O
ELP	O
(	O
BC	O
)	O
self	O
-	O
assembly	O
;	O
(	O
2	O
)	O
both	O
multivalent	O
ligand	O
presentation	O
and	O
upregulated	O
receptor	O
expression	O
are	O
needed	O
for	O
receptor	O
-	O
mediated	O
interaction	O
;	O
(	O
3	O
)	O
increased	O
size	O
of	O
the	O
hydrophobic	O
segment	O
of	O
the	O
block	O
copolymer	O
promotes	O
multivalent	O
interaction	O
with	O
membrane	B-COMP
receptors	O
,	O
potentially	O
due	O
to	O
changes	O
in	O
the	O
nanoscale	O
architecture	O
of	O
the	O
micelle	O
;	O
and	O
(	O
4	O
)	O
nanoscale	O
presentation	O
of	O
the	O
ligand	O
is	O
important	O
,	O
as	O
presentation	O
of	O
the	O
ligand	O
by	O
micrometer	O
-	O
sized	O
aggregates	O
of	O
an	O
ELP	O
showed	O
a	O
low	O
level	O
of	O
binding	O
/	O
uptake	O
by	O
receptor	O
-	O
positive	O
cells	B-COMP
compared	O
to	O
its	O
presentation	O
on	O
the	O
corona	O
of	O
a	O
micelle	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
infected	O
cells	B-COMP
secrete	O
a	O
broad	O
range	O
of	O
interferons	O
(	O
IFN	O
)	O
which	O
confer	O
resistance	O
to	O
yet	O
uninfected	O
cells	B-COMP
by	O
triggering	O
the	O
synthesis	O
of	O
antiviral	O
factors	O
.	O

A	O
previous	O
study	O
indicated	O
that	O
ACE2	O
from	O
a	O
horseshoe	O
bat	O
,	O
the	O
host	B-COMP
of	O
a	O
highly	O
related	O
SARS	O
-	O
like	O
coronavirus	O
,	O
could	O
not	O
function	O
as	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
a	O
3	O
aa	O
change	O
from	O
SHE	O
(	O
aa	O
40	O
-	O
42	O
)	O
to	O
FYQ	O
was	O
sufficient	O
to	O
convert	O
the	O
bat	O
ACE2	O
into	O
a	O
fully	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
We	O
further	O
demonstrate	O
that	O
an	O
ACE2	O
molecule	O
from	O
a	O
fruit	O
bat	O
,	O
which	O
contains	O
the	O
FYQ	O
motif	O
,	O
was	O
able	O
to	O
support	O
SARS	O
-	O
CoV	O
infection	O
,	O
indicating	O
a	O
potentially	O
much	O
wider	O
host	B-COMP
range	O
for	O
SARS	O
-	O
CoV	O
-	O
related	O
viruses	O
among	O
different	O
bat	O
populations	O
.	O

This	O
study	O
aimed	O
to	O
quantify	O
the	O
variation	O
in	O
individual	O
test	O
-	O
day	O
milk	O
yield	O
and	O
somatic	O
cell	B-COMP
count	O
,	O
risk	O
of	O
reproductive	O
failure	O
after	O
first	O
service	O
of	O
dairy	O
cows	O
,	O
and	O
risk	O
of	O
death	O
of	O
calves	O
and	O
heifers	O
according	O
to	O
the	O
BCV	O
and	O
BRSV	O
status	O
of	O
the	O
herd	O
.	O

Curiously	O
,	O
we	O
observed	O
no	O
block	O
in	O
the	O
well	O
-	O
defined	O
IFN	O
-	O
beta	O
signaling	O
pathway	O
that	O
leads	O
to	O
STAT1	O
-	O
STAT2	O
phosphorylation	O
and	O
translocation	O
to	O
the	O
nucleus	B-COMP
in	O
cultures	O
infected	O
with	O
MHV	O
.	O

After	O
that	O
,	O
the	O
protein	O
chip	O
was	O
reacted	O
with	O
the	O
corresponding	O
positive	O
serum	B-COMP
against	O
these	O
viruses	O
,	O
hybridized	O
with	O
a	O
colloidal	O
gold	O
-	O
labeled	O
secondary	O
antibody	B-COMP
and	O
visualized	O
by	O
silver	O
staining	O
.	O

A	O
diagnostic	O
protein	O
chip	O
was	O
constructed	O
to	O
differentiate	O
antibodies	B-COMP
of	O
four	O
poultry	O
diseases	O
This	O
protein	O
chip	O
showed	O
good	O
sensitivity	O
compared	O
with	O
traditional	O
methods	O
,	O
and	O
it	O
was	O
more	O
than	O
400	O
times	O
as	O
sensitive	O
as	O
the	O
agar	O
gel	O
precipitin	O
methods	O
used	O
to	O
detect	O
avian	O
influenza	O
and	O
infectious	O
bursal	O
disease	O
.	O

Studies	O
of	O
host	B-COMP
responses	O
to	O
MHV	O
indicate	O
that	O
both	O
innate	O
and	O
adaptive	O
responses	O
are	O
crucial	O
to	O
antiviral	O
defense	O
.	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
the	O
identification	O
of	O
a	O
novel	O
linear	O
B	O
-	O
cell	B-COMP
epitope	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
.	O

We	O
propose	O
that	O
this	O
motif	O
is	O
a	O
linear	O
B	O
-	O
cell	B-COMP
epitope	O
of	O
N	O
protein	O
,	O
and	O
is	O
the	O
core	O
sequence	O
for	O
reactivity	O
,	O
as	O
demonstrated	O
by	O
binding	O
of	O
2D2	O
to	O
the	O
truncated	O
peptides	O
and	O
different	O
IBV	O
strains	O
.	O

In	O
this	O
study	O
,	O
we	O
expressed	O
a	O
219	O
-	O
mer	O
(	O
residues	O
318	O
-	O
536	O
)	O
RBD	O
protein	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)-	O
K1	O
cells	B-COMP
(	O
RBD219	O
-	O
CHO	O
),	O
and	O
tested	O
its	O
immune	O
responses	O
and	O
protective	O
immunity	O
in	O
a	O
mouse	O
model	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
severe	O
trauma	O
patients	O
with	O
bleeding	O
shock	O
.	O

The	O
results	O
showed	O
that	O
groups	O
with	O
at	O
least	O
50	O
%	O
positive	O
sera	B-COMP
in	O
the	O
IgM	O
ELISA	O
at	O
10	O
days	O
post	O
vaccination	O
had	O
a	O
high	O
level	O
of	O
protection	O
against	O
challenge	O
.	O

A	O
high	O
viral	O
load	O
in	O
nasopharyngeal	O
aspirate	O
(	O
with	O
or	O
without	O
a	O
high	O
viral	O
load	O
in	O
serum	B-COMP
)	O
is	O
a	O
useful	O
prognostic	O
indicator	O
of	O
respiratory	O
failure	O
or	O
mortality	O
.	O

Furthermore	O
,	O
VLPs	O
that	O
were	O
administered	O
intraperitoneally	O
elicited	O
cellular	B-COMP
immune	O
responses	O
as	O
demonstrated	O
by	O
enzyme	O
-	O
linked	O
immunospot	O
(	O
ELISPOT	O
)	O
assay	O
analyses	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
focused	O
on	O
the	O
binding	O
of	O
E	O
protein	O
to	O
nsp3	O
in	O
infected	O
cells	B-COMP
and	O
cell	B-COMP
-	O
free	O
systems	O
.	O

Antiviral	O
assays	O
showed	O
that	O
NO	O
significantly	O
inhibited	O
PRCV	O
replication	O
in	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	B-COMP
,	O
whereas	O
PRRSV	O
was	O
not	O
susceptible	O
to	O
NO	O
based	O
on	O
the	O
conditions	O
tested	O
.	O

Analysis	O
of	O
stretched	O
versus	O
nonstretched	O
cells	B-COMP
identified	O
significant	O
enrichment	O
for	O
genes	O
containing	O
putative	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
activating	O
transcription	O
factor	O
3	O
(	O
ATF3	O
).	O

ABSTRACT	O
:	O
The	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
induced	O
the	O
expression	O
of	O
type	O
I	O
interferon	O
(	O
alpha	O
/	O
beta	O
interferon	O
[	O
IFN	O
-	O
alpha	O
/	O
beta	O
])	O
in	O
mouse	O
oligodendrocytic	O
N20	O
.	O
1	O
cells	B-COMP
.	O

We	O
show	O
that	O
MHV	O
infection	O
activated	O
both	O
transcription	O
factors	O
,	O
the	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
)	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
),	O
as	O
evidenced	O
by	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
IRF	O
-	O
3	O
and	O
an	O
increased	O
promoter	O
binding	O
activity	O
for	O
IRF	O
-	O
3	O
and	O
NF	O
-	O
kappaB	O
.	O
Furthermore	O
,	O
the	O
cytoplasmic	B-COMP
pattern	O
recognition	O
receptor	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
was	O
induced	O
by	O
MHV	O
infection	O
.	O

This	O
concept	O
arises	O
from	O
the	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
experience	O
.	O

The	O
serum	B-COMP
levels	O
of	O
IFN	O
-	O
γ	O
and	O
IL	O
-	O
4	O
in	O
groups	O
1	O
-	O
4	O
were	O
higher	O
than	O
those	O
in	O
groups	O
5	O
and	O
6	O
.	O

All	O
patients	O
were	O
on	O
mechanical	O
ventilation	O
and	O
inhaled	O
nitric	O
oxide	O
,	O
and	O
one	O
patient	O
was	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

Four	O
patients	O
underwent	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
.	O

Overall	O
the	O
low	O
frequency	O
of	O
major	O
pathogens	O
suggests	O
a	O
balanced	O
relationship	O
between	O
host	B-COMP
and	O
agents	O
.	O

TITLE	O
:	O
A	O
small	O
-	O
molecule	O
oxocarbazate	O
inhibitor	O
of	O
human	O
cathepsin	O
L	O
blocks	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
ebola	O
pseudotype	O
virus	O
infection	O
into	O
human	O
embryonic	O
kidney	O
293T	O
cells	B-COMP
.	O

Here	O
we	O
detail	O
a	O
high	O
throughput	O
quantitative	O
proteomics	O
analysis	O
of	O
Vero	O
cells	B-COMP
infected	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
positive	O
strand	O
RNA	O
virus	O
that	O
replicates	O
in	O
the	O
cytoplasm	B-COMP
.	O

Stable	O
isotope	O
labeling	O
with	O
amino	O
acids	O
in	O
cell	B-COMP
culture	O
(	O
SILAC	O
)	O
was	O
used	O
in	O
conjunction	O
with	O
LC	O
-	O
MS	O
/	O
MS	O
to	O
identify	O
and	O
quantify	O
1830	O
cellular	B-COMP
and	O
two	O
viral	O
proteins	O
from	O
IBV	O
-	O
infected	O
cells	B-COMP
.	O

Anti	O
-	O
neutrophil	O
cytoplasmic	B-COMP
antibody	B-COMP
(	O
ANCA	O
)	O
associated	O
vasculitis	O
""""	O
and	O
glomerular	O
basement	B-COMP
membrane	I-COMP
"("""	O
Goodpasture	O
'	O
s	O
""")"	O
disease	O
are	O
the	O
commonest	O
causes	O
but	O
other	O
pathologies	O
including	O
systemic	O
lupus	O
erythematosus	O
and	O
the	O
anti	O
-	O
phospholipid	O
syndrome	O
are	O
also	O
implicated	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	B-COMP
proteasome	I-COMP
;	O
this	O
large	O
,	O
multi	O
-	O
protein	B-COMP
complex	I-COMP
is	O
a	O
component	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	B-COMP
processes	O
and	O
inflammatory	O
responses	O
.	O

Moreover	O
,	O
TSL	O
-	O
1	O
treatment	O
decreased	O
the	O
cell	B-COMP
-	O
cycle	O
regulators	O
;	O
cyclin	O
D1	O
and	O
CDK4	O
proteins	O
by	O
up	O
regulating	O
p27	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

ABSTRACT	O
:	O
Alveolar	O
hypoxia	O
and	O
hypoxic	O
vasoconstriction	O
lead	O
to	O
trapping	O
of	O
sickle	O
cells	B-COMP
within	O
the	O
pulmonary	O
vasculature	O
.	O

To	O
understand	O
the	O
pathogenesis	O
of	O
SARS	O
-	O
CoV	O
,	O
human	O
type	O
II	O
pneumocyte	O
(	O
A549	O
)	O
cells	B-COMP
were	O
incubated	O
with	O
the	O
viral	O
spike	O
protein	O
or	O
with	O
SARS	O
-	O
CoV	O
virus	O
-	O
like	O
particles	O
containing	O
the	O
viral	O
spike	O
protein	O
to	O
examine	O
cytokine	O
modulation	O
in	O
lung	O
cells	B-COMP
.	O

84	O
:	O
7869	O
-	O
7879	O
,	O
2010	O
)	O
to	O
strongly	O
inhibit	O
mouse	O
hepatitis	O
CoV	O
(	O
MHV	O
)	O
infection	O
in	O
cultured	O
cells	B-COMP
,	O
seemed	O
an	O
attractive	O
candidate	O
for	O
testing	O
its	O
antiviral	O
properties	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Like	O
most	O
other	O
positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
induces	O
changes	O
in	O
the	O
host	B-COMP
cell	I-COMP
'	O
s	O
membranes	O
,	O
resulting	O
in	O
a	O
membranous	O
web	O
.	O

Electron	O
microscopy	O
of	O
ultrathin	O
sections	O
of	O
these	O
cells	B-COMP
revealed	O
the	O
presence	O
of	O
numerous	O
double	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
),	O
resembling	O
those	O
observed	O
for	O
other	O
RNA	O
viruses	O
such	O
as	O
poliovirus	O
and	O
coronavirus	O
.	O

More	O
detailed	O
characterization	O
of	O
these	O
virus	O
-	O
cell	B-COMP
interactions	O
may	O
facilitate	O
the	O
development	O
of	O
new	O
treatments	O
active	O
against	O
HCV	O
and	O
other	O
RNA	O
viruses	O
that	O
are	O
dependent	O
on	O
newly	O
synthesized	O
cellular	B-COMP
membranes	O
for	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
the	O
treatment	O
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
controversial	O
,	O
notwithstanding	O
the	O
recent	O
publication	O
of	O
the	O
results	O
of	O
the	O
CESAR	O
(	O
Conventional	O
Ventilation	O
or	O
ECMO	O
for	O
Severe	O
Adult	O
Respiratory	O
Failure	O
)	O
trial	O
.	O

TITLE	O
:	O
Expression	O
,	O
crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nucleocapsid	B-COMP
protein	O
C	O
-	O
terminal	O
domain	O
.	O

The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
,	O
one	O
of	O
the	O
structural	O
proteins	O
,	O
interacts	O
with	O
the	O
30	O
.	O
4	O
kb	O
virus	O
genomic	O
RNA	O
to	O
form	O
the	O
helical	O
nucleocapsid	B-COMP
and	O
associates	O
with	O
the	O
membrane	B-COMP
glycoprotein	O
via	O
its	O
C	O
-	O
terminus	O
to	O
stabilize	O
virion	B-COMP
assembly	O
.	O

The	O
crystals	O
diffracted	O
to	O
2	O
.	O
20	O
A	O
resolution	O
and	O
belonged	O
to	O
space	O
group	O
P422	O
,	O
with	O
unit	O
-	O
cell	B-COMP
parameters	O
a	O
=	O
66	O
.	O
6	O
,	O
c	O
=	O
50	O
.	O
8	O
A	O
.	O
Assuming	O
the	O
presence	O
of	O
two	O
molecules	O
in	O
the	O
asymmetric	O
unit	O
,	O
the	O
solvent	O
content	O
is	O
43	O
.	O
0	O
%	O
(	O
V	O
(	O
M	O
)	O
=	O
2	O
.	O
16	O
A	O
(	O
3	O
)	O
Da	O
(-	O
1	O
)).	O

For	O
educational	O
purposes	O
,	O
the	O
classic	O
signs	O
of	O
a	O
widened	O
mediastinum	O
,	O
right	O
tracheal	O
deviation	O
,	O
and	O
left	O
-	O
sided	O
hemothorax	O
(	O
in	O
a	O
context	O
of	O
significant	O
deceleration	O
injury	O
)	O
are	O
incorporated	O
into	O
an	O
acute	O
care	O
triad	B-COMP
for	O
traumatic	O
aortic	O
rupture	O
.	O

Subsequently	O
,	O
we	O
carried	O
out	O
lead	O
optimization	O
and	O
structure	O
-	O
activity	O
studies	O
to	O
provide	O
a	O
series	O
of	O
improved	O
inhibitors	O
that	O
show	O
potent	O
PLpro	O
inhibition	O
and	O
antiviral	O
activity	O
against	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	B-COMP
.	O

RESULTS	O
:	O
Apart	O
from	O
the	O
virus	O
-	O
encoded	O
structural	O
proteins	O
,	O
we	O
detected	O
60	O
host	B-COMP
proteins	O
in	O
the	O
purified	O
virions	B-COMP
which	O
can	O
be	O
grouped	O
into	O
several	O
functional	O
categories	O
including	O
intracellular	B-COMP
trafficking	O
proteins	O
(	O
20	O
%),	O
molecular	O
chaperone	O
(	O
18	O
%),	O
macromolcular	O
biosynthesis	O
proteins	O
(	O
17	O
%),	O
cytoskeletal	B-COMP
proteins	O
(	O
15	O
%),	O
signal	O
transport	O
proteins	O
(	O
15	O
%),	O
protein	O
degradation	O
(	O
8	O
%),	O
chromosome	B-COMP
associated	O
proteins	O
(	O
2	O
%),	O
ribosomal	B-COMP
proteins	O
(	O
2	O
%),	O
and	O
other	O
function	O
proteins	O
(	O
3	O
%).	O

TITLE	O
:	O
Migration	O
of	O
engrafted	O
neural	O
stem	O
cells	B-COMP
is	O
mediated	O
by	O
CXCL12	O
signaling	O
through	O
CXCR4	O
in	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
.	O

We	O
have	O
used	O
a	O
model	O
of	O
viral	O
-	O
induced	O
demyelination	O
to	O
characterize	O
signaling	O
cues	O
associated	O
with	O
positional	O
migration	O
of	O
transplanted	O
remyelination	O
-	O
competent	O
cells	B-COMP
.	O

Here	O
,	O
we	O
show	O
that	O
,	O
in	O
apparent	O
contrast	O
to	O
human	O
and	O
ungulate	O
host	B-COMP
range	O
variants	O
of	O
Betacoronavirus	O
-	O
1	O
,	O
murine	O
coronaviruses	O
actually	O
bind	O
to	O
O	O
-	O
Ac	O
-	O
Sias	O
via	O
HE	O
exclusively	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
),	O
including	O
SARS	O
and	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
are	O
enveloped	O
RNA	O
viruses	O
that	O
induce	O
formation	O
of	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
)	O
and	O
target	O
their	O
replication	O
and	O
transcription	O
complexes	O
(	O
RTCs	O
)	O
on	O
the	O
DMV	O
-	O
limiting	O
membranes	O
.	O

We	O
also	O
show	O
that	O
previously	O
immunized	O
susceptible	O
C3H	O
/	O
HeJ	O
mice	O
do	O
not	O
develop	O
any	O
morbidity	O
and	O
are	O
completely	O
protected	O
following	O
a	O
lethal	O
-	O
dose	O
MHV	O
-	O
1	O
challenge	O
despite	O
mounting	O
only	O
a	O
modest	O
secondary	O
T	O
cell	B-COMP
response	O
.	O

The	O
prolonged	O
depletion	O
of	O
peripheral	O
CD4	O
(+)	O
T	O
cells	B-COMP
did	O
not	O
alter	O
the	O
levels	O
of	O
serum	B-COMP
IgG	O
or	O
IgM	O
.	O
The	O
impact	O
of	O
CB	O
/	O
05	O
infection	O
on	O
the	O
immune	O
performance	O
of	O
infected	O
pups	O
is	O
discussed	O
.	O

ABSTRACT	O
:	O
The	O
involvement	O
of	O
host	B-COMP
proteins	O
in	O
the	O
replication	O
and	O
transcription	O
of	O
viral	O
RNA	O
is	O
a	O
poorly	O
understood	O
area	O
for	O
many	O
RNA	O
viruses	O
.	O

To	O
search	O
for	O
such	O
cellular	B-COMP
proteins	O
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
carried	O
out	O
by	O
using	O
the	O
nonstructural	O
protein	O
14	O
(	O
nsp14	O
)	O
from	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
as	O
a	O
bait	O
protein	O
,	O
leading	O
to	O
the	O
identification	O
of	O
DDX1	O
,	O
a	O
cellular	B-COMP
RNA	O
helicase	O
in	O
the	O
DExD	O
/	O
H	O
helicase	O
family	O
,	O
as	O
a	O
potential	O
interacting	O
partner	O
.	O

Mutagenesis	O
indicated	O
that	O
a	O
single	O
N	O
-	O
linked	O
glycosylation	O
site	O
,	O
N330	O
,	O
was	O
critical	O
for	O
the	O
specific	O
interactions	O
between	O
MBL	O
and	O
SARS	O
-	O
S	O
.	O
Despite	O
the	O
proximity	O
of	O
N330	O
to	O
the	O
receptor	O
-	O
binding	O
motif	O
of	O
SARS	O
-	O
S	O
,	O
MBL	O
did	O
not	O
affect	O
interactions	O
with	O
the	O
ACE2	O
receptor	O
or	O
cathepsin	O
L	O
-	O
mediated	O
activation	O
of	O
SARS	O
-	O
S	O
-	O
driven	O
membrane	B-COMP
fusion	O
.	O

To	O
determine	O
role	O
of	O
the	O
combination	O
of	O
Systemic	O
Inflammatory	O
Response	O
Syndrome	O
(	O
SIRS	O
)	O
score	O
and	O
serum	B-COMP
Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
level	O
on	O
admission	O
as	O
predictor	O
of	O
illness	O
severity	O
and	O
outcome	O
of	O
Severe	O
Acute	O
Pancreatitis	O
(	O
SAP	O
).	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
nucleocapsid	B-COMP
protein	O
from	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
)	O
mostly	O
contains	O
positively	O
charged	O
residues	O
and	O
has	O
been	O
identified	O
as	O
being	O
responsible	O
for	O
RNA	O
binding	O
during	O
ribonucleocapsid	O
formation	O
in	O
the	O
coronavirus	O
.	O

These	O
results	O
indicate	O
for	O
the	O
first	O
time	O
that	O
IBV	O
undergoes	O
intraspatial	O
variation	O
during	O
host	B-COMP
invasion	O
,	O
i	O
.	O
e	O
.,	O
the	O
dominant	O
genotype	O
/	O
phenotype	O
further	O
changes	O
during	O
host	B-COMP
invasion	O
as	O
the	O
microenvironment	O
of	O
distinct	O
tissues	O
exerts	O
selective	O
pressure	O
on	O
the	O
replicating	O
virus	O
population	O
.	O

Enhancement	O
of	O
the	O
number	O
of	O
virus	O
-	O
specific	O
CD8	O
T	O
cells	B-COMP
by	O
immunization	O
with	O
SARS	O
-	O
CoV	O
peptide	O
-	O
pulsed	O
dendritic	B-COMP
cells	B-COMP
also	O
resulted	O
in	O
a	O
robust	O
T	O
cell	B-COMP
response	O
,	O
earlier	O
virus	O
clearance	O
,	O
and	O
increased	O
survival	O
.	O

Viral	O
nucleic	B-COMP
acid	O
was	O
present	O
in	O
5	O
of	O
98	O
sera	B-COMP
(	O
5	O
%)	O
from	O
a	O
single	O
colony	O
of	O
free	O
-	O
ranging	O
bats	O
.	O

The	O
results	O
suggest	O
that	O
the	O
major	O
antibody	B-COMP
-	O
binding	O
domains	O
of	O
pAPN	O
may	O
associate	O
with	O
the	O
receptor	O
-	O
binding	O
determinants	O
.	O

ABSTRACT	O
:	O
All	O
serum	B-COMP
protein	O
electrophoresis	O
(	O
SPE	O
)	O
results	O
obtained	O
between	O
2002	O
and	O
2009	O
from	O
clinical	O
cases	O
presented	O
to	O
the	O
University	O
of	O
Bristol	O
Feline	O
Centre	O
were	O
examined	O
retrospectively	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
an	O
in	O
vitro	O
model	O
of	O
dual	O
infection	O
with	O
cell	B-COMP
culture	O
-	O
adapted	O
PEDV	O
and	O
Chlamydia	O
abortus	O
or	O
Chlamydia	O
pecorum	O
in	O
Vero	O
cells	B-COMP
was	O
established	O
.	O

Infected	O
cultures	O
were	O
investigated	O
by	O
immunofluorescence	O
(	O
IF	O
),	O
transmission	O
electron	O
microscopy	O
(	O
TEM	B-COMP
)	O
and	O
re	O
-	O
infection	O
experiments	O
.	O

TEM	B-COMP
examinations	O
of	O
mixed	O
infections	O
with	O
Chlamydia	O
abortus	O
and	O
Chlamydia	O
pecorum	O
revealed	O
aberrant	O
chlamydial	O
inclusions	O
containing	O
reticulate	O
-	O
like	O
,	O
pleomorphic	O
ABs	O
,	O
which	O
were	O
up	O
to	O
2	O
microm	O
in	O
diameter	O
.	O

In	O
re	O
-	O
infection	O
experiments	O
,	O
co	O
-	O
infected	O
cells	B-COMP
produced	O
fewer	O
EBs	O
than	O
monoinfected	O
cells	B-COMP
.	O

RESULTS	O
:	O
Infected	O
cultures	O
were	O
investigated	O
by	O
immunofluorescence	O
(	O
IF	O
),	O
transmission	O
electron	O
microscopy	O
(	O
TEM	B-COMP
)	O
and	O
re	O
-	O
infection	O
experiments	O
.	O

SSDRB	O
-	O
mediated	O
changes	O
in	O
gene	O
expression	O
profiles	O
of	O
B	O
lymphoma	O
cells	B-COMP
were	O
analyzed	O
by	O
microarray	O
.	O

Transmission	O
electron	O
microscopy	O
showed	O
that	O
,	O
compared	O
to	O
revertant	O
virus	O
,	O
the	O
number	O
of	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
in	O
MHV	O
-	O
Brts31	O
-	O
infected	O
cells	B-COMP
is	O
reduced	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

Like	O
its	O
PL2	O
(	O
pro	O
)	O
paralogs	O
from	O
several	O
coronaviruses	O
,	O
TGEV	O
PL1	O
(	O
pro	O
)	O
was	O
also	O
found	O
to	O
have	O
deubiquitinating	O
activity	O
in	O
an	O
in	O
vitro	O
cleavage	O
assay	O
,	O
implicating	O
it	O
in	O
counteracting	O
ubiquitin	O
-	O
regulated	O
host	B-COMP
cell	I-COMP
pathways	O
,	O
likely	O
including	O
innate	O
immune	O
responses	O
.	O

ABSTRACT	O
:	O
Serum	B-COMP
cell	B-COMP
-	O
free	O
DNA	O
concentrations	O
have	O
been	O
reported	O
to	O
increase	O
in	O
many	O
acute	O
diseases	O
as	O
well	O
as	O
in	O
some	O
chronic	O
conditions	O
such	O
as	O
cancer	O
and	O
autoimmune	O
diseases	O
.	O

The	O
strong	O
pathogenicity	O
of	O
the	O
virus	O
is	O
still	O
not	O
completely	O
explained	O
,	O
but	O
the	O
deep	O
location	O
of	O
infection	O
in	O
the	O
lungs	O
and	O
the	O
deregulation	O
of	O
cytokine	O
production	O
by	O
the	O
target	O
cells	B-COMP
,	O
particularly	O
macrophages	O
,	O
may	O
be	O
part	O
of	O
the	O
explanation	O
.	O

Strict	O
associations	O
between	O
CoV	O
RGU	O
and	O
host	B-COMP
bat	O
genera	O
were	O
confirmed	O
for	O
six	O
independent	O
RGU	O
represented	O
simultaneously	O
in	O
China	O
and	O
Europe	O
.	O

In	O
dogs	O
,	O
CK	O
-	O
MB	O
was	O
essentially	O
absent	O
from	O
both	O
serum	B-COMP
and	O
homogenized	O
hearts	O
.	O

RESULTS	O
:	O
CK	O
-	O
MM	O
was	O
the	O
predominant	O
isoenzyme	O
in	O
the	O
serum	B-COMP
of	O
healthy	O
dogs	O
and	O
cats	O
,	O
followed	O
by	O
macro	O
-	O
CK2	O
and	O
CK	O
-	O
BB	O
in	O
dogs	O
and	O
by	O
both	O
macroenzymes	O
in	O
cats	O
.	O

Among	O
10	O
bats	O
with	O
complete	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
genes	O
sequenced	O
,	O
three	O
and	O
two	O
sequence	O
clades	O
for	O
all	O
three	O
genes	O
were	O
codetected	O
in	O
two	O
and	O
five	O
bats	O
,	O
respectively	O
,	O
suggesting	O
the	O
coexistence	O
of	O
two	O
or	O
three	O
distinct	O
genotypes	O
of	O
Ro	O
-	O
BatCoV	O
HKU9	O
in	O
the	O
same	O
bat	O
.	O

Antibodies	B-COMP
were	O
detected	O
in	O
75	O
(	O
43	O
%)	O
of	O
175	O
and	O
224	O
(	O
64	O
%)	O
of	O
350	O
tested	O
serum	B-COMP
samples	O
from	O
Leschenault	O
'	O
s	O
rousette	O
bats	O
by	O
Ro	O
-	O
BatCoV	O
HKU9	O
N	O
-	O
protein	O
-	O
based	O
Western	O
blot	O
and	O
enzyme	O
immunoassays	O
,	O
respectively	O
.	O

TITLE	O
:	O
The	O
successful	O
use	O
of	O
extra	O
-	O
corporeal	O
membrane	B-COMP
oxygenation	O
in	O
the	O
management	O
of	O
a	O
pregnant	O
woman	O
with	O
severe	O
H1N1	O
2009	O
influenza	O
complicated	O
by	O
pneumonitis	O
and	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Computational	O
modeling	O
studies	O
including	O
multi	O
nanosecond	O
molecular	O
dynamics	O
simulations	O
in	O
a	O
hydrated	O
POPC	O
lipid	O
bilayer	O
are	O
done	O
with	O
a	O
22	O
amino	O
acid	O
transmembrane	B-COMP
helix	O
to	O
predict	O
a	O
putative	O
homooligomeric	O
helical	O
bundle	O
model	O
.	O

TITLE	O
:	O
CD8	O
+	O
T	O
cell	B-COMP
response	O
in	O
HLA	O
-	O
A	O
*	O
0201	O
transgenic	O
mice	O
is	O
elicited	O
by	O
epitopes	O
from	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

Most	O
of	O
the	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
peptide	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
represented	O
a	O
memory	O
subset	O
with	O
CD45RB	O
(	O
high	O
)	O
and	O
CD62L	O
(	O
low	O
).	O

We	O
provide	O
novel	O
information	O
in	O
cellular	B-COMP
immune	O
responses	O
of	O
SARS	O
S	O
antigen	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
,	O
which	O
are	O
important	O
in	O
the	O
development	O
of	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
might	O
exert	O
their	O
antiviral	O
activities	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	B-COMP
by	O
inducing	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
the	O
activation	O
of	O
extracellular	B-COMP
signal	O
-	O
related	O
kinase	O
(	O
ERK	O
)	O
and	O
p38	O
or	O
ERK	O
alone	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Sophorae	O
radix	O
,	O
Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
reduced	O
intracellular	B-COMP
viral	O
RNA	O
levels	O
with	O
comparable	O
reductions	O
in	O
viral	O
proteins	O
and	O
MHV	O
-	O
A59	O
production	O
.	O

TITLE	O
:	O
Panton	O
-	O
Valentine	O
leukocidin	O
expressing	O
Staphylococcus	O
aureus	O
pneumonia	O
managed	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
experience	O
and	O
outcome	O
.	O

Locally	O
held	O
register	O
of	O
all	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
patients	O
at	O
Glenfield	O
Hospital	O
.	O

After	O
varying	O
periods	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
with	O
appropriate	O
antibiotic	O
and	O
ancillary	O
care	O
,	O
all	O
four	O
patients	O
were	O
discharged	O
home	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
viral	O
growth	O
between	O
25V16G	O
and	O
JHMV	O
in	O
cell	B-COMP
lines	O
cultured	O
in	O
vitro	O
.	O

TITLE	O
:	O
Production	O
and	O
characterization	O
of	O
a	O
monoclonal	O
antibody	B-COMP
against	O
spike	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
.	O

The	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
mediates	O
the	O
interaction	O
between	O
TGEV	O
and	O
its	O
susceptible	O
cells	B-COMP
.	O

To	O
determine	O
if	O
HCoV	O
-	O
HKU1	O
could	O
replicate	O
in	O
in	O
vitro	O
models	O
of	O
human	O
ciliated	O
airway	O
epithelial	O
cell	B-COMP
cultures	O
(	O
HAE	O
)	O
that	O
recapitulate	O
the	O
morphology	O
,	O
biochemistry	O
,	O
and	O
physiology	O
of	O
the	O
human	O
airway	O
epithelium	O
,	O
the	O
apical	O
surfaces	O
of	O
HAE	O
were	O
inoculated	O
with	O
a	O
clinical	O
sample	O
of	O
HCoV	O
-	O
HKU1	O
(	O
Cean1	O
strain	O
).	O

Two	O
patients	O
admitted	O
to	O
ICU	O
for	O
respiratory	O
insufficiency	O
and	O
a	O
diagnosis	O
of	O
severe	O
acute	O
pancreatitis	O
developed	O
pancreatic	O
necrosis	O
and	O
were	O
treated	O
by	O
necrosectomy	O
,	O
lesser	O
sac	B-COMP
marsupialisation	O
and	O
posterior	O
lumbotomic	O
opening	O
.	O

ANP	O
treatment	O
stimulated	O
Rac	O
-	O
dependent	O
PAK1	O
phosphorylation	O
,	O
attenuated	O
endothelial	O
permeability	O
caused	O
by	O
LPS	O
,	O
TNF	O
-	O
α	O
,	O
and	O
IL	O
-	O
6	O
,	O
decreased	O
LPS	O
-	O
induced	O
cell	B-COMP
and	O
protein	O
accumulation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
suppressed	O
Evans	O
blue	O
extravasation	O
in	O
the	O
murine	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
A	O
conserved	O
nucleic	B-COMP
acid	O
fragment	O
of	O
the	O
nucleocapsid	B-COMP
gene	O
of	O
Swine	O
Transmissible	O
Gastroenteritis	O
Coronavirus	O
(	O
TGEV	O
)	O
was	O
chosen	O
as	O
the	O
target	O
,	O
six	O
special	O
primers	O
were	O
designed	O
successfully	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
protein	O
6	O
impeded	O
nuclear	O
import	O
only	O
in	O
the	O
context	O
of	O
a	O
lipophilic	O
N	O
-	O
terminus	O
,	O
which	O
could	O
be	O
derived	O
from	O
membrane	B-COMP
proteins	O
unrelated	O
to	O
protein	O
6	O
.	O

The	O
analyses	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
showed	O
the	O
significant	O
increases	O
in	O
pulmonary	O
permeability	O
(	O
total	O
cells	B-COMP
and	O
protein	O
)	O
and	O
the	O
levels	O
of	O
proinflammatory	O
cytokines	O
,	O
including	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
).	O

TITLE	O
:	O
Generating	O
stable	O
Chinese	O
hamster	O
ovary	O
cell	B-COMP
clones	O
to	O
produce	O
a	O
truncated	O
SARS	O
-	O
CoV	O
spike	O
protein	O
for	O
vaccine	O
development	O
.	O

RESULTS	O
:	O
we	O
have	O
developed	O
VIGOR	O
(	O
Viral	B-COMP
Genome	I-COMP
ORF	O
Reader	O
),	O
a	O
web	O
application	O
tool	O
for	O
gene	O
prediction	O
in	O
influenza	O
virus	O
,	O
rotavirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
subtypes	O
.	O

We	O
determined	O
peak	O
and	O
trough	O
serum	B-COMP
TMP	O
and	O
SMX	O
concentrations	O
and	O
the	O
extent	O
of	O
TMP	O
/	O
SMX	O
CVVHDF	O
clearance	O
at	O
steady	O
-	O
state	O
while	O
the	O
patients	O
were	O
still	O
anuric	O
and	O
oliguric	O
.	O

TITLE	O
:	O
The	O
membrane	B-COMP
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
acts	O
as	O
a	O
dominant	O
immunogen	O
revealed	O
by	O
a	O
clustering	O
region	O
of	O
novel	O
functionally	O
and	O
structurally	O
defined	O
cytotoxic	O
T	O
-	O
lymphocyte	O
epitopes	O
.	O

The	O
M	O
protein	O
of	O
SARS	O
-	O
CoV	O
holds	O
dominant	O
cellular	B-COMP
immunogenicity	O
.	O

TITLE	O
:	O
Lung	O
transplantation	O
for	O
severe	O
antineutrophilic	O
cytoplasmic	B-COMP
antibody	B-COMP
-	O
associated	O
vasculitis	O
.	O

ABSTRACT	O
:	O
Antineutrophil	O
cytoplasmic	B-COMP
antibody	B-COMP
-	O
associated	O
vasculitis	O
is	O
a	O
life	O
-	O
threatening	O
disorder	O
for	O
which	O
medical	O
therapy	O
has	O
greatly	O
improved	O
survival	O
.	O

ABSTRACT	O
:	O
Antigenic	O
peptides	O
recognized	O
by	O
virus	O
-	O
specific	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
are	O
presented	O
by	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
;	O
or	O
human	O
leukocyte	O
antigen	O
[	O
HLA	O
]	O
in	O
humans	O
)	O
molecules	O
,	O
and	O
the	O
peptide	O
selection	O
and	O
presentation	O
strategy	O
of	O
the	O
host	B-COMP
has	O
been	O
studied	O
to	O
guide	O
our	O
understanding	O
of	O
cellular	B-COMP
immunity	O
and	O
vaccine	O
development	O
.	O

Single	O
application	O
of	O
only	O
low	O
vector	O
doses	O
elicited	O
strong	O
and	O
long	O
-	O
lasting	O
cytotoxic	O
T	O
-	O
cell	B-COMP
responses	O
,	O
providing	O
protective	O
antiviral	O
and	O
antitumor	O
immunity	O
.	O

ABSTRACT	O
:	O
Ubiquitination	O
is	O
a	O
critical	O
regulator	O
of	O
the	O
host	B-COMP
immune	O
response	O
to	O
viral	O
infection	O
,	O
and	O
many	O
viruses	O
,	O
including	O
coronaviruses	O
,	O
encode	O
proteins	O
that	O
target	O
the	O
ubiquitination	O
system	O
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
E	O
protein	O
interacts	O
with	O
PALS1	O
and	O
alters	O
tight	B-COMP
junction	I-COMP
formation	O
and	O
epithelial	O
morphogenesis	O
.	O

ABSTRACT	O
:	O
Intercellular	O
tight	B-COMP
junctions	I-COMP
define	O
epithelial	O
apicobasal	O
polarity	O
and	O
form	O
a	O
physical	O
fence	O
which	O
protects	O
underlying	O
tissues	O
from	O
pathogen	O
invasions	O
.	O

RESULTS	O
:	O
We	O
identified	O
Neural	O
Cell	B-COMP
Adhesion	O
Molecule	O
(	O
NCAM	O
)	O
as	O
a	O
novel	O
interacting	O
partner	O
of	O
the	O
PHE	O
-	O
CoV	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
T	O
cell	B-COMP
inhibitory	O
ligand	O
B7	O
-	O
H1	O
hinders	O
T	O
cell	B-COMP
-	O
mediated	O
virus	O
control	O
,	O
but	O
also	O
ameliorates	O
clinical	O
disease	O
during	O
autoimmune	O
and	O
virus	O
-	O
induced	O
CNS	O
disease	O
.	O

B7	O
-	O
H1	O
deficiency	O
did	O
not	O
affect	O
peripheral	O
T	O
or	O
B	O
cell	B-COMP
activation	O
or	O
alter	O
the	O
magnitude	O
or	O
composition	O
of	O
CNS	O
-	O
infiltrating	O
cells	B-COMP
.	O

These	O
data	O
are	O
the	O
first	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
demonstrate	O
that	O
B7	O
-	O
H1	O
-	O
mediated	O
protection	O
from	O
viral	O
-	O
induced	O
immune	O
pathology	O
associated	O
with	O
encephalomyelitis	O
resides	O
in	O
limiting	O
T	O
cell	B-COMP
-	O
mediated	O
axonal	O
bystander	O
damage	O
rather	O
than	O
direct	O
elimination	O
of	O
infected	O
myelinating	O
cells	B-COMP
.	O

Adjuvant	O
Systems	O
AS01	O
(	O
B	O
)	O
and	O
AS03	O
(	O
A	O
)	O
were	O
selected	O
and	O
tested	O
for	O
their	O
capacity	O
to	O
elicit	O
high	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
to	O
WI	O
-	O
SARS	O
vaccine	O
.	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
TNF	O
-	O
α	O
,	O
MCP	O
-	O
1	O
,	O
and	O
IL	O
-	O
10	O
increased	O
at	O
2	O
h	O
.	O
Both	O
in	O
wild	O
type	O
and	O
iNOS	O
knockout	O
mice	O
,	O
hypertonic	O
saline	O
resuscitation	O
decreased	O
plasma	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
α	O
,	O
and	O
MCP	O
-	O
1	O
levels	O
at	O
2	O
h	O
;	O
CD4	O
(+)	O
T	O
cells	B-COMP
in	O
spleen	O
and	O
thymus	O
decreased	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
,	O
and	O
Foxp3	O
(+)	O
Tregs	O
in	O
spleen	O
at	O
48	O
h	O
increased	O
,	O
however	O
,	O
hypertonic	O
saline	O
resuscitation	O
did	O
not	O
affect	O
the	O
Foxp3	O
(+).	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
TNF	O
-	O
α	O
,	O
MCP	O
-	O
1	O
,	O
and	O
IL	O
-	O
10	O
increased	O
at	O
2	O
h	O
.	O
Both	O
in	O
wild	O
type	O
and	O
iNOS	O
knockout	O
mice	O
,	O
hypertonic	O
saline	O
resuscitation	O
decreased	O
plasma	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
α	O
,	O
and	O
MCP	O
-	O
1	O
levels	O
at	O
2	O
h	O
;	O
CD4	O
(+)	O
T	O
cells	B-COMP
in	O
spleen	O
and	O
thymus	O
decreased	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
,	O
and	O
Foxp3	O
(+)	O
Tregs	O
in	O
spleen	O
at	O
48	O
h	O
increased	O
,	O
however	O
,	O
hypertonic	O
saline	O
resuscitation	O
did	O
not	O
affect	O
the	O
Foxp3	O
(+).	O

TITLE	O
:	O
Anti	O
-	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
activity	O
of	O
1	O
,	O
8	O
-	O
cineole	O
:	O
effect	O
on	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
.	O

Results	O
indicate	O
that	O
TMPRSS2	O
needs	O
to	O
be	O
expressed	O
in	O
the	O
opposing	O
(	O
target	O
)	O
cell	B-COMP
membrane	I-COMP
to	O
activate	O
S	O
protein	O
rather	O
than	O
in	O
the	O
producer	O
cell	B-COMP
,	O
as	O
found	O
for	O
influenza	O
A	O
virus	O
and	O
metapneumoviruses	O
.	O

Independent	O
of	O
transfusion	O
strategy	O
,	O
the	O
number	O
of	O
transfused	O
red	O
blood	O
cell	B-COMP
units	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
clinical	O
complications	O
or	O
death	O
at	O
30	O
days	O
(	O
hazard	O
ratio	O
for	O
each	O
additional	O
unit	O
transfused	O
,	O
1	O
.	O
2	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
1	O
.	O
4	O
];	O
P	O
=	O
.	O
002	O
).	O

TITLE	O
:	O
Prevalence	O
of	O
antibodies	B-COMP
to	O
four	O
human	O
coronaviruses	O
is	O
lower	O
in	O
nasal	O
secretions	O
than	O
in	O
serum	B-COMP
.	O

Patients	O
likely	O
had	O
experienced	O
infections	O
with	O
more	O
than	O
one	O
HCoV	O
strain	O
,	O
and	O
IgG	O
antibodies	B-COMP
to	O
these	O
HCoV	O
strains	O
in	O
serum	B-COMP
were	O
more	O
likely	O
to	O
be	O
detected	O
than	O
IgA	O
antibodies	B-COMP
to	O
these	O
HCoV	O
strains	O
in	O
nasal	O
wash	O
specimens	O
.	O

In	O
some	O
cases	O
,	O
the	O
patient	O
autoantibody	O
titers	O
remained	O
elevated	O
through	O
the	O
last	O
serum	B-COMP
sample	O
collected	O
.	O

We	O
localized	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
in	O
DRMs	O
in	O
the	O
viral	B-COMP
envelope	I-COMP
.	O

Though	O
S	O
protein	O
was	O
not	O
solubilized	O
by	O
cold	O
non	O
-	O
ionic	O
detergents	O
,	O
this	O
behavior	O
was	O
unchanged	O
when	O
cholesterol	O
was	O
depleted	O
from	O
viral	B-COMP
membrane	I-COMP
by	O
methyl	O
-	O
β	O
-	O
cyclodextrin	O
(	O
MβCD	O
)	O
and	O
the	O
protein	O
did	O
not	O
comigrate	O
with	O
cellular	B-COMP
DRM	O
marker	O
proteins	O
in	O
flotation	O
analyses	O
.	O

Cholesterol	O
depletion	O
from	O
viral	B-COMP
membrane	I-COMP
may	O
not	O
affect	O
the	O
adsorption	O
process	O
as	O
neither	O
the	O
sialic	O
acid	O
binding	O
activity	O
nor	O
the	O
binding	O
to	O
aminopeptidase	O
N	O
was	O
reduced	O
post	O
-	O
MβCD	O
treatment	O
.	O

Cholesterol	O
is	O
important	O
for	O
a	O
post	O
-	O
adsorption	O
step	O
,	O
allowing	O
membrane	B-COMP
rearrangements	O
that	O
facilitate	O
virus	O
entry	O
.	O

A	O
set	O
of	O
double	O
-	O
stable	O
eukaryotic	O
cell	B-COMP
lines	O
(	O
BHK	O
-	O
Tet	O
-	O
SARS	O
-	O
N	O
)	O
with	O
inducible	O
control	O
of	O
the	O
SARS	O
-	O
CoV	O
neucleocapsid	O
gene	O
expression	O
was	O
identified	O
by	O
using	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
analysis	O
.	O

ABSTRACT	O
:	O
Our	O
study	O
investigated	O
the	O
host	B-COMP
cell	I-COMP
protein	O
which	O
can	O
interact	O
with	O
SARS	O
-	O
CoV	O
N	O
protein	O
,	O
and	O
explored	O
the	O
functional	O
connections	O
.	O

However	O
,	O
non	O
-	O
protein	O
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
are	O
transcribed	O
in	O
mammalian	O
cells	B-COMP
,	O
and	O
the	O
roles	O
of	O
many	O
of	O
these	O
ncRNAs	O
remain	O
enigmas	O
.	O

During	O
infection	O
with	O
SARS	O
-	O
CoV	O
not	O
only	O
a	O
variety	O
of	O
IRGs	O
were	O
upregulated	O
,	O
but	O
also	O
a	O
significantly	O
broader	O
range	O
of	O
genes	O
involved	O
in	O
cell	B-COMP
migration	O
and	O
inflammation	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
mouse	O
oligodendrocytes	O
with	O
a	O
recombinant	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
expressing	O
a	O
green	O
fluorescence	O
protein	O
facilitated	O
specific	O
selection	O
of	O
virus	O
-	O
infected	O
cells	B-COMP
and	O
subsequent	O
establishment	O
of	O
persistence	O
.	O

Overexpression	O
of	O
ISG20	O
,	O
however	O
,	O
did	O
not	O
inhibit	O
propagation	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
a	O
highly	O
-	O
pathogenic	O
human	O
coronavirus	O
in	O
Huh7	O
.	O
5	O
cells	B-COMP
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
IBV	O
E	O
,	O
but	O
not	O
EG3	O
,	O
dramatically	O
reduced	O
the	O
delivery	O
of	O
cargo	O
to	O
the	O
plasma	B-COMP
membrane	I-COMP
by	O
impeding	O
movement	O
through	O
the	O
Golgi	B-COMP
complex	I-COMP
.	O

Our	O
results	O
indicated	O
that	O
the	O
hydrophobic	O
domain	O
of	O
IBV	O
E	O
alters	O
the	O
host	B-COMP
secretory	O
pathway	O
to	O
the	O
apparent	O
advantage	O
of	O
the	O
virus	O
.	O

Coupling	O
analysis	O
of	O
TEM	B-COMP
and	O
ES	O
-	O
DMA	O
derived	O
data	O
requires	O
the	O
creation	O
and	O
use	O
of	O
analytical	O
models	O
to	O
determine	O
the	O
size	O
and	O
number	O
of	O
constituents	O
in	O
nanoparticle	O
complexes	O
from	O
the	O
difference	O
between	O
the	O
two	O
measurements	O
.	O

ABSTRACT	O
:	O
Spike	O
(	O
S	O
)	O
proteins	O
,	O
the	O
defining	O
projections	O
of	O
the	O
enveloped	O
coronaviruses	O
(	O
CoVs	O
),	O
mediate	O
cell	B-COMP
entry	O
by	O
connecting	O
viruses	O
to	O
plasma	B-COMP
membrane	I-COMP
receptors	O
and	O
by	O
catalyzing	O
subsequent	O
virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusions	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
endogenously	O
expressed	O
PTX3	O
plays	O
a	O
protective	O
role	O
in	O
the	O
pathogenesis	O
of	O
ALI	O
and	O
that	O
a	O
lack	O
of	O
PTX3	O
may	O
enhance	O
neutrophil	O
recruitment	O
,	O
cell	B-COMP
death	O
,	O
activation	O
of	O
coagulation	O
cascades	O
,	O
and	O
inflammatory	O
responses	O
in	O
the	O
lung	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
the	O
endogenously	O
expressed	O
PTX3	O
plays	O
a	O
protective	O
role	O
in	O
the	O
pathogenesis	O
of	O
ALI	O
and	O
that	O
a	O
lack	O
of	O
PTX3	O
may	O
enhance	O
neutrophil	O
recruitment	O
,	O
cell	B-COMP
death	O
,	O
activation	O
of	O
coagulation	O
cascades	O
,	O
and	O
inflammatory	O
responses	O
in	O
the	O
lung	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
double	O
-	O
antibody	B-COMP
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
DAS	O
-	O
ELISA	O
)	O
as	O
a	O
potential	O
tool	O
for	O
identification	O
and	O
differentiation	O
between	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
229E	O
.	O

The	O
activation	O
followed	O
the	O
Hofmeister	O
series	O
of	O
anions	O
,	O
with	O
two	O
orders	O
of	O
magnitude	O
enhancement	O
in	O
the	O
presence	O
of	O
Na₂SO₄	O
,	O
whereas	O
the	O
crowding	O
agents	O
polyethylene	O
glycol	O
and	O
bovine	O
serum	B-COMP
albumin	O
increased	O
the	O
hydrolytic	O
rate	O
up	O
to	O
3	O
times	O
.	O

Polyclonal	O
antibody	B-COMP
against	O
SARS	O
-	O
CoV	O
S1	O
protein	O
was	O
generated	O
in	O
a	O
rabbit	O
immunized	O
with	O
the	O
purified	O
S1	O
protein	O
.	O

TGEV	O
-	O
specific	O
antibodies	B-COMP
were	O
detected	O
in	O
all	O
the	O
inoculated	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
rotavirus	O
-	O
specific	O
antibodies	B-COMP
were	O
found	O
only	O
after	O
immunization	O
by	O
the	O
intraperitoneal	O
route	O
.	O

Cav	O
-	O
1	O
regulates	O
critical	O
cell	B-COMP
functions	O
including	O
proliferation	O
,	O
apoptosis	O
,	O
cell	B-COMP
differentiation	O
,	O
and	O
transcytosis	O
via	O
diverse	O
signaling	O
pathways	O
.	O

We	O
further	O
discuss	O
the	O
potential	O
molecular	O
and	O
cellular	B-COMP
mechanisms	O
by	O
which	O
cav	O
-	O
1	O
expression	O
contributes	O
to	O
ALI	O
.	O

It	O
is	O
considered	O
a	O
variant	O
form	O
of	O
Guillain	O
-	O
Barré	O
syndrome	O
,	O
which	O
is	O
associated	O
with	O
anti	O
-	O
GQ1b	O
antibodies	B-COMP
.	O

We	O
sought	O
to	O
determine	O
whether	O
the	O
degree	O
of	O
pulmonary	O
hypoplasia	O
could	O
be	O
measured	O
using	O
bedside	O
pulmonary	O
graphics	O
and	O
whether	O
survival	O
could	O
be	O
predicted	O
in	O
potential	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
candidates	O
.	O

In	O
addition	O
,	O
CD20	O
+	O
B	O
-	O
cell	B-COMP
infiltration	O
into	O
the	O
fascia	O
was	O
also	O
detected	O
in	O
all	O
of	O
the	O
cases	O
,	O
indicating	O
further	O
transition	O
to	O
DM	O
.	O

Three	O
pairs	O
of	O
primers	O
targeting	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
of	O
TGEV	O
were	O
synthesized	O
and	O
used	O
in	O
the	O
RT	O
-	O
LAMP	O
.	O

ABSTRACT	O
:	O
Myasthenia	O
gravis	O
is	O
a	O
neuromuscular	B-COMP
junction	I-COMP
post	O
-	O
synaptic	O
autoimmune	O
disorder	O
.	O

We	O
present	O
evidence	O
that	O
suggests	O
M	O
can	O
adopt	O
two	O
conformations	O
and	O
that	O
membrane	B-COMP
curvature	O
is	O
regulated	O
by	O
one	O
M	O
conformer	O
.	O

The	O
biological	O
activity	O
of	O
CTB	O
-	O
COE	O
fusion	O
protein	O
to	O
its	O
receptor	O
,	O
G	O
(	O
M1	O
)-	O
ganglioside	O
,	O
in	O
transgenic	O
plants	O
was	O
confirmed	O
via	O
G	O
(	O
M1	O
)-	O
ELISA	O
with	O
anti	O
-	O
cholera	O
toxin	O
and	O
anti	O
-	O
COE	O
antibody	B-COMP
.	O

The	O
biopsy	O
results	O
of	O
the	O
5	O
patients	O
were	O
as	O
follows	O
:	O
1	O
case	O
diagnosed	O
as	O
""""	O
signet	O
-	O
ring	O
cell	B-COMP
carcinoma	O
of	O
the	O
stomach	O
and	O
rectum	O
multiple	O
transfer	O
""","	O
1	O
case	O
of	O
gastric	O
polyp	O
,	O
1	O
case	O
of	O
superficial	O
antral	O
gastritis	O
and	O
2	O
cases	O
were	O
normal	O
.	O

Multiple	O
myeloma	O
or	O
plasma	O
cell	B-COMP
neoplasia	O
was	O
diagnosed	O
based	O
on	O
cytopathology	O
and	O
post	O
mortem	O
examination	O
.	O

Based	O
on	O
this	O
finding	O
,	O
a	O
liposome	O
vaccine	O
that	O
is	O
capable	O
of	O
inducing	O
CTL	O
response	O
against	O
internal	O
antigens	O
of	O
influenza	O
viruses	O
and	O
removing	O
virus	O
-	O
infected	O
cells	B-COMP
in	O
the	O
host	B-COMP
has	O
been	O
developed	O
.	O

Intensive	O
passages	O
of	O
the	O
virus	O
in	O
its	O
natural	O
host	B-COMP
may	O
enhance	O
the	O
appearance	O
of	O
mutations	O
and	O
therefore	O
may	O
contribute	O
to	O
any	O
attenuated	O
form	O
of	O
the	O
virus	O
.	O

The	O
variety	O
of	O
the	O
virus	O
'	O
s	O
evolutionary	O
forms	O
may	O
be	O
a	O
result	O
,	O
not	O
only	O
of	O
the	O
multiple	O
passages	O
in	O
natural	O
hosts	B-COMP
,	O
but	O
also	O
of	O
other	O
factors	O
,	O
such	O
as	O
different	O
pathogens	O
co	O
-	O
infection	O
,	O
nutrition	O
,	O
immunity	O
,	O
and	O
others	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
the	O
S	O
mutation	O
on	O
MHV	O
infectivity	O
and	O
foreign	O
protein	O
expression	O
were	O
further	O
examined	O
in	O
rat	O
or	O
mouse	O
L2	O
,	O
NIH	O
/	O
3T3	O
and	O
Neuro	O
-	O
2a	O
cells	B-COMP
.	O

TITLE	O
:	O
A	O
type	O
-	O
specific	O
blocking	O
ELISA	O
for	O
the	O
detection	O
of	O
infectious	O
bronchitis	O
virus	O
antibody	B-COMP
.	O

Current	O
commercially	O
available	O
ELISA	O
kits	O
detect	O
group	O
-	O
specific	O
antibodies	B-COMP
;	O
however	O
,	O
to	O
understand	O
the	O
status	O
of	O
field	O
infection	O
,	O
a	O
monoclonal	O
antibody	B-COMP
(	O
mAb	O
)	O
blocking	O
ELISA	O
(	O
b	O
-	O
ELISA	O
)	O
against	O
local	O
IBVs	O
was	O
developed	O
.	O

This	O
b	O
-	O
ELISA	O
provides	O
type	O
-	O
specific	O
antibody	B-COMP
detection	O
of	O
local	O
IBV	O
strains	O
.	O

The	O
similarity	O
between	O
the	O
structures	O
of	O
these	O
two	O
domains	O
from	O
SARS	O
-	O
CoV	O
,	O
IBV	O
and	O
MHV	O
corroborates	O
a	O
conserved	O
mechanism	O
of	O
nucleocapsid	B-COMP
formation	O
for	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
prepared	O
neutralizing	O
monoclonal	O
antibody	B-COMP
(	O
MAb	O
)-	O
resistant	O
(	O
mar	O
)	O
mutant	O
viruses	O
using	O
a	O
laboratory	O
strain	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
79	O
-	O
1146	O
(	O
Kida	O
et	O
al	O
.,	O
1999	O
).	O

In	O
the	O
S2	O
domain	O
of	O
type	O
II	O
FIPV	O
,	O
4	O
peptides	O
containing	O
linear	O
immunodominant	O
antibody	B-COMP
-	O
binding	O
epitopes	O
were	O
identified	O
in	O
the	O
HR2	O
region	O
.	O

The	O
Th1	O
epitopes	O
in	O
the	O
S2	O
domain	O
of	O
type	O
I	O
and	O
II	O
FIPV	O
were	O
located	O
in	O
different	O
regions	O
,	O
but	O
the	O
linear	O
immunodominant	O
antibody	B-COMP
-	O
binding	O
epitopes	O
were	O
mostly	O
located	O
in	O
the	O
HR2	O
region	O
.	O

The	O
packed	O
cell	B-COMP
volume	O
,	O
bilirubin	O
,	O
AST	O
,	O
potassium	O
,	O
and	O
sodium	O
levels	O
were	O
established	O
to	O
predict	O
disease	O
staging	O
and	O
survival	O
time	O
.	O

ABSTRACT	O
:	O
This	O
work	O
aims	O
to	O
characterize	O
the	O
utility	O
of	O
four	O
newly	O
generated	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
against	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

Four	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
against	O
the	O
N	O
-	O
terminal	O
half	O
of	O
spike	O
protein	O
(	O
S1	O
protein	O
)	O
of	O
TGEV	O
were	O
identified	O
.	O

The	O
Virochip	O
also	O
successfully	O
detected	O
porcine	O
circovirus	O
type	O
2	O
(	O
PCV2	O
)	O
in	O
serum	B-COMP
containing	O
2	O
.	O
50	O
×	O
10	O
(	O
8	O
)	O
viral	O
copies	O
per	O
microliter	O
and	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
in	O
turbinate	O
tissue	O
homogenate	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
suppressed	O
alpha	O
interferon	O
-	O
induced	O
responses	O
through	O
downregulation	O
of	O
extracellular	B-COMP
signal	O
-	O
regulated	O
kinase	O
1	O
-	O
mediated	O
signalling	O
pathways	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
ensure	O
life	O
-	O
sustaining	O
gas	O
exchange	O
in	O
patients	O
with	O
severe	O
vitally	O
compromised	O
pulmonary	O
failure	O
,	O
to	O
provide	O
time	O
for	O
lung	O
tissue	O
to	O
heal	O
and	O
reduce	O
ventilatory	O
stress	O
.	O

HCoV	O
-	O
HKU1	O
S	O
protein	O
was	O
constructed	O
in	O
the	O
eukaryotic	O
expression	O
plasmids	O
,	O
and	O
confirmed	O
by	O
Western	O
Blotting	O
,	O
S	O
antibody	B-COMP
assay	O
was	O
established	O
using	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
).	O

Higher	O
positive	O
detection	O
rate	O
of	O
anti	O
-	O
S	O
or	O
anti	O
-	O
N	O
antibody	B-COMP
was	O
found	O
in	O
the	O
normal	O
adults	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
applied	O
as	O
rescue	O
-	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
FMDV	O
Lb	O
(	O
pro	O
)	O
possesses	O
DUB	O
activity	O
in	O
addition	O
to	O
serving	O
as	O
a	O
viral	O
proteinase	O
and	O
describe	O
a	O
novel	O
mechanism	O
evolved	O
by	O
FMDV	O
to	O
counteract	O
host	B-COMP
innate	O
antiviral	O
responses	O
.	O

In	O
this	O
article	O
,	O
we	O
show	O
that	O
IL	O
-	O
10	O
,	O
a	O
potent	O
anti	O
-	O
inflammatory	O
cytokine	O
,	O
is	O
produced	O
transiently	O
at	O
the	O
peak	O
of	O
infection	O
by	O
CD8	O
T	O
cells	B-COMP
in	O
the	O
brains	O
of	O
coronavirus	O
-	O
infected	O
mice	O
.	O

Earlier	O
research	O
determined	O
metabolic	O
oxidative	O
stress	O
in	O
hosts	B-COMP
deficient	O
in	O
antioxidant	O
selenium	O
(	O
Se	O
)	O
(<	O
1	O
μMol	O
Se	O
/	O
L	O
of	O
blood	O
)	O
induces	O
both	O
impaired	O
human	O
host	B-COMP
immunocompetence	O
and	O
rapidly	O
mutated	O
benign	O
variants	O
of	O
RNA	O
viruses	O
to	O
virulence	O
.	O

Because	O
African	O
green	O
monkeys	O
developed	O
more	O
severe	O
ALI	O
than	O
macaques	O
,	O
with	O
hyaline	O
membrane	B-COMP
formation	O
,	O
some	O
of	O
these	O
differentially	O
expressed	O
proinflammatory	O
genes	O
may	O
be	O
critically	O
involved	O
in	O
development	O
of	O
the	O
observed	O
pathological	O
changes	O
.	O

cis	O
-	O
cleavage	O
resulted	O
in	O
release	O
of	O
SARS	O
S	O
fragments	O
into	O
the	O
cellular	B-COMP
supernatant	O
and	O
in	O
inhibition	O
of	O
antibody	B-COMP
-	O
mediated	O
neutralization	O
,	O
most	O
likely	O
because	O
SARS	O
S	O
fragments	O
function	O
as	O
antibody	B-COMP
decoys	O
.	O

trans	O
-	O
cleavage	O
activated	O
SARS	O
S	O
on	O
effector	O
cells	B-COMP
for	O
fusion	O
with	O
target	O
cells	B-COMP
and	O
allowed	O
efficient	O
SARS	O
S	O
-	O
driven	O
viral	O
entry	O
into	O
targets	O
treated	O
with	O
a	O
lysosomotropic	O
agent	O
or	O
a	O
cathepsin	O
inhibitor	O
.	O

Virus	O
replication	O
assay	O
in	O
17C1	O
-	O
1	O
cells	B-COMP
showed	O
the	O
plaque	O
phenotype	O
and	O
replication	O
characterization	O
of	O
constructed	O
Wu	O
"""-"	O
ts18	O
(	O
cd	O
)	O
were	O
indistinguishable	O
from	O
the	O
reported	O
ts	O
mutant	O
Wu	O
"""-"	O
ts18	O
.	O

Both	O
passage	O
levels	O
were	O
tested	O
for	O
efficacy	O
in	O
SPF	O
chickens	O
and	O
passage	O
level	O
85	O
was	O
tested	O
for	O
efficacy	O
in	O
commercial	O
chickens	O
with	O
maternally	O
derived	O
antibodies	B-COMP
(	O
MDA	O
)	O
against	O
a	O
challenge	O
with	O
QX	O
-	O
like	O
strain	O
IB	O
D388	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
first	O
successful	O
use	O
of	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
refractory	O
respiratory	O
failure	O
in	O
an	O
infant	O
with	O
DiGeorge	O
anomaly	O
,	O
following	O
thymus	O
transplantation	O
.	O

To	O
evaluate	O
the	O
importance	O
of	O
cellular	B-COMP
immunity	O
for	O
FIPV	O
infection	O
,	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	B-COMP
)	O
against	O
feline	O
interferon	O
(	O
fIFN	O
)-	O
γ	O
were	O
first	O
created	O
to	O
establish	O
fIFN	O
-	O
γ	O
detection	O
systems	O
using	O
the	O
MAbs	B-COMP
.	O

Apart	O
from	O
being	O
cytotoxic	O
,	O
these	O
cells	B-COMP
are	O
also	O
involved	O
in	O
maintaining	O
inflammatory	O
reactions	O
by	O
the	O
release	O
of	O
cytokines	O
and	O
bioactive	O
lipids	O
such	O
as	O
platelet	O
-	O
activating	O
factor	O
and	O
arachidonic	O
acid	O
metabolites	O
.	O

Entry	O
and	O
release	O
of	O
canine	O
coronavirus	O
from	O
polarized	O
epithelial	O
cells	B-COMP
.	O

To	O
establish	O
the	O
reciprocal	O
binding	O
of	O
CCoV	O
on	O
plasma	B-COMP
membrane	I-COMP
,	O
A72	O
cells	B-COMP
on	O
a	O
permeable	O
support	O
were	O
preincubated	O
with	O
a	O
mAb	O
specific	O
for	O
CCoV	O
.	O
Infection	O
from	O
the	O
apical	O
side	O
was	O
blocked	O
by	O
mAb	O
applied	O
to	O
that	O
side	O
;	O
in	O
contrast	O
,	O
such	O
treatment	O
on	O
the	O
basolateral	O
side	O
had	O
no	O
effect	O
on	O
the	O
infectious	O
process	O
.	O

A	O
pan	B-COMP
-	O
coronavirus	O
and	O
a	O
genus	O
-	O
specific	O
RT	O
-	O
PCR	O
assay	O
were	O
used	O
initially	O
to	O
demonstrate	O
that	O
the	O
newly	O
discovered	O
mink	O
CoVs	O
(	O
MCoVs	O
)	O
were	O
members	O
of	O
the	O
genus	O
Alphacoronavirus	O
.	O

For	O
neutralizing	O
antibodies	B-COMP
,	O
neutralizing	O
activity	O
was	O
detectable	O
in	O
89	O
%	O
of	O
recovered	O
patients	O
in	O
the	O
3rd	O
y	O
.	O
S	O
protein	O
-	O
specific	O
IgG	O
levels	O
(	O
r	O
=	O
0	O
.	O
717	O
)	O
correlated	O
better	O
with	O
neutralizing	O
activity	O
than	O
SARS	O
coronavirus	O
-	O
specific	O
IgG	O
levels	O
(	O
r	O
=	O
0	O
.	O
571	O
).	O

Efficacy	O
was	O
determined	O
by	O
qRT	O
-	O
PCR	O
of	O
intracellular	B-COMP
viral	O
genomic	O
and	O
messenger	O
RNA	O
,	O
TCID50	O
infectivity	O
assay	O
of	O
extracellular	B-COMP
virus	O
,	O
and	O
direct	O
IFA	O
for	O
viral	O
protein	O
expression	O
.	O

Examination	O
of	O
CPE	O
demonstrated	O
that	O
the	O
four	O
siRNAs	O
were	O
capable	O
of	O
protecting	O
cells	B-COMP
against	O
PHE	O
-	O
CoV	O
invasion	O
with	O
very	O
high	O
specificity	O
and	O
efficiency	O
.	O

Furthermore	O
,	O
treatment	O
with	O
siRNAs	O
caused	O
a	O
53	O
-	O
91	O
%	O
reduction	O
in	O
the	O
viral	B-COMP
genome	I-COMP
copy	O
number	O
as	O
assessed	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

In	O
the	O
context	O
of	O
CoV	O
RNA	O
synthesis	O
,	O
these	O
cellular	B-COMP
ribonucleoproteins	O
might	O
also	O
participate	O
in	O
RNA	O
-	O
protein	O
complexes	O
to	O
bring	O
into	O
physical	O
proximity	O
TRS	O
-	O
L	O
and	O
distant	O
TRS	O
-	O
B	O
,	O
as	O
proposed	O
for	O
CoV	O
discontinuous	O
transcription	O
.	O

These	O
proteins	O
mostly	O
related	O
to	O
the	O
cytoskeleton	B-COMP
,	O
binding	O
of	O
calcium	O
ions	O
,	O
the	O
stress	O
response	O
,	O
anti	O
-	O
oxidative	O
,	O
and	O
macromolecular	O
metabolism	O
.	O

When	O
the	O
immunochromatographic	O
strip	O
was	O
used	O
for	O
serological	O
diagnosis	O
of	O
1	O
,	O
117	O
serum	B-COMP
samples	O
in	O
Jilin	O
Province	O
in	O
China	O
,	O
the	O
seropositivity	O
ranged	O
from	O
6	O
.	O
5	O
%	O
in	O
the	O
Liaoyuan	O
District	O
to	O
81	O
.	O
6	O
%	O
in	O
the	O
Changchun	O
District	O
.	O

These	O
cytoplasmic	B-COMP
ribonucleoprotein	B-COMP
complexes	O
might	O
be	O
involved	O
in	O
posttranscriptional	O
regulation	O
of	O
virus	O
gene	O
expression	O
.	O

ABSTRACT	O
:	O
How	O
viruses	O
evolve	O
to	O
select	O
their	O
receptor	O
proteins	O
for	O
host	B-COMP
cell	I-COMP
entry	O
is	O
puzzling	O
.	O

ABSTRACT	O
:	O
The	O
RNA	O
replication	O
and	O
transcription	O
complex	O
of	O
coronaviruses	O
is	O
associated	O
with	O
an	O
elaborate	O
reticulovesicular	O
network	O
(	O
RVN	O
)	O
of	O
modified	O
endoplasmic	B-COMP
reticulum	I-COMP
.	O

All	O
the	O
recombinant	O
proteins	O
,	O
including	O
nucleocapsid	B-COMP
(	O
N	O
)	O
and	O
3	O
subunits	O
of	O
spike	O
protein	O
,	O
S1	O
,	O
S2	O
,	O
and	O
Smid	O
,	O
showed	O
positive	O
reactivity	O
in	O
MFI	O
with	O
mouse	O
antisera	O
to	O
4	O
MHV	O
strains	O
(	O
MHV	O
-	O
S	O
,	O
-	O
A59	O
,	O
-	O
JHM	O
,	O
and	O
-	O
Nu67	O
)	O
and	O
rat	O
antiserum	O
to	O
a	O
strain	O
of	O
sialodacryoadenitis	O
virus	O
(	O
SDAV	O
-	O
681	O
).	O

Based	O
on	O
the	O
assessment	O
by	O
MFI	O
using	O
the	O
S2	O
and	O
N	O
antigens	O
,	O
only	O
3	O
serum	B-COMP
samples	O
showed	O
double	O
-	O
negative	O
results	O
,	O
indicating	O
a	O
false	O
-	O
negative	O
rate	O
of	O
1	O
.	O
3	O
%.	O

TITLE	O
:	O
Different	O
host	B-COMP
cell	I-COMP
proteases	O
activate	O
the	O
SARS	O
-	O
coronavirus	O
spike	O
-	O
protein	O
for	O
cell	B-COMP
-	O
cell	B-COMP
and	O
virus	O
-	O
cell	B-COMP
fusion	O
.	O

We	O
found	O
that	O
R667	O
was	O
dispensable	O
for	O
SARS	O
-	O
S	O
-	O
driven	O
virus	O
-	O
cell	B-COMP
fusion	O
and	O
for	O
SARS	O
-	O
S	O
-	O
activation	O
by	O
trypsin	O
and	O
cathepsin	O
L	O
in	O
a	O
virus	O
-	O
virus	O
fusion	O
assay	O
.	O

Instead	O
,	O
a	O
so	O
far	O
unknown	O
leupeptin	O
-	O
sensitive	O
host	B-COMP
cell	I-COMP
protease	O
activated	O
cellular	B-COMP
SARS	O
-	O
S	O
for	O
fusion	O
with	O
target	O
cells	B-COMP
expressing	O
high	O
levels	O
of	O
ACE2	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
two	O
bacterial	O
pathogens	O
(	O
Fusobacterium	O
necrophorum	O
and	O
Acinetobacter	O
baumannii	O
)	O
causing	O
sepsis	O
were	O
detected	O
by	O
DNA	O
-	O
probe	O
hybridization	O
and	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
was	O
detected	O
by	O
antigen	O
-	O
antibody	B-COMP
interaction	O
using	O
the	O
functional	O
PCs	O
.	O

Equid	O
herpesvirus	O
1	O
and	O
equine	O
rhinitis	O
A	O
virus	O
were	O
prevalent	O
,	O
and	O
equine	O
arteritis	O
virus	O
and	O
equid	O
herpesvirus	O
3	O
were	O
detected	O
over	O
a	O
wide	O
area	O
though	O
their	O
rates	O
of	O
antibody	B-COMP
-	O
positivity	O
were	O
not	O
high	O
.	O

The	O
rates	O
of	O
horses	O
antibody	B-COMP
-	O
positive	O
for	O
Japanese	O
encephalitis	O
virus	O
and	O
equine	O
influenza	O
virus	O
were	O
low	O
,	O
but	O
these	O
were	O
detected	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
Golgi	B-COMP
complex	I-COMP
-	O
targeting	O
signal	O
in	O
the	O
cytoplasmic	B-COMP
tail	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	B-COMP
protein	O
.	O

Almost	O
all	O
of	O
them	O
put	O
stress	O
on	O
analyzing	O
nucleic	B-COMP
acid	O
sequences	O
or	O
protein	O
primary	O
sequences	O
.	O

Learning	O
from	O
viruses	O
how	O
to	O
target	O
cell	B-COMP
surface	I-COMP
receptors	O
not	O
only	O
helps	O
us	O
understand	O
viral	O
strategies	O
to	O
escape	O
from	O
the	O
host	B-COMP
immune	O
surveillance	O
,	O
but	O
also	O
provides	O
novel	O
avenues	O
in	O
rational	O
drug	O
design	O
and	O
the	O
development	O
of	O
new	O
therapies	O
for	O
immune	O
disorders	O
.	O

To	O
develop	O
gene	O
therapy	O
strategies	O
for	O
Friedreich	O
'	O
s	O
ataxia	O
(	O
FRDA	O
),	O
we	O
have	O
examined	O
the	O
persistence	O
of	O
transgene	O
expression	O
in	O
the	O
brain	O
in	O
vivo	O
provided	O
by	O
the	O
entire	O
135	O
kb	O
FXN	O
genomic	O
DNA	O
locus	O
delivered	O
as	O
an	O
infectious	O
bacterial	O
artificial	O
chromosome	B-COMP
(	O
iBAC	O
)	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)-	O
based	O
vector	O
injected	O
in	O
the	O
adult	O
mouse	O
cerebellum	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
RNA	O
synthesis	O
is	O
a	O
sophisticated	O
process	O
performed	O
by	O
a	O
viral	O
multienzymatic	O
replicase	O
complex	O
,	O
together	O
with	O
cellular	B-COMP
factors	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
is	O
a	O
transmembrane	B-COMP
protein	O
.	O

The	O
data	O
suggest	O
that	O
macrodomain	O
-	O
associated	O
ADRP	O
activities	O
may	O
have	O
a	O
role	O
in	O
viral	O
escape	O
from	O
the	O
innate	O
immune	O
responses	O
of	O
the	O
host	B-COMP
.	O

Moreover	O
,	O
a	O
shift	O
from	O
predominant	O
IL	O
-	O
10	O
production	O
by	O
CD25	O
(+)	O
CD4	O
(+)	O
T	O
cells	B-COMP
to	O
CD25	O
(-)	O
CD4	O
(+)	O
T	O
cells	B-COMP
suggests	O
that	O
a	O
transition	O
to	O
nonclassical	O
regulatory	O
T	O
cells	B-COMP
precedes	O
and	O
is	O
retained	O
during	O
CNS	O
viral	O
persistence	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
epidemic	O
was	O
characterized	O
by	O
increased	O
pathogenicity	O
in	O
the	O
elderly	O
due	O
to	O
an	O
early	O
exacerbated	O
innate	O
host	B-COMP
response	O
.	O

SARS	O
-	O
CoV	O
is	O
a	O
zoonotic	O
pathogen	O
that	O
entered	O
the	O
human	O
population	O
through	O
an	O
intermediate	O
host	B-COMP
like	O
the	O
palm	O
civet	O
.	O

All	O
the	O
putative	O
bundles	O
show	O
water	O
molecules	O
trapped	O
within	O
the	O
lumen	O
of	O
the	O
pore	B-COMP
with	O
only	O
occasional	O
events	O
of	O
complete	O
crossing	O
.	O

The	O
RBT	O
cell	B-COMP
line	O
is	O
suitable	O
for	O
determining	O
the	O
infectious	O
activity	O
of	O
the	O
coronavirus	O
reproduced	O
in	O
the	O
other	O
cell	B-COMP
cultures	O
.	O

We	O
evaluated	O
the	O
antiviral	O
effects	O
of	O
antisense	O
peptide	O
nucleic	B-COMP
acids	O
(	O
PNAs	O
)	O
targeting	O
a	O
highly	O
conserved	O
RNA	O
sequence	O
on	O
the	O
-	O
PRF	O
signal	O
.	O

The	O
ribosomal	B-COMP
frameshifting	O
was	O
inhibited	O
by	O
the	O
PNA	O
,	O
which	O
bound	O
sequence	O
-	O
specifically	O
a	O
pseudoknot	O
structure	O
in	O
the	O
-	O
1	O
PRF	O
signal	O
,	O
in	O
cell	B-COMP
lines	O
as	O
assessed	O
using	O
a	O
dual	O
luciferase	O
-	O
based	O
reporter	O
plasmid	O
containing	O
the	O
-	O
1	O
PRF	O
signal	O
.	O

Two	O
passages	O
of	O
eluates	O
in	O
cell	B-COMP
cultures	O
or	O
these	O
eggs	O
did	O
not	O
reveal	O
the	O
presence	O
of	O
any	O
live	O
virus	O
.	O

Sequence	O
analyses	O
revealed	O
a	O
strong	O
selection	O
for	O
the	O
S	O
gene	O
of	O
83P	O
-	O
5	O
in	O
Vero	O
cells	B-COMP
,	O
and	O
virtually	O
all	O
mutations	O
occurring	O
at	O
the	O
34th	O
and	O
61st	O
passages	O
had	O
been	O
carried	O
over	O
to	O
the	O
100th	O
-	O
passaged	O
virus	O
.	O

However	O
,	O
the	O
effect	O
of	O
3b	O
on	O
the	O
activity	O
of	O
other	O
common	O
host	B-COMP
transcription	O
factors	O
remains	O
unexplored	O
.	O

Our	O
findings	O
elucidate	O
augmentation	O
of	O
AP	O
-	O
1	O
-	O
dependent	O
gene	O
expression	O
in	O
3b	O
-	O
transfected	O
Huh7	O
cells	B-COMP
.	O

In	O
the	O
current	O
study	O
,	O
the	O
action	O
mechanism	O
of	O
LiCl	O
on	O
cell	B-COMP
infection	O
by	O
TGEV	O
was	O
investigated	O
.	O

The	O
RBD	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
plays	O
important	O
roles	O
in	O
receptor	O
binding	O
and	O
induction	O
of	O
specific	O
neutralizing	O
antibodies	B-COMP
against	O
virus	O
infection	O
.	O

TITLE	O
:	O
Identification	O
of	O
RNA	O
pseudoknot	O
-	O
binding	O
ligand	O
that	O
inhibits	O
the	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
of	O
SARS	O
-	O
coronavirus	O
by	O
structure	O
-	O
based	O
virtual	O
screening	O
.	O

ABSTRACT	O
:	O
Programmed	O
-	O
1	O
ribosomal	B-COMP
frameshifting	O
(-	O
1	O
RF	O
)	O
is	O
an	O
essential	O
regulating	O
mechanism	O
of	O
translation	O
used	O
by	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
to	O
synthesize	O
the	O
key	O
replicative	O
proteins	O
encoded	O
by	O
two	O
overlapping	O
open	O
reading	O
frames	O
.	O

This	O
study	O
represents	O
a	O
platform	O
to	O
produce	O
fully	O
human	O
antibodies	B-COMP
against	O
emerging	O
infectious	O
diseases	O
in	O
a	O
timely	O
and	O
safe	O
manner	O
.	O

Thereafter	O
,	O
intracellular	B-COMP
virus	B-COMP
particles	I-COMP
were	O
observed	O
to	O
be	O
present	O
in	O
vacuoles	B-COMP
or	O
present	O
freely	O
in	O
the	O
cytoplasm	B-COMP
.	O

IL	O
-	O
10	O
functions	O
by	O
dampening	O
the	O
innate	O
or	O
very	O
early	O
T	O
cell	B-COMP
immune	O
response	O
.	O

Polyclonal	O
antibodies	B-COMP
raised	O
against	O
expressed	O
S1	O
(	O
amino	O
acid	O
position	O
1	O
to	O
573	O
from	O
start	O
codon	O
of	O
S	O
protein	O
),	O
4F	O
/	O
4R	O
(	O
482	O
-	O
678	O
),	O
6F	O
/	O
6R	O
(	O
830	O
-	O
1071	O
),	O
or	O
Mod4F	O
/	O
Epi4R	O
(	O
476	O
-	O
520	O
)	O
S	O
fragment	O
recognized	O
native	O
S1	O
protein	O
and	O
TCoV	O
in	O
the	O
intestines	O
of	O
TCoV	O
-	O
infected	O
turkey	O
embryos	O
.	O

TITLE	O
:	O
Role	O
of	O
proteases	O
in	O
the	O
release	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
from	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Cellular	B-COMP
and	O
viral	O
S	O
-	O
adenosylmethionine	O
-	O
dependent	O
methyltransferases	O
are	O
involved	O
in	O
many	O
regulated	O
processes	O
such	O
as	O
metabolism	O
,	O
detoxification	O
,	O
signal	O
transduction	O
,	O
chromatin	B-COMP
remodeling	O
,	O
nucleic	B-COMP
acid	O
processing	O
,	O
and	O
mRNA	O
capping	O
.	O

If	O
clinical	O
signs	O
and	O
histopathology	O
suggest	O
FHV	O
-	O
1	O
infection	O
in	O
the	O
absence	O
of	O
typical	O
inclusion	B-COMP
bodies	I-COMP
,	O
IHC	O
is	O
the	O
preferred	O
diagnostic	O
test	O
;	O
PCR	O
may	O
be	O
useful	O
for	O
initial	O
screening	O
,	O
but	O
due	O
to	O
false	O
positives	O
is	O
not	O
sufficient	O
for	O
a	O
definitive	O
diagnosis	O
.	O

ABSTRACT	O
:	O
We	O
report	O
our	O
first	O
experience	O
of	O
treating	O
an	O
immunocompetent	O
adult	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
type	O
1	O
herpes	O
simplex	O
(	O
HSV1	O
)	O
pneumonitis	O
,	O
using	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

These	O
findings	O
indicate	O
that	O
trypsin	O
affects	O
only	O
cell	B-COMP
-	O
attached	O
PEDV	O
and	O
increases	O
infectivity	O
and	O
syncytium	O
formation	O
in	O
PEDV	O
-	O
infected	O
Vero	O
cells	B-COMP
by	O
cleavage	O
of	O
the	O
PEDV	O
S	O
protein	O
.	O

We	O
propose	O
that	O
coronavirus	O
NTDs	O
originated	O
from	O
a	O
host	B-COMP
galectin	O
and	O
retained	O
sugar	O
-	O
binding	O
functions	O
in	O
some	O
contemporary	O
coronaviruses	O
,	O
but	O
evolved	O
new	O
structural	O
features	O
in	O
MHV	O
for	O
mCEACAM1a	O
binding	O
.	O

In	O
protein	O
7	O
a	O
conserved	O
sequence	O
motif	O
that	O
potentially	O
mediates	O
binding	O
to	O
protein	O
phosphatase	O
1	O
catalytic	O
subunit	O
(	O
PP1c	O
),	O
a	O
key	O
regulator	O
of	O
the	O
cell	B-COMP
antiviral	O
defenses	O
,	O
was	O
identified	O
.	O

Persistent	O
infection	O
of	O
this	O
cell	B-COMP
line	O
with	O
viruses	O
and	O
mycoplasma	O
was	O
not	O
detected	O
.	O

In	O
these	O
patients	O
,	O
rescue	O
therapies	O
such	O
as	O
high	O
-	O
frequency	O
ventilation	O
,	O
prone	O
ventilation	O
,	O
nitric	O
oxide	O
,	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
are	O
considered	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
5	O
patients	O
with	O
bronchial	O
fistula	O
with	O
severe	O
acute	O
lung	O
injury	O
.	O

We	O
sought	O
to	O
evaluate	O
the	O
efficacy	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
associated	O
with	O
lung	O
-	O
protective	O
ventilation	O
in	O
case	O
of	O
failure	O
of	O
conventional	O
management	O
.	O

A	O
stepwise	O
increase	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
output	O
and	O
a	O
decrease	O
of	O
mechanical	O
ventilation	O
settings	O
were	O
simultaneously	O
performed	O
,	O
aiming	O
at	O
lung	O
-	O
protective	O
ventilation	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
susceptibility	O
to	O
bovine	O
tuberculosis	O
(	O
bTB	O
),	O
and	O
the	O
prevalence	O
of	O
antibody	B-COMP
to	O
feline	O
viruses	O
of	O
native	O
lions	O
,	O
and	O
compared	O
the	O
findings	O
with	O
those	O
from	O
translocated	O
outbred	O
lions	O
and	O
their	O
offspring	O
.	O

Histologic	O
analysis	O
disclosed	O
acute	O
necrosis	O
in	O
the	O
cardiac	O
apex	O
and	O
interventricular	O
septum	B-COMP
,	O
and	O
focal	O
chronic	O
inflammatory	O
and	O
granulation	O
tissue	O
in	O
the	O
aortic	O
wall	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
TMV	O
-	O
RNA	O
was	O
translated	O
into	O
CP	O
(	O
coat	O
protein	O
)	O
in	O
the	O
ER	O
(	O
endoplasmic	B-COMP
reticulum	I-COMP
)	O
and	O
that	O
TMV	O
-	O
positive	O
RNA	O
translocated	O
from	O
the	O
cytoplasm	B-COMP
to	O
the	O
nucleolus	B-COMP
.	O

These	O
AER	B-COMP
/	O
AED	O
mice	O
developed	O
life	O
-	O
threatening	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
displayed	O
by	O
diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
resulting	O
from	O
i	O
)	O
dramatic	O
interstitial	O
alveolar	O
septa	O
-	O
thickening	O
with	O
mononuclear	O
cells	B-COMP
,	O
ii	O
)	O
some	O
hyperplasia	O
of	O
alveolar	O
type	O
-	O
II	O
pneumocytes	O
,	O
iii	O
)	O
copious	O
intra	O
-	O
alveolar	O
protein	O
secretion	O
,	O
iv	O
)	O
some	O
hyaline	O
membrane	B-COMP
-	O
covered	O
alveolar	O
walls	O
,	O
and	O
v	O
)	O
DENV	O
-	O
2	O
antigen	O
-	O
positive	O
alveolar	O
macrophages	O
.	O

ABSTRACT	O
:	O
Multiple	O
respiratory	B-COMP
chain	I-COMP
deficiencies	O
represent	O
a	O
common	O
cause	O
of	O
mitochondrial	B-COMP
diseases	O
and	O
often	O
result	O
in	O
hepatic	O
failure	O
.	O

Using	O
MHC	O
class	O
II	O
/	O
peptide	O
tetramers	O
and	O
intracellular	B-COMP
cytokine	O
staining	O
,	O
we	O
identify	O
T	O
reg	O
cells	B-COMP
recognizing	O
two	O
virus	O
-	O
specific	O
CD4	O
T	O
cell	B-COMP
epitopes	O
in	O
the	O
coronavirus	O
-	O
infected	O
central	O
nervous	O
system	O
as	O
well	O
as	O
naive	O
T	O
cell	B-COMP
precursor	O
pools	O
.	O

These	O
T	O
reg	O
cells	B-COMP
are	O
detected	O
at	O
the	O
same	O
time	O
as	O
effector	O
T	O
cells	B-COMP
(	O
T	O
eff	O
cells	B-COMP
)	O
exhibiting	O
the	O
same	O
specificity	O
and	O
can	O
suppress	O
T	O
eff	O
cell	B-COMP
proliferation	O
after	O
stimulation	O
with	O
cognate	O
peptide	O
.	O

These	O
data	O
imply	O
that	O
the	O
ability	O
of	O
MHV	O
to	O
replicate	O
in	O
macrophages	O
is	O
a	O
prerequisite	O
for	O
replication	O
in	O
the	O
liver	O
and	O
induction	O
of	O
hepatitis	O
but	O
not	O
for	O
replication	O
or	O
disease	O
in	O
the	O
CNS	O
,	O
underscoring	O
the	O
importance	O
of	O
IFN	O
signaling	O
in	O
macrophages	O
in	O
vivo	O
for	O
protection	O
of	O
the	O
host	B-COMP
from	O
hepatitis	O
.	O

ABSTRACT	O
:	O
Superoxide	O
is	O
produced	O
by	O
activated	O
neutrophils	O
during	O
the	O
inflammatory	O
response	O
to	O
stimuli	O
such	O
as	O
endotoxin	O
,	O
can	O
directly	O
or	O
indirectly	O
injure	O
host	B-COMP
cells	B-COMP
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
wished	O
to	O
determine	O
the	O
potential	O
for	O
pulmonary	O
overexpression	O
of	O
the	O
extracellular	B-COMP
isoform	O
of	O
superoxide	O
dismutase	O
(	O
EC	O
-	O
SOD	O
)	O
to	O
reduce	O
the	O
severity	O
of	O
endotoxin	O
-	O
induced	O
lung	O
injury	O
.	O

The	O
host	B-COMP
'	O
s	O
phylogeny	O
,	O
biogeography	O
and	O
behaviour	O
,	O
combined	O
with	O
already	O
described	O
roles	O
of	O
pathogen	O
plasticity	O
and	O
anthropic	O
changes	O
are	O
likely	O
to	O
be	O
co	O
-	O
factors	O
of	O
disease	O
emergence	O
.	O

The	O
expressions	O
of	O
four	O
segments	O
of	O
spike	O
proteins	O
in	O
recombinant	O
vaccinia	O
viruses	O
were	O
showed	O
at	O
appropriate	O
level	O
and	O
with	O
posttranslational	O
modification	O
(	O
glycosylation	O
),	O
and	O
S1	O
,	O
RL	O
and	O
RS	O
were	O
mainly	O
distributed	O
in	O
the	O
cell	B-COMP
membrane	I-COMP
,	O
while	O
the	O
S2	O
was	O
mainly	O
distributed	O
in	O
the	O
cytoplasm	B-COMP
.	O

TITLE	O
:	O
Cytokine	O
levels	O
in	O
bronchoalveolar	O
lavage	O
and	O
serum	B-COMP
in	O
3	O
patients	O
with	O
2009	O
Influenza	O
A	O
(	O
H1N1	O
)	O
v	O
severe	O
pneumonia	O
.	O

IL	O
-	O
6	O
levels	O
in	O
serum	B-COMP
were	O
(	O
94	O
,	O
pg	O
/	O
ml	O
,	O
77	O
pg	O
/	O
ml	O
and	O
84	O
pg	O
/	O
ml	O
)	O
respectively	O
in	O
the	O
three	O
patients	O
,	O
while	O
IL	O
-	O
8	O
levels	O
were	O
(	O
30	O
,	O
2	O
pg	O
/	O
ml	O
,	O
128	O
pg	O
/	O
ml	O
and	O
40	O
,	O
5	O
pg	O
/	O
ml	O
).	O

ABSTRACT	O
:	O
Nucleic	B-COMP
acid	O
amplification	O
is	O
enormously	O
useful	O
to	O
the	O
biotechnology	O
and	O
clinical	O
diagnostic	O
communities	O
;	O
however	O
,	O
to	O
date	O
point	O
-	O
of	O
-	O
use	O
PCR	O
has	O
been	O
hindered	O
by	O
thermal	O
cycling	O
architectures	O
and	O
protocols	O
that	O
do	O
not	O
allow	O
for	O
near	O
-	O
instantaneous	O
results	O
.	O

Our	O
results	O
showed	O
that	O
:	O
(	O
i	O
)	O
deletion	O
of	O
18aa	O
from	O
the	O
C	O
-	O
terminus	O
enhanced	O
the	O
S	O
protein	O
accumulation	O
and	O
virus	O
entry	O
,	O
which	O
might	O
be	O
due	O
to	O
the	O
deletion	O
of	O
intracellular	B-COMP
retention	O
signals	O
;	O
(	O
ii	O
)	O
further	O
deletion	O
to	O
residue	O
29	O
also	O
enhanced	O
the	O
amount	O
of	O
S	O
protein	O
on	O
the	O
cell	B-COMP
surface	I-COMP
and	O
in	O
virion	B-COMP
,	O
but	O
reduced	O
virus	O
entry	O
by	O
25	O
%,	O
suggesting	O
that	O
residues	O
19	O
-	O
29	O
contributes	O
to	O
membrane	B-COMP
fusion	O
;	O
(	O
iii	O
)	O
a	O
29aa	O
-	O
deletion	O
mutant	O
had	O
a	O
defect	O
in	O
anchoring	O
on	O
the	O
plasma	B-COMP
membrane	I-COMP
,	O
which	O
led	O
to	O
a	O
dramatic	O
decrease	O
of	O
S	O
protein	O
in	O
virion	B-COMP
and	O
virus	O
entry	O
;	O
(	O
iv	O
)	O
a	O
total	O
of	O
15	O
residues	O
(	O
Y498	O
,	O
V499	O
,	O
V531	O
,	O
G534	O
,	O
G537	O
,	O
D538	O
,	O
S540	O
,	O
G575	O
,	O
S576	O
,	O
E582	O
,	O
W585	O
,	O
Y590	O
,	O
T591	O
,	O
V593	O
and	O
G594	O
)	O
within	O
RBD	O
were	O
important	O
for	O
receptor	O
binding	O
and	O
virus	O
entry	O
.	O

ABSTRACT	O
:	O
Autophagy	O
is	O
a	O
cellular	B-COMP
response	O
to	O
starvation	O
which	O
generates	O
autophagosomes	O
to	O
carry	O
cellular	B-COMP
organelles	B-COMP
and	O
long	O
-	O
lived	O
proteins	O
to	O
lysosomes	B-COMP
for	O
degradation	O
.	O

These	O
multiple	O
-	O
spanning	O
transmembrane	B-COMP
proteins	O
located	O
to	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
where	O
they	O
generated	O
Atg5	O
and	O
LC3II	O
-	O
positive	O
vesicles	B-COMP
,	O
and	O
vesicle	B-COMP
formation	O
was	O
dependent	O
on	O
Atg5	O
and	O
class	O
III	O
PI3	O
kinase	O
.	O

Depletion	O
of	O
neutrophils	O
reduced	O
CNS	O
accumulation	O
of	O
monocytes	O
and	O
T	O
cells	B-COMP
,	O
albeit	O
without	O
affecting	O
overall	O
pathogenesis	O
.	O

The	O
results	O
will	O
help	O
to	O
identify	O
the	O
nucleolar	O
localization	O
signals	O
in	O
PEDV	O
N	O
protein	O
and	O
to	O
elucidate	O
the	O
mechanism	O
of	O
N	O
protein	O
located	O
in	O
nucleus	B-COMP
.	O

RESULTS	O
:	O
The	O
fusion	O
proteins	O
successfully	O
expressed	O
in	O
transfected	O
Vero	O
E6	O
cells	B-COMP
by	O
western	O
blot	O
analysis	O
,	O
and	O
the	O
PEDV	O
N	O
protein	O
and	O
the	O
B23	O
.	O
1	O
phosphoprotein	O
showed	O
co	O
-	O
localization	O
features	O
in	O
co	O
-	O
transfected	O
cells	B-COMP
through	O
confocal	O
microscopy	O
analysis	O
.	O

We	O
use	O
four	O
case	O
studies	O
to	O
demonstrate	O
that	O
advances	O
in	O
disease	O
forecasting	O
require	O
better	O
understanding	O
of	O
zoonotic	O
host	B-COMP
and	O
vector	O
populations	O
,	O
as	O
well	O
of	O
the	O
dynamics	O
that	O
facilitate	O
pathogen	O
amplification	O
and	O
disease	O
spillover	O
into	O
humans	O
.	O

TITLE	O
:	O
Mutation	O
in	O
the	O
cytoplasmic	B-COMP
retrieval	O
signal	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
spike	O
(	O
S	O
)	O
protein	O
is	O
responsible	O
for	O
enhanced	O
fusion	O
activity	O
.	O

The	O
MK	O
-	O
p10	O
and	O
MK	O
-	O
H1381R	O
S	O
proteins	O
induced	O
larger	O
cell	B-COMP
fusions	O
than	O
others	O
.	O

We	O
also	O
examined	O
the	O
distribution	O
of	O
these	O
S	O
proteins	O
;	O
the	O
MK	O
-	O
p10	O
and	O
MK	O
-	O
H1381R	O
S	O
proteins	O
were	O
transported	O
onto	O
the	O
cell	B-COMP
surface	I-COMP
more	O
efficiently	O
than	O
others	O
.	O

TITLE	O
:	O
Massive	O
systemic	O
air	O
embolism	O
during	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
of	O
a	O
neonate	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
cardiac	O
surgery	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
HC	O
on	O
cell	B-COMP
infection	O
by	O
IBV	O
was	O
determined	O
using	O
plaque	O
assay	O
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

However	O
,	O
a	O
better	O
understanding	O
of	O
common	O
cell	B-COMP
signalling	O
pathways	O
associated	O
with	O
acute	O
lung	O
injury	O
caused	O
by	O
influenza	O
and	O
other	O
pathogens	O
is	O
necessary	O
to	O
understand	O
immunopathologic	O
causes	O
of	O
lung	O
injury	O
.	O

The	O
sensitivity	O
of	O
the	O
assay	O
ranged	O
from	O
10	O
(	O
2	O
)	O
to	O
10	O
(	O
6	O
)	O
and	O
from	O
10	O
(	O
5	O
)	O
to	O
10	O
(	O
9	O
)	O
RNA	O
copy	O
numbers	O
for	O
individual	O
corona	O
-/	O
torovirus	O
templates	O
when	O
tested	O
,	O
respectively	O
,	O
with	O
and	O
without	O
an	O
excess	O
of	O
RNA	O
from	O
human	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Nucleic	B-COMP
acid	O
amplification	O
tests	O
are	O
increasingly	O
being	O
used	O
to	O
diagnose	O
viral	O
and	O
bacterial	O
respiratory	O
tract	O
infections	O
.	O

ABSTRACT	O
:	O
Caspase	O
-	O
8	O
(	O
casp8	O
)	O
is	O
required	O
for	O
extrinsic	O
apoptosis	O
,	O
and	O
mice	O
deficient	O
in	O
casp8	O
fail	O
to	O
develop	O
and	O
die	O
in	O
utero	O
while	O
ultimately	O
failing	O
to	O
maintain	O
the	O
proliferation	O
of	O
T	O
cells	B-COMP
,	O
B	O
cells	B-COMP
,	O
and	O
a	O
host	B-COMP
of	O
other	O
cell	B-COMP
types	O
.	O

Indeed	O
,	O
following	O
mitogenic	O
stimulation	O
,	O
T	O
cells	B-COMP
lacking	O
casp8	O
or	O
its	O
adaptor	O
protein	O
FADD	O
(	O
Fas	O
-	O
associated	O
death	O
domain	O
protein	O
)	O
develop	O
a	O
hyperautophagic	O
morphology	O
,	O
and	O
die	O
a	O
programmed	O
necrosis	O
-	O
like	O
death	O
process	O
termed	O
necroptosis	O
.	O

Enhanced	O
recovery	O
of	O
these	O
double	O
-	O
mutant	O
T	O
cells	B-COMP
following	O
stimulation	O
demonstrates	O
that	O
FADD	O
,	O
casp8	O
,	O
and	O
RIPK3	O
are	O
all	O
essential	O
for	O
clonal	O
expansion	O
,	O
contraction	O
,	O
and	O
antiviral	O
responses	O
.	O

The	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
III	O
and	O
I	O
and	O
pyruvate	O
dehydrogenase	O
might	O
lead	O
to	O
the	O
increased	O
production	O
of	O
free	O
radical	O
resulting	O
in	O
oxidative	O
stress	O
and	O
cerebral	O
energy	O
disturbances	O
thereby	O
leading	O
to	O
mitochondrial	B-COMP
swelling	O
and	O
further	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
FHF	O
.	O

Mutations	O
in	O
MTU1	O
are	O
associated	O
with	O
acute	O
infantile	O
liver	O
failure	O
,	O
and	O
this	O
has	O
been	O
ascribed	O
to	O
a	O
transient	O
lack	O
of	O
cysteine	O
,	O
the	O
sulfur	O
donor	O
for	O
the	O
thiouridylation	O
reaction	O
,	O
resulting	O
in	O
a	O
mitochondrial	B-COMP
translation	O
defect	O
during	O
early	O
development	O
.	O

The	O
only	O
respiratory	B-COMP
chain	I-COMP
abnormality	O
that	O
we	O
could	O
observe	O
in	O
these	O
cells	B-COMP
was	O
an	O
accumulation	O
of	O
a	O
Complex	O
II	O
assembly	O
intermediate	O
,	O
which	O
,	O
however	O
,	O
did	O
not	O
affect	O
the	O
level	O
of	O
the	O
fully	O
assembled	O
enzyme	O
.	O

Several	O
different	O
methods	O
have	O
been	O
used	O
to	O
generate	O
SARS	O
-	O
CoV	O
specific	O
neutralizing	O
hmAbs	O
including	O
the	O
immunization	O
of	O
transgenic	O
mice	O
,	O
cloning	O
of	O
small	O
chain	O
variable	O
regions	O
from	O
naïve	O
and	O
convalescent	O
patients	O
,	O
and	O
the	O
immortalization	O
of	O
convalescent	O
B	O
cells	B-COMP
.	O

However	O
,	O
when	O
the	O
adsorption	O
time	O
was	O
reduced	O
to	O
5	O
min	O
the	O
infectivity	O
on	O
desialylated	O
cells	B-COMP
decreased	O
by	O
more	O
than	O
60	O
%.	O

We	O
first	O
confirmed	O
the	O
binding	O
of	O
ANXA2	O
to	O
IBV	O
pseudoknot	O
RNA	O
by	O
ultraviolet	O
crosslinking	O
and	O
showed	O
its	O
binding	O
to	O
RNA	O
pseudoknot	O
with	O
ANXA2	O
protein	O
in	O
vitro	O
and	O
in	O
the	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
One	O
-	O
hundred	O
and	O
thirty	O
confirmed	O
cases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
were	O
recruited	O
to	O
evaluate	O
their	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
antibody	B-COMP
status	O
and	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
types	O
in	O
September	O
2006	O
,	O
3	O
y	O
after	O
the	O
SARS	O
outbreaks	O
in	O
Taiwan	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
as	O
a	O
bridge	O
to	O
liver	O
transplantation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
-	O
induced	O
life	O
-	O
threatening	O
hypoxaemia	O
aggravated	O
by	O
hepatopulmonary	O
syndrome	O
.	O

TITLE	O
:	O
Regulation	O
of	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
and	O
dual	O
-	O
specificity	O
phosphatase	O
1	O
feedback	O
loop	O
modulates	O
the	O
induction	O
of	O
interleukin	O
6	O
and	O
8	O
in	O
cells	B-COMP
infected	O
with	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Antiviral	O
activity	O
of	O
antioxidants	O
such	O
as	O
NAC	B-COMP
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
),	O
and	O
the	O
vitamin	O
E	O
derivative	O
,	O
trolox	O
,	O
were	O
hardly	O
noticed	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
requires	O
proteolytic	O
cleavage	O
by	O
elastase	O
,	O
cathepsin	O
or	O
TMPRSS2	O
for	O
S	O
-	O
mediated	O
cell	B-COMP
-	O
cell	B-COMP
or	O
virus	O
-	O
cell	B-COMP
membrane	I-COMP
fusion	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
reported	O
that	O
the	O
S	O
protein	O
of	O
mouse	O
hepatitis	O
virus	O
type	O
2	O
(	O
MHV	O
-	O
2	O
),	O
which	O
is	O
highly	O
similar	O
to	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
requires	O
two	O
-	O
step	O
conformational	O
changes	O
mediated	O
by	O
sequential	O
receptor	O
binding	O
and	O
proteolysis	O
to	O
be	O
activated	O
for	O
membrane	B-COMP
fusion	O
.	O

There	O
were	O
acute	O
complications	O
,	O
consisting	O
of	O
infection	O
of	O
the	O
skin	O
areas	O
(	O
Candida	O
),	O
gastrointestinal	O
bleeding	O
,	O
pleural	O
effusion	O
,	O
and	O
severe	O
ocular	O
mucous	O
membrane	B-COMP
damage	O
.	O

Variable	O
numbers	O
of	O
small	O
ORFs	O
are	O
present	O
between	O
the	O
various	O
conserved	O
genes	O
(	O
ORF1ab	O
,	O
spike	O
,	O
envelope	B-COMP
,	O
membrane	B-COMP
and	O
nucleocapsid	B-COMP
)	O
and	O
downstream	O
to	O
nucleocapsid	B-COMP
gene	O
in	O
different	O
coronavirus	O
lineages	O
.	O

The	O
present	O
study	O
shows	O
that	O
serum	B-COMP
MBL	O
levels	O
influence	O
the	O
ability	O
of	O
chickens	O
to	O
clear	O
the	O
respiratory	O
tract	O
of	O
virus	O
genomes	O
after	O
an	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
This	O
study	O
determined	O
the	O
effect	O
of	O
sample	O
mishandling	O
on	O
the	O
performance	O
of	O
ELISAs	O
for	O
detection	O
of	O
antibodies	B-COMP
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
avian	O
encephalomyelitis	O
virus	O
(	O
AEV	O
)	O
and	O
chicken	O
anaemia	O
virus	O
(	O
CAV	O
)	O
in	O
the	O
serum	B-COMP
of	O
chickens	O
.	O

Each	O
mishandling	O
treatment	O
was	O
experimentally	O
applied	O
under	O
laboratory	O
conditions	O
and	O
then	O
samples	O
were	O
assayed	O
for	O
antibodies	B-COMP
against	O
IBV	O
,	O
AEV	O
and	O
CAV	O
using	O
commercial	O
ELISA	O
kits	O
.	O

The	O
expression	O
of	O
proinflammatory	O
cytokines	O
was	O
reduced	O
in	O
rSARS	O
-	O
CoV	O
-	O
ΔE	O
-	O
infected	O
cells	B-COMP
compared	O
to	O
rSARS	O
-	O
CoV	O
-	O
infected	O
cells	B-COMP
,	O
suggesting	O
that	O
the	O
increase	O
in	O
stress	O
responses	O
and	O
the	O
reduction	O
of	O
inflammation	O
in	O
the	O
absence	O
of	O
the	O
E	O
gene	O
contributed	O
to	O
the	O
attenuation	O
of	O
rSARS	O
-	O
CoV	O
-	O
ΔE	O
.	O

Fourteen	O
patients	O
had	O
active	O
chronic	O
graft	O
-	O
versus	O
-	O
host	B-COMP
disease	O
(	O
cGvHD	O
)	O
at	O
the	O
time	O
of	O
vaccination	O
/	O
infection	O
and	O
seven	O
patients	O
had	O
cGvHD	O
in	O
remission	O
;	O
11	O
patients	O
had	O
no	O
immunosuppressive	O
therapy	O
,	O
and	O
27	O
patients	O
were	O
on	O
immunosuppressive	O
therapy	O
.	O

Title	O
compounds	O
were	O
tested	O
in	O
cell	B-COMP
-	O
based	O
assays	O
for	O
cytotoxicity	O
and	O
antiviral	O
activity	O
against	O
RNA	O
viruses	O
representative	O
of	O
the	O
three	O
genera	O
of	O
the	O
Flaviviridae	O
family	O
,	O
that	O
is	O
BVDV	O
(	O
Pestivirus	O
),	O
YFV	O
(	O
Flavivirus	O
)	O
and	O
HCV	O
(	O
Hepacivirus	O
).	O

Pulmonary	O
arterial	O
hypertension	O
is	O
a	O
progressive	O
and	O
debilitating	O
lung	O
disorder	O
,	O
which	O
is	O
characterized	O
by	O
hallmark	O
pathological	O
features	O
in	O
the	O
small	O
peripheral	O
pulmonary	O
arteries	O
,	O
including	O
intimal	O
hyperplasia	O
and	O
fibrosis	O
,	O
medial	O
hypertrophy	O
,	O
increased	O
deposition	O
of	O
extracellular	B-COMP
matrix	I-COMP
,	O
infiltration	O
of	O
inflammatory	O
mediators	O
,	O
and	O
in	O
many	O
instances	O
of	O
advanced	O
disease	O
,	O
plexiform	O
lesions	O
.	O

By	O
western	O
blotting	O
and	O
ELISA	O
test	O
,	O
all	O
recombinant	O
proteins	O
were	O
recognized	O
by	O
the	O
antibody	B-COMP
against	O
native	O
porcine	O
aminopeptidase	O
N	O
.	O
Recombinant	O
proteins	O
,	O
rpAPN	O
-	O
C2	O
(	O
aa	O
623	O
-	O
722	O
)	O
and	O
rpAPN	O
-	O
C3	O
(	O
aa	O
673	O
-	O
772	O
),	O
had	O
the	O
highest	O
binding	O
activity	O
with	O
swine	O
transmissible	O
gastroenteritis	O
virus	O
among	O
the	O
truncated	O
pAPN	O
-	O
C	O
recombinant	O
proteins	O
.	O

These	O
findings	O
represent	O
the	O
first	O
integrated	O
sequencing	O
analysis	O
of	O
the	O
response	O
of	O
host	B-COMP
small	O
RNAs	O
to	O
virus	O
infection	O
and	O
show	O
that	O
small	O
RNAs	O
are	O
an	O
integrated	O
component	O
of	O
complex	O
networks	O
involved	O
in	O
regulating	O
the	O
host	B-COMP
response	O
to	O
infection	O
.	O

Using	O
this	O
approach	O
,	O
we	O
recently	O
discovered	O
widespread	O
differential	O
expression	O
of	O
host	B-COMP
long	O
(>	O
200	O
nucleotide	O
[	O
nt	O
])	O
ncRNAs	O
in	O
response	O
to	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
replication	O
and	O
transcription	O
are	O
processes	O
mediated	O
by	O
a	O
protein	B-COMP
complex	I-COMP
,	O
with	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
as	O
a	O
main	O
component	O
.	O

However	O
,	O
lower	O
respiratory	O
tract	O
infections	O
can	O
occur	O
in	O
some	O
individuals	O
,	O
indicating	O
that	O
cells	B-COMP
in	O
the	O
distal	O
lung	O
are	O
susceptible	O
to	O
HCoV	O
-	O
229E	O
.	O

TITLE	O
:	O
Construction	O
and	O
characterization	O
of	O
single	O
-	O
chain	O
variable	O
fragment	O
antibody	B-COMP
library	O
derived	O
from	O
germline	O
rearranged	O
immunoglobulin	O
variable	O
genes	O
.	O

To	O
examine	O
whether	O
germline	O
rearranged	O
immunoglobulin	O
(	O
Ig	O
)	O
variable	O
region	O
genes	O
could	O
be	O
used	O
as	O
source	O
of	O
antibody	B-COMP
repertoire	O
,	O
an	O
immunized	O
phage	O
-	O
displayed	O
scFv	O
library	O
was	O
prepared	O
using	O
splenocytic	O
genomic	O
DNA	O
as	O
template	O
.	O

To	O
determine	O
whether	O
germline	O
library	O
represented	O
the	O
endogenous	O
immune	O
status	O
,	O
specific	O
scFv	O
clones	O
for	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCoV	O
)	O
were	O
obtained	O
both	O
from	O
naïve	O
and	O
immunized	O
germline	O
scFv	O
libraries	O
.	O

T	O
cells	B-COMP
are	O
necessary	O
for	O
viral	O
clearance	O
,	O
and	O
many	O
age	O
-	O
dependent	O
intrinsic	O
T	O
cell	B-COMP
defects	O
have	O
been	O
documented	O
.	O

However	O
,	O
the	O
development	O
of	O
robust	O
T	O
cell	B-COMP
responses	O
in	O
the	O
lung	O
also	O
requires	O
respiratory	O
DCs	O
(	O
rDCs	O
),	O
which	O
must	O
process	O
antigen	O
and	O
migrate	O
to	O
draining	O
LNs	O
(	O
DLNs	O
),	O
and	O
little	O
is	O
known	O
about	O
age	O
-	O
related	O
defects	O
in	O
these	O
T	O
cell	B-COMP
-	O
extrinsic	O
functions	O
.	O

Decreased	O
rDC	O
migration	O
resulted	O
in	O
diminished	O
T	O
cell	B-COMP
responses	O
and	O
more	O
severe	O
clinical	O
disease	O
in	O
older	O
mice	O
infected	O
with	O
respiratory	O
viruses	O
.	O

Blocking	O
PGD	O
(	O
2	O
)	O
function	O
with	O
small	O
-	O
molecule	O
antagonists	O
enhanced	O
rDC	O
migration	O
,	O
T	O
cell	B-COMP
responses	O
,	O
and	O
survival	O
.	O

At	O
the	O
histological	O
point	O
of	O
view	O
,	O
there	O
is	O
an	O
extensive	O
interstitial	O
and	O
intra	O
-	O
alveolar	O
pulmonary	O
infiltration	O
by	O
maturing	O
myeloid	O
cells	B-COMP
,	O
endothelial	O
cell	B-COMP
damage	O
,	O
intra	O
-	O
alveolar	O
edema	O
,	O
inter	O
-	O
alveolar	O
hemorrhage	O
,	O
and	O
fibrinous	O
exsudates	O
.	O

To	O
confirm	O
MHVR	O
-	O
independence	O
in	O
vitro	O
,	O
we	O
used	O
a	O
combination	O
of	O
spinoculation	O
and	O
ultraviolet	O
radiation	O
to	O
detect	O
distinct	O
plaque	O
formation	O
(	O
SpinoPlaque	O
(	O
UV	O
+))	O
afrer	O
infection	O
of	O
BHK	O
cells	B-COMP
,	O
which	O
do	O
not	O
express	O
MHVR	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
of	O
a	O
child	O
with	O
severe	O
chemical	O
pneumonia	O
].	O

Using	O
lower	O
inoculum	O
dilutions	O
than	O
those	O
normally	O
applied	O
for	O
preparations	O
containing	O
influenza	O
virus	O
(	O
total	O
dilution	O
of	O
the	O
original	O
sample	O
of	O
∼	O
10	O
(	O
4	O
)),	O
the	O
positive	O
results	O
for	O
the	O
different	O
viruses	O
turned	O
negative	O
already	O
after	O
2	O
or	O
3	O
passages	O
in	O
MDCK	O
33016PF	O
cells	B-COMP
.	O

Additionally	O
,	O
compound	O
1	O
also	O
shows	O
high	O
anti	O
-	O
SARS	O
activity	O
at	O
an	O
EC	O
(	O
50	O
)	O
of	O
7	O
.	O
08μM	O
and	O
toxicity	O
with	O
a	O
CC	O
(	O
50	O
)	O
of	O
118	O
.	O
6μM	O
against	O
MDCK	O
cells	B-COMP
.	O

Cell	B-COMP
adhesion	O
molecules	O
were	O
expressed	O
at	O
higher	O
levels	O
in	O
FXR	O
-/-	O
mice	O
as	O
compared	O
with	O
control	O
mice	O
.	O

Sickle	O
cell	B-COMP
disease	O
is	O
an	O
autosomal	B-COMP
recessive	O
disorder	O
inducing	O
,	O
in	O
certain	O
circumstances	O
,	O
sickling	O
of	O
red	O
cells	B-COMP
.	O

Acute	O
chest	O
syndrome	O
is	O
defined	O
by	O
the	O
association	O
of	O
chest	O
pain	O
or	O
fever	O
and	O
recent	O
radiographic	O
infiltrates	O
,	O
in	O
patients	O
suffering	O
from	O
sickle	O
cell	B-COMP
disease	O
.	O

TITLE	O
:	O
Performance	O
of	O
different	O
mono	O
-	O
and	O
multiplex	O
nucleic	B-COMP
acid	O
amplification	O
tests	O
on	O
a	O
multipathogen	O
external	O
quality	O
assessment	O
panel	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
SCoV	O
)	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
1	O
,	O
a	O
potent	O
inhibitor	O
of	O
host	B-COMP
gene	O
expression	O
,	O
possesses	O
a	O
unique	O
mode	O
of	O
action	O
:	O
it	O
binds	O
to	O
40S	O
ribosomes	B-COMP
to	O
inactivate	O
their	O
translation	O
functions	O
and	O
induces	O
host	B-COMP
mRNA	O
degradation	O
.	O

Remarkably	O
,	O
SCoV	O
mRNAs	O
,	O
which	O
have	O
a	O
5	O
'	O
cap	O
structure	O
and	O
3	O
'	O
poly	O
A	O
tail	O
like	O
those	O
of	O
typical	O
host	B-COMP
mRNAs	O
,	O
were	O
not	O
susceptible	O
to	O
nsp1	O
-	O
mediated	O
RNA	O
cleavage	O
and	O
importantly	O
,	O
the	O
presence	O
of	O
the	O
5	O
'-	O
end	O
leader	O
sequence	O
protected	O
the	O
SCoV	O
mRNAs	O
from	O
nsp1	O
-	O
induced	O
endonucleolytic	O
RNA	O
cleavage	O
.	O

ABSTRACT	O
:	O
Positive	O
-	O
sense	O
RNA	O
((+)	O
RNA	O
)	O
viruses	O
such	O
as	O
hepatitis	O
C	O
virus	O
exploit	O
host	B-COMP
cells	B-COMP
by	O
subverting	O
host	B-COMP
proteins	O
,	O
remodelling	O
subcellular	O
membranes	O
,	O
co	O
-	O
opting	O
and	O
modulating	O
protein	O
and	O
ribonucleoprotein	B-COMP
complexes	O
,	O
and	O
altering	O
cellular	B-COMP
metabolic	O
pathways	O
during	O
infection	O
.	O

In	O
this	O
study	O
we	O
sought	O
to	O
uncover	O
the	O
host	B-COMP
transcriptional	O
responses	O
underlying	O
differences	O
between	O
high	O
-	O
and	O
low	O
-	O
pathogenic	O
infections	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
induced	O
membrane	B-COMP
structures	O
support	O
the	O
assembly	O
and	O
function	O
of	O
positive	O
-	O
strand	O
RNA	O
virus	O
replication	O
complexes	O
.	O

In	O
our	O
electron	O
tomograms	O
,	O
connections	O
between	O
the	O
DMV	O
interior	O
and	O
cytosol	B-COMP
could	O
not	O
be	O
unambiguously	O
identified	O
,	O
suggesting	O
that	O
the	O
double	O
-	O
stranded	O
RNA	O
is	O
compartmentalized	O
by	O
the	O
DMV	O
membranes	O
.	O

To	O
prevent	O
the	O
development	O
of	O
CVID	O
in	O
IgA	O
-	O
and	O
IgG2	B-COMP
-	O
deficient	O
patients	O
with	O
SLE	O
,	O
it	O
is	O
important	O
to	O
prevent	O
immune	O
dysregulation	O
by	O
the	O
avoidance	O
of	O
infections	O
through	O
the	O
use	O
of	O
IVIG	O
therapy	O
.	O

The	O
differentiation	O
of	O
leukemic	O
blasts	O
and	O
promyelocytes	O
induced	O
by	O
ATRA	O
and	O
/	O
or	O
ATO	O
may	O
lead	O
to	O
cellular	B-COMP
migration	O
,	O
endothelial	O
activation	O
,	O
and	O
release	O
of	O
interleukins	O
and	O
vascular	O
factors	O
responsible	O
of	O
tissue	O
damage	O
.	O

Cellular	B-COMP
pyruvate	O
kinase	O
activity	O
in	O
hepatoma	O
cells	B-COMP
was	O
repressed	O
by	O
SARS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
in	O
either	O
transiently	O
transfected	O
or	O
stably	O
transfected	O
cells	B-COMP
.	O

TITLE	O
:	O
Characterization	O
of	O
germline	O
antibody	B-COMP
libraries	O
from	O
human	O
umbilical	O
cord	O
blood	O
and	O
selection	O
of	O
monoclonal	O
antibodies	B-COMP
to	O
viral	B-COMP
envelope	I-COMP
glycoproteins	O
:	O
Implications	O
for	O
mechanisms	O
of	O
immune	O
evasion	O
and	O
design	O
of	O
vaccine	O
immunogens	O
.	O

Despite	O
a	O
high	O
sequence	O
and	O
combinatorial	O
diversity	O
observed	O
in	O
the	O
cord	O
blood	O
-	O
derived	O
IgM	B-COMP
antibody	I-COMP
repertoire	O
,	O
no	O
enrichment	O
for	O
binders	O
of	O
Envs	O
was	O
observed	O
in	O
contrast	O
to	O
considerable	O
specific	O
enrichments	O
produced	O
with	O
panning	O
against	O
RBD	O
and	O
sG	O
;	O
one	O
of	O
the	O
selected	O
monoclonal	O
antibodies	B-COMP
(	O
against	O
the	O
RBD	O
)	O
was	O
of	O
high	O
(	O
nM	O
)	O
affinity	O
with	O
only	O
few	O
somatic	O
mutations	O
.	O

Instead	O
,	O
Th1	O
responses	O
were	O
correlated	O
with	O
the	O
capacity	O
to	O
induce	O
IFN	O
-	O
α	O
secretion	O
,	O
which	O
in	O
cord	O
cells	B-COMP
were	O
induced	O
by	O
S	O
.	O
aureus	O
and	O
influenza	O
virus	O
alone	O
.	O

We	O
show	O
here	O
that	O
whereas	O
antibody	B-COMP
-	O
or	O
B	O
cell	B-COMP
-	O
deficient	O
mice	O
failed	O
to	O
contain	O
MHV	O
CNS	O
infection	O
and	O
developed	O
progressive	O
demyelinating	O
disease	O
,	O
germline	O
IgM	O
produced	O
in	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
-	O
deficient	O
mice	O
(	O
aicda	O
(-/-))	O
provided	O
long	O
-	O
term	O
protection	O
against	O
the	O
chronic	O
multiple	O
sclerosis	O
-	O
like	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
endodomain	O
of	O
several	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
proteins	O
contains	O
palmitylated	O
cysteine	O
residues	O
and	O
enables	O
co	O
-	O
localization	O
and	O
interaction	O
with	O
the	O
CoV	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
.	O

ORF3	O
protein	O
can	O
be	O
detected	O
in	O
PEDV	O
-	O
infected	O
cells	B-COMP
and	O
it	O
functions	O
as	O
an	O
ion	O
channel	O
in	O
both	O
Xenopus	O
laevis	O
oocytes	O
and	O
yeast	O
.	O

ABSTRACT	O
:	O
We	O
determined	O
prevalence	O
of	O
antibody	B-COMP
to	O
selected	O
viral	O
pathogens	O
important	O
for	O
domestic	O
pigs	O
and	O
livestock	O
in	O
556	O
wild	O
boar	O
(	O
Sus	O
scrofa	O
)	O
sera	B-COMP
collected	O
during	O
2005	O
-	O
06	O
and	O
2009	O
-	O
10	O
in	O
four	O
counties	O
in	O
Croatia	O
.	O

Almost	O
all	O
virus	B-COMP
particles	I-COMP
in	O
the	O
cytoplasm	B-COMP
of	O
satellite	O
cells	B-COMP
were	O
contained	O
in	O
groups	O
within	O
vesicles	B-COMP
and	O
lysosome	B-COMP
-	O
like	O
structures	O
,	O
suggesting	O
that	O
these	O
glial	O
cells	B-COMP
may	O
restrict	O
the	O
local	O
diffusion	O
of	O
HEV	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
last	O
decade	O
,	O
technical	O
improvements	O
in	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
equipment	O
have	O
reduced	O
procedure	O
-	O
related	O
complications	O
and	O
have	O
made	O
ECMO	O
an	O
effective	O
option	O
for	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
if	O
conventional	O
therapy	O
fails	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
induced	O
apoptosis	O
and	O
viral	O
mechanisms	O
that	O
regulate	O
this	O
cell	B-COMP
death	O
program	O
are	O
key	O
issues	O
in	O
understanding	O
virus	O
-	O
host	B-COMP
interactions	O
and	O
viral	O
pathogenesis	O
.	O

Our	O
findings	O
illustrate	O
the	O
ease	O
with	O
which	O
viruses	O
can	O
change	O
receptor	O
-	O
binding	O
specificity	O
with	O
potential	O
consequences	O
for	O
host	B-COMP
-,	O
organ	O
and	O
/	O
or	O
cell	B-COMP
tropism	O
,	O
and	O
for	O
pathogenesis	O
.	O

Dogs	O
from	O
Fort	O
Resolution	O
,	O
NWT	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
less	O
likely	O
to	O
have	O
moderate	O
or	O
high	O
antibody	B-COMP
titers	O
to	O
the	O
3	O
agents	O
than	O
dogs	O
in	O
the	O
shelter	O
.	O

Expression	O
of	O
the	O
sNsp15	O
in	O
cells	B-COMP
resulted	O
in	O
an	O
increased	O
abundance	O
of	O
pRb	O
in	O
the	O
cytoplasm	B-COMP
,	O
decreased	O
overall	O
levels	O
of	O
pRb	O
,	O
an	O
increased	O
proportion	O
of	O
cells	B-COMP
in	O
the	O
S	O
phase	O
of	O
the	O
cell	B-COMP
cycle	O
,	O
and	O
an	O
enhanced	O
expression	O
from	O
a	O
promoter	O
normally	O
repressed	O
by	O
pRb	O
.	O

We	O
have	O
cloned	O
a	O
novel	O
full	O
-	O
length	O
isoform	O
of	O
psg16	O
that	O
is	O
also	O
expressed	O
in	O
the	O
brain	O
,	O
placenta	O
,	O
and	O
retina	O
but	O
,	O
like	O
the	O
truncated	O
form	O
,	O
lacks	O
MHV	O
receptor	O
activity	O
when	O
expressed	O
on	O
293T	O
cells	B-COMP
,	O
suggesting	O
that	O
PSG16	O
does	O
not	O
mediate	O
CEACAM1a	O
-	O
independent	O
spread	O
of	O
MHV	O
.	O

Oral	O
vaccination	O
of	O
an	O
attenuated	O
Salmonella	O
typhimurium	O
strain	O
transformed	O
with	O
plasmids	O
encoding	O
CEA	O
-	O
SARS	O
-	O
CoV	O
fusion	O
gene	O
into	O
BALB	O
/	O
c	O
mice	O
elicited	O
significant	O
increases	O
in	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
10	O
in	O
the	O
serum	B-COMP
.	O

In	O
this	O
paper	O
,	O
different	O
aspects	O
of	O
the	O
genetics	O
,	O
host	B-COMP
cell	I-COMP
tropism	O
,	O
and	O
pathogenesis	O
of	O
the	O
feline	O
and	O
canine	O
coronaviruses	O
(	O
FCoV	O
and	O
CCoV	O
)	O
will	O
be	O
discussed	O
,	O
with	O
a	O
view	O
to	O
illustrating	O
how	O
study	O
of	O
FCoVs	O
and	O
CCoVs	O
can	O
improve	O
our	O
general	O
understanding	O
of	O
the	O
pathobiology	O
of	O
coronaviruses	O
.	O

The	O
reason	O
for	O
ANA	O
was	O
unclear	O
:	O
reactive	O
samples	O
were	O
negative	O
for	O
Erhlichia	O
canis	O
antibodies	B-COMP
;	O
seven	O
were	O
feline	O
immunodeficiency	O
virus	O
positive	O
,	O
but	O
15	O
were	O
negative	O
.	O

These	O
data	O
suggest	O
that	O
pDCs	O
facilitate	O
CD4	O
(+)	O
helper	O
T	O
-	O
cell	B-COMP
responses	O
to	O
persistent	O
viruses	O
independently	O
of	O
direct	O
antigen	O
presentation	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
therapeutic	O
effects	O
and	O
safety	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
on	O
mortality	O
in	O
adult	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Physiological	O
parameters	O
2	O
-	O
6	O
hours	O
prior	O
to	O
ECMO	O
use	O
were	O
:	O
(	O
53	O
±	O
14	O
)	O
mm	O
Hg	O
of	O
PaO2	O
/	O
FiO2	O
,	O
(	O
17	O
±	O
5	O
)	O
cm	O
H2O	O
of	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	O
),	O
3	O
.	O
80	O
±	O
0	O
.	O
29	O
of	O
Murray	O
lung	O
injury	O
score	O
,	O
(	O
7	O
.	O
38	O
±	O
0	O
.	O
10	O
)	O
of	O
arterial	O
pH	O
,	O
(	O
3	O
.	O
3	O
±	O
2	O
.	O
3	O
)	O
mmol	O
/	O
L	O
of	O
serum	B-COMP
lactate	O
,	O
16	O
±	O
8	O
of	O
APACHE	O
II	O
score	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
quantitative	O
detection	O
system	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
targeting	O
the	O
nucleocapsid	B-COMP
protein	O
(	O
NP	O
),	O
to	O
determine	O
the	O
presence	O
and	O
degree	O
of	O
infection	O
in	O
suspected	O
individuals	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
down	O
-	O
regulated	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
Bax	O
expression	O
,	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	B-COMP
,	O
activated	O
mitochondria	B-COMP
-	O
mediated	O
apoptotic	O
pathway	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	O
c	O
and	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
.	O

Both	O
extrinsic	O
and	O
intrinsic	O
pathways	O
activated	O
downstream	O
effector	O
caspase	O
-	O
3	O
,	O
followed	O
by	O
the	O
cleavage	O
of	O
PARP	O
,	O
resulting	O
in	O
cell	B-COMP
apoptosis	O
.	O

Replacement	O
with	O
the	O
BCoV	O
32	O
-	O
nucleotide	O
(	O
nt	O
)	O
inter	O
-	O
stem	O
-	O
loop	O
fourth	O
domain	O
between	O
stem	O
-	O
loops	O
III	O
and	O
IV	O
,	O
however	O
,	O
required	O
blind	O
cell	B-COMP
passaging	O
for	O
virus	O
recovery	O
.	O

The	O
bfFp	O
is	O
a	O
recombinant	O
fusion	O
protein	O
consisting	O
of	O
truncated	O
core	O
-	O
streptavidin	O
fused	O
with	O
anti	O
-	O
DEC	O
-	O
205	O
single	O
chain	O
antibody	B-COMP
(	O
scFv	O
).	O

TITLE	O
:	O
Abdominal	O
compartment	O
syndrome	O
in	O
newborns	O
and	O
children	O
supported	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

Host	B-COMP
proteins	O
that	O
are	O
strongly	O
targeted	O
by	O
a	O
virus	O
seem	O
to	O
be	O
particularly	O
attractive	O
for	O
other	O
viruses	O
.	O

The	O
mean	O
serum	B-COMP
malondialdehyde	O
(	O
MDA	O
)	O
levels	O
were	O
0	O
.	O
82	O
±	O
0	O
.	O
43	O
μmol	O
/	O
L	O
,	O
2	O
.	O
97	O
±	O
1	O
.	O
11	O
μmol	O
/	O
L	O
,	O
and	O
6	O
.	O
86	O
±	O
2	O
.	O
62	O
μmol	O
/	O
L	O
,	O
respectively	O
,	O
in	O
healthy	O
controls	O
,	O
in	O
patients	O
with	O
uncomplicated	O
FM	O
,	O
and	O
in	O
those	O
with	O
severe	O
FM	O
with	O
ARF	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
Tregs	O
preserve	O
CNS	O
immune	O
privilege	O
through	O
selective	O
control	O
of	O
CNS	O
-	O
specific	O
Th	O
cells	B-COMP
while	O
keeping	O
protective	O
antiviral	O
immunity	O
fully	O
operative	O
.	O

Loss	O
of	O
cardiolipin	O
in	O
the	O
inner	B-COMP
mitochondrial	I-COMP
membrane	I-COMP
results	O
in	O
respiratory	B-COMP
chain	I-COMP
dysfunction	O
.	O

Respiratory	B-COMP
chain	I-COMP
analysis	O
performed	O
on	O
skin	O
fibroblasts	O
revealed	O
a	O
decreased	O
activity	O
of	O
complexes	O
I	O
,	O
III	O
and	O
IV	O
.	O

Even	O
in	O
severe	O
bleeding	O
DAH	O
has	O
been	O
shown	O
to	O
respond	O
promptly	O
without	O
thromboembolic	O
complication	O
when	O
FVIIa	O
was	O
administered	O
locally	O
via	O
the	O
air	O
side	O
,	O
because	O
the	O
FVIIa	O
does	O
not	O
penetrate	O
the	O
alveolo	O
-	O
capillary	O
membrane	B-COMP
to	O
the	O
blood	O
-	O
side	O
.	O

We	O
have	O
provided	O
evidence	O
for	O
the	O
involvement	O
of	O
recruited	O
neutrophils	O
,	O
their	O
toxic	O
enzymes	O
such	O
as	O
myeloperoxidase	O
and	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
and	O
neutrophil	O
extracellular	B-COMP
traps	O
in	O
aggravating	O
alveolar	O
-	O
capillary	O
damage	O
.	O

TITLE	O
:	O
Clinical	O
experience	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
pneumonia	O
in	O
children	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
a	O
single	O
center	O
'	O
s	O
experience	O
with	O
pediatric	O
patients	O
receiving	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
respiratory	O
failure	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
associated	O
with	O
pneumonia	O
and	O
to	O
investigate	O
the	O
factors	O
associated	O
with	O
mortality	O
.	O

However	O
,	O
as	O
pores	O
connecting	O
the	O
DMV	O
interior	O
with	O
the	O
cytoplasm	B-COMP
have	O
not	O
been	O
detected	O
,	O
it	O
is	O
unclear	O
whether	O
RNA	O
synthesis	O
occurs	O
at	O
these	O
same	O
sites	O
.	O

Late	O
in	O
infection	O
,	O
the	O
correlation	O
between	O
dsRNA	O
dots	O
,	O
then	O
found	O
dispersed	O
throughout	O
the	O
cytoplasm	B-COMP
,	O
and	O
nsp	O
'	O
s	O
and	O
nascent	O
RNAs	O
was	O
less	O
obvious	O
.	O

ABSTRACT	O
:	O
Viruses	O
enter	O
the	O
host	B-COMP
cell	I-COMP
by	O
binding	O
cellular	B-COMP
receptors	O
that	O
allow	O
appropriate	O
delivery	O
of	O
the	O
viral	B-COMP
genome	I-COMP
.	O

As	O
bats	O
have	O
ancient	O
evolutionary	O
origins	O
and	O
are	O
the	O
only	O
flying	O
mammals	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
some	O
of	O
their	O
unique	O
biological	O
features	O
may	O
have	O
made	O
them	O
especially	O
suitable	O
hosts	B-COMP
for	O
different	O
viruses	O
.	O

ABSTRACT	O
:	O
Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
resulting	O
in	O
cumulative	O
neurologic	O
deficits	O
associated	O
with	O
progressive	O
myelin	B-COMP
loss	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
caudatin	O
derivatives	O
were	O
synthesized	O
,	O
and	O
their	O
anti	O
-	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
activity	O
was	O
evaluated	O
in	O
HepG	O
2	O
.	O
2	O
.	O
15	O
cells	B-COMP
.	O

TITLE	O
:	O
Effect	O
of	O
pulmonary	O
support	O
using	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
adult	O
liver	O
transplant	O
recipients	O
with	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Simultaneous	O
treatment	O
of	O
human	O
bronchial	O
epithelial	O
cells	B-COMP
with	O
serine	O
and	O
cysteine	O
protease	O
inhibitors	O
prevents	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
entry	O
.	O

This	O
efficient	O
inhibition	O
could	O
be	O
attributed	O
to	O
the	O
dual	O
blockade	O
of	O
entry	O
from	O
the	O
cell	B-COMP
surface	I-COMP
and	O
through	O
the	O
endosomal	O
pathway	O
.	O

However	O
,	O
mice	O
that	O
were	O
vaccinated	O
twice	O
with	O
the	O
DNA	O
vaccine	O
and	O
boosted	O
with	O
the	O
IPV	O
could	O
mount	O
a	O
sufficient	O
neutralizing	O
antibody	B-COMP
response	O
against	O
live	O
PHE	O
-	O
CoV	O
,	O
with	O
little	O
variation	O
in	O
IgG1	B-COMP
and	O
IgG2a	B-COMP
levels	O
,	O
and	O
showed	O
high	O
levels	O
of	O
IL	O
-	O
2	O
and	O
IL	O
-	O
4	O
.	O

Furthermore	O
,	O
the	O
fusion	O
protein	O
,	O
but	O
not	O
rS450	O
-	O
650	O
alone	O
,	O
was	O
able	O
to	O
elicit	O
S450	O
-	O
650	O
-	O
specific	O
IgG	O
responses	O
in	O
T	O
cell	B-COMP
deficient	O
nude	O
mice	O
.	O

A	O
new	O
strain	O
of	O
Enterococcus	O
faecium	O
,	O
a	O
non	O
pathogenic	O
lactic	O
acid	O
bacteria	O
(	O
LAB	O
)	O
with	O
strong	O
cell	B-COMP
adhesion	O
ability	O
,	O
was	O
identified	O
and	O
used	O
as	O
a	O
vaccine	O
vector	O
to	O
deliver	O
two	O
model	O
antigens	O
.	O

A	O
new	O
scorpion	O
venom	O
peptide	O
derivative	O
Kn2	O
-	O
7	O
was	O
identified	O
as	O
the	O
most	O
potent	O
anti	O
-	O
HIV	O
-	O
1	O
peptide	O
by	O
screening	O
assays	O
with	O
an	O
EC	O
(	O
50	O
)	O
value	O
of	O
2	O
.	O
76	O
µg	O
/	O
ml	O
(	O
1	O
.	O
65	O
µM	O
)	O
and	O
showed	O
low	O
cytotoxicity	O
to	O
host	B-COMP
cells	B-COMP
with	O
a	O
selective	O
index	O
(	O
SI	O
)	O
of	O
13	O
.	O
93	O
.	O

These	O
SARS	O
-	O
CoV	O
vaccines	O
all	O
induced	O
antibody	B-COMP
and	O
protection	O
against	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
challenge	O
of	O
mice	O
given	O
any	O
of	O
the	O
vaccines	O
led	O
to	O
occurrence	O
of	O
Th2	O
-	O
type	O
immunopathology	O
suggesting	O
hypersensitivity	O
to	O
SARS	O
-	O
CoV	O
components	O
was	O
induced	O
.	O

Neither	O
cell	B-COMP
growth	O
nor	O
viability	O
changed	O
in	O
the	O
presence	O
of	O
either	O
CsA	O
or	O
FK506	O
,	O
and	O
these	O
factors	O
did	O
not	O
affect	O
the	O
NF	O
-	O
AT	O
pathway	O
in	O
fcwf	O
-	O
4	O
cells	B-COMP
.	O

Although	O
airway	O
epithelial	O
cells	B-COMP
represent	O
an	O
important	O
target	O
for	O
infection	O
,	O
the	O
respiratory	O
epithelium	O
is	O
also	O
composed	O
of	O
an	O
elaborate	O
network	O
of	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
)	O
that	O
are	O
essential	O
sentinels	O
of	O
the	O
immune	O
system	O
,	O
sensing	O
pathogens	O
and	O
presenting	O
foreign	O
antigens	O
to	O
T	O
lymphocytes	O
.	O

As	O
a	O
result	O
,	O
15	O
-	O
16kb	O
nucleotide	O
sequences	O
encoding	O
complete	O
RNA	O
dependent	O
RNA	O
polymerase	O
,	O
spike	O
,	O
envelope	B-COMP
,	O
membrane	B-COMP
,	O
and	O
nucleocapsid	B-COMP
proteins	O
plus	O
other	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
were	O
generated	O
.	O

We	O
found	O
that	O
a	O
transmembrane	B-COMP
topology	O
was	O
required	O
for	O
disrupting	O
the	O
secretory	O
pathway	O
,	O
but	O
was	O
less	O
efficient	O
for	O
virus	B-COMP
-	I-COMP
like	I-COMP
particle	I-COMP
production	O
.	O

Gene	O
transcription	O
signatures	O
unique	O
to	O
SARS	O
-	O
CoV	O
disease	O
states	O
have	O
been	O
identified	O
,	O
but	O
host	B-COMP
factors	O
that	O
regulate	O
exacerbated	O
disease	O
phenotypes	O
still	O
remain	O
largely	O
undetermined	O
.	O

ABSTRACT	O
:	O
For	O
antiviral	O
screenings	O
purposes	O
,	O
infection	O
of	O
cell	B-COMP
cultures	O
with	O
the	O
virus	O
under	O
study	O
,	O
should	O
ideally	O
result	O
in	O
the	O
induction	O
,	O
within	O
just	O
a	O
few	O
days	O
,	O
of	O
(	O
nearly	O
)	O
complete	O
CPE	O
and	O
allow	O
the	O
calculation	O
of	O
acceptable	O
Z	O
'	O
factors	O
(>	O
0	O
.	O
5	O
).	O

In	O
conclusion	O
,	O
in	O
conditions	O
where	O
a	O
viability	O
staining	O
is	O
inadequate	O
to	O
quantitate	O
virus	O
-	O
induced	O
CPE	O
,	O
a	O
novel	O
simple	O
and	O
convenient	O
method	O
that	O
detects	O
cell	B-COMP
-	O
death	O
and	O
that	O
is	O
suitable	O
for	O
high	O
-	O
throughput	O
screening	O
purposes	O
can	O
be	O
employed	O
.	O

Coronavirus	O
S	O
proteins	O
acquire	O
membrane	B-COMP
fusion	O
competence	O
by	O
receptor	O
interactions	O
,	O
proteolysis	O
,	O
and	O
acidification	O
in	O
endosomes	O
.	O

We	O
focus	O
on	O
receptors	O
and	O
proteases	O
in	O
prompting	O
entry	O
and	O
highlight	O
the	O
type	O
II	O
transmembrane	B-COMP
serine	O
proteases	O
(	O
TTSPs	O
)	O
known	O
to	O
activate	O
several	O
virus	O
fusion	O
proteins	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
in	O
a	O
situation	O
of	O
diagnostic	O
dilemma	O
.	O

We	O
demonstrated	O
that	O
the	O
enzyme	O
unwinds	O
nucleic	B-COMP
acid	O
in	O
discrete	O
steps	O
of	O
9	O
.	O
3	O
base	O
-	O
pairs	O
(	O
bp	O
)	O
each	O
,	O
with	O
a	O
catalytic	O
rate	O
of	O
30	O
steps	O
per	O
second	O
.	O

Therefore	O
,	O
it	O
was	O
important	O
to	O
verify	O
that	O
the	O
host	B-COMP
responses	O
to	O
self	O
will	O
not	O
affect	O
the	O
adjuvanticity	O
of	O
rOv	O
-	O
ASP	O
-	O
1	O
when	O
it	O
is	O
used	O
in	O
subsequent	O
vaccinations	O
with	O
the	O
same	O
or	O
different	O
vaccine	O
antigens	O
.	O

Hence	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
a	O
broader	O
range	O
of	O
antigenic	O
regions	O
that	O
have	O
strong	O
antibody	B-COMP
eliciting	O
ability	O
;	O
these	O
could	O
then	O
be	O
applied	O
for	O
development	O
of	O
an	O
IBV	O
-	O
diagnostic	O
tool	O
.	O

BTLA	O
-	O
deficient	O
(	O
BTLA	O
-/-)	O
mice	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
were	O
infected	O
with	O
murine	O
hepatitis	O
virus	O
strain	O
-	O
3	O
(	O
MHV	O
-	O
3	O
),	O
and	O
the	O
levels	O
of	O
tissue	O
damage	O
,	O
cell	B-COMP
apoptosis	O
,	O
serum	B-COMP
liver	O
enzymes	O
,	O
fibrinogen	B-COMP
-	O
like	O
protein	O
2	O
(	O
FGL2	O
)	O
and	O
cytokine	O
production	O
were	O
measured	O
and	O
compared	O
.	O

Transfer	O
of	O
GKO	O
memory	O
CD4	O
+	O
T	O
cells	B-COMP
into	O
infected	O
SCID	O
mice	O
induced	O
rapid	O
mortality	O
compared	O
to	O
recipients	O
of	O
WT	O
memory	O
CD4	O
+	O
T	O
cells	B-COMP
,	O
despite	O
similar	O
virus	O
control	O
and	O
demyelination	O
.	O

In	O
contrast	O
to	O
recipients	O
of	O
WT	O
CD4	O
+	O
T	O
cells	B-COMP
,	O
extensive	O
neutrophil	O
infiltration	O
and	O
IL	O
-	O
17	O
expression	O
within	O
the	O
CNS	O
in	O
recipients	O
of	O
GKO	O
CD4	O
+	O
T	O
cells	B-COMP
provided	O
a	O
model	O
to	O
directly	O
assess	O
their	O
contribution	O
(	O
s	O
)	O
to	O
disease	O
.	O

The	O
Spike	O
(	O
S	O
)	O
protein	O
is	O
one	O
of	O
the	O
main	O
structural	O
proteins	O
of	O
PEDV	O
capable	O
of	O
inducing	O
neutralizing	O
antibodies	B-COMP
in	O
vivo	O
.	O

Drugs	O
can	O
induce	O
all	O
types	O
of	O
immunological	O
reactions	O
described	O
by	O
Gell	O
and	O
Coombs	O
;	O
however	O
,	O
most	O
reactions	O
in	O
immune	O
-	O
mediated	O
DILD	O
may	O
be	O
T	O
cell	B-COMP
-	O
mediated	O
.	O

This	O
different	O
antigenic	O
phenotype	O
was	O
also	O
confirmed	O
by	O
a	O
neutralizing	O
test	O
with	O
clinically	O
isolated	O
human	O
sera	B-COMP
.	O

ABSTRACT	O
:	O
Carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-COMP
adhesion	O
molecule	O
1	O
(	O
CEACAM1	O
)	O
is	O
the	O
sole	O
known	O
receptor	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
A59	O
,	O
but	O
the	O
available	O
,	O
often	O
qualitative	O
,	O
data	O
about	O
CEACAM1	O
expression	O
does	O
not	O
explain	O
MHV	O
organ	O
tropism	O
.	O

In	O
vivo	O
,	O
the	O
lowest	O
receptor	O
mRNA	O
levels	O
were	O
found	O
in	O
brain	O
and	O
muscle	O
and	O
these	O
were	O
similar	O
to	O
those	O
in	O
easily	O
infectable	O
cultured	O
cells	B-COMP
.	O

TITLE	O
:	O
Increased	O
antibody	B-COMP
affinity	O
confers	O
broad	O
in	O
vitro	O
protection	O
against	O
escape	O
mutants	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

This	O
suggests	O
that	O
the	O
increased	O
disorder	O
content	O
in	O
eukaryotic	O
proteomes	O
might	O
be	O
used	O
by	O
nature	O
to	O
deal	O
with	O
the	O
increased	O
cell	B-COMP
complexity	O
due	O
to	O
the	O
appearance	O
of	O
the	O
various	O
cellular	B-COMP
compartments	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
well	O
known	O
for	O
their	O
potential	O
to	O
change	O
their	O
host	B-COMP
or	O
tissue	O
tropism	O
,	O
resulting	O
in	O
unpredictable	O
new	O
diseases	O
and	O
changes	O
in	O
pathogenicity	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
feline	O
coronaviruses	O
,	O
respectively	O
,	O
are	O
the	O
most	O
recognized	O
examples	O
.	O

We	O
investigated	O
whether	O
cellular	B-COMP
ACE2	O
downregulation	O
occurs	O
at	O
optimal	O
replication	O
conditions	O
of	O
HCoV	O
-	O
NL63	O
infection	O
.	O

Nevertheless	O
,	O
the	O
dynamics	O
of	O
IFNα	O
/	O
β	O
induction	O
and	O
responsiveness	O
by	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
resident	O
cells	B-COMP
in	O
vivo	O
in	O
response	O
to	O
viral	O
infections	O
are	O
poorly	O
understood	O
.	O

Expression	O
of	O
genes	O
associated	O
with	O
the	O
IFNα	O
/	O
β	O
pathways	O
was	O
monitored	O
in	O
microglia	O
and	O
oligodendroglia	O
purified	O
from	O
naïve	O
and	O
infected	O
mice	O
by	O
fluorescent	O
activated	O
cell	B-COMP
sorting	O
.	O

Although	O
PRRs	O
and	O
ISGs	O
were	O
upregulated	O
by	O
infection	O
in	O
both	O
cell	B-COMP
types	O
,	O
the	O
repertoire	O
and	O
absolute	O
mRNA	O
levels	O
were	O
more	O
limited	O
in	O
oligodendroglia	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	O
A	O
(	O
H1N1	O
)-	O
related	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
preliminary	O
experience	O
from	O
a	O
single	O
center	O
.	O

Highly	O
activated	O
liver	O
TCRγδ	O
(+)	O
DN	O
T	O
cells	B-COMP
were	O
cytotoxic	O
to	O
MHV	O
-	O
3	O
-	O
infected	O
hepatocytes	O
in	O
vitro	O
and	O
this	O
effect	O
did	O
not	O
require	O
cell	B-COMP
-	O
cell	B-COMP
contact	O
.	O

ABSTRACT	O
:	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
is	O
not	O
only	O
a	O
poor	O
inducer	O
of	O
type	O
I	O
interferon	O
but	O
also	O
inhibits	O
the	O
efficient	O
induction	O
of	O
type	O
I	O
interferon	O
by	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
synthetic	O
dsRNA	O
molecules	O
,	O
Poly	O
I	O
:	O
C	O
.	O
However	O
,	O
the	O
mechanistic	O
basis	O
by	O
which	O
PRRSV	O
interferes	O
with	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
in	O
its	O
natural	O
host	B-COMP
cells	B-COMP
remains	O
less	O
well	O
defined	O
.	O

This	O
review	O
discusses	O
the	O
development	O
and	O
biology	O
of	O
regulatory	O
T	O
cells	B-COMP
in	O
the	O
context	O
of	O
arteriviral	O
and	O
coronaviral	O
infection	O
.	O

Reduction	O
of	O
infiltration	O
of	O
inflammatory	O
cells	B-COMP
,	O
deposition	O
of	O
fibroblastic	O
loci	O
and	O
collagen	B-COMP
,	O
formation	O
of	O
reactive	O
oxygen	O
species	O
,	O
and	O
production	O
of	O
cytokines	O
,	O
as	O
well	O
as	O
recovery	O
from	O
imbalance	O
of	O
MMP	O
-	O
9	O
/	O
TIMP	O
-	O
1	O
,	O
were	O
observed	O
in	O
fibrotic	O
rats	O
after	O
treatment	O
with	O
Cordyceps	O
in	O
preventive	O
(	O
from	O
the	O
day	O
of	O
BLM	O
administration	O
)	O
and	O
therapeutic	O
(	O
from	O
14	O
days	O
after	O
BLM	O
)	O
regimens	O
.	O

TITLE	O
:	O
The	O
long	O
duration	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
a	O
child	O
with	O
acute	O
severe	O
hypoxic	O
respiratory	O
failure	O
treated	O
in	O
a	O
resource	O
-	O
limited	O
center	O
.	O

University	O
-	O
affiliated	O
level	O
I	O
trauma	O
center	O
in	O
Seattle	O
,	O
WA	O
,	O
and	O
nine	O
hospitals	O
participating	O
in	O
the	O
Inflammation	O
and	O
Host	B-COMP
Response	O
to	O
Injury	O
Consortium	O
.	O

TITLE	O
:	O
Mechanisms	O
of	O
coronavirus	O
cell	B-COMP
entry	O
mediated	O
by	O
the	O
viral	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
whether	O
alpha	O
-	O
1	O
-	O
acid	O
glycoprotein	O
(	O
AGP	O
)	O
can	O
be	O
detected	O
on	O
the	O
membrane	B-COMP
of	O
feline	O
circulating	O
leucocytes	O
.	O

Furthermore	O
,	O
the	O
impact	O
of	O
the	O
appearance	O
of	O
new	O
hosts	B-COMP
in	O
paediatric	O
-	O
very	O
low	O
birthweight	O
infants	O
,	O
immunosuppressed	O
patients	O
-	O
is	O
evaluated	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nsp1	O
facilitates	O
efficient	O
propagation	O
in	O
cells	B-COMP
through	O
a	O
specific	O
translational	O
shutoff	O
of	O
host	B-COMP
mRNA	O
.	O

Then	O
the	O
spleen	O
cells	B-COMP
of	O
the	O
immunized	O
mice	O
were	O
fused	O
with	O
Sp2	O
/	O
0	O
myeloma	O
cells	B-COMP
by	O
conventional	O
hybridoma	O
techniques	O
.	O

RESULTS	O
:	O
We	O
obtained	O
four	O
hybridoma	O
cell	B-COMP
lines	O
secreting	O
mAbs	O
against	O
recombinant	O
N	O
protein	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
antibody	B-COMP
maturation	O
intermediates	O
that	O
are	O
related	O
to	O
bnAbs	O
against	O
the	O
HIV	O
-	O
1	O
and	O
other	O
viruses	O
as	O
observed	O
in	O
normal	O
individuals	O
,	O
and	O
compared	O
their	O
genetic	O
diversity	O
and	O
somatic	O
mutation	O
level	O
along	O
with	O
available	O
structural	O
and	O
functional	O
data	O
.	O

Further	O
computational	O
analysis	O
will	O
provide	O
framework	O
for	O
understanding	O
the	O
underlying	O
genetic	O
and	O
molecular	O
determinants	O
related	O
to	O
maturation	O
pathways	O
of	O
antiviral	O
bnAbs	O
that	O
could	O
be	O
useful	O
for	O
applying	O
novel	O
approaches	O
to	O
the	O
design	O
of	O
effective	O
vaccine	O
immunogens	O
and	O
antibody	B-COMP
-	O
based	O
therapeutics	O
.	O

Additionally	O
,	O
pulmonary	O
surfactant	O
proteins	O
were	O
gradually	O
increased	O
in	O
mouse	O
serum	B-COMP
,	O
suggesting	O
a	O
decrease	O
in	O
pulmonary	O
surfactant	O
in	O
the	O
lung	O
.	O

Although	O
the	O
early	O
elevation	O
of	O
CC16	O
serum	B-COMP
levels	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
pulmonary	O
damage	O
in	O
patients	O
with	O
multiple	O
injuries	O
,	O
the	O
subsequent	O
time	O
course	O
of	O
CC16	O
serum	B-COMP
levels	O
has	O
not	O
been	O
investigated	O
in	O
these	O
patients	O
.	O

EPEC	O
show	O
similarities	O
to	O
enterohaemorrhagic	O
E	O
.	O
coli	O
(	O
EHEC	O
)	O
additionally	O
carrying	O
shiga	O
toxin	O
genes	O
integrated	O
into	O
the	O
chromosome	B-COMP
by	O
lambdoid	O
phages	O
.	O

Major	O
technological	O
improvements	O
in	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
machines	O
and	O
the	O
positive	O
results	O
of	O
the	O
conventional	O
ventilatory	O
support	O
versus	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
severe	O
adult	O
respiratory	O
failure	O
(	O
CESAR	O
)	O
trial	O
have	O
reignited	O
interest	O
in	O
VV	O
-	O
ECMO	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
persistent	O
hypoxemia	O
or	O
hypercarbia	O
on	O
conventional	O
mechanical	O
ventilation	O
.	O

All	O
compounds	O
were	O
highly	O
effective	O
against	O
the	O
majority	O
of	O
tested	O
viruses	O
,	O
with	O
half	O
-	O
maximal	O
inhibitory	O
concentrations	O
in	O
the	O
high	O
nanomolar	O
or	O
low	O
micromolar	O
range	O
in	O
enzyme	O
-	O
and	O
/	O
or	O
cell	B-COMP
-	O
based	O
assays	O
and	O
with	O
high	O
therapeutic	O
indices	O
.	O

In	O
S	O
-	O
pseudovirus	O
,	O
the	O
incorporation	O
of	O
S	O
protein	O
into	O
viral	B-COMP
particles	I-COMP
was	O
obviously	O
inhibited	O
.	O

Coronaviruses	O
'	O
widespread	O
prevalence	O
,	O
extensive	O
host	B-COMP
range	O
,	O
various	O
disease	O
manifestations	O
and	O
increased	O
frequency	O
of	O
recombination	O
events	O
all	O
underline	O
their	O
potential	O
for	O
interspecies	O
transmission	O
(	O
Methods	O
Mol	O
.	O

A	O
seroepidemiological	O
cohort	O
study	O
was	O
completed	O
,	O
for	O
which	O
302	O
canine	O
-	O
exposed	O
and	O
99	O
non	O
-	O
canine	O
-	O
exposed	O
study	O
subjects	O
enrolled	O
in	O
the	O
study	O
by	O
providing	O
a	O
serum	B-COMP
sample	O
and	O
completing	O
a	O
self	O
-	O
administered	O
questionnaire	O
.	O

Hot	O
spots	O
of	O
substitutions	O
were	O
situated	O
in	O
the	O
S1	O
region	O
of	O
the	O
Spike	O
,	O
the	O
nucleocapsid	B-COMP
gene	O
,	O
and	O
the	O
non	O
-	O
structural	O
protein	O
3	O
gene	O
,	O
whereas	O
several	O
deletions	O
were	O
detected	O
in	O
the	O
3	O
'	O
UTR	O
.	O

TITLE	O
:	O
In	O
vitro	O
inhibition	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
replication	O
in	O
swine	O
testicular	O
cells	B-COMP
by	O
short	O
hairpin	O
RNAs	O
targeting	O
the	O
ORF	O
7	O
gene	O
.	O

Observation	O
of	O
the	O
cytopathic	O
effect	O
and	O
apoptosis	O
,	O
as	O
well	O
as	O
a	O
cell	B-COMP
proliferation	O
assay	O
demonstrated	O
that	O
the	O
three	O
shRNAs	O
were	O
capable	O
of	O
protecting	O
ST	O
cells	B-COMP
against	O
TGEV	O
destruction	O
,	O
with	O
high	O
specificity	O
and	O
efficiency	O
.	O

ABSTRACT	O
:	O
Although	O
coronaviruses	O
are	O
known	O
to	O
infect	O
various	O
animals	O
by	O
adapting	O
to	O
new	O
hosts	B-COMP
,	O
interspecies	O
transmission	O
events	O
are	O
still	O
poorly	O
understood	O
.	O

The	O
presence	O
,	O
however	O
,	O
of	O
anti	O
-	O
Ro	O
/	O
SSA	O
antibodies	B-COMP
led	O
us	O
to	O
understand	O
that	O
we	O
were	O
dealing	O
here	O
with	O
a	O
more	O
severe	O
form	O
of	O
interstitial	O
lung	O
disease	O
.	O

Development	O
of	O
rapid	O
and	O
broadly	O
applicable	O
methods	O
for	O
complete	O
viral	B-COMP
genome	I-COMP
sequencing	O
is	O
highly	O
desirable	O
to	O
fully	O
understand	O
all	O
aspects	O
of	O
these	O
infectious	O
agents	O
as	O
well	O
as	O
for	O
surveillance	O
of	O
viral	O
pandemic	O
threats	O
and	O
emerging	O
pathogens	O
.	O

This	O
study	O
has	O
been	O
developed	O
to	O
gain	O
a	O
detailed	O
interdisciplinary	O
understanding	O
,	O
and	O
it	O
combines	O
cutting	O
-	O
edge	O
perspectives	O
from	O
both	O
natural	O
and	O
social	O
sciences	O
,	O
linked	O
to	O
policy	O
impacts	O
on	O
public	O
health	O
,	O
land	B-COMP
use	O
and	O
conservation	O
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
allogeneic	O
NPCs	O
are	O
antigenic	O
,	O
and	O
T	O
-	O
cells	B-COMP
contribute	O
to	O
rejection	O
following	O
transplantation	O
into	O
an	O
inflamed	O
CNS	O
suggesting	O
that	O
immunomodulatory	O
treatments	O
may	O
be	O
necessary	O
to	O
prolong	O
survival	O
of	O
allogeneic	O
cells	B-COMP
.	O

As	O
a	O
consequence	O
,	O
the	O
thymus	O
begins	O
an	O
involution	O
process	O
,	O
producing	O
a	O
severe	O
impairment	O
in	O
cellular	B-COMP
and	O
humoral	O
immunity	O
.	O

The	O
6x	O
His	O
-	O
tagged	O
N	O
protein	O
was	O
used	O
as	O
antigen	O
for	O
ELISA	O
assay	O
and	O
evaluated	O
for	O
the	O
serum	B-COMP
samples	O
from	O
patients	O
with	O
SARS	O
positive	O
and	O
the	O
plasma	O
samples	O
from	O
the	O
HIV	O
-	O
1	O
positive	O
and	O
negative	O
IDUs	O
.	O

RESULTS	O
:	O
all	O
sera	B-COMP
samples	O
from	O
patients	O
with	O
SARS	O
positive	O
were	O
the	O
ELISA	O
positive	O
(	O
100	O
%	O
sensitivity	O
).	O

Moreover	O
,	O
there	O
are	O
very	O
few	O
bat	O
cell	B-COMP
lines	O
or	O
reagents	O
available	O
for	O
investigating	O
CoV	O
replication	O
in	O
bat	O
cells	B-COMP
or	O
for	O
isolating	O
bat	O
CoVs	O
adapted	O
to	O
specific	O
bat	O
species	O
.	O

To	O
characterize	O
the	O
susceptibility	O
of	O
other	O
human	O
and	O
animal	O
cells	B-COMP
to	O
IBV	O
,	O
15	O
human	O
and	O
animal	O
cell	B-COMP
lines	O
were	O
infected	O
with	O
the	O
Vero	O
-	O
adapted	O
IBV	O
and	O
productive	O
infection	O
was	O
observed	O
in	O
four	O
human	O
cell	B-COMP
lines	O
:	O
H1299	O
,	O
HepG2	O
,	O
Hep3B	O
and	O
Huh7	O
.	O

TITLE	O
:	O
Quantitative	O
and	O
sensitive	O
detection	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
using	O
bispecific	O
monoclonal	O
antibody	B-COMP
-	O
based	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O

The	O
sensitivity	O
was	O
improved	O
(	O
detection	O
limit	O
of	O
0	O
.	O
019μg	O
/	O
ml	O
),	O
however	O
,	O
when	O
using	O
bi	O
-	O
specific	O
monoclonal	O
antibody	B-COMP
(	O
F157	O
)	O
as	O
the	O
detection	O
antibody	B-COMP
.	O

Bone	O
marrow	O
chimera	O
experiments	O
demonstrated	O
that	O
hematopoietic	O
cells	B-COMP
are	O
responsible	O
for	O
the	O
pathogenesis	O
in	O
STAT1	O
(-/-)	O
mice	O
,	O
and	O
because	O
of	O
an	O
induction	O
of	O
alternatively	O
activated	O
(	O
AA	O
)	O
macrophages	O
after	O
infection	O
,	O
we	O
hypothesized	O
that	O
the	O
AA	O
macrophages	O
were	O
critical	O
for	O
disease	O
severity	O
.	O

ABSTRACT	O
:	O
The	O
study	O
of	O
Mycoplasma	O
gallisepticum	O
(	O
MG	O
)	O
infection	O
is	O
needed	O
,	O
not	O
only	O
to	O
understand	O
the	O
disease	O
process	O
but	O
also	O
to	O
understand	O
the	O
mechanisms	O
by	O
which	O
MG	O
vaccines	O
protect	O
the	O
host	B-COMP
.	O

ABSTRACT	O
:	O
The	O
major	O
structural	O
protein	O
of	O
coronaviruses	O
,	O
the	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
,	O
can	O
elicit	O
the	O
formation	O
of	O
protective	O
antibodies	B-COMP
,	O
but	O
little	O
information	O
is	O
available	O
about	O
the	O
M	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

Accumulating	O
evidence	O
suggests	O
that	O
multiple	O
environmental	O
forces	O
within	O
the	O
host	B-COMP
,	O
including	O
immune	O
responses	O
(	O
or	O
lack	O
thereof	O
)	O
and	O
affinity	O
for	O
cell	B-COMP
receptors	O
,	O
as	O
well	O
as	O
physical	O
and	O
biochemical	O
conditions	O
,	O
are	O
responsible	O
for	O
the	O
selection	O
process	O
.	O

In	O
ovo	O
vaccination	O
with	O
a	O
low	O
dose	O
of	O
AdArkIBV	O
.	O
S1	O
(	O
ck	O
)	O
resulted	O
in	O
a	O
mild	O
increase	O
of	O
systemic	O
antibody	B-COMP
and	O
reduced	O
viral	O
shedding	O
but	O
no	O
protection	O
against	O
IBV	O
signs	O
and	O
lesions	O
.	O

Domestic	O
dogs	O
had	O
antibodies	B-COMP
to	O
CDV	O
,	O
canine	O
adenovirus	O
,	O
canine	O
herpesvirus	O
,	O
and	O
canine	O
parvovirus	O
.	O

We	O
provide	O
the	O
first	O
data	O
on	O
exposure	O
of	O
free	O
-	O
ranging	O
Geoffroy	O
'	O
s	O
cats	O
to	O
pathogens	O
at	O
two	O
sites	O
within	O
the	O
core	O
area	O
of	O
the	O
species	O
distribution	O
range	O
,	O
including	O
the	O
first	O
report	O
of	O
antibodies	B-COMP
to	O
CDV	O
in	O
this	O
species	O
.	O

CLINICAL	O
APPLICATIONS	O
OF	O
EXTRACORPOREAL	O
LUNG	O
SUPPORT	O
:	O
Extracorporeal	O
lung	O
support	O
technologies	O
[	O
i	O
.	O
e	O
.,	O
Interventional	O
Lung	O
Assist	O
(	O
ILA	O
)	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)]	O
have	O
been	O
advocated	O
for	O
use	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
respiratory	O
failure	O
.	O

Recently	O
,	O
the	O
first	O
commercially	O
available	O
extracorporeal	O
membrane	B-COMP
ventilator	O
(	O
NovaLung	O
GmbH	O
,	O
Hechingen	O
,	O
Germany	O
)	O
was	O
approved	O
for	O
clinical	O
use	O
by	O
Health	O
Canada	O
for	O
patients	O
in	O
respiratory	O
failure	O
.	O

DAMPs	O
originate	O
from	O
multiple	O
sources	O
,	O
including	O
injured	O
and	O
dying	O
cells	B-COMP
,	O
the	O
extracellular	B-COMP
matrix	I-COMP
,	O
or	O
exist	O
as	O
immunomodulatory	O
proteins	O
within	O
the	O
airspace	O
and	O
interstitium	O
.	O

All	O
mutant	O
viruses	O
demonstrated	O
impaired	O
replication	O
compared	O
to	O
wildtype	O
MHV	O
,	O
but	O
no	O
nsp4	O
N258T	O
mutant	O
virus	O
was	O
ts	O
,	O
and	O
all	O
variants	O
colocalized	O
with	O
viral	O
protein	O
markers	O
for	O
replication	O
complexes	O
,	O
but	O
not	O
with	O
markers	O
for	O
mitochondria	B-COMP
.	O

ABSTRACT	O
:	O
Calf	O
diarrhea	O
is	O
a	O
multifactorial	O
disease	O
related	O
to	O
a	O
combination	O
of	O
host	B-COMP
and	O
pathogen	O
factors	O
.	O

TITLE	O
:	O
The	O
heptide	O
repeat	O
2	O
and	O
upstream	O
region	O
of	O
TGEV	O
induces	O
potent	O
cross	O
-	O
neutralizing	O
antibodies	B-COMP
against	O
group	O
I	O
coronaviruses	O
.	O

To	O
deeply	O
reveal	O
the	O
interaction	O
of	O
host	B-COMP
and	O
SARS	O
-	O
CoV	O
,	O
based	O
on	O
the	O
basic	O
structural	O
feature	O
of	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
,	O
we	O
created	O
a	O
new	O
bioinformatics	O
method	O
for	O
searching	O
potential	O
pathogenic	O
molecules	O
and	O
identified	O
a	O
set	O
of	O
SARS	O
-	O
CoV	O
specific	O
GU	O
-	O
rich	O
ssRNA	O
fragments	O
with	O
a	O
high	O
-	O
density	O
distribution	O
in	O
the	O
genome	O
.	O

In	O
the	O
absence	O
of	O
A14	O
,	O
electron	O
-	O
dense	O
virosomes	O
and	O
distinct	O
clusters	O
of	O
small	O
vesicles	B-COMP
accumulate	O
;	O
in	O
the	O
absence	O
of	O
A17	O
,	O
small	O
vesicles	B-COMP
form	O
a	O
corona	O
around	O
the	O
virosomes	O
.	O

TITLE	O
:	O
Effect	O
of	O
Chaiqinchengqi	O
decoction	O
on	O
serum	B-COMP
amyloid	O
A	O
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
history	O
of	O
clinical	O
application	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
has	O
been	O
more	O
than	O
30	O
years	O
.	O

Infection	O
was	O
documented	O
in	O
3	O
cases	O
,	O
hyperbilirubinemia	O
in	O
2	O
cases	O
,	O
lower	O
limb	O
ischemia	O
in	O
1	O
case	O
,	O
hyperglycemia	O
in	O
3	O
cases	O
,	O
disseminated	O
intravascular	O
coagulation	O
in	O
1	O
case	O
,	O
membrane	B-COMP
lung	O
leakage	O
in	O
2	O
cases	O
,	O
systemic	O
hemolysis	O
in	O
3	O
cases	O
,	O
oxygenator	O
failure	O
in	O
2	O
cases	O
and	O
oxygenator	O
thrombosis	O
in	O
one	O
case	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
a	O
Vero	O
cell	B-COMP
-	O
adapted	O
isolate	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
eastern	O
China	O
.	O

This	O
report	O
describes	O
the	O
complete	O
genome	O
sequence	O
,	O
genome	O
organization	O
,	O
and	O
expression	O
strategy	O
of	O
HCoV	O
-	O
EMC	B-COMP
/	O
2012	O
and	O
its	O
relation	O
with	O
known	O
coronaviruses	O
.	O

In	O
accordance	O
with	O
the	O
guidelines	O
of	O
the	O
International	O
Committee	O
on	O
Taxonomy	O
of	O
Viruses	O
,	O
and	O
in	O
view	O
of	O
the	O
75	O
%	O
and	O
77	O
%	O
amino	O
acid	O
sequence	O
identity	O
in	O
7	O
conserved	O
replicase	O
domains	O
with	O
BtCoV	O
-	O
HKU4	O
and	O
BtCoV	O
-	O
HKU5	O
,	O
respectively	O
,	O
we	O
propose	O
that	O
HCoV	O
-	O
EMC	B-COMP
/	O
2012	O
prototypes	O
a	O
novel	O
species	O
in	O
the	O
genus	O
Betacoronavirus	O
.	O

However	O
,	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
caused	O
by	O
SARS	O
-	O
CoV	O
in	O
2002	O
to	O
2003	O
and	O
the	O
fatal	O
infection	O
of	O
a	O
human	O
by	O
HCoV	O
-	O
EMC	B-COMP
/	O
2012	O
in	O
2012	O
show	O
that	O
coronaviruses	O
are	O
able	O
to	O
cause	O
severe	O
,	O
sometimes	O
fatal	O
disease	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
reported	O
that	O
a	O
prokaryotic	O
-	O
expressed	O
recombinant	O
nucleocapsid	B-COMP
protein	O
(	O
NP	O
)	O
is	O
a	O
suitable	O
reagent	O
for	O
the	O
epidemiological	O
screening	O
of	O
coronavirus	O
infection	O
.	O

Sera	B-COMP
from	O
26	O
young	O
adults	O
,	O
17	O
middle	O
-	O
aged	O
and	O
elderly	O
patients	O
with	O
respiratory	O
infection	O
,	O
and	O
15	O
cord	O
blood	O
samples	O
were	O
also	O
tested	O
.	O

TITLE	O
:	O
Oligomerization	O
of	O
the	O
carboxyl	O
terminal	O
domain	O
of	O
the	O
human	O
coronavirus	O
229E	O
nucleocapsid	B-COMP
protein	O
.	O

Replication	O
of	O
EAV	O
,	O
however	O
,	O
was	O
not	O
affected	O
in	O
autophagy	O
-	O
deficient	O
cells	B-COMP
lacking	O
autophagy	O
-	O
related	O
protein	O
7	O
(	O
ATG7	O
).	O

These	O
data	O
indicate	O
that	O
HmAbs	O
which	O
bind	O
to	O
conserved	O
regions	O
of	O
the	O
S	O
protein	O
are	O
more	O
suitable	O
for	O
conferring	O
protection	O
against	O
a	O
wide	O
range	O
of	O
SARS	O
-	O
CoV	O
variants	O
and	O
have	O
implications	O
for	O
generating	O
therapeutic	O
antibodies	B-COMP
or	O
subunit	O
vaccines	O
against	O
other	O
enveloped	O
viruses	O
.	O

Control	O
of	O
viral	O
replication	O
during	O
acute	O
disease	O
is	O
mediated	O
by	O
infiltrating	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
via	O
cytokine	O
secretion	O
and	O
cytolytic	O
activity	O
,	O
however	O
sterile	O
immunity	O
is	O
not	O
achieved	O
and	O
virus	O
persists	O
resulting	O
in	O
chronic	O
neuroinflammation	O
associated	O
with	O
demyelination	O
.	O

CXCR2	O
is	O
a	O
chemokine	O
receptor	O
that	O
upon	O
binding	O
to	O
specific	O
ligands	O
promotes	O
host	B-COMP
defense	O
through	O
recruitment	O
of	O
myeloid	O
cells	B-COMP
to	O
the	O
CNS	O
as	O
well	O
as	O
protecting	O
oligodendroglia	O
from	O
cytokine	O
-	O
mediated	O
death	O
in	O
response	O
to	O
MHV	O
infection	O
.	O

ABSTRACT	O
:	O
Measurement	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibody	B-COMP
titres	O
is	O
utilised	O
mainly	O
for	O
diagnosing	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
for	O
quarantine	O
purposes	O
.	O

However	O
,	O
occasional	O
samples	O
show	O
a	O
falsely	O
low	O
or	O
negative	O
FCoV	O
antibody	B-COMP
test	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
such	O
results	O
are	O
due	O
to	O
virus	O
in	O
the	O
sample	O
binding	O
antibody	B-COMP
and	O
rendering	O
it	O
unavailable	O
to	O
antigen	O
in	O
the	O
test	O
.	O

Two	O
additional	O
RT	O
-	O
PCR	O
assays	O
for	O
sequencing	O
are	O
described	O
,	O
targeting	O
the	O
RdRp	O
gene	O
(	O
RdRpSeq	O
assay	O
)	O
and	O
N	O
gene	O
(	O
NSeq	O
assay	O
),	O
where	O
an	O
insertion	O
/	O
deletion	O
polymorphism	O
might	O
exist	O
among	O
different	O
hCoV	O
-	O
EMC	B-COMP
strains	O
.	O

As	O
human	O
CoV	O
normally	O
cannot	O
replicate	O
in	O
bat	O
cells	B-COMP
from	O
different	O
families	O
,	O
this	O
suggests	O
that	O
hCoV	O
-	O
EMC	B-COMP
might	O
use	O
a	O
receptor	O
molecule	O
that	O
is	O
conserved	O
in	O
bats	O
,	O
pigs	O
,	O
and	O
humans	O
,	O
implicating	O
a	O
low	O
barrier	O
against	O
cross	O
-	O
host	B-COMP
transmission	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
B7	O
-	O
H1	O
-/-	O
mice	O
were	O
infected	O
with	O
a	O
gliatropic	O
coronavirus	O
and	O
CD4	O
T	O
cells	B-COMP
depleted	O
to	O
specifically	O
block	O
T	O
helper	O
function	O
in	O
the	O
CNS	O
.	O

The	O
local	O
requirement	O
of	O
CD4	O
T	O
-	O
cell	B-COMP
help	O
for	O
CD8	O
T	O
-	O
cell	B-COMP
function	O
is	O
not	O
overcome	O
if	O
B7	O
-	O
H1	O
inhibitory	O
signals	O
are	O
lost	O
.	O

This	O
vaccine	O
is	O
comprised	O
of	O
a	O
recombinant	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
and	O
formulated	O
on	O
alum	O
,	O
together	O
with	O
a	O
synthetic	O
glucopyranosyl	O
lipid	O
A	O
.	O
The	O
vaccine	O
would	O
induce	O
neutralizing	O
antibodies	B-COMP
without	O
causing	O
Th2	O
-	O
type	O
immunopathology	O
.	O

Adoptive	O
transfer	O
of	O
DN	O
T	O
cells	B-COMP
from	O
MHV	O
-	O
3	O
infected	O
mice	O
led	O
to	O
a	O
significant	O
increase	O
in	O
mice	O
survival	O
.	O

In	O
these	O
patients	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
be	O
used	O
as	O
a	O
rescue	O
therapy	O
.	O

By	O
study	O
day	O
14	O
dogs	O
had	O
seroconverted	O
to	O
CRCoV	O
and	O
the	O
antibodies	B-COMP
raised	O
were	O
neutralising	O
against	O
both	O
homologous	O
and	O
heterologous	O
strains	O
of	O
CRCoV	O
in	O
vitro	O
,	O
thus	O
demonstrating	O
antigenic	O
homogeneity	O
among	O
CRCoV	O
strains	O
from	O
the	O
two	O
continents	O
.	O

The	O
mean	O
PaO2	O
/	O
fraction	O
of	O
inspired	O
oxygenation	O
(	O
FiO2	O
)	O
ratio	O
was	O
(	O
54	O
±	O
18	O
)	O
mm	O
Hg	O
(	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
),	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
was	O
(	O
11	O
±	O
6	O
)	O
cm	O
H2O	O
(	O
1	O
cm	O
H2O	O
=	O
0	O
.	O
098	O
kPa	O
),	O
Murray	O
lung	O
injury	O
score	O
was	O
3	O
.	O
6	O
±	O
0	O
.	O
5	O
,	O
serum	B-COMP
lactate	O
was	O
(	O
2	O
.	O
5	O
±	O
2	O
.	O
0	O
)	O
mmol	O
/	O
L	O
,	O
serum	B-COMP
white	O
blood	O
cell	B-COMP
count	O
was	O
(	O
16	O
±	O
6	O
)×	O
10	O
(	O
9	O
)/	O
L	O
,	O
and	O
APACHEII	O
score	O
was	O
17	O
±	O
8	O
.	O

Blood	O
gases	O
and	O
hemodynamic	O
parameters	O
were	O
evaluated	O
after	O
changing	O
one	O
of	O
three	O
ECMO	O
settings	O
,	O
namely	O
,	O
circuit	O
blood	O
flow	O
,	O
FiO	O
(	O
2ECMO	O
)	O
(	O
fraction	O
of	O
inspired	O
oxygen	O
in	O
circuit	O
),	O
or	O
sweep	O
gas	O
flow	O
ventilating	O
the	O
membrane	B-COMP
,	O
while	O
leaving	O
the	O
other	O
two	O
parameters	O
at	O
their	O
maximum	O
setting	O
.	O

HCoV	O
-	O
EMC	B-COMP
may	O
represent	O
a	O
sporadic	O
spillover	O
to	O
humans	O
from	O
an	O
unknown	O
animal	O
reservoir	O
.	O

In	O
a	O
recent	O
article	O
,	O
van	O
Boheemen	O
et	O
al	O
.	O
demonstrated	O
how	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
sequencing	O
technology	O
and	O
bioinformatic	O
analysis	O
can	O
quickly	O
provide	O
critical	O
insight	O
into	O
the	O
viral	B-COMP
genome	I-COMP
sequence	O
,	O
phylogeny	O
,	O
replication	O
strategy	O
,	O
and	O
potential	O
drug	O
and	O
vaccine	O
targets	O
and	O
generate	O
tools	O
to	O
evaluate	O
the	O
possible	O
epidemic	O
risk	O
associated	O
with	O
this	O
novel	O
human	O
virus	O
.	O

TITLE	O
:	O
Astrocyte	O
-	O
derived	O
CXCL10	O
drives	O
accumulation	O
of	O
antibody	B-COMP
-	O
secreting	O
cells	B-COMP
in	O
the	O
central	O
nervous	O
system	O
during	O
viral	O
encephalomyelitis	O
.	O

T	O
cell	B-COMP
accumulation	O
,	O
localization	O
,	O
and	O
effector	O
functions	O
were	O
also	O
not	O
affected	O
in	O
either	O
CXCL9	O
(-/-)	O
or	O
CXCL10	O
(-/-)	O
mice	O
,	O
consistent	O
with	O
similar	O
control	O
of	O
infectious	O
virus	O
.	O

The	O
insert	O
coded	O
for	O
three	O
arginine	O
residues	O
,	O
occurred	O
in	O
a	O
region	O
associated	O
with	O
fusion	O
entry	O
into	O
host	B-COMP
cells	B-COMP
,	O
and	O
may	O
allow	O
infection	O
of	O
new	O
cell	B-COMP
types	O
via	O
heparin	O
sulfate	O
binding	O
.	O

Baseline	O
low	O
-	O
serum	B-COMP
magnesium	O
was	O
an	O
independent	O
predictor	O
of	O
the	O
refeeding	O
syndrome	O
(	O
p	O
=	O
0	O
.	O
021	O
).	O

These	O
results	O
provide	O
a	O
strong	O
incentive	O
for	O
identifying	O
the	O
host	B-COMP
cell	I-COMP
receptor	O
used	O
by	O
HCoV	O
-	O
EMC	B-COMP
.	O

However	O
,	O
expression	O
of	O
IBV	O
nonstructural	O
protein	O
6	O
alone	O
did	O
induce	O
autophagic	O
signaling	O
in	O
avian	O
cells	B-COMP
,	O
as	O
seen	O
previously	O
in	O
mammalian	O
cells	B-COMP
.	O

Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
h	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	O
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	O
therapy	O
within	O
1	O
h	O
of	O
the	O
recognition	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	O
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
h	O
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	B-COMP
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	O
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	B-COMP
to	O
maintain	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1B	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	O
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	O
improvement	O
is	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	O
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	O
pressure	O
≥	O
65	O
mmHg	O
(	O
1B	O
);	O
epinephrine	O
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	O
pressure	O
(	O
2B	O
);	O
vasopressin	O
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	O
to	O
either	O
raise	O
mean	O
arterial	O
pressure	O
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	O
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	O
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	O
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
(	O
a	O
)	O
myocardial	O
dysfunction	O
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
(	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	O
in	O
adult	O
septic	O
shock	O
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	O
stability	O
(	O
2C	O
);	O
hemoglobin	O
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
ARDS	O
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	O
for	O
patients	O
with	O
sepsis	O
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	O
(	O
2C	O
);	O
recruitment	O
maneuvers	O
in	O
sepsis	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	O
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
patients	O
with	O
a	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
≤	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	O
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
targeting	O
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	O
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
h	O
)	O
for	O
patients	O
with	O
early	O
ARDS	O
and	O
a	O
PaO	O
(	O
2	O
)/	O
FI	O
O	O
(	O
2	O
)	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	O
management	O
commencing	O
insulin	O
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	O
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	O
an	O
upper	O
blood	O
glucose	O
≤	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1B	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
in	O
patients	O
with	O
bleeding	O
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	O
within	O
the	O
first	O
48	O
h	O
after	O
a	O
diagnosis	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
h	O
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

Our	O
data	O
demonstrated	O
that	O
ORF6	O
protein	O
expression	O
attenuates	O
the	O
activity	O
of	O
numerous	O
karyopherin	O
-	O
dependent	O
host	B-COMP
transcription	O
factors	O
(	O
VDR	O
,	O
CREB1	O
,	O
SMAD4	O
,	O
p53	O
,	O
EpasI	O
,	O
and	O
Oct3	O
/	O
4	O
)	O
that	O
are	O
critical	O
for	O
establishing	O
antiviral	O
responses	O
and	O
regulating	O
key	O
host	B-COMP
responses	O
during	O
virus	O
infection	O
.	O

The	O
data	O
strongly	O
support	O
the	O
hypothesis	O
that	O
viral	O
antagonists	O
of	O
nuclear	O
import	O
actively	O
manipulate	O
host	B-COMP
responses	O
in	O
specific	O
hierarchical	O
patterns	O
,	O
contributing	O
to	O
the	O
viral	O
pathogenic	O
potential	O
in	O
vivo	O
.	O

TITLE	O
:	O
Genetic	O
variation	O
of	O
nucleocapsid	B-COMP
genes	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
field	O
strains	O
in	O
China	O
.	O

TITLE	O
:	O
Sequence	O
and	O
phylogenetic	O
analysis	O
of	O
nucleocapsid	B-COMP
genes	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
strains	O
in	O
China	O
.	O

PMVEC	O
septic	O
responses	O
were	O
compared	O
in	O
the	O
presence	O
/	O
absence	O
of	O
co	O
-	O
cultured	O
A549	O
epithelial	O
cell	B-COMP
line	O
or	O
primary	O
human	O
AEC	O
.	O

The	O
presence	O
of	O
A549	O
cells	B-COMP
or	O
primary	O
human	O
AEC	O
in	O
a	O
non	O
-	O
contact	O
co	O
-	O
culture	O
model	O
attenuated	O
septic	O
PMVEC	O
hyper	O
-	O
permeability	O
by	O
39	O
±	O
4	O
%	O
to	O
100	O
±	O
3	O
%,	O
depending	O
on	O
the	O
septic	O
stimulation	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
conclusion	O
,	O
the	O
cultivation	O
of	O
alveolar	O
type	O
II	O
cells	B-COMP
at	O
an	O
air	O
-	O
liquid	O
interface	O
provides	O
primary	O
cultures	O
in	O
which	O
to	O
study	O
the	O
pulmonary	O
innate	O
immune	O
responses	O
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
,	O
and	O
to	O
explore	O
possible	O
therapeutic	O
approaches	O
to	O
modulating	O
these	O
innate	O
immune	O
responses	O
.	O

TITLE	O
:	O
Hemagglutination	O
mediated	O
by	O
the	O
spike	O
protein	O
of	O
cell	B-COMP
-	O
adapted	O
bovine	O
torovirus	O
.	O

Like	O
SARS	O
-	O
CoV	O
,	O
HCoV	O
-	O
EMC	B-COMP
is	O
of	O
zoonotic	O
origin	O
and	O
closely	O
related	O
to	O
bat	O
coronaviruses	O
.	O

We	O
show	O
that	O
human	O
bronchial	O
epithelia	O
are	O
highly	O
susceptible	O
to	O
HCoV	O
-	O
EMC	B-COMP
infection	O
.	O

Irregular	O
media	O
changes	O
and	O
mechanical	O
or	O
physical	O
disruption	O
of	O
the	O
cell	B-COMP
layers	O
or	O
plates	O
negatively	O
impact	O
polarization	O
for	O
several	O
hours	O
or	O
days	O
.	O

Studies	O
of	O
the	O
fundamental	O
aspects	O
of	O
these	O
HCoV	O
infections	O
at	O
the	O
primary	O
entry	O
port	O
,	O
such	O
as	O
cell	B-COMP
tropism	O
,	O
are	O
seriously	O
hampered	O
by	O
the	O
lack	O
of	O
a	O
universal	O
culture	O
system	O
or	O
suitable	O
animal	O
models	O
.	O

To	O
expand	O
the	O
knowledge	O
on	O
fundamental	O
virus	O
-	O
host	B-COMP
interactions	O
for	O
all	O
four	O
HCoVs	O
at	O
the	O
site	O
of	O
primary	O
infection	O
,	O
we	O
used	O
pseudostratified	O
HAE	O
cell	B-COMP
cultures	O
to	O
isolate	O
and	O
characterize	O
representative	O
clinical	O
HCoV	O
strains	O
directly	O
from	O
nasopharyngeal	O
material	O
.	O

Eighty	O
-	O
five	O
contacts	O
provided	O
blood	O
for	O
a	O
serological	O
test	O
using	O
a	O
two	O
-	O
stage	O
approach	O
with	O
an	O
initial	O
immunofluorescence	O
assay	O
as	O
screening	O
test	O
,	O
followed	O
by	O
recombinant	O
immunofluorescence	O
assays	O
and	O
a	O
NCoV	O
-	O
specific	O
serum	B-COMP
neutralisation	O
test	O
.	O

TITLE	O
:	O
Human	O
cell	B-COMP
tropism	O
and	O
innate	O
immune	O
system	O
interactions	O
of	O
human	O
respiratory	O
coronavirus	O
EMC	B-COMP
compared	O
to	O
those	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Infections	O
with	O
human	O
coronavirus	O
EMC	B-COMP
(	O
HCoV	O
-	O
EMC	B-COMP
)	O
are	O
associated	O
with	O
severe	O
pneumonia	O
.	O

ABSTRACT	O
:	O
A	O
cohort	O
of	O
154	O
French	O
Hajj	O
pilgrims	O
participating	O
in	O
the	O
2012	O
Hajj	O
were	O
systematically	O
sampled	O
with	O
nasal	O
swabs	O
prior	O
to	O
returning	O
to	O
France	O
,	O
and	O
screened	O
for	O
the	O
novel	O
HCoV	O
-	O
EMC	B-COMP
coronavirus	O
by	O
two	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
.	O

TITLE	O
:	O
The	O
spike	O
protein	O
of	O
the	O
emerging	O
betacoronavirus	O
EMC	B-COMP
uses	O
a	O
novel	O
coronavirus	O
receptor	O
for	O
entry	O
,	O
can	O
be	O
activated	O
by	O
TMPRSS2	O
,	O
and	O
is	O
targeted	O
by	O
neutralizing	O
antibodies	B-COMP
.	O

We	O
found	O
that	O
the	O
spike	O
protein	O
of	O
hCoV	O
-	O
EMC	B-COMP
(	O
EMC	B-COMP
-	O
S	O
)	O
is	O
incorporated	O
into	O
lentiviral	O
particles	O
and	O
mediates	O
transduction	O
of	O
human	O
cell	B-COMP
lines	O
derived	O
from	O
different	O
organs	O
,	O
including	O
the	O
lungs	O
,	O
kidneys	O
,	O
and	O
colon	O
,	O
as	O
well	O
as	O
primary	O
human	O
macrophages	O
.	O

Finally	O
,	O
EMC	B-COMP
-	O
S	O
-	O
driven	O
transduction	O
was	O
abrogated	O
by	O
serum	B-COMP
from	O
an	O
hCoV	O
-	O
EMC	B-COMP
-	O
infected	O
patient	O
,	O
indicating	O
that	O
EMC	B-COMP
-	O
S	O
-	O
specific	O
neutralizing	O
antibodies	B-COMP
can	O
be	O
generated	O
in	O
patients	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
hCoV	O
-	O
EMC	B-COMP
uses	O
a	O
novel	O
receptor	O
for	O
protease	O
-	O
activated	O
entry	O
into	O
human	O
cells	B-COMP
and	O
might	O
be	O
capable	O
of	O
extrapulmonary	O
spread	O
.	O

For	O
primary	O
response	O
to	O
SRBC	O
administered	O
at	O
7	O
d	O
of	O
age	O
,	O
HYPER	O
chicks	O
recorded	O
higher	O
total	O
,	O
IgM	O
(	O
d	O
14	O
),	O
and	O
IgG	O
(	O
d	O
21	O
)	O
anti	O
-	O
SRBC	O
antibody	B-COMP
titers	O
.	O

ABSTRACT	O
:	O
Toxoplasma	O
gondii	O
is	O
an	O
obligate	O
intracellular	B-COMP
protozoan	O
parasite	O
that	O
can	O
infect	O
almost	O
all	O
warm	O
-	O
blooded	O
animals	O
and	O
humans	O
with	O
a	O
worldwide	O
distribution	O
.	O

We	O
tested	O
acute	O
and	O
convalescent	O
sera	B-COMP
for	O
antigen	O
and	O
antibody	B-COMP
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
avian	O
influenza	O
,	O
and	O
plague	O
.	O

We	O
utilized	O
ex	O
vivo	O
cultures	O
of	O
human	O
bronchial	O
and	O
lung	O
tissue	O
specimens	O
to	O
investigate	O
the	O
tissue	O
tropism	O
and	O
virus	O
replication	O
kinetics	O
following	O
experimental	O
infection	O
with	O
HCoV	O
-	O
EMC	B-COMP
compared	O
with	O
those	O
following	O
infection	O
with	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Human	O
T	O
-	O
cell	B-COMP
Immunoglobulin	O
and	O
Mucin	O
-	O
domain	O
containing	O
proteins	O
(	O
TIM1	O
,	O
3	O
,	O
and	O
4	O
)	O
specifically	O
bind	O
phosphatidylserine	O
(	O
PS	O
).	O

TIM1	O
has	O
been	O
proposed	O
to	O
serve	O
as	O
a	O
cellular	B-COMP
receptor	O
for	O
hepatitis	O
A	O
virus	O
and	O
Ebola	O
virus	O
and	O
as	O
an	O
entry	O
factor	O
for	O
dengue	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
mast	O
cells	B-COMP
(	O
MCs	B-COMP
)	O
in	O
allergic	O
reactions	O
and	O
parasitic	O
infections	O
is	O
well	O
established	O
.	O

The	O
average	O
total	O
MCC	B-COMP
per	O
high	O
-	O
power	O
field	O
in	O
ECA	O
(	O
40	O
.	O
8	O
±	O
2	O
.	O
2	O
)	O
and	O
IBD	O
(	O
24	O
.	O
7	O
±	O
2	O
.	O
1	O
)	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
.	O
05	O
)	O
than	O
in	O
the	O
control	O
(	O
3	O
.	O
4	O
±	O
0	O
.	O
6	O
).	O

TITLE	O
:	O
The	O
emergence	O
of	O
human	O
coronavirus	O
EMC	B-COMP
:	O
how	O
scared	O
should	O
we	O
be	O
?	O

ABSTRACT	O
:	O
A	O
novel	O
betacoronavirus	O
,	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
EMC	B-COMP
),	O
has	O
recently	O
been	O
detected	O
in	O
humans	O
with	O
severe	O
respiratory	O
disease	O
.	O

While	O
the	O
full	O
-	O
length	O
ectodomain	O
(	O
S	O
)	O
of	O
the	O
spike	O
protein	O
,	O
the	O
full	O
-	O
length	O
ectodomain	O
fused	O
to	O
foldon	O
(	O
S	O
-	O
foldon	O
),	O
the	O
S1	O
domain	O
(	O
S1	O
),	O
S1	O
-	O
foldon	O
,	O
and	O
the	O
S2	O
domain	O
(	O
S2	O
)	O
antigens	O
all	O
elicited	O
comparable	O
antibody	B-COMP
titers	O
as	O
measured	O
by	O
ELISA	O
,	O
S	O
-	O
foldon	O
induced	O
a	O
significantly	O
higher	O
titer	O
of	O
neutralizing	O
antibody	B-COMP
and	O
S2	O
protein	O
did	O
not	O
elicit	O
virus	O
neutralizing	O
antibodies	B-COMP
.	O

ABSTRACT	O
:	O
Immobilized	O
fibrinogen	B-COMP
and	O
fibrin	O
facilitate	O
leukocyte	O
adhesion	O
,	O
as	O
they	O
are	O
potent	O
ligands	O
for	O
leukocyte	O
MAC	B-COMP
-	O
1	O
(	O
CD11b	O
/	O
CD18	O
).	O

Importantly	O
soluble	O
fibrinogen	B-COMP
in	O
acute	O
-	O
phase	O
concentrations	O
(	O
4	O
-	O
10	O
mg	O
mL	O
(-	O
1	O
)	O
)	O
dose	O
-	O
dependently	O
reduced	O
neutrophil	O
firm	O
adhesion	O
to	O
tumor	O
necrosis	O
factor	O
-	O
α	O
-	O
activated	O
endothelium	O
to	O
40	O
%	O
under	O
flow	O
conditions	O
.	O

We	O
conducted	O
a	O
seroprevalence	O
study	O
on	O
archived	O
sera	B-COMP
from	O
94	O
game	O
-	O
food	O
animal	O
handlers	O
at	O
a	O
wild	O
life	O
market	O
,	O
28	O
SARS	O
patients	O
,	O
and	O
152	O
healthy	O
blood	O
donors	O
in	O
Southern	O
China	O
to	O
assess	O
the	O
zoonotic	O
potential	O
and	O
evidence	O
for	O
intrusion	O
of	O
HCoV	O
-	O
EMC	B-COMP
and	O
related	O
viruses	O
into	O
humans	O
.	O

ABSTRACT	O
:	O
Despite	O
the	O
lack	O
of	O
evidence	O
in	O
the	O
literature	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
man	O
involved	O
in	O
a	O
road	O
traffic	O
accident	O
,	O
who	O
had	O
an	O
inferior	O
vena	O
cava	O
(	O
IVC	O
)	O
injury	O
and	O
severe	O
lung	O
contusion	O
with	O
parenchymal	O
bleeding	O
requiring	O
an	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

ABSTRACT	O
:	O
The	O
identification	O
of	O
a	O
novel	O
β	O
coronavirus	O
,	O
nCoV	O
,	O
as	O
the	O
causative	O
agent	O
of	O
severe	O
respiratory	O
illness	O
in	O
humans	O
originating	O
in	O
Saudi	O
Arabia	O
,	O
Qatar	O
and	O
Jordan	O
has	O
raised	O
concerns	O
about	O
the	O
possibility	O
of	O
a	O
coronavirus	O
pandemic	O
similar	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
.	O
As	O
a	O
definitive	O
treatment	O
regimen	O
has	O
never	O
been	O
thoroughly	O
evaluated	O
for	O
coronavirus	O
infections	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
rapidly	O
identify	O
potential	O
therapeutics	O
to	O
address	O
future	O
cases	O
of	O
nCoV	O
.	O
To	O
determine	O
an	O
intervention	O
strategy	O
,	O
the	O
effect	O
of	O
interferon	O
-	O
α2b	O
and	O
ribavirin	O
on	O
nCoV	O
isolate	O
hCoV	O
-	O
EMC	B-COMP
/	O
2012	O
replication	O
in	O
Vero	O
and	O
LLC	B-COMP
-	O
MK2	O
cells	B-COMP
was	O
evaluated	O
.	O

hCoV	O
-	O
EMC	B-COMP
/	O
2012	O
was	O
sensitive	O
to	O
both	O
interferon	O
-	O
α2b	O
and	O
ribavirin	O
alone	O
in	O
Vero	O
and	O
LLC	B-COMP
-	O
MK2	O
cells	B-COMP
,	O
but	O
only	O
at	O
relatively	O
high	O
concentrations	O
;	O
however	O
,	O
when	O
combined	O
,	O
lower	O
concentrations	O
of	O
interferon	O
-	O
α2b	O
and	O
ribavirin	O
achieved	O
comparable	O
endpoints	O
.	O

Mechanical	O
ventilation	O
is	O
a	O
mainstay	O
in	O
the	O
treatment	O
of	O
ARDS	O
,	O
but	O
may	O
induce	O
mechano	O
-	O
physical	O
stresses	O
on	O
unstable	O
alveoli	O
,	O
which	O
can	O
paradoxically	O
propagate	O
the	O
cellular	B-COMP
and	O
molecular	O
processes	O
exacerbating	O
ARDS	O
pathology	O
.	O

Moreover	O
,	O
blood	O
oxygen	O
saturation	O
(	O
SpO2	O
),	O
gastric	O
intramucosal	O
pH	O
value	O
(	O
pHi	O
),	O
intra	O
-	O
abdominal	O
pressure	O
(	O
IAP	O
),	O
inflammation	O
cytokines	O
,	O
urine	O
lactulose	O
/	O
mannitol	O
(	O
L	O
/	O
M	O
)	O
ratio	O
,	O
and	O
serum	B-COMP
endotoxin	O
were	O
investigated	O
to	O
evaluate	O
the	O
inflammatory	O
reaction	O
and	O
gut	O
barrier	O
.	O

ABSTRACT	O
:	O
The	O
variable	O
regions	O
of	O
the	O
heavy	O
chain	O
(	O
VH	O
)	O
and	O
light	O
chain	O
(	O
VL	O
)	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
from	O
the	O
hybridoma	O
6E6	O
,	O
which	O
secretes	O
the	O
monoclonal	O
antibody	B-COMP
against	O
PEDV	O
S	O
protein	O
.	O

T	O
regulatory	O
(	O
T	O
(	O
reg	O
))	O
cells	B-COMP
in	O
the	O
lungs	O
are	O
reported	O
to	O
modify	O
innate	O
immune	O
responses	O
during	O
resolution	O
of	O
acute	O
lung	O
injury	O
.	O

Immunohistochemistry	O
for	O
intracellular	B-COMP
feline	O
coronavirus	O
(	O
FeCoV	O
)	O
antigen	O
demonstrated	O
positive	O
staining	O
in	O
dermal	O
macrophages	O
providing	O
an	O
antemortem	O
diagnosis	O
of	O
a	O
moderate	O
,	O
nodular	O
to	O
diffuse	O
,	O
pyogranulomatous	O
perivascular	O
dermatitis	O
due	O
to	O
FIP	O
infection	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
adults	O
.	O

Electron	O
microscopy	O
of	O
infected	O
Vero	O
cells	B-COMP
revealed	O
extensive	O
membrane	B-COMP
rearrangements	O
,	O
including	O
the	O
formation	O
of	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
and	O
convoluted	O
membranes	O
,	O
which	O
have	O
been	O
implicated	O
previously	O
in	O
the	O
RNA	O
synthesis	O
of	O
SARS	O
-	O
CoV	O
and	O
other	O
CoVs	O
.	O

Additionally	O
,	O
MHV	O
S	O
assembly	O
could	O
also	O
be	O
rescued	O
by	O
the	O
acidic	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
.	O

Identification	O
of	O
a	O
novel	O
coronavirus	O
causing	O
fatal	O
respiratory	O
infection	O
in	O
humans	O
raises	O
concerns	O
about	O
a	O
possible	O
widespread	O
outbreak	O
of	O
severe	O
respiratory	O
infection	O
similar	O
to	O
the	O
one	O
caused	O
by	O
SARS	O
-	O
CoV	O
.	O
Using	O
a	O
human	O
lung	O
epithelial	O
cell	B-COMP
line	O
and	O
global	O
transcriptomic	O
profiling	O
,	O
we	O
identified	O
differences	O
in	O
the	O
host	B-COMP
response	O
between	O
HCoV	O
-	O
EMC	B-COMP
and	O
SARS	O
-	O
CoV	O
.	O
This	O
enables	O
rapid	O
assessment	O
of	O
viral	O
properties	O
and	O
the	O
ability	O
to	O
anticipate	O
possible	O
differences	O
in	O
human	O
clinical	O
responses	O
to	O
HCoV	O
-	O
EMC	B-COMP
and	O
SARS	O
-	O
CoV	O
.	O
We	O
used	O
this	O
information	O
to	O
predict	O
potential	O
effective	O
drugs	O
against	O
HCoV	O
-	O
EMC	B-COMP
,	O
a	O
method	O
that	O
could	O
be	O
more	O
generally	O
used	O
to	O
identify	O
candidate	O
therapeutics	O
in	O
future	O
disease	O
outbreaks	O
.	O

ABSTRACT	O
:	O
The	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
cleaves	O
two	O
virion	B-COMP
polyproteins	O
(	O
pp1a	O
and	O
pp1ab	O
);	O
this	O
essential	O
process	O
represents	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
plays	O
a	O
multifunctional	O
role	O
in	O
the	O
virus	O
life	O
cycle	O
,	O
from	O
regulation	O
of	O
replication	O
and	O
transcription	O
and	O
genome	O
packaging	O
to	O
modulation	O
of	O
host	O
cell	B-COMP
processes	I-COMP
.	O

TITLE	O
:	O
Regulation	O
of	O
programmed	O
ribosomal	B-COMP
frameshifting	O
by	O
co	O
-	O
translational	O
refolding	O
RNA	O
hairpins	O
.	O

An	O
example	O
is	O
the	O
stimulation	O
of	O
-	O
1	O
programmed	O
ribosomal	B-COMP
frameshifting	O
,	O
leading	O
to	O
3	O
'	O
direction	O
slippage	O
of	O
the	O
reading	O
-	O
frame	O
during	O
elongation	O
,	O
by	O
specific	O
pseudoknot	O
stimulators	O
downstream	O
of	O
the	O
frameshifting	O
site	O
.	O

Since	O
the	O
upstream	O
hairpin	O
is	O
unwound	O
(	O
by	O
a	O
marching	O
ribosome	B-COMP
)	O
before	O
the	O
downstream	O
stimulator	O
,	O
this	O
study	O
'	O
s	O
findings	O
suggest	O
a	O
new	O
mode	O
of	O
translational	O
regulation	O
that	O
is	O
mediated	O
by	O
the	O
reformed	O
stem	O
of	O
a	O
ribosomal	B-COMP
unwound	O
RNA	O
hairpin	O
during	O
elongation	O
.	O

Murine	O
alveolar	O
cells	B-COMP
cultured	O
to	O
maintain	O
an	O
ATII	O
cell	B-COMP
phenotype	O
,	O
determined	O
by	O
expression	O
of	O
LBP180	O
,	O
were	O
susceptible	O
to	O
infection	O
by	O
all	O
three	O
viruses	O
.	O

While	O
MHV	O
-	O
1	O
and	O
PR8	O
induced	O
expression	O
of	O
a	O
number	O
of	O
shared	O
cytokines	O
in	O
ATI	O
cells	B-COMP
,	O
there	O
were	O
several	O
cytokines	O
whose	O
expression	O
was	O
induced	O
uniquely	O
by	O
MHV	O
-	O
1	O
infection	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
(	O
8	O
)	O
phlorotannin	O
chemotype	O
significantly	O
blocking	O
the	O
cleavage	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
in	O
a	O
cell	B-COMP
-	O
based	O
assay	O
with	O
no	O
toxicity	O
.	O

Thus	O
,	O
nsp1	O
is	O
a	O
promising	O
target	O
for	O
drugs	O
,	O
as	O
inhibition	O
of	O
nsp1	O
would	O
make	O
SARS	O
-	O
CoV	O
more	O
susceptible	O
to	O
the	O
host	B-COMP
antiviral	O
defenses	O
.	O

Serum	B-COMP
potassium	O
levels	O
must	O
be	O
monitored	O
closely	O
in	O
these	O
patients	O
,	O
as	O
failure	O
to	O
do	O
so	O
can	O
lead	O
to	O
potentially	O
lethal	O
consequences	O
.	O

then	O
antibodies	B-COMP
titers	O
declined	O
rapidly	O
in	O
some	O
cases	O
.	O

RESULTS	O
:	O
90	O
%	O
of	O
257	O
patient	O
serum	B-COMP
specimens	O
after	O
20	O
days	O
of	O
disease	O
onset	O
showed	O
positive	O
SARS	O
-	O
CoV	O
IgG	O
either	O
using	O
ELISA	O
or	O
IFA	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
infection	O
induces	O
cell	B-COMP
apoptosis	O
via	O
activation	O
of	O
p53	O
signalling	O
.	O

ABSTRACT	O
:	O
Induction	O
of	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
is	O
an	O
adaptive	O
cellular	B-COMP
response	O
to	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	B-COMP
)	O
stress	O
that	O
allows	O
a	O
cell	B-COMP
to	O
reestablish	O
ER	B-COMP
homeostasis	O
.	O

Demographic	O
differences	O
were	O
observed	O
between	O
patients	O
with	O
different	O
viruses	O
,	O
suggesting	O
that	O
host	B-COMP
and	O
viral	O
factors	O
play	O
a	O
role	O
in	O
phenotypic	O
expression	O
of	O
viral	O
illness	O
.	O

Thus	O
,	O
RNase	O
L	O
activation	O
during	O
MHV	O
infection	O
is	O
cell	B-COMP
type	I-COMP
specific	O
and	O
correlates	O
with	O
relatively	O
high	O
levels	O
of	O
expression	O
of	O
OAS	O
genes	O
,	O
which	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
induction	O
of	O
an	O
effective	O
RNase	O
L	O
antiviral	O
response	O
.	O

TITLE	O
:	O
Identifying	O
SARS	O
-	O
CoV	O
membrane	B-COMP
protein	O
amino	O
acid	O
residues	O
linked	O
to	O
virus	B-COMP
-	I-COMP
like	I-COMP
particle	I-COMP
assembly	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
phosphoprotein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
packages	O
the	O
viral	B-COMP
genome	I-COMP
into	O
a	O
helical	O
ribonucleocapsid	O
and	O
plays	O
a	O
fundamental	O
role	O
during	O
viral	O
self	O
-	O
assembly	O
.	O

The	O
positivity	O
was	O
significantly	O
higher	O
in	O
males	O
(	O
51	O
.	O
5	O
%)	O
than	O
in	O
females	O
(	O
35	O
.	O
7	O
%)	O
(	O
P	O
<	O
0	O
.	O
0001	O
),	O
whereas	O
no	O
gender	O
difference	O
has	O
generally	O
been	O
noted	O
in	O
FCoV	O
antibody	B-COMP
prevalence	O
,	O
indicating	O
that	O
FIP	O
more	O
frequently	O
develops	O
in	O
males	O
among	O
FCoV	O
-	O
infected	O
cats	O
.	O

A	O
flow	O
cytometric	O
method	O
based	O
on	O
ingestion	O
of	O
fluoresceinated	O
bacteria	O
and	O
adapted	O
to	O
feline	O
blood	O
was	O
used	O
to	O
assess	O
phagocytosis	O
of	O
leukocytes	O
incubated	O
with	O
'	O
non	O
-	O
pathological	O
'	O
fAGP	O
(	O
purified	O
from	O
sera	B-COMP
with	O
normal	O
concentrations	O
of	O
AGP	O
)	O
and	O
'	O
pathological	O
'	O
fAGP	O
(	O
purified	O
from	O
sera	B-COMP
with	O
>	O
1	O
.	O
5mg	O
/	O
mL	O
hyposialylated	O
AGP	O
).	O

Serology	O
for	O
feline	O
coronavirus	O
antibody	B-COMP
was	O
positive	O
with	O
an	O
elevated	O
alpha	O
-	O
1	O
acid	O
glycoprotein	O
.	O

A	O
21	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
head	O
injury	O
after	O
a	O
car	B-COMP
accident	O
was	O
endotracheally	O
intubated	O
,	O
mechanically	O
ventilated	O
,	O
and	O
hemodynamically	O
stabilized	O
before	O
transfer	O
to	O
our	O
university	O
hospital	O
.	O

TITLE	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
induces	O
apoptosis	O
in	O
a	O
porcine	O
kidney	O
cell	B-COMP
line	O
via	O
caspase	O
-	O
dependent	O
pathways	O
.	O

Staining	O
with	O
Hoechst	O
33	O
,	O
342	O
revealed	O
morphological	O
changes	O
in	O
the	O
nuclei	O
and	O
chromatin	B-COMP
fragmentation	O
.	O

Major	O
outcome	O
of	O
interest	O
was	O
to	O
analyze	O
the	O
direct	O
impact	O
of	O
24	O
-	O
hour	O
crystalloid	B-COMP
volume	O
on	O
HRR	O
MTP	O
patients	O
who	O
received	O
10	O
or	O
more	O
units	O
of	O
PRBC	O
.	O

CONCLUSIONS	O
:	O
Severe	O
chest	O
injury	O
,	O
increasing	O
age	O
,	O
and	O
crystalloid	B-COMP
-	O
based	O
resuscitation	O
,	O
but	O
not	O
blood	O
transfusions	O
,	O
were	O
associated	O
with	O
increased	O
risk	O
of	O
developing	O
moderate	O
-	O
to	O
-	O
severe	O
hypoxemia	O
following	O
injury	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
recently	O
emerged	O
human	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
mediates	O
infection	O
by	O
binding	O
to	O
the	O
cellular	B-COMP
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

Here	O
we	O
mapped	O
the	O
receptor	O
binding	O
domain	O
in	O
the	O
S	O
protein	O
to	O
a	O
231	O
-	O
amino	O
-	O
acid	O
fragment	O
(	O
residues	O
358	O
to	O
588	O
)	O
by	O
evaluating	O
the	O
interaction	O
of	O
spike	O
truncation	O
variants	O
with	O
receptor	O
-	O
expressing	O
cells	B-COMP
and	O
soluble	O
DPP4	O
.	O

Antibodies	B-COMP
to	O
this	O
domain	O
--	O
much	O
less	O
so	O
those	O
to	O
the	O
preceding	O
N	O
-	O
terminal	O
region	O
--	O
efficiently	O
neutralize	O
MERS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
Human	O
serum	B-COMP
albumin	O
(	O
HSA	O
)	O
is	O
the	O
most	O
abundant	O
circulating	O
protein	O
and	O
accounts	O
for	O
about	O
70	O
%	O
of	O
the	O
plasma	O
colloid	O
osmotic	O
pressure	O
.	O

Within	O
twelve	O
hrs	O
after	O
cell	B-COMP
cultures	O
were	O
initiated	O
,	O
cytoplasmic	B-COMP
vacuoles	B-COMP
appeared	O
in	O
many	O
of	O
the	O
RPTEC	O
.	O

The	O
BCoV	O
RT	O
-	O
RPA	B-COMP
constitutes	O
a	O
suitable	O
accurate	O
,	O
sensitive	O
and	O
rapid	O
alternative	O
to	O
the	O
common	O
measures	O
used	O
for	O
BCoV	O
diagnosis	O
.	O

Neutralizing	O
antibodies	B-COMP
from	O
individuals	O
who	O
have	O
recovered	O
from	O
an	O
infection	O
confer	O
therapeutic	O
protection	O
to	O
others	O
infected	O
with	O
the	O
same	O
pathogen	O
.	O

We	O
recommend	O
enhanced	O
surveillance	O
,	O
active	O
contact	O
tracing	O
,	O
and	O
vigorous	O
searches	O
for	O
the	O
MERS	O
-	O
CoV	O
animal	O
hosts	B-COMP
and	O
transmission	O
routes	O
to	O
human	O
beings	O
.	O

ABSTRACT	O
:	O
The	O
newly	O
emergent	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
can	O
cause	O
severe	O
pulmonary	O
disease	O
in	O
humans	O
,	O
representing	O
the	O
second	O
example	O
of	O
a	O
highly	O
pathogenic	O
coronavirus	O
,	O
the	O
first	O
being	O
SARS	O
-	O
CoV	O
.	O
CD26	O
(	O
also	O
known	O
as	O
dipeptidyl	O
peptidase	O
4	O
,	O
DPP4	O
)	O
was	O
recently	O
identified	O
as	O
the	O
cellular	B-COMP
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
engagement	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
with	O
CD26	O
mediates	O
viral	O
attachment	O
to	O
host	B-COMP
cells	B-COMP
and	O
virus	O
-	O
cell	B-COMP
fusion	O
,	O
thereby	O
initiating	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
(	O
S	O
)	O
of	O
recently	O
identified	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
targets	O
the	O
cellular	B-COMP
receptor	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

Mutagenesis	O
studies	O
have	O
identified	O
several	O
key	O
residues	O
in	O
the	O
receptor	O
-	O
binding	O
subdomain	O
that	O
are	O
critical	O
for	O
viral	O
binding	O
to	O
DPP4	O
and	O
entry	O
into	O
the	O
target	O
cell	B-COMP
.	O

Our	O
results	O
indicate	O
that	O
H7N9	O
viruses	O
have	O
the	O
capacity	O
for	O
efficient	O
replication	O
in	O
mammals	O
and	O
human	O
airway	O
cells	B-COMP
and	O
highlight	O
the	O
need	O
for	O
continued	O
public	O
health	O
surveillance	O
of	O
this	O
emerging	O
virus	O
.	O

The	O
identified	O
proteins	O
were	O
involved	O
in	O
the	O
regulation	O
of	O
essential	O
processes	O
such	O
as	O
cellular	B-COMP
structure	I-COMP
and	O
integrity	O
,	O
RNA	O
processing	O
,	O
protein	O
biosynthesis	O
and	O
modification	O
,	O
vesicle	B-COMP
transport	O
,	O
signal	O
transduction	O
,	O
and	O
the	O
mitochondrial	B-COMP
pathway	O
.	O

The	O
present	O
study	O
provides	O
protein	O
-	O
related	O
information	O
that	O
should	O
be	O
useful	O
for	O
understanding	O
the	O
host	B-COMP
cell	I-COMP
response	O
to	O
TGEV	O
infection	O
and	O
the	O
underlying	O
mechanism	O
of	O
TGEV	O
replication	O
and	O
pathogenicity	O
.	O

Use	O
of	O
a	O
transfusion	O
protocol	O
with	O
a	O
predefined	O
ratio	O
of	O
1	O
:	O
1	O
:	O
1	O
(	O
1	O
each	O
of	O
red	O
blood	O
cells	B-COMP
[	O
RBC	O
],	O
frozen	O
plasma	O
[	O
FP	O
]	O
and	O
platelets	O
)	O
has	O
been	O
associated	O
with	O
improved	O
survival	O
in	O
retrospective	O
studies	O
in	O
military	O
and	O
civilian	O
settings	O
,	O
but	O
such	O
a	O
protocol	O
has	O
its	O
challenges	O
and	O
may	O
increase	O
the	O
risk	O
of	O
respiratory	O
complications	O
.	O

After	O
24	O
hours	O
,	O
the	O
number	O
of	O
endothelial	O
progenitor	O
cells	B-COMP
in	O
peripheral	O
blood	O
increased	O
in	O
the	O
acute	O
lung	O
injury	O
group	O
but	O
was	O
not	O
altered	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

Furthermore	O
,	O
plasma	O
stromal	O
cell	B-COMP
-	O
derived	O
factor	O
-	O
1	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
concentrations	O
were	O
higher	O
in	O
acute	O
lung	O
injury	O
than	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
at	O
24	O
hours	O
.	O

Lung	O
CD34	O
,	O
KDR	O
,	O
and	O
lung	O
stromal	O
cell	B-COMP
-	O
derived	O
factor	O
-	O
1	O
messenger	O
RNA	O
expression	O
were	O
higher	O
in	O
the	O
acute	O
lung	O
injury	O
group	O
than	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
group	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
CD34	O
,	O
KDR	O
,	O
and	O
CD133	O
messenger	O
RNA	O
in	O
lung	O
tissue	O
was	O
correlated	O
with	O
stromal	O
cell	B-COMP
-	O
derived	O
factor	O
-	O
1	O
in	O
the	O
lung	O
.	O

In	O
the	O
serum	B-COMP
the	O
acute	O
phase	O
proteins	O
(	O
haptoglobin	O
and	O
serum	B-COMP
amyloid	O
A	O
),	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
interferon	O
-	O
γ	O
and	O
tumor	O
necrosis	O
factor	O
-	O
α	O
),	O
and	O
serum	B-COMP
sialic	O
acid	O
(	O
total	O
,	O
TSA	O
;	O
lipid	O
-	O
bound	O
,	O
LBSA	O
;	O
and	O
protein	O
-	O
bound	O
,	O
PBSA	O
)	O
concentrations	O
were	O
measured	O
using	O
validated	O
standard	O
procedures	O
.	O

This	O
is	O
particularly	O
true	O
for	O
the	O
very	O
real	O
threat	O
of	O
""""	O
novel	O
pathogens	O
""""	O
such	O
as	O
the	O
avian	O
-	O
origin	O
influenzas	O
H7N9	O
and	O
H5N1	O
,	O
and	O
new	O
coronaviruses	O
such	O
as	O
hCoV	O
-	O
EMC	B-COMP
.	O

Systematically	O
varying	O
these	O
triggers	O
in	O
this	O
platform	O
provides	O
a	O
new	O
route	O
to	O
study	O
how	O
viruses	O
rapidly	O
adapt	O
to	O
other	O
hosts	B-COMP
,	O
and	O
to	O
identify	O
factors	O
that	O
led	O
to	O
the	O
emergence	O
of	O
zoonotic	O
viruses	O
,	O
such	O
as	O
human	O
SARS	O
-	O
CoV	O
and	O
the	O
newly	O
emerging	O
human	O
MERS	O
-	O
CoV	O
.	O

The	O
communicable	O
disease	O
risks	O
include	O
emerging	O
and	O
re	O
-	O
emerging	O
diseases	O
in	O
host	B-COMP
and	O
visiting	O
populations	O
.	O

TITLE	O
:	O
A	O
2	O
-	O
year	O
-	O
old	O
girl	O
with	O
co	O
-	O
inherited	O
cystic	O
fibrosis	O
and	O
sickle	O
cell	B-COMP
-	O
β	O
+	O
thalassemia	O
presenting	O
with	O
recurrent	O
vaso	O
-	O
occlusive	O
events	O
during	O
cystic	O
fibrosis	O
pulmonary	O
exacerbations	O
:	O
a	O
case	O
report	O
.	O

To	O
assess	O
pulmonary	O
co	O
-	O
morbidities	O
,	O
we	O
used	O
infant	O
pulmonary	O
function	O
testing	O
through	O
the	O
raised	O
volume	O
rapid	O
thoracoabdominal	O
compression	O
technique	O
as	O
both	O
an	O
established	O
study	O
of	O
early	O
cystic	O
fibrosis	O
and	O
also	O
as	O
a	O
newer	O
study	O
of	O
mechanism	O
for	O
early	O
sickle	O
cell	B-COMP
lung	O
disease	O
.	O

Furthermore	O
,	O
these	O
studies	O
demonstrate	O
that	O
human	O
alveolar	O
cells	B-COMP
can	O
be	O
used	O
to	O
isolate	O
and	O
study	O
novel	O
human	O
respiratory	O
viruses	O
that	O
cause	O
lower	O
respiratory	O
tract	O
disease	O
.	O

Elevated	O
serum	B-COMP
lactate	O
levels	O
in	O
the	O
ED	O
and	O
a	O
recently	O
validated	O
clinical	O
prediction	O
score	O
were	O
independently	O
associated	O
with	O
the	O
development	O
of	O
ARDS	O
in	O
severe	O
sepsis	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
(	O
IL	O
-	O
9	O
,	O
IFN	O
-	O
γ	O
and	O
TNF	O
-	O
α	O
)	O
were	O
also	O
examined	O
by	O
using	O
intracellular	B-COMP
staining	O
.	O

Furthermore	O
,	O
viral	O
production	O
decreased	O
when	O
the	O
ORF4a	O
protein	O
expression	O
was	O
suppressed	O
by	O
siRNA	O
in	O
infected	O
cells	B-COMP
.	O

Cytologically	O
assessed	O
plasma	O
cell	B-COMP
number	O
was	O
correlated	O
with	O
keratic	O
precipitates	O
and	O
disease	O
duration	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
applied	O
in	O
adults	O
with	O
acute	O
refractory	O
respiratory	O
failure	O
that	O
is	O
deemed	O
reversible	O
.	O

We	O
took	O
sera	B-COMP
from	O
animals	O
in	O
the	O
Middle	O
East	O
(	O
Oman	O
)	O
and	O
from	O
elsewhere	O
(	O
Spain	O
,	O
Netherlands	O
,	O
Chile	O
).	O

50	O
of	O
50	O
(	O
100	O
%)	O
sera	B-COMP
from	O
Omani	O
camels	O
and	O
15	O
of	O
105	O
(	O
14	O
%)	O
from	O
Spanish	O
camels	O
had	O
protein	O
-	O
specific	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
spike	O
.	O

Despite	O
efforts	O
to	O
identify	O
the	O
critical	O
interactions	O
of	O
these	O
viruses	O
with	O
host	B-COMP
machinery	O
,	O
the	O
key	O
regulatory	O
events	O
that	O
lead	O
to	O
disease	O
pathology	O
remain	O
poorly	O
targeted	O
with	O
therapeutics	O
.	O

In	O
addition	O
,	O
we	O
inserted	O
heterologous	O
genes	O
(	O
i	O
.	O
e	O
.	O
the	O
GFP	O
and	O
Renilla	O
luciferase	O
genes	O
)	O
at	O
two	O
positions	O
in	O
the	O
viral	B-COMP
genome	I-COMP
,	O
either	O
as	O
an	O
extra	O
expression	O
cassette	O
or	O
as	O
a	O
replacement	O
for	O
the	O
ORF3	O
gene	O
.	O

Specifically	O
,	O
coronaviruses	O
induce	O
the	O
formation	O
of	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
in	O
infected	O
cells	B-COMP
.	O

Together	O
,	O
nsp3	O
,	O
nsp4	O
,	O
and	O
nsp6	O
have	O
the	O
ability	O
to	O
induce	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
that	O
are	O
similar	O
to	O
those	O
observed	O
in	O
SARS	O
coronavirus	O
-	O
infected	O
cells	B-COMP
.	O

TITLE	O
:	O
Cell	B-COMP
-	O
mediated	O
immune	O
responses	O
in	O
the	O
head	O
-	O
associated	O
lymphoid	O
tissues	O
induced	O
to	O
a	O
live	O
attenuated	O
avian	O
coronavirus	O
vaccine	O
.	O

This	O
interpretation	O
was	O
supported	O
by	O
observations	O
that	O
changes	O
in	O
mononuclear	O
cells	B-COMP
were	O
mirrored	O
by	O
that	O
in	O
CD3	O
(+)	O
CD44	O
(+)	O
T	O
cell	B-COMP
abundance	O
,	O
which	O
presumably	O
represent	O
T	O
effector	O
cells	B-COMP
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
severe	O
respiratory	O
failure	O
in	O
adult	O
patients	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
current	O
evidence	O
.	O

While	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
are	O
genetically	O
closely	O
related	O
to	O
bat	O
coronaviruses	O
,	O
intermediate	O
host	B-COMP
(	O
s	O
)	O
is	O
(	O
are	O
)	O
likely	O
to	O
be	O
involved	O
in	O
the	O
emergence	O
and	O
cross	O
-	O
species	O
transmission	O
of	O
these	O
novel	O
human	O
viruses	O
.	O

High	O
prevalence	O
of	O
SARS	O
-	O
like	O
coronaviruses	O
have	O
been	O
found	O
from	O
masked	O
palm	O
civet	O
cats	O
and	O
raccoon	O
dogs	O
collected	O
from	O
markets	O
around	O
the	O
time	O
of	O
outbreaks	O
in	O
humans	O
,	O
but	O
these	O
animals	O
are	O
likely	O
to	O
be	O
a	O
transient	O
accidental	O
host	B-COMP
rather	O
than	O
a	O
persisting	O
reservoir	O
.	O

To	O
accomplish	O
this	O
,	O
it	O
is	O
necessary	O
to	O
evaluate	O
neutralizing	O
antibodies	B-COMP
and	O
screen	O
for	O
MERS	O
-	O
CoV	O
entry	O
inhibitors	O
.	O

The	O
mean	O
of	O
the	O
highest	O
plasma	O
-	O
free	O
haemoglobin	O
during	O
MCS	B-COMP
was	O
21	O
.	O
0	O
(±	O
42	O
.	O
9	O
)	O
mg	O
/	O
dl	O
.	O

The	O
increase	O
in	O
plasma	O
-	O
free	O
haemoglobin	O
correlated	O
moderately	O
with	O
the	O
duration	O
of	O
MCS	B-COMP
(	O
Pearson	O
'	O
s	O
r	O
:	O
0	O
.	O
78	O
).	O

TITLE	O
:	O
Combination	O
of	O
positioning	O
therapy	O
and	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
ARDS	O
patients	O
.	O

Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
vvECMO	O
)	O
is	O
a	O
rescue	O
strategy	O
that	O
may	O
ensure	O
sufficient	O
gas	O
exchange	O
in	O
ARDS	O
patients	O
failing	O
conventional	O
therapy	O
.	O

In	O
this	O
series	O
,	O
experts	O
in	O
many	O
different	O
aspects	O
of	O
coronavirus	O
replication	O
and	O
disease	O
will	O
provide	O
authoritative	O
,	O
up	O
-	O
to	O
-	O
date	O
reviews	O
of	O
the	O
following	O
topics	O
:	O
-	O
clinical	O
management	O
and	O
infection	O
control	O
of	O
SARS	O
;	O
-	O
reservoir	O
hosts	B-COMP
of	O
coronaviruses	O
;	O
-	O
receptor	O
recognition	O
and	O
cross	O
-	O
species	O
transmission	O
of	O
SARS	O
-	O
CoV	O
;	O
-	O
SARS	O
-	O
CoV	O
evasion	O
of	O
innate	O
immune	O
responses	O
;	O
-	O
structures	O
and	O
functions	O
of	O
individual	O
coronaviral	O
proteins	O
;	O
-	O
anti	O
-	O
coronavirus	O
drug	O
discovery	O
and	O
development	O
;	O
and	O
-	O
the	O
public	O
health	O
legacy	O
of	O
the	O
SARS	O
outbreak	O
.	O

ABSTRACT	O
:	O
Poly	O
-	O
γ	O
-	O
glutamic	O
acid	O
(	O
γ	O
-	O
PGA	O
)	O
is	O
an	O
anionic	O
polypeptide	O
secreted	O
by	O
Bacillus	O
sp	O
.	O
that	O
has	O
been	O
shown	O
to	O
activate	O
immune	O
cells	B-COMP
through	O
interactions	O
with	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
).	O

The	O
construction	O
of	O
a	O
full	O
-	O
length	O
infectious	O
cDNA	O
clone	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
in	O
a	O
bacterial	O
artificial	O
chromosome	B-COMP
is	O
reported	O
here	O
,	O
providing	O
a	O
reverse	O
genetics	O
system	O
to	O
study	O
the	O
molecular	O
biology	O
of	O
the	O
virus	O
and	O
to	O
develop	O
attenuated	O
viruses	O
as	O
vaccine	O
candidates	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
mediated	O
by	O
the	O
transmembrane	B-COMP
serine	O
protease	O
TMPRSS2	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
utilizes	O
host	B-COMP
proteases	O
for	O
virus	O
entry	O
into	O
lung	O
cells	B-COMP
.	O

In	O
the	O
current	O
study	O
,	O
Vero	O
cells	B-COMP
constitutively	O
expressing	O
type	O
II	O
transmembrane	B-COMP
serine	O
protease	O
(	O
Vero	O
-	O
TMPRSS2	O
cells	B-COMP
)	O
showed	O
larger	O
syncytia	O
at	O
18	O
h	O
after	O
infection	O
with	O
MERS	O
-	O
CoV	O
than	O
after	O
infection	O
with	O
other	O
coronaviruses	O
.	O

Simultaneous	O
treatment	O
with	O
inhibitors	O
of	O
cathepsin	O
L	O
and	O
TMPRSS2	O
completely	O
blocked	O
virus	O
entry	O
into	O
Vero	O
-	O
TMPRSS2	O
cells	B-COMP
,	O
indicating	O
that	O
MERS	O
-	O
CoV	O
employs	O
both	O
the	O
cell	B-COMP
surface	I-COMP
and	O
the	O
endosomal	O
pathway	O
to	O
infect	O
Vero	O
-	O
TMPRSS2	O
cells	B-COMP
.	O

In	O
contrast	O
,	O
a	O
single	O
camostat	O
treatment	O
suppressed	O
MERS	O
-	O
CoV	O
entry	O
into	O
human	O
bronchial	O
submucosal	O
gland	O
-	O
derived	O
Calu	O
-	O
3	O
cells	B-COMP
by	O
10	O
-	O
fold	O
and	O
virus	O
growth	O
by	O
270	O
-	O
fold	O
,	O
although	O
treatment	O
with	O
both	O
camostat	O
and	O
(	O
23	O
,	O
25	O
)-	O
trans	O
-	O
epoxysuccinyl	O
-	O
L	O
-	O
leucylamindo	O
-	O
3	O
-	O
methylbutane	O
ethyl	O
ester	O
,	O
a	O
cathepsin	O
inhibitor	O
,	O
or	O
treatment	O
with	O
leupeptin	O
,	O
an	O
inhibitor	O
of	O
cysteine	O
,	O
serine	O
,	O
and	O
threonine	O
peptidases	O
,	O
was	O
no	O
more	O
efficacious	O
than	O
treatment	O
with	O
camostat	O
alone	O
.	O

Further	O
,	O
these	O
inhibitors	O
were	O
not	O
efficacious	O
against	O
MERS	O
-	O
CoV	O
infection	O
of	O
MRC	O
-	O
5	O
and	O
WI	O
-	O
38	O
cells	B-COMP
,	O
which	O
were	O
derived	O
from	O
lung	O
,	O
but	O
these	O
characters	O
differed	O
from	O
those	O
of	O
mature	O
pneumocytes	O
.	O

To	O
measure	O
antibodies	B-COMP
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
four	O
common	O
non	O
-	O
SARS	O
HCoVs	O
,	O
recombinant	O
S	O
proteins	O
of	O
the	O
four	O
HCoVs	O
were	O
expressed	O
and	O
characterised	O
in	O
293	O
T	O
cell	B-COMP
.	O

The	O
hepatocyte	O
-	O
specific	O
IL	O
-	O
33	O
expression	O
was	O
down	O
-	O
regulated	O
in	O
NK	O
-	O
depleted	O
poly	O
(	O
I	O
:	O
C	O
)	O
treated	O
mice	O
suggesting	O
a	O
partial	O
regulation	O
of	O
IL	O
-	O
33	O
by	O
NK	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
To	O
investigate	O
effects	O
of	O
low	O
dietary	O
vitamin	O
A	O
content	O
on	O
antibody	B-COMP
responses	O
in	O
feedlot	O
calves	O
inoculated	O
with	O
an	O
inactivated	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
vaccine	O
.	O

After	O
the	O
BCoV	O
inoculation	O
and	O
booster	O
injections	O
,	O
predominantly	O
serum	B-COMP
IgG1	B-COMP
antibodies	B-COMP
were	O
induced	O
in	O
calves	O
fed	O
the	O
high	O
vitamin	O
A	O
diet	O
;	O
however	O
,	O
IgG1	B-COMP
titers	O
were	O
compromised	O
at	O
day	O
140	O
in	O
calves	O
fed	O
the	O
low	O
vitamin	O
A	O
diet	O
.	O

Dietary	O
vitamin	O
A	O
restriction	O
increases	O
marbling	O
in	O
feedlot	O
cattle	O
;	O
however	O
,	O
its	O
effect	O
on	O
antibody	B-COMP
responses	O
to	O
vaccines	O
is	O
unknown	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
by	O
anti	O
-	O
CD26	O
monoclonal	O
antibody	B-COMP
.	O

ABSTRACT	O
:	O
We	O
identified	O
the	O
domains	O
of	O
CD26	O
involved	O
in	O
the	O
binding	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
using	O
distinct	O
clones	O
of	O
anti	O
-	O
CD26	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
).	O

HA1	B-COMP
region	O
characterization	O
showed	O
an	O
overall	O
protein	O
identity	O
of	O
98	O
.	O
5	O
-	O
99	O
.	O
4	O
%.	O

ABSTRACT	O
:	O
A	O
12	O
-	O
year	O
-	O
old	O
,	O
3	O
.	O
5	O
-	O
kg	O
spayed	O
female	O
domestic	O
shorthair	O
cat	O
had	O
a	O
tracheal	O
mass	O
identified	O
as	O
malignant	O
B	O
-	O
cell	B-COMP
lymphoma	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
infection	O
induces	O
cell	B-COMP
cycle	O
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
via	O
p53	O
-	O
dependent	O
pathway	O
.	O

The	O
titer	O
of	O
anti	O
-	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
IgG	O
antibodies	B-COMP
was	O
increased	O
,	O
that	O
indicated	O
VZV	O
reactivation	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
),	O
although	O
VZV	O
DNA	O
PCR	O
was	O
not	O
detected	O
.	O

Because	O
coronavirus	O
spike	O
glycoproteins	O
(	O
S	O
)	O
mediate	O
virus	O
entry	O
,	O
affect	O
viral	O
host	B-COMP
range	O
,	O
and	O
elicit	O
neutralizing	O
antibodies	B-COMP
,	O
analyzing	O
the	O
functions	O
of	O
MERS	O
-	O
CoV	O
S	O
protein	O
is	O
a	O
high	O
research	O
priority	O
.	O

MERS	O
-	O
CoV	O
S	O
on	O
lentivirus	O
pseudovirions	O
mediated	O
entry	O
into	O
a	O
variety	O
of	O
cell	B-COMP
types	O
including	O
embryo	O
cells	B-COMP
from	O
New	O
World	O
Eptesicus	O
fuscus	O
bats	O
.	O

MERS	O
-	O
CoV	O
utilizes	O
the	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
host	B-COMP
cell	I-COMP
receptor	O
,	O
and	O
analysis	O
of	O
the	O
long	O
-	O
term	O
interaction	O
between	O
virus	O
and	O
receptor	O
provides	O
key	O
information	O
on	O
the	O
evolutionary	O
events	O
that	O
lead	O
to	O
the	O
viral	O
emergence	O
.	O

ABSTRACT	O
:	O
A	O
class	O
of	O
tripeptidyl	O
transition	O
state	O
inhibitors	O
containing	O
a	O
P1	O
glutamine	O
surrogate	O
,	O
a	O
P2	O
leucine	O
,	O
and	O
a	O
P3	O
arylalanines	O
,	O
was	O
found	O
to	O
potently	O
inhibit	O
Norwalk	O
virus	O
replication	O
in	O
enzyme	O
and	O
cell	B-COMP
based	O
assays	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
refractory	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
severe	O
malaria	O
.	O

Females	O
are	O
also	O
a	O
mosaic	O
of	O
cells	B-COMP
with	O
genes	O
from	O
either	O
paternal	O
or	O
maternal	O
X	B-COMP
chromosome	I-COMP
.	O

Thirteen	O
of	O
27	O
(	O
48	O
.	O
2	O
%)	O
hedgehog	O
sera	B-COMP
contained	O
non	O
-	O
neutralizing	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
.	O
The	O
animal	O
origins	O
of	O
this	O
betacoronavirus	O
clade	O
that	O
includes	O
MERS	O
-	O
CoV	O
may	O
thus	O
include	O
both	O
bat	O
and	O
nonbat	O
hosts	B-COMP
.	O

The	O
drug	O
is	O
systemically	O
distributed	O
,	O
accumulating	O
to	O
high	O
levels	O
in	O
the	O
serum	B-COMP
and	O
plasma	O
after	O
subcutaneous	O
delivery	O
.	O

Previous	O
work	O
studying	O
closely	O
related	O
betacoronaviruses	O
identified	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
)	O
and	O
convoluted	O
membranes	O
(	O
CMs	O
)	O
derived	O
from	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
in	O
infected	O
cells	B-COMP
.	O

In	O
response	O
,	O
we	O
developed	O
two	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
targeting	O
the	O
MERS	O
-	O
CoV	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
and	O
evaluated	O
these	O
assays	O
as	O
a	O
panel	O
with	O
a	O
previously	O
published	O
assay	O
targeting	O
the	O
region	O
upstream	O
of	O
the	O
MERS	O
-	O
CoV	O
envelope	B-COMP
gene	O
(	O
upE	O
)	O
for	O
the	O
detection	O
and	O
confirmation	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

An	O
enigma	O
in	O
understanding	O
the	O
contribution	O
of	O
T	O
cell	B-COMP
subsets	O
in	O
pathogenesis	O
resides	O
in	O
their	O
distinct	O
migration	O
pattern	O
across	O
the	O
BBB	O
(	O
blood	O
brain	O
barrier	O
).	O

Moreover	O
,	O
decreased	O
CD4	O
⁺	O
T	O
cell	B-COMP
recruitment	O
into	O
the	O
CNS	O
parenchyma	O
of	O
TIMP	O
-	O
1	O
deficient	O
mice	O
was	O
not	O
associated	O
with	O
impaired	O
T	O
cell	B-COMP
recruiting	O
chemokines	O
or	O
MMP	O
expression	O
,	O
and	O
no	O
compensation	O
by	O
other	O
TIMP	O
molecules	O
was	O
identified	O
.	O

Gene	O
ontology	O
category	O
,	O
KEGG	O
pathway	O
,	O
and	O
gene	O
interaction	O
networks	O
(	O
STRING	O
analysis	O
)	O
were	O
analyzed	O
to	O
identify	O
relationships	O
among	O
differentially	O
expressed	O
genes	O
involved	O
in	O
signal	O
transduction	O
,	O
cell	B-COMP
adhesion	O
,	O
immune	O
responses	O
,	O
apoptosis	O
regulation	O
,	O
positive	O
regulation	O
of	O
the	O
I	O
-	O
kappaB	O
kinase	O
/	O
NF	O
-	O
kappaB	O
cascade	O
and	O
response	O
to	O
cytokine	O
stimulus	O
.	O

Diagnosis	O
of	O
botulinum	O
toxin	O
poisoning	O
was	O
made	O
and	O
confirmed	O
by	O
serum	B-COMP
antibody	B-COMP
testing	O
in	O
the	O
mouse	O
inoculation	O
test	O
.	O

These	O
results	O
together	O
suggest	O
that	O
the	O
uORF	O
represses	O
ORF1	O
translation	O
yet	O
plays	O
a	O
beneficial	O
but	O
nonessential	O
role	O
in	O
coronavirus	O
replication	O
in	O
cell	B-COMP
culture	O
.	O

Based	O
on	O
the	O
morphology	O
of	O
virus	O
-	O
induced	O
membrane	B-COMP
rearrangements	O
,	O
we	O
propose	O
two	O
separate	O
subclasses	O
:	O
the	O
invaginated	O
vesicle	B-COMP
/	O
spherule	O
type	O
and	O
the	O
double	O
membrane	B-COMP
vesicle	B-COMP
type	O
.	O

We	O
then	O
conduct	O
a	O
comprehensive	O
phylogenetic	O
analysis	O
of	O
the	O
genera	O
Alpha	O
-	O
and	O
Betacoronavirus	O
,	O
to	O
show	O
that	O
bats	O
harbour	O
more	O
CoV	O
diversity	O
than	O
other	O
mammalian	O
hosts	B-COMP
and	O
are	O
widely	O
represented	O
in	O
most	O
,	O
but	O
not	O
all	O
parts	O
of	O
the	O
tree	O
of	O
mammalian	O
CoVs	O
.	O

Obtaining	O
a	O
U	O
.	O
S	O
.	O
PEDV	O
isolate	O
that	O
can	O
grow	O
efficiently	O
in	O
cell	B-COMP
culture	O
is	O
critical	O
for	O
investigating	O
pathogenesis	O
and	O
developing	O
diagnostic	O
assays	O
and	O
for	O
vaccine	O
development	O
.	O

Most	O
important	O
,	O
treatment	O
with	O
drugs	O
that	O
inhibited	O
NF	O
-	O
κB	O
activation	O
led	O
to	O
a	O
reduction	O
in	O
inflammation	O
and	O
lung	O
pathology	O
in	O
both	O
SARS	O
-	O
CoV	O
-	O
infected	O
cultured	O
cells	B-COMP
and	O
mice	O
and	O
significantly	O
increased	O
mouse	O
survival	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

Real	O
time	O
RT	O
-	O
qPCR	O
was	O
developed	O
for	O
further	O
transcriptional	O
profiling	O
of	O
three	O
genes	O
(	O
PD	O
-	O
1	O
,	O
PD	O
-	O
L1	O
and	O
A3H	O
)	O
in	O
infected	O
CRFK	O
cells	B-COMP
and	O
Peripheral	O
Blood	O
Mononuclear	O
Cells	B-COMP
(	O
PBMCs	O
)	O
from	O
healthy	O
and	O
FIP	O
-	O
diseased	O
cats	O
.	O

ABSTRACT	O
:	O
The	O
influence	O
of	O
CD25	O
(+)	O
CD4	O
(+)	O
regulatory	O
T	O
cells	B-COMP
(	O
Treg	O
)	O
on	O
acute	O
and	O
chronic	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
was	O
examined	O
using	O
a	O
glial	O
tropic	O
murine	O
coronavirus	O
.	O

Treg	O
in	O
the	O
CNS	O
were	O
highest	O
during	O
initial	O
T	O
cell	B-COMP
mediated	O
virus	O
control	O
,	O
decreased	O
and	O
then	O
remained	O
relatively	O
stable	O
during	O
persistence	O
.	O

We	O
investigated	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
using	O
a	O
staged	O
approach	O
involving	O
an	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
a	O
differential	O
recombinant	O
IFA	O
,	O
and	O
a	O
plaque	O
-	O
reduction	O
serum	B-COMP
neutralization	O
assay	O
.	O

Previous	O
studies	O
indicate	O
that	O
TGEV	O
infection	O
induces	O
cell	B-COMP
apoptosis	O
in	O
host	B-COMP
cells	B-COMP
.	O

Clearance	O
of	O
virus	O
was	O
associated	O
with	O
a	O
specific	O
antibody	B-COMP
response	O
against	O
the	O
nucleocapsid	B-COMP
of	O
BdCoV	O
HKU22	O
.	O

Mechanistically	O
,	O
TNFR1	O
deficiency	O
directly	O
impeded	O
the	O
serum	B-COMP
and	O
tissue	O
levels	O
of	O
fibrinogen	B-COMP
-	O
like	O
protein	O
2	O
(	O
FGL2	O
),	O
a	O
virus	O
-	O
induced	O
procoagulant	O
molecule	O
that	O
promotes	O
cell	B-COMP
apoptosis	O
.	O

Moreover	O
,	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cell	B-COMP
levels	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	B-COMP
were	O
assayed	O
by	O
flow	O
cytometry	O
.	O

The	O
clinical	O
indicators	O
,	O
including	O
the	O
initial	O
Balthazar	O
'	O
s	O
computed	O
tomography	O
(	O
CT	O
)	O
score	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
scores	O
on	O
1st	O
,	O
3rd	O
,	O
5th	O
and	O
7th	O
day	O
,	O
incidences	O
and	O
durations	O
of	O
complications	O
and	O
the	O
serum	B-COMP
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
levels	O
of	O
MMP	O
-	O
9	O
on	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
and	O
7th	O
day	O
,	O
were	O
recorded	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O

CQCQD	O
could	O
decrease	O
the	O
serum	B-COMP
MMP	O
-	O
9	O
to	O
relieve	O
the	O
severity	O
of	O
clinical	O
symptoms	O
and	O
prevent	O
the	O
development	O
of	O
multiple	O
organ	O
dysfunction	O
syndrome	O
in	O
patients	O
with	O
SAP	O
.	O

CONCLUSIONS	O
:	O
CQCQD	O
could	O
decrease	O
the	O
serum	B-COMP
MMP	O
-	O
9	O
to	O
relieve	O
the	O
severity	O
of	O
clinical	O
symptoms	O
and	O
prevent	O
the	O
development	O
of	O
multiple	O
organ	O
dysfunction	O
syndrome	O
in	O
patients	O
with	O
SAP	O
.	O

In	O
dairy	O
herds	O
,	O
milk	O
is	O
more	O
readily	O
collected	O
than	O
serum	B-COMP
.	O

Hence	O
,	O
in	O
order	O
to	O
investigate	O
the	O
test	O
agreement	O
between	O
serum	B-COMP
and	O
milk	O
,	O
both	O
serum	B-COMP
and	O
milk	O
samples	O
from	O
105	O
cows	O
in	O
27	O
dairy	O
herds	O
were	O
analyzed	O
in	O
parallel	O
for	O
presence	O
of	O
immunoglobulin	O
G	O
antibodies	B-COMP
to	O
BCV	O
and	O
BRSV	O
.	O

In	O
contrast	O
,	O
IL	O
-	O
2	O
-	O
or	O
IL	O
-	O
15	O
-	O
encoding	O
vectors	O
showed	O
a	O
substantially	O
lower	O
efficacy	O
in	O
CD8	O
(+)	O
T	O
cell	B-COMP
priming	O
and	O
failed	O
to	O
protect	O
the	O
host	B-COMP
once	O
tumors	O
had	O
been	O
established	O
.	O

This	O
study	O
detected	O
20	O
significant	O
(	O
P	O
<	O
1	O
.	O
16	O
×	O
10	O
(-	O
6	O
))	O
effect	O
single	O
nucleotide	O
polymorphisms	O
for	O
the	O
antibody	B-COMP
level	O
against	O
IBV	O
.	O

These	O
single	O
nucleotide	O
polymorphisms	O
were	O
distributed	O
on	O
five	O
chicken	O
chromosomes	B-COMP
(	O
GGA	O
),	O
involving	O
GGA1	O
,	O
GGA3	O
,	O
GGA5	O
,	O
GGA8	O
,	O
and	O
GGA9	O
.	O

In	O
addition	O
,	O
the	O
major	O
loci	O
significantly	O
associated	O
with	O
the	O
antibody	B-COMP
level	O
against	O
IBV	O
on	O
GGA1	O
and	O
GGA5	O
could	O
explain	O
about	O
12	O
%	O
and	O
13	O
%	O
of	O
the	O
phenotypic	O
variation	O
,	O
respectively	O
.	O

In	O
the	O
first	O
case	O
(	O
a	O
65	O
-	O
year	O
-	O
old	O
man	O
),	O
high	O
levels	O
of	O
anti	O
-	O
C	O
.	O
pneumoniae	O
antibodies	B-COMP
(	O
IgG	O
and	O
IgA	O
)	O
were	O
detected	O
on	O
admission	O
,	O
and	O
the	O
anti	O
-	O
C	O
.	O
pneumoniae	O
IgA	O
level	O
rose	O
by	O
Day	O
30	O
.	O

Neither	O
of	O
the	O
patients	O
displayed	O
other	O
pathogen	O
-	O
specific	O
antigens	O
or	O
antibodies	B-COMP
.	O

BV	O
-	O
Dual	O
-	O
S1	O
elicited	O
stronger	O
humoral	O
and	O
cell	B-COMP
-	O
mediated	O
immune	O
responses	O
,	O
and	O
showed	O
greater	O
capacity	O
for	O
induction	O
of	O
cytotoxic	O
T	O
lymphocyte	O
responses	O
,	O
compared	O
with	O
Ac	O
-	O
CMV	O
-	O
S1	O
in	O
specific	O
pathogen	O
-	O
free	O
chickens	O
.	O

Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
infected	O
sera	B-COMP
from	O
cattle	O
had	O
no	O
cross	O
-	O
reactivity	O
in	O
MERS	O
-	O
CoV	O
ppNT	O
or	O
MNT	O
,	O
while	O
many	O
dromedary	O
camels	O
’	O
sera	B-COMP
reacted	O
to	O
both	O
BCoV	O
and	O
MERS	O
-	O
CoV	O
.	O
Some	O
nevertheless	O
displayed	O
specific	O
serologic	O
reaction	O
profiles	O
to	O
MERS	O
-	O
CoV	O
.	O

All	O
camels	O
had	O
MERS	O
-	O
CoV	O
spike	O
-	O
binding	O
antibodies	B-COMP
that	O
correlated	O
well	O
with	O
the	O
presence	O
of	O
neutralising	O
antibodies	B-COMP
to	O
MERS	O
-	O
CoV	O
.	O
Our	O
study	O
provides	O
virological	O
confirmation	O
of	O
MERS	O
-	O
CoV	O
in	O
camels	O
and	O
suggests	O
a	O
recent	O
outbreak	O
affecting	O
both	O
human	O
beings	O
and	O
camels	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
a	O
candidate	O
SARS	O
vaccine	O
antigen	O
consisting	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
can	O
induce	O
potent	O
neutralizing	O
antibody	B-COMP
responses	O
and	O
protection	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
vaccinated	O
animals	O
.	O

ABSTRACT	O
:	O
Hemagglutinin	O
-	O
esterases	O
(	O
HE	O
)	O
are	O
viral	B-COMP
envelope	I-COMP
proteins	O
present	O
in	O
some	O
members	O
from	O
the	O
toro	O
-,	O
corona	O
-	O
and	O
orthomyxovirus	O
families	O
,	O
all	O
related	O
with	O
enteric	O
and	O
/	O
or	O
respiratory	O
tract	O
infections	O
.	O

TITLE	O
:	O
In	O
-	O
vitro	O
renal	O
epithelial	O
cell	B-COMP
infection	O
reveals	O
a	O
viral	O
kidney	O
tropism	O
as	O
a	O
potential	O
mechanism	O
for	O
acute	O
renal	O
failure	O
during	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
Coronavirus	O
infection	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
decrease	O
in	O
metabolic	O
syndrome	O
scores	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
003	O
)	O
for	O
AER	B-COMP
(-	O
0	O
.	O
59	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
-	O
0	O
.	O
21	O
)	O
and	O
AER	B-COMP
+	O
RES	O
(-	O
0	O
.	O
79	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
40	O
to	O
-	O
0	O
.	O
35	O
),	O
both	O
being	O
significant	O
(	O
P	O
≤	O
0	O
.	O
02	O
)	O
versus	O
control	O
(	O
0	O
.	O
26	O
,	O
95	O
%	O
CI	O
=	O
-	O
0	O
.	O
58	O
to	O
0	O
.	O
40	O
)	O
and	O
RES	O
(-	O
0	O
.	O
13	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
0	O
.	O
24	O
).	O

Serum	B-COMP
levels	O
of	O
pro	O
-	O
inflammatory	O
,	O
regulatory	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
were	O
measured	O
in	O
each	O
individual	O
participant	O
.	O

Both	O
S	O
proteins	O
were	O
found	O
in	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
.	O

The	O
virus	O
load	O
decreased	O
when	O
any	O
of	O
the	O
Ah	O
,	O
Ns	O
or	O
Cs	O
extracts	O
was	O
added	O
to	O
the	O
CoV	O
infected	O
cells	B-COMP
with	O
Ah	O
extract	O
treatment	O
leading	O
to	O
undetectable	O
virus	O
load	O
for	O
both	O
6	O
and	O
8	O
hpi	O
.	O

JHMV	O
infection	O
leads	O
to	O
increased	O
cell	B-COMP
death	O
and	O
dampens	O
IFN	O
-	O
γ	O
-	O
induced	O
MHC	O
class	O
II	O
expression	O
.	O

TITLE	O
:	O
BST2	O
/	O
CD317	O
counteracts	O
human	O
coronavirus	O
229E	O
productive	O
infection	O
by	O
tethering	O
virions	B-COMP
at	O
the	O
cell	B-COMP
surface	I-COMP
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
--	O
forms	O
and	O
functions	O
.	O

TITLE	O
:	O
The	O
ORF4b	O
-	O
encoded	O
accessory	O
proteins	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
two	O
related	O
bat	O
coronaviruses	O
localize	O
to	O
the	O
nucleus	B-COMP
and	O
inhibit	O
innate	O
immune	O
signalling	O
.	O

A	O
hallmark	O
of	O
highly	O
pathogenic	O
respiratory	O
viruses	O
is	O
their	O
ability	O
to	O
evade	O
the	O
innate	O
immune	O
response	O
of	O
the	O
host	B-COMP
.	O

We	O
immunized	O
cats	O
with	O
peptides	O
containing	O
T	O
-	O
helper	O
(	O
Th	O
)	O
1	O
epitopes	O
derived	O
from	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
the	O
type	O
I	O
FIPV	O
KU	O
-	O
2	O
strain	O
(	O
NP7	O
and	O
NP8	O
)	O
with	O
feline	O
CpG	O
-	O
oligodeoxynucleotides	O
(	O
fCpG	O
-	O
ODNs	O
)	O
as	O
a	O
vaccine	O
adjuvant	O
.	O

The	O
developed	O
isothermal	O
real	O
-	O
time	O
RT	O
-	O
RPA	B-COMP
is	O
ideal	O
for	O
rapid	O
mobile	O
molecular	O
MERS	O
-	O
CoV	O
monitoring	O
in	O
acute	O
patients	O
and	O
may	O
also	O
facilitate	O
the	O
search	O
for	O
the	O
animal	O
reservoir	O
of	O
MERS	O
-	O
CoV	O
.	O

We	O
report	O
the	O
successful	O
rehabilitation	O
of	O
an	O
8	O
-	O
year	O
-	O
old	O
boy	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

A	O
child	O
who	O
is	O
critically	O
ill	O
may	O
safely	O
perform	O
active	O
rehabilitation	O
while	O
on	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

Preventing	O
recognition	O
by	O
the	O
host	B-COMP
immune	O
response	O
represents	O
a	O
critical	O
aspect	O
necessary	O
for	O
successful	O
viral	O
infection	O
.	O

ABSTRACT	O
:	O
Mesenchymal	O
stem	O
/	O
stromal	O
cells	B-COMP
(	O
MSCs	O
)	O
offer	O
considerable	O
promise	O
as	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

This	O
work	O
describes	O
the	O
interactions	O
of	O
the	O
two	O
RNA	O
-	O
binding	O
domains	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
of	O
a	O
model	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
was	O
more	O
frequently	O
needed	O
in	O
H1N1	O
-	O
ARDS	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
IFN	O
-	O
antagonizing	O
activity	O
is	O
specific	O
to	O
SARS	O
coronavirus	O
M	O
protein	O
and	O
is	O
mediated	O
through	O
its	O
first	O
transmembrane	B-COMP
domain	O
(	O
TM1	O
)	O
located	O
at	O
the	O
N	O
terminus	O
.	O

Recently	O
,	O
the	O
MERS	O
-	O
CoV	O
and	O
its	O
neutralizing	O
antibodies	B-COMP
were	O
detected	O
in	O
dromedary	O
camels	O
.	O

Recombinant	O
FCoV	O
nucleocapsid	B-COMP
protein	O
(	O
rNP	B-COMP
)	O
was	O
used	O
as	O
a	O
conjugate	O
or	O
test	O
line	O
in	O
all	O
3	O
ICA	O
kits	O
(	O
CJIgG	O
/	O
TNP	O
,	O
CJNP	O
/	O
TNP	O
,	O
and	O
CJNP	O
/	O
TPA	O
).	O

The	O
development	O
of	O
simple	O
antibody	B-COMP
test	O
methods	O
using	O
the	O
principle	O
of	O
ICA	O
(	O
CJNP	O
/	O
TPA	O
)	O
for	O
other	O
coronavirus	O
and	O
feline	O
viral	O
infections	O
is	O
expected	O
in	O
the	O
future	O
.	O

Upon	O
binding	O
of	O
antibodies	B-COMP
,	O
these	O
proteins	O
are	O
quickly	O
internalised	O
through	O
a	O
new	O
clathrin	O
-	O
and	O
caveolae	B-COMP
-	O
independent	O
internalisation	O
pathway	O
.	O

Myosin	O
6	O
co	O
-	O
localised	O
with	O
the	O
internalising	O
complexes	O
during	O
passage	O
through	O
the	O
cortical	O
actin	O
,	O
were	O
it	O
might	O
play	O
a	O
role	O
in	O
moving	O
or	O
disintegrating	O
actin	B-COMP
filaments	I-COMP
,	O
to	O
overcome	O
the	O
actin	O
barrier	O
.	O

It	O
will	O
therefore	O
be	O
critical	O
to	O
clarify	O
how	O
MERS	O
-	O
CoV	O
cripples	O
the	O
host	B-COMP
proteins	O
that	O
sense	O
viruses	O
and	O
to	O
compare	O
MERS	O
-	O
CoV	O
with	O
its	O
ancestral	O
viruses	O
in	O
bats	O
in	O
the	O
counteraction	O
of	O
virus	O
sensing	O
.	O

Herein	O
,	O
four	O
representative	O
Ag	O
NMs	O
including	O
spherical	O
Ag	O
nanoparticles	O
(	O
Ag	O
NPs	O
,	O
NM	O
-	O
300	O
),	O
two	O
kinds	O
of	O
silver	O
nanowires	O
(	O
XFJ011	O
)	O
and	O
silver	O
colloids	O
(	O
XFJ04	O
)	O
were	O
selected	O
to	O
study	O
their	O
inhibitory	O
effect	O
on	O
TGEV	O
-	O
induced	O
host	B-COMP
cell	I-COMP
infection	O
in	O
vitro	O
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
,	O
quick	O
,	O
and	O
safe	O
cell	B-COMP
adhesion	O
inhibition	O
assay	O
was	O
developed	O
to	O
determine	O
the	O
potential	O
cellular	B-COMP
binding	O
site	O
on	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

Glycoforms	O
of	O
serum	B-COMP
IgG1	B-COMP
and	O
IgG2	B-COMP
were	O
determined	O
separately	O
by	O
liquid	O
chromatography	O
mass	O
spectrometry	O
.	O

IVIg	O
preparations	O
contained	O
relatively	O
high	O
levels	O
of	O
galactosylated	O
and	O
sialylated	O
IgG	O
Fc	O
glycoforms	O
compared	O
with	O
serum	B-COMP
IgG	O
in	O
patients	O
.	O

Moreover	O
,	O
the	O
expression	O
of	O
TGEV	O
N	O
gene	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	B-COMP
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	O
c	O
,	O
followed	O
by	O
activation	O
of	O
caspase	O
-	O
3	O
,	O
resulting	O
in	O
cell	B-COMP
apoptosis	O
in	O
the	O
transfected	O
PK	O
-	O
15	O
cells	B-COMP
following	O
cell	B-COMP
cycle	O
arrest	O
.	O

Quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qRTPCR	O
)	O
was	O
performed	O
after	O
extraction	O
of	O
RNA	O
from	O
BAL	O
cells	B-COMP
of	O
MERS	O
-	O
CoV	O
infected	O
patients	O
and	O
control	O
patients	O
.	O

Host	B-COMP
recognition	O
of	O
viral	O
dsRNA	O
determines	O
outcome	O
in	O
the	O
early	O
stage	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

However	O
,	O
even	O
the	O
low	O
-	O
affinity	O
receptors	O
could	O
hypersensitize	O
cells	B-COMP
to	O
infection	O
when	O
an	O
S	O
-	O
cleaving	O
protease	O
(	O
s	O
)	O
was	O
present	O
,	O
indicating	O
that	O
affinity	O
thresholds	O
for	O
virus	O
entry	O
must	O
be	O
considered	O
in	O
the	O
context	O
of	O
host	B-COMP
-	O
cell	B-COMP
proteolytic	O
environments	O
.	O

From	O
January	O
2007	O
to	O
December	O
2009	O
,	O
19	O
adult	O
patients	O
required	O
extracorporeal	O
membrane	B-COMP
oxygenator	O
support	O
after	O
cardiac	O
surgery	O
or	O
catheter	O
interventions	O
.	O

The	O
patient	O
required	O
salvage	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

Thus	O
,	O
timely	O
identification	O
of	O
new	O
MERS	O
cases	O
followed	O
by	O
their	O
quarantine	O
,	O
combined	O
with	O
measures	O
to	O
limit	O
spread	O
of	O
the	O
virus	O
from	O
the	O
(	O
intermediate	O
)	O
host	B-COMP
to	O
humans	O
,	O
may	O
be	O
crucial	O
in	O
controlling	O
the	O
outbreak	O
of	O
this	O
emerging	O
CoV	O
.	O

Bioinformatics	O
analysis	O
showed	O
that	O
IBV	O
,	O
NDV	O
,	O
and	O
AIV	O
H9	O
induced	O
similar	O
core	O
host	B-COMP
responses	O
involved	O
in	O
biosynthetic	O
,	O
catabolic	O
,	O
metabolic	O
,	O
signal	O
transduction	O
,	O
transport	O
,	O
cytoskeleton	B-COMP
organization	O
,	O
macromolecular	B-COMP
complex	I-COMP
assembly	O
,	O
cell	B-COMP
death	O
,	O
response	O
to	O
stress	O
,	O
and	O
immune	O
system	O
process	O
.	O

The	O
changes	O
in	O
the	O
expression	O
of	O
genes	O
related	O
to	O
eggshell	O
formation	O
(	O
collagen	B-COMP
types	O
I	O
and	O
V	O
,	O
and	O
CaBP	O
-	O
D28K	O
),	O
densities	O
of	O
cytotoxic	O
cells	B-COMP
(	O
CD8	O
(+)	O
and	O
TCR	B-COMP
-	O
γδ	O
(+)	O
T	O
cells	B-COMP
),	O
and	O
gene	O
expression	O
of	O
molecules	O
related	O
to	O
cytotoxic	O
immunoreaction	O
(	O
B	O
-	O
NK	O
,	O
perforin	O
,	O
granzyme	O
,	O
and	O
IL	O
-	O
2	O
)	O
and	O
proinflammatory	O
cytokines	O
(	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
and	O
IFN	O
-	O
γ	O
)	O
were	O
examined	O
by	O
quantitative	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

Gene	O
expression	O
of	O
IL	O
-	O
1β	O
and	O
IL	O
-	O
6receptors	O
in	O
the	O
tubular	O
gland	O
cells	B-COMP
of	O
the	O
isthmus	O
and	O
uterus	O
was	O
analyzed	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
.	O

The	O
frequencies	O
of	O
CD8	O
(+)	O
cells	B-COMP
and	O
TCR	B-COMP
-	O
γδ	O
(+)	O
T	O
cells	B-COMP
in	O
the	O
isthmus	O
and	O
uterus	O
were	O
significantly	O
higher	O
in	O
the	O
aIBV	O
group	O
than	O
in	O
the	O
control	O
group	O
.	O

The	O
expression	O
of	O
IL	O
-	O
6	O
receptor	O
,	O
but	O
not	O
IL	O
-	O
1β	O
receptor	O
,	O
was	O
identified	O
in	O
the	O
tubular	O
gland	O
cells	B-COMP
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

We	O
found	O
that	O
expression	O
of	O
the	O
membrane	B-COMP
-	O
anchored	O
PLpro	O
domain	O
(	O
PLpro	O
-	O
TM	O
)	O
from	O
SARS	O
-	O
CoV	O
inhibits	O
STING	O
/	O
TBK1	O
/	O
IKKε	O
-	O
mediated	O
activation	O
of	O
type	O
I	O
IFNs	O
and	O
disrupts	O
the	O
phosphorylation	O
and	O
dimerization	O
of	O
IRF3	O
,	O
which	O
are	O
activated	O
by	O
STING	O
and	O
TBK1	O
.	O

These	O
results	O
collectively	O
point	O
to	O
a	O
new	O
mechanism	O
used	O
by	O
SARS	O
-	O
CoV	O
through	O
which	O
PLpro	O
negatively	O
regulates	O
IRF3	O
activation	O
by	O
interaction	O
with	O
STING	O
-	O
TRAF3	O
-	O
TBK1	O
complex	O
,	O
yielding	O
a	O
SARS	O
-	O
CoV	O
countermeasure	O
against	O
host	B-COMP
innate	O
immunity	O
.	O

Previous	O
studies	O
of	O
coronavirus	O
replication	O
complex	O
organization	O
and	O
protein	O
interactions	O
have	O
utilized	O
protein	O
overexpression	O
studies	O
and	O
immunofluorescence	O
of	O
fixed	O
cells	B-COMP
.	O

Although	O
a	O
small	O
number	O
of	O
camels	O
have	O
been	O
found	O
to	O
have	O
positive	O
nasal	O
swabs	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
to	O
carry	O
antibody	B-COMP
against	O
MERS	O
-	O
CoV	O
,	O
the	O
transmission	O
route	O
and	O
the	O
intermediary	O
animal	O
source	O
remain	O
uncertain	O
amongst	O
the	O
sporadic	O
primary	O
cases	O
.	O

Furthermore	O
,	O
by	O
utilizing	O
fusion	O
proteins	O
with	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
),	O
deletion	O
mutations	O
or	O
site	O
-	O
directed	O
mutagenesis	O
of	O
PEDV	O
N	O
protein	O
,	O
coupled	O
with	O
live	O
cell	B-COMP
imaging	O
and	O
confocal	O
microscopy	O
,	O
it	O
was	O
revealed	O
that	O
,	O
a	O
region	O
spanning	O
amino	O
acids	O
(	O
aa	O
),	O
71	O
-	O
90	O
in	O
region	O
1	O
of	O
the	O
N	O
protein	O
was	O
sufficient	O
for	O
nucleolar	O
localization	O
and	O
R87	O
and	O
R89	O
were	O
critical	O
for	O
its	O
function	O
.	O

Instead	O
,	O
delayed	O
MHV	O
-	O
3	O
replication	O
coincided	O
with	O
high	O
levels	O
of	O
cellular	B-COMP
ISGylation	O
.	O

Most	O
(	O
632	O
/	O
651	O
,	O
97	O
.	O
1	O
%)	O
camels	O
had	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
.	O
This	O
result	O
included	O
all	O
151	O
serum	B-COMP
samples	O
obtained	O
in	O
2003	O
.	O

Ten	O
contacts	O
experienced	O
mild	O
symptoms	O
,	O
but	O
test	O
results	O
for	O
respiratory	O
and	O
serum	B-COMP
samples	O
were	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O
Serologic	O
testing	O
was	O
done	O
for	O
53	O
(	O
75	O
%)	O
of	O
71	O
nonsymptomatic	O
contacts	O
;	O
all	O
results	O
were	O
negative	O
.	O

Notably	O
,	O
ectopically	O
expressed	O
μ1	O
and	O
σ1	O
induced	O
similar	O
pathological	O
apoptosis	O
,	O
independent	O
of	O
BYD1	O
infection	O
,	O
in	O
host	B-COMP
cells	B-COMP
in	O
which	O
they	O
were	O
expressed	O
,	O
which	O
suggests	O
that	O
μ1	O
and	O
σ1	O
are	O
both	O
apoptotic	O
virulence	O
factors	O
.	O

TITLE	O
:	O
Human	O
adult	O
bone	O
marrow	O
-	O
derived	O
stem	O
cells	B-COMP
decrease	O
severity	O
of	O
lipopolysaccharide	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
sheep	O
.	O

Even	O
though	O
the	O
majority	O
of	O
the	O
developed	O
assays	O
showed	O
high	O
sensitivity	O
and	O
specificity	O
,	O
numerous	O
studies	O
reported	O
on	O
cross	O
-	O
reactive	O
antibodies	B-COMP
to	O
antigens	O
from	O
wide	O
-	O
spread	O
common	O
cold	O
associated	O
CoVs	O
.	O

Antibody	B-COMP
titer	O
against	O
Newcastle	O
disease	O
(	O
ND	O
),	O
infectious	O
bursal	O
disease	O
(	O
IBD	O
),	O
and	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
T2	O
and	O
T3	O
groups	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
detection	O
of	O
IBV	O
vaccine	O
virus	O
early	O
after	O
administration	O
,	O
regardless	O
of	O
strain	O
or	O
route	O
,	O
correlated	O
with	O
protection	O
against	O
homologous	O
challenge	O
and	O
may	O
thus	O
be	O
a	O
good	O
indicator	O
of	O
vaccine	O
efficacy	O
in	O
the	O
field	O
because	O
humoral	O
antibody	B-COMP
titers	O
are	O
typically	O
low	O
or	O
undetectable	O
after	O
vaccination	O
.	O

TITLE	O
:	O
Competitive	O
fitness	O
in	O
coronaviruses	O
is	O
not	O
correlated	O
with	O
size	O
or	O
number	O
of	O
double	O
-	O
membrane	B-COMP
vesicles	B-COMP
under	O
reduced	O
-	O
temperature	O
growth	O
conditions	O
.	O

For	O
the	O
first	O
time	O
,	O
this	O
directly	O
demonstrates	O
that	O
replication	O
and	O
organelle	B-COMP
formation	O
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
studied	O
separately	O
during	O
infection	O
with	O
positive	O
-	O
stranded	O
RNA	O
virus	O
.	O

Specifically	O
,	O
the	O
potential	O
to	O
explore	O
and	O
exploit	O
this	O
newfound	O
relationship	O
to	O
study	O
coevolution	O
and	O
cross	O
species	O
transmission	O
together	O
with	O
fundamental	O
aspects	O
of	O
poxvirus	O
host	B-COMP
tropism	O
as	O
well	O
as	O
bat	O
virology	O
and	O
immunology	O
.	O

We	O
demonstrated	O
minimal	O
delay	O
and	O
retention	O
of	O
unprimed	O
neutrophils	O
transiting	O
the	O
healthy	O
human	O
pulmonary	O
vasculature	O
,	O
but	O
marked	O
retention	O
of	O
primed	O
neutrophils	O
;	O
these	O
latter	O
cells	B-COMP
then	O
'	O
deprime	O
'	O
and	O
are	O
re	O
-	O
released	O
into	O
the	O
systemic	O
circulation	O
.	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
and	O
antiviral	O
effects	O
of	O
indirubin	O
derivatives	O
in	O
influenza	O
A	O
(	O
H5N1	O
)	O
virus	O
infected	O
primary	O
human	O
peripheral	O
blood	O
-	O
derived	O
macrophages	O
and	O
alveolar	O
epithelial	O
cells	B-COMP
.	O

Although	O
many	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
coronaviruses	O
(	O
SARS	O
-	O
like	O
CoVs	O
)	O
have	O
been	O
discovered	O
in	O
bats	O
worldwide	O
,	O
there	O
are	O
significant	O
different	O
genic	O
structures	O
,	O
particularly	O
in	O
the	O
S1	O
domain	O
,	O
which	O
are	O
responsible	O
for	O
host	B-COMP
tropism	O
determination	O
,	O
between	O
bat	O
SARS	O
-	O
like	O
CoVs	O
and	O
human	O
SARS	O
CoVs	O
,	O
indicating	O
that	O
most	O
reported	O
bat	O
SARS	O
-	O
like	O
CoVs	O
are	O
not	O
the	O
progenitors	O
of	O
human	O
SARS	O
CoV	O
.	O
We	O
have	O
identified	O
diverse	O
alphacoronaviruses	O
and	O
a	O
close	O
relative	O
(	O
LYRa11	O
)	O
to	O
SARS	O
CoV	O
in	O
bats	O
collected	O
in	O
Yunnan	O
,	O
China	O
.	O

MERS	O
-	O
CoV	O
patients	O
were	O
more	O
likely	O
to	O
have	O
a	O
normal	O
white	O
blood	O
cell	B-COMP
count	O
than	O
the	O
control	O
group	O
(	O
82	O
%	O
vs	O
52	O
%;	O
OR	O
,	O
4	O
.	O
33	O
;	O
P	O
=	O
.	O
029	O
).	O

TITLE	O
:	O
Impact	O
of	O
serum	B-COMP
biomarkers	O
and	O
clinical	O
factors	O
on	O
intensive	O
care	O
unit	O
mortality	O
and	O
6	O
-	O
month	O
outcome	O
in	O
relatively	O
healthy	O
patients	O
with	O
severe	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Furthermore	O
,	O
passive	O
immunization	O
(	O
post	O
-	O
infection	O
)	O
with	O
homologous	O
(	O
murine	O
)	O
anti	O
-	O
SARS	O
-	O
CoV	O
antiserum	O
showed	O
greater	O
elimination	O
efficacy	O
against	O
SARS	O
-	O
CoV	O
than	O
that	O
with	O
heterologous	O
(	O
rabbit	O
)	O
antiserum	O
,	O
despite	O
the	O
use	O
of	O
equivalent	O
titers	O
of	O
neutralizing	O
antibodies	B-COMP
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
the	O
availability	O
of	O
existing	O
nucleic	B-COMP
acid	O
amplification	O
-	O
based	O
diagnostic	O
methods	O
for	O
MERS	O
-	O
CoV	O
infections	O
by	O
providing	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
kit	O
,	O
including	O
an	O
internal	O
control	O
and	O
two	O
target	O
regions	O
recommended	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
).	O

ABSTRACT	O
:	O
Viral	O
respiratory	O
infections	O
(	O
VRIs	O
)	O
are	O
frequent	O
after	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
and	O
constitute	O
a	O
potential	O
cause	O
of	O
mortality	O
.	O

The	O
spike	O
glycoprotein	O
is	O
the	O
major	O
immunodominant	O
antigen	O
of	O
coronaviruses	O
and	O
has	O
proven	O
to	O
be	O
an	O
excellent	O
target	O
for	O
vaccine	O
designs	O
that	O
seek	O
to	O
block	O
coronavirus	O
entry	O
and	O
promote	O
antibody	B-COMP
targeting	O
of	O
infected	O
cells	B-COMP
.	O

We	O
compared	O
dynamics	O
of	O
vaccine	O
viral	O
subpopulations	O
,	O
viral	O
loads	O
,	O
persistence	O
in	O
trachea	O
and	O
cloaca	O
,	O
and	O
the	O
magnitude	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
1BV	O
)-	O
specific	O
antibody	B-COMP
induction	O
after	O
vaccination	O
with	O
two	O
commercial	O
ArkDPI	O
-	O
derived	O
Arkansas	O
(	O
Ark	O
)	O
serotype	O
vaccines	O
.	O

Their	O
interaction	O
with	O
receptors	O
expressed	O
on	O
cells	B-COMP
located	O
in	O
the	O
respiratory	O
tract	O
is	O
an	O
essential	O
first	O
step	O
in	O
the	O
infection	O
.	O

Although	O
the	O
catalytic	O
activity	O
of	O
the	O
ACE2	O
,	O
APN	O
,	O
and	O
DPP4	O
peptidases	O
is	O
not	O
required	O
for	O
virus	O
entry	O
,	O
co	O
-	O
expression	O
of	O
other	O
host	B-COMP
proteases	O
allows	O
efficient	O
viral	O
entry	O
.	O

The	O
independence	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
enhancement	O
effect	O
on	O
VLP	B-COMP
production	O
from	O
its	O
viral	O
packaging	O
capacity	O
suggests	O
a	O
distinct	O
SARS	O
-	O
CoV	O
E	O
role	O
in	O
virus	O
assembly	O
.	O

Entry	O
of	O
MERS	O
-	O
CoV	O
into	O
target	O
cells	B-COMP
depends	O
on	O
binding	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	B-COMP
envelope	I-COMP
spike	O
glycoprotein	O
to	O
the	O
cellular	B-COMP
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

We	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
two	O
potent	O
human	O
RBD	O
-	O
specific	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
(	O
MERS	O
-	O
4	O
and	O
MERS	O
-	O
27	O
)	O
derived	O
from	O
single	O
-	O
chain	O
variable	O
region	O
fragments	O
of	O
a	O
nonimmune	O
human	O
antibody	B-COMP
library	O
.	O

ABSTRACT	O
:	O
ABSTRACT	O
Complete	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
genome	O
sequences	O
were	O
obtained	O
from	O
nasal	O
swabs	O
of	O
dromedary	O
camels	O
sampled	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
through	O
direct	O
analysis	O
of	O
nucleic	B-COMP
acid	O
extracts	O
or	O
following	O
virus	O
isolation	O
in	O
cell	B-COMP
culture	O
.	O

Antibodies	B-COMP
to	O
and	O
viral	O
nucleic	B-COMP
acids	O
of	O
MERS	O
-	O
CoV	O
have	O
been	O
found	O
in	O
dromedaries	O
,	O
suggesting	O
the	O
possibility	O
that	O
they	O
may	O
serve	O
as	O
a	O
reservoir	O
or	O
vector	O
for	O
human	O
infection	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	B-COMP
protein	O
ion	O
channel	O
activity	O
promotes	O
virus	O
fitness	O
and	O
pathogenesis	O
.	O

The	O
avidity	O
for	O
IgG1	B-COMP
m336	O
,	O
m337	O
,	O
and	O
m338	O
was	O
even	O
higher	O
:	O
99	O
,	O
820	O
,	O
and	O
560	O
pM	O
,	O
respectively	O
.	O

Peptide	O
modification	O
by	O
altering	O
the	O
anchor	O
residue	O
facilitates	O
increased	O
binding	O
affinity	O
and	O
may	O
elicit	O
T	O
cells	B-COMP
with	O
increased	O
functional	O
avidity	O
toward	O
the	O
native	O
epitope	O
"("""	O
heteroclitic	O
""")."	O

Using	O
these	O
assays	O
,	O
the	O
expression	O
of	O
each	O
of	O
the	O
tested	O
genes	O
could	O
be	O
detected	O
in	O
ferret	O
lymph	O
node	O
cells	B-COMP
stimulated	O
with	O
mitogens	O
or	O
infected	O
with	O
influenza	O
virus	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Human	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
are	O
candidates	O
for	O
prophylactic	O
and	O
therapeutic	O
interventions	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
.	O

He	O
was	O
found	O
to	O
have	O
severely	O
low	O
serum	B-COMP
folate	O
and	O
megaloblastic	O
anemia	O
,	O
which	O
was	O
at	O
first	O
suspected	O
to	O
cause	O
his	O
dyspnea	O
.	O

Together	O
with	O
histological	O
hemophagocytosis	O
and	O
high	O
level	O
of	O
serum	B-COMP
iron	O
and	O
ferritin	O
,	O
DAD	O
was	O
considered	O
to	O
be	O
caused	O
by	O
hypercytokinemia	O
triggered	O
by	O
the	O
presence	O
of	O
EBV	O
-	O
positive	O
diffuse	O
large	O
B	O
-	O
cell	B-COMP
lymphoma	O
.	O

We	O
considered	O
that	O
low	O
serum	B-COMP
folate	O
in	O
this	O
case	O
was	O
not	O
by	O
the	O
low	O
intake	O
but	O
by	O
increased	O
consumption	O
of	O
folate	O
by	O
rapid	O
progression	O
of	O
the	O
lymphoma	O
.	O

We	O
report	O
here	O
a	O
case	O
of	O
a	O
young	O
man	O
affected	O
by	O
multiple	O
pathological	O
symptomatic	O
vertebral	O
fractures	O
at	O
the	O
thoraco	O
-	O
lumbar	O
junction	O
,	O
secondary	O
to	O
a	O
well	O
controlled	O
but	O
severe	O
form	O
of	O
sickle	O
cell	B-COMP
disease	O
.	O

The	O
ability	O
of	O
macrophages	O
to	O
support	O
or	O
clear	O
the	O
virus	O
infection	O
,	O
as	O
well	O
as	O
the	O
host	B-COMP
cellular	B-COMP
immune	O
responses	O
,	O
did	O
not	O
significantly	O
differ	O
between	O
WT	O
and	O
α7	O
(-/-)	O
mice	O
.	O

Some	O
drugs	O
that	O
had	O
a	O
well	O
-	O
defined	O
cellular	B-COMP
pathway	O
as	O
target	O
were	O
included	O
.	O

Although	O
poorly	O
understood	O
,	O
it	O
has	O
long	O
been	O
recognized	O
that	O
host	B-COMP
regulation	O
of	O
virus	O
-	O
associated	O
disease	O
severity	O
is	O
multigenic	O
.	O

These	O
findings	O
indicate	O
that	O
NPCs	O
transplanted	O
into	O
an	O
inflammatory	O
demyelinating	O
microenvironment	O
participate	O
directly	O
in	O
therapeutic	O
outcome	O
through	O
the	O
wrapping	O
of	O
myelin	B-COMP
around	O
damaged	O
neurons	O
.	O

TITLE	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
therapy	O
of	O
a	O
severely	O
injured	O
patient	O
after	O
secondary	O
survey	O
.	O

In	O
both	O
cohorts	O
,	O
we	O
identified	O
a	O
hyperinflammatory	O
subphenotype	O
(	O
phenotype	O
2	O
)	O
that	O
was	O
characterised	O
by	O
higher	O
plasma	O
concentrations	O
of	O
inflammatory	O
biomarkers	O
,	O
a	O
higher	O
prevalence	O
of	O
vasopressor	O
use	O
,	O
lower	O
serum	B-COMP
bicarbonate	O
concentrations	O
,	O
and	O
a	O
higher	O
prevalence	O
of	O
sepsis	O
than	O
phenotype	O
1	O
.	O

α	O
-	O
Fodrin	O
protein	O
was	O
used	O
for	O
further	O
analysis	O
and	O
western	O
blot	O
reactivity	O
was	O
seen	O
only	O
in	O
sera	B-COMP
from	O
virus	O
infected	O
BALB	O
/	O
c	O
mice	O
.	O

Virus	O
isolation	O
using	O
the	O
Vero	O
cell	B-COMP
culture	O
was	O
unsuccessful	O
.	O

Using	O
a	O
glia	O
-	O
tropic	O
coronavirus	O
infection	O
,	O
which	O
is	O
initiated	O
in	O
the	O
brain	O
but	O
rapidly	O
spreads	O
to	O
and	O
predominantly	O
persists	O
in	O
the	O
spinal	O
cord	O
,	O
this	O
study	O
characterizes	O
longitudinal	O
changes	O
in	O
B	O
cell	B-COMP
subsets	O
at	O
both	O
infected	O
anatomical	O
sites	O
.	O

We	O
suggest	O
that	O
these	O
results	O
have	O
implications	O
for	O
viral	B-COMP
genome	I-COMP
replication	O
and	O
explain	O
,	O
in	O
part	O
,	O
why	O
coronavirus	O
sgmRNAs	O
fail	O
to	O
replicate	O
.	O

Here	O
,	O
we	O
report	O
the	O
full	O
-	O
genome	O
sequence	O
of	O
the	O
Jordan	O
-	O
N3	O
/	O
2012	O
strain	O
after	O
serial	O
passage	O
in	O
two	O
distinct	O
mammalian	O
cell	B-COMP
lines	O
.	O

ABSTRACT	O
:	O
To	O
initiate	O
infections	O
,	O
many	O
coronaviruses	O
use	O
sialic	O
acids	O
,	O
either	O
as	O
receptor	O
determinants	O
or	O
as	O
attachment	O
factors	O
helping	O
the	O
virus	O
find	O
its	O
receptor	O
underneath	O
the	O
heavily	O
glycosylated	O
mucus	B-COMP
layer	I-COMP
.	O

In	O
patients	O
with	O
severe	O
ARDS	O
,	O
alveolar	O
epithelial	O
cell	B-COMP
death	O
is	O
a	O
major	O
mechanism	O
that	O
prevents	O
the	O
resolution	O
of	O
lung	O
edema	O
.	O

Multiple	O
sequence	O
alignment	O
(	O
MSA	O
)	O
approach	O
was	O
employed	O
among	O
spike	O
(	O
S	O
),	O
membrane	B-COMP
(	O
M	O
),	O
enveloped	O
(	O
E	O
)	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
and	O
replicase	O
polyprotein	O
1ab	O
to	O
identify	O
which	O
one	O
is	O
highly	O
conserve	O
in	O
all	O
coronaviruses	O
strains	O
.	O

Furthermore	O
,	O
the	O
reduction	O
in	O
cell	B-COMP
numbers	O
in	O
the	O
spleens	O
of	O
wild	O
-	O
type	O
mice	O
after	O
infection	O
was	O
not	O
observed	O
in	O
the	O
infected	O
Fut9	O
(-/-)	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
Le	O
(	O
x	O
)	O
structures	O
are	O
involved	O
in	O
host	B-COMP
responses	O
against	O
viral	O
or	O
bacterial	O
challenges	O
.	O

ABSTRACT	O
:	O
Three	O
phage	O
-	O
displayed	O
peptides	O
designated	O
H	O
,	O
S	O
and	O
F	O
that	O
recognize	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
),	O
the	O
cellular	B-COMP
receptor	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
able	O
to	O
inhibit	O
cell	B-COMP
infection	O
by	O
TGEV	O
.	O

Abrogation	O
of	O
IL	O
-	O
27	O
signaling	O
did	O
not	O
affect	O
virus	O
-	O
specific	O
CD8	O
+	O
T	O
cell	B-COMP
-	O
mediated	O
IL	O
-	O
10	O
production	O
or	O
cytolytic	O
activity	O
or	O
Foxp3	O
+	O
regulatory	O
T	O
cell	B-COMP
populations	O
.	O

Although	O
bats	O
and	O
dromedary	O
camels	O
have	O
been	O
identified	O
as	O
potential	O
MERS	O
-	O
CoV	O
hosts	B-COMP
,	O
the	O
virus	O
has	O
so	O
far	O
not	O
been	O
isolated	O
from	O
any	O
species	O
other	O
than	O
humans	O
.	O

Some	O
potentially	O
important	O
host	B-COMP
factors	O
for	O
the	O
antiviral	O
response	O
,	O
whose	O
functions	O
remain	O
largely	O
unexplored	O
,	O
are	O
long	O
non	O
-	O
coding	O
RNAs	O
(	O
lncRNAs	O
).	O

As	O
most	O
IBV	O
strains	O
do	O
not	O
infect	O
permanent	O
cell	B-COMP
lines	O
and	O
show	O
infection	O
only	O
in	O
primary	O
chicken	O
cells	B-COMP
of	O
the	O
target	O
organs	O
,	O
we	O
developed	O
a	O
culture	O
system	O
for	O
chicken	O
oviduct	O
explants	O
.	O

Other	O
stages	O
including	O
reverse	O
transcription	O
initiation	O
in	O
retroviruses	O
,	O
nuclear	O
export	O
and	O
viral	O
packaging	O
are	O
specifically	O
dependent	O
on	O
the	O
proper	O
3	O
-	O
dimensional	O
folding	O
of	O
multiple	O
RNA	O
domains	O
to	O
recruit	O
necessary	O
viral	O
and	O
host	B-COMP
factors	O
required	O
for	O
activity	O
.	O

Using	O
the	O
method	O
of	O
GST	O
pull	O
-	O
down	O
with	O
the	O
nucleocapsid	B-COMP
(	O
N	O
),	O
N	O
protein	O
was	O
found	O
to	O
interact	O
with	O
swine	O
testes	O
(	O
ST	O
)	O
cells	B-COMP
elongation	O
factor	O
1	O
-	O
alpha	O
(	O
EF1A	O
),	O
an	O
essential	O
component	O
of	O
the	O
translational	O
machinery	O
with	O
an	O
important	O
role	O
in	O
cells	B-COMP
.	O

This	O
is	O
a	O
novel	O
mechanism	O
by	O
which	O
respiratory	O
viral	O
infection	O
activates	O
inflammasomes	O
,	O
and	O
identifies	O
sensing	O
of	O
disturbances	O
in	O
intracellular	B-COMP
ionic	O
concentrations	O
as	O
a	O
novel	O
pathogen	O
-	O
recognition	O
pathway	O
in	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
Viral	O
2	O
',	O
5	O
'-	O
phosphodiesterases	O
(	O
2	O
',	O
5	O
'-	O
PDEs	O
)	O
help	O
disparate	O
RNA	O
viruses	O
evade	O
the	O
antiviral	O
activity	O
of	O
interferon	O
(	O
IFN	O
)	O
by	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
activators	O
of	O
RNase	O
L	O
.	O
A	O
kinase	O
anchoring	O
proteins	O
(	O
AKAPs	O
)	O
bind	O
the	O
regulatory	O
subunits	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	B-COMP
)	O
to	O
localize	O
and	O
organize	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
signaling	O
during	O
diverse	O
physiological	O
processes	O
.	O

Here	O
we	O
report	O
that	O
a	O
cellular	B-COMP
protein	O
,	O
AKAP7	O
,	O
has	O
an	O
analogous	O
2	O
',	O
5	O
'-	O
phosphodiesterase	O
(	O
2	O
',	O
5	O
'-	O
PDE	O
)	O
domain	O
that	O
is	O
able	O
to	O
restore	O
the	O
growth	O
of	O
chimeric	O
MHV	O
expressing	O
inactive	O
ns2	O
.	O

Coronavirus	O
infection	O
of	O
cultured	O
cells	B-COMP
was	O
previously	O
shown	O
to	O
cause	O
ER	O
stress	O
and	O
induce	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
),	O
a	O
process	O
that	O
aims	O
to	O
restore	O
the	O
ER	O
homeostasis	O
by	O
global	O
translation	O
shutdown	O
and	O
increasing	O
the	O
ER	O
folding	O
capacity	O
.	O

In	O
addition	O
,	O
20MT	O
and	O
40MT	O
stimulated	O
the	O
differentiation	O
of	O
innate	O
immune	O
cells	B-COMP
,	O
including	O
T	O
helper	O
cell	B-COMP
subclasses	O
and	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	B-COMP
,	O
which	O
induced	O
robust	O
T	O
helper	O
type	O
1	O
and	O
T	O
helper	O
type	O
17	O
(	O
Th17	O
)	O
responses	O
and	O
reduced	O
Treg	O
T	O
cell	B-COMP
immune	O
responses	O
in	O
the	O
20MT	O
and	O
40MT	O
groups	O
,	O
respectively	O
.	O

Low	O
serum	B-COMP
albumin	O
and	O
low	O
lymphocyte	O
count	O
were	O
identified	O
as	O
possible	O
pre	O
-	O
treatment	O
risk	O
factors	O
,	O
while	O
severe	O
lymphopenia	O
was	O
identified	O
as	O
a	O
post	O
-	O
treatment	O
risk	O
factor	O
.	O

Low	O
serum	B-COMP
albumin	O
and	O
low	O
lymphocyte	O
count	O
were	O
identified	O
as	O
possible	O
pre	O
-	O
treatment	O
risk	O
factors	O
,	O
while	O
severe	O
lymphopenia	O
was	O
identified	O
as	O
a	O
post	O
-	O
treatment	O
risk	O
factor	O
.	O

Alteration	O
of	O
cytokines	O
profiles	O
through	O
manipulation	O
of	O
the	O
innate	O
immune	O
system	O
by	O
innate	O
immune	O
stimulants	O
may	O
be	O
helpful	O
in	O
inhibiting	O
virus	O
replication	O
in	O
otherwise	O
permissive	O
cells	B-COMP
.	O

Title	O
compounds	O
were	O
tested	O
in	O
cell	B-COMP
-	O
based	O
assays	O
for	O
cytotoxicity	O
and	O
antiviral	O
activity	O
against	O
representatives	O
of	O
two	O
DNA	O
virus	O
families	O
as	O
wells	O
as	O
against	O
representatives	O
of	O
RNA	O
virus	O
families	O
containing	O
single	O
-	O
stranded	O
,	O
either	O
positive	O
-	O
sense	O
(	O
ssRNA	O
(+))	O
or	O
negative	O
-	O
sense	O
(	O
ssRNA	O
(-)),	O
and	O
double	O
-	O
stranded	O
genomes	O
(	O
dsRNA	O
).	O

The	O
increased	O
response	O
detected	O
for	O
both	O
IgA	O
and	O
IgG	O
lymphocytes	O
after	O
challenge	O
might	O
be	O
explained	O
by	O
vaccine	O
-	O
induced	O
B	O
memory	O
cells	B-COMP
.	O

TITLE	O
:	O
Virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	B-COMP
provide	O
substantial	O
protection	O
from	O
lethal	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

Virus	O
-	O
specific	O
CD8	O
T	O
cells	B-COMP
are	O
required	O
for	O
pathogen	O
clearance	O
following	O
primary	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
prime	O
-	O
boost	O
immunization	O
approach	O
,	O
we	O
showed	O
that	O
virus	O
-	O
specific	O
CD8	O
T	O
cells	B-COMP
protect	O
susceptible	O
8	O
-	O
to	O
10	O
-	O
month	O
-	O
old	O
mice	O
from	O
lethal	O
SARS	O
-	O
CoV	O
challenge	O
.	O

We	O
also	O
generated	O
monoclonal	O
antibodies	B-COMP
against	O
SARS	O
-	O
CoV	O
spike	O
proteins	O
and	O
observed	O
that	O
most	O
of	O
them	O
promoted	O
SARS	O
-	O
CoV	O
infection	O
.	O

We	O
showed	O
that	O
camels	O
sampled	O
in	O
different	O
regions	O
in	O
Kenya	O
during	O
1992	O
-	O
2013	O
have	O
antibodies	B-COMP
against	O
this	O
virus	O
.	O

Microarray	O
profiles	O
of	O
host	B-COMP
responses	O
to	O
IAPV	O
infection	O
revealed	O
that	O
mitochondrial	B-COMP
function	O
is	O
the	O
most	O
significantly	O
affected	O
biological	O
process	O
,	O
suggesting	O
that	O
viral	O
infection	O
causes	O
significant	O
disturbance	O
in	O
energy	O
-	O
related	O
host	B-COMP
processes	O
.	O

We	O
believe	O
that	O
the	O
knowledge	O
and	O
insights	O
gained	O
from	O
this	O
study	O
will	O
provide	O
a	O
new	O
platform	O
for	O
continuing	O
studies	O
of	O
the	O
IAPV	O
-	O
host	B-COMP
interactions	O
and	O
have	O
positive	O
implications	O
for	O
disease	O
management	O
that	O
will	O
lead	O
to	O
mitigation	O
of	O
escalating	O
honey	O
bee	O
colony	O
losses	O
worldwide	O
.	O

The	O
internalized	O
PEDV	O
was	O
co	O
-	O
localized	O
with	O
the	O
clathrin	O
-	O
mediated	O
endocytic	O
marker	O
,	O
but	O
not	O
with	O
the	O
caveolae	B-COMP
-	O
mediated	O
endocytic	O
marker	O
.	O

Multiplex	O
differential	O
RT	O
-	O
PCR	O
was	O
performed	O
with	O
primers	O
based	O
on	O
the	O
highly	O
conserved	O
coronavirus	O
membrane	B-COMP
protein	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
infection	O
is	O
usually	O
detected	O
by	O
cellular	B-COMP
sensors	O
,	O
which	O
trigger	O
the	O
activation	O
of	O
the	O
innate	O
immune	O
system	O
.	O

ABSTRACT	O
:	O
Macropinocytosis	O
is	O
exploited	O
by	O
many	O
pathogens	O
for	O
entry	O
into	O
cells	B-COMP
.	O

MHV	O
-	O
induced	O
macropinocytosis	O
results	O
in	O
vesicle	B-COMP
internalization	O
,	O
as	O
well	O
as	O
extended	O
filopodia	B-COMP
capable	O
of	O
fusing	O
with	O
distant	O
cells	B-COMP
.	O

These	O
results	O
indicate	O
that	O
macropinocytosis	O
likely	O
facilitates	O
CoV	O
infection	O
through	O
enhanced	O
cell	B-COMP
-	O
to	O
-	O
cell	B-COMP
spreading	O
.	O

This	O
system	O
provides	O
an	O
important	O
tool	O
to	O
rapidly	O
assess	O
the	O
efficacy	O
of	O
protease	O
inhibitors	O
targeting	O
existing	O
and	O
emerging	O
human	O
pathogens	O
,	O
as	O
well	O
as	O
other	O
enzymes	O
capable	O
of	O
removing	O
ISG15	O
from	O
cellular	B-COMP
proteins	O
.	O

TITLE	O
:	O
Virus	O
-	O
specific	O
regulatory	O
T	O
cells	B-COMP
ameliorate	O
encephalitis	O
by	O
repressing	O
effector	O
T	O
cell	B-COMP
functions	O
from	O
priming	O
to	O
effector	O
stages	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	B-COMP
(	O
N	O
)	O
is	O
a	O
structural	O
protein	O
that	O
forms	O
complexes	O
with	O
genomic	O
RNA	O
,	O
interacts	O
with	O
the	O
viral	B-COMP
membrane	I-COMP
protein	O
during	O
virion	B-COMP
assembly	O
and	O
plays	O
a	O
critical	O
role	O
in	O
enhancing	O
the	O
efficiency	O
of	O
virus	O
transcription	O
and	O
assembly	O
.	O

To	O
increase	O
the	O
understanding	O
of	O
the	O
mechanisms	O
involved	O
in	O
these	O
processes	O
,	O
we	O
focused	O
on	O
the	O
evaluation	O
of	O
local	O
inflammatory	O
and	O
cell	B-COMP
-	O
mediated	O
immune	O
responses	O
after	O
challenge	O
with	O
the	O
M41	O
strain	O
of	O
IBV	O
,	O
associating	O
these	O
responses	O
with	O
pathologic	O
changes	O
in	O
the	O
tracheal	O
mucosa	O
.	O

Mutation	O
of	O
individual	O
cysteine	O
clusters	O
in	O
the	O
cysteine	O
-	O
rich	O
motif	O
of	O
S	O
revealed	O
that	O
all	O
cysteines	O
must	O
be	O
replaced	O
to	O
abolish	O
acylation	O
and	O
incorporation	O
of	O
S	O
into	O
virus	O
-	O
like	O
particles	O
(	O
VLP	B-COMP
).	O

TITLE	O
:	O
The	O
PDZ	O
-	O
binding	O
motif	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	B-COMP
protein	O
is	O
a	O
determinant	O
of	O
viral	O
pathogenesis	O
.	O

In	O
sum	O
,	O
we	O
identified	O
two	O
host	B-COMP
cell	I-COMP
proteases	O
that	O
could	O
promote	O
the	O
amplification	O
of	O
influenza	O
viruses	O
and	O
emerging	O
coronaviruses	O
in	O
humans	O
and	O
might	O
constitute	O
targets	O
for	O
antiviral	O
intervention	O
.	O

Closer	O
inspection	O
of	O
the	O
predicted	O
targets	O
for	O
several	O
highly	O
supported	O
novel	O
miRNA	O
candidates	O
suggests	O
putative	O
roles	O
in	O
host	B-COMP
-	O
virus	O
interaction	O
.	O

Closer	O
inspection	O
of	O
the	O
predicted	O
targets	O
for	O
several	O
highly	O
supported	O
novel	O
miRNA	O
candidates	O
suggests	O
putative	O
roles	O
in	O
host	B-COMP
-	O
virus	O
interaction	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
adults	O
for	O
severe	O
acute	O
respiratory	O
failure	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
examine	O
the	O
indications	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Detection	O
of	O
antibodies	B-COMP
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
serum	B-COMP
and	O
colostrum	O
by	O
indirect	O
ELISA	O
.	O

In	O
field	O
serum	B-COMP
samples	O
(	O
n	O
=	O
239	O
),	O
the	O
diagnostic	O
sensitivity	O
of	O
the	O
S1	O
ELISA	O
was	O
100	O
%	O
and	O
the	O
diagnostic	O
specificity	O
was	O
94	O
%.	O

TITLE	O
:	O
The	O
cellular	B-COMP
redox	O
environment	O
alters	O
antigen	O
presentation	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
protein	O
encoded	O
by	O
SARS	O
-	O
CoV	O
designated	O
as	O
open	O
reading	O
frame	O
-	O
9b	O
(	O
ORF	O
-	O
9b	O
)	O
localizes	O
to	O
mitochondria	B-COMP
and	O
causes	O
mitochondrial	B-COMP
elongation	O
by	O
triggering	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
dynamin	O
-	O
like	O
protein	O
1	O
,	O
a	O
host	B-COMP
protein	O
involved	O
in	O
mitochondrial	B-COMP
fission	O
.	O

This	O
severely	O
limits	O
host	B-COMP
cell	I-COMP
IFN	O
responses	O
.	O

These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
ORF	O
-	O
9b	O
manipulates	O
host	B-COMP
cell	I-COMP
mitochondria	B-COMP
and	O
mitochondrial	B-COMP
function	O
to	O
help	O
evade	O
host	B-COMP
innate	O
immunity	O
.	O

Since	O
it	O
has	O
been	O
reported	O
that	O
sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
contribute	O
to	O
brain	O
dysfunction	O
,	O
we	O
investigated	O
the	O
brain	O
-	O
lung	O
crosstalk	O
using	O
a	O
combined	O
experimental	O
in	O
vitro	O
airway	O
epithelial	O
and	O
brain	O
cell	B-COMP
injury	O
model	O
.	O

Conditioned	O
medium	O
at	O
15	O
%	O
significantly	O
increased	O
apoptosis	O
in	O
brain	O
cell	B-COMP
cultures	O
24	O
h	O
after	O
treatment	O
,	O
whereas	O
25	O
%	O
and	O
50	O
%	O
significantly	O
increased	O
both	O
necrosis	O
and	O
apoptosis	O
.	O

Treatment	O
with	O
FTY720	O
did	O
not	O
affect	O
virus	O
-	O
specific	O
T	O
cell	B-COMP
proliferation	O
,	O
expression	O
of	O
IFN	O
-	O
γ	O
,	O
TNF	O
-	O
α	O
or	O
cytolytic	O
activity	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
FTY720	O
mutes	O
effective	O
anti	O
-	O
viral	O
immune	O
responses	O
through	O
impacting	O
migration	O
and	O
accumulation	O
of	O
virus	O
-	O
specific	O
T	O
cells	B-COMP
within	O
the	O
CNS	O
during	O
acute	O
viral	O
-	O
induced	O
encephalomyelitis	O
.	O

UPR	O
resolves	O
ER	O
stress	O
by	O
activating	O
a	O
cascade	O
of	O
cellular	B-COMP
responses	O
,	O
including	O
the	O
induction	O
of	O
molecular	O
chaperones	O
,	O
translational	O
attenuation	O
,	O
ER	O
-	O
associated	O
degradation	O
,	O
and	O
other	O
mechanisms	O
.	O

The	O
increase	O
in	O
disease	O
severity	O
in	O
dogs	O
and	O
the	O
emergence	O
of	O
novel	O
CCoVs	O
can	O
be	O
attributed	O
to	O
the	O
high	O
level	O
of	O
recombination	O
within	O
the	O
spike	O
gene	O
that	O
can	O
occur	O
during	O
infection	O
by	O
more	O
than	O
one	O
CCoV	O
type	O
in	O
the	O
same	O
host	B-COMP
.	O

TITLE	O
:	O
Automated	O
inhaled	O
nitric	O
oxide	O
alerts	O
for	O
adult	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
patient	O
identification	O
.	O

A	O
total	O
of	O
310	O
chicken	O
sera	B-COMP
samples	O
were	O
tested	O
using	O
the	O
commercial	O
IDEXX	O
kit	O
along	O
with	O
the	O
assay	O
developed	O
.	O

ABSTRACT	O
:	O
Viral	O
infection	O
converts	O
the	O
normal	O
constitution	O
of	O
a	O
cell	B-COMP
to	O
optimise	O
viral	O
entry	O
,	O
replication	O
,	O
and	O
virion	B-COMP
production	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygen	O
(	O
ECMO	O
)	O
has	O
been	O
used	O
for	O
many	O
years	O
in	O
patients	O
with	O
life	O
-	O
threatening	O
hypoxaemia	O
and	O
/	O
or	O
hypercarbia	O
.	O

On	O
arrival	O
,	O
her	O
vital	O
signs	O
indicated	O
septic	O
shock	O
,	O
with	O
a	O
white	O
blood	O
cell	B-COMP
count	O
of	O
3	O
.	O
5	O
×	O
10	O
(	O
3	O
)/	O
μl	O
.	O

All	O
the	O
vaccinated	O
animals	O
had	O
antibody	B-COMP
responses	O
against	O
spike	O
protein	O
,	O
which	O
neutralized	O
MERS	O
-	O
CoV	O
in	O
vitro	O
.	O

TITLE	O
:	O
[	O
High	O
-	O
efficiency	O
expression	O
of	O
a	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
in	O
tobacco	O
chloroplasts	B-COMP
].	O

However	O
,	O
it	O
has	O
not	O
been	O
well	O
established	O
whether	O
the	O
level	O
of	O
serum	B-COMP
IL	O
-	O
8	O
is	O
associated	O
with	O
the	O
severity	O
of	O
lung	O
injury	O
and	O
whether	O
it	O
is	O
a	O
prognosis	O
marker	O
for	O
severe	O
lung	O
contusion	O
.	O

CONCLUSIONS	O
:	O
The	O
elevated	O
levels	O
of	O
plasma	O
vWF	O
and	O
serum	B-COMP
IL	O
-	O
8	O
in	O
severe	O
pulmonary	O
contusion	O
patients	O
reflect	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
patients	O
outcomes	O
,	O
suggesting	O
that	O
the	O
plasma	O
vWF	O
and	O
serum	B-COMP
IL	O
-	O
8	O
are	O
sensitive	O
markers	O
for	O
clinical	O
evaluation	O
of	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
predication	O
of	O
patient	O
prognosis	O
.	O

The	O
isolation	O
of	O
PEDV	O
in	O
cell	B-COMP
culture	O
is	O
the	O
first	O
step	O
toward	O
the	O
development	O
of	O
an	O
attenuated	O
vaccine	O
,	O
to	O
study	O
the	O
biology	O
of	O
PEDV	O
and	O
to	O
develop	O
in	O
vitro	O
PEDV	O
immunoassays	O
,	O
inactivation	O
assays	O
and	O
screen	O
for	O
PEDV	O
antivirals	O
.	O

We	O
provided	O
the	O
initial	O
evidence	O
supporting	O
this	O
antibody	B-COMP
germline	O
/	O
maturation	O
hypothesis	O
,	O
which	O
prompted	O
a	O
number	O
of	O
studies	O
to	O
design	O
vaccine	O
immunogens	O
that	O
could	O
bind	O
putative	O
germline	O
predecessors	O
of	O
known	O
bnAbs	O
and	O
to	O
explore	O
complex	O
B	O
cell	B-COMP
lineages	O
.	O

Altogether	O
,	O
TRIM56	O
is	O
a	O
versatile	O
antiviral	O
host	B-COMP
factor	O
that	O
confers	O
resistance	O
to	O
YFV	O
,	O
DENV2	O
,	O
and	O
HCoV	O
-	O
OC43	O
through	O
overlapping	O
and	O
distinct	O
molecular	O
determinants	O
.	O

We	O
previously	O
reported	O
tripartite	O
motif	O
protein	O
56	O
(	O
TRIM56	O
)	O
as	O
a	O
host	B-COMP
restriction	O
factor	O
of	O
bovine	O
viral	O
diarrhea	O
virus	O
,	O
a	O
ruminant	O
pathogen	O
.	O

In	O
293T	O
cells	B-COMP
,	O
IFITM	O
-	O
mediated	O
inhibition	O
of	O
cellular	B-COMP
entry	O
of	O
the	O
emerging	O
MERS	O
-	O
and	O
SARS	O
-	O
CoV	O
was	O
less	O
efficient	O
than	O
blockade	O
of	O
entry	O
of	O
the	O
globally	O
circulating	O
human	O
coronaviruses	O
229E	O
and	O
NL63	O
.	O

Serum	B-COMP
SP	O
-	O
A	O
levels	O
may	O
allow	O
the	O
detection	O
of	O
SAP	O
-	O
induced	O
ARDS	O
and	O
may	O
help	O
to	O
support	O
the	O
clinical	O
diagnosis	O
of	O
ARDS	O
.	O

Uniaxial	O
stretch	O
(	O
10	O
-	O
30	O
%	O
in	O
strain	O
)	O
was	O
applied	O
to	O
fibroblasts	O
cultured	O
in	O
a	O
silicone	O
chamber	O
coated	O
with	O
type	O
I	O
collagen	B-COMP
using	O
a	O
stretching	O
apparatus	O
.	O

HSCTs	O
performed	O
in	O
patients	O
with	O
DS	O
-	O
ALL	O
were	O
identified	O
in	O
the	O
Japan	O
Society	O
for	O
Hematopoietic	O
Cell	B-COMP
Transplantation	O
registry	O
.	O

In	O
the	O
current	O
study	O
,	O
in	O
a	O
lipopolysaccharide	O
-	O
based	O
mouse	O
model	O
of	O
ALI	O
,	O
we	O
found	O
that	O
insulin	O
alleviated	O
pulmonary	O
edema	O
by	O
promoting	O
ENaC	O
-	O
mediated	O
alveolar	O
fluid	O
clearance	O
through	O
serum	B-COMP
and	O
glucocorticoid	O
induced	O
kinase	O
-	O
1	O
(	O
SGK1	O
).	O

Finally	O
,	O
we	O
testified	O
the	O
role	O
of	O
mTORC2	B-COMP
in	O
vivo	O
by	O
demonstrating	O
that	O
PP242	O
prevented	O
insulin	O
-	O
stimulated	O
SGK1	O
activation	O
and	O
ENaC	O
increase	O
during	O
ALI	O
.	O

Viral	O
clearance	O
and	O
subsequent	O
recovery	O
from	O
infection	O
require	O
activation	O
of	O
an	O
effective	O
host	B-COMP
immune	O
response	O
;	O
however	O
,	O
many	O
immune	O
effector	O
cells	B-COMP
may	O
also	O
cause	O
injury	O
to	O
host	B-COMP
tissues	O
.	O

While	O
these	O
viruses	O
are	O
susceptible	O
to	O
interferon	O
treatment	O
in	O
vitro	O
,	O
they	O
both	O
encode	O
numerous	O
genes	O
that	O
allow	O
for	O
successful	O
evasion	O
of	O
the	O
host	B-COMP
immune	O
system	O
until	O
after	O
high	O
virus	O
titres	O
have	O
been	O
achieved	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
viral	O
gene	O
products	O
are	O
capable	O
of	O
inducing	O
apoptosis	O
by	O
interfering	O
with	O
various	O
cellular	B-COMP
signalling	O
cascades	O
.	O

In	O
in	O
vitro	O
experiments	O
,	O
specific	O
knock	O
down	O
of	O
Spred	O
-	O
2	O
by	O
siRNA	O
or	O
overexpression	O
of	O
Spred	O
-	O
2	O
by	O
transfection	O
with	O
a	O
plasmid	O
encoding	O
the	O
Spred	O
-	O
2	O
sense	O
sequence	O
was	O
introduced	O
into	O
murine	O
RAW264	O
.	O
7	O
macrophage	O
cells	B-COMP
or	O
MLE	O
-	O
12	O
lung	O
epithelial	O
cells	B-COMP
.	O

In	O
multivariable	O
analysis	O
,	O
high	O
T	O
-	O
reg	O
%	O
(	O
HR	O
0	O
.	O
41	O
,	O
95	O
%	O
CI	O
0	O
.	O
20	O
-	O
0	O
.	O
81	O
)	O
and	O
high	O
CMV	O
-	O
reactive	O
CD4	O
+	O
T	O
-	O
cell	B-COMP
%	O
(	O
HR	O
1	O
.	O
69	O
,	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
2	O
.	O
78	O
)	O
were	O
predictive	O
of	O
respiratory	O
viral	O
infection	O
.	O

TITLE	O
:	O
Host	B-COMP
cell	I-COMP
entry	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
after	O
two	O
-	O
step	O
,	O
furin	O
-	O
mediated	O
activation	O
of	O
the	O
spike	O
protein	O
.	O

We	O
find	O
that	O
phosphorylation	O
of	O
the	O
viral	B-COMP
nucleocapsid	I-COMP
(	O
N	O
)	O
by	O
host	B-COMP
glycogen	O
synthase	O
kinase	O
-	O
3	O
(	O
GSK	O
-	O
3	O
)	O
is	O
required	O
for	O
template	O
switching	O
.	O

The	O
possible	O
mechanism	O
of	O
the	O
inhibitory	O
action	O
on	O
the	O
male	O
immunity	O
was	O
associated	O
with	O
the	O
protein	O
kinase	O
cascade	O
,	O
including	O
protein	O
kinase	O
C	O
,	O
activated	O
by	O
phorbolmyristate	O
in	O
the	O
cells	B-COMP
of	O
the	O
immune	O
system	O
.	O

TITLE	O
:	O
Coronavirus	O
-	O
induced	O
ER	O
stress	O
response	O
and	O
its	O
involvement	O
in	O
regulation	O
of	O
coronavirus	O
-	O
host	B-COMP
interactions	O
.	O

TITLE	O
:	O
Coronavirus	O
membrane	B-COMP
-	O
associated	O
papain	O
-	O
like	O
proteases	O
induce	O
autophagy	O
through	O
interacting	O
with	O
Beclin1	O
to	O
negatively	O
regulate	O
antiviral	O
innate	O
immunity	O
.	O

In	O
addition	O
,	O
H9N2	O
viral	O
infection	O
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	O
,	O
and	O
a	O
significant	O
increase	O
in	O
interleukin	O
1	O
,	O
interleukin	O
6	O
,	O
tumor	O
necrosis	O
factor	O
,	O
and	O
interferon	O
in	O
BALF	O
and	O
serum	B-COMP
.	O

In	O
addition	O
,	O
H9N2	O
viral	O
infection	O
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	O
,	O
and	O
a	O
significant	O
increase	O
in	O
interleukin	O
1	O
,	O
interleukin	O
6	O
,	O
tumor	O
necrosis	O
factor	O
,	O
and	O
interferon	O
in	O
BALF	O
and	O
serum	B-COMP
.	O

These	O
activities	O
have	O
been	O
suggested	O
to	O
suppress	O
host	B-COMP
antiviral	O
responses	O
during	O
infection	O
.	O

TITLE	O
:	O
Red	O
blood	O
cells	B-COMP
induce	O
necroptosis	O
of	O
lung	O
endothelial	O
cells	B-COMP
and	O
increase	O
susceptibility	O
to	O
lung	O
inflammation	O
.	O

ABSTRACT	O
:	O
Red	O
blood	O
cell	B-COMP
(	O
RBC	B-COMP
)	O
transfusions	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
the	O
critically	O
ill	O
,	O
yet	O
the	O
mechanisms	O
for	O
enhanced	O
susceptibility	O
to	O
ARDS	O
conferred	O
by	O
RBC	B-COMP
transfusions	O
remain	O
unknown	O
.	O

To	O
determine	O
the	O
mechanisms	O
of	O
lung	O
endothelial	O
cell	B-COMP
(	O
EC	O
)	O
High	O
Mobility	O
Group	O
Box	O
1	O
(	O
HMGB1	O
)	O
release	O
following	O
exposure	O
to	O
RBCs	O
and	O
to	O
determine	O
whether	O
RBC	O
transfusion	O
increases	O
susceptibility	O
to	O
lung	O
inflammation	O
in	O
vivo	O
through	O
release	O
of	O
the	O
danger	O
signal	O
HMGB1	O
.	O

After	O
incubation	O
with	O
RBCs	O
,	O
lung	O
ECs	O
underwent	O
regulated	O
necrotic	O
cell	B-COMP
death	O
(	O
necroptosis	O
)	O
and	O
released	O
the	O
essential	O
mediator	O
of	O
necroptosis	O
,	O
receptor	O
-	O
interacting	O
serine	O
/	O
threonine	O
-	O
protein	O
kinase	O
3	O
(	O
RIP3	O
),	O
and	O
HMGB1	O
.	O

TITLE	O
:	O
Characterization	O
of	O
cellular	B-COMP
and	O
humoral	O
immune	O
responses	O
after	O
IBV	O
infection	O
in	O
chicken	O
lines	O
differing	O
in	O
MBL	O
serum	B-COMP
concentration	O
.	O

The	O
numbers	O
of	O
B	O
cells	B-COMP
at	O
week	O
3	O
p	O
.	O
i	O
.	O

Hence	O
,	O
in	O
addition	O
to	O
reducing	O
the	O
production	O
of	O
infectious	O
virions	B-COMP
,	O
inhibition	O
of	O
ER	O
glucosidases	O
also	O
impairs	O
the	O
entry	O
of	O
selected	O
viruses	O
via	O
a	O
post	O
-	O
receptor	O
-	O
binding	O
mechanism	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
determine	O
whether	O
patients	O
with	O
different	O
serum	B-COMP
PCT	O
concentrations	O
exhibit	O
different	O
rates	O
of	O
developing	O
moderate	O
to	O
severe	O
ARDS	O
.	O

White	O
cell	B-COMP
counts	O
were	O
normal	O
or	O
decreased	O
.	O

CONCLUSIONS	O
:	O
Retinal	O
artery	O
occlusion	O
is	O
a	O
rare	O
but	O
potentially	O
devastating	O
complication	O
of	O
sickle	O
cell	B-COMP
disease	O
.	O

While	O
some	O
viruses	O
fuse	O
with	O
the	O
plasma	B-COMP
membrane	I-COMP
,	O
many	O
viruses	O
are	O
endocytosed	O
prior	O
to	O
fusion	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
from	O
both	O
the	O
Alphacoronavirus	O
and	O
Betacoronavirus	O
genera	O
interfere	O
with	O
the	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
response	O
in	O
various	O
ways	O
,	O
ensuring	O
the	O
limited	O
activation	O
of	O
the	O
IFN	O
response	O
in	O
most	O
cell	B-COMP
types	O
.	O

The	O
RBD	O
efficiently	O
elicited	O
neutralizing	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
by	O
blocking	O
viral	O
entry	O
at	O
the	O
binding	O
step	O
.	O

Interventions	O
to	O
decrease	O
the	O
probability	O
of	O
virus	O
spillover	O
can	O
be	O
implemented	O
at	O
multiple	O
levels	O
from	O
targeting	O
the	O
reservoir	O
host	B-COMP
to	O
managing	O
recipient	O
host	B-COMP
exposure	O
and	O
susceptibility	O
.	O

It	O
has	O
been	O
identified	O
to	O
increase	O
permeability	O
of	O
the	O
lipid	O
membrane	B-COMP
for	O
cations	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
antibody	B-COMP
response	O
of	O
killed	O
and	O
live	O
vaccines	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
a	O
field	O
study	O
.	O

Among	O
recombinant	O
spike	O
S1	O
,	O
S2	O
,	O
S3	O
,	O
and	O
nucleocapsid	B-COMP
N	O
protein	O
of	O
PEDV	O
,	O
S3	O
protein	O
presented	O
the	O
highest	O
antibody	B-COMP
level	O
in	O
the	O
K	O
/	O
K	O
group	O
.	O

RESULTS	O
:	O
Vaccination	O
with	O
K	O
/	O
K	O
vaccine	O
induced	O
the	O
highest	O
level	O
of	O
IgG	O
and	O
IgA	O
in	O
sow	O
serum	B-COMP
,	O
colostrum	O
,	O
and	O
especially	O
in	O
piglet	O
serum	B-COMP
,	O
with	O
the	O
lowest	O
levels	O
found	O
in	O
the	O
L	O
/	O
L	O
group	O
.	O

RESULTS	O
:	O
Absence	O
of	O
ATF3	O
in	O
myeloid	O
-	O
derived	O
cells	B-COMP
caused	O
increased	O
pulmonary	O
cellular	B-COMP
infiltration	O
.	O

TITLE	O
:	O
Comparison	O
of	O
serum	B-COMP
neutralization	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
on	O
sera	B-COMP
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
vaccinated	O
pigs	O
.	O

For	O
prokaryotic	O
expression	O
of	O
partial	O
fragments	O
of	O
spike	O
protein	O
the	O
size	O
and	O
location	O
of	O
S1	O
,	O
S2	O
,	O
and	O
S3	O
,	O
and	O
full	O
nucleocapsid	B-COMP
protein	O
,	O
polymerase	O
chain	O
reaction	O
was	O
performed	O
using	O
specific	O
primers	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
remains	O
an	O
unsolved	O
problem	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
which	O
can	O
be	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
).	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
distribution	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
seropositive	O
dromedary	O
camels	O
in	O
eastern	O
Africa	O
,	O
we	O
tested	O
189	O
archived	O
serum	B-COMP
samples	O
accumulated	O
during	O
the	O
past	O
30	O
years	O
.	O

This	O
is	O
the	O
first	O
known	O
case	O
of	O
a	O
patient	O
who	O
survived	O
Aspergillus	O
sepsis	O
after	O
being	O
treated	O
early	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
(	O
ECMO	O
)	O
and	O
antifungal	O
therapy	O
.	O

To	O
determine	O
whether	O
this	O
attenuated	O
phenotype	O
is	O
applicable	O
to	O
multiple	O
disease	O
models	O
,	O
we	O
mutated	O
the	O
catalytic	O
residue	O
in	O
the	O
JHM	O
strain	O
of	O
MHV	O
(	O
JHMV	O
),	O
which	O
causes	O
acute	O
and	O
chronic	O
encephalomyelitis	O
,	O
using	O
a	O
newly	O
developed	O
bacterial	O
artificial	O
chromosome	B-COMP
(	O
BAC	O
)-	O
based	O
MHV	O
reverse	O
genetics	O
system	O
.	O

Understanding	O
the	O
mechanism	O
used	O
by	O
this	O
enzyme	O
to	O
promote	O
viral	O
pathogenesis	O
will	O
open	O
up	O
novel	O
avenues	O
for	O
therapies	O
and	O
may	O
give	O
further	O
insight	O
into	O
the	O
role	O
of	O
macrodomain	O
proteins	O
in	O
the	O
host	B-COMP
cell	I-COMP
since	O
these	O
proteins	O
are	O
found	O
in	O
all	O
living	O
organisms	O
.	O

Coronaviruses	O
recognize	O
a	O
variety	O
of	O
host	B-COMP
receptors	O
,	O
infect	O
many	O
hosts	B-COMP
,	O
and	O
are	O
health	O
threats	O
to	O
humans	O
and	O
animals	O
.	O

TITLE	O
:	O
Coronavirus	O
nonstructural	O
protein	O
1	O
:	O
Common	O
and	O
distinct	O
functions	O
in	O
the	O
regulation	O
of	O
host	B-COMP
and	O
viral	O
gene	O
expression	O
.	O

The	O
nonstructural	O
protein	O
1	O
(	O
nsp1	O
)	O
of	O
CoVs	O
has	O
attracted	O
considerable	O
attention	O
in	O
this	O
regard	O
as	O
a	O
potential	O
virulence	O
factor	O
and	O
a	O
target	O
for	O
CoV	O
vaccine	O
development	O
because	O
of	O
accumulating	O
evidence	O
that	O
point	O
to	O
its	O
role	O
in	O
the	O
downregulation	O
of	O
host	B-COMP
innate	O
immune	O
responses	O
to	O
CoV	O
infection	O
.	O

It	O
has	O
been	O
shown	O
that	O
host	B-COMP
phylogeny	O
is	O
the	O
primary	O
factor	O
that	O
determines	O
a	O
virus	O
'	O
s	O
persistence	O
,	O
replicative	O
ability	O
,	O
and	O
can	O
act	O
as	O
a	O
predictor	O
of	O
new	O
emerging	O
disease	O
.	O

29	O
patients	O
(	O
69	O
%)	O
were	O
transported	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
,	O
while	O
13	O
patients	O
(	O
31	O
%)	O
were	O
transported	O
with	O
conventional	O
ventilation	O
.	O

Tryptase	O
levels	O
are	O
seldom	O
increased	O
because	O
of	O
infant	O
anaphylaxis	O
,	O
although	O
baseline	O
tryptase	O
levels	O
can	O
be	O
increased	O
in	O
the	O
first	O
few	O
months	O
of	O
life	O
,	O
reflecting	O
mast	O
cell	B-COMP
burden	O
in	O
the	O
developing	O
immune	O
system	O
.	O

Autopsy	O
lung	O
tissue	O
was	O
assigned	O
scores	O
for	O
histologic	O
abnormalities	O
in	O
9	O
categories	O
,	O
including	O
alveolar	O
and	O
interstitial	O
fibrosis	O
,	O
hyaline	O
membranes	O
,	O
and	O
type	O
II	O
epithelial	O
cell	B-COMP
proliferation	O
.	O

While	O
coronavirus	O
cell	B-COMP
and	O
tissue	O
tropism	O
,	O
host	B-COMP
range	O
,	O
and	O
pathogenesis	O
are	O
initially	O
controlled	O
by	O
interactions	O
between	O
the	O
spike	O
envelope	B-COMP
glycoprotein	O
and	O
host	B-COMP
cell	I-COMP
receptor	O
,	O
it	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
proteolytic	O
activation	O
of	O
spike	O
by	O
host	B-COMP
cell	I-COMP
proteases	O
also	O
plays	O
a	O
critical	O
role	O
.	O

Receptor	O
-	O
binding	O
domains	O
(	O
RBD	O
)	O
have	O
been	O
identified	O
in	O
the	O
S	O
of	O
diverse	O
CoV	O
;	O
they	O
usually	O
contain	O
antigenic	O
determinants	O
targeted	O
by	O
antibodies	B-COMP
that	O
neutralize	O
CoV	O
infections	O
.	O

Here	O
we	O
review	O
the	O
CoV	O
-	O
receptor	B-COMP
complex	I-COMP
structures	O
reported	O
to	O
date	O
,	O
and	O
highlight	O
the	O
distinct	O
receptor	O
recognition	O
modes	O
,	O
common	O
features	O
,	O
and	O
key	O
determinants	O
of	O
the	O
binding	O
specificity	O
.	O

Macrophage	O
cultures	O
from	O
the	O
two	O
types	O
of	O
animals	O
differed	O
dramatically	O
in	O
the	O
percentage	O
of	O
cells	B-COMP
infected	O
.	O

Here	O
,	O
we	O
summarize	O
recent	O
advances	O
in	O
identifying	O
human	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
against	O
MERS	O
-	O
CoV	O
,	O
describe	O
their	O
mechanisms	O
of	O
action	O
,	O
and	O
analyze	O
their	O
potential	O
for	O
treatment	O
of	O
MERS	O
-	O
CoV	O
infections	O
.	O

Selectivity	O
indices	O
calculated	O
based	O
on	O
in	O
vitro	O
cytotoxicity	O
screening	O
and	O
reductions	O
in	O
extracellular	B-COMP
viral	O
titre	O
were	O
217	O
,	O
24	O
,	O
and	O
20	O
for	O
chloroquine	O
,	O
mefloquine	O
,	O
and	O
hexamethylene	O
amiloride	O
respectively	O
.	O

Both	O
liquid	O
and	O
dried	O
samples	O
were	O
subjected	O
to	O
three	O
passages	O
on	O
VERO	O
cell	B-COMP
monolayers	O
to	O
determine	O
PEDV	O
infectivity	O
.	O

ABSTRACT	O
:	O
Newly	O
emerging	O
human	O
viruses	O
such	O
as	O
Ebola	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
virus	O
,	O
and	O
HIV	O
likely	O
originate	O
within	O
an	O
extant	O
population	O
of	O
viruses	O
in	O
nonhuman	O
hosts	B-COMP
and	O
acquire	O
the	O
ability	O
to	O
infect	O
and	O
cause	O
disease	O
in	O
humans	O
.	O

The	O
viral	B-COMP
genome	I-COMP
has	O
an	O
abundance	O
of	O
codons	O
that	O
are	O
rare	O
in	O
the	O
host	B-COMP
and	O
are	O
decoded	O
by	O
wobble	O
tRNA	O
pairing	O
,	O
although	O
the	O
phage	O
grows	O
well	O
and	O
expression	O
of	O
most	O
of	O
the	O
genes	O
is	O
detected	O
by	O
mass	O
spectrometry	O
.	O

The	O
different	O
steps	O
are	O
:	O
incubation	O
with	O
the	O
serum	B-COMP
sample	O
,	O
secondary	O
antibodies	B-COMP
and	O
fluorescent	O
reporters	O
and	O
finally	O
washing	O
to	O
remove	O
any	O
non	O
-	O
specifically	O
bound	O
species	O
.	O

Three	O
regions	O
of	O
the	O
S2	O
subunit	O
have	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
.	O

These	O
results	O
may	O
help	O
in	O
the	O
future	O
to	O
identify	O
the	O
role	O
of	O
cellular	B-COMP
proteins	O
during	O
coronavirus	O
assembly	O
at	O
the	O
ER	B-COMP
-	I-COMP
Golgi	I-COMP
intermediate	I-COMP
compartment	I-COMP
.	O

Interestingly	O
,	O
molecular	O
analyses	O
targeting	O
small	O
subunit	O
ribosomal	B-COMP
RNA	I-COMP
as	O
well	O
as	O
glycoprotein	O
60	O
(	O
GP60	O
)	O
genes	O
revealed	O
that	O
the	O
C	O
.	O
parvum	O
nucleotide	O
sequences	O
from	O
the	O
two	O
prefectures	O
were	O
identical	O
,	O
indicating	O
that	O
C	O
.	O
parvum	O
with	O
a	O
uniform	O
characteristic	O
is	O
distributed	O
throughout	O
Japan	O
.	O

One	O
key	O
area	O
of	O
research	O
in	O
the	O
positive	O
sense	O
RNA	O
virus	O
field	O
,	O
due	O
to	O
its	O
central	O
role	O
in	O
virus	O
replication	O
,	O
is	O
the	O
induction	O
of	O
cellular	B-COMP
membrane	I-COMP
rearrangements	O
by	O
this	O
class	O
of	O
viruses	O
for	O
the	O
assembly	O
of	O
virus	O
replication	O
complexes	O
.	O

The	O
virus	O
in	O
the	O
harvest	O
can	O
be	O
used	O
to	O
characterize	O
the	O
viral	B-COMP
genome	I-COMP
sequence	O
and	O
cell	B-COMP
tropism	O
,	O
but	O
also	O
provides	O
progeny	O
virus	O
to	O
initiate	O
experiments	O
to	O
fulfill	O
the	O
Koch	O
'	O
s	O
postulates	O
.	O

Cells	B-COMP
were	O
stained	O
with	O
convalescent	O
serum	B-COMP
of	O
the	O
patients	O
to	O
identify	O
infected	O
cells	B-COMP
and	O
apical	O
washes	O
were	O
analyzed	O
by	O
VIDISCA	O
-	O
454	O
,	O
a	O
next	O
-	O
generation	O
sequencing	O
virus	O
discovery	O
technique	O
.	O

The	O
crystals	O
diffracted	O
to	O
2	O
.	O
6	O
Å	O
resolution	O
and	O
belonged	O
to	O
space	O
group	O
P212121	O
,	O
with	O
unit	O
-	O
cell	B-COMP
parameters	O
a	O
=	O
31	O
.	O
9	O
,	O
b	O
=	O
85	O
.	O
0	O
,	O
c	O
=	O
95	O
.	O
0	O
Å	O
.	O
Two	O
molecules	O
were	O
identified	O
per	O
asymmetric	O
unit	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
the	O
effects	O
of	O
specific	O
kinase	O
inhibitors	O
on	O
MERS	O
-	O
CoV	O
infection	O
in	O
tissue	O
culture	O
models	O
confirmed	O
these	O
cellular	B-COMP
response	O
observations	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
reservoir	O
hosts	B-COMP
of	O
several	O
high	O
-	O
impact	O
viruses	O
that	O
cause	O
significant	O
human	O
diseases	O
,	O
including	O
Nipah	O
virus	O
,	O
Marburg	O
virus	O
and	O
rabies	O
virus	O
.	O

Their	O
functions	O
range	O
from	O
nucleic	B-COMP
acid	O
duplex	O
unwinding	O
to	O
protein	O
displacement	O
and	O
double	O
-	O
strand	O
translocation	O
.	O

The	O
physiologic	O
effects	O
of	O
hypercapnia	O
are	O
increasingly	O
well	O
understood	O
,	O
and	O
important	O
recent	O
insights	O
have	O
emerged	O
regarding	O
the	O
cellular	B-COMP
and	O
molecular	O
mechanisms	O
of	O
action	O
of	O
hypercapnia	O
and	O
acidosis	O
.	O

Thus	O
,	O
our	O
study	O
reveals	O
that	O
coronavirus	O
engages	O
PLPs	O
to	O
escape	O
from	O
the	O
innate	O
antiviral	O
response	O
of	O
the	O
host	B-COMP
by	O
inhibiting	O
p53	O
-	O
IRF7	O
-	O
IFNβ	O
signaling	O
.	O

This	O
may	O
simply	O
be	O
due	O
to	O
the	O
universal	O
IBV	O
qRT	O
-	O
PCR	O
assay	O
being	O
more	O
sensitive	O
than	O
virus	O
detection	O
in	O
eggs	O
or	O
to	O
the	O
assay	O
detecting	O
nucleic	B-COMP
acid	O
from	O
nonviable	O
virus	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
a	O
tool	O
for	O
prediction	O
of	O
the	O
host	B-COMP
tropism	O
of	O
the	O
virus	O
based	O
on	O
the	O
host	B-COMP
receptor	O
binding	O
interface	O
.	O

Serum	B-COMP
antibodies	B-COMP
as	O
measured	O
by	O
indirect	O
immunofluorescence	O
appeared	O
after	O
2	O
weeks	O
p	O
.	O
i	O
.	O
and	O
correlated	O
with	O
the	O
onset	O
of	O
disease	O
signs	O
.	O

ABSTRACT	O
:	O
Nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
packages	O
viral	O
RNA	O
genome	O
to	O
form	O
a	O
ribonucleoprotein	B-COMP
complex	I-COMP
.	O

To	O
identify	O
cellular	B-COMP
proteins	O
that	O
interacted	O
with	O
N	O
protein	O
of	O
TGEV	O
,	O
methods	O
of	O
GST	O
pull	O
-	O
down	O
and	O
Co	O
-	O
IP	O
were	O
utilized	O
to	O
precipitate	O
cellular	B-COMP
proteins	O
of	O
swine	O
testicular	O
(	O
ST	O
).	O

Bound	O
cellular	B-COMP
proteins	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
.	O

Vimentin	B-COMP
cytoskeleton	B-COMP
was	O
required	O
for	O
virus	O
replication	O
.	O

RESULTS	O
:	O
Using	O
topological	O
techniques	O
,	O
including	O
persistence	O
homology	O
and	O
filtered	O
clustering	O
,	O
we	O
performed	O
a	O
comparative	O
transcriptional	O
analysis	O
of	O
human	O
Calu	O
-	O
3	O
cell	B-COMP
host	B-COMP
responses	O
to	O
the	O
different	O
MERS	O
-	O
CoV	O
strains	O
,	O
with	O
MERS	O
-	O
CoV	O
Eng	O
1	O
inducing	O
early	O
kinetic	O
changes	O
,	O
between	O
3	O
and	O
12	O
hours	O
post	O
infection	O
,	O
compared	O
to	O
MERS	O
-	O
CoV	O
SA	O
1	O
.	O

Combining	O
statistical	O
analysis	O
of	O
infection	O
and	O
cytokine	O
-	O
stimulated	O
Calu	O
-	O
3	O
transcriptomics	O
,	O
we	O
identified	O
differential	O
innate	O
responses	O
,	O
including	O
up	O
-	O
regulation	O
of	O
extracellular	B-COMP
remodeling	O
genes	O
following	O
MERS	O
-	O
CoV	O
Eng	O
1	O
infection	O
and	O
differential	O
pro	O
-	O
inflammatory	O
responses	O
.	O

This	O
has	O
resulted	O
in	O
an	O
urgent	O
need	O
to	O
identify	O
antiviral	O
drugs	O
that	O
are	O
active	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
papain	O
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
of	O
MERS	O
-	O
CoV	O
represents	O
an	O
important	O
antiviral	O
target	O
as	O
it	O
is	O
not	O
only	O
essential	O
for	O
viral	O
maturation	O
,	O
but	O
also	O
antagonizes	O
interferon	O
stimulation	O
of	O
the	O
host	B-COMP
via	O
its	O
deubiquitination	O
activity	O
.	O

Under	O
hyperoxic	O
conditions	O
,	O
the	O
lungs	O
of	O
NLRP3	O
(-/-)	O
mice	O
exhibited	O
reduced	O
inflammatory	O
responses	O
,	O
such	O
as	O
inflammatory	O
cell	B-COMP
infiltration	O
and	O
cytokine	O
expression	O
,	O
as	O
well	O
as	O
increased	O
and	O
decreased	O
expression	O
of	O
MMP	O
-	O
9	O
and	O
Bcl	O
-	O
2	O
,	O
respectively	O
.	O

Endotoxin	O
infusion	O
increased	O
serum	B-COMP
ET	O
-	O
1	O
,	O
and	O
INO	O
almost	O
doubled	O
the	O
ratio	O
between	O
mRNA	O
expression	O
of	O
endothelin	O
receptor	O
A	O
(	O
mediating	O
vasoconstriction	O
)	O
and	O
B	O
(	O
mediating	O
vasodilation	O
and	O
clearance	O
of	O
ET	O
-	O
1	O
)	O
(	O
ET	O
-	O
A	O
/	O
ET	O
-	O
B	O
)	O
in	O
atelectatic	O
lung	O
regions	O
.	O

Here	O
,	O
we	O
collect	O
and	O
interpret	O
the	O
recent	O
experimental	O
evidence	O
about	O
the	O
role	O
and	O
importance	O
of	O
membrane	B-COMP
-	O
bound	O
organelles	B-COMP
in	O
coronavirus	O
replication	O
.	O

TITLE	O
:	O
Ebola	O
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
display	O
late	O
cell	B-COMP
entry	O
kinetics	O
:	O
evidence	O
that	O
transport	O
to	O
NPC1	O
+	O
endolysosomes	O
is	O
a	O
rate	O
-	O
defining	O
step	O
.	O

Despite	O
the	O
fact	O
that	O
the	O
SARS	O
-	O
CoV	O
pandemic	O
infected	O
over	O
8500	O
individuals	O
,	O
claimed	O
over	O
800	O
lives	O
and	O
cost	O
billions	O
of	O
dollars	O
in	O
economic	O
loss	O
worldwide	O
,	O
there	O
still	O
are	O
no	O
clinically	O
approved	O
antiviral	O
drugs	O
,	O
vaccines	O
or	O
monoclonal	O
antibody	B-COMP
therapies	O
to	O
treat	O
SARS	O
-	O
CoV	O
infections	O
.	O

This	O
determined	O
six	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
that	O
were	O
associated	O
with	O
antibody	B-COMP
levels	O
against	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
):	O
rsZ2494661	O
,	O
rsZ2494710	O
,	O
rs1211307701	O
,	O
rs1211307711	O
,	O
rs1218289310	O
and	O
rs420701988	O
.	O

Biologically	O
,	O
PEDV	O
strain	O
CV777	O
induced	O
greater	O
cell	B-COMP
fusion	O
in	O
Vero	O
cells	B-COMP
than	O
did	O
U	O
.	O
S	O
.	O
PEDV	O
strains	O
.	O

The	O
frequency	O
of	O
CD8	O
(+)	O
and	O
TCRγδ	O
(+)	O
T	O
cells	B-COMP
expression	O
was	O
examined	O
by	O
immunohistochemistry	O
,	O
followed	O
by	O
image	O
analysis	O
.	O

We	O
previously	O
reported	O
the	O
successful	O
in	O
vitro	O
inhibition	O
of	O
FIPV	O
replication	O
by	O
synthetic	O
siRNA	O
mediated	O
RNA	O
interference	O
(	O
RNAi	O
)	O
in	O
an	O
immortalised	O
cell	B-COMP
line	O
(	O
McDonagh	O
et	O
al	O
.,	O
2011	O
).	O

ABSTRACT	O
:	O
Animal	O
cells	B-COMP
use	O
a	O
wide	O
variety	O
of	O
mechanisms	O
to	O
slow	O
or	O
prevent	O
replication	O
of	O
viruses	O
.	O

TITLE	O
:	O
Proteome	O
analysis	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)-	O
infected	O
Vero	O
cells	B-COMP
.	O

These	O
results	O
demonstrate	O
that	O
substrate	O
specificities	O
of	O
IBV	O
PLpro	O
are	O
different	O
from	O
other	O
PLpros	O
and	O
that	O
IBV	O
PLpro	O
might	O
target	O
different	O
ubiquitinated	O
host	B-COMP
factors	O
to	O
aid	O
the	O
propagation	O
of	O
the	O
virus	O
.	O

The	O
high	O
virulence	O
and	O
mortality	O
rate	O
prompted	O
us	O
to	O
analyze	O
aspects	O
of	O
MERS	O
-	O
CoV	O
pathogenesis	O
,	O
especially	O
its	O
interaction	O
with	O
innate	O
immune	O
cells	B-COMP
such	O
as	O
antigen	O
-	O
presenting	O
cells	B-COMP
(	O
APCs	O
).	O

Here	O
,	O
we	O
show	O
that	O
small	O
deletions	O
and	O
modifications	O
within	O
the	O
E	O
protein	O
led	O
to	O
virus	O
attenuation	O
,	O
manifested	O
by	O
minimal	O
lung	O
injury	O
,	O
limited	O
neutrophil	O
influx	O
to	O
the	O
lungs	O
,	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
,	O
increased	O
anti	O
-	O
inflammatory	O
cytokine	O
levels	O
,	O
and	O
enhanced	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cell	B-COMP
counts	O
in	O
vivo	O
,	O
suggesting	O
that	O
these	O
phenomena	O
contribute	O
to	O
virus	O
attenuation	O
.	O

To	O
determine	O
the	O
effectiveness	O
and	O
safety	O
of	O
transfusing	O
patients	O
with	O
severe	O
trauma	O
and	O
major	O
bleeding	O
using	O
plasma	O
,	O
platelets	O
,	O
and	O
red	O
blood	O
cells	B-COMP
in	O
a	O
1	O
:	O
1	O
:	O
1	O
ratio	O
compared	O
with	O
a	O
1	O
:	O
1	O
:	O
2	O
ratio	O
.	O

Despite	O
the	O
1	O
:	O
1	O
:	O
1	O
group	O
receiving	O
more	O
plasma	O
(	O
median	O
of	O
7	O
U	O
vs	O
5	O
U	O
,	O
P	O
<	O
.	O
001	O
)	O
and	O
platelets	O
(	O
12	O
U	O
vs	O
6	O
U	O
,	O
P	O
<	O
.	O
001	O
)	O
and	O
similar	O
amounts	O
of	O
red	O
blood	O
cells	B-COMP
(	O
9	O
U	O
)	O
over	O
the	O
first	O
24	O
hours	O
,	O
no	O
differences	O
between	O
the	O
2	O
groups	O
were	O
found	O
for	O
the	O
23	O
prespecified	O
complications	O
,	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
multiple	O
organ	O
failure	O
,	O
venous	O
thromboembolism	O
,	O
sepsis	O
,	O
and	O
transfusion	O
-	O
related	O
complications	O
.	O

Lack	O
of	O
ATP1A1	O
did	O
not	O
affect	O
virus	O
binding	O
to	O
host	B-COMP
cells	B-COMP
but	O
resulted	O
in	O
inhibited	O
entry	O
of	O
MHV	O
and	O
VSV	O
.	O

As	O
deletions	O
in	O
CoV	O
accessory	O
proteins	O
have	O
already	O
been	O
involved	O
in	O
tissue	O
or	O
host	B-COMP
switch	O
,	O
studies	O
of	O
these	O
different	O
gp3	O
proteins	O
were	O
conducted	O
in	O
canine	O
and	O
feline	O
cell	B-COMP
.	O

However	O
,	O
it	O
is	O
currently	O
unclear	O
which	O
protease	O
(	O
s	O
)	O
facilitate	O
viral	O
spread	O
in	O
the	O
infected	O
host	B-COMP
.	O

We	O
report	O
here	O
that	O
the	O
cysteine	O
protease	O
inhibitor	O
K11777	O
,	O
((	O
2S	O
)-	O
N	O
-[(	O
1E	O
,	O
3S	O
)-	O
1	O
-(	O
benzenesulfonyl	O
)-	O
5	O
-	O
phenylpent	O
-	O
1	O
-	O
en	O
-	O
3	O
-	O
yl	O
]-	O
2	O
-{[(	O
E	O
)-	O
4	O
-	O
methylpiperazine	O
-	O
1	O
-	O
carbonyl	O
]	O
amino	O
}-	O
3	O
-	O
phenylpropanamide	O
)	O
and	O
closely	O
-	O
related	O
vinylsulfones	O
act	O
as	O
broad	O
-	O
spectrum	O
antivirals	O
by	O
targeting	O
cathepsin	O
-	O
mediated	O
cell	B-COMP
entry	O
.	O

Ala	O
substitutions	O
of	O
Trp	O
inhibited	O
its	O
association	O
with	O
cellular	B-COMP
membranes	O
.	O

Overall	O
,	O
our	O
results	O
show	O
that	O
Trp	O
residues	O
of	O
MPER	O
play	O
a	O
key	O
role	O
in	O
maintaining	O
the	O
structure	O
and	O
functions	O
of	O
MPER	O
,	O
allowing	O
it	O
to	O
interact	O
with	O
IFP	O
to	O
form	O
a	O
MPER	O
-	O
IFP	O
heteromer	O
,	O
a	O
putative	O
quaternary	O
structure	O
extending	O
from	O
the	O
6	O
-	O
HB	O
,	O
and	O
function	O
in	O
membrane	B-COMP
fusion	O
.	O

Indirect	O
immunofluorescence	O
assay	O
,	O
real	O
-	O
time	O
PCR	O
,	O
and	O
transmission	O
electron	O
microscopy	O
confirmed	O
PEDV	O
can	O
be	O
successfully	O
propagated	O
in	O
immortalized	O
swine	O
small	O
intestine	O
epithelial	O
cells	B-COMP
(	O
IECs	O
).	O

In	O
this	O
study	O
,	O
nine	O
alkylated	O
chalcones	O
(	O
1	O
-	O
9	O
)	O
and	O
four	O
coumarins	O
(	O
10	O
-	O
13	O
)	O
were	O
isolated	O
from	O
Angelica	O
keiskei	O
,	O
and	O
the	O
inhibitory	O
activities	O
of	O
these	O
constituents	O
against	O
SARS	O
-	O
CoV	O
proteases	O
(	O
3CL	O
(	O
pro	O
)	O
and	O
PL	O
(	O
pro	O
))	O
were	O
determined	O
(	O
cell	B-COMP
-	O
free	O
/	O
based	O
).	O

It	O
serves	O
to	O
reach	O
specificity	O
and	O
considerable	O
affinity	O
to	O
target	O
molecules	O
,	O
including	O
those	O
of	O
viral	O
origin	O
,	O
both	O
proteins	O
and	O
nucleic	B-COMP
acids	O
.	O

The	O
presentation	O
of	O
E2S	O
-	O
like	O
,	O
SARS	O
spike	O
protein	O
-	O
like	O
,	O
or	O
toxin	O
-	O
like	O
domains	O
by	O
the	O
N10	O
and	O
N11	O
proteins	O
in	O
these	O
emerging	O
viruses	O
may	O
indicate	O
that	O
H17N10	O
and	O
H18N11	O
sialidase	O
-	O
facilitated	O
cell	B-COMP
entry	O
has	O
been	O
supplemented	O
or	O
replaced	O
by	O
sialidase	O
-	O
independent	O
receptor	O
binding	O
to	O
an	O
expanded	O
cell	B-COMP
population	O
that	O
may	O
include	O
neurons	O
and	O
T	O
-	O
cells	B-COMP
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
the	O
unusual	O
role	O
of	O
cathepsin	O
proteases	O
in	O
the	O
life	O
cycle	O
of	O
bat	O
-	O
borne	O
viruses	O
is	O
not	O
due	O
to	O
the	O
lack	O
of	O
active	O
furin	O
-	O
like	O
proteases	O
in	O
these	O
natural	O
reservoir	O
species	O
;	O
however	O
,	O
differences	O
may	O
exist	O
between	O
furin	O
proteases	O
present	O
in	O
fruit	O
bats	O
compared	O
to	O
furins	O
in	O
other	O
mammalian	O
species	O
,	O
and	O
these	O
differences	O
may	O
impact	O
protease	O
usage	O
for	O
viral	B-COMP
glycoprotein	I-COMP
processing	O
.	O

Blood	O
samples	O
were	O
obtained	O
at	O
I	O
,	O
2	O
,	O
5	O
,	O
and	O
12	O
weeks	O
for	O
determination	O
of	O
serum	B-COMP
neutralization	O
antibody	B-COMP
titers	O
against	O
the	O
vaccine	O
viruses	O
,	O
bovine	O
coronavirus	O
,	O
and	O
Mannheimia	O
haemolytica	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
the	O
short	O
-	O
term	O
(	O
days	O
to	O
weeks	O
)	O
support	O
of	O
patients	O
with	O
severe	O
respiratory	O
and	O
/	O
or	O
cardiac	O
failure	O
.	O

These	O
characteristics	O
make	O
coronaviruses	O
an	O
interesting	O
model	O
system	O
to	O
study	O
the	O
mechanisms	O
involved	O
in	O
viral	O
evolution	O
and	O
the	O
ways	O
viruses	O
adapt	O
to	O
switch	O
host	B-COMP
or	O
to	O
gain	O
novel	O
functions	O
.	O

TITLE	O
:	O
The	O
preparation	O
of	O
chicken	O
kidney	O
cell	B-COMP
cultures	O
for	O
virus	O
propagation	O
.	O

Embryonated	O
eggs	O
also	O
provide	O
a	O
potential	O
host	B-COMP
system	O
for	O
detection	O
and	O
characterization	O
of	O
other	O
,	O
novel	O
coronaviruses	O
.	O

Receptors	O
can	O
be	O
major	O
determinants	O
of	O
tropism	O
,	O
host	B-COMP
range	O
,	O
and	O
pathogenesis	O
.	O

Identification	O
of	O
the	O
cellular	B-COMP
factors	O
required	O
for	O
viral	O
survival	O
or	O
eliminating	O
virus	O
infected	O
cells	B-COMP
could	O
help	O
scientists	O
develop	O
more	O
effective	O
antiviral	O
drugs	O
.	O

ABSTRACT	O
:	O
Transmission	O
electron	O
microscopy	O
(	O
TEM	B-COMP
)	O
is	O
an	O
invaluable	O
technique	O
used	O
for	O
imaging	O
the	O
ultrastructure	O
of	O
samples	O
and	O
it	O
is	O
particularly	O
useful	O
when	O
determining	O
virus	O
-	O
host	B-COMP
interactions	O
at	O
a	O
cellular	B-COMP
level	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
managing	O
acute	O
respiratory	O
distress	O
syndrome	O
had	O
been	O
accepted	O
.	O

The	O
monoclonal	O
antibody	B-COMP
2D1	O
may	O
provide	O
a	O
useful	O
tool	O
as	O
a	O
specific	O
diagnostic	O
reagent	O
for	O
detecting	O
S	O
protein	O
of	O
the	O
Chinese	O
variant	O
of	O
PEDV	O
and	O
for	O
further	O
investigation	O
into	O
the	O
virus	O
'	O
pathogenic	O
mechanism	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
with	O
the	O
aim	O
to	O
develop	O
anti	O
-	O
spike	O
1	O
(	O
S1	O
)	O
subunit	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)	O
that	O
could	O
react	O
with	O
IBV	O
strains	O
of	O
different	O
genotypes	O
.	O

End	O
-	O
point	O
neutralizing	O
assay	O
performed	O
in	O
chicken	O
embro	O
kidney	O
(	O
CEK	O
)	O
cells	B-COMP
revealed	O
that	O
the	O
neutralization	O
titer	O
of	O
1C8	O
and	O
2C10	O
against	O
Sczy3	O
reached	O
1	O
:	O
2	O
.	O
82	O
and	O
1	O
:	O
4	O
.	O
70	O
,	O
respectively	O
.	O

E	O
protein	O
localized	O
in	O
the	O
ERGIC	B-COMP
and	O
Golgi	B-COMP
with	O
the	O
amino	O
and	O
carboxy	O
termini	O
in	O
the	O
lumen	O
and	O
cytoplasm	B-COMP
,	O
respectively	O
.	O

It	O
might	O
be	O
speculated	O
that	O
host	B-COMP
factors	O
such	O
as	O
the	O
function	O
of	O
the	O
immune	O
system	O
influence	O
the	O
clinical	O
outcome	O
of	O
the	O
infection	O
.	O

The	O
detection	O
limit	O
corresponds	O
to	O
a	O
cycle	O
treshold	O
value	O
of	O
∼	O
35	O
with	O
standard	O
upE	O
real	O
time	O
PCR	O
assays	O
on	O
RNA	O
isolated	O
from	O
MERS	O
-	O
CoV	O
EMC	B-COMP
.	O

Although	O
there	O
was	O
no	O
abnormal	O
finding	O
in	O
the	O
testes	O
,	O
serum	B-COMP
testicular	O
tumor	O
markers	O
showed	O
marked	O
elevation	O
.	O

The	O
full	O
-	O
length	O
S	O
and	O
N	O
genes	O
were	O
sequenced	O
to	O
study	O
PDCoV	O
genetic	O
changes	O
after	O
passage	O
in	O
Gn	O
pigs	O
and	O
cell	B-COMP
culture	O
(	O
passage	O
11	O
[	O
P11	O
]	O
and	O
P20	O
).	O

TITLE	O
:	O
CD107a	O
as	O
a	O
marker	O
of	O
activation	O
in	O
chicken	O
cytotoxic	O
T	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
was	O
expressed	O
in	O
a	O
prokaryotic	O
system	O
and	O
used	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	B-COMP
to	O
TCoV	O
.	O
Anti	O
-	O
TCoV	O
hyperimmune	O
turkey	O
serum	B-COMP
and	O
normal	O
turkey	O
serum	B-COMP
were	O
used	O
as	O
positive	O
or	O
negative	O
controls	O
for	O
optimization	O
of	O
the	O
ELISA	O
.	O

It	O
is	O
shown	O
that	O
the	O
brain	O
extracellular	B-COMP
matrix	I-COMP
(	O
ECM	B-COMP
)	O
strongly	O
limits	O
penetration	O
of	O
polymer	O
-	O
based	O
gene	O
vector	O
nanoparticles	O
(	O
NP	O
)	O
through	O
the	O
brain	O
parenchyma	O
,	O
even	O
when	O
they	O
are	O
very	O
small	O
(<	O
60	O
nm	O
)	O
and	O
coated	O
with	O
a	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
corona	O
of	O
typical	O
density	O
.	O

We	O
describe	O
herein	O
the	O
optimization	O
of	O
dipeptidyl	O
inhibitors	O
of	O
norovirus	O
3C	O
-	O
like	O
protease	O
using	O
iterative	O
SAR	O
,	O
X	O
-	O
ray	O
crystallographic	O
,	O
and	O
enzyme	O
and	O
cell	B-COMP
-	O
based	O
studies	O
.	O

Intragastric	O
administration	O
of	O
either	O
Ad5	O
-	O
S	O
or	O
Ad41	O
-	O
S	O
induced	O
antigen	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-COMP
in	O
serum	B-COMP
;	O
however	O
,	O
antigen	O
-	O
specific	O
T	O
-	O
cell	B-COMP
responses	O
were	O
not	O
detected	O
.	O

Both	O
rAd	O
-	O
based	O
vaccines	O
administered	O
intramuscularly	O
induced	O
systemic	O
humoral	O
immune	O
responses	O
(	O
neutralizing	O
IgG	O
antibodies	B-COMP
).	O

In	O
contrast	O
,	O
zVAD	O
did	O
not	O
reduce	O
apoptosis	O
of	O
lung	O
epithelial	O
cells	B-COMP
and	O
did	O
not	O
affect	O
the	O
degree	O
of	O
lung	O
injury	O
,	O
permeability	O
,	O
and	O
viral	O
titers	O
in	O
PVM	O
disease	O
.	O

Deep	O
sequencing	O
generated	O
3	O
,	O
704	O
,	O
353	O
and	O
2	O
,	O
763	O
,	O
665	O
reads	O
from	O
uninfected	O
ST	O
cells	B-COMP
and	O
infected	O
ST	O
cells	B-COMP
,	O
respectively	O
.	O

TITLE	O
:	O
Receptor	O
usage	O
and	O
cell	B-COMP
entry	O
of	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
.	O

Moreover	O
,	O
PEDV	O
infects	O
cells	B-COMP
from	O
pig	O
,	O
human	O
,	O
monkey	O
,	O
and	O
bat	O
.	O

Western	O
blot	O
analysis	O
using	O
recombinant	O
DcEV	O
VP1	O
polypeptide	O
showed	O
a	O
high	O
seroprevalence	O
of	O
52	O
%	O
among	O
serum	B-COMP
samples	O
from	O
172	O
dromedaries	O
for	O
IgG	O
,	O
concurring	O
with	O
its	O
much	O
higher	O
infection	O
rates	O
in	O
dromedary	O
calves	O
than	O
in	O
adults	O
.	O

Here	O
,	O
we	O
elucidated	O
for	O
the	O
first	O
time	O
to	O
our	O
knowledge	O
the	O
potential	O
mechanism	O
of	O
PEDV	O
-	O
mediated	O
NF	O
-	O
κB	O
activation	O
in	O
porcine	O
small	O
intestinal	O
epithelial	O
cells	B-COMP
(	O
IECs	O
).	O

The	O
pathogenicity	O
and	O
pathogenesis	O
of	O
PDCoV	O
was	O
investigated	O
following	O
orogastric	O
inoculation	O
of	O
5	O
-	O
day	O
-	O
old	O
piglets	O
with	O
a	O
plaque	O
-	O
purified	O
PDCoV	O
cell	B-COMP
culture	O
isolate	O
(	O
3	O
×	O
10	O
(	O
4	O
)	O
TCID50	O
per	O
pig	O
).	O

Most	O
of	O
these	O
viruses	O
are	O
genetically	O
simple	O
and	O
rely	O
heavily	O
on	O
co	O
-	O
opting	O
cellular	B-COMP
proteins	O
,	O
particularly	O
cellular	B-COMP
RNA	O
-	O
binding	O
proteins	O
,	O
into	O
new	O
roles	O
for	O
support	O
of	O
virus	O
infection	O
at	O
the	O
level	O
of	O
virus	O
-	O
specific	O
translation	O
,	O
and	O
building	O
RNA	O
replication	O
complexes	O
.	O

It	O
was	O
identified	O
to	O
be	O
approximately	O
32	O
kDa	O
as	O
a	O
His	O
-	O
tagged	O
fusion	O
protein	O
and	O
can	O
bind	O
IBV	O
positive	O
serum	B-COMP
by	O
western	O
blot	O
analysis	O
.	O

Similarly	O
,	O
cells	B-COMP
with	O
reduced	O
levels	O
of	O
the	O
tetraspanin	O
CD9	O
resisted	O
CoV	O
pseudoparticle	O
transductions	O
but	O
were	O
made	O
susceptible	O
by	O
overproducing	O
TEM	B-COMP
-	O
associated	O
proteases	O
.	O

The	O
ΔTNC	O
has	O
a	O
high	O
diagnostic	O
accuracy	O
for	O
FIP	O
-	O
related	O
effusions	O
by	O
providing	O
an	O
estimate	O
of	O
precipitable	O
proteins	O
,	O
as	O
the	O
Rivalta	O
'	O
s	O
test	O
,	O
in	O
addition	O
to	O
the	O
cell	B-COMP
count	O
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
respiratory	O
virus	O
infections	O
prior	O
to	O
hematopoietic	O
cell	B-COMP
transplant	O
(	O
HCT	O
)	O
is	O
difficult	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
blastomycosis	O
-	O
related	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
case	O
series	O
.	O

For	O
efficient	O
virion	B-COMP
assembly	O
,	O
these	O
proteins	O
must	O
be	O
targeted	O
to	O
the	O
budding	O
site	O
and	O
to	O
interact	O
with	O
each	O
other	O
or	O
the	O
ribonucleoprotein	B-COMP
.	O

ABSTRACT	O
:	O
The	O
transmission	O
potential	O
of	O
a	O
novel	O
infection	O
depends	O
on	O
both	O
the	O
inherent	O
transmissibility	O
of	O
a	O
pathogen	O
,	O
and	O
the	O
level	O
of	O
susceptibility	O
in	O
the	O
host	B-COMP
population	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
may	O
be	O
a	O
useful	O
tool	O
in	O
non	O
-	O
operative	O
management	O
of	O
tracheal	O
injury	O
in	O
the	O
setting	O
of	O
severe	O
respiratory	O
failure	O
and	O
need	O
for	O
prolonged	O
intubation	O
.	O

In	O
the	O
cross	O
-	O
sectional	O
serosurvey	O
,	O
we	O
tested	O
human	O
serum	B-COMP
samples	O
obtained	O
from	O
healthy	O
individuals	O
older	O
than	O
15	O
years	O
who	O
attended	O
primary	O
health	O
-	O
care	O
centres	O
or	O
participated	O
in	O
a	O
national	O
burden	O
-	O
of	O
-	O
disease	O
study	O
in	O
all	O
13	O
provinces	O
of	O
Saudi	O
Arabia	O
.	O

Protection	O
studies	O
showed	O
that	O
the	O
percentage	O
of	O
antibody	B-COMP
-	O
positive	O
chickens	O
,	O
which	O
were	O
vaccinated	O
with	O
rBeau	O
-	O
H120	O
(	O
S1	O
)	O
at	O
7	O
days	O
after	O
hatching	O
,	O
rose	O
to	O
90	O
%	O
at	O
21	O
days	O
post	O
-	O
inoculation	O
.	O

Particularly	O
,	O
S377	O
-	O
588	O
-	O
Fc	O
at	O
1	O
μg	O
elicited	O
strong	O
neutralizing	O
antibody	B-COMP
responses	O
against	O
both	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
similar	O
to	O
those	O
induced	O
at	O
5	O
and	O
20	O
μg	O
,	O
respectively	O
.	O

IgM	B-COMP
antibody	I-COMP
was	O
positive	O
in	O
all	O
the	O
17	O
cases	O
,	O
which	O
included	O
9	O
male	O
cases	O
,	O
8	O
female	O
cases	O
,	O
and	O
their	O
age	O
was	O
from	O
2	O
months	O
to	O
10	O
years	O
.	O

The	O
clinical	O
feature	O
like	O
dyspnoea	O
,	O
cough	O
,	O
low	O
blood	O
pressure	O
(	O
MAP	O
<	O
65	O
mmHg	O
),	O
IVC	O
collapsibility	O
(	O
by	O
ultrasound	O
)	O
and	O
laboratory	O
parameters	O
like	O
decreased	O
Hemoglobin	O
,	O
Hematocrit	O
,	O
Serum	B-COMP
albumin	O
,	O
and	O
increased	O
serum	B-COMP
creatinine	O
,	O
serum	B-COMP
total	O
bilirubin	O
,	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
,	O
CPK	O
,	O
and	O
serum	B-COMP
lactate	O
were	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
in	O
scrub	O
typhus	O
patients	O
group	O
with	O
ARDS	O
.	O

Marked	O
monocytopenia	O
combined	O
with	O
B	O
-	O
cell	B-COMP
lymphopenia	O
led	O
to	O
a	O
suspicion	O
of	O
GATA	O
-	O
2	O
deficiency	O
.	O

We	O
conclude	O
that	O
a	O
diagnosis	O
of	O
GATA	O
-	O
2	O
deficiency	O
should	O
be	O
considered	O
in	O
all	O
patients	O
with	O
diffuse	O
parenchymal	O
lung	O
disease	O
presenting	O
together	O
with	O
leukocytopenia	O
,	O
namely	O
monocyto	O
-,	O
dendritic	B-COMP
cell	B-COMP
-	O
and	O
B	O
-	O
lymphopenia	O
,	O
irrespective	O
of	O
severity	O
of	O
the	O
clinical	O
phenotype	O
.	O

A	O
total	O
of	O
968	O
serum	B-COMP
samples	O
were	O
tested	O
including	O
samples	O
with	O
confirmed	O
infection	O
with	O
PDCoV	O
,	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
or	O
porcine	O
respiratory	O
coronavirus	O
.	O

Among	O
355	O
arbitrarily	O
selected	O
serum	B-COMP
samples	O
collected	O
in	O
2014	O
and	O
originating	O
from	O
51	O
farms	O
across	O
18	O
U	O
.	O
S	O
.	O
states	O
,	O
anti	O
-	O
PDCoV	O
IgG	O
antibodies	B-COMP
were	O
detected	O
in	O
8	O
.	O
7	O
%	O
of	O
the	O
samples	O
and	O
in	O
25	O
.	O
5	O
%	O
of	O
the	O
farms	O
whereas	O
anti	O
-	O
PEDV	O
IgG	O
was	O
detected	O
in	O
22	O
.	O
8	O
%	O
of	O
the	O
samples	O
and	O
in	O
54	O
.	O
9	O
%	O
of	O
the	O
farms	O
.	O

Due	O
to	O
the	O
difficulty	O
in	O
isolating	O
and	O
growing	O
this	O
virus	O
in	O
cell	B-COMP
culture	O
,	O
few	O
vaccine	O
studies	O
using	O
cell	B-COMP
culture	O
propagated	O
PEDV	O
have	O
been	O
performed	O
on	O
U	O
.	O
S	O
.	O
strains	O
in	O
pigs	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
child	O
with	O
severe	O
epileptic	O
disorder	O
treated	O
successfully	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
a	O
case	O
report	O
.	O

TITLE	O
:	O
The	O
ratio	O
of	O
Th17	O
/	O
Treg	O
cells	B-COMP
as	O
a	O
risk	O
indicator	O
in	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Meanwhile	O
,	O
compound	O
c26	O
reduced	O
the	O
LPS	O
-	O
induced	O
inflammatory	O
gene	O
expression	O
in	O
human	O
pulmonary	O
epithelial	O
cells	B-COMP
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
whether	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
an	O
emerging	O
veterinary	O
virus	O
,	O
infects	O
Vero	O
cells	B-COMP
by	O
attaching	O
to	O
heparan	O
sulfate	O
.	O

TITLE	O
:	O
Deoxynivalenol	O
in	O
chicken	O
feed	O
alters	O
the	O
vaccinal	O
immune	O
response	O
and	O
clinical	O
biochemical	O
serum	B-COMP
parameters	O
but	O
not	O
the	O
intestinal	O
and	O
carcass	O
characteristics	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
impacts	O
of	O
deoxynivalenol	O
(	O
DON	O
)	O
feeding	O
either	O
alone	O
or	O
in	O
combination	O
with	O
a	O
microbial	O
feed	O
additive	O
(	O
MFA	O
)	O
on	O
the	O
immune	O
response	O
to	O
a	O
viral	O
vaccine	O
and	O
serum	B-COMP
clinical	O
chemical	O
parameters	O
.	O

At	O
35	O
days	O
of	O
age	O
,	O
birds	O
were	O
slaughtered	O
and	O
blood	O
was	O
collected	O
for	O
investigating	O
the	O
antibody	B-COMP
titre	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
clinical	O
chemical	O
parameters	O
.	O

However	O
,	O
DON	O
in	O
combination	O
with	O
MFA	O
did	O
not	O
affect	O
serum	B-COMP
IBV	O
titre	O
.	O

A	O
total	O
of	O
98	O
specialist	O
registrars	O
(	O
in	O
Anesthesiology	O
,	O
n	O
=	O
51	O
;	O
in	O
Emergency	O
Medicine	O
(	O
EM	O
),	O
n	O
=	O
21	O
;	O
and	O
in	O
Intensive	O
Care	O
Medicine	O
(	O
ICM	B-COMP
)	O
n	O
=	O
26	O
)	O
completed	O
hand	O
-	O
delivered	O
surveys	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
98	O
specialist	O
registrars	O
(	O
in	O
Anesthesiology	O
,	O
n	O
=	O
51	O
;	O
in	O
Emergency	O
Medicine	O
(	O
EM	O
),	O
n	O
=	O
21	O
;	O
and	O
in	O
Intensive	O
Care	O
Medicine	O
(	O
ICM	B-COMP
)	O
n	O
=	O
26	O
)	O
completed	O
hand	O
-	O
delivered	O
surveys	O
.	O

SARS	O
-	O
CoV	O
protein	O
6	O
(	O
P6	O
)	O
is	O
one	O
of	O
the	O
previously	O
studied	O
accessory	O
proteins	O
that	O
have	O
been	O
documented	O
to	O
enhance	O
viral	O
replication	O
and	O
suppress	O
host	B-COMP
interferon	O
(	O
IFN	O
)	O
signaling	O
pathways	O
.	O

Serum	B-COMP
specimens	O
were	O
also	O
collected	O
and	O
serological	O
test	O
were	O
performed	O
.	O

Full	O
-	O
length	O
nucleocapsid	B-COMP
and	O
spike	O
gene	O
coding	O
sequences	O
were	O
later	O
obtained	O
from	O
the	O
positive	O
swab	O
sample	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
may	O
mediate	O
infection	O
by	O
binding	O
to	O
a	O
cellular	B-COMP
neural	O
cell	B-COMP
adhesion	O
molecule	O
(	O
NCAM	O
).	O

These	O
results	O
demonstrate	O
that	O
hCoV	O
-	O
HKU1	O
exploits	O
O	O
-	O
Ac	O
-	O
Sia	O
as	O
a	O
cellular	B-COMP
attachment	O
receptor	O
determinant	O
to	O
initiate	O
the	O
infection	O
of	O
host	B-COMP
cells	B-COMP
and	O
that	O
its	O
HE	O
protein	O
possesses	O
the	O
corresponding	O
sialate	O
-	O
O	O
-	O
acetylesterase	O
RDE	O
activity	O
.	O

For	O
pathology	O
and	O
immunofluorescence	O
staining	O
for	O
Ki67	O
(	O
marker	O
for	O
crypt	O
proliferation	O
)	O
and	O
LGR5	O
(	O
marker	O
for	O
crypt	O
stem	O
cell	B-COMP
),	O
3	O
-	O
4	O
pigs	O
were	O
euthanized	O
at	O
postinoculation	O
days	O
(	O
PIDs	O
)	O
1	O
,	O
3	O
and	O
5	O
.	O

For	O
years	O
,	O
the	O
diagnosis	O
of	O
viral	O
pneumonia	O
was	O
based	O
on	O
cell	B-COMP
culture	O
and	O
antigen	O
detection	O
,	O
but	O
since	O
the	O
introduction	O
of	O
polymerase	O
chain	O
reaction	O
techniques	O
in	O
the	O
clinical	O
setting	O
,	O
identification	O
of	O
these	O
pathogens	O
has	O
increased	O
and	O
new	O
microorganisms	O
such	O
as	O
human	O
bocavirus	O
have	O
been	O
discovered	O
.	O

Focal	B-COMP
adhesion	I-COMP
kinase	O
(	O
FAK	O
)	O
activation	O
was	O
reduced	O
in	O
HS	O
group	O
as	O
well	O
as	O
neutrophil	O
infiltration	O
,	O
NOS2	O
expression	O
and	O
NO	O
content	O
.	O

This	O
study	O
aimed	O
at	O
screening	O
available	O
sera	B-COMP
from	O
100	O
free	O
-	O
ranging	O
,	O
frugivorous	O
bats	O
(	O
Eidolon	O
helvum	O
)	O
sampled	O
in	O
2009	O
/	O
10	O
in	O
Ghana	O
,	O
for	O
the	O
presence	O
of	O
antibodies	B-COMP
against	O
the	O
complete	O
panel	O
of	O
influenza	O
A	O
haemagglutinin	O
(	O
HA	O
)	O
types	O
ranging	O
from	O
H1	O
to	O
H18	O
by	O
means	O
of	O
a	O
protein	O
microarray	O
platform	O
.	O

Using	O
next	O
-	O
generation	O
transcriptome	O
sequencing	O
(	O
mRNA	O
-	O
seq	O
),	O
we	O
profiled	O
the	O
transcriptional	O
response	O
of	O
Pteropus	O
vampyrus	O
bat	O
kidney	O
(	O
PVK	O
)	O
cells	B-COMP
to	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
an	O
avian	O
paramyxovirus	O
known	O
to	O
elicit	O
a	O
strong	O
innate	O
immune	O
response	O
in	O
mammalian	O
cells	B-COMP
.	O

Bats	O
are	O
the	O
reservoir	O
host	B-COMP
for	O
many	O
highly	O
pathogenic	O
human	O
viruses	O
,	O
including	O
henipaviruses	O
,	O
lyssaviruses	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
filoviruses	O
,	O
and	O
many	O
other	O
viruses	O
have	O
also	O
been	O
isolated	O
from	O
bats	O
.	O

This	O
program	O
generated	O
47	O
transcriptomic	O
and	O
proteomic	O
datasets	O
from	O
30	O
studies	O
that	O
investigate	O
in	O
vivo	O
and	O
in	O
vitro	O
host	B-COMP
responses	O
to	O
viral	O
infections	O
.	O

Extracellular	B-COMP
histone	O
appearance	O
required	O
both	O
C5a	O
receptors	O
(	O
C5aR	O
,	O
C5L2	O
)	O
as	O
well	O
as	O
neutrophils	O
(	O
PMNs	O
)	O
and	O
lung	O
macrophages	O
,	O
as	O
genetic	O
loss	O
of	O
either	O
C5a	O
receptor	O
or	O
depletion	O
of	O
PMNs	O
or	O
macrophages	O
reduced	O
histone	O
levels	O
found	O
in	O
BALF	O
during	O
ALI	O
.	O

We	O
examined	O
free	O
-	O
ranging	O
coyotes	O
from	O
central	O
North	O
Carolina	O
,	O
US	O
,	O
for	O
selected	O
parasites	O
and	O
prevalence	O
of	O
antibodies	B-COMP
against	O
viral	O
and	O
bacterial	O
agents	O
.	O

We	O
present	O
a	O
case	O
where	O
a	O
large	O
pulmonary	O
bleb	B-COMP
mimics	O
the	O
lung	O
point	O
and	O
therefore	O
inaccurately	O
suggests	O
pneumothorax	O
.	O

Similarly	O
,	O
CBH	O
response	O
and	O
antibody	B-COMP
titers	O
against	O
Newcastle	O
and	O
infectious	O
bronchitis	O
disease	O
viruses	O
were	O
markedly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
greater	O
in	O
chicks	O
fed	O
on	O
diets	O
supplemented	O
with	O
20	O
to	O
80	O
mg	O
/	O
kg	O
of	O
genistein	O
.	O

The	O
dromedary	O
camel	O
is	O
the	O
intermediate	O
host	B-COMP
of	O
MERS	O
-	O
CoV	O
,	O
but	O
the	O
transmission	O
cycle	O
is	O
not	O
fully	O
understood	O
.	O

Distinct	O
alterations	O
in	O
inflammation	O
were	O
present	O
in	O
TRIF	O
(-/-)	O
mice	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
including	O
excess	O
infiltration	O
of	O
neutrophils	O
and	O
inflammatory	O
cell	B-COMP
types	O
that	O
correlate	O
with	O
increased	O
pathology	O
of	O
other	O
known	O
causes	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
including	O
influenza	O
virus	O
infections	O
.	O

In	O
February	O
-	O
March	O
2013	O
the	O
number	O
of	O
children	O
protected	O
by	O
antibodies	B-COMP
against	O
influenza	O
decreased	O
,	O
and	O
circulation	O
of	O
influenza	O
viruses	O
A	O
/	O
H3N2	O
and	O
A	O
/	O
H1N1	O
/	O
pdm09	O
was	O
detected	O
.	O

RESULTS	O
:	O
In	O
February	O
-	O
March	O
2013	O
the	O
number	O
of	O
children	O
protected	O
by	O
antibodies	B-COMP
against	O
influenza	O
decreased	O
,	O
and	O
circulation	O
of	O
influenza	O
viruses	O
A	O
/	O
H3N2	O
and	O
A	O
/	O
H1N1	O
/	O
pdm09	O
was	O
detected	O
.	O

In	O
all	O
cases	O
,	O
MVA	O
-	O
MERS	O
-	O
S	O
induced	O
MERS	O
-	O
CoV	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	B-COMP
and	O
virus	O
-	O
neutralizing	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Factors	O
secreted	O
from	O
dental	O
pulp	O
stem	O
cells	B-COMP
show	O
multifaceted	O
benefits	O
for	O
treating	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

We	O
evaluated	O
the	O
use	O
of	O
stem	O
cells	B-COMP
derived	O
from	O
human	O
exfoliated	O
deciduous	O
teeth	O
(	O
SHEDs	O
)	O
or	O
SHED	O
-	O
derived	O
serum	B-COMP
-	O
free	O
conditioned	O
medium	O
(	O
SHED	O
-	O
CM	O
)	O
as	O
treatments	O
for	O
bleomycin	O
(	O
BLM	O
)-	O
induced	O
mice	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
exhibiting	O
several	O
pathogenic	O
features	O
associated	O
with	O
the	O
human	O
disease	O
ARDS	O
.	O

Patients	O
with	O
severe	O
ARDS	O
who	O
received	O
statin	O
therapy	O
had	O
significantly	O
more	O
vasopressor	O
-	O
free	O
days	O
compared	O
with	O
those	O
without	O
statin	O
therapy	O
(	O
13	O
±	O
7	O
and	O
9	O
±	O
7	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0034	O
),	O
and	O
they	O
also	O
required	O
less	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
and	O
had	O
more	O
ECMO	O
-	O
free	O
days	O
(	O
18	O
±	O
9	O
and	O
15	O
±	O
9	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0873	O
).	O

TITLE	O
:	O
Influenza	O
induces	O
IL	O
-	O
8	O
and	O
GM	O
-	O
CSF	O
secretion	O
by	O
human	O
alveolar	O
epithelial	O
cells	B-COMP
through	O
HGF	O
/	O
c	O
-	O
Met	O
and	O
TGF	O
-	O
α	O
/	O
EGFR	O
signaling	O
.	O

TITLE	O
:	O
Host	B-COMP
tissue	O
and	O
glycan	O
binding	O
specificities	O
of	O
avian	O
viral	O
attachment	O
proteins	O
using	O
novel	O
avian	O
tissue	O
microarrays	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
severe	O
respiratory	O
infections	O
associated	O
with	O
a	O
novel	O
group	O
C	O
betacoronavirus	O
(	O
HCoV	O
-	O
EMC	B-COMP
)	O
from	O
Saudi	O
Arabia	O
has	O
drawn	O
global	O
attention	O
to	O
another	O
highly	O
probable	O
""""	O
SARS	O
-	O
like	O
""""	O
animal	O
-	O
to	O
-	O
human	O
interspecies	O
jumping	O
event	O
in	O
coronavirus	O
(	O
CoV	O
).	O

The	O
genome	O
of	O
HCoV	O
-	O
EMC	B-COMP
is	O
most	O
closely	O
related	O
to	O
Tylonycteris	O
bat	O
coronavirus	O
HKU4	O
(	O
Ty	O
-	O
BatCoV	O
HKU4	O
)	O
and	O
Pipistrellus	O
bat	O
coronavirus	O
HKU5	O
(	O
Pi	O
-	O
BatCoV	O
HKU5	O
)	O
we	O
discovered	O
in	O
2006	O
.	O

More	O
intensive	O
surveillance	O
studies	O
in	O
bats	O
and	O
other	O
animals	O
may	O
reveal	O
the	O
natural	O
host	B-COMP
of	O
HCoV	O
-	O
EMC	B-COMP
.	O

In	O
contrast	O
,	O
there	O
is	O
little	O
data	O
on	O
the	O
kinetics	O
of	O
T	O
cell	B-COMP
responses	O
during	O
SARS	O
-	O
CoV	O
infection	O
and	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
the	O
recovery	O
process	O
.	O

TITLE	O
:	O
A	O
Kinome	O
-	O
Wide	O
Small	O
Interfering	O
RNA	O
Screen	O
Identifies	O
Proviral	O
and	O
Antiviral	O
Host	B-COMP
Factors	O
in	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
Replication	O
,	O
Including	O
Double	O
-	O
Stranded	O
RNA	O
-	O
Activated	O
Protein	O
Kinase	O
and	O
Early	O
Secretory	O
Pathway	O
Proteins	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
host	B-COMP
factors	O
relevant	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
replication	O
,	O
we	O
performed	O
a	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
library	O
screen	O
targeting	O
the	O
human	O
kinome	O
.	O

Following	O
the	O
detection	O
of	O
PEDV	O
infection	O
in	O
transfected	O
MDCK	O
cells	B-COMP
after	O
PEDV	O
challenge	O
,	O
we	O
clearly	O
demonstrated	O
that	O
the	O
SPC	O
subdomain	O
plays	O
a	O
key	O
role	O
in	O
cell	B-COMP
entry	O
of	O
PEDV	O
and	O
its	O
expression	O
permits	O
PEDV	O
growth	O
in	O
transfected	O
MDCK	O
cells	B-COMP
,	O
while	O
virus	O
propagation	O
can	O
be	O
inhibited	O
by	O
anti	O
-	O
SPC	O
serum	B-COMP
,	O
indicating	O
that	O
the	O
SPC	O
subdomain	O
appears	O
to	O
be	O
a	O
crucial	O
functional	O
domain	O
in	O
contributing	O
to	O
efficient	O
PEDV	O
infection	O
.	O

Dromedary	O
camels	O
,	O
hosts	B-COMP
for	O
MERS	O
-	O
CoV	O
,	O
are	O
implicated	O
in	O
direct	O
or	O
indirect	O
transmission	O
to	O
human	O
beings	O
,	O
although	O
the	O
exact	O
mode	O
of	O
transmission	O
is	O
unknown	O
.	O

We	O
recently	O
described	O
an	O
important	O
role	O
for	O
extracellular	B-COMP
histones	O
during	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
mice	O
(	O
Bosmann	O
et	O
al	O
.,	O

The	O
viral	B-COMP
genome	I-COMP
harbors	O
a	O
tandem	O
repeat	O
which	O
is	O
rare	O
in	O
vertebrate	O
RNA	O
viruses	O
.	O

The	O
present	O
review	O
will	O
be	O
focused	O
on	O
recent	O
structural	O
and	O
protein	O
-	O
protein	O
interaction	O
information	O
involving	O
two	O
viroporins	O
found	O
in	O
enveloped	O
viruses	O
that	O
target	O
the	O
respiratory	O
tract	O
;	O
(	O
i	O
)	O
the	O
envelope	B-COMP
protein	O
in	O
coronaviruses	O
and	O
(	O
ii	O
)	O
the	O
small	O
hydrophobic	O
protein	O
in	O
paramyxoviruses	O
.	O

Although	O
HKU4	O
spike	O
cannot	O
mediate	O
viral	O
entry	O
into	O
human	O
cells	B-COMP
,	O
two	O
mutations	O
enabled	O
it	O
to	O
do	O
so	O
by	O
allowing	O
it	O
to	O
be	O
activated	O
by	O
human	O
proteases	O
.	O

In	O
2013	O
,	O
a	O
PEDV	O
-	O
positive	O
sample	O
from	O
a	O
sow	O
with	O
very	O
mild	O
clinical	O
sign	O
was	O
used	O
to	O
inoculate	O
in	O
Vero	O
cells	B-COMP
to	O
isolate	O
the	O
virus	O
.	O

DCs	O
uptake	O
and	O
present	O
viral	O
antigens	O
to	O
T	O
cells	B-COMP
,	O
which	O
then	O
initiate	O
a	O
distinct	O
immune	O
response	O
.	O

The	O
median	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
duration	O
was	O
9	O
days	O
(	O
6	O
-	O
15	O
d	O
).	O

The	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
differed	O
significantly	O
for	O
patients	O
without	O
renal	O
replacement	O
therapy	O
versus	O
patients	O
with	O
renal	O
replacement	O
therapy	O
prior	O
to	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
(	O
p	O
=	O
0	O
.	O
003	O
).	O

ABSTRACT	O
:	O
Compared	O
to	O
other	O
respiratory	O
viruses	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
clinical	O
impact	O
of	O
coronavirus	O
(	O
CoV	O
)	O
infection	O
after	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
(	O
HSCT	O
)	O
or	O
in	O
patients	O
with	O
hematologic	O
malignancies	O
.	O

TITLE	O
:	O
Endothelin	O
-	O
1	O
induces	O
VCAM	O
-	O
1	O
expression	O
-	O
mediated	O
inflammation	O
via	O
receptor	O
tyrosine	O
kinases	O
and	O
Elk	O
/	O
p300	O
in	O
human	O
tracheal	O
smooth	B-COMP
muscle	I-COMP
cells	I-COMP
.	O

Post	O
-	O
treatment	O
surface	O
swabs	O
of	O
the	O
coupons	O
tested	O
RT	O
-	O
PCR	O
positive	O
but	O
were	O
not	O
infectious	O
to	O
cultured	O
cells	B-COMP
or	O
naïve	O
pigs	O
.	O

Increased	O
maternal	O
-	O
fetal	O
risk	O
occurs	O
in	O
pregnancy	O
with	O
sickle	O
cell	B-COMP
disease	O
.	O

Preincubation	O
of	O
HTBE	O
cells	B-COMP
with	O
a	O
truncated	O
HKU1	O
S	O
protein	O
that	O
includes	O
the	O
C	O
domain	O
blocked	O
infection	O
with	O
HKU1	O
virus	O
,	O
but	O
preincubation	O
of	O
cells	B-COMP
with	O
truncated	O
S	O
protein	O
containing	O
only	O
the	O
NTD	O
did	O
not	O
block	O
infection	O
.	O

However	O
,	O
recent	O
studies	O
provided	O
strong	O
supports	O
that	O
RNAi	O
also	O
plays	O
a	O
role	O
in	O
antiviral	O
mechanism	O
in	O
mammalian	O
cells	B-COMP
.	O

Using	O
the	O
MHV	O
-	O
A59	O
as	O
the	O
coronavirus	O
replication	O
model	O
,	O
we	O
showed	O
that	O
ectopic	O
expression	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	O
could	O
promote	O
MHV	O
replication	O
in	O
RNAi	O
-	O
active	O
cells	B-COMP
but	O
not	O
in	O
RNAi	O
-	O
depleted	O
cells	B-COMP
.	O

Respiratory	O
secretions	O
were	O
tested	O
for	O
nucleic	B-COMP
acids	O
of	O
a	O
panel	O
of	O
respiratory	O
viruses	O
.	O

PDGF	O
activated	O
p38	O
MAPK	O
and	O
p42	O
/	O
p44	O
MAPK	O
,	O
but	O
not	O
SMAD3	O
in	O
HLF	O
cells	B-COMP
.	O

Activation	O
of	O
SMAD3	O
by	O
TGFβ1	O
did	O
not	O
affect	O
either	O
collagen	B-COMP
I	O
or	O
α	O
-	O
SMA	O
in	O
HLF	O
cells	B-COMP
.	O

The	O
affected	O
cellular	B-COMP
proteins	O
that	O
we	O
identified	O
in	O
this	O
study	O
were	O
classified	O
into	O
the	O
functional	O
groups	O
involved	O
in	O
various	O
cellular	B-COMP
processes	O
such	O
as	O
cell	B-COMP
division	O
,	O
metabolism	O
,	O
the	O
stress	O
response	O
,	O
protein	O
biosynthesis	O
and	O
transport	O
,	O
cytoskeleton	B-COMP
networks	O
and	O
cell	B-COMP
communication	O
.	O

We	O
found	O
that	O
5	O
-	O
nonyloxytryptamine	O
(	O
5	O
-	O
NT	O
)	O
impairs	O
reovirus	O
infection	O
by	O
altering	O
viral	O
transport	O
during	O
cell	B-COMP
entry	O
.	O

The	O
20	O
,	O
54	O
,	O
and	O
87th	O
generations	O
of	O
CEK	O
-	O
adapted	O
IBV	O
-	O
Sczy3	O
strains	O
were	O
used	O
to	O
infect	O
CEK	O
cells	B-COMP
,	O
and	O
then	O
nucleic	B-COMP
copy	O
numbers	O
in	O
the	O
samples	O
of	O
supernatant	O
collected	O
at	O
12	O
,	O
24	O
,	O
36	O
,	O
48	O
,	O
60	O
,	O
and	O
72	O
h	O
were	O
detected	O
.	O

The	O
results	O
showed	O
that	O
the	O
rapid	O
growth	O
period	O
of	O
the	O
virus	O
load	O
of	O
all	O
the	O
3	O
generations	O
was	O
approximately	O
12	O
-	O
36	O
h	O
post	O
-	O
infection	O
;	O
the	O
peak	O
of	O
the	O
virus	O
load	O
appeared	O
at	O
36	O
h	O
post	O
-	O
infection	O
and	O
then	O
decreased	O
gradually	O
in	O
the	O
order	O
of	O
20th	O
>	O
54th	O
>	O
87th	O
for	O
the	O
3	O
generations	O
of	O
CEK	O
-	O
adapted	O
strains	O
;	O
the	O
dynamic	O
change	O
curve	O
of	O
the	O
IBV	O
load	O
in	O
the	O
supernatant	O
of	O
primary	O
CEK	O
cells	B-COMP
showed	O
a	O
single	O
peak	O
.	O

Specific	O
residues	O
in	O
the	O
HD	O
regulate	O
the	O
ion	O
-	O
conducting	O
pore	B-COMP
formed	O
by	O
SARS	O
-	O
CoV	O
E	O
in	O
artificial	O
bilayers	O
and	O
the	O
pathogenicity	O
of	O
the	O
virus	O
during	O
infection	O
.	O

The	O
results	O
demonstrate	O
a	O
crucial	O
role	O
for	O
Myd88	O
both	O
in	O
early	O
induction	O
of	O
innate	O
immune	O
responses	O
during	O
coronavirus	O
-	O
induced	O
encephalomyelitis	O
and	O
in	O
specifically	O
promoting	O
protective	O
CD4	O
T	O
cell	B-COMP
activation	O
.	O

TGEV	O
infection	O
has	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
severe	O
gastroenteritis	O
and	O
leads	O
to	O
alterations	O
of	O
many	O
cellular	B-COMP
processes	O
.	O

Moreover	O
,	O
the	O
Tottori2	O
PEDV	O
strain	O
was	O
successfully	O
isolated	O
in	O
Vero	O
cells	B-COMP
by	O
serial	O
passage	O
.	O

ABSTRACT	O
:	O
Because	O
some	O
bats	O
host	B-COMP
viruses	O
with	O
zoonotic	O
potential	O
,	O
we	O
investigated	O
human	O
-	O
bat	O
interactions	O
in	O
rural	O
Ghana	O
during	O
2011	O
-	O
2012	O
.	O

ABSTRACT	O
:	O
Sixty	O
-	O
seven	O
-	O
year	O
-	O
old	O
patient	O
,	O
diagnosed	O
with	O
multiple	O
myeloma	O
who	O
had	O
received	O
autologous	O
stem	O
cell	B-COMP
transplantation	O
,	O
following	O
bortezomib	O
,	O
dexamethasone	O
and	O
thalidomide	O
conventional	O
regimen	O
,	O
achieving	O
complete	O
response	O
,	O
developed	O
rash	O
,	O
diarrhea	O
,	O
and	O
severe	O
respiratory	O
failure	O
,	O
80	O
days	O
after	O
the	O
transplantation	O
procedure	O
.	O

He	O
was	O
diagnosed	O
with	O
graft	O
-	O
versus	O
-	O
host	B-COMP
disease	O
and	O
bronchiolitis	O
obliterans	O
syndrome	O
.	O

BH6870	O
(	O
36	O
),	O
showing	O
higher	O
antiviral	O
potency	O
and	O
a	O
good	O
cell	B-COMP
safety	O
index	O
,	O
was	O
identified	O
.	O

The	O
antibody	B-COMP
,	O
named	O
LCA60	O
,	O
binds	O
to	O
a	O
novel	O
site	O
on	O
the	O
spike	O
protein	O
and	O
potently	O
neutralizes	O
infection	O
of	O
multiple	O
MERS	O
-	O
CoV	O
isolates	O
by	O
interfering	O
with	O
the	O
binding	O
to	O
the	O
cellular	B-COMP
receptor	O
CD26	O
.	O

The	O
fact	O
that	O
it	O
took	O
only	O
4	O
mo	O
from	O
the	O
initial	O
screening	O
of	O
B	O
cells	B-COMP
derived	O
from	O
a	O
convalescent	O
patient	O
for	O
the	O
development	O
of	O
a	O
stable	O
chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	B-COMP
line	O
producing	O
neutralizing	O
antibodies	B-COMP
at	O
more	O
than	O
5	O
g	O
/	O
L	O
provides	O
an	O
example	O
of	O
a	O
rapid	O
pathway	O
toward	O
the	O
generation	O
of	O
effective	O
antiviral	O
therapies	O
against	O
emerging	O
viruses	O
.	O

Efforts	O
focused	O
solely	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
Spike	O
(	O
S	O
)	O
glycoprotein	O
may	O
not	O
optimize	O
neutralizing	O
antibody	B-COMP
(	O
NAb	O
)	O
responses	O
.	O

Here	O
we	O
show	O
that	O
immunogens	O
based	O
on	O
full	O
-	O
length	O
S	O
DNA	O
and	O
S1	O
subunit	O
protein	O
elicit	O
robust	O
serum	B-COMP
-	O
neutralizing	O
activity	O
against	O
several	O
MERS	O
-	O
CoV	O
strains	O
in	O
mice	O
and	O
non	O
-	O
human	O
primates	O
.	O

The	O
mortality	O
rate	O
ranged	O
from	O
0	O
%	O
to	O
31	O
%	O
in	O
malignancy	O
/	O
stem	O
cell	B-COMP
transplant	O
recipients	O
treated	O
with	O
oral	O
ribavirin	O
,	O
and	O
1	O
/	O
108	O
(	O
0	O
.	O
9	O
%)	O
ribavirin	O
-	O
treated	O
lung	O
transplant	O
recipients	O
died	O
at	O
30	O
days	O
.	O

Oral	O
ribavirin	O
should	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
NIRVI	O
in	O
immunocompromised	O
adults	O
(	O
malignancy	O
/	O
stem	O
cell	B-COMP
transplant	O
or	O
lung	O
transplant	O
)	O
or	O
adults	O
with	O
MERS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
monitoring	O
and	O
surveillance	O
of	O
antibodies	B-COMP
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
based	O
on	O
a	O
recombinant	O
membrane	B-COMP
protein	O
.	O

Nevertheless	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
life	O
-	O
saving	O
technology	O
in	O
patients	O
with	O
respiratory	O
failure	O
refractory	O
to	O
maximal	O
medical	O
therapy	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
the	O
neutralization	O
of	O
MERS	O
-	O
CoV	O
by	O
a	O
human	O
monoclonal	O
antibody	B-COMP
MERS	O
-	O
27	O
.	O

We	O
previously	O
reported	O
two	O
human	O
monoclonal	O
antibodies	B-COMP
that	O
target	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
and	O
exhibit	O
strong	O
neutralization	O
activity	O
against	O
live	O
and	O
pesudotyped	O
MERS	O
-	O
CoV	O
infection	O
.	O

Unfortunately	O
,	O
prophylactic	O
and	O
therapeutic	O
treatments	O
against	O
these	O
pathogens	O
are	O
limited	O
.	O
+	O
RNA	O
viruses	O
have	O
limited	O
coding	O
capacity	O
and	O
thus	O
rely	O
extensively	O
on	O
host	B-COMP
factors	O
for	O
successful	O
infection	O
and	O
propagation	O
.	O

These	O
viral	O
replication	O
complexes	O
(	O
VRCs	O
)	O
serve	O
two	O
main	O
functions	O
:	O
To	O
increase	O
replication	O
efficiency	O
by	O
concentrating	O
critical	O
factors	O
and	O
to	O
protect	O
the	O
viral	B-COMP
genome	I-COMP
from	O
host	B-COMP
anti	O
-	O
viral	O
systems	O
.	O

TITLE	O
:	O
Effects	O
of	O
Adaptation	O
of	O
Infectious	O
Bronchitis	O
Virus	O
Arkansas	O
Attenuated	O
Vaccine	O
to	O
Embryonic	O
Kidney	O
Cells	B-COMP
.	O

This	O
review	O
focuses	O
on	O
fundamental	O
aspects	O
of	O
immune	O
responses	O
against	O
IBV	O
,	O
including	O
the	O
role	O
of	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
in	O
identification	O
of	O
conserved	O
viral	O
structures	O
and	O
the	O
role	O
of	O
different	O
components	O
of	O
innate	O
immunity	O
(	O
e	O
.	O
g	O
.,	O
heterophils	O
,	O
macrophages	O
,	O
dendritic	B-COMP
cells	B-COMP
,	O
acute	O
phase	O
protein	O
,	O
and	O
cytokines	O
).	O

Furthermore	O
,	O
significant	O
downregulation	O
was	O
observed	O
as	O
early	O
as	O
10	O
min	O
after	O
trauma	O
for	O
cytokines	O
and	O
complement	O
factors	O
(	O
LCR	O
-	O
1	O
,	O
C4	O
)	O
as	O
well	O
as	O
for	O
intracellular	B-COMP
signaling	O
molecules	O
(	O
inhibitory	O
protein	O
phosphatase	O
)	O
and	O
ion	O
-	O
channels	O
(	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+)	O
channel	O
).	O

Using	O
genome	O
-	O
wide	O
siRNA	O
screening	O
,	O
we	O
identified	O
novel	O
genes	O
supporting	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
replication	O
in	O
human	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Replication	O
of	O
coronaviruses	O
is	O
inhibited	O
in	O
vitro	O
by	O
cyclosporin	O
A	O
,	O
a	O
well	O
-	O
known	O
immunosuppressive	O
drug	O
which	O
binds	O
to	O
cellular	B-COMP
cyclophilins	O
thus	O
inactivating	O
their	O
enzymatic	O
cis	O
-	O
trans	O
peptidyl	O
-	O
prolyl	O
isomerase	O
function	O
.	O

Latter	O
is	O
required	O
for	O
proper	O
folding	O
of	O
cellular	B-COMP
proteins	O
and	O
of	O
proteins	O
of	O
several	O
viruses	O
.	O

The	O
crystals	O
belonged	O
to	O
space	O
group	O
C2221	O
,	O
with	O
unit	O
-	O
cell	B-COMP
parameters	O
a	O
=	O
85	O
.	O
9	O
,	O
b	O
=	O
137	O
.	O
5	O
,	O
c	O
=	O
423	O
.	O
1	O
Å	O
,	O
α	O
=	O
β	O
=	O
γ	O
=	O
90	O
°.	O

For	O
these	O
zoonotic	O
viruses	O
,	O
a	O
number	O
of	O
bat	O
species	O
are	O
considered	O
as	O
important	O
reservoir	O
hosts	B-COMP
,	O
efficient	O
disseminators	O
or	O
even	O
directly	O
responsible	O
of	O
the	O
transmission	O
.	O

Murine	O
sialic	O
acid	O
-	O
binding	O
immunoglobulin	O
-	O
like	O
lectin	O
-	O
E	O
(	O
Siglec	O
-	O
E	O
)	O
and	O
its	O
human	O
orthologs	O
Siglec	O
-	O
7	O
and	O
Siglec	O
-	O
9	O
are	O
immunomodulatory	O
receptors	O
found	O
predominantly	O
on	O
hematopoietic	O
cells	B-COMP
.	O

Our	O
data	O
demonstrate	O
that	O
complement	O
inhibition	O
effectively	O
attenuates	O
collagen	B-COMP
deposition	O
and	O
fibrotic	O
responses	O
in	O
the	O
lung	O
after	O
severe	O
sepsis	O
.	O

Therefore	O
,	O
our	O
findings	O
revealed	O
that	O
the	O
ns12	O
.	O
9	O
viroporin	O
facilitates	O
virion	B-COMP
morphogenesis	O
to	O
enhance	O
viral	O
production	O
,	O
and	O
these	O
results	O
provided	O
a	O
deeper	O
understanding	O
of	O
HCoV	O
-	O
OC43	O
pathogenesis	O
.	O

Based	O
on	O
these	O
data	O
we	O
sought	O
to	O
compare	O
two	O
isolates	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
followed	O
disease	O
progression	O
in	O
common	O
marmosets	O
after	O
intratracheal	O
exposure	O
with	O
:	O
MERS	O
-	O
CoV	O
-	O
EMC	B-COMP
/	O
2012	O
,	O
MERS	O
-	O
CoV	O
-	O
Jordan	O
-	O
n3	O
/	O
2012	O
,	O
media	O
,	O
or	O
inactivated	O
virus	O
.	O

ABSTRACT	O
:	O
During	O
attempts	O
to	O
clone	O
retroviral	O
determinants	O
associated	O
with	O
a	O
mouse	O
model	O
of	O
Langerhans	O
cell	B-COMP
histiocytosis	O
(	O
LCH	O
),	O
suppression	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
was	O
used	O
to	O
identify	O
unique	O
viruses	O
in	O
the	O
liver	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
transplanted	O
with	O
LCH	O
tissues	O
.	O

TITLE	O
:	O
Host	B-COMP
-	O
directed	O
therapies	O
for	O
improving	O
poor	O
treatment	O
outcomes	O
associated	O
with	O
the	O
middle	O
east	O
respiratory	O
syndrome	O
coronavirus	O
infections	O
.	O

A	O
large	O
proportion	O
of	O
MERS	O
patients	O
who	O
die	O
have	O
a	O
range	O
of	O
pulmonary	O
pathology	O
ranging	O
from	O
pneumonia	O
to	O
adult	O
respiratory	O
distress	O
syndrome	O
with	O
multi	O
-	O
organ	O
failure	O
,	O
compounded	O
by	O
co	O
-	O
morbidities	O
,	O
reflecting	O
a	O
precarious	O
balance	O
of	O
interactions	O
between	O
the	O
host	B-COMP
-	O
immune	O
system	O
and	O
MERS	O
-	O
CoV	O
.	O
Whilst	O
we	O
wait	O
for	O
new	O
MERS	O
-	O
CoV	O
specific	O
drugs	O
,	O
therapeutics	O
and	O
vaccines	O
to	O
be	O
developed	O
,	O
there	O
is	O
a	O
need	O
to	O
advance	O
a	O
range	O
of	O
Host	B-COMP
-	O
Directed	O
Therapies	O
.	O

Analysis	O
of	O
antibodies	B-COMP
from	O
69	O
healthy	O
humans	O
suggests	O
an	O
important	O
role	O
of	O
the	O
V	O
(	O
D	O
)	O
J	O
recombination	O
-	O
generated	O
junctional	O
and	O
allele	O
-	O
specific	O
residues	O
for	O
achieving	O
high	O
affinity	O
of	O
binding	O
at	O
such	O
low	O
levels	O
of	O
somatic	O
hypermutation	O
.	O

Through	O
such	O
an	O
analysis	O
,	O
the	O
regression	O
period	O
of	O
maternally	O
derived	O
antibodies	B-COMP
and	O
optimum	O
vaccination	O
time	O
in	O
calves	O
can	O
be	O
recommended	O
.	O

FIPV	O
infected	O
cells	B-COMP
underwent	O
early	O
apoptosis	O
at	O
9	O
hpi	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
followed	O
by	O
late	O
apoptosis	O
at	O
12	O
hpi	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
necrosis	O
from	O
24	O
hpi	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
median	O
pig	O
diarrhea	O
dose	O
(	O
PDD50	O
)	O
of	O
the	O
virus	O
pool	O
was	O
determined	O
as	O
7	O
.	O
35	O
log10	O
PDD50	O
/	O
mL	O
,	O
similar	O
to	O
the	O
cell	B-COMP
culture	O
infectious	O
titer	O
,	O
7	O
.	O
75	O
log10	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
.	O
100	O
PDD50	O
caused	O
watery	O
diarrhea	O
in	O
all	O
conventional	O
suckling	O
piglets	O
(	O
n	O
=	O
12	O
)	O
derived	O
from	O
a	O
PEDV	O
-	O
naive	O
sow	O
,	O
whereas	O
1000	O
and	O
10	O
000	O
PDD50	O
did	O
not	O
cause	O
diarrhea	O
in	O
piglets	O
derived	O
from	O
two	O
PEDV	O
-	O
field	O
exposed	O
-	O
recovered	O
sows	O
.	O

TITLE	O
:	O
Bioinformatics	O
Analysis	O
of	O
Proteome	O
Changes	O
in	O
Calu	O
-	O
3	O
Cell	B-COMP
Infected	O
by	O
Influenza	O
A	O
Virus	O
(	O
H5N1	O
).	O

We	O
downloaded	O
proteome	O
data	O
(	O
BTO	O
:	O
0000762	O
)	O
from	O
the	O
Proteomics	O
Identifications	O
database	O
and	O
identified	O
the	O
DEPs	O
in	O
the	O
IAV	O
-	O
infected	O
Calu	O
-	O
3	O
cells	B-COMP
.	O

A	O
total	O
of	O
4	O
protein	O
groups	O
between	O
the	O
normal	O
cells	B-COMP
and	O
the	O
Calu	O
-	O
3	O
cells	B-COMP
infected	O
by	O
IAV	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
or	O
swine	O
influenza	O
were	O
identified	O
.	O

These	O
devices	O
have	O
a	O
simpler	O
configuration	O
than	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
devices	O
and	O
uses	O
lower	O
blood	O
flows	O
which	O
could	O
reduce	O
the	O
potential	O
complications	O
.	O

CD3	O
+	O
CD4	O
+	O
T	O
cell	B-COMP
frequencies	O
were	O
significantly	O
higher	O
in	O
ileum	O
of	O
suckling	O
pigs	O
than	O
in	O
weaned	O
pigs	O
,	O
whereas	O
there	O
was	O
no	O
difference	O
in	O
CD3	O
+	O
CD8	O
+	O
T	O
cell	B-COMP
frequencies	O
.	O

The	O
M	O
protein	O
altered	O
swine	O
intestinal	O
epithelial	O
cell	B-COMP
line	O
(	O
IEC	O
)	O
growth	O
and	O
induced	O
cell	B-COMP
cycle	O
arrest	O
at	O
the	O
S	O
-	O
phase	O
via	O
the	O
cyclin	O
A	O
pathway	O
.	O

The	O
patient	O
'	O
s	O
pre	O
and	O
post	O
eculizumab	O
skin	O
biopsies	O
showed	O
a	O
striking	O
pauci	O
-	O
inflammatory	O
thrombogenic	O
vasculopathy	O
associated	O
with	O
marked	O
endothelial	O
cell	B-COMP
injury	O
along	O
with	O
deposits	O
of	O
C3d	O
and	O
C4d	O
within	O
the	O
cutaneous	O
vasculature	O
;	O
the	O
C5b	O
-	O
9	O
deposits	O
were	O
limited	O
to	O
the	O
pre	O
-	O
eculizumab	O
biopsy	O
.	O

A	O
U	O
.	O
S	O
.	O
virulent	O
PEDV	O
prototype	O
isolate	O
(	O
USA	O
/	O
IN19338	O
/	O
2013	O
)	O
with	O
known	O
infectious	O
titer	O
was	O
serially	O
ten	O
-	O
fold	O
diluted	O
in	O
virus	O
-	O
negative	O
cell	B-COMP
culture	O
medium	O
.	O

ABSTRACT	O
:	O
We	O
collected	O
rectal	O
swabs	O
from	O
dogs	O
in	O
Japan	O
during	O
2011	O
to	O
2014	O
,	O
and	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
nucleocapsid	B-COMP
gene	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
sera	B-COMP
were	O
tested	O
with	O
a	O
neutralizing	O
antibody	B-COMP
test	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
often	O
used	O
in	O
patients	O
with	O
severe	O
respiratory	O
failure	O
to	O
improve	O
oxygenation	O
and	O
survival	O
.	O

The	O
method	O
employed	O
six	O
primers	O
that	O
recognized	O
sequences	O
of	O
a	O
nucleocapsid	B-COMP
gene	O
for	O
amplification	O
of	O
nucleic	B-COMP
acids	O
under	O
isothermal	O
conditions	O
at	O
63	O
degrees	O
C	O
for	O
60	O
min	O
.	O

TITLE	O
:	O
Serological	O
Evidence	O
of	O
MERS	O
-	O
CoV	O
Antibodies	B-COMP
in	O
Dromedary	O
Camels	O
(	O
Camelus	O
dromedaries	O
)	O
in	O
Laikipia	O
County	O
,	O
Kenya	O
.	O

In	O
Kenya	O
,	O
where	O
no	O
human	O
MERS	O
cases	O
have	O
been	O
reported	O
,	O
our	O
survey	O
of	O
335	O
dromedary	O
camels	O
,	O
representing	O
nine	O
herds	O
in	O
Laikipia	O
County	O
,	O
showed	O
a	O
high	O
seroprevalence	O
(	O
46	O
.	O
9	O
%)	O
to	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
.	O

Obviously	O
,	O
decreasing	O
IBV	O
infection	O
and	O
replication	O
in	O
the	O
upper	O
respiratory	O
tract	O
will	O
decrease	O
transmission	O
and	O
mutations	O
,	O
leading	O
to	O
variant	O
viruses	O
,	O
and	O
herein	O
we	O
demonstrate	O
that	O
protection	O
of	O
the	O
cilia	B-COMP
will	O
decrease	O
secondary	O
bacterial	O
infections	O
,	O
which	O
have	O
been	O
shown	O
to	O
lead	O
to	O
condemnations	O
and	O
increased	O
mortality	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
a	O
well	O
-	O
established	O
treatment	O
for	O
these	O
patients	O
.	O

Hence	O
,	O
the	O
role	O
of	O
the	O
RBM	O
is	O
a	O
bi	O
-	O
functional	O
bioactive	O
surface	O
that	O
can	O
be	O
demonstrated	O
by	O
antibodies	B-COMP
such	O
as	O
the	O
neutralizing	O
human	O
anti	O
-	O
SARS	O
monoclonal	O
antibody	B-COMP
(	O
mAb	O
)	O
80R	O
which	O
targets	O
the	O
RBM	O
and	O
competes	O
with	O
the	O
ACE2	O
receptor	O
for	O
binding	O
.	O

IMPORTANCE	O
We	O
previously	O
reported	O
that	O
Ad	O
-	O
infected	O
human	O
cells	B-COMP
exhibit	O
E1B	O
19K	O
-	O
dependent	O
repression	O
of	O
virally	O
induced	O
,	O
NF	O
-	O
κB	O
-	O
dependent	O
macrophage	O
cytokine	O
responses	O
(	O
J	O
.	O
R	O
.	O
Radke	O
,	O
F	O
.	O
Grigera	O
,	O
D	O
.	O
S	O
.	O
Ucker	O
,	O
and	O
J	O
.	O
L	O
.	O
Cook	O
,	O
J	O
Virol	O
88	O
:	O
2658	O
-	O
2669	O
,	O
2014	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1128	O
/	O
JVI	O
.	O
02372	O
-	O
13	O
).	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	B-COMP
are	O
known	O
to	O
have	O
several	O
applications	O
in	O
clinical	O
diagnosis	O
and	O
therapy	O
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
mutant	O
virus	O
regained	O
fitness	O
after	O
serial	O
passages	O
in	O
cell	B-COMP
culture	O
or	O
in	O
vivo	O
,	O
resulting	O
in	O
the	O
partial	O
duplication	O
of	O
the	O
membrane	B-COMP
gene	O
or	O
in	O
the	O
insertion	O
of	O
a	O
new	O
sequence	O
in	O
gene	O
8a	O
,	O
respectively	O
.	O

Deletions	O
in	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
nsp1	O
protein	O
led	O
to	O
higher	O
host	B-COMP
interferon	O
responses	O
and	O
virus	O
attenuation	O
.	O

The	O
risk	O
factors	O
for	O
mortality	O
independently	O
associated	O
with	O
ARDS	O
renal	O
recipients	O
with	O
ESKAPE	O
pneumonia	O
were	O
severe	O
ARDS	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
4	O
.	O
3	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
1	O
-	O
16	O
.	O
4	O
),	O
P	O
=	O
.	O
032	O
),	O
serum	B-COMP
creatinine	O
level	O
>	O
1	O
.	O
5	O
mg	O
/	O
dL	O
(	O
OR	O
4	O
.	O
2	O
95	O
%	O
CI	O
(	O
1	O
.	O
0	O
-	O
17	O
.	O
9	O
),	O
P	O
=	O
.	O
05	O
)	O
and	O
body	O
temperature	O
less	O
than	O
38	O
°	O
C	O
(	O
OR	O
5	O
.	O
0	O
(	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
19	O
.	O
6	O
),	O
P	O
=	O
.	O
02	O
)	O
at	O
ARDS	O
onset	O
.	O

ABSTRACT	O
:	O
Host	B-COMP
genetic	O
factors	O
have	O
frequently	O
been	O
implicated	O
in	O
respiratory	O
infectious	O
diseases	O
,	O
often	O
with	O
inconsistent	O
results	O
in	O
replication	O
studies	O
.	O

by	O
blocking	O
microtubule	B-COMP
,	O
sodium	O
and	O
calcium	O
channels	O
causing	O
conduction	O
abnormalities	O
.	O

However	O
,	O
its	O
influence	O
on	O
cell	B-COMP
cycle	O
and	O
subcellular	O
structure	O
still	O
require	O
more	O
research	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
virtual	O
screening	O
and	O
experimental	O
validation	O
of	O
the	O
discovery	O
of	O
inhibitors	O
targeted	O
towards	O
the	O
human	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
.	O

Potential	O
antigen	O
-	O
presenting	O
cells	B-COMP
(	O
APC	B-COMP
)	O
ingesting	O
myelin	B-COMP
were	O
characterized	O
by	O
flow	O
cytometry	O
and	O
their	O
ability	O
to	O
activate	O
SR	O
T	O
cells	B-COMP
tested	O
by	O
co	O
-	O
culture	O
with	O
carboxyfluorescein	O
succinimidyl	O
ester	O
(	O
CFSE	O
)-	O
labeled	O
myelin	B-COMP
-	O
specific	O
CD4	O
T	O
cells	B-COMP
.	O

Endogenous	O
SR	O
T	O
cell	B-COMP
kinetics	O
was	O
analyzed	O
within	O
both	O
cervical	O
lymph	O
nodes	O
and	O
CNS	O
by	O
Enzyme	O
-	O
Linked	O
ImmunoSpot	O
(	O
ELISPOT	O
)	O
following	O
viral	O
infection	O
.	O

(	O
18	O
)	O
F	O
-	O
Fluorodeoxyglucose	O
([(	O
18	O
)	O
F	O
]-	O
FDG	O
)-	O
positron	O
emission	O
tomography	O
/	O
computed	O
tomography	O
(	O
PET	O
/	O
CT	O
)	O
as	O
a	O
longitudinal	O
noninvasive	O
approach	O
can	O
be	O
beneficial	O
in	O
providing	O
biomarkers	O
for	O
host	B-COMP
immune	O
response	O
.	O

The	O
present	O
study	O
indicates	O
a	O
strong	O
astrocytic	O
response	O
,	O
including	O
the	O
presence	O
of	O
many	O
less	O
differentiated	O
vimentin	B-COMP
-	O
positive	O
astrocytes	O
and	O
gitter	O
cells	B-COMP
positive	O
for	O
RCA	O
-	O
1	O
in	O
severe	O
lesions	O
in	O
the	O
CNS	O
of	O
cats	O
with	O
FIP	O
.	O

This	O
indicates	O
that	O
host	B-COMP
specificity	O
may	O
be	O
more	O
important	O
than	O
host	B-COMP
ecology	O
for	O
the	O
presence	O
of	O
certain	O
viruses	O
in	O
bats	O
.	O

TITLE	O
:	O
Influenza	O
virus	O
emitted	O
by	O
naturally	O
-	O
infected	O
hosts	B-COMP
in	O
a	O
healthcare	O
setting	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
has	O
been	O
used	O
increasingly	O
since	O
the	O
mid	O
-	O
2000s	O
in	O
part	O
due	O
to	O
the	O
H1N1	O
epidemic	O
.	O

DPP4	O
was	O
also	O
found	O
in	O
a	O
subset	O
of	O
mononuclear	O
leukocytes	O
and	O
in	O
serous	O
cells	B-COMP
of	O
submucosal	O
glands	O
.	O

In	O
the	O
parenchyma	O
,	O
DPP4	O
was	O
found	O
principally	O
in	O
type	O
I	O
and	O
II	O
cells	B-COMP
and	O
alveolar	O
macrophages	O
and	O
was	O
also	O
detected	O
in	O
vascular	O
endothelium	O
(	O
eg	O
,	O
lymphatics	O
)	O
and	O
pleural	O
mesothelia	O
.	O

However	O
,	O
recent	O
studies	O
have	O
shown	O
that	O
histones	O
,	O
also	O
known	O
as	O
chromatin	B-COMP
-	O
basic	O
structure	O
proteins	O
,	O
could	O
be	O
released	O
into	O
the	O
extracellular	B-COMP
space	I-COMP
during	O
severe	O
stress	O
and	O
physical	O
challenges	O
to	O
the	O
body	O
(	O
e	O
.	O
g	O
.,	O
sepsis	O
and	O
ARDS	O
).	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
a	O
coronavirus	O
that	O
infects	O
cells	B-COMP
lining	O
the	O
small	O
intestine	O
of	O
swine	O
,	O
resulting	O
in	O
vomiting	O
,	O
diarrhea	O
,	O
and	O
dehydration	O
.	O

Antigenicity	O
was	O
compared	O
by	O
detection	O
of	O
polyclonal	O
antibodies	B-COMP
(	O
PAbs	O
)	O
against	O
the	O
virus	O
and	O
S	O
protein	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
an	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
and	O
a	O
serum	B-COMP
cross	O
-	O
neutralization	O
(	O
SN	O
)	O
assay	O
.	O

Identifying	O
ARDS	O
patients	O
who	O
should	O
be	O
transferred	O
to	O
an	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
center	O
is	O
an	O
important	O
task	O
for	O
emergency	O
providers	O
.	O

TITLE	O
:	O
Assembly	O
of	O
Viral	B-COMP
Membrane	I-COMP
Proteins	O
.	O

For	O
the	O
first	O
time	O
a	O
structural	O
model	O
for	O
a	O
fully	O
assembled	O
transmembrane	B-COMP
part	O
of	O
3a	O
from	O
SARS	O
-	O
CoV	O
is	O
proposed	O
.	O

In	O
the	O
CP	O
collection	O
phase	O
,	O
potential	O
donors	O
will	O
be	O
tested	O
by	O
the	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
the	O
indirect	O
fluorescent	O
antibody	B-COMP
(	O
IFA	O
)	O
techniques	O
for	O
the	O
presence	O
of	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
ORF4b	O
protein	O
inhibits	O
type	O
I	O
interferon	O
production	O
through	O
both	O
cytoplasmic	B-COMP
and	O
nuclear	O
targets	O
.	O

Based	O
on	O
the	O
maximum	O
HLA	O
binding	O
alleles	O
,	O
top	O
10	O
helper	O
T	O
-	O
cell	B-COMP
epitopes	O
and	O
CTL	O
epitopes	O
that	O
may	O
elicit	O
protective	O
cellular	B-COMP
immune	O
responses	O
against	O
MERS	O
-	O
CoV	O
were	O
selected	O
as	O
MERS	O
vaccine	O
candidates	O
.	O

Population	O
coverage	O
analysis	O
showed	O
that	O
the	O
putative	O
helper	O
T	O
-	O
cell	B-COMP
epitopes	O
and	O
CTL	O
epitopes	O
could	O
cover	O
the	O
vast	O
majority	O
of	O
the	O
population	O
in	O
15	O
geographic	O
regions	O
considered	O
where	O
vaccine	O
would	O
be	O
employed	O
.	O

During	O
coevolution	O
with	O
its	O
hosts	B-COMP
,	O
PEDV	O
has	O
acquired	O
mechanisms	O
to	O
subvert	O
host	B-COMP
innate	O
immune	O
responses	O
for	O
its	O
survival	O
advantage	O
.	O

We	O
present	O
a	O
case	O
of	O
accidental	O
inhalation	O
of	O
rice	O
starch	O
powder	O
in	O
a	O
17	O
-	O
month	O
-	O
old	O
girl	O
,	O
which	O
led	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
responsive	O
to	O
conventional	O
treatment	O
,	O
ultimately	O
requiring	O
venous	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Negative	O
Pressure	O
Pulmonary	O
Hemorrhage	O
in	O
an	O
Elderly	O
Patient	O
.	O

This	O
may	O
provide	O
a	O
basis	O
for	O
understanding	O
how	O
structural	O
alterations	O
of	O
astrocytic	O
gap	B-COMP
junctions	I-COMP
can	O
disrupt	O
gap	B-COMP
junction	I-COMP
communication	O
between	O
other	O
CNS	O
cells	B-COMP
in	O
altered	O
CNS	O
environments	O
due	O
to	O
infection	O
and	O
inflammation	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
:	O
virus	O
-	O
host	B-COMP
cell	I-COMP
interactions	O
and	O
implications	O
on	O
pathogenesis	O
.	O

A	O
subset	O
of	O
WUPyV	O
-	O
positive	O
cells	B-COMP
in	O
the	O
lung	O
had	O
morphologic	O
features	O
of	O
macrophages	O
.	O

RESULTS	O
:	O
Serum	B-COMP
potassium	O
levels	O
upon	O
arrival	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
abnormal	O
electrocardiogram	O
findings	O
were	O
significantly	O
more	O
common	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
K	O
-	O
group	O
(	O
n	O
=	O
55	O
)	O
than	O
in	O
the	O
O	O
-	O
group	O
(	O
n	O
=	O
62	O
).	O

ABSTRACT	O
:	O
Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)-	O
deficient	O
cells	B-COMP
are	O
highly	O
susceptible	O
to	O
viral	O
infection	O
.	O

The	O
HSCARG	O
protein	O
,	O
a	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
(	O
NADPH	O
)	O
sensor	O
and	O
negative	O
regulator	O
of	O
NF	O
-	O
κB	O
,	O
was	O
upregulated	O
in	O
G6PD	O
-	O
knockdown	O
cells	B-COMP
with	O
decreased	O
NADPH	O
/	O
NADP	O
⁺	O
ratio	O
.	O

The	O
antiviral	O
activity	O
of	O
xiamycin	O
D	O
(	O
2	O
)	O
was	O
also	O
supported	O
by	O
both	O
Western	O
blotting	O
of	O
the	O
GP2	O
spike	O
and	O
GP6	O
nucleocapsid	B-COMP
protein	O
synthesis	O
of	O
PEDV	O
.	O

TITLE	O
:	O
Severe	O
Tumor	O
Lysis	O
Syndrome	O
and	O
Acute	O
Pulmonary	O
Edema	O
Requiring	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
Following	O
Initiation	O
of	O
Chemotherapy	O
for	O
Metastatic	O
Alveolar	O
Rhabdomyosarcoma	O
.	O

The	O
pathogen	O
detection	O
capabilities	O
hosted	O
on	O
Pathosphere	O
were	O
tested	O
by	O
analyzing	O
pathogen	O
-	O
containing	O
samples	O
sequenced	O
by	O
NGS	O
with	O
both	O
spiked	O
human	O
samples	O
as	O
well	O
as	O
human	O
and	O
zoonotic	O
host	B-COMP
backgrounds	O
.	O

TITLE	O
:	O
Lipid	O
-	O
Mediated	O
Targeting	O
with	O
Membrane	B-COMP
-	O
Wrapped	O
Nanoparticles	O
in	O
the	O
Presence	O
of	O
Corona	O
Formation	O
.	O

We	O
characterize	O
nonspecific	O
protein	O
adsorption	O
(	O
corona	O
formation	O
)	O
to	O
membrane	B-COMP
-	O
wrapped	O
nanoparticles	O
with	O
core	O
diameters	O
of	O
approximately	O
35	O
and	O
80	O
nm	O
and	O
its	O
effect	O
on	O
the	O
GM3	O
-	O
mediated	O
targeting	O
efficacy	O
as	O
a	O
function	O
of	O
surface	O
charge	O
through	O
combined	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O

TITLE	O
:	O
Prolonged	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
in	O
a	O
Patient	O
With	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

This	O
may	O
be	O
explained	O
by	O
the	O
recent	O
studies	O
which	O
highlighted	O
the	O
role	O
of	O
the	O
pulmonary	O
endothelium	O
as	O
the	O
center	O
of	O
innate	O
immune	O
cells	B-COMP
recruitment	O
and	O
excessive	O
pro	O
-	O
inflammatory	O
cytokines	O
production	O
.	O

A	O
double	O
strand	O
probe	O
with	O
an	O
optimized	O
fluorescent	O
-	O
quencher	O
couple	O
was	O
designed	O
for	O
the	O
detection	O
of	O
different	O
lengths	O
of	O
nucleic	B-COMP
acids	O
(	O
39	O
nt	O
and	O
100	O
nt	O
).	O

PDE	O
activity	O
is	O
required	O
for	O
robust	O
replication	O
in	O
myeloid	O
cells	B-COMP
,	O
as	O
a	O
mutant	O
of	O
MHV	O
(	O
ns2	O
(	O
H126R	O
))	O
encoding	O
an	O
inactive	O
PDE	O
fails	O
to	O
antagonize	O
RNase	O
L	O
activation	O
and	O
replicates	O
poorly	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMM	O
),	O
while	O
ns2	O
(	O
H126R	O
)	O
replicates	O
to	O
high	O
titer	O
in	O
several	O
types	O
of	O
nonmyeloid	O
cells	B-COMP
,	O
as	O
well	O
as	O
in	O
IFN	O
receptor	O
-	O
deficient	O
(	O
Ifnar1	O
(-/-))	O
BMM	O
.	O

However	O
,	O
ns2	O
(	O
H126R	O
)	O
failed	O
to	O
induce	O
RNase	O
L	O
activation	O
in	O
BMM	O
treated	O
with	O
IFNAR1	O
-	O
blocking	O
antibody	B-COMP
,	O
as	O
well	O
as	O
in	O
Ifnar1	O
(-/-)	O
BMM	O
,	O
both	O
expressing	O
low	O
basal	O
levels	O
of	O
Oas	O
genes	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
cells	B-COMP
with	O
high	O
basal	O
Oas	O
gene	O
expression	O
levels	O
can	O
activate	O
RNase	O
L	O
and	O
thereby	O
inhibit	O
virus	O
replication	O
early	O
in	O
infection	O
upon	O
exposure	O
to	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
before	O
the	O
induction	O
of	O
interferon	O
and	O
prior	O
to	O
transcription	O
of	O
interferon	O
-	O
stimulated	O
antiviral	O
genes	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
acute	O
respiratory	O
failure	O
was	O
proposed	O
more	O
than	O
40	O
years	O
ago	O
.	O

We	O
compared	O
the	O
properties	O
of	O
cells	B-COMP
incubated	O
with	O
the	O
sera	B-COMP
of	O
healthy	O
volunteers	O
(	O
n	O
=	O
5	O
),	O
patients	O
presenting	O
with	O
acute	O
cardiogenic	O
pulmonary	O
edema	O
(	O
ACPE	O
;	O
n	O
=	O
6	O
),	O
and	O
patients	O
with	O
ARDS	O
(	O
n	O
=	O
22	O
),	O
of	O
whom	O
13	O
were	O
classified	O
as	O
having	O
moderate	O
to	O
severe	O
disease	O
and	O
the	O
remaining	O
9	O
as	O
having	O
mild	O
disease	O
.	O

Systematic	O
measurements	O
with	O
the	O
THP	O
-	O
1	O
cell	B-COMP
line	O
allowed	O
for	O
the	O
establishment	O
of	O
a	O
strong	O
correlation	O
between	O
stiffening	O
and	O
the	O
severity	O
of	O
respiratory	O
status	O
(	O
mean	O
ET	O
0	O
.	O
82	O
±	O
0	O
.	O
08	O
seconds	O
for	O
healthy	O
subjects	O
,	O
1	O
.	O
6	O
±	O
1	O
.	O
0	O
seconds	O
for	O
ACPE	O
groups	O
,	O
10	O
.	O
5	O
±	O
6	O
.	O
1	O
seconds	O
for	O
mild	O
ARDS	O
,	O
and	O
20	O
.	O
0	O
±	O
8	O
.	O
1	O
seconds	O
for	O
moderate	O
to	O
severe	O
ARDS	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
inhibition	O
of	O
leukocyte	O
stiffening	O
with	O
blocking	O
antibodies	B-COMP
might	O
inspire	O
future	O
therapeutic	O
strategies	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
Neutralizing	O
Monoclonal	O
Antibody	B-COMP
Against	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
S1	O
Protein	O
.	O

The	O
two	O
monoclonal	O
antibodies	B-COMP
specifically	O
reacted	O
with	O
PEDV	O
rS1	O
protein	O
,	O
as	O
proven	O
by	O
Western	O
blot	O
and	O
indirect	O
immunofluorescence	O
assay	O
.	O

The	O
sole	O
accessory	O
protein	O
ORF3	O
,	O
structure	O
protein	O
envelope	B-COMP
(	O
E	O
),	O
membrane	B-COMP
(	O
M	O
),	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
were	O
also	O
shown	O
to	O
inhibit	O
such	O
activities	O
.	O

They	O
also	O
allow	O
the	O
initial	O
characterization	O
of	O
aspects	O
of	O
infection	O
such	O
as	O
cellular	B-COMP
tropism	O
for	O
difficult	O
to	O
culture	O
viruses	O
.	O

The	O
use	O
of	O
monoclonal	O
antibodies	B-COMP
targeting	O
the	O
stem	O
of	O
the	O
influenza	O
virus	O
surface	O
hemagglutinin	O
(	O
HA	O
)	O
is	O
a	O
rapidly	O
developing	O
strategy	O
for	O
the	O
control	O
of	O
viruses	O
of	O
multiple	O
HA	O
subtypes	O
.	O

In	O
vitro	O
studies	O
indicate	O
this	O
virus	O
may	O
have	O
a	O
broad	O
host	B-COMP
range	O
suggesting	O
an	O
increased	O
pandemic	O
potential	O
.	O

The	O
results	O
demonstrate	O
the	O
occurrence	O
of	O
FIV	O
infection	O
in	O
inflammatory	O
cells	B-COMP
in	O
the	O
myocardium	O
of	O
five	O
cats	O
with	O
myocarditis	O
and	O
HCM	O
.	O

Soon	O
after	O
the	O
deadly	O
disease	O
outbreak	O
,	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
was	O
identified	O
as	O
a	O
functional	O
cellular	B-COMP
receptor	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

Moreover	O
,	O
flow	O
cytometry	O
data	O
demonstrated	O
an	O
increase	O
of	O
the	O
cell	B-COMP
surface	I-COMP
vimentin	B-COMP
level	O
by	O
16	O
.	O
5	O
%	O
after	O
SARS	O
-	O
CoV	O
permissive	O
Vero	O
E6	O
cells	B-COMP
were	O
treated	O
with	O
SARS	O
-	O
CoV	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
).	O

RESULTS	O
:	O
A	O
host	B-COMP
intracellular	I-COMP
filamentous	O
cytoskeletal	B-COMP
protein	O
vimentin	B-COMP
was	O
identified	O
by	O
immunoprecipitation	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
following	O
chemical	O
cross	O
-	O
linking	O
on	O
Vero	O
E6	O
cells	B-COMP
that	O
were	O
pre	O
-	O
incubated	O
with	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

TITLE	O
:	O
[	O
The	O
value	O
of	O
determination	O
of	O
serum	B-COMP
cholinesterase	O
levels	O
in	O
judgment	O
of	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
severe	O
pneumonia	O
].	O

At	O
12	O
months	O
following	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
,	O
89	O
patients	O
(	O
66	O
.	O
9	O
%)	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
had	O
died	O
.	O

TITLE	O
:	O
RNA	O
sequencing	O
-	O
based	O
analysis	O
of	O
the	O
spleen	O
transcriptome	O
following	O
infectious	O
bronchitis	O
virus	O
infection	O
of	O
chickens	O
selected	O
for	O
different	O
mannose	O
-	O
binding	O
lectin	O
serum	B-COMP
concentrations	O
.	O

To	O
this	O
end	O
,	O
two	O
chicken	O
lines	O
,	O
selected	O
for	O
high	O
(	O
L10H	O
line	O
)	O
and	O
low	O
(	O
L10L	O
line	O
)	O
serum	B-COMP
concentration	O
of	O
mannose	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
were	O
studied	O
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
1	O
,	O
320	O
tracheal	O
samples	O
from	O
66	O
broiler	O
flocks	O
sent	O
to	O
slaughterhouses	O
and	O
42	O
tracheal	O
samples	O
from	O
42	O
flocks	O
of	O
local	O
chickens	O
in	O
the	O
field	O
were	O
collected	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
gene	O
detection	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
using	O
nucleocapsid	B-COMP
-	O
specific	O
primers	O
and	O
spike	O
-	O
specific	O
primers	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
results	O
from	O
mutations	O
in	O
the	O
viral	B-COMP
genome	I-COMP
during	O
a	O
common	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
)	O
infection	O
.	O

Leukocyte	O
numbers	O
were	O
not	O
different	O
compared	O
to	O
the	O
other	O
cats	O
,	O
except	O
for	O
the	O
CD8	O
(+)	O
regulatory	O
T	O
cells	B-COMP
.	O

These	O
data	O
indicate	O
that	O
FECV	O
can	O
infect	O
immune	O
cells	B-COMP
even	O
in	O
the	O
absence	O
of	O
intestinal	O
replication	O
and	O
raise	O
the	O
hypothesis	O
that	O
the	O
gradual	O
adaptation	O
to	O
these	O
cells	B-COMP
can	O
allow	O
non	O
-	O
enterotropic	O
mutants	O
to	O
arise	O
.	O

TITLE	O
:	O
Cross	O
host	B-COMP
transmission	O
in	O
the	O
emergence	O
of	O
MERS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
able	O
to	O
infect	O
humans	O
emerge	O
through	O
cross	O
-	O
host	B-COMP
transmission	O
from	O
animals	O
.	O

After	O
LPS	O
inhalation	O
,	O
cigarette	O
smokers	O
had	O
increased	O
alveolar	O
-	O
capillary	O
membrane	B-COMP
permeability	O
as	O
measured	O
by	O
BAL	O
total	O
protein	O
,	O
compared	O
with	O
non	O
-	O
smokers	O
(	O
median	O
274	O
vs	O
208	O
μg	O
/	O
mL	O
,	O
p	O
=	O
0	O
.	O
04	O
).	O

The	O
actual	O
contributing	O
factors	O
to	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
are	O
yet	O
to	O
be	O
systematically	O
studied	O
,	O
but	O
data	O
to	O
date	O
suggest	O
viral	O
,	O
host	B-COMP
and	O
environmental	O
factors	O
play	O
a	O
major	O
role	O
.	O

These	O
organotypic	O
human	O
airway	O
cultures	O
represent	O
a	O
universal	O
platform	O
to	O
study	O
respiratory	O
virus	O
-	O
host	B-COMP
interaction	O
by	O
offering	O
more	O
detailed	O
insights	O
compared	O
to	O
cell	B-COMP
lines	O
.	O

TITLE	O
:	O
The	O
Protein	O
Corona	O
of	O
Plant	O
Virus	O
Nanoparticles	O
Influences	O
their	O
Dispersion	O
Properties	O
,	O
Cellular	B-COMP
Interactions	O
,	O
and	O
In	O
Vivo	O
Fates	O
.	O

The	O
impact	O
of	O
the	O
VNP	O
protein	O
corona	O
on	O
molecular	O
recognition	O
and	O
cell	B-COMP
targeting	O
in	O
the	O
context	O
of	O
cancer	O
and	O
thrombosis	O
is	O
investigated	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
,	O
a	O
close	O
relative	O
of	O
the	O
Severe	O
Acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
,	O
both	O
of	O
which	O
caused	O
a	O
lethal	O
respiratory	O
infection	O
in	O
humans	O
,	O
reinforces	O
the	O
need	O
for	O
further	O
understanding	O
of	O
coronavirus	O
pathogenesis	O
and	O
the	O
host	B-COMP
immune	O
response	O
.	O

Double	O
staining	O
immunoassays	O
that	O
used	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
paired	O
with	O
immunohistochemistry	O
for	O
cytokeratin	O
and	O
surfactant	O
identified	O
pneumocytes	O
and	O
epithelial	O
syncytial	O
cells	B-COMP
as	O
important	O
targets	O
of	O
MERS	O
-	O
CoV	O
antigen	O
;	O
double	O
immunostaining	O
with	O
dipeptidyl	O
peptidase	O
4	O
showed	O
colocalization	O
in	O
scattered	O
pneumocytes	O
and	O
syncytial	O
cells	B-COMP
.	O

The	O
antagonist	O
of	O
both	O
TLR2	O
and	O
TLR4	O
did	O
not	O
impede	O
M	O
-	O
mediated	O
IFN	O
-	O
β	O
induction	O
,	O
indicating	O
that	O
the	O
driving	O
force	O
for	O
the	O
activation	O
of	O
IFN	O
-	O
β	O
production	O
was	O
generated	O
from	O
inside	O
the	O
cells	B-COMP
.	O

In	O
the	O
case	O
of	O
HIV	O
,	O
it	O
has	O
been	O
shown	O
that	O
CBAs	O
select	O
for	O
mutant	O
viruses	O
with	O
N	O
-	O
glycosylation	O
site	O
deletions	O
which	O
are	O
more	O
sensitive	O
to	O
neutralizing	O
antibodies	B-COMP
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
in	O
contrast	O
to	O
HIV	O
,	O
HCV	O
resistance	O
to	O
CBAs	O
is	O
not	O
directly	O
conferred	O
by	O
mutations	O
in	O
the	O
envelope	B-COMP
protein	O
genes	O
but	O
could	O
occur	O
through	O
an	O
indirect	O
mechanism	O
involving	O
mutations	O
in	O
other	O
viral	O
proteins	O
.	O

Approximately	O
three	O
quarters	O
of	O
reported	O
malaria	O
cases	O
in	O
the	O
UK	O
are	O
caused	O
by	O
Plasmodium	O
falciparum	O
,	O
which	O
is	O
capable	O
of	O
invading	O
a	O
high	O
proportion	O
of	O
red	O
blood	O
cells	B-COMP
and	O
rapidly	O
leading	O
to	O
severe	O
or	O
life	O
-	O
threatening	O
multi	O
-	O
organ	O
disease	O
.	O

ABSTRACT	O
:	O
Ligands	O
of	O
the	O
endothelial	O
-	O
enriched	O
tunica	O
interna	O
endothelial	O
cell	B-COMP
kinase	O
2	O
(	O
Tie2	O
)	O
are	O
markedly	O
imbalanced	O
in	O
severe	O
infections	O
associated	O
with	O
vascular	O
leakage	O
,	O
yet	O
regulation	O
of	O
the	O
receptor	O
itself	O
has	O
been	O
understudied	O
in	O
this	O
context	O
.	O

Two	O
experimental	O
MERS	O
-	O
CoV	O
vaccines	O
were	O
used	O
to	O
vaccinate	O
two	O
groups	O
of	O
transchromosomic	O
(	O
Tc	O
)	O
bovines	O
that	O
were	O
genetically	O
modified	O
to	O
produce	O
large	O
quantities	O
of	O
fully	O
human	O
polyclonal	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
antibodies	B-COMP
.	O

Vaccination	O
with	O
a	O
clade	O
A	O
γ	O
-	O
irradiated	O
whole	O
killed	O
virion	B-COMP
vaccine	O
(	O
Jordan	O
strain	O
)	O
or	O
a	O
clade	O
B	O
spike	O
protein	O
nanoparticle	O
vaccine	O
(	O
Al	O
-	O
Hasa	O
strain	O
)	O
resulted	O
in	O
Tc	O
bovine	O
sera	B-COMP
with	O
high	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
neutralizing	O
antibody	B-COMP
titers	O
in	O
vitro	O
.	O

Two	O
purified	O
Tc	O
bovine	O
human	O
IgG	O
immunoglobulins	O
(	O
Tc	O
hIgG	O
),	O
SAB	O
-	O
300	O
(	O
produced	O
after	O
Jordan	O
strain	O
vaccination	O
)	O
and	O
SAB	O
-	O
301	O
(	O
produced	O
after	O
Al	O
-	O
Hasa	O
strain	O
vaccination	O
),	O
also	O
had	O
high	O
ELISA	O
and	O
neutralizing	O
antibody	B-COMP
titers	O
without	O
antibody	B-COMP
-	O
dependent	O
enhancement	O
in	O
vitro	O
.	O

TITLE	O
:	O
Analyses	O
of	O
Coronavirus	O
Assembly	O
Interactions	O
with	O
Interspecies	O
Membrane	B-COMP
and	O
Nucleocapsid	B-COMP
Protein	O
Chimeras	O
.	O

The	O
results	O
clarify	O
our	O
understanding	O
of	O
the	O
interaction	O
between	O
the	O
coronavirus	O
M	O
protein	O
and	O
the	O
nucleocapsid	B-COMP
protein	O
.	O

Mechanistically	O
,	O
TRIM56	O
was	O
found	O
to	O
specifically	O
impede	O
intracellular	B-COMP
influenza	O
virus	O
RNA	O
synthesis	O
.	O

Understanding	O
novel	O
virus	O
-	O
host	B-COMP
interactions	O
that	O
alter	O
influenza	O
virus	O
fitness	O
may	O
reveal	O
new	O
targets	O
/	O
approaches	O
for	O
therapeutic	O
interventions	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
is	O
used	O
as	O
life	O
support	O
for	O
lung	O
impairment	O
resulting	O
from	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
hypothesized	O
that	O
intratracheal	O
transplantation	O
of	O
isogeneic	O
primary	O
type	O
II	O
alveolar	O
epithelial	O
cells	B-COMP
in	O
combination	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
may	O
facilitate	O
lung	O
reparation	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Increased	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generated	O
by	O
neutrophils	O
(	O
PMNs	O
)	O
and	O
other	O
inflammatory	O
cells	B-COMP
play	O
an	O
important	O
role	O
in	O
increasing	O
endothelial	O
permeability	O
.	O

Furthermore	O
,	O
the	O
cell	B-COMP
tropisms	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
have	O
been	O
characterized	O
by	O
live	O
and	O
pseudotyped	O
viruses	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
safety	O
and	O
effectiveness	O
of	O
a	O
novel	O
therapeutic	O
regimen	O
for	O
bronchiolitis	O
obliterans	O
sydrome	O
(	O
BOS	O
)	O
affter	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
(	O
HSCT	O
).	O

Contrary	O
to	O
expectations	O
,	O
ribosomes	B-COMP
were	O
not	O
found	O
to	O
pause	O
at	O
the	O
ribosomal	B-COMP
frameshift	O
site	O
.	O

The	O
serum	B-COMP
creatinine	O
level	O
was	O
found	O
mildly	O
elevated	O
.	O

The	O
spike	O
glycoprotein	O
,	O
nucleocapsid	B-COMP
,	O
and	O
1a	O
genes	O
were	O
sequenced	O
for	O
phylogenetic	O
reconstruction	O
and	O
Bayesian	O
coalescent	O
inference	O
.	O

The	O
TGEV	O
spike	O
protein	O
is	O
capable	O
of	O
binding	O
with	O
EGFR	O
,	O
activating	O
the	O
downstream	O
phosphoinositide	O
-	O
3	O
kinase	O
(	O
PI3K	O
),	O
then	O
causing	O
the	O
phosphorylation	O
of	O
cofilin	O
and	O
F	B-COMP
-	I-COMP
actin	I-COMP
polymerization	O
via	O
Rac1	O
/	O
Cdc42	O
GTPases	O
.	O

ABSTRACT	O
:	O
Since	O
there	O
is	O
no	O
available	O
serological	O
methods	O
to	O
detect	O
antibodies	B-COMP
to	O
ferret	O
coronavirus	O
(	O
FRCoV	O
),	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
recombinant	O
partial	O
nucleocapsid	B-COMP
(	O
N	O
)	O
proteins	O
of	O
the	O
ferret	O
coronavirus	O
(	O
FRCoV	O
)	O
Yamaguchi	O
-	O
1	O
strain	O
was	O
developed	O
to	O
establish	O
a	O
serological	O
method	O
for	O
detection	O
of	O
FRCoV	O
infection	O
.	O

Many	O
serum	B-COMP
samples	O
collected	O
from	O
ferrets	O
recognized	O
both	O
a	O
.	O
a	O
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Adults	O
:	O
Prognostic	O
Factors	O
for	O
Outcomes	O
.	O

The	O
central	O
hypothesis	O
is	O
that	O
macrophage	O
tropism	O
enhances	O
viral	O
dissemination	O
and	O
persistence	O
,	O
but	O
these	O
changes	O
may	O
come	O
at	O
the	O
cost	O
of	O
reduced	O
replication	O
in	O
cells	B-COMP
other	O
than	O
macrophages	O
.	O

Fourteen	O
days	O
after	O
infection	O
,	O
the	O
specific	O
antibody	B-COMP
to	O
virus	O
structural	O
protein	O
and	O
neutralizing	O
antibody	B-COMP
were	O
analyzed	O
,	O
the	O
high	O
dosage	O
group	O
induced	O
higher	O
level	O
antibody	B-COMP
.	O

TITLE	O
:	O
Memory	O
T	O
cell	B-COMP
responses	O
targeting	O
the	O
SARS	O
coronavirus	O
persist	O
up	O
to	O
11	O
years	O
post	O
-	O
infection	O
.	O

An	O
absence	O
of	O
cross	O
-	O
reactivity	O
of	O
these	O
CD8	O
(+)	O
T	O
cell	B-COMP
responses	O
against	O
the	O
newly	O
-	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
also	O
demonstrated	O
.	O

ABSTRACT	O
:	O
A	O
large	O
number	O
of	O
viruses	O
,	O
including	O
many	O
human	O
pathogens	O
,	O
bind	O
cell	B-COMP
-	O
surface	O
glycans	O
during	O
the	O
initial	O
steps	O
of	O
infection	O
.	O

Importantly	O
,	O
available	O
SARS	O
monoclonal	O
antibodies	B-COMP
offered	O
success	O
in	O
limiting	O
viral	O
infection	O
absent	O
from	O
available	O
vaccine	O
approaches	O
.	O

TITLE	O
:	O
Neonatal	O
Fc	O
Receptor	O
-	O
Mediated	O
IgG	O
Transport	O
Across	O
Porcine	O
Intestinal	O
Epithelial	O
Cells	B-COMP
:	O
Potentially	O
Provide	O
the	O
Mucosal	O
Protection	O
.	O

Our	O
results	O
indicate	O
that	O
pFcRn	O
-	O
dependent	O
bidirectional	O
IgG	O
transport	O
across	O
the	O
intestinal	O
epithelium	O
plays	O
critical	O
role	O
in	O
the	O
acquisition	O
of	O
humoral	O
immunity	O
in	O
early	O
life	O
and	O
in	O
host	B-COMP
defense	O
at	O
mucosal	O
surfaces	O
.	O

Both	O
LAV	O
and	O
MAS	B-COMP
significantly	O
decreased	O
lung	O
compliance	O
,	O
increased	O
airway	O
resistance	O
,	O
and	O
caused	O
severe	O
hypoxemia	O
,	O
hypercarbia	O
,	O
and	O
acidosis	O
.	O

Immunomodulatory	O
and	O
tissue	O
-	O
regenerative	O
host	B-COMP
-	O
directed	O
therapies	O
(	O
HDT	O
)	O
may	O
improve	O
treatment	O
outcomes	O
.	O

ABSTRACT	O
:	O
The	O
amount	O
of	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
may	O
influence	O
respiratory	O
drive	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
undergoing	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

Whereas	O
adult	O
rats	O
developed	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
spike	O
protein	O
after	O
intranasal	O
inoculation	O
,	O
there	O
was	O
no	O
evidence	O
of	O
viral	O
replication	O
in	O
the	O
lungs	O
of	O
adult	O
,	O
young	O
,	O
or	O
neonatal	O
rats	O
after	O
intranasal	O
inoculation	O
with	O
MERS	O
-	O
CoV	O
.	O
In	O
addition	O
,	O
human	O
DPP4	O
-	O
expressing	O
rat	O
kidney	O
fibroblasts	O
,	O
but	O
not	O
rat	O
DPP4	O
-	O
expressing	O
cells	B-COMP
,	O
were	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
rat	O
is	O
not	O
a	O
useful	O
animal	O
model	O
for	O
studying	O
MERS	O
-	O
CoV	O
infection	O
.	O

We	O
provide	O
the	O
first	O
evidence	O
that	O
conserved	O
epitope	O
(	O
s	O
)	O
on	O
the	O
respective	O
viral	B-COMP
nucleocapsid	I-COMP
proteins	O
cross	O
-	O
react	O
with	O
each	O
other	O
although	O
virus	O
neutralization	O
cross	O
-	O
reactivity	O
was	O
not	O
observed	O
.	O

Serum	B-COMP
bilirubin	O
,	O
AST	O
and	O
ALT	O
levels	O
were	O
higher	O
while	O
age	O
was	O
lower	O
in	O
both	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	O
malaria	O
cases	O
with	O
hepatopathy	O
than	O
without	O
hepatopathy	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
).	O

TITLE	O
:	O
A	O
phase	O
trial	O
of	O
the	O
oral	O
Lactobacillus	O
casei	O
vaccine	O
polarizes	O
Th2	O
cell	B-COMP
immunity	O
against	O
transmissible	O
gastroenteritis	O
coronavirus	O
infection	O
.	O

In	O
picornavirus	O
-	O
infected	O
cells	B-COMP
,	O
lipids	O
are	O
exchanged	O
at	O
membrane	B-COMP
contact	O
sites	O
between	O
ROs	O
and	O
other	O
organelles	B-COMP
.	O

This	O
retrospective	O
observational	O
study	O
was	O
performed	O
in	O
a	O
23	O
-	O
bed	O
adult	O
intensive	O
care	O
unit	O
in	O
a	O
tertiary	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
referral	O
centre	O
.	O

Activated	O
RNase	O
L	O
cleaves	O
viral	O
and	O
host	B-COMP
single	O
-	O
stranded	O
RNA	O
(	O
ssRNA	O
),	O
which	O
leads	O
to	O
translational	O
arrest	O
and	O
subsequent	O
cell	B-COMP
death	O
,	O
preventing	O
viral	O
replication	O
and	O
spread	O
.	O

However	O
,	O
the	O
expression	O
level	O
of	O
cytoplasmic	B-COMP
MERS	O
-	O
CoV	O
NS4b	O
protein	O
is	O
sufficient	O
to	O
prevent	O
activation	O
of	O
RNase	O
L	O
.	O
Finally	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
RNase	O
L	O
antagonist	O
expressed	O
by	O
a	O
human	O
or	O
bat	O
coronavirus	O
and	O
provides	O
a	O
specific	O
mechanism	O
by	O
which	O
this	O
occurs	O
.	O

This	O
dynamic	O
nature	O
of	O
coronaviruses	O
may	O
facilitate	O
cross	O
-	O
species	O
transmission	O
and	O
shifts	O
in	O
tissue	O
or	O
cell	B-COMP
tropism	O
in	O
a	O
host	B-COMP
,	O
resulting	O
in	O
substantial	O
change	O
in	O
virulence	O
.	O

Selective	O
autophagy	O
of	O
mitochondria	B-COMP
(	O
mitophagy	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
quality	O
control	O
of	O
mitochondria	B-COMP
and	O
maintenance	O
of	O
cell	B-COMP
homeostasis	O
.	O

The	O
TGEV	O
-	O
specific	O
IgA	O
level	O
in	O
the	O
intestinal	O
tract	O
and	O
the	O
TGEV	O
-	O
specific	O
IgG	O
level	O
in	O
serum	B-COMP
significantly	O
increased	O
following	O
immunization	O
with	O
ITGEV	O
plus	O
CpG	O
DNA	O
(	O
P	O
≤	O
0	O
.	O
05	O
).	O

Using	O
ELISA	O
,	O
low	O
to	O
moderate	O
levels	O
of	O
the	O
antibodies	B-COMP
to	O
IBV	O
was	O
detected	O
in	O
the	O
SPF	O
compared	O
to	O
broiler	O
infected	O
chicks	O
.	O

However	O
,	O
the	O
function	O
of	O
soluble	O
form	O
of	O
RAGE	O
(	O
sRAGE	O
),	O
which	O
is	O
composed	O
of	O
an	O
extracellular	B-COMP
domain	O
of	O
RAGE	O
,	O
in	O
ARDS	O
remains	O
elusive	O
.	O

Our	O
result	O
revealed	O
that	O
RAGE	O
was	O
highly	O
expressed	O
on	O
the	O
alveolar	O
type	O
I	O
epithelial	O
cells	B-COMP
in	O
the	O
healthy	O
rat	O
lung	O
including	O
sRAGE	O
isoform	O
sized	O
45	O
kDa	O
.	O

On	O
the	O
day	O
of	O
the	O
donation	O
(	O
Day	O
-	O
2	O
),	O
her	O
white	O
blood	O
cell	B-COMP
count	O
was	O
5	O
.	O
83	O
×	O
10	O
The	O
isolates	O
from	O
the	O
donor	O
'	O
s	O
blood	O
cultures	O
,	O
the	O
APC	B-COMP
bag	O
,	O
the	O
attached	O
tube	O
,	O
and	O
the	O
donor	O
'	O
s	O
nasal	O
sample	O
all	O
gave	O
identical	O
profiles	O
;	O
they	O
were	O
thus	O
identified	O
as	O
the	O
same	O
strain	O
and	O
the	O
TTBI	O
was	O
confirmed	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
contraindications	O
to	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
among	O
adults	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
assess	O
the	O
impact	O
of	O
contraindications	O
on	O
the	O
number	O
of	O
patients	O
receiving	O
ECMO	O
(	O
case	O
volume	O
).	O

Thus	O
,	O
our	O
findings	O
are	O
consistent	O
with	O
a	O
scenario	O
wherein	O
the	O
current	O
diversity	O
and	O
host	B-COMP
specificity	O
of	O
coronaviruses	O
reflects	O
co	O
-	O
evolution	O
with	O
the	O
occasional	O
host	B-COMP
shift	O
.	O

Rhesus	O
macaques	O
inoculated	O
with	O
MERS	O
-	O
CoV	O
VLPs	O
and	O
Alum	O
adjuvant	O
induced	O
virus	O
-	O
neutralizing	O
antibodies	B-COMP
titers	O
up	O
to	O
1	O
:	O
40	O
and	O
induced	O
specific	O
IgG	O
antibodies	B-COMP
against	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
),	O
with	O
endpoint	O
titers	O
reaching	O
1	O
:	O
1	O
,	O
280	O
.	O

Each	O
treatment	O
was	O
designed	O
to	O
achieve	O
a	O
different	O
level	O
of	O
circulating	O
anti	O
-	O
PEDV	O
antibody	B-COMP
via	O
intraperitoneally	O
administration	O
of	O
concentrated	O
serum	B-COMP
antibody	B-COMP
.	O

The	O
data	O
were	O
evaluated	O
for	O
the	O
effects	O
of	O
systemic	O
PEDV	O
antibody	B-COMP
levels	O
on	O
growth	O
,	O
body	O
temperature	O
,	O
fecal	O
shedding	O
,	O
survival	O
,	O
and	O
antibody	B-COMP
response	O
.	O

When	O
combined	O
with	O
previous	O
literature	O
on	O
PEDV	O
,	O
it	O
can	O
be	O
concluded	O
that	O
both	O
systemic	O
antibodies	B-COMP
and	O
maternal	O
secretory	O
IgA	O
in	O
milk	O
contribute	O
to	O
the	O
protection	O
of	O
the	O
neonatal	O
pig	O
against	O
PEDV	O
infections	O
.	O

The	O
extension	O
of	O
two	O
fragments	O
allowed	O
us	O
to	O
classify	O
our	O
sequences	O
within	O
the	O
RdRp	O
Group	O
Unit	O
defined	O
for	O
Kenyan	O
Betacoronavirus	O
from	O
the	O
same	O
host	B-COMP
species	O
.	O

Ex	O
vivo	O
transepithelial	O
electrical	O
resistance	O
(	O
TER	B-COMP
)	O
did	O
not	O
differ	O
between	O
CON	O
and	O
PRRS	O
pigs	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
was	O
reduced	O
by	O
40	O
%	O
in	O
PED	O
alone	O
(	O
<	O
0	O
.	O
01	O
).	O

The	O
current	O
US	O
PDCoV	O
strains	O
are	O
enteropathogenic	O
and	O
infect	O
villous	O
epithelial	O
cells	B-COMP
of	O
the	O
entire	O
small	O
and	O
large	O
intestines	O
although	O
the	O
jejunum	O
and	O
ileum	O
are	O
the	O
primary	O
sites	O
of	O
infection	O
.	O

Using	O
a	O
novel	O
alternative	O
method	O
we	O
successfully	O
propagated	O
the	O
PEDV	O
strain	O
(	O
CH	O
/	O
QX	O
-	O
2	O
)	O
in	O
Vero	O
cells	B-COMP
,	O
confirmed	O
by	O
ultrathin	O
sections	O
of	O
the	O
cells	B-COMP
and	O
Immunofluorescence	O
assay	O
(	O
IFA	O
).	O

Only	O
four	O
months	O
were	O
required	O
from	O
the	O
initial	O
screening	O
of	O
B	O
cells	B-COMP
to	O
the	O
development	O
of	O
a	O
stable	O
CHO	O
cell	B-COMP
line	O
suitable	O
for	O
the	O
production	O
of	O
clinical	O
grade	O
antibody	B-COMP
,	O
thereby	O
delineating	O
a	O
rapid	O
pathway	O
for	O
the	O
development	O
of	O
antiviral	O
therapies	O
against	O
emerging	O
viruses	O
.	O

Currently	O
,	O
the	O
LCA60	O
antibody	B-COMP
is	O
being	O
considered	O
for	O
clinical	O
development	O
,	O
which	O
includes	O
prophylaxis	O
in	O
individuals	O
at	O
risk	O
and	O
a	O
treatment	O
for	O
severe	O
MERS	O
-	O
CoV	O
infections	O
.	O

In	O
the	O
meninges	O
,	O
ERfibs	O
together	O
with	O
collagen	B-COMP
fibers	O
,	O
lining	O
in	O
a	O
striped	O
pattern	O
,	O
made	O
up	O
a	O
pile	O
of	O
thin	O
sheets	O
.	O

At	O
lower	O
TPCK	O
concentration	O
(	O
3	O
-	O
10	O
μg	O
/	O
inoculum	O
),	O
no	O
changes	O
at	O
the	O
cellular	B-COMP
level	O
were	O
observed	O
,	O
while	O
cells	B-COMP
activated	O
with	O
25	O
-	O
30	O
μg	O
of	O
trypsin	O
/	O
inoculums	O
,	O
they	O
degenerated	O
and	O
trypsin	O
cytotoxicity	O
was	O
enhanced	O
.	O

There	O
was	O
significant	O
correlation	O
between	O
the	O
antibody	B-COMP
titers	O
determined	O
by	O
immunofluorescence	O
and	O
neutralization	O
assays	O
(	O
Pearson	O
coefficient	O
=	O
0	O
.	O
525	O
,	O
p	O
<	O
0	O
.	O
0001	O
).	O

During	O
infection	O
of	O
target	O
cell	B-COMP
,	O
MERS	O
-	O
CoV	O
S	O
protein	O
S1	O
subunit	O
binds	O
to	O
the	O
cellular	B-COMP
receptor	O
(	O
DPP4	O
),	O
and	O
its	O
S2	O
subunit	O
HR1	O
and	O
HR2	O
regions	O
intact	O
with	O
each	O
other	O
to	O
form	O
a	O
stable	O
six	O
-	O
helix	O
bundle	O
to	O
mediate	O
the	O
fusion	O
between	O
virus	O
and	O
target	O
cell	B-COMP
membranes	I-COMP
.	O

Further	O
study	O
showed	O
that	O
ORFX	O
could	O
inhibit	O
interferon	O
production	O
and	O
activate	O
NF	O
-	O
κB	O
.	O
Our	O
results	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
the	O
unique	O
ORFX	O
in	O
the	O
WIV1	O
strain	O
is	O
a	O
functional	O
gene	O
involving	O
modulation	O
of	O
the	O
host	B-COMP
immune	O
response	O
but	O
is	O
not	O
essential	O
for	O
in	O
vitro	O
viral	O
replication	O
.	O

This	O
study	O
investigates	O
the	O
mechanisms	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
-	O
induced	O
TGF	O
-	O
β1	O
promoter	O
activation	O
in	O
human	O
lung	O
epithelial	O
cells	B-COMP
and	O
mouse	O
models	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
after	O
intravenous	O
injection	O
of	O
paraffin	O
oil	O
.	O

Although	O
highly	O
pathogenic	O
to	O
their	O
spillover	O
hosts	B-COMP
,	O
bats	O
harbor	O
these	O
viruses	O
,	O
and	O
a	O
large	O
number	O
of	O
other	O
viruses	O
,	O
with	O
little	O
or	O
no	O
clinical	O
signs	O
of	O
disease	O
.	O

Infection	O
-	O
related	O
mortality	O
in	O
kidney	O
transplant	O
patients	O
with	O
ARDS	O
was	O
associated	O
with	O
high	O
serum	B-COMP
creatinine	O
level	O
and	O
severe	O
ARDS	O
.	O

CONCLUSIONS	O
:	O
Infection	O
-	O
related	O
mortality	O
in	O
kidney	O
transplant	O
patients	O
with	O
ARDS	O
was	O
associated	O
with	O
high	O
serum	B-COMP
creatinine	O
level	O
and	O
severe	O
ARDS	O
.	O

We	O
show	O
that	O
(	O
i	O
)	O
common	O
principles	O
pertaining	O
to	O
the	O
stereochemistry	O
of	O
protein	O
-	O
carbohydrate	O
interactions	O
were	O
at	O
the	O
core	O
of	O
the	O
transition	O
in	O
lectin	O
ligand	O
and	O
esterase	O
substrate	O
specificity	O
;	O
(	O
ii	O
)	O
in	O
consequence	O
,	O
the	O
switch	O
in	O
O	O
-	O
Ac	O
-	O
Sia	O
specificity	O
could	O
be	O
readily	O
accomplished	O
via	O
convergent	O
intramolecular	O
coevolution	O
with	O
only	O
modest	O
architectural	O
changes	O
in	O
lectin	O
and	O
esterase	O
domains	O
;	O
and	O
(	O
iii	O
)	O
a	O
single	O
,	O
inconspicuous	O
Ala	O
-	O
to	O
-	O
Ser	B-COMP
substitution	O
in	O
the	O
catalytic	O
site	O
was	O
key	O
to	O
the	O
emergence	O
of	O
the	O
type	O
II	O
HEs	O
.	O

Many	O
diagnostic	O
tests	O
have	O
been	O
recently	O
developed	O
and	O
are	O
currently	O
available	O
for	O
the	O
detection	O
of	O
PEDV	O
,	O
its	O
proteins	O
or	O
nucleic	B-COMP
acid	O
,	O
including	O
virus	O
isolation	O
,	O
immunofluorescence	O
(	O
IF	O
)	O
or	O
immunohistochemistry	O
(	O
IHC	O
),	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
isothermal	O
amplification	O
assays	O
.	O

Prevalence	O
of	O
CCV	O
antibodies	B-COMP
also	O
declined	O
during	O
the	O
6	O
-	O
yr	O
study	O
with	O
high	O
prevalence	O
during	O
spring	O
2006	O
-	O
08	O
(	O
80	O
%,	O
n	O
=	O
24	O
)	O
and	O
low	O
prevalence	O
during	O
spring	O
2009	O
-	O
11	O
(	O
4	O
%,	O
n	O
=	O
24	O
).	O

Protecting	O
suckling	O
piglets	O
through	O
lactogenic	O
immunity	O
is	O
dependent	O
on	O
trafficking	O
of	O
pathogen	O
-	O
specific	O
IgA	O
plasmablasts	O
to	O
the	O
mammary	O
gland	O
and	O
accumulation	O
of	O
secretory	O
IgA	O
(	O
sIgA	O
)	O
antibodies	B-COMP
in	O
milk	O
,	O
defined	O
as	O
the	O
gut	O
-	O
mammary	O
-	O
sIgA	O
axis	O
.	O

We	O
developed	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
targeting	O
antibodies	B-COMP
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
EqCoV	O
and	O
validated	O
its	O
use	O
,	O
using	O
acute	O
and	O
convalescent	O
sera	B-COMP
from	O
83	O
adult	O
horses	O
involved	O
in	O
6	O
outbreaks	O
.	O

This	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
in	O
dromedary	O
camels	O
as	O
early	O
as	O
the	O
1980s	O
.	O

Serum	B-COMP
samples	O
from	O
all	O
contacts	O
were	O
collected	O
within	O
14	O
days	O
of	O
last	O
contact	O
and	O
one	O
month	O
later	O
.	O

Our	O
previous	O
work	O
showed	O
that	O
in	O
addition	O
to	O
the	O
conserved	O
coronavirus	O
double	O
membrane	B-COMP
vesicles	B-COMP
(	O
DMVs	O
),	O
Beau	O
-	O
R	O
,	O
an	O
apathogenic	O
strain	O
of	O
avian	O
Gammacoronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
induces	O
regions	O
of	O
ER	O
that	O
are	O
zippered	O
together	O
and	O
tethered	O
open	O
-	O
necked	O
double	O
membrane	B-COMP
spherules	O
that	O
resemble	O
replication	O
organelles	B-COMP
induced	O
by	O
other	O
+	O
RNA	O
viruses	O
.	O

Here	O
we	O
compared	O
structures	O
induced	O
by	O
Beau	O
-	O
R	O
with	O
the	O
pathogenic	O
lab	O
strain	O
M41	O
to	O
determine	O
whether	O
membrane	B-COMP
rearrangements	O
are	O
strain	O
dependent	O
.	O

The	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
severe	O
ARDS	O
is	O
increasing	O
worldwide	O
,	O
but	O
because	O
of	O
a	O
lack	O
of	O
randomized	O
trials	O
is	O
still	O
considered	O
a	O
rescue	O
therapy	O
.	O

In	O
addition	O
,	O
immunization	O
of	O
mice	O
with	O
20	O
μg	O
of	O
purified	O
S25	O
-	O
229	O
elicited	O
highly	O
potent	O
serum	B-COMP
IgG	O
titers	O
.	O

The	O
specific	O
histological	O
lesions	O
finding	O
in	O
all	O
infected	O
birds	O
,	O
exhibited	O
tracheal	O
lesions	O
with	O
mucosal	O
thickening	O
,	O
hyperplasia	O
of	O
the	O
surface	O
epithelium	O
,	O
mononuclear	O
inflammatory	O
cell	B-COMP
infiltrate	O
of	O
lamina	O
propria	O
.	O

The	O
resulting	O
mAbs	O
were	O
evaluated	O
for	O
use	O
in	O
fluorescent	O
antibody	B-COMP
staining	O
methods	O
to	O
detect	O
PDCoV	O
infected	O
cells	B-COMP
following	O
virus	O
isolation	O
attempts	O
and	O
for	O
immunohistochemistry	O
staining	O
of	O
intestinal	O
tissues	O
of	O
infected	O
pigs	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
5b	O
-	O
null	O
viruses	O
,	O
unlike	O
wild	O
-	O
type	O
viruses	O
,	O
induce	O
production	O
of	O
high	O
concentrations	O
of	O
type	O
I	O
interferon	O
protein	O
in	O
vitro	O
,	O
indicating	O
that	O
host	B-COMP
shutoff	O
by	O
IBV	O
plays	O
an	O
important	O
role	O
in	O
antagonizing	O
the	O
host	B-COMP
'	O
s	O
innate	O
immune	O
response	O
.	O

This	O
process	O
is	O
referred	O
to	O
as	O
host	B-COMP
shutoff	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
accessory	O
protein	O
5b	O
of	O
IBV	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
onset	O
of	O
host	B-COMP
shutoff	O
.	O

Comparison	O
of	O
FRCoV	O
-	O
NL	O
-	O
2010	O
with	O
the	O
partially	O
sequenced	O
ferret	O
systemic	O
coronavirus	O
MSU	O
-	O
1	O
and	O
ferret	O
enteric	O
coronavirus	O
MSU	O
-	O
2	O
revealed	O
that	O
recombination	O
in	O
the	O
spike	O
,	O
3c	O
and	O
envelope	B-COMP
genes	O
occurred	O
between	O
different	O
FRCoVs	O
.	O

Once	O
considered	O
as	O
salvage	O
or	O
experimental	O
therapy	O
in	O
adults	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
evolving	O
into	O
a	O
mainstream	O
treatment	O
for	O
adult	O
critical	O
care	O
.	O

TITLE	O
:	O
Airway	O
Memory	O
CD4	O
(+)	O
T	O
Cells	B-COMP
Mediate	O
Protective	O
Immunity	O
against	O
Emerging	O
Respiratory	O
Coronaviruses	O
.	O

Protection	O
was	O
dependent	O
on	O
interferon	O
-	O
γ	O
and	O
required	O
early	O
induction	O
of	O
robust	O
innate	O
and	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cell	B-COMP
responses	O
.	O

We	O
compared	O
the	O
antigenicity	O
of	O
the	O
vaccine	O
type	O
strain	O
and	O
newly	O
isolated	O
strains	O
by	O
means	O
of	O
a	O
neutralization	O
test	O
using	O
sera	B-COMP
from	O
a	O
number	O
of	O
pigs	O
from	O
various	O
farms	O
;	O
the	O
results	O
revealed	O
that	O
they	O
are	O
antigenically	O
similar	O
.	O

The	O
method	O
employed	O
six	O
specially	O
designed	O
primers	O
that	O
recognized	O
eight	O
distinct	O
regions	O
of	O
the	O
HCoV	O
-	O
NL63	O
nucleocapsid	B-COMP
protein	O
gene	O
for	O
amplification	O
of	O
target	O
sequences	O
under	O
isothermal	O
conditions	O
at	O
63	O
degrees	O
C	O
for	O
1	O
h	O
Amplification	O
of	O
RT	O
-	O
LAMP	O
was	O
monitored	O
by	O
addition	O
of	O
calcein	O
before	O
amplification	O
.	O

Two	O
weeks	O
after	O
gene	O
transfer	O
,	O
animals	O
received	O
LPS	O
(	O
7	O
.	O
5	O
mg	O
/	O
Kg	O
)	O
injection	O
alone	O
or	O
in	O
combination	O
with	O
Mas	B-COMP
receptor	O
antagonist	O
A779	O
(	O
10	O
μg	O
/	O
Kg	O
)	O
or	O
ACE2	O
inhibitor	O
MLN	O
-	O
4760	O
(	O
1	O
mg	O
/	O
Kg	O
)	O
pretreatment	O
.	O

TITLE	O
:	O
Single	O
-	O
dose	O
treatment	O
with	O
a	O
humanized	O
neutralizing	O
antibody	B-COMP
affords	O
full	O
protection	O
of	O
a	O
human	O
transgenic	O
mouse	O
model	O
from	O
lethal	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
coronavirus	O
infection	O
.	O

Here	O
we	O
review	O
the	O
current	O
data	O
on	O
PEDV	O
entry	O
into	O
its	O
host	B-COMP
cell	I-COMP
,	O
including	O
therein	O
our	O
new	O
observations	O
regarding	O
the	O
functional	O
role	O
of	O
the	O
sialic	O
acid	O
binding	O
activity	O
of	O
the	O
S	O
protein	O
in	O
virus	O
infection	O
.	O

Antibodies	B-COMP
,	O
including	O
neutralizing	O
antibodies	B-COMP
,	O
were	O
detectable	O
in	O
6	O
(	O
86	O
%)	O
of	O
7	O
persons	O
for	O
at	O
least	O
34	O
months	O
after	O
the	O
outbreak	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
being	O
applied	O
as	O
life	O
support	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
.	O

This	O
study	O
indicated	O
a	O
CoV	O
-	O
to	O
-	O
host	B-COMP
specificity	O
and	O
draws	O
attention	O
for	O
CoV	O
detection	O
in	O
Cynomops	O
sp	O
,	O
a	O
potential	O
new	O
reservoir	O
.	O

The	O
pandemic	O
G2a	O
virus	O
was	O
partial	O
neutralized	O
by	O
the	O
antibodies	B-COMP
invoked	O
by	O
the	O
G1	O
-	O
based	O
PED	O
vaccine	O
virus	O
.	O

ABSTRACT	O
:	O
During	O
the	O
co	O
-	O
evolution	O
of	O
viruses	O
and	O
their	O
hosts	B-COMP
,	O
the	O
viruses	O
have	O
evolved	O
numerous	O
strategies	O
to	O
counter	O
and	O
evade	O
host	B-COMP
antiviral	O
immune	O
responses	O
in	O
order	O
to	O
establish	O
a	O
successful	O
infection	O
,	O
replicate	O
and	O
persist	O
in	O
the	O
host	B-COMP
.	O

The	O
assessment	O
of	O
virus	O
replication	O
inhibition	O
was	O
determined	O
via	O
titration	O
of	O
extracellular	B-COMP
virus	O
using	O
the	O
TCID	O

We	O
determined	O
optimal	O
homogenization	O
methods	O
for	O
isolating	O
viral	O
nucleic	B-COMP
acids	O
from	O
sputum	O
.	O

Additionally	O
,	O
this	O
recombinant	O
virus	O
remained	O
stable	O
for	O
at	O
least	O
10	O
passages	O
in	O
BHK	O
-	O
21	O
cells	B-COMP
.	O

The	O
next	O
phase	O
is	O
extravasated	O
platelet	O
aggregation	O
(	O
EPA	O
),	O
promoted	O
by	O
NET	O
-	O
facilitated	O
detachment	O
of	O
endothelial	O
cells	B-COMP
.	O

The	O
close	O
association	O
of	O
coronavirus	O
replication	O
with	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	B-COMP
)	O
results	O
in	O
the	O
ER	B-COMP
stress	O
responses	O
,	O
which	O
impose	O
a	O
challenge	O
to	O
the	O
viruses	O
.	O

Here	O
,	O
we	O
review	O
the	O
strategies	O
exploited	O
by	O
coronavirus	O
to	O
modulate	O
cellular	B-COMP
stress	O
response	O
pathways	O
.	O

This	O
study	O
uses	O
Affymetrix	O
microarray	O
analysis	O
to	O
compare	O
differential	O
spinal	O
cord	O
mRNA	O
levels	O
between	O
mice	O
infected	O
with	O
demyelinating	O
and	O
non	O
-	O
demyelinating	O
strains	O
of	O
MHV	O
to	O
identify	O
host	B-COMP
immune	O
genes	O
expressed	O
in	O
this	O
demyelinating	O
disease	O
model	O
.	O

To	O
this	O
end	O
,	O
host	B-COMP
cell	I-COMP
signaling	O
pathways	O
influencing	O
porcine	O
CoV	O
virulence	O
should	O
be	O
identified	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
being	O
used	O
to	O
treat	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
severe	O
pulmonary	O
tuberculosis	O
treated	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
A	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

There	O
has	O
been	O
no	O
external	O
validation	O
of	O
survival	O
prediction	O
models	O
for	O
severe	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
in	O
China	O
.	O

ABSTRACT	O
:	O
In	O
the	O
present	O
study	O
,	O
the	O
replication	O
kinetics	O
of	O
nephropathogenic	O
(	O
B1648	O
)	O
and	O
respiratory	O
(	O
Massachusetts	O
-	O
M41	O
)	O
IBV	O
strains	O
were	O
compared	O
in	O
vitro	O
in	O
respiratory	O
mucosa	O
explants	O
and	O
blood	O
monocytes	O
(	O
KUL01	O
(+)	O
cells	B-COMP
),	O
and	O
in	O
vivo	O
in	O
chickens	O
to	O
understand	O
why	O
some	O
IBV	O
strains	O
have	O
a	O
kidney	O
tropism	O
.	O

Coronaviruses	O
are	O
enveloped	O
viruses	O
,	O
with	O
the	O
spike	O
proteins	O
present	O
on	O
their	O
surface	O
responsible	O
for	O
virus	O
entry	O
into	O
the	O
target	O
cell	B-COMP
.	O

TITLE	O
:	O
Maternal	O
antibody	B-COMP
decay	O
and	O
antibody	B-COMP
-	O
mediated	O
immune	O
responses	O
in	O
chicken	O
pullets	O
fed	O
prebiotics	O
and	O
synbiotics	O
.	O

ABSTRACT	O
:	O
Three	O
experiments	O
were	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
yeast	O
-	O
derived	O
carbohydrates	O
(	O
YDC	O
),	O
and	O
a	O
blend	O
of	O
probiotics	O
and	O
YDC	O
(	O
synbiotic	O
,	O
SNB	O
)	O
on	O
serum	B-COMP
IgG	O
concentration	O
,	O
maternal	O
-	O
derived	O
antibody	B-COMP
(	O
MDA	O
)	O
decay	O
,	O
and	O
specific	O
antibody	B-COMP
-	O
mediated	O
immune	O
response	O
in	O
chick	O
pullets	O
following	O
immunization	O
with	O
T	O
-	O
cell	B-COMP
dependent	O
antigens	O
.	O

Here	O
,	O
we	O
show	O
that	O
viral	O
macro	O
domains	O
reverse	O
cellular	B-COMP
ADP	O
-	O
ribosylation	O
,	O
potentially	O
cutting	O
the	O
signal	O
of	O
a	O
viral	O
infection	O
in	O
the	O
cell	B-COMP
.	O

TITLE	O
:	O
Detection	O
of	O
RSV	O
Antibodies	B-COMP
in	O
Human	O
Plasma	O
by	O
Enzyme	O
Immunoassays	O
.	O

The	O
second	O
EIA	O
uses	O
RSV	O
F	O
or	O
G	O
gene	O
-	O
expressed	O
antigen	O
in	O
HEp	O
-	O
2	O
cells	B-COMP
.	O

We	O
specifically	O
identified	O
the	O
imatinib	O
target	O
,	O
Abelson	O
tyrosine	O
-	O
protein	O
kinase	O
2	O
(	O
Abl2	O
),	O
as	O
required	O
for	O
efficient	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
These	O
data	O
demonstrate	O
that	O
specific	O
approved	O
drugs	O
can	O
be	O
characterized	O
in	O
vitro	O
for	O
their	O
anticoronavirus	O
activity	O
and	O
used	O
to	O
identify	O
host	B-COMP
proteins	O
required	O
for	O
coronavirus	O
replication	O
.	O

These	O
data	O
demonstrate	O
that	O
interaction	O
of	O
Alphacoronavirus	O
spike	O
proteins	O
with	O
tubulin	O
supports	O
S	O
protein	O
transport	O
and	O
incorporation	O
into	O
virus	B-COMP
particles	I-COMP
.	O

During	O
investigation	O
of	O
a	O
multi	O
-	O
facility	O
outbreak	O
of	O
MERS	O
-	O
CoV	O
in	O
Taif	O
,	O
Saudi	O
Arabia	O
,	O
we	O
identified	O
a	O
mixed	O
population	O
of	O
wild	O
-	O
type	O
and	O
variant	O
sequences	O
with	O
a	O
large	O
530	O
nucleotide	O
deletion	O
in	O
the	O
spike	O
gene	O
from	O
the	O
serum	B-COMP
of	O
one	O
patient	O
.	O

Spike	O
glycoprotein	O
of	O
coronavirus	O
is	O
responsible	O
for	O
induction	O
of	O
neutralizing	O
antibody	B-COMP
response	O
.	O

ABSTRACT	O
:	O
Under	O
physiological	O
conditions	O
,	O
the	O
liver	O
sinusoidal	O
endothelial	O
cells	B-COMP
(	O
LSECs	O
)	O
mediate	O
hepatic	O
immune	O
tolerance	O
toward	O
self	O
or	O
foreign	O
antigens	O
through	O
constitutive	O
expression	O
of	O
anti	O
-	O
inflammatory	O
mediators	O
.	O

Previous	O
reports	O
have	O
demonstrated	O
that	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
predominantly	O
utilizes	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
for	O
cell	B-COMP
entry	O
.	O

However	O
,	O
additional	O
cellular	B-COMP
binding	O
targets	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
that	O
may	O
augment	O
MERS	O
-	O
CoV	O
infection	O
have	O
not	O
been	O
further	O
explored	O
.	O

In	O
the	O
current	O
study	O
,	O
using	O
the	O
virus	O
overlay	O
protein	O
binding	O
assay	O
(	O
VOPBA	O
),	O
we	O
identified	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-COMP
adhesion	O
molecule	O
5	O
(	O
CEACAM5	O
)	O
as	O
a	O
novel	O
cell	B-COMP
surface	I-COMP
binding	O
target	O
of	O
MERS	O
-	O
CoV	O
.	O
CEACAM5	O
coimmunoprecipitated	O
with	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
in	O
both	O
overexpressed	O
and	O
endogenous	O
settings	O
.	O

Furthermore	O
,	O
phylogenetic	O
analysis	O
of	O
spike	O
(	O
S	O
)	O
and	O
nucleocapsid	B-COMP
(	O
N	O
)	O
gene	O
sequences	O
of	O
PDCoVs	O
revealed	O
that	O
currently	O
circulating	O
PDCoVs	O
in	O
southern	O
China	O
were	O
more	O
closely	O
related	O
to	O
other	O
Chinese	O
strains	O
of	O
PDCoVs	O
than	O
to	O
those	O
reported	O
in	O
United	O
States	O
,	O
South	O
Korea	O
and	O
Thailand	O
.	O

An	O
ELISA	O
using	O
sporozoite	O
antigen	O
was	O
developed	O
for	O
the	O
specific	O
detection	O
of	O
anti	O
-	O
Cryptosporidium	O
-	O
IgG	O
in	O
blood	O
-	O
and	O
colostral	O
serum	B-COMP
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
study	O
the	O
effect	O
of	O
ROS	O
produced	O
by	O
hypoxanthine	O
-	O
xanthine	O
oxidase	O
(	O
Hx	O
-	O
XO	O
)	O
on	O
the	O
adhesion	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	B-COMP
(	O
HUVEC	O
)	O
and	O
on	O
the	O
signaling	O
pathways	O
involved	O
.	O

Here	O
,	O
we	O
developed	O
a	O
cell	B-COMP
-	O
based	O
fusion	O
assay	O
for	O
S	O
in	O
a	O
TMPRSS2	O
-	O
dependent	O
manner	O
using	O
cell	B-COMP
lines	O
expressing	O
Renilla	O
luciferase	O
(	O
RL	O
)-	O
based	O
split	O
reporter	O
proteins	O
.	O

The	O
assay	O
was	O
optimized	O
for	O
a	O
384	O
-	O
well	O
format	O
,	O
and	O
nafamostat	O
,	O
a	O
serine	O
protease	O
inhibitor	O
,	O
was	O
identified	O
as	O
a	O
potent	O
inhibitor	O
of	O
S	O
-	O
mediated	O
membrane	B-COMP
fusion	O
in	O
a	O
screening	O
of	O
about	O
1	O
,	O
000	O
drugs	O
approved	O
for	O
use	O
by	O
the	O
U	O
.	O
S	O
.	O
Food	O
and	O
Drug	O
Administration	O
.	O

Following	O
removal	O
of	O
free	O
proteins	O
,	O
antigen	O
-	O
laden	O
particles	O
were	O
recovered	O
and	O
showed	O
morphological	O
semblance	O
to	O
natural	O
viral	B-COMP
particles	I-COMP
under	O
nanoparticle	O
tracking	O
analysis	O
and	O
transmission	O
electron	O
microscopy	O
.	O

Furthermore	O
,	O
treatment	O
of	O
TGEV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	B-COMP
with	O
the	O
NF	O
-	O
κB	O
-	O
specific	O
inhibitor	O
BAY	O
11	O
-	O
7082	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
pFcRn	O
expression	O
.	O

TITLE	O
:	O
The	O
establishment	O
and	O
characteristics	O
of	O
cell	B-COMP
-	O
adapted	O
IBV	O
strain	O
H120	O
.	O

The	O
PEDV	O
S	O
was	O
inserted	O
into	O
the	O
ORFV121	O
gene	O
locus	O
,	O
an	O
immunomodulatory	O
gene	O
that	O
inhibits	O
activation	O
of	O
the	O
NF	O
-	O
κB	O
signalling	O
pathway	O
and	O
contributes	O
to	O
ORFV	O
virulence	O
in	O
the	O
natural	O
host	B-COMP
.	O

It	O
first	O
binds	O
to	O
a	O
receptor	O
on	O
the	O
host	B-COMP
cell	I-COMP
surface	I-COMP
through	O
its	O
S1	O
subunit	O
and	O
then	O
fuses	O
viral	O
and	O
host	B-COMP
membranes	O
through	O
its	O
S2	O
subunit	O
.	O

Cryo	O
-	O
preserved	O
serum	B-COMP
obtained	O
at	O
this	O
time	O
showed	O
high	O
titers	O
of	O
IgM	O
class	O
antibodies	B-COMP
against	O
ganglioside	O
(	O
GD3	O
+++,	O
GT1a	O
++++,	O
GT1b	O
++,	O
GQ1b	O
+++,	O
and	O
GD1b	O
+++),	O
which	O
had	O
been	O
negative	O
on	O
admission	O
.	O

The	O
PF	O
-	O
d	O
group	O
was	O
older	O
(	O
49	O
±	O
2	O
.	O
1	O
years	O
versus	O
41	O
±	O
1	O
.	O
8	O
years	O
)	O
and	O
presented	O
lower	O
Respiratory	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
Survival	O
Prediction	O
(	O
RESP	O
)	O
scores	O
(	O
0	O
.	O
57	O
±	O
0	O
.	O
63	O
versus	O
2	O
.	O
2	O
±	O
0	O
.	O
52	O
).	O

(	O
4	O
)	O
The	O
differences	O
of	O
occurrence	O
rates	O
of	O
BE	O
,	O
white	O
blood	O
cell	B-COMP
count	O
,	O
procalcitonin	O
,	O
calcium	O
,	O
alanine	O
aminotransferase	O
,	O
aspartate	O
aminotransferase	O
,	O
creatinine	O
,	O
urea	O
nitrogen	O
,	O
lactate	O
dehydrogenase	O
,	O
CKMB	O
among	O
the	O
three	O
groups	O
were	O
statistically	O
significant	O
(	O
χ	O
(	O
2	O
)=	O
59	O
.	O
485	O
,	O
27	O
.	O
634	O
,	O
125	O
.	O
564	O
,	O
102	O
.	O
258	O
,	O
10	O
.	O
175	O
,	O
27	O
.	O
338	O
,	O
80	O
.	O
616	O
,	O
140	O
.	O
521	O
,	O
72	O
.	O
830	O
,	O
72	O
.	O
136	O
,	O
P	O
all	O
<	O
0	O
.	O
05	O
).	O

Morbidity	O
and	O
mortality	O
,	O
viral	O
load	O
and	O
immune	O
cell	B-COMP
accumulation	O
in	O
the	O
CNS	O
,	O
and	O
spinal	O
cord	O
demyelination	O
were	O
assessed	O
at	O
defined	O
points	O
post	O
-	O
infection	O
.	O

These	O
findings	O
support	O
a	O
novel	O
role	O
for	O
miR	O
-	O
155	O
in	O
host	B-COMP
defense	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
encephalomyelitis	O
.	O

A	O
range	O
of	O
vertebrate	O
cell	B-COMP
lines	O
were	O
shown	O
to	O
be	O
susceptible	O
to	O
Tioman	O
virus	O
.	O

We	O
have	O
isolated	O
and	O
passaged	O
the	O
PDCoV	O
strain	O
OH	O
-	O
FD22	O
in	O
an	O
LLC	B-COMP
porcine	O
kidney	O
(	O
LLC	B-COMP
-	O
PK	O
)	O
cell	B-COMP
line	O
.	O

They	O
developed	O
high	O
titers	O
of	O
PDCoV	O
-	O
specific	O
IgG	O
/	O
IgA	O
and	O
virus	O
-	O
neutralizing	O
antibodies	B-COMP
in	O
serum	B-COMP
at	O
PID	O
23	O
-	O
24	O
.	O

Two	O
inoculated	O
pigs	O
tested	O
at	O
PID	O
23	O
-	O
24	O
had	O
small	O
to	O
moderate	O
numbers	O
of	O
PDCoV	O
antigen	O
-	O
positive	O
cells	B-COMP
in	O
the	O
intestinal	O
lamina	O
propria	O
and	O
mesenteric	O
lymph	O
nodes	O
,	O
but	O
not	O
in	O
enterocytes	O
.	O

The	O
TC	O
-	O
PDCoV	O
OH	O
-	O
FD22	O
will	O
be	O
useful	O
for	O
further	O
pathogenesis	O
studies	O
and	O
for	O
evaluating	O
if	O
higher	O
-	O
level	O
cell	B-COMP
-	O
culture	O
passaged	O
virus	O
becomes	O
attenuated	O
for	O
vaccine	O
development	O
.	O

This	O
peptide	O
exhibited	O
a	O
high	O
level	O
of	O
serological	O
reactivity	O
(	O
64	O
%),	O
which	O
resulted	O
from	O
the	O
additive	O
responses	O
of	O
two	O
tandem	O
epitopes	O
(	O
S597	O
-	O
603	O
and	O
S604	O
-	O
625	O
)	O
and	O
a	O
long	O
-	O
term	O
human	O
B	O
-	O
cell	B-COMP
memory	O
response	O
with	O
antisera	O
from	O
convalescent	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
Initial	O
success	O
with	O
chimeric	O
antigen	O
receptor	O
-	O
modified	O
T	O
cell	B-COMP
therapy	O
for	O
relapsed	O
/	O
refractory	O
acute	O
lymphoblastic	O
leukemia	O
is	O
leading	O
to	O
expanded	O
use	O
through	O
multicenter	O
trials	O
.	O

We	O
sought	O
to	O
characterize	O
the	O
timing	O
,	O
severity	O
,	O
and	O
intensive	O
care	O
management	O
of	O
cytokine	O
release	O
syndrome	O
after	O
chimeric	O
antigen	O
receptor	O
-	O
modified	O
T	O
cell	B-COMP
therapy	O
.	O

Fourteen	O
(	O
36	O
%)	O
developed	O
cardiovascular	O
dysfunction	O
treated	O
with	O
vasoactive	O
infusions	O
a	O
median	O
of	O
5	O
days	O
after	O
T	O
cell	B-COMP
therapy	O
.	O

Currently	O
,	O
few	O
bat	O
cell	B-COMP
lines	O
have	O
been	O
developed	O
and	O
only	O
Tb1	O
-	O
Lu	O
,	O
derived	O
from	O
Tadarida	O
brasiliensis	O
is	O
commercially	O
available	O
.	O

All	O
lions	O
were	O
negative	O
for	O
antibodies	B-COMP
to	O
feline	O
coronavirus	O
.	O

Herein	O
,	O
we	O
identified	O
a	O
novel	O
coronavirus	O
,	O
provisionally	O
designated	O
Rousettus	O
bat	O
coronavirus	O
GCCDC1	O
(	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
),	O
in	O
the	O
rectal	O
swab	O
samples	O
of	O
Rousettus	O
leschenaulti	O
bats	O
by	O
using	O
pan	B-COMP
-	O
coronavirus	O
RT	O
-	O
PCR	O
and	O
next	O
-	O
generation	O
sequencing	O
.	O

Subgenomic	O
mRNA	O
and	O
cellular	B-COMP
-	O
level	O
observations	O
demonstrated	O
that	O
the	O
p10	O
gene	O
is	O
functional	O
and	O
induces	O
the	O
formation	O
of	O
cell	B-COMP
syncytia	O
.	O

In	O
addition	O
,	O
the	O
antibodies	B-COMP
represent	O
useful	O
tools	O
for	O
investigating	O
the	O
antigenic	O
properties	O
of	O
the	O
N	O
protein	O
.	O

Moreover	O
,	O
the	O
extracellular	B-COMP
RNA	O
content	O
began	O
to	O
rise	O
at	O
24h	O
after	O
inoculation	O
and	O
then	O
reduced	O
gradually	O
at	O
approximately	O
48h	O
.	O

TITLE	O
:	O
Tissue	O
localization	O
,	O
shedding	O
,	O
virus	O
carriage	O
,	O
antibody	B-COMP
response	O
,	O
and	O
aerosol	O
transmission	O
of	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
following	O
inoculation	O
of	O
4	O
-	O
week	O
-	O
old	O
feeder	O
pigs	O
.	O

ABSTRACT	O
:	O
We	O
determined	O
tissue	O
localization	O
,	O
shedding	O
patterns	O
,	O
virus	O
carriage	O
,	O
antibody	B-COMP
response	O
,	O
and	O
aerosol	O
transmission	O
of	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
following	O
inoculation	O
of	O
4	O
-	O
week	O
-	O
old	O
feeder	O
pigs	O
.	O

As	O
the	O
mechanistic	O
pathway	O
for	O
this	O
ability	O
is	O
not	O
fully	O
known	O
,	O
we	O
extended	O
previous	O
studies	O
on	O
influenza	O
virus	O
tropism	O
in	O
cultured	O
human	O
pulmonary	O
endothelial	O
cells	B-COMP
.	O

Unlike	O
numerous	O
cell	B-COMP
types	O
,	O
including	O
epithelial	O
cells	B-COMP
,	O
we	O
found	O
that	O
pulmonary	O
endothelial	O
cells	B-COMP
constitutively	O
express	O
a	O
high	O
level	O
of	O
the	O
restriction	O
protein	O
IFITM3	O
in	O
endosomal	O
compartments	O
.	O

We	O
also	O
review	O
the	O
current	O
classification	O
of	O
FCoVs	O
into	O
distinct	O
serotypes	O
and	O
biotypes	O
,	O
cellular	B-COMP
receptors	O
of	O
FCoVs	O
and	O
their	O
presumed	O
role	O
in	O
viral	O
virulence	O
,	O
and	O
discuss	O
other	O
aspects	O
of	O
FIPV	O
-	O
induced	O
pathogenesis	O
.	O

The	O
development	O
of	O
attenuated	O
virus	O
vaccines	O
to	O
combat	O
infections	O
caused	O
by	O
highly	O
pathogenic	O
CoVs	O
was	O
largely	O
based	O
on	O
the	O
identification	O
and	O
characterization	O
of	O
viral	O
virulence	O
proteins	O
that	O
,	O
for	O
example	O
,	O
interfere	O
with	O
the	O
innate	O
and	O
adaptive	O
immune	O
response	O
or	O
are	O
involved	O
in	O
interactions	O
with	O
specific	O
cell	B-COMP
types	O
,	O
such	O
as	O
macrophages	O
,	O
dendritic	B-COMP
and	O
epithelial	O
cells	B-COMP
,	O
and	O
T	O
lymphocytes	O
,	O
thereby	O
modulating	O
antiviral	O
host	B-COMP
responses	O
and	O
viral	O
pathogenesis	O
and	O
potentially	O
resulting	O
in	O
deleterious	O
side	O
effects	O
following	O
vaccination	O
.	O

In	O
contrast	O
to	O
mycoplasma	O
pneumonia	O
,	O
infiltrating	O
cells	B-COMP
were	O
predominantly	O
mononuclear	O
rather	O
than	O
polymorphonuclear	O
.	O

Coronavirus	O
spike	O
proteins	O
mediate	O
virus	O
entry	O
into	O
cells	B-COMP
,	O
a	O
process	O
that	O
requires	O
the	O
spike	O
proteins	O
to	O
be	O
proteolytically	O
activated	O
.	O

In	O
the	O
latter	O
,	O
domain	O
VII	O
was	O
linked	O
to	O
the	O
transmembrane	B-COMP
segment	O
through	O
domain	O
III	O
.	O

Therefore	O
,	O
therapeutic	O
agents	O
for	O
coronavirus	O
-	O
mediated	O
diseases	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
should	O
target	O
cell	B-COMP
surface	I-COMP
TMPRSS2	O
rather	O
than	O
endosomal	O
cathepsin	O
.	O

However	O
,	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
analyses	O
showed	O
the	O
susceptibility	O
of	O
quail	O
also	O
to	O
Deltacoronaviruses	O
,	O
suggesting	O
that	O
quail	O
and	O
pheasant	O
avian	O
coronaviruses	O
share	O
spike	O
genes	O
identical	O
to	O
chicken	O
IBV	O
spike	O
genes	O
and	O
quail	O
might	O
host	B-COMP
Deltacoronavirus	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
discuss	O
the	O
function	O
of	O
proteins	O
responsible	O
for	O
formation	O
of	O
the	O
coronavirus	O
replicative	O
organelle	B-COMP
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
adult	O
respiratory	O
distress	O
syndrome	O
in	O
trauma	O
patients	O
:	O
A	O
case	O
series	O
and	O
systematic	O
literature	O
review	O
.	O

It	O
is	O
unknown	O
whether	O
cellular	B-COMP
infection	O
by	O
MERS	O
-	O
CoV	O
activates	O
the	O
stress	O
response	O
pathway	O
or	O
whether	O
the	O
virus	O
has	O
evolved	O
strategies	O
to	O
suppress	O
this	O
infection	O
-	O
limiting	O
pathway	O
.	O

Uncleaved	O
viruses	O
were	O
less	O
infectious	O
to	O
human	O
airway	O
epithelial	O
and	O
Calu3	O
cell	B-COMP
cultures	O
because	O
they	O
lacked	O
sufficient	O
endosomal	O
fusion	O
-	O
activating	O
proteases	O
.	O

Thus	O
,	O
by	O
sensitizing	O
viruses	O
to	O
receptor	O
-	O
induced	O
conformational	O
changes	O
,	O
the	O
first	O
S	O
cleavages	O
expand	O
virus	O
tropism	O
to	O
cell	B-COMP
types	O
that	O
are	O
relevant	O
to	O
lung	O
infection	O
,	O
and	O
therefore	O
may	O
be	O
significant	O
determinants	O
of	O
MERS	O
-	O
CoV	O
virulence	O
.	O

Like	O
the	O
RBD	O
of	O
prototype	O
EMC2012	O
(	O
EMC	B-COMP
-	O
RBD	O
),	O
all	O
five	O
RBDs	O
maintained	O
good	O
antigenicity	O
and	O
functionality	O
,	O
the	O
ability	O
to	O
bind	O
RBD	O
-	O
specific	O
neutralizing	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)	O
and	O
the	O
DPP4	O
receptor	O
,	O
and	O
high	O
immunogenicity	O
,	O
able	O
to	O
elicit	O
S	O
-	O
specific	O
antibodies	B-COMP
.	O

They	O
induced	O
potent	O
neutralizing	O
antibodies	B-COMP
cross	O
-	O
neutralizing	O
17	O
MERS	O
pseudoviruses	O
expressing	O
S	O
proteins	O
of	O
representative	O
human	O
and	O
camel	O
MERS	O
-	O
CoV	O
strains	O
identified	O
during	O
the	O
2012	O
-	O
2015	O
outbreaks	O
,	O
5	O
MAb	O
escape	O
MERS	O
-	O
CoV	O
mutants	O
,	O
and	O
2	O
live	O
human	O
MERS	O
-	O
CoV	O
strains	O
.	O

We	O
then	O
constructed	O
two	O
RBDs	O
mutated	O
in	O
multiple	O
key	O
residues	O
in	O
the	O
receptor	O
-	O
binding	O
motif	O
(	O
RBM	O
)	O
of	O
RBD	O
and	O
demonstrated	O
their	O
strong	O
cross	O
-	O
reactivity	O
with	O
anti	O
-	O
EMC	B-COMP
-	O
RBD	O
antibodies	B-COMP
.	O

High	O
levels	O
of	O
PCV3	O
nucleic	B-COMP
acid	O
were	O
observed	O
in	O
aborted	O
fetuses	O
by	O
quantitative	O
PCR	O
,	O
and	O
PCV3	O
antigen	O
was	O
localized	O
in	O
histologic	O
lesions	O
typical	O
of	O
PDNS	O
in	O
sows	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
analysis	O
.	O

TITLE	O
:	O
Fibroblastic	O
reticular	O
cells	B-COMP
regulate	O
intestinal	O
inflammation	O
via	O
IL	O
-	O
15	O
-	O
mediated	O
control	O
of	O
group	O
1	O
ILCs	O
.	O

ABSTRACT	O
:	O
Fibroblastic	O
reticular	O
cells	B-COMP
(	O
FRCs	O
)	O
of	O
secondary	O
lymphoid	O
organs	O
form	O
distinct	O
niches	O
for	O
interaction	O
with	O
hematopoietic	O
cells	B-COMP
.	O

MERS	O
-	O
CoV	O
(	O
EMC	B-COMP
strain	O
)	O
was	O
used	O
to	O
inoculate	O
plasma	O
units	O
that	O
then	O
underwent	O
treatment	O
with	O
riboflavin	O
and	O
UV	O
light	O
.	O

ABSTRACT	O
:	O
For	O
patients	O
with	O
a	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
represents	O
a	O
life	O
-	O
saving	O
measure	O
.	O

Remarkably	O
,	O
reverse	O
-	O
genetics	O
-	O
derived	O
cell	B-COMP
culture	O
-	O
adapted	O
PEDV	O
Recurrent	O
PEDV	O
outbreaks	O
have	O
resulted	O
in	O
enormous	O
economic	O
losses	O
to	O
swine	O
industries	O
worldwide	O
.	O

GILZ	O
protein	O
and	O
gene	O
expression	O
was	O
quantified	O
in	O
blood	O
neutrophils	O
,	O
along	O
with	O
markers	O
of	O
inflammation	O
(	O
CRP	O
,	O
extracellular	B-COMP
DNA	O
)	O
or	O
its	O
resolution	O
(	O
Annexin	O
A1	O
).	O

ABSTRACT	O
:	O
Several	O
biosafety	O
level	O
3	O
and	O
/	O
or	O
4	O
(	O
BSL	O
-	O
3	O
/	O
4	O
)	O
pathogens	O
are	O
high	O
-	O
consequence	O
,	O
single	O
-	O
stranded	O
RNA	O
viruses	O
,	O
and	O
their	O
genomes	O
,	O
when	O
introduced	O
into	O
permissive	O
cells	B-COMP
,	O
are	O
infectious	O
.	O

TITLE	O
:	O
Characterization	O
of	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
against	O
various	O
recombinant	O
structural	O
antigens	O
of	O
MERS	O
-	O
CoV	O
in	O
an	O
imported	O
case	O
in	O
China	O
.	O

Microscopic	O
examinations	O
of	O
the	O
LPS	O
-	O
injected	O
swim	O
bladders	O
further	O
revealed	O
in	O
situ	O
injuries	O
,	O
including	O
epithelial	O
distortion	O
,	O
endoplasmic	B-COMP
reticulum	I-COMP
swelling	O
and	O
mitochondrial	B-COMP
injuries	O
.	O

BAL	O
fluid	O
from	O
mice	O
with	O
ARDS	O
dampens	O
the	O
TNF	O
-	O
α	O
production	O
compared	O
to	O
cells	B-COMP
cultured	O
with	O
BAL	O
lacking	O
sPD	O
-	O
1	O
(	O
2	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
3	O
.	O
8	O
)	O
vs	O
.	O
52	O
.	O
38	O
pg	O
/	O
mL	O
(	O
SD	O
25	O
.	O
1	O
),	O
p	O
=	O
0	O
.	O
002	O
).	O

While	O
postponing	O
the	O
response	O
to	O
treatment	O
,	O
to	O
limit	O
mechanical	O
ventilation	O
side	O
effects	O
,	O
extracorporeal	O
membrane	B-COMP
oxygene	O
can	O
be	O
proposed	O
.	O

It	O
has	O
been	O
confirmed	O
that	O
T	O
-	O
cell	B-COMP
immunity	O
plays	O
an	O
important	O
role	O
in	O
recovery	O
from	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
plasmids	O
were	O
constructed	O
and	O
transiently	O
transfected	O
into	O
a	O
porcine	O
kidney	O
cells	B-COMP
,	O
PK	O
-	O
15	O
,	O
to	O
determine	O
whether	O
these	O
constructs	O
inhibited	O
TGEV	O
production	O
.	O

The	O
analysis	O
of	O
cytopathic	O
effects	O
demonstrated	O
that	O
pRNAT	O
-	O
2	O
and	O
pRNAT	O
-	O
3	O
could	O
protect	O
PK	O
-	O
15	O
cells	B-COMP
against	O
pathological	O
changes	O
specifically	O
and	O
efficiently	O
.	O

However	O
,	O
the	O
current	O
methods	O
are	O
limited	O
to	O
antigen	O
detection	O
by	O
conjugating	O
IgG	O
antibodies	B-COMP
on	O
S	O
.	O
aureus	O
nanoparticles	O
.	O

Based	O
on	O
this	O
novel	O
design	O
,	O
simple	O
agglutination	O
tests	O
of	O
the	O
IgG	O
antibodies	B-COMP
of	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
nucleoprotein	O
(	O
NP	O
)	O
and	O
Middle	O
East	O
Respiratory	O
Virus	O
(	O
MERS	O
)	O
NP	O
in	O
rabbit	O
sera	B-COMP
were	O
successfully	O
developed	O
by	O
conjugating	O
the	O
S	O
.	O
aureus	O
nanobioparticles	O
with	O
two	O
fusion	O
proteins	O
EBOV	O
NP	O
-	O
CBD	O
and	O
MERS	O
NP	O
-	O
CBD	O
,	O
respectively	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
beyond	O
rescue	O
therapy	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
?	O

In	O
rodents	O
,	O
exposure	O
to	O
CIH	O
-	O
related	O
redox	O
stress	O
causes	O
upper	O
airway	O
muscle	O
weakness	O
and	O
fatigue	O
,	O
associated	O
with	O
mitochondrial	B-COMP
dysfunction	O
.	O

Importantly	O
,	O
therapeutic	O
countermeasures	O
comprising	O
MERS	O
-	O
CoV	O
neutralizing	O
antibody	B-COMP
treatment	O
or	O
a	O
MERS	O
-	O
CoV	O
spike	O
protein	O
vaccine	O
protected	O
the	O
engineered	O
mice	O
against	O
MERS	O
-	O
CoV	O
-	O
induced	O
ARDS	O
.	O

Early	O
involvement	O
of	O
an	O
ARDS	O
or	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
center	O
should	O
be	O
considered	O
to	O
ensure	O
optimal	O
care	O
.	O

To	O
better	O
understand	O
the	O
pathogenesis	O
mechanism	O
and	O
the	O
virus	O
-	O
host	B-COMP
interaction	O
during	O
infection	O
with	O
both	O
PEDV	O
YN13	O
and	O
YN144	O
strains	O
,	O
a	O
comparative	O
proteomic	O
analysis	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
proteomic	O
changes	O
produced	O
in	O
the	O
primary	O
target	O
organ	O
,	O
using	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantitation	O
(	O
iTRAQ	O
)	O
labeling	O
,	O
followed	O
by	O
liquid	O
chromatography	O
tandem	O
-	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
).	O

ABSTRACT	O
:	O
The	O
occurrence	O
of	O
a	O
noninfectious	O
interstitial	O
lung	O
disease	O
is	O
a	O
rare	O
but	O
life	O
-	O
threatening	O
side	O
effect	O
of	O
infliximab	O
,	O
an	O
antitumor	O
necrosis	O
factor	O
alpha	O
antibody	B-COMP
.	O

TITLE	O
:	O
Antiviral	O
Innate	O
Immune	O
Response	O
Interferes	O
with	O
the	O
Formation	O
of	O
Replication	O
-	O
Associated	O
Membrane	B-COMP
Structures	O
Induced	O
by	O
a	O
Positive	O
-	O
Strand	O
RNA	O
Virus	O
.	O

Moreover	O
,	O
these	O
astroviruses	O
showed	O
an	O
important	O
genetic	O
diversity	O
and	O
low	O
host	B-COMP
restriction	O
in	O
bat	O
species	O
.	O

Seventeen	O
patients	O
with	O
genetically	O
proven	O
late	O
-	O
onset	O
Pompe	O
disease	O
(	O
50	O
±	O
18	O
years	O
,	O
11	O
male	O
)	O
and	O
18	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
(	O
44	O
±	O
10	O
year	O
,	O
12	O
male	O
)	O
underwent	O
comprehensive	O
cardiovascular	O
magnetic	O
resonance	O
(	O
CMR	O
)	O
including	O
conventional	O
and	O
advanced	O
techniques	O
:	O
cine	O
and	O
feature	O
tracking	O
-	O
based	O
strain	O
imaging	O
for	O
depiction	O
of	O
(	O
even	O
subtle	O
)	O
systolic	O
LV	O
dysfunction	O
as	O
well	O
as	O
late	O
gadolinium	O
enhancement	O
(	O
LGE	O
)	O
and	O
myocardial	O
extracellular	B-COMP
volume	O
fraction	O
(	O
ECV	O
)	O
quantification	O
for	O
focal	O
and	O
diffuse	O
fibrosis	O
detection	O
.	O

To	O
assess	O
the	O
properties	O
of	O
various	O
diagnostic	O
assays	O
for	O
the	O
detection	O
of	O
PEDV	O
infection	O
,	O
multiple	O
panels	O
of	O
porcine	O
sera	B-COMP
have	O
been	O
shared	O
and	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	B-COMP
against	O
PEDV	O
in	O
an	O
inter	O
-	O
laboratory	O
ring	O
trial	O
.	O

Piglets	O
on	O
sows	O
without	O
(	O
Group	O
1	O
)	O
or	O
with	O
(	O
Group	O
2	O
)	O
anti	O
-	O
PEDV	O
antibody	B-COMP
showed	O
significantly	O
different	O
responses	O
to	O
PEDV	O
infection	O
in	O
virus	O
shedding	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
thermoregulation	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
growth	O
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
survivability	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

However	O
,	O
when	O
combined	O
with	O
previous	O
PEDV	O
literature	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
optimal	O
protection	O
to	O
piglets	O
will	O
be	O
provided	O
by	O
dams	O
able	O
to	O
deliver	O
sufficient	O
lactogenic	O
immunity	O
,	O
both	O
humoral	O
and	O
cellular	B-COMP
,	O
to	O
their	O
offspring	O
.	O

Further	O
,	O
macrodomain	O
mutant	O
virus	O
elicited	O
an	O
early	O
,	O
enhanced	O
interferon	O
(	O
IFN	O
),	O
interferon	O
-	O
stimulated	O
gene	O
(	O
ISG	O
),	O
and	O
proinflammatory	O
cytokine	O
response	O
in	O
mice	O
and	O
in	O
a	O
human	O
bronchial	O
epithelial	O
cell	B-COMP
line	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
two	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
;	O
1C3	O
and	O
4C7	O
)	O
directed	O
against	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
M	O
protein	O
.	O

ABSTRACT	O
:	O
After	O
risk	O
assessment	O
,	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
has	O
been	O
achieved	O
in	O
a	O
superobese	O
adult	O
patient	O
as	O
a	O
bridge	O
to	O
recovery	O
of	O
respiratory	O
failure	O
,	O
despite	O
the	O
weight	O
-	O
related	O
difficulties	O
.	O

The	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
protein	O
)	O
of	O
PEDV	O
presents	O
strong	O
immunogenicity	O
and	O
contributes	O
to	O
the	O
cross	O
-	O
reactivity	O
between	O
PEDV	O
and	O
TGEV	O
.	O

Activated	O
platelets	O
,	O
neutrophils	O
,	O
endothelial	O
cells	B-COMP
,	O
neutrophil	O
extracellular	B-COMP
traps	O
,	O
microparticles	O
,	O
and	O
coagulation	O
proteases	O
,	O
participate	O
in	O
the	O
complex	O
process	O
of	O
immunothrombosis	O
,	O
which	O
is	O
a	O
key	O
event	O
in	O
ARDS	O
pathophysiology	O
.	O

Viruses	O
,	O
bacteria	O
and	O
pathogen	O
-	O
related	O
molecules	O
interact	O
with	O
cells	B-COMP
present	O
in	O
the	O
human	O
alveolus	O
by	O
numerous	O
,	O
yet	O
poorly	O
understood	O
ways	O
.	O

ABSTRACT	O
:	O
The	O
lipid	O
kinase	O
phosphatidylinositol	O
4	O
-	O
kinase	O
IIIβ	O
(	O
PI4KB	O
)	O
is	O
an	O
essential	O
host	B-COMP
factor	O
for	O
many	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
(+	O
RNA	O
)	O
viruses	O
including	O
human	O
pathogens	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
coxsackie	O
viruses	O
,	O
and	O
rhinoviruses	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
coumarin	O
-	O
labeled	O
inhibitor	O
can	O
be	O
used	O
to	O
image	O
PI4KB	O
in	O
cells	B-COMP
using	O
fluorescence	O
-	O
lifetime	O
imaging	O
microscopy	O
(	O
FLIM	O
)	O
microscopy	O
.	O

The	O
effect	O
of	O
end	O
-	O
organ	O
damage	O
on	O
NMBA	O
clearance	O
was	O
less	O
commonly	O
identified	O
by	O
NPs	O
/	O
PAs	B-COMP
for	O
both	O
hepatic	O
(	O
P	O
=.	O
0077	O
)	O
and	O
renal	O
(	O
P	O
=.	O
0272	O
)	O
dysfunction	O
compared	O
with	O
physicians	O
.	O

These	O
synthetic	O
viral	B-COMP
particles	I-COMP
are	O
safer	O
surrogates	O
of	O
native	O
viruses	O
and	O
acquire	O
the	O
tropism	O
and	O
host	B-COMP
entry	O
pathway	O
characteristics	O
governed	O
by	O
the	O
heterologous	O
envelope	B-COMP
glycoprotein	O
used	O
.	O

ABSTRACT	O
:	O
Hosts	B-COMP
and	O
pathogens	O
are	O
locked	O
in	O
an	O
evolutionary	O
arms	O
race	O
.	O

In	O
addition	O
,	O
binding	O
of	O
N	O
protein	O
to	O
NPM1	O
protects	O
it	O
from	O
proteolytic	O
degradation	O
by	O
caspase	O
-	O
3	O
,	O
leading	O
to	O
increased	O
cell	B-COMP
survival	O
.	O

Through	O
systematic	O
surveillance	O
in	O
Egypt	O
,	O
nasal	O
,	O
rectal	O
,	O
milk	O
,	O
urine	O
and	O
serum	B-COMP
samples	O
were	O
collected	O
from	O
camels	O
between	O
June	O
2014	O
and	O
February	O
2016	O
.	O

Maternal	O
antibodies	B-COMP
titers	O
were	O
very	O
low	O
in	O
calves	O
regardless	O
of	O
the	O
antibody	B-COMP
titers	O
of	O
the	O
mothers	O
.	O

Adapted	O
to	O
growth	O
in	O
avian	O
cells	B-COMP
MVA	O
lost	O
the	O
ability	O
to	O
replicate	O
in	O
mammalian	O
hosts	B-COMP
and	O
lacks	O
many	O
of	O
the	O
genes	O
orthopoxviruses	O
use	O
to	O
conquer	O
their	O
host	B-COMP
(	O
cell	B-COMP
)	O
environment	O
.	O

Extensive	O
infection	O
of	O
alveolar	O
epithelial	O
cells	B-COMP
caused	O
apoptosis	O
and	O
leakage	O
of	O
albumin	O
into	O
airways	O
,	O
reflecting	O
loss	O
of	O
epithelial	O
barrier	O
function	O
.	O

TITLE	O
:	O
Roles	O
of	O
regulatory	O
T	O
cells	B-COMP
and	O
IL	O
-	O
10	O
in	O
virus	O
-	O
induced	O
demyelination	O
.	O

Since	O
the	O
resulting	O
morphology	O
closely	O
resembles	O
the	O
3	O
-	O
dimensional	O
fibrous	O
network	O
of	O
an	O
extracellular	B-COMP
matrix	I-COMP
(	O
ECM	B-COMP
),	O
the	O
capability	O
of	O
the	O
TMV	O
assemblies	O
to	O
support	O
the	O
adhesion	O
of	O
NIH	O
-	O
3T3	O
fibroblast	O
cells	B-COMP
was	O
investigated	O
,	O
demonstrating	O
potential	O
utility	O
in	O
regenerative	O
medicine	O
.	O

In	O
spite	O
of	O
its	O
rarity	O
as	O
an	O
opportunistic	O
pathogen	O
,	O
we	O
recommend	O
that	O
R	O
.	O
equi	O
,	O
an	O
intracellular	B-COMP
pathogen	O
,	O
be	O
included	O
in	O
the	O
differential	O
list	O
of	O
pathogens	O
associated	O
with	O
IRIS	O
.	O

TITLE	O
:	O
Bedside	O
Contribution	O
of	O
Electrical	O
Impedance	O
Tomography	O
to	O
Setting	O
Positive	O
End	O
-	O
Expiratory	O
Pressure	O
for	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
-	O
treated	O
Patients	O
with	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

A	O
new	O
concept	O
is	O
introduced	O
that	O
SR	O
T	O
cells	B-COMP
can	O
be	O
dampened	O
by	O
distinct	O
regulatory	O
mechanisms	O
in	O
the	O
periphery	O
and	O
the	O
CNS	O
,	O
thereby	O
preventing	O
autoimmune	O
disease	O
.	O

In	O
addition	O
,	O
rpIFN	O
-	O
L1	O
exhibited	O
greater	O
antiviral	O
activity	O
against	O
PEDV	O
infection	O
of	O
IPEC	O
-	O
J2	O
cells	B-COMP
than	O
that	O
of	O
porcine	O
IFN	O
-	O
alpha	O
.	O

Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
an	O
Alphacoronavirus	O
genera	O
virus	O
,	O
is	O
an	O
important	O
pathogen	O
that	O
mainly	O
infects	O
piglet	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
activation	O
of	O
the	O
host	B-COMP
immune	O
response	O
.	O

Widespread	O
lymphoid	O
cell	B-COMP
infiltrates	O
were	O
detected	O
in	O
the	O
renal	O
cortex	O
and	O
medullary	O
regions	O
of	O
the	O
kidneys	O
.	O

Although	O
virus	O
-	O
infected	O
cells	B-COMP
were	O
found	O
in	O
the	O
kidney	O
and	O
liver	O
of	O
FmoRV	O
RNA	O
-	O
positive	O
cats	O
,	O
tubulointerstitial	O
nephritis	O
,	O
cholangiohepatitis	O
and	O
focal	O
necrosis	O
seen	O
in	O
FmoRV	O
RNA	O
-	O
positive	O
cats	O
were	O
similar	O
to	O
those	O
observed	O
in	O
FmoRV	O
RNA	O
-	O
negative	O
cats	O
.	O

TITLE	O
:	O
Dynamic	O
driving	O
pressure	O
associated	O
mortality	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

ABSTRACT	O
:	O
Emerging	O
pathogenic	O
viruses	O
such	O
as	O
Ebola	O
and	O
Middle	O
Eastern	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
can	O
cause	O
acute	O
infections	O
through	O
the	O
evasion	O
of	O
the	O
host	B-COMP
'	O
s	O
antiviral	O
immune	O
responses	O
and	O
by	O
inducing	O
the	O
upregulation	O
of	O
inflammatory	O
cytokines	O
.	O

DC	O
-	O
SIGN	O
was	O
found	O
colocalized	O
with	O
DENV	O
inside	O
cells	B-COMP
suggesting	O
hand	O
-	O
off	O
at	O
the	O
plasma	B-COMP
membrane	I-COMP
to	O
another	O
receptor	O
did	O
not	O
occur	O
.	O

Despite	O
recent	O
advances	O
in	O
defining	O
many	O
aspects	O
of	O
the	O
pathogenesis	O
of	O
sepsis	O
-	O
related	O
MOD	O
,	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
there	O
are	O
currently	O
no	O
effective	O
pharmacological	O
or	O
cell	B-COMP
-	O
based	O
treatments	O
for	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
(	O
CoV	O
)	O
S	O
protein	O
requires	O
cleavage	O
by	O
host	B-COMP
cell	I-COMP
proteases	O
to	O
mediate	O
virus	O
-	O
cell	B-COMP
and	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
.	O

TITLE	O
:	O
The	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
Nucleocapsid	B-COMP
Inhibits	O
Type	O
I	O
Interferon	O
Production	O
by	O
Interfering	O
with	O
TRIM25	O
-	O
Mediated	O
RIG	O
-	O
I	O
Ubiquitination	O
.	O

Replication	O
of	O
EndoU	O
-	O
deficient	O
coronaviruses	O
is	O
greatly	O
attenuated	O
in	O
vivo	O
and	O
severely	O
restricted	O
in	O
primary	O
cells	B-COMP
even	O
during	O
the	O
early	O
phase	O
of	O
the	O
infection	O
.	O

Accordingly	O
,	O
EndoU	O
-	O
deficient	O
viruses	O
can	O
retain	O
replication	O
only	O
in	O
cells	B-COMP
that	O
are	O
deficient	O
in	O
IFN	O
-	O
I	O
expression	O
or	O
sensing	O
,	O
and	O
in	O
cells	B-COMP
lacking	O
both	O
RNase	O
L	O
and	O
PKR	O
.	O

In	O
our	O
studies	O
,	O
we	O
found	O
that	O
glycyrrhizin	O
,	O
the	O
major	O
component	O
of	O
licorice	O
root	O
extracts	O
,	O
could	O
moderately	O
inhibit	O
PEDV	O
infection	O
in	O
Vero	O
cells	B-COMP
,	O
when	O
analyzed	O
by	O
western	O
blot	O
,	O
qRT	O
-	O
PCR	O
and	O
a	O
plaque	O
formation	O
assay	O
.	O

Pediatric	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
recipients	O
requiring	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Interhospital	O
Transport	O
System	O
for	O
Critically	O
Ill	O
Patients	O
:	O
Mobile	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
without	O
a	O
Ventilator	O
.	O

ABSTRACT	O
:	O
BACKGROUND	O
No	O
definitive	O
conclusions	O
have	O
been	O
drawn	O
from	O
the	O
available	O
data	O
about	O
the	O
utilization	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
to	O
treat	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

APACHE	O
II	O
score	O
on	O
admission	O
,	O
onset	O
of	O
acute	O
kidney	O
injury	O
,	O
and	O
membrane	B-COMP
oxygenator	O
replacement	O
,	O
and	O
the	O
evolution	O
of	O
levels	O
of	O
urea	O
nitrogen	O
,	O
platelet	O
,	O
and	O
fibrinogen	B-COMP
during	O
hospitalization	O
may	O
help	O
to	O
determine	O
the	O
in	O
-	O
hospital	O
patient	O
prognosis	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
performed	O
as	O
an	O
acceptable	O
life	O
-	O
saving	O
bridging	O
procedure	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O
To	O
patients	O
with	O
avian	O
influenza	O
A	O
(	O
H7N9	O
)-	O
associated	O
ARDS	O
,	O
ECMO	O
could	O
be	O
adopted	O
as	O
a	O
feasible	O
therapeutic	O
solution	O
.	O

In	O
the	O
second	O
experiment	O
,	O
another	O
two	O
groups	O
were	O
established	O
by	O
transfusion	O
with	O
either	O
mtDNA	B-COMP
(	O
mtDNA	B-COMP
group	O
)	O
or	O
phosphate	O
-	O
buffered	O
saline	O
(	O
phosphate	O
-	O
buffered	O
saline	O
group	O
).	O

Significant	O
increases	O
in	O
mtDNA	B-COMP
and	O
inflammatory	O
mediator	O
plasma	O
concentrations	O
were	O
seen	O
in	O
the	O
thermal	O
injury	O
and	O
EGCG	O
groups	O
when	O
compared	O
with	O
controls	O
(	O
P	O
<	O
.	O
05	O
).	O

Intravenous	O
administration	O
of	O
mtDNA	B-COMP
significantly	O
increased	O
concentrations	O
of	O
inflammatory	O
mediators	O
and	O
caused	O
severe	O
ARDS	O
(	O
P	O
<	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
primarily	O
replicates	O
in	O
epithelial	O
cells	B-COMP
of	O
the	O
upper	O
respiratory	O
tract	O
of	O
chickens	O
,	O
inducing	O
both	O
morphological	O
and	O
immune	O
modulatory	O
changes	O
.	O

Moreover	O
,	O
50	O
μg	O
/	O
ml	O
DOX	O
significantly	O
decreased	O
production	O
of	O
interferon	O
-	O
β	O
and	O
facilitated	O
replication	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
in	O
IPEC	O
-	O
J2	O
cells	B-COMP
.	O

We	O
evaluated	O
whether	O
supernatants	O
from	O
effusions	O
retain	O
the	O
ability	O
to	O
induce	O
cell	B-COMP
clumping	O
and	O
assessed	O
the	O
diagnostic	O
accuracy	O
of	O
this	O
modified	O
ΔTNC	O
method	O
.	O

Although	O
the	O
serum	B-COMP
vitamin	O
B12	O
level	O
was	O
normal	O
,	O
the	O
patient	O
was	O
treated	O
with	O
cyanocobalamin	O
,	O
with	O
no	O
improvement	O
.	O

When	O
support	O
with	O
mechanical	O
ventilation	O
failed	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
was	O
initiated	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
this	O
binding	O
domain	O
in	O
a	O
different	O
strain	O
,	O
as	O
well	O
as	O
the	O
cellular	B-COMP
proteins	O
that	O
interact	O
with	O
it	O
.	O

The	O
main	O
histopathological	O
findings	O
in	O
the	O
lungs	O
of	O
rhesus	O
macaques	O
and	O
common	O
marmosets	O
were	O
varying	O
degrees	O
of	O
pulmonary	O
lesions	O
,	O
including	O
pneumonia	O
,	O
pulmonary	O
oedema	O
,	O
haemorrhage	O
,	O
degeneration	O
and	O
necrosis	O
of	O
the	O
pneumocytes	O
and	O
bronchial	O
epithelial	O
cells	B-COMP
,	O
and	O
inflammatory	O
cell	B-COMP
infiltration	O
.	O

Correspondingly	O
,	O
the	O
entry	O
receptor	O
DDP4	O
was	O
found	O
in	O
type	O
I	O
and	O
II	O
pneumocytes	O
,	O
bronchial	O
epithelial	O
cells	B-COMP
,	O
and	O
alveolar	O
macrophages	O
.	O

TITLE	O
:	O
Viral	O
rewiring	O
of	O
cellular	B-COMP
lipid	O
metabolism	O
to	O
create	O
membranous	O
replication	O
compartments	O
.	O

N	O
-	O
Acetylcysteine	O
(	O
NAC	B-COMP
)	O
has	O
been	O
shown	O
to	O
reduce	O
endotoxin	O
-	O
induced	O
intestinal	O
dysfunction	O
.	O

In	O
summary	O
,	O
a	O
single	O
infection	O
at	O
gilt	O
acclimatization	O
resulted	O
in	O
slightly	O
increased	O
serum	B-COMP
antibody	B-COMP
titers	O
as	O
determined	O
by	O
VN	O
assay	O
and	O
IgG	O
ELISA	O
,	O
but	O
not	O
by	O
IgA	O
ELISA	O
.	O

However	O
,	O
the	O
macropinocytosis	O
inhibitors	O
could	O
not	O
impede	O
virus	O
replication	O
once	O
the	O
virus	O
had	O
entered	O
host	B-COMP
cells	B-COMP
.	O

In	O
this	O
study	O
,	O
an	O
original	O
US	O
,	O
highly	O
virulent	O
PED	O
virus	O
(	O
PEDV	O
)	O
strain	O
PC22A	O
was	O
serially	O
passaged	O
in	O
Vero	O
CCL81	O
and	O
Vero	O
BI	O
cells	B-COMP
.	O

Further	O
validation	O
was	O
captured	O
using	O
LysoTracker	O
and	O
lysosome	B-COMP
-	O
associated	O
membrane	B-COMP
protein	O
by	O
indirect	O
immunofluorescence	O
labeling	O
in	O
PHEV	O
-	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Respiratory	O
virus	O
infection	O
(	O
RVI	O
)	O
is	O
a	O
prevalent	O
infection	O
in	O
patients	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
(	O
allo	O
-	O
HSCT	O
)	O
and	O
can	O
result	O
in	O
significant	O
morbidity	O
and	O
mortality	O
.	O

Host	B-COMP
inosine	O
-	O
5	O
'-	O
monophosphate	O
dehydrogenase	O
(	O
IMPDH	O
)	O
involved	O
in	O
the	O
synthesis	O
of	O
guanine	O
nucleotides	O
,	O
is	O
known	O
to	O
be	O
a	O
potential	O
target	O
to	O
inhibit	O
the	O
replication	O
of	O
viruses	O
.	O

The	O
pattern	O
of	O
ECM	B-COMP
production	O
in	O
vitro	O
indicated	O
the	O
process	O
of	O
forming	O
mature	O
ERfibs	O
in	O
the	O
brain	O
,	O
that	O
is	O
,	O
fibers	O
made	O
of	O
collagen	B-COMP
fibers	O
and	O
ERag	O
are	O
wrapped	O
by	O
laminin	O
prepared	O
as	O
a	O
sheet	O
structure	O
.	O

However	O
,	O
the	O
effect	O
of	O
urbanization	O
on	O
natural	O
host	B-COMP
-	O
pathogen	O
systems	O
remains	O
poorly	O
understood	O
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
as	O
a	O
Treatment	O
for	O
Obesity	O
Hypoventilation	O
Syndrome	O
.	O

TITLE	O
:	O
Outcome	O
and	O
Management	O
of	O
Refractory	O
Respiratory	O
Failure	O
With	O
Timely	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
:	O
Single	O
-	O
Center	O
Experience	O
With	O
Legionella	O
Pneumonia	O
.	O

Overall	O
,	O
this	O
study	O
expands	O
our	O
understanding	O
of	O
the	O
initial	O
steps	O
of	O
N	O
protein	O
-	O
nucleic	B-COMP
acid	O
interaction	O
and	O
may	O
facilitate	O
future	O
efforts	O
to	O
control	O
the	O
associated	O
infections	O
.	O

The	O
presence	O
of	O
neutralising	O
antibodies	B-COMP
in	O
one	O
sheep	O
apparently	O
in	O
contact	O
with	O
seropositive	O
camels	O
calls	O
for	O
further	O
studies	O
on	O
domestic	O
animals	O
in	O
contact	O
with	O
camels	O
.	O

Serum	B-COMP
IP	O
-	O
10	O
concentrations	O
were	O
measured	O
by	O
ELISA	O
(	O
R	O
&	O
D	O
Systems	O
,	O
Inc	O
.,	O
Quantikine	O
ELISA	O
,	O
Minneapolis	O
,	O
MN	O
).	O

RESULTS	O
:	O
Serum	B-COMP
IP	O
-	O
10	O
concentrations	O
from	O
225	O
ARI	O
episodes	O
correlated	O
with	O
ARI	O
global	O
severity	O
(	O
rho	O
0	O
.	O
28	O
[	O
95	O
%	O
CI	O
:	O
0	O
.	O
15	O
-	O
0	O
.	O
39	O
];	O
p	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Aminopeptidase	O
N	O
is	O
not	O
required	O
for	O
porcine	O
epidemic	O
diarrhea	O
virus	O
cell	B-COMP
entry	O
.	O

The	O
nanoparticles	O
modified	O
with	O
amidated	O
TAT	O
peptide	O
(	O
NLpT	O
-	O
CA	O
and	O
NPpT	O
-	O
CA	O
)	O
avoided	O
interactions	O
with	O
LS174T	O
colon	O
cancer	O
cells	B-COMP
and	O
J774A	O
.	O
1	O
macrophages	O
at	O
pH	O
7	O
.	O
4	O
but	O
restored	O
the	O
ability	O
to	O
interact	O
with	O
LS174T	O
cells	B-COMP
at	O
pH	O
6	O
.	O
5	O
,	O
delivering	O
paclitaxel	O
efficiently	O
to	O
the	O
cells	B-COMP
following	O
a	O
brief	O
contact	O
time	O
.	O

TITLE	O
:	O
Cell	B-COMP
Attachment	I-COMP
Domains	O
of	O
the	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Spike	O
Protein	O
Are	O
Key	O
Targets	O
of	O
Neutralizing	O
Antibodies	B-COMP
.	O

However	O
,	O
knowledge	O
of	O
antibody	B-COMP
epitopes	O
,	O
their	O
nature	O
and	O
location	O
in	O
the	O
spike	O
structure	O
,	O
and	O
the	O
mechanisms	O
by	O
which	O
the	O
antibodies	B-COMP
interfere	O
with	O
infection	O
is	O
scarce	O
.	O

Characterization	O
of	O
antibodies	B-COMP
for	O
cross	O
-	O
reactivity	O
and	O
cross	O
-	O
neutralization	O
revealed	O
antigenic	O
differences	O
among	O
PEDV	O
strains	O
.	O

Our	O
observations	O
picture	O
the	O
antibody	B-COMP
epitope	O
landscape	O
of	O
the	O
PEDV	O
S1	O
subunit	O
and	O
reveal	O
that	O
its	O
cell	B-COMP
attachment	I-COMP
domains	O
are	O
key	O
targets	O
of	O
neutralizing	O
antibodies	B-COMP
.	O

After	O
binding	O
to	O
their	O
respective	O
IFN	O
receptors	O
and	O
activation	O
of	O
the	O
cellular	B-COMP
JAK	O
/	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
signaling	O
cascade	O
,	O
they	O
stimulate	O
the	O
transcription	O
of	O
a	O
plethora	O
of	O
IFN	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
infected	O
as	O
well	O
as	O
bystander	O
cells	B-COMP
such	O
as	O
the	O
non	O
-	O
infected	O
epithelium	O
and	O
cells	B-COMP
of	O
the	O
immune	O
system	O
.	O

In	O
addition	O
,	O
drugs	O
that	O
bind	O
the	O
active	O
site	O
inhibited	O
both	O
coronavirus	O
binding	O
to	O
cell	B-COMP
surface	I-COMP
APN	O
and	O
infection	O
;	O
the	O
drugs	O
probably	O
hindered	O
APN	O
transition	O
to	O
the	O
virus	O
-	O
specific	O
open	O
form	O
.	O

The	O
oligonucleotide	O
targets	O
were	O
detected	O
by	O
measuring	O
the	O
color	O
change	O
of	O
AgNPs	O
,	O
giving	O
detection	O
limits	O
of	O
1	O
.	O
53	O
(	O
MERS	O
-	O
CoV	O
),	O
1	O
.	O
27	O
(	O
MTB	B-COMP
),	O
and	O
1	O
.	O
03	O
nM	O
(	O
HPV	O
).	O

Discouraging	O
survival	O
rates	O
in	O
patients	O
treated	O
early	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	B-COMP
transplantation	O
do	O
not	O
support	O
the	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
this	O
group	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	O
-	O
like	O
protease	O
up	O
-	O
regulates	O
the	O
collagen	B-COMP
expression	O
through	O
non	O
-	O
Samd	O
TGF	O
-	O
β1	O
signaling	O
.	O

This	O
study	O
investigated	O
the	O
correlation	O
of	O
PLpro	O
-	O
induced	O
TGF	O
-	O
β1	O
with	O
the	O
expression	O
of	O
Type	O
I	O
collagen	B-COMP
in	O
human	O
lung	O
epithelial	O
cells	B-COMP
and	O
mouse	O
pulmonary	O
tissues	O
.	O

One	O
protease	O
,	O
transmembrane	B-COMP
protease	O
serine	O
2	O
(	O
TMPRSS2	O
)	O
was	O
recently	O
proven	O
to	O
be	O
crucial	O
for	O
hemagglutinin	O
cleavage	O
of	O
some	O
human	O
influenza	O
viruses	O
.	O

Though	O
still	O
in	O
its	O
infancy	O
,	O
airway	O
protease	O
inhibition	O
represents	O
an	O
attractive	O
host	B-COMP
-	O
cell	B-COMP
targeting	O
approach	O
to	O
combat	O
respiratory	O
viruses	O
such	O
as	O
influenza	O
.	O

The	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
applied	O
in	O
the	O
experienced	O
centers	O
seems	O
to	O
improve	O
the	O
survival	O
of	O
patients	O
with	O
severe	O
ARDS	O
.	O

ABSTRACT	O
:	O
There	O
are	O
a	O
large	O
number	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
systems	O
and	O
configurations	O
.	O

At	O
1	O
:	O
16	O
,	O
CFS	O
dilution	O
(	O
pH	O
6	O
.	O
3	O
-	O
6	O
.	O
8	O
)	O
showed	O
no	O
cytotoxicity	O
in	O
Vero	O
cells	B-COMP
and	O
was	O
therefore	O
used	O
as	O
the	O
dilution	O
for	O
antiviral	O
assays	O
.	O

ABSTRACT	O
:	O
GATA2	O
mutations	O
have	O
been	O
identified	O
in	O
various	O
diseases	O
,	O
such	O
as	O
MonoMAC	O
syndrome	O
,	O
Emberger	O
syndrome	O
,	O
familial	O
myelodysplastic	O
syndrome	O
,	O
acute	O
myeloid	O
leukaemia	O
and	O
dendritic	B-COMP
cell	B-COMP
,	O
monocyte	O
,	O
B	O
-	O
cell	B-COMP
and	O
natural	O
killer	O
-	O
cell	B-COMP
deficiency	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
TGEV	O
infection	O
activates	O
transcription	O
factors	O
NF	O
-	O
κB	O
,	O
IRF3	O
and	O
AP	O
-	O
1	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
in	O
porcine	O
kidney	O
cells	B-COMP
.	O

Kaplan	O
-	O
Meier	O
survival	O
curve	O
analysis	O
indicated	O
that	O
the	O
patients	O
whose	O
PCT	O
more	O
than	O
4	O
.	O
35	O
μg	O
/	O
L	O
,	O
had	O
lower	O
28	O
-	O
day	O
cummulative	O
survival	O
rate	O
as	O
compared	O
with	O
those	O
with	O
PCT	O
≤	O
4	O
.	O
35	O
μg	O
/	O
L	O
(	O
log	O
-	O
rank	O
test	O
:	O
χ	O
The	O
elevated	O
serum	B-COMP
PCT	O
level	O
in	O
patients	O
with	O
ARDS	O
seems	O
to	O
be	O
correlated	O
well	O
with	O
the	O
severity	O
of	O
lung	O
injury	O
,	O
and	O
appears	O
to	O
be	O
a	O
useful	O
prognostic	O
marker	O
of	O
outcome	O
in	O
the	O
early	O
phases	O
of	O
ARDS	O
.	O

By	O
reviewing	O
the	O
mechanism	O
of	O
stem	O
cell	B-COMP
therapy	O
for	O
ALI	O
,	O
therapeutic	O
potential	O
of	O
hUCMSCs	O
in	O
the	O
treatment	O
of	O
severe	O
burns	O
with	O
ALI	O
and	O
a	O
new	O
approach	O
for	O
clinical	O
treatment	O
was	O
provided	O
.	O

In	O
a	O
6	O
hour	O
pilot	O
study	O
,	O
we	O
analyzed	O
the	O
use	O
of	O
the	O
combination	O
of	O
both	O
stem	O
cell	B-COMP
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
strategies	O
to	O
prevent	O
or	O
treat	O
severe	O
lung	O
injury	O
.	O

We	O
believe	O
that	O
the	O
combination	O
of	O
stem	O
cells	B-COMP
with	O
the	O
ECMO	O
treatment	O
may	O
be	O
useful	O
in	O
future	O
studies	O
investigating	O
the	O
diagnosis	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
ARDS	O
.	O

TITLE	O
:	O
Anticoagulation	O
and	O
Transfusions	O
Management	O
in	O
Veno	O
-	O
Venous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
Assessment	O
of	O
Factors	O
Associated	O
With	O
Transfusion	O
Requirements	O
and	O
Mortality	O
.	O

After	O
immunizations	O
,	O
cells	B-COMP
from	O
the	O
spleen	O
of	O
the	O
mice	O
were	O
fused	O
with	O
SP2	O
/	O
0	O
myeloma	O
cells	B-COMP
.	O

Following	O
culturing	O
and	O
subcloning	O
,	O
a	O
strain	O
,	O
1B9	O
,	O
secreting	O
neutralizing	O
antibody	B-COMP
,	O
was	O
obtained	O
.	O

TITLE	O
:	O
Characterization	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infectivity	O
in	O
human	O
embryonic	O
kidney	O
cells	B-COMP
.	O

We	O
isolated	O
a	O
fully	O
human	O
neutralizing	O
antibody	B-COMP
,	O
MCA1	O
,	O
from	O
a	O
human	O
survivor	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
ORF3	O
accessory	O
protein	O
in	O
replication	O
of	O
cell	B-COMP
-	O
adapted	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

Immunofluorescence	O
imaging	O
of	O
nsp15	O
mutant	O
virus	O
-	O
infected	O
macrophages	O
revealed	O
significant	O
dispersal	O
of	O
dsRNA	O
early	O
during	O
infection	O
,	O
whereas	O
in	O
WT	O
virus	O
-	O
infected	O
cells	B-COMP
,	O
the	O
majority	O
of	O
the	O
dsRNA	O
was	O
associated	O
with	O
replication	O
complexes	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
outcomes	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
requiring	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

Immunity	O
plays	O
a	O
major	O
role	O
in	O
keeping	O
the	O
host	B-COMP
free	O
from	O
disease	O
,	O
and	O
it	O
is	O
evident	O
that	O
the	O
host	B-COMP
'	O
s	O
genetic	O
make	O
-	O
up	O
influences	O
immunity	O
and	O
disease	O
resistance	O
/	O
susceptibility	O
in	O
chickens	O
.	O

Stimulation	O
methods	O
established	O
for	O
lymphoid	O
tissue	O
cells	B-COMP
using	O
prolonged	O
stimulation	O
with	O
viral	O
lysate	O
resulted	O
in	O
substantial	O
ASC	O
loss	O
and	O
minimal	O
Bmem	O
to	O
ASC	O
conversion	O
of	O
CNS	O
-	O
derived	O
cells	B-COMP
.	O

By	O
varying	O
stimulation	O
duration	O
,	O
TLR	O
activators	O
,	O
and	O
culture	O
supplements	O
,	O
we	O
achieved	O
optimal	O
conversion	O
by	O
culturing	O
cells	B-COMP
with	O
TLR7	O
/	O
8	O
agonist	O
R848	O
in	O
the	O
presence	O
of	O
feeder	O
cells	B-COMP
for	O
2days	O
.	O

TITLE	O
:	O
Differential	O
Protein	O
Analysis	O
of	O
IPEC	O
-	O
J2	O
Cells	B-COMP
Infected	O
with	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Pandemic	O
and	O
Classical	O
Strains	O
Elucidates	O
the	O
Pathogenesis	O
of	O
Infection	O
.	O

In	O
this	O
protocol	O
we	O
describe	O
a	O
well	O
-	O
developed	O
reverse	O
genetic	O
platform	O
strategy	O
for	O
CoVs	O
that	O
is	O
comprised	O
of	O
partitioning	O
the	O
viral	B-COMP
genome	I-COMP
into	O
5	O
-	O
7	O
independent	O
DNA	O
fragments	O
(	O
depending	O
on	O
the	O
CoV	O
genome	O
),	O
each	O
subcloned	O
into	O
a	O
plasmid	O
for	O
increased	O
stability	O
and	O
ease	O
of	O
genetic	O
manipulation	O
and	O
amplification	O
.	O

Using	O
this	O
method	O
,	O
recombinant	O
CoVs	O
can	O
be	O
rapidly	O
generated	O
and	O
used	O
to	O
investigate	O
host	B-COMP
range	O
,	O
gene	O
function	O
,	O
pathogenesis	O
,	O
and	O
candidate	O
therapeutics	O
for	O
emerging	O
and	O
preemergent	O
CoVs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Glypican	O
-	O
3	O
(	O
GPC3	O
)	O
is	O
a	O
cell	B-COMP
surface	I-COMP
-	O
bound	O
proteoglycan	O
which	O
has	O
been	O
identified	O
as	O
a	O
potential	O
biomarker	O
candidate	O
in	O
hepatocellular	O
carcinoma	O
,	O
lung	O
carcinoma	O
,	O
severe	O
pneumonia	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Increased	O
serum	B-COMP
levels	O
of	O
GPC3	O
have	O
been	O
demonstrated	O
in	O
ARDS	O
patients	O
with	O
severe	O
pneumonia	O
.	O

Modulating	O
miR	O
-	O
142	O
-	O
5p	O
activity	O
by	O
microRNA	O
mimics	O
or	O
inhibitors	O
induced	O
neurodegeneration	O
,	O
including	O
stunted	O
axon	B-COMP
elongation	O
,	O
unstable	O
dendritic	B-COMP
spine	I-COMP
formation	O
,	O
and	O
irregular	O
swelling	O
and	O
disconnection	O
in	O
neurites	B-COMP
.	O

Our	O
data	O
revealed	O
that	O
PHEV	O
adapted	O
to	O
use	O
spatiotemporal	O
control	O
of	O
host	B-COMP
microRNAs	O
to	O
invade	O
CNS	O
,	O
and	O
provided	O
new	O
insights	O
into	O
the	O
virus	O
-	O
associated	O
neurological	O
dysfunction	O
microenvironment	O
.	O

Anecdotal	O
reports	O
suggest	O
that	O
plasma	O
with	O
high	O
antibody	B-COMP
titres	O
to	O
influenza	O
might	O
be	O
of	O
benefit	O
in	O
the	O
treatment	O
of	O
severe	O
influenza	O
.	O

Leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
),	O
a	O
member	O
of	O
the	O
IL	O
-	O
6	O
cytokine	O
family	O
,	O
is	O
a	O
critical	O
determinant	O
of	O
lung	O
tissue	O
protection	O
during	O
pneumonia	O
,	O
but	O
the	O
cellular	B-COMP
sources	O
of	O
LIF	O
and	O
the	O
signaling	O
pathways	O
leading	O
to	O
its	O
production	O
in	O
the	O
infected	O
lung	O
are	O
not	O
known	O
.	O

Blood	O
samples	O
(	O
309	O
)	O
were	O
randomly	O
collected	O
from	O
pigs	O
at	O
farms	O
throughout	O
T	O
&	O
T	O
.	O
Serum	B-COMP
samples	O
were	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	B-COMP
to	O
the	O
aforementioned	O
viruses	O
using	O
commercial	O
ELISA	O
kits	O
,	O
and	O
the	O
circulating	O
strains	O
of	O
SwIV	O
were	O
identified	O
by	O
the	O
hemagglutination	O
inhibition	O
test	O
(	O
HIT	O
).	O

TITLE	O
:	O
Is	O
There	O
a	O
Preinterventional	O
Mechanical	O
Ventilation	O
Time	O
Limit	O
for	O
Candidates	O
of	O
Adult	O
Respiratory	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
.	O

Neonatal	O
complications	O
resulting	O
from	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-COMP
)	O
and	O
sepsis	O
were	O
more	O
common	O
in	O
the	O
non	O
-	O
obstetric	O
causes	O
group	O
;	O
however	O
,	O
neurological	O
development	O
impairment	O
was	O
more	O
common	O
in	O
the	O
obstetric	O
causes	O
group	O
.	O

In	O
addition	O
to	O
mAbs	O
with	O
neutralizing	O
epitopes	O
located	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
,	O
one	O
mAb	O
,	O
5F9	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
S1	O
subunit	O
,	O
showed	O
efficient	O
neutralizing	O
activity	O
against	O
the	O
wild	O
-	O
type	O
MERS	O
-	O
CoV	O
strain	O
EMC	B-COMP
/	O
2012	O
,	O
with	O
a	O
half	O
maximal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
2	O
μg	O
/	O
mL	O
.	O
We	O
concluded	O
that	O
a	O
novel	O
neutralizing	O
epitope	O
for	O
MERS	O
-	O
CoV	O
also	O
resides	O
on	O
the	O
NTD	O
of	O
the	O
S	O
protein	O
,	O
indicating	O
that	O
the	O
NTD	O
might	O
be	O
important	O
during	O
the	O
viral	O
infection	O
process	O
.	O

As	O
compared	O
to	O
the	O
survival	O
group	O
,	O
the	O
white	O
blood	O
cell	B-COMP
count	O
(	O
AKI	O
due	O
to	O
snake	O
bite	O
is	O
severe	O
and	O
a	O
high	O
proportion	O
requires	O
renal	O
replacement	O
therapy	O
.	O

The	O
differences	O
in	O
serum	B-COMP
CC16	O
and	O
other	O
laboratory	O
indicators	O
between	O
two	O
groups	O
were	O
analyzed	O
.	O

The	O
serum	B-COMP
CC16	O
levels	O
were	O
significantly	O
greater	O
in	O
non	O
-	O
survivors	O
than	O
in	O
survivors	O
from	O
the	O
ARDS	O
group	O
.	O

No	O
significant	O
cellular	B-COMP
toxicity	O
was	O
observed	O
at	O
the	O
effective	O
concentrations	O
.	O

Surprisingly	O
,	O
FA	O
-	O
613	O
lost	O
its	O
antiviral	O
potency	O
in	O
the	O
interferon	O
-	O
deficient	O
Vero	O
cell	B-COMP
line	O
,	O
while	O
maintaining	O
its	O
inhibitory	O
activity	O
in	O
an	O
interferon	O
-	O
competent	O
cell	B-COMP
line	O
which	O
showed	O
elevated	O
expression	O
of	O
host	B-COMP
antiviral	O
genes	O
when	O
infected	O
in	O
the	O
presence	O
of	O
FA	O
-	O
613	O
.	O

ABSTRACT	O
:	O
Gap	B-COMP
junctions	I-COMP
(	O
GJs	O
)	O
are	O
important	O
for	O
maintenance	O
of	O
CNS	O
homeostasis	O
.	O

GJ	O
proteins	O
,	O
connexin	O
43	O
(	O
Cx43	O
)	O
and	O
connexin	O
47	O
(	O
Cx47	O
),	O
play	O
a	O
crucial	O
role	O
in	O
production	O
and	O
maintenance	O
of	O
CNS	O
myelin	B-COMP
.	O

TITLE	O
:	O
Cytoplasmic	B-COMP
tail	O
of	O
coronavirus	O
spike	O
protein	O
has	O
intracellular	B-COMP
targeting	O
signals	O
.	O

Finally	O
,	O
the	O
results	O
of	O
our	O
analysis	O
suggest	O
that	O
serum	B-COMP
cytokines	O
profiles	O
of	O
HPS	O
and	O
HFRS	O
cases	O
are	O
consistent	O
with	O
the	O
presence	O
of	O
extracellular	B-COMP
matrix	I-COMP
degradation	O
,	O
increased	O
mononuclear	O
leukocyte	O
proliferation	O
,	O
and	O
transendothelial	O
migration	O
.	O

To	O
predict	O
the	O
potential	O
B	O
cell	B-COMP
epitopes	O
of	O
E	O
protein	O
,	O
three	O
most	O
effective	O
online	O
epitope	O
prediction	O
programs	O
,	O
the	O
ABCpred	O
,	O
Bepipred	O
,	O
and	O
Protean	O
programs	O
from	O
the	O
LaserGene	O
software	O
were	O
used	O
.	O

TITLE	O
:	O
ChAdOx1	O
and	O
MVA	O
based	O
vaccine	O
candidates	O
against	O
MERS	O
-	O
CoV	O
elicit	O
neutralising	O
antibodies	B-COMP
and	O
cellular	B-COMP
immune	O
responses	O
in	O
mice	O
.	O

Nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
is	O
the	O
most	O
abundant	O
viral	O
protein	O
in	O
CoV	O
-	O
infected	O
cells	B-COMP
,	O
and	O
has	O
been	O
identified	O
as	O
an	O
innate	O
immunity	O
antagonist	O
in	O
several	O
CoVs	O
,	O
including	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
.	O
However	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
(	O
s	O
)	O
remain	O
unclear	O
.	O

Further	O
studies	O
showed	O
that	O
both	O
MHV	O
and	O
SARS	O
-	O
CoV	O
N	O
proteins	O
directly	O
interacted	O
with	O
protein	O
activator	O
of	O
protein	O
kinase	O
R	O
(	O
PACT	O
),	O
a	O
cellular	B-COMP
dsRNA	O
-	O
binding	O
protein	O
that	O
can	O
bind	O
to	O
RIG	O
-	O
I	O
and	O
MDA5	O
to	O
activate	O
IFN	O
production	O
.	O

TITLE	O
:	O
Sedation	O
Management	O
in	O
Children	O
Supported	O
on	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Acute	O
Respiratory	O
Failure	O
.	O

Most	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
patients	O
received	O
neuromuscular	O
blockade	O
(	O
46	O
%)	O
or	O
were	O
heavily	O
sedated	O
with	O
State	O
Behavioral	O
Scale	O
scores	O
-	O
3	O
/-	O
2	O
(	O
34	O
%)	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
day	O
3	O
.	O

In	O
children	O
,	O
the	O
initiation	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
is	O
associated	O
with	O
deep	O
sedation	O
,	O
substantial	O
sedative	O
exposure	O
,	O
and	O
increased	O
frequency	O
of	O
iatrogenic	O
withdrawal	O
syndrome	O
.	O

This	O
finding	O
presents	O
various	O
hypotheses	O
about	O
the	O
timing	O
of	O
the	O
emergence	O
and	O
spread	O
of	O
MERS	O
-	O
CoV	O
throughout	O
populations	O
of	O
camels	O
in	O
Africa	O
and	O
Asia	O
,	O
which	O
can	O
be	O
partially	O
resolved	O
by	O
testing	O
sera	B-COMP
from	O
camels	O
from	O
the	O
original	O
source	O
region	O
,	O
which	O
we	O
have	O
inferred	O
was	O
mainly	O
northwestern	O
Pakistan	O
.	O

To	O
ultimately	O
prevent	O
spread	O
of	O
the	O
virus	O
into	O
the	O
human	O
population	O
,	O
however	O
,	O
vaccination	O
of	O
dromedary	O
camels	O
-	O
currently	O
the	O
only	O
confirmed	O
animal	O
host	B-COMP
for	O
MERS	O
-	O
CoV	O
-	O
may	O
be	O
the	O
best	O
option	O
to	O
achieve	O
a	O
sustained	O
drop	O
in	O
human	O
MERS	O
cases	O
in	O
time	O
.	O

Chickens	O
were	O
sacrificed	O
at	O
three	O
days	O
post	O
inoculation	O
,	O
and	O
the	O
lung	O
,	O
trachea	O
,	O
and	O
air	O
sac	B-COMP
samples	O
were	O
taken	O
to	O
determine	O
histological	O
changes	O
and	O
expression	O
levels	O
of	O
cSP	O
-	O
A	O
mRNA	O
and	O
cSP	O
-	O
A	O
protein	O
.	O

TGEV	O
Miller	O
mildly	O
and	O
TGEV	O
GFP	O
extensively	O
infected	O
the	O
cells	B-COMP
in	O
the	O
jejunum	O
based	O
on	O
the	O
amount	O
of	O
positive	O
stained	O
epithelial	O
cells	B-COMP
.	O

In	O
this	O
study	O
,	O
the	O
PEDV	O
strain	O
85	O
-	O
7	O
could	O
be	O
proliferated	O
effectively	O
in	O
MARC	O
-	O
145	O
cells	B-COMP
,	O
and	O
caused	O
a	O
distinct	O
inhibition	O
of	O
the	O
expression	O
of	O
interferon	O
-	O
β	O
(	O
IFN	O
-	O
β	O
,	O
encoded	O
by	O
IFNB1	O
),	O
which	O
suggested	O
that	O
a	O
full	O
understanding	O
how	O
this	O
virus	O
manipulates	O
the	O
host	B-COMP
immune	O
responses	O
is	O
critical	O
in	O
the	O
fight	O
against	O
the	O
spread	O
of	O
PEDV	O
.	O

Notably	O
,	O
the	O
antiviral	O
activity	O
and	O
transcription	O
of	O
the	O
antiviral	O
effectors	O
induced	O
by	O
overexpression	O
of	O
HSP27	O
could	O
be	O
counteracted	O
by	O
the	O
knockdown	O
of	O
IFNB1	O
via	O
RNA	O
interference	O
,	O
indicating	O
that	O
HSP27	O
was	O
an	O
upstream	O
regulator	O
of	O
the	O
intracellular	B-COMP
antiviral	O
effect	O
against	O
PEDV	O
infection	O
.	O

To	O
study	O
the	O
relation	O
of	O
codon	O
usage	O
among	O
viruses	O
and	O
their	O
hosts	B-COMP
is	O
essential	O
to	O
understand	O
host	B-COMP
-	O
pathogen	O
interaction	O
,	O
evasion	O
from	O
host	B-COMP
'	O
s	O
immune	O
system	O
and	O
evolution	O
.	O

Retrospective	O
analysis	O
of	O
outcomes	O
of	O
a	O
cohort	O
of	O
children	O
with	O
oncologic	O
disease	O
or	O
after	O
stem	O
cell	B-COMP
transplantation	O
and	O
severe	O
respiratory	O
failure	O
in	O
comparison	O
with	O
a	O
historical	O
control	O
cohort	O
.	O

Cleavage	O
and	O
activation	O
of	O
SARS	O
S	O
by	O
a	O
host	B-COMP
cell	I-COMP
protease	O
is	O
essential	O
for	O
infectious	O
viral	O
entry	O
and	O
the	O
responsible	O
enzymes	O
are	O
potential	O
targets	O
for	O
antiviral	O
intervention	O
.	O

NF	O
-	O
κB	O
activation	O
is	O
a	O
common	O
pro	O
-	O
inflammatory	O
response	O
of	O
host	B-COMP
cells	B-COMP
to	O
viral	O
infection	O
.	O

Next	O
to	O
a	O
role	O
in	O
basic	O
virus	O
replication	O
or	O
virus	O
assembly	O
,	O
many	O
of	O
the	O
coronavirus	O
proteins	O
expressed	O
in	O
the	O
infected	O
cell	B-COMP
contribute	O
to	O
the	O
coronavirus	O
-	O
host	B-COMP
interplay	O
.	O

These	O
coronavirus	O
-	O
host	B-COMP
interactions	O
are	O
key	O
to	O
viral	O
pathogenesis	O
and	O
will	O
ultimately	O
determine	O
the	O
outcome	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
infection	O
of	O
resting	O
CD4	O
T	O
cells	B-COMP
plays	O
a	O
crucial	O
and	O
numerically	O
dominant	O
role	O
during	O
virus	O
transmission	O
at	O
mucosal	O
sites	O
and	O
during	O
subsequent	O
acute	O
replication	O
and	O
T	O
cell	B-COMP
depletion	O
.	O

TITLE	O
:	O
Determination	O
of	O
the	O
cell	B-COMP
tropism	O
of	O
serotype	O
1	O
feline	O
infectious	O
peritonitis	O
virus	O
using	O
the	O
spike	O
affinity	O
histochemistry	O
in	O
paraffin	O
-	O
embedded	O
tissues	O
.	O

The	O
QIAP401	O
isolate	O
propagated	O
well	O
in	O
Vero	O
cells	B-COMP
for	O
70	O
passages	O
,	O
with	O
titers	O
of	O
10	O

The	O
loss	O
of	O
EPCR	O
and	O
TM	O
was	O
primarily	O
identified	O
in	O
ARDS	O
patients	O
and	O
was	O
related	O
to	O
the	O
level	O
of	O
hemozoin	O
,	O
parasitized	O
red	O
blood	O
cell	B-COMP
(	O
PRBC	O
)	O
and	O
white	O
blood	O
cell	B-COMP
accumulation	O
in	O
the	O
lung	O
.	O

Moreover	O
,	O
an	O
in	O
vitro	O
analysis	O
demonstrated	O
that	O
interleukin	O
-	O
13	O
and	O
-	O
31	O
and	O
hemozoin	O
induced	O
pneumocytic	O
cell	B-COMP
injury	O
and	O
apoptosis	O
,	O
as	O
assessed	O
by	O
EB	O
/	O
AO	O
staining	O
,	O
electron	O
microscopy	O
and	O
the	O
up	O
-	O
regulation	O
of	O
CARD	O
-	O
9	O
mRNA	O
(	O
caspase	O
recruitment	O
domain	O
-	O
9	O
messenger	O
-	O
ribonucleic	O
acid	O
).	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
being	O
used	O
more	O
often	O
as	O
a	O
bridge	O
to	O
transplantation	O
(	O
BTT	O
)	O
in	O
patients	O
with	O
acutely	O
decompensated	O
end	O
-	O
stage	O
lung	O
disease	O
in	O
Korea	O
.	O

In	O
addition	O
,	O
we	O
revealed	O
that	O
the	O
nsp3	O
-	O
nsp4	O
interaction	O
is	O
not	O
sufficient	O
to	O
induce	O
membrane	B-COMP
rearrangement	O
,	O
suggesting	O
the	O
participation	O
of	O
other	O
factors	O
such	O
as	O
host	B-COMP
proteins	O
.	O

Through	O
cell	B-COMP
culture	O
adaptation	O
,	O
we	O
obtained	O
four	O
distinct	O
deletion	O
(	O
DEL	O
)	O
mutants	O
by	O
plaque	O
purification	O
followed	O
by	O
nucleotide	O
sequencing	O
of	O
the	O
spike	O
(	O
S	O
)/	O
ORF3	O
gene	O
-	O
coding	O
region	O
,	O
which	O
were	O
designated	O
KNU	O
-	O
141112	O
-	O
S	O
DEL2	O
,	O
-	O
S	O
DEL5	O
,	O
-	O
S	O
DEL2	O
/	O
ORF3	O
,	O
and	O
-	O
S	O
DEL5	O
/	O
ORF3	O
.	O

Furthermore	O
,	O
these	O
cell	B-COMP
-	O
adapted	O
strains	O
elicited	O
potent	O
neutralizing	O
antibody	B-COMP
responses	O
in	O
immunized	O
pigs	O
.	O

The	O
data	O
show	O
that	O
(	O
i	O
)	O
7b	O
localizes	O
to	O
and	O
is	O
retained	O
in	O
the	O
medial	O
-	O
and	O
/	O
or	O
trans	O
-	O
Golgi	B-COMP
compartment	O
,	O
(	O
ii	O
)	O
the	O
C	O
-	O
terminal	O
KTEL	O
sequence	O
acts	O
as	O
a	O
Golgi	B-COMP
[	O
rather	O
than	O
an	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	B-COMP
)]	O
retention	O
signal	O
,	O
(	O
iii	O
)	O
minor	O
changes	O
in	O
the	O
KTEL	O
motif	O
(	O
such	O
as	O
KTE	O
,	O
KTEV	O
,	O
or	O
the	O
addition	O
of	O
a	O
C	O
-	O
terminal	O
tag	O
)	O
abolish	O
Golgi	B-COMP
retention	O
,	O
resulting	O
in	O
relocalization	O
and	O
secretion	O
of	O
7b	O
,	O
and	O
(	O
iv	O
)	O
a	O
KTEL	O
-	O
to	O
-	O
KDEL	O
replacement	O
causes	O
retention	O
of	O
7b	O
in	O
the	O
ER	B-COMP
of	O
rFIPV	O
-	O
infected	O
feline	O
cells	B-COMP
.	O

Effusion	O
and	O
/	O
or	O
serum	B-COMP
/	O
plasma	O
samples	O
were	O
examined	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
targeting	O
the	O
two	O
FCoV	O
spike	O
gene	O
fusion	O
peptide	O
mutations	O
M1058	O
L	O
and	O
S1060A	O
using	O
an	O
allelic	O
discrimination	O
approach	O
.	O

The	O
use	O
of	O
serum	B-COMP
/	O
plasma	O
cannot	O
be	O
recommended	O
due	O
to	O
a	O
low	O
viral	O
load	O
in	O
blood	O
.	O

Correspondence	O
analysis	O
revealed	O
that	O
MERS	O
CoV	O
genomes	O
have	O
three	O
genetic	O
clusters	O
,	O
which	O
were	O
distinct	O
in	O
their	O
codon	O
usage	O
,	O
host	B-COMP
,	O
and	O
geographic	O
distribution	O
.	O

MERS	O
was	O
recently	O
identified	O
as	O
a	O
candidate	O
for	O
vaccine	O
development	O
,	O
but	O
most	O
efforts	O
focus	O
on	O
antibody	B-COMP
responses	O
,	O
which	O
are	O
often	O
transient	O
after	O
CoV	O
infections	O
.	O

CoV	O
-	O
specific	O
T	O
cells	B-COMP
are	O
generally	O
long	O
-	O
lived	O
,	O
but	O
the	O
virus	O
-	O
specific	O
T	O
cell	B-COMP
response	O
has	O
not	O
been	O
addressed	O
in	O
MERS	O
patients	O
.	O

This	O
is	O
in	O
accordance	O
with	O
in	O
vivo	O
experiments	O
,	O
revealing	O
cell	B-COMP
innate	O
immune	O
answers	O
to	O
both	O
PRCoV	O
and	O
SIV	O
that	O
are	O
able	O
to	O
restrict	O
the	O
virulence	O
and	O
pathogenicity	O
of	O
the	O
viruses	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
U18666A	O
,	O
the	O
cholesterol	O
synthesis	O
and	O
transport	O
inhibitor	O
,	O
shows	O
antiviral	O
effects	O
against	O
type	O
I	O
FCoV	O
.	O
U18666A	O
induced	O
cholesterol	O
accumulation	O
in	O
cells	B-COMP
and	O
inhibited	O
type	O
I	O
FCoV	O
replication	O
.	O

The	O
patient	O
'	O
s	O
respiratory	O
status	O
continued	O
to	O
decline	O
postpartum	O
,	O
and	O
she	O
ultimately	O
required	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

These	O
data	O
help	O
to	O
appreciate	O
the	O
range	O
of	O
disease	O
severity	O
observed	O
in	O
vivo	O
and	O
the	O
occurrence	O
of	O
chronic	O
respiratory	O
tract	O
infections	O
in	O
immunocompromised	O
hosts	B-COMP
.	O

Here	O
we	O
conjugated	O
fusion	O
-	O
inhibiting	O
peptides	O
to	O
various	O
lipids	O
,	O
expecting	O
this	O
to	O
secure	O
peptides	O
onto	O
cell	B-COMP
membranes	I-COMP
and	O
thereby	O
increase	O
antiviral	O
potencies	O
.	O

Cell	B-COMP
imaging	O
revealed	O
intracellular	B-COMP
peptide	O
aggregates	O
,	O
consistent	O
with	O
their	O
endocytosis	O
into	O
compartments	O
where	O
CoV	O
entry	O
takes	O
place	O
.	O

There	O
are	O
10	O
case	O
reports	O
in	O
the	O
literature	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
use	O
in	O
HIV	O
-	O
positive	O
patients	O
,	O
of	O
whom	O
seven	O
survived	O
to	O
hospital	O
discharge	O
.	O

The	O
identity	O
of	O
the	O
Chowsingha	O
tissues	O
used	O
for	O
PPRV	O
isolation	O
was	O
confirmed	O
by	O
the	O
12S	O
ribosomal	B-COMP
RNA	I-COMP
gene	O
sequencing	O
,	O
and	O
the	O
amplified	O
gene	O
was	O
analysed	O
identically	O
to	O
the	O
Chowsingha	O
mitochondrial	B-COMP
12S	O
ribosomal	B-COMP
RNA	I-COMP
gene	O
.	O

The	O
RT	O
-	O
RPA	B-COMP
assay	O
was	O
performed	O
successfully	O
at	O
40	O
°	O
C	O
,	O
and	O
the	O
results	O
were	O
obtained	O
within	O
3	O
min	O
-	O
12	O
min	O
.	O

The	O
analytical	O
sensitivity	O
of	O
RT	O
-	O
RPA	B-COMP
was	O
31	O
.	O
8	O
copies	O
in	O
vitro	O
transcribed	O
CDV	O
RNA	O
,	O
which	O
is	O
10	O
times	O
lower	O
than	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Previously	O
reported	O
surviving	O
patients	O
in	O
China	O
and	O
Taiwan	O
required	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
and	O
other	O
invasive	O
modalities	O
.	O

Interestingly	O
,	O
passive	O
transfer	O
of	O
serum	B-COMP
from	O
previously	O
infected	O
rabbits	O
to	O
naïve	O
rabbits	O
was	O
associated	O
with	O
enhanced	O
inflammation	O
upon	O
infection	O
.	O

Non	O
-	O
survivors	O
needed	O
significantly	O
more	O
frequent	O
renal	O
replacement	O
therapy	O
(	O
37	O
.	O
5	O
%	O
vs	O
.	O
18	O
.	O
2	O
%;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
transfusion	O
of	O
red	O
blood	O
cell	B-COMP
concentrates	O
[	O
0	O
.	O
4	O
units	O
(	O
0	O
.	O
3	O
to	O
1	O
.	O
2	O
)	O
vs	O
.	O
0	O
.	O
9	O
units	O
(	O
0	O
.	O
5	O
to	O
1	O
.	O
6	O
);	O
p	O
<	O
0	O
.	O
01	O
]	O
during	O
ECMO	O
support	O
compared	O
to	O
patients	O
who	O
survived	O
.	O

TITLE	O
:	O
Neural	O
precursor	O
cells	B-COMP
derived	O
from	O
induced	O
pluripotent	O
stem	O
cells	B-COMP
exhibit	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
a	O
neurotropic	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
examines	O
the	O
susceptibility	O
of	O
mouse	O
induced	O
pluripotent	O
stem	O
cell	B-COMP
-	O
derived	O
neural	O
precursor	O
cells	B-COMP
(	O
iPSC	O
-	O
NPCs	O
)	O
to	O
infection	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
).	O

In	O
this	O
study	O
,	O
APS	O
were	O
employed	O
as	O
an	O
adjuvant	O
for	O
an	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
,	O
and	O
its	O
effects	O
on	O
the	O
cellular	B-COMP
immune	O
and	O
humoral	O
immune	O
responses	O
to	O
vaccination	O
in	O
chicken	O
were	O
investigated	O
.	O

To	O
determine	O
whether	O
neurons	O
or	O
other	O
CNS	O
cells	B-COMP
survive	O
acute	O
infection	O
with	O
this	O
virulent	O
virus	O
,	O
we	O
developed	O
a	O
recombinant	O
JHMV	O
that	O
expresses	O
Cre	O
recombinase	O
(	O
rJ	O
-	O
Cre	O
)	O
and	O
infected	O
mice	O
that	O
universally	O
expressed	O
a	O
silent	O
(	O
floxed	O
)	O
version	O
of	O
tdTomato	O
.	O

The	O
results	O
showed	O
that	O
some	O
cells	B-COMP
were	O
able	O
to	O
survive	O
the	O
infection	O
,	O
as	O
demonstrated	O
by	O
continued	O
tdTomato	O
expression	O
after	O
virus	O
antigen	O
could	O
no	O
longer	O
be	O
detected	O
.	O

The	O
mean	O
serum	B-COMP
anti	O
-	O
BCV	O
antibody	B-COMP
abundance	O
at	O
weaning	O
for	O
a	O
group	O
of	O
calves	O
was	O
inversely	O
related	O
with	O
the	O
subsequent	O
incidence	O
of	O
BRD	O
in	O
that	O
group	O
;	O
however	O
,	O
the	O
serum	B-COMP
anti	O
-	O
BCV	O
antibody	B-COMP
abundance	O
at	O
weaning	O
for	O
individual	O
calves	O
was	O
not	O
predictive	O
of	O
which	O
calves	O
would	O
develop	O
BRD	O
after	O
feedlot	O
entry	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
Results	O
indicated	O
that	O
serum	B-COMP
anti	O
-	O
BCV	O
antibody	B-COMP
abundance	O
as	O
determined	O
with	O
ELISA	O
were	O
not	O
associated	O
with	O
BCV	O
shedding	O
or	O
risk	O
of	O
BRD	O
in	O
individual	O
beef	O
calves	O
from	O
birth	O
through	O
the	O
first	O
5	O
weeks	O
after	O
feedlot	O
entry	O
.	O

ABSTRACT	O
:	O
Recent	O
data	O
suggest	O
that	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
pneumonia	O
is	O
associated	O
with	O
significant	O
mortality	O
in	O
hematopoietic	O
cell	B-COMP
transplant	O
(	O
HCT	O
)	O
recipients	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
invades	O
porcine	O
intestinal	O
epithelial	O
cells	B-COMP
(	O
IECs	O
)	O
and	O
causes	O
diarrhea	O
and	O
dehydration	O
in	O
pigs	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
a	O
suppression	O
of	O
PEDV	O
infection	O
in	O
porcine	O
jejunum	O
intestinal	O
epithelial	O
cells	B-COMP
(	O
IPEC	O
-	O
J2	O
)	O
by	O
an	O
increase	O
in	O
autophagy	O
.	O

The	O
nsp1	O
of	O
CoV	O
is	O
thought	O
to	O
be	O
a	O
major	O
virulence	O
factor	O
because	O
it	O
suppresses	O
protein	O
synthesis	O
through	O
the	O
degradation	O
of	O
host	B-COMP
mRNA	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
inhibits	O
the	O
host	B-COMP
typeⅠinterferon	O
and	O
cellular	B-COMP
antiviral	O
response	O
,	O
but	O
its	O
inhibition	O
mechanism	O
is	O
unclear	O
,	O
and	O
the	O
roles	O
of	O
PEDV	O
nonstructural	O
proteins	O
in	O
regulating	O
typeⅠinterferon	O
responses	O
have	O
been	O
seldom	O
studied	O
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
mutation	O
sites	O
in	O
spike	O
and	O
envelope	B-COMP
proteins	O
mediating	O
optimal	O
cellular	B-COMP
infection	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
from	O
different	O
pathways	O
.	O

ABSTRACT	O
:	O
Entry	O
of	O
the	O
α	O
-	O
coronavirus	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
requires	O
specific	O
proteases	O
to	O
activate	O
spike	O
(	O
S	O
)	O
protein	O
for	O
the	O
membrane	B-COMP
fusion	O
of	O
the	O
virion	B-COMP
to	O
the	O
host	B-COMP
cell	I-COMP
following	O
receptor	O
binding	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
has	O
become	O
a	O
viable	O
and	O
increasingly	O
utilized	O
option	O
for	O
the	O
treatment	O
of	O
refractory	O
hypoxemia	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
analysed	O
the	O
post	O
-	O
mortem	O
histopathological	O
findings	O
and	O
investigated	O
localisation	O
of	O
viral	B-COMP
particles	I-COMP
in	O
the	O
pulmonary	O
and	O
extrapulmonary	O
tissue	O
by	O
transmission	O
electron	O
microscopic	O
examination	O
in	O
a	O
33	O
-	O
year	O
-	O
old	O
male	O
patient	O
of	O
T	O
cell	B-COMP
lymphoma	O
,	O
who	O
acquired	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Sedation	O
and	O
Mobilization	O
During	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Acute	O
Respiratory	O
Failure	O
:	O
An	O
International	O
Survey	O
.	O

TITLE	O
:	O
Neurologic	O
Injury	O
With	O
Severe	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Patients	O
Undergoing	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
:	O
A	O
Single	O
-	O
Center	O
Retrospective	O
Analysis	O
.	O

We	O
found	O
that	O
the	O
susceptibility	O
of	O
septic	O
mice	O
to	O
Secondary	O
Pseudomonas	O
aeruginosa	O
pneumonia	O
could	O
be	O
down	O
-	O
regulated	O
by	O
ethyl	O
pyruvate	O
treatment	O
and	O
the	O
protective	O
effects	O
of	O
EP	O
may	O
via	O
decreasing	O
lung	O
IL	O
-	O
10	O
and	O
plasma	O
HMGB1	O
expression	O
,	O
inhibiting	O
the	O
function	O
of	O
Tregs	O
and	O
relieving	O
the	O
apoptosis	O
of	O
splenic	O
immune	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Sickle	O
-	O
cell	B-COMP
disease	O
(	O
SCD	O
)	O
affects	O
millions	O
worldwide	O
.	O

Based	O
on	O
the	O
lack	O
of	O
correlation	O
between	O
nucleic	B-COMP
acid	O
and	O
serological	O
analysis	O
,	O
we	O
conclude	O
that	O
MERS	O
-	O
CoV	O
-	O
IgG	O
testing	O
may	O
not	O
be	O
suitable	O
for	O
diagnosing	O
acute	O
infection	O
or	O
estimating	O
its	O
prevalence	O
during	O
an	O
outbreak	O
.	O

As	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
Is	O
Being	O
Considered	O
.	O

TITLE	O
:	O
Transport	O
While	O
on	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
Support	O
.	O

His	O
corresponding	O
blood	O
urea	O
and	O
serum	B-COMP
antistreptolysin	O
O	O
(	O
ASO	O
)	O
levels	O
were	O
raised	O
with	O
low	O
C3	O
levels	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
study	O
if	O
maternal	O
IgG1	B-COMP
antibodies	B-COMP
(	O
Abs	O
)	O
to	O
BCoV	O
acquired	O
by	O
colostrum	O
intake	O
modulate	O
the	O
development	O
of	O
BCoV	O
infection	O
in	O
calves	O
reared	O
in	O
a	O
dairy	O
farm	O
in	O
Argentina	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
respiratory	O
support	O
,	O
also	O
known	O
as	O
extracorporeal	O
gas	O
exchange	O
,	O
may	O
be	O
used	O
to	O
rescue	O
the	O
most	O
severe	O
forms	O
of	O
acute	O
hypoxemic	O
respiratory	O
failure	O
with	O
high	O
blood	O
flow	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

The	O
effectiveness	O
of	O
antibodies	B-COMP
induced	O
by	O
the	O
rSPV	O
-	O
St	O
vaccine	O
in	O
protection	O
against	O
PEDV	O
was	O
tested	O
in	O
a	O
passive	O
-	O
transfer	O
model	O
in	O
which	O
piglets	O
were	O
challenged	O
with	O
the	O
homologous	O
virus	O
SQ2014	O
and	O
the	O
heterologous	O
strain	O
CV777	O
.	O

Pooled	O
analysis	O
showed	O
that	O
NAC	B-COMP
did	O
not	O
contribute	O
to	O
reduce	O
short	O
-	O
term	O
mortality	O
[	O
risk	O
ratio	O
(	O
RR	O
)=	O
0	O
.	O
73	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
0	O
.	O
50	O
-	O
1	O
.	O
07	O
;	O
P	O
=	O
0	O
.	O
10	O
]	O
or	O
30	O
-	O
day	O
mortality	O
(	O
RR	O
=	O
0	O
.	O
72	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
44	O
-	O
1	O
.	O
19	O
;	O
P	O
=	O
0	O
.	O
20	O
)	O
when	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
.	O

The	O
current	O
study	O
demonstrates	O
that	O
the	O
replication	O
intermediates	O
of	O
minus	O
strand	O
of	O
subgenomic	O
RNA	O
(	O
sgRNA	O
)	O
can	O
be	O
readily	O
recovered	O
from	O
SARS	O
-	O
CoV	O
infected	O
cells	B-COMP
.	O

As	O
part	O
of	O
its	O
viral	B-COMP
genome	I-COMP
,	O
MERS	O
-	O
CoV	O
encodes	O
a	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
that	O
has	O
been	O
observed	O
to	O
act	O
as	O
a	O
deubiquitinase	O
and	O
deISGylase	O
to	O
antagonize	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
immune	O
pathways	O
.	O

TITLE	O
:	O
Prognostic	O
value	O
of	O
serum	B-COMP
zinc	O
levels	O
in	O
patients	O
with	O
acute	O
HC	O
/	O
zinc	O
chloride	O
smoke	O
inhalation	O
.	O

Here	O
we	O
dissected	O
the	O
molecular	O
mechanism	O
underlying	O
cellular	B-COMP
entry	O
and	O
intracellular	B-COMP
trafficking	O
of	O
PHEV	O
in	O
mouse	O
neuroblastoma	O
(	O
Neuro	O
-	O
2a	O
)	O
cells	B-COMP
.	O

To	O
verify	O
the	O
roles	O
of	O
distinct	O
endocytic	O
pathways	O
,	O
systematic	O
approaches	O
were	O
used	O
,	O
including	O
pharmacological	O
inhibition	O
,	O
RNA	O
interference	O
,	O
confocal	O
microscopy	O
analysis	O
,	O
use	O
of	O
fluorescently	O
labeled	O
virus	B-COMP
particles	I-COMP
,	O
and	O
overexpression	O
of	O
a	O
dominant	O
negative	O
(	O
DN	O
)	O
mutant	O
.	O

In	O
total	O
,	O
40	O
different	O
host	B-COMP
species	O
were	O
identified	O
.	O

Another	O
approach	O
relies	O
on	O
the	O
co	O
-	O
administration	O
of	O
antitoxin	O
antibodies	B-COMP
with	O
immunomodulatory	O
drugs	O
,	O
thereby	O
neutralizing	O
the	O
toxin	O
while	O
attenuating	O
lung	O
injury	O
.	O

This	O
review	O
focuses	O
on	O
the	O
current	O
treatment	O
options	O
for	O
pulmonary	O
ricin	O
intoxication	O
using	O
anti	O
-	O
ricin	O
antibodies	B-COMP
,	O
disease	O
-	O
modifying	O
countermeasures	O
,	O
anti	O
-	O
ricin	O
small	O
molecules	O
and	O
their	O
various	O
combinations	O
.	O

Engagement	O
of	O
specific	O
glycan	O
receptors	O
such	O
as	O
sialylated	O
carbohydrates	O
,	O
glycosaminoglycans	O
,	O
or	O
histo	O
-	O
blood	O
group	O
antigens	O
can	O
determine	O
host	B-COMP
range	O
,	O
tissue	O
tropism	O
,	O
and	O
pathogenicity	O
.	O

Glycan	O
receptor	O
-	O
binding	O
sites	O
are	O
typically	O
located	O
in	O
exposed	O
regions	O
on	O
viral	O
surfaces	O
-	O
sites	O
that	O
are	O
also	O
generally	O
prone	O
to	O
binding	O
of	O
neutralizing	O
antibodies	B-COMP
that	O
directly	O
interfere	O
with	O
virus	O
-	O
glycan	O
receptor	O
interactions	O
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
locations	O
and	O
architecture	O
of	O
the	O
glycan	O
-	O
and	O
antibody	B-COMP
-	O
binding	O
sites	O
in	O
four	O
different	O
viruses	O
with	O
stalk	O
-	O
like	O
attachment	O
proteins	O
(	O
reovirus	O
,	O
influenza	O
virus	O
,	O
norovirus	O
,	O
and	O
coronavirus	O
)	O
and	O
investigate	O
the	O
mechanisms	O
by	O
which	O
antibodies	B-COMP
block	O
glycan	O
recognition	O
.	O

TITLE	O
:	O
NMR	O
structure	O
and	O
localization	O
of	O
a	O
large	O
fragment	O
of	O
the	O
SARS	O
-	O
CoV	O
fusion	O
protein	O
:	O
Implications	O
in	O
viral	O
cell	B-COMP
fusion	O
.	O

Competitive	O
ELISA	O
(	O
cELISA	O
),	O
in	O
which	O
a	O
labeled	O
monoclonal	O
antibody	B-COMP
(	O
MAb	O
)	O
competes	O
with	O
test	O
serum	B-COMP
antibodies	B-COMP
for	O
target	O
epitopes	O
,	O
may	O
be	O
a	O
suitable	O
alternative	O
because	O
it	O
detects	O
antibodies	B-COMP
in	O
a	O
species	O
-	O
independent	O
manner	O
.	O

The	O
cELISA	O
detected	O
MERS	O
-	O
CoV	O
-	O
specific	O
antibodies	B-COMP
in	O
sera	B-COMP
from	O
MERS	O
-	O
CoV	O
-	O
infected	O
rats	O
and	O
rabbits	O
immunized	O
with	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
MAb	O
-	O
based	O
cELISA	O
was	O
validated	O
using	O
sera	B-COMP
from	O
Ethiopian	O
dromedary	O
camels	O
.	O

Relative	O
to	O
the	O
neutralization	O
test	O
,	O
the	O
cELISA	O
detected	O
MERS	O
-	O
CoV	O
-	O
specific	O
antibodies	B-COMP
in	O
66	O
Ethiopian	O
dromedary	O
camels	O
with	O
a	O
sensitivity	O
and	O
specificity	O
of	O
98	O
%	O
and	O
100	O
%,	O
respectively	O
.	O

This	O
study	O
investigated	O
antibody	B-COMP
response	O
to	O
ECoV	O
in	O
horses	O
inoculated	O
with	O
BCoV	O
vaccine	O
.	O

In	O
light	O
of	O
the	O
pathogenic	O
mechanism	O
of	O
feline	O
coronavirus	O
that	O
relies	O
on	O
endosomal	O
acidification	O
for	O
cytoplasmic	B-COMP
entry	O
,	O
a	O
novel	O
vacuolar	B-COMP
ATPase	O
blocker	O
,	O
diphyllin	O
,	O
and	O
its	O
nanoformulation	O
are	O
herein	O
investigated	O
for	O
their	O
antiviral	O
activity	O
against	O
the	O
type	O
II	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
).	O

The	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
A	O
(	O
VEGF	O
-	O
A	O
)	O
and	O
the	O
placental	O
growth	O
factor	O
(	O
PlGF	O
)	O
are	O
vascular	O
permeability	O
factors	O
and	O
may	O
be	O
involved	O
in	O
the	O
disruption	O
of	O
the	O
alveolar	O
-	O
capillary	O
membrane	B-COMP
,	O
leading	O
to	O
alveolar	O
edema	O
.	O

We	O
discuss	O
the	O
origins	O
of	O
ROS	O
within	O
the	O
cell	B-COMP
,	O
cellular	B-COMP
defense	O
mechanisms	O
against	O
oxidative	O
damage	O
,	O
the	O
role	O
of	O
ROS	O
in	O
the	O
development	O
of	O
endothelial	O
permeability	O
,	O
and	O
potential	O
therapies	O
targeted	O
at	O
oxidative	O
stress	O
.	O

Entry	O
of	O
CoVs	O
into	O
host	B-COMP
cells	B-COMP
is	O
mediated	O
by	O
the	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
,	O
which	O
is	O
structurally	O
categorized	O
as	O
a	O
class	O
I	O
viral	O
fusion	O
protein	O
,	O
within	O
the	O
same	O
group	O
as	O
influenza	O
virus	O
and	O
HIV	O
.	O

Glial	B-COMP
fibrillary	I-COMP
acidic	I-COMP
protein	I-COMP
expression	O
was	O
increased	O
in	O
the	O
retina	O
in	O
cases	O
of	O
FIP	O
.	O

Müller	O
cell	B-COMP
proliferation	O
was	O
present	O
within	O
lesions	O
of	O
retinal	O
detachment	O
.	O

Macrophages	O
were	O
present	O
in	O
FIP	O
-	O
associated	O
ocular	O
lesions	O
,	O
but	O
they	O
were	O
the	O
most	O
numerous	O
inflammatory	O
cells	B-COMP
only	O
within	O
granulomas	O
(	O
2	O
/	O
15	O
cats	O
,	O
13	O
%).	O

IBV	O
titres	O
in	O
the	O
supernatant	O
were	O
significantly	O
increased	O
when	O
CD59	O
proteins	O
were	O
overexpressed	O
in	O
cells	B-COMP
followed	O
by	O
IBV	O
infection	O
,	O
and	O
this	O
observation	O
was	O
further	O
supported	O
by	O
knockdown	O
or	O
cleavage	O
of	O
CD59	O
.	O

Furthermore	O
,	O
dendritic	B-COMP
cells	B-COMP
(	O
DCs	O
),	O
professional	O
antigen	O
-	O
presenting	O
cells	B-COMP
,	O
link	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
for	O
homeostasis	O
of	O
the	O
intestinal	O
immune	O
environment	O
.	O

TITLE	O
:	O
Tectonic	O
conformational	O
changes	O
of	O
a	O
coronavirus	O
spike	O
glycoprotein	O
promote	O
membrane	B-COMP
fusion	O
.	O

TITLE	O
:	O
Targeting	O
and	O
Enrichment	O
of	O
Viral	O
Pathogen	O
by	O
Cell	B-COMP
Membrane	I-COMP
Cloaked	O
Magnetic	O
Nanoparticles	O
for	O
Enhanced	O
Detection	O
.	O

Using	O
the	O
influenza	O
virus	O
as	O
a	O
model	O
,	O
erythrocyte	O
membrane	B-COMP
cloaked	O
nanoparticles	O
are	O
prepared	O
and	O
modified	O
with	O
magnetic	O
functionalities	O
(	O
RBC	O
-	O
mNP	O
)	O
for	O
virus	O
targeting	O
and	O
isolation	O
.	O

The	O
work	O
also	O
sheds	O
light	O
on	O
the	O
efficient	O
membrane	B-COMP
cloaking	O
mechanism	O
that	O
bestows	O
nanoparticles	O
with	O
cell	B-COMP
mimicking	O
functionalities	O
.	O

In	O
order	O
to	O
evaluate	O
piglet	O
diarrhea	O
caused	O
TGEV	O
and	O
ETEC	O
K88	O
,	O
the	O
authors	O
examin	O
the	O
effects	O
of	O
coinfection	O
in	O
IPEC	O
-	O
J2	O
cells	B-COMP
.	O

In	O
TGEV	O
pre	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	B-COMP
,	O
ETEC	O
K88	O
adhesion	O
is	O
enhanced	O
over	O
uninfected	O
cells	B-COMP
.	O

The	O
attenuated	O
virus	O
induced	O
a	O
high	O
level	O
of	O
virus	O
-	O
specific	O
neutralizing	O
antibodies	B-COMP
until	O
120	O
days	O
after	O
immunization	O
in	O
piglets	O
and	O
provided	O
complete	O
protection	O
when	O
challenged	O
with	O
an	O
emerging	O
virus	O
strain	O
on	O
day	O
14	O
post	O
immunization	O
.	O

In	O
addition	O
,	O
PEDV	O
pigs	O
had	O
increased	O
stem	O
cell	B-COMP
proliferation	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
a	O
numerical	O
increase	O
in	O
DNA	O
fragmentation	O
compared	O
with	O
controls	O
through	O
dpi	O
7	O
which	O
coincided	O
with	O
an	O
observed	O
return	O
of	O
digestive	O
function	O
to	O
that	O
of	O
controls	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
NH	O
ABSTRACT	O
:	O
Neuraminidase	O
inhibitors	O
can	O
deter	O
nascent	O
viruses	O
from	O
infecting	O
intact	O
cells	B-COMP
by	O
preventing	O
their	O
release	O
from	O
host	B-COMP
cells	B-COMP
.	O

qRT	O
-	O
PCR	O
positive	O
samples	O
with	O
low	O
antibody	B-COMP
titres	O
mostly	O
contained	O
low	O
FCoV	O
RNA	O
loads	O
,	O
although	O
the	O
highest	O
antibody	B-COMP
titres	O
were	O
detected	O
in	O
effusions	O
with	O
C	O

Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
infectious	O
agents	O
in	O
chickens	O
,	O
and	O
in	O
chicken	O
cells	B-COMP
,	O
it	O
can	O
be	O
recognized	O
by	O
MDA5	O
to	O
activate	O
interferon	O
production	O
.	O

The	O
relationship	O
between	O
this	O
decline	O
in	O
platelet	O
aggregation	O
and	O
ARDS	O
differed	O
by	O
cigarette	O
smoke	O
exposure	O
status	O
,	O
suggesting	O
that	O
impaired	O
platelet	O
activation	O
differentially	O
affects	O
the	O
risk	O
of	O
ARDS	O
in	O
those	O
with	O
cigarette	O
smoke	O
exposure	O
(	O
arachidonic	O
acid	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
005	O
,	O
collagen	B-COMP
p	O
for	O
interaction	O
:	O
0	O
.	O
02	O
,	O
adenosine	O
diphosphate	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
05	O
).	O

In	O
this	O
study	O
,	O
we	O
mapped	O
the	O
process	O
of	O
HCoV	O
-	O
NL63	O
entry	O
into	O
the	O
LLC	B-COMP
-	O
Mk2	O
cell	B-COMP
line	O
and	O

Histological	O
examination	O
revealed	O
MERS	O
-	O
CoV	O
enteric	O
infection	O
in	O
all	O
inoculated	O
mice	O
,	O
as	O
shown	O
by	O
the	O
presence	O
of	O
virus	O
-	O
positive	O
cells	B-COMP
,	O
progressive	O
inflammation	O
,	O
and	O
epithelial	O
degeneration	O
in	O
small	O
intestines	O
,	O
which	O
were	O
exaggerated	O
in	O
the	O
mice	O
pretreated	O
with	O
the	O
proton	B-COMP
pump	I-COMP
inhibitor	O
pantoprazole	O
.	O

With	O
the	O
progression	O
of	O
the	O
enteric	O
infection	O
,	O
inflammation	O
,	O
virus	O
-	O
positive	O
cells	B-COMP
,	O
and	O
live	O
viruses	O
emerged	O
in	O
the	O
lung	O
tissues	O
,	O
indicating	O
the	O
development	O
of	O
sequential	O
respiratory	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
if	O
mobile	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
reduces	O
patient	O
mortality	O
during	O
and	O
after	O
transport	O
of	O
patients	O
requiring	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Epidemiologic	O
and	O
Clinical	O
Characteristics	O
of	O
Coronavirus	O
and	O
Bocavirus	O
Respiratory	O
Infections	O
after	O
Allogeneic	O
Stem	O
Cell	B-COMP
Transplantation	O
:	O
A	O
Prospective	O
Single	O
-	O
Center	O
Study	O
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibodies	B-COMP
as	O
candidate	O
therapeutics	O
against	O
emerging	O
viruses	O
.	O

Previous	O
evidence	O
suggested	O
that	O
the	O
nonstructural	O
proteins	O
(	O
nsp	O
'	O
s	O
)	O
3	O
,	O
4	O
,	O
and	O
6	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
which	O
contain	O
transmembrane	B-COMP
domains	O
,	O
would	O
all	O
be	O
required	O
for	O
DMV	O
formation	O
.	O

TITLE	O
:	O
Interleukin	O
-	O
36γ	O
and	O
IL	O
-	O
36	O
receptor	O
signaling	O
mediate	O
impaired	O
host	B-COMP
immunity	O
and	O
lung	O
injury	O
in	O
cytotoxic	O
Pseudomonas	O
aeruginosa	O
pulmonary	O
infection	O
:	O
Role	O
of	O
prostaglandin	O
E2	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
cytosolic	B-COMP
phospholipase	O
A	O

We	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
apparent	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
requiring	O
life	O
-	O
sustaining	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
).	O

TITLE	O
:	O
Comparative	O
transcriptome	O
analysis	O
reveals	O
induction	O
of	O
apoptosis	O
in	O
chicken	O
kidney	O
cells	B-COMP
associated	O
with	O
the	O
virulence	O
of	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
.	O

To	O
study	O
the	O
possible	O
immune	O
evasion	O
of	O
the	O
type	O
III	O
IFN	O
response	O
by	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
a	O
line	O
of	O
porcine	O
intestinal	O
epithelial	O
cells	B-COMP
was	O
developed	O
as	O
a	O
cell	B-COMP
model	O
for	O
PEDV	O
replication	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
peptide	O
derived	O
from	O
the	O
heptad	O
repeat	O
2	O
region	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
spike	O
glycoprotein	O
that	O
is	O
capable	O
of	O
suppressing	O
PEDV	O
entry	O
and	O
inducing	O
neutralizing	O
antibodies	B-COMP
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoVs	O
)	O
enter	O
cells	B-COMP
via	O
two	O
distinct	O
pathways	O
:	O
the	O
endosomal	O
pathway	O
using	O
cathepsins	O
to	O
activate	O
spike	O
protein	O
and	O
the	O
cell	B-COMP
-	O
surface	O
or	O
early	B-COMP
endosome	I-COMP
pathway	O
using	O
extracellular	B-COMP
proteases	O
such	O
as	O
transmembrane	B-COMP
protease	O
serine	O
2	O
(	O
TMPRSS2	O
).	O

We	O
previously	O
reported	O
that	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
preferred	O
cell	B-COMP
-	O
surface	O
TMPRSS2	O
to	O
endosomal	O
cathepsin	O
for	O
cell	B-COMP
entry	O
,	O
and	O
that	O
they	O
acquired	O
the	O
ability	O
to	O
use	O
cathepsin	O
L	O
by	O
repeated	O
passage	O
in	O
cultured	O
cells	B-COMP
and	O
were	O
then	O
able	O
to	O
enter	O
cells	B-COMP
via	O
the	O
endosomal	O
pathway	O
.	O

These	O
results	O
suggest	O
that	O
circulating	O
HCoVs	O
in	O
the	O
field	O
generally	O
use	O
cell	B-COMP
-	O
surface	O
TMPRSS2	O
for	O
cell	B-COMP
entry	O
,	O
not	O
endosomal	O
cathepsins	O
,	O
in	O
human	O
airway	O
epithelial	O
cells	B-COMP
.	O

The	O
effects	O
of	O
miR	O
-	O
4331	O
and	O
its	O
target	O
RB1	O
on	O
mitochondrial	B-COMP
Ca	O

TITLE	O
:	O
Diagnostic	O
and	O
Prognostic	O
Plasma	O
Biomarkers	O
for	O
Idiopathic	O
Pneumonia	O
Syndrome	O
after	O
Hematopoietic	O
Cell	B-COMP
Transplantation	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
host	B-COMP
susceptibility	O
factors	O
to	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
,	O
we	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
from	O
the	O
single	O
largest	O
exposure	O
event	O
of	O
the	O
2015	O
Korean	O
MERS	O
outbreak	O
.	O

TITLE	O
:	O
Age	O
is	O
a	O
predictor	O
of	O
a	O
small	O
decrease	O
in	O
lung	O
function	O
in	O
children	O
with	O
sickle	O
cell	B-COMP
anemia	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
increase	O
in	O
serum	B-COMP
levels	O
of	O
IL	O
-	O
10	O
,	O
CINC	O
-	O
1	O
,	O
uric	O
acid	O
and	O
circulating	O
,	O
but	O
not	O
bone	O
marrow	O
,	O
leukocyte	O
numbers	O
.	O

TITLE	O
:	O
Intratracheal	O
instillation	O
of	O
alveolar	O
type	O
II	O
cells	B-COMP
enhances	O
recovery	O
from	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

In	O
this	O
study	O
ATII	O
cells	B-COMP
(	O
2	O
.	O
5	O
×	O
10	O
ATII	O
cell	B-COMP
transplantation	O
promoted	O
recovery	O
of	O
lung	O
function	O
,	O
decrease	O
mortality	O
and	O
lung	O
inflammation	O
of	O
the	O
animals	O
with	O
ALI	O
.	O

Previously	O
,	O
activation	O
of	O
the	O
JNK	O
pathway	O
has	O
been	O
detected	O
in	O
cells	B-COMP
infected	O
with	O
several	O
coronaviruses	O
.	O

The	O
mean	O
MERS	O
-	O
CoV	O
infectious	O
titer	O
in	O
pretreatment	O
samples	O
was	O
4	O
.	O
67	O
±	O
0	O
.	O
25	O
log	O
plaque	O
-	O
forming	O
units	O
(	O
pfu	O
)/	O
mL	O
,	O
which	O
was	O
reduced	O
to	O
undetectable	O
levels	O
after	O
inactivation	O
with	O
amotosalen	O
/	O
UVA	O
demonstrating	O
a	O
mean	O
log	O
reduction	O
of	O
more	O
than	O
4	O
.	O
67	O
±	O
0	O
.	O
25	O
pfu	O
/	O
mL	O
.	O
Furthermore	O
,	O
inoculation	O
of	O
inactivated	O
plasma	O
on	O
Vero	O
E6	O
cells	B-COMP
did	O
not	O
result	O
in	O
any	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
even	O
after	O
7	O
days	O
of	O
incubation	O
and	O
three	O
consecutive	O
passages	O
,	O
nor	O
the	O
detection	O
of	O
MERS	O
RNA	O
compared	O
to	O
pretreatment	O
samples	O
which	O
showed	O
complete	O
CPE	O
within	O
2	O
to	O
3	O
days	O
postinoculation	O
and	O
log	O
viral	O
RNA	O
titer	O
ranging	O
from	O
9	O
.	O
48	O
to	O
10	O
.	O
22	O
copies	O
/	O
mL	O
in	O
all	O
three	O
passages	O
.	O

The	O
S	O
protein	O
efficiently	O
incorporated	O
into	O
the	O
viral	B-COMP
envelope	I-COMP
and	O
mediated	O
cell	B-COMP
entry	O
through	O
binding	O
its	O
receptor	O
,	O
human	O
DPP4	O
.	O

ABSTRACT	O
:	O
Mobile	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
retrieval	O
teams	O
(	O
MERTs	O
)	O
assure	O
ECMO	O
implantation	O
and	O
under	O
-	O
ECMO	O
retrieval	O
of	O
patients	O
with	O
most	O
severe	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
to	O
experienced	O
ECMO	O
centers	O
.	O

These	O
prior	O
studies	O
are	O
difficult	O
to	O
compare	O
,	O
since	O
different	O
nidoviruses	O
,	O
cell	B-COMP
lines	O
and	O
experimental	O
set	O
-	O
ups	O
were	O
used	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
CypA	O
dependence	O
of	O
three	O
distantly	O
related	O
nidoviruses	O
that	O
can	O
all	O
replicate	O
in	O
Huh7	O
cells	B-COMP
:	O
the	O
arterivirus	O
equine	O
arteritis	O
virus	O
(	O
EAV	O
),	O
the	O
alphacoronavirus	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
and	O
the	O
betacoronavirus	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Using	O
the	O
Crisis	O
and	O
Emergency	O
Risk	O
Communication	O
(	O
CERC	O
)	O
theoretical	O
framework	O
,	O
the	O
study	O
analyzes	O
how	O
the	O
performed	O
ERC	B-COMP
strategies	O
during	O
the	O
first	O
days	O
of	O
the	O
outbreak	O
might	O
have	O
contributed	O
to	O
the	O
outbreak	O
management	O
.	O

We	O
found	O
that	O
three	O
distinct	O
mutations	O
in	O
IFITM1	O
or	O
IFITM3	O
converted	O
the	O
host	B-COMP
restriction	O
factors	O
to	O
enhance	O
entry	O
driven	O
by	O
the	O
spike	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
/	O
or	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

These	O
findings	O
suggest	O
that	O
these	O
residues	O
and	O
structural	O
motifs	O
of	O
IFITM	O
proteins	O
are	O
key	O
determinants	O
for	O
modulating	O
the	O
entry	O
of	O
HCoVs	O
,	O
most	O
likely	O
through	O
interaction	O
with	O
viral	O
and	O
/	O
or	O
host	B-COMP
cellular	B-COMP
components	O
at	O
the	O
site	O
of	O
viral	O
entry	O
to	O
modulate	O
the	O
fusion	O
of	O
viral	B-COMP
envelope	I-COMP
and	O
cellular	B-COMP
membranes	O
.	O

ABSTRACT	O
:	O
Adaptation	O
to	O
air	O
breathing	O
after	O
birth	O
is	O
dependent	O
upon	O
the	O
synthesis	O
and	O
secretion	O
of	O
pulmonary	O
surfactant	O
by	O
alveolar	O
type	O
2	O
(	O
AT2	O
)	O
cells	B-COMP
.	O

M2	O
-	O
like	O
macrophages	O
were	O
recruited	O
to	O
sites	O
of	O
AT2	O
cell	B-COMP
proliferation	O
during	O
the	O
regenerative	O
process	O
and	O
were	O
present	O
in	O
lung	O
tissue	O
from	O
patients	O
with	O
severe	O
lung	O
disease	O
caused	O
by	O
mutations	O
in	O
ABCA3	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
metagenomic	O
next	O
-	O
generation	O
sequencing	O
(	O
mNGS	O
)	O
of	O
a	O
human	O
coronavirus	O
229E	O
from	O
a	O
patient	O
with	O
AML	O
and	O
persistent	O
upper	O
respiratory	O
symptoms	O
,	O
who	O
underwent	O
hematopoietic	O
cell	B-COMP
transplantation	O
(	O
HCT	O
).	O

We	O
have	O
established	O
a	O
mouse	O
model	O
of	O
severe	O
ARDS	O
,	O
developed	O
by	O
intratracheal	O
injection	O
of	O
α	O
-	O
galactosylceramide	O
(	O
α	O
-	O
GalCer	O
),	O
an	O
activator	O
of	O
natural	O
killer	O
T	O
(	O
NKT	O
)	O
cells	B-COMP
,	O
followed	O
by	O
LPS	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
if	O
serum	B-COMP
MBL	O
levels	O
correlate	O
with	O
the	O
risk	O
of	O
mortality	O
in	O
intensive	O
care	O
units	O
(	O
ICU	O
)	O
patients	O
with	O
A	O
(	O
H1N1	O
)	O
pdm09	O
infection	O
.	O

A	O
clear	O
association	O
between	O
viruses	O
and	O
hosts	B-COMP
was	O
observed	O
.	O

Of	O
this	O
HFOV	O
cohort	O
,	O
the	O
overall	O
pediatric	O
ICU	O
survival	O
was	O
23	O
.	O
5	O
%	O
(	O
In	O
this	O
large	O
database	O
of	O
pediatric	O
allogeneic	O
hematopoietic	O
cell	B-COMP
transplant	O
subjects	O
who	O
had	O
acute	O
respiratory	O
failure	O
requiring	O
invasive	O
mechanical	O
ventilation	O
for	O
critical	O
illness	O
with	O
severe	O
pediatric	O
ARDS	O
,	O
early	O
use	O
of	O
HFOV	O
was	O
associated	O
with	O
improved	O
survival	O
compared	O
to	O
late	O
implementation	O
of	O
HFOV	O
,	O
and	O
the	O
subjects	O
had	O
outcomes	O
similar	O
to	O
those	O
treated	O
only	O
with	O
conventional	O
mechanical	O
ventilation	O
.	O

Moreover	O
,	O
coinfection	O
was	O
found	O
to	O
modulate	O
several	O
host	B-COMP
proteins	O
that	O
could	O
bolster	O
pathogen	O
persistence	O
.	O

For	O
a	O
decade	O
and	O
a	O
half	O
,	O
our	O
laboratories	O
have	O
focused	O
on	O
HDL	O
'	O
s	O
exploitation	O
,	O
repurposing	O
,	O
and	O
reengineering	O
for	O
diagnostic	O
and	O
therapeutic	O
applications	O
,	O
generating	O
versatile	O
hybrid	O
nanomaterials	O
,	O
referred	O
to	O
as	O
nanobiologics	O
,	O
that	O
are	O
inherently	O
biocompatible	O
and	O
biodegradable	O
,	O
efficiently	O
cross	O
different	O
biological	O
barriers	O
,	O
and	O
intrinsically	O
interact	O
with	O
immune	O
cells	B-COMP
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
in	O
the	O
PEDV	O
capsid	O
structure	O
can	O
carry	O
the	O
major	O
B	O
lymphocyte	O
epitope	O
,	O
which	O
induces	O
production	O
of	O
neutralizing	O
antibodies	B-COMP
and	O
provides	O
immunoprotective	O
effects	O
.	O

ABSTRACT	O
:	O
Using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
limited	O
dilution	O
methods	O
to	O
screen	O
and	O
clone	O
antigen	O
-	O
specific	O
hybridoma	O
cells	B-COMP
is	O
extremely	O
time	O
-	O
consuming	O
and	O
labor	O
-	O
intensive	O
.	O

This	O
work	O
features	O
a	O
simple	O
and	O
rapid	O
cell	B-COMP
surface	I-COMP
fluorescence	O
immunosorbent	O
assay	O
(	O
CSFIA	O
),	O
designed	O
for	O
the	O
detection	O
and	O
isolation	O
of	O
antigen	O
-	O
specific	O
hybridoma	O
clones	O
.	O

In	O
the	O
vaccinated	O
sow	O
,	O
DC	O
-	O
targeted	O
PEDV	O
vaccine	O
enhanced	O
T	O
helper	O
1	O
-	O
like	O
cluster	O
of	O
differentiation	O
(	O
CD	O
)	O
4	O
T	O
cell	B-COMP
responses	O
and	O
induced	O
IgG	O
but	O
not	O
IgA	O
-	O
specific	O
immune	O
responses	O
.	O

Human	O
lung	O
epithelial	O
(	O
BEAS	O
-	O
2B	O
)	O
cells	B-COMP
were	O
incubated	O
with	O
LPS	O
in	O
the	O
presence	O
or	O
absence	O
of	O
UTI	O
.	O

We	O
investigated	O
NET	O
production	O
in	O
plasma	O
and	O
supernatant	O
of	O
cultured	O
neutrophils	O
by	O
measuring	O
cell	B-COMP
-	O
free	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
and	O
myeloperoxidase	O
(	O
MPO	O
)-	O
DNA	O
complexes	O
with	O
PicoGreen	O
dye	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
methods	O
,	O
respectively	O
.	O

Till	O
date	O
,	O
it	O
is	O
not	O
known	O
if	O
viral	O
infection	O
can	O
modulate	O
Cx43	O
expression	O
and	O
function	O
in	O
cells	B-COMP
of	O
the	O
brain	O
meninges	O
and	O
thus	O
affect	O
BBB	O
permeability	O
.	O

Our	O
results	O
show	O
that	O
MHV	O
infection	O
reduces	O
total	O
Cx43	O
levels	O
and	O
causes	O
its	O
intracellular	B-COMP
retention	O
in	O
the	O
perinuclear	O
compartments	O
reducing	O
its	O
surface	O
expression	O
.	O

We	O
report	O
the	O
safety	O
of	O
a	O
fully	O
human	O
polyclonal	O
IgG	B-COMP
antibody	I-COMP
(	O
SAB	O
-	O
301	O
)	O
produced	O
from	O
the	O
hyperimmune	O
plasma	O
of	O
transchromosomic	O
cattle	O
immunised	O
with	O
a	O
MERS	O
coronavirus	O
vaccine	O
.	O

Human	O
immunoglobulin	O
derived	O
from	O
transchromosomic	O
cattle	O
could	O
offer	O
a	O
new	O
platform	O
technology	O
to	O
produce	O
fully	O
human	O
polyclonal	O
IgG	O
antibodies	B-COMP
for	O
other	O
medical	O
conditions	O
.	O

PEDV	O
RNA	O
positive	O
rate	O
was	O
55	O
.	O
3	O
%	O
(	O
42	O
/	O
76	O
)	O
by	O
RT	O
-	O
RPA	B-COMP
and	O
59	O
.	O
2	O
%	O
(	O
45	O
/	O
76	O
)	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

However	O
,	O
broilers	O
supplemented	O
with	O
0	O
mg	O
/	O
kg	O
of	O
VE	O
had	O
lower	O
antibody	B-COMP
titers	O
against	O
SRBC	O
than	O
those	O
fed	O
100	O
mg	O
/	O
kg	O
of	O
VE	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
the	O
24th	O
day	O
.	O

A	O
severe	O
ARDS	O
with	O
a	O
PaO	O
RESULTS	O
:	O
Out	O
of	O
1234	O
ARDS	O
patients	O
,	O
431	O
(	O
34	O
.	O
9	O
%)	O
were	O
transported	O
,	O
and	O
52	O
of	O
these	O
(	O
12	O
.	O
1	O
%)	O
treated	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

The	O
HKU25	O
-	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
can	O
bind	O
to	O
hDPP4	O
protein	O
and	O
hDPP4	O
-	O
expressing	O
cells	B-COMP
,	O
but	O
it	O
does	O
so	O
with	O
lower	O
efficiency	O
than	O
that	O
of	O
MERS	O
-	O
RBD	O
.	O

For	O
BRSV	O
,	O
35	O
%	O
(	O
n	O
=	O
26	O
)	O
of	O
the	O
human	O
nasal	O
mucosa	O
swabs	O
collected	O
30	O
min	O
after	O
exposure	O
,	O
were	O
positive	O
by	O
RT	O
-	O
ddPCR	O
,	O
but	O
none	O
were	O
positive	O
for	O
infective	O
virions	B-COMP
.	O

No	O
patient	O
had	O
previous	O
renal	O
failure	O
and	O
the	O
serum	B-COMP
creatinine	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
at	O
the	O
time	O
of	O
ECMO	O
initiation	O
.	O

A	O
PDCoV	O
strain	O
named	O
HB	O
-	O
BD	O
was	O
successfully	O
isolated	O
from	O
the	O
intestinal	O
contents	O
of	O
a	O
diarrhoeic	O
piglet	O
and	O
serially	O
propagated	O
in	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	B-COMP
for	O
>	O
40	O
passages	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
has	O
supported	O
gas	O
exchange	O
in	O
children	O
with	O
severe	O
respiratory	O
failure	O
for	O
more	O
than	O
40	O
years	O
,	O
without	O
ECMO	O
efficacy	O
studies	O
.	O

Microglia	O
are	O
not	O
only	O
vital	O
cells	B-COMP
in	O
maintaining	O
CNS	O
homeostasis	O
,	O
but	O
also	O
respond	O
to	O
injury	O
,	O
infection	O
,	O
and	O
disease	O
by	O
undergoing	O
proliferation	O
and	O
changes	O
in	O
transcription	O
and	O
morphology	O
.	O

Additionally	O
,	O
microglia	O
depletion	O
resulted	O
in	O
ineffective	O
T	O
cell	B-COMP
responses	O
.	O

ABSTRACT	O
:	O
Objective	O
To	O
construct	O
a	O
phage	O
display	O
library	O
of	O
specific	O
nano	O
-	O
antibodies	B-COMP
against	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
apply	O
it	O
to	O
the	O
screening	O
of	O
neutralizing	O
nano	O
-	O
antibodies	B-COMP
.	O

Since	O
the	O
introduction	O
of	O
SECD	O
,	O
research	O
has	O
focused	O
on	O
investigating	O
viral	O
pathogenesis	O
through	O
experimental	O
inoculation	O
,	O
increasing	O
maternal	O
antibody	B-COMP
for	O
neonatal	O
protection	O
,	O
understanding	O
transmission	O
risks	O
through	O
feed	O
and	O
transportation	O
,	O
and	O
outlining	O
the	O
importance	O
of	O
biosecurity	O
in	O
preventing	O
SECD	O
introduction	O
and	O
spread	O
.	O

The	O
intestinal	O
M	O
cells	B-COMP
-	O
and	O
DCs	O
-	O
targeting	O
oral	O
delivery	O
of	O
genetically	O
engineered	O
Lactobacillus	O
expressing	O
the	O
COE	O
antigen	O
of	O
PEDV	O
can	O
efficiently	O
induce	O
anti	O
-	O
PEDV	O
mucosal	O
,	O
humoral	O
,	O
and	O
cellular	B-COMP
immune	O
responses	O
via	O
oral	O
administration	O
,	O
suggesting	O
a	O
promising	O
vaccine	O
strategy	O
against	O
PEDV	O
infection	O
.	O

VP35	O
is	O
essential	O
for	O
EBOV	O
replication	O
,	O
is	O
a	O
component	O
of	O
the	O
viral	O
RNA	O
polymerase	O
and	O
participates	O
in	O
nucleocapsid	B-COMP
formation	O
.	O

Receiver	O
operating	O
characteristic	O
analysis	O
revealed	O
improved	O
prognostic	O
accuracy	O
of	O
CURB	O
-	O
65	O
for	O
28	O
-	O
day	O
survival	O
,	O
intensive	O
care	O
treatment	O
,	O
and	O
length	O
of	O
hospital	O
stay	O
if	O
combined	O
with	O
angiopoietin	O
-	O
2	O
serum	B-COMP
levels	O
.	O

Progress	O
in	O
understanding	O
bat	O
-	O
virus	O
interactions	O
and	O
the	O
isolation	O
of	O
bat	O
-	O
borne	O
viruses	O
has	O
been	O
accelerated	O
in	O
recent	O
years	O
by	O
the	O
development	O
of	O
susceptible	O
bat	O
cell	B-COMP
lines	O
.	O

ABSTRACT	O
:	O
HCoV	O
-	O
229E	O
spike	O
(	O
S	O
)	O
protein	O
mediates	O
virion	B-COMP
attachment	O
to	O
cells	B-COMP
and	O
subsequent	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	B-COMP
membranes	O
.	O

Therefore	O
,	O
understanding	O
the	O
relationship	O
between	O
the	O
molecular	O
regulation	O
of	O
immune	O
cells	B-COMP
and	O
the	O
pulmonary	O
microenvironment	O
is	O
critical	O
for	O
disease	O
management	O
.	O

Recent	O
guidelines	O
on	O
mechanical	O
ventilation	O
in	O
ARDS	O
provide	O
evidence	O
-	O
based	O
recommendations	O
related	O
to	O
6	O
interventions	O
,	O
including	O
low	O
tidal	O
volume	O
and	O
inspiratory	O
pressure	O
ventilation	O
,	O
prone	O
positioning	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
higher	O
vs	O
lower	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
lung	O
recruitment	O
maneuvers	O
,	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

To	O
obtain	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
events	O
at	O
the	O
earliest	O
time	O
points	O
,	O
we	O
used	O
RNA	O
-	O
Seq	O
to	O
quantify	O
and	O
compare	O
the	O
host	B-COMP
mRNA	O
and	O
miRNA	O
transcriptomes	O
induced	O
by	O
the	O
highly	O
pathogenic	O
influenza	O
A	O
H5N1	O
(	O
A	O
/	O
Vietnam	O
/	O
3212	O
/	O
04	O
)	O
or	O
low	O
virulent	O
H1N1	O
(	O
A	O
/	O
Hong	O
Kong	O
/	O
54	O
/	O
98	O
)	O
viruses	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
at	O
1	O
-,	O
3	O
-,	O
and	O
6	O
-	O
h	O
post	O
infection	O
.	O

Furthermore	O
,	O
altered	O
expression	O
of	O
genes	O
in	O
these	O
pathways	O
,	O
which	O
have	O
been	O
previously	O
implicated	O
in	O
viral	O
host	B-COMP
response	O
,	O
occurs	O
specifically	O
in	O
the	O
M1	O
subtype	O
.	O

Elevated	O
levels	O
of	O
these	O
suppressors	O
could	O
lead	O
to	O
the	O
eventual	O
suppression	O
of	O
cellular	B-COMP
antiviral	O
genes	O
,	O
contributing	O
to	O
pathophysiology	O
of	O
H5N1	O
virus	O
infection	O
.	O

The	O
recent	O
application	O
of	O
advanced	O
techniques	O
,	O
such	O
as	O
next	O
generation	O
sequencing	O
and	O
ribosomal	B-COMP
profiling	O
,	O
in	O
studies	O
of	O
arteriviruses	O
and	O
coronaviruses	O
has	O
revealed	O
an	O
expanded	O
sg	O
mRNA	O
transcriptome	O
and	O
coding	O
capacity	O
.	O

To	O
prepare	O
for	O
the	O
manufacture	O
and	O
first	O
-	O
in	O
-	O
human	O
testing	O
of	O
the	O
vaccine	O
,	O
we	O
have	O
developed	O
a	O
process	O
to	O
stably	O
produce	O
the	O
recombinant	O
MERS	O
S377	O
-	O
588	O
protein	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	B-COMP
.	O

ARDS	O
patients	O
suffer	O
from	O
severe	O
hypoxemia	O
,	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
may	O
be	O
necessary	O
to	O
ensure	O
oxygenation	O
.	O

However	O
,	O
it	O
is	O
still	O
controversial	O
whether	O
the	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
counterpart	O
on	O
Vero	O
cells	B-COMP
(	O
Vero	O
-	O
APN	O
)	O
confers	O
PEDV	O
entry	O
.	O

We	O
found	O
that	O
endogenous	O
expression	O
of	O
Vero	O
-	O
APN	O
was	O
undetectable	O
in	O
the	O
mRNA	O
and	O
the	O
protein	O
levels	O
in	O
Vero	O
cells	B-COMP
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
an	O
additional	O
cellular	B-COMP
receptor	O
on	O
Vero	O
or	O
porcine	O
jejunal	O
cells	B-COMP
independent	O
of	O
APN	O
for	O
PEDV	O
entry	O
.	O

There	O
was	O
significantly	O
more	O
Ty	O
-	O
BatCoV	O
-	O
HKU4	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
than	O
Pi	O
-	O
BatCoV	O
-	O
HKU5	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
that	O
were	O
tested	O
positive	O
by	O
the	O
rapid	O
MERS	O
-	O
CoV	O
nucleocapsid	B-COMP
protein	O
detection	O
assay	O
(	O
P	O
<	O
0	O
.	O
001	O
by	O
Chi	O
-	O
square	O
test	O
).	O

Importantly	O
,	O
combining	O
RBD	O
-	O
and	O
non	O
-	O
RBD	O
MAbs	O
delayed	O
the	O
emergence	O
of	O
escape	O
mutations	O
in	O
a	O
cell	B-COMP
-	O
based	O
virus	O
escape	O
assay	O
.	O

Here	O
,	O
we	O
show	O
that	O
MHV	O
-	O
A59	O
S	O
protein	O
is	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
at	O
37	O
°	O
C	O
to	O
induce	O
receptor	O
-	O
independent	O
syncytium	O
(	O
RIS	O
)	O
formation	O
on	O
293T	O
cells	B-COMP
,	O
and	O
that	O
the	O
conformational	O
changes	O
in	O
S	O
proteins	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
are	O
very	O
similar	O
to	O
those	O
triggered	O
by	O
receptor	O
binding	O
.	O

Immunohistochemistry	O
was	O
performed	O
for	O
FoxP3	O
,	O
CD3	O
,	O
and	O
IL	O
-	O
17A	O
,	O
and	O
positive	O
cells	B-COMP
were	O
quantified	O
in	O
multiple	O
images	O
of	O
each	O
sample	O
.	O

Cells	B-COMP
stained	O
positive	O
for	O
IL	O
-	O
17A	O
in	O
idiopathic	O
uveitis	O
but	O
not	O
in	O
FIP	O
samples	O
.	O

The	O
numbers	O
of	O
FoxP3	O
RESULTS	O
:	O
Cells	B-COMP
stained	O
positive	O
for	O
IL	O
-	O
17A	O
in	O
idiopathic	O
uveitis	O
but	O
not	O
in	O
FIP	O
samples	O
.	O

TITLE	O
:	O
Cellular	B-COMP
hnRNP	O
A1	O
Interacts	O
with	O
Nucleocapsid	B-COMP
Protein	O
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
and	O
Impairs	O
Viral	O
Replication	O
.	O

In	O
this	O
report	O
,	O
PEDV	O
N	O
protein	O
was	O
discovered	O
to	O
colocalize	O
with	O
cellular	B-COMP
hnRNP	O
A1	O
in	O
perinuclear	O
region	O
of	O
PEDV	O
infected	O
cells	B-COMP
.	O

Her	O
sputum	O
and	O
throat	O
swabs	O
were	O
checked	O
for	O
nucleic	B-COMP
acid	O
of	O
influenza	O
A	O
and	O
the	O
result	O
was	O
positive	O
for	O
influenza	O
A	O
H7N9	O
.	O

However	O
,	O
some	O
symptoms	O
exacerbated	O
again	O
2	O
days	O
later	O
with	O
ground	O
-	O
glass	O
changes	O
appearing	O
in	O
upper	O
area	O
of	O
right	O
lung	O
and	O
the	O
titer	O
of	O
antibody	B-COMP
to	O
Mycoplasma	O
pneumoniae	O
rising	O
from	O
1	O
:	O
80	O
to	O
1	O
:	O
640	O
.	O

Oseltamivir	O
was	O
discontinued	O
because	O
of	O
three	O
consecutive	O
negative	O
results	O
of	O
nucleic	B-COMP
acid	O
for	O
influenza	O
A	O
H7N9	O
,	O
but	O
anti	O
-	O
Mycoplasma	O
treatment	O
was	O
continued	O
.	O

Inadequate	O
or	O
inappropriate	O
host	B-COMP
responses	O
lead	O
to	O
more	O
severe	O
outcomes	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
to	O
organ	O
dysfunction	O
beyond	O
the	O
lungs	O
and	O
over	O
extended	O
time	O
frames	O
after	O
pathogen	O
clearance	O
,	O
some	O
of	O
which	O
increase	O
the	O
risk	O
for	O
subsequent	O
pneumonia	O
.	O

In	O
this	O
study	O
,	O
the	O
antiviral	O
effect	O
of	O
LiCl	O
on	O
PEDV	O
in	O
Vero	O
cells	B-COMP
was	O
evaluated	O
.	O

Although	O
time	O
consuming	O
,	O
immunisation	O
still	O
remains	O
the	O
preferred	O
route	O
for	O
the	O
isolation	O
of	O
high	O
-	O
affinity	O
antibodies	B-COMP
and	O
antibody	B-COMP
-	O
like	O
fragments	O
.	O

Here	O
we	O
highlight	O
the	O
many	O
benefits	O
of	O
combining	O
immunisation	O
with	O
phage	O
display	O
in	O
combating	O
infectious	O
diseases	O
,	O
and	O
how	O
our	O
knowledge	O
of	O
antibody	B-COMP
engineering	O
has	O
played	O
a	O
crucial	O
role	O
in	O
fully	O
exploiting	O
these	O
platforms	O
in	O
generating	O
therapeutic	O
and	O
diagnostic	O
biologics	O
towards	O
antigenic	O
targets	O
of	O
infectious	O
organisms	O
.	O

Using	O
the	O
in	O
vitro	O
transcribed	O
TGEV	O
RNA	O
as	O
template	O
,	O
the	O
limit	O
of	O
detection	O
of	O
the	O
developed	O
RT	O
-	O
RPA	B-COMP
was	O
100	O
copies	O
per	O
reaction	O
.	O

Coronaviruses	O
,	O
including	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
fuse	O
at	O
the	O
plasma	B-COMP
membrane	I-COMP
or	O
use	O
receptor	O
-	O
mediated	O
endocytosis	O
and	O
fuse	O
with	O
endosomes	O
,	O
depending	O
on	O
the	O
cell	B-COMP
or	O
tissue	O
type	O
.	O

The	O
virus	O
spike	O
(	O
S	O
)	O
protein	O
mediates	O
fusion	O
with	O
the	O
host	B-COMP
cell	I-COMP
membrane	I-COMP
.	O

Studying	O
the	O
effects	O
of	O
Abl	O
kinase	O
inhibitors	O
on	O
IBV	O
will	O
be	O
useful	O
in	O
identifying	O
the	O
host	B-COMP
cell	I-COMP
pathways	O
required	O
for	O
coronavirus	O
infection	O
.	O

Even	O
if	O
not	O
significantly	O
(	O
P	O
=	O
.	O
127	O
),	O
lower	O
serum	B-COMP
Ig	O
concentrations	O
were	O
observed	O
in	O
sick	O
calves	O
that	O
had	O
been	O
treated	O
with	O
antibiotics	O
compared	O
to	O
those	O
that	O
had	O
not	O
been	O
treated	O
.	O

Patients	O
with	O
H7N9	O
had	O
higher	O
rates	O
of	O
invasive	O
mechanical	O
ventilation	O
;	O
serious	O
complications	O
,	O
including	O
alimentary	O
tract	O
hemorrhage	O
,	O
pneumothorax	O
or	O
septum	B-COMP
emphysema	O
,	O
hospital	O
-	O
acquired	O
pneumonia	O
(	O
HAP	O
)	O
and	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
);	O
and	O
hospital	O
mortality	O
(	O
P	O
<	O
.	O
05	O
).	O

The	O
process	O
of	O
preclinical	O
drug	O
discovery	O
from	O
small	O
molecules	O
,	O
cellular	B-COMP
and	O
immunologic	O
therapies	O
,	O
and	O
approaches	O
to	O
identifying	O
new	O
targets	O
were	O
also	O
presented	O
.	O

She	O
was	O
transfused	O
with	O
3	O
units	O
of	O
packed	O
red	O
blood	O
cells	B-COMP
(	O
PRBC	O
)	O
and	O
underwent	O
emergent	O
splenectomy	O
.	O

In	O
contrast	O
to	O
other	O
complications	O
of	O
babesiosis	O
,	O
SR	O
is	O
not	O
correlated	O
with	O
parasite	O
burden	O
or	O
immune	O
status	O
of	O
the	O
affected	O
host	B-COMP
.	O

Intensivists	O
should	O
be	O
aware	O
of	O
this	O
rare	O
but	O
rapid	O
complication	O
on	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
that	O
may	O
directly	O
impact	O
outcome	O
.	O

We	O
found	O
that	O
vaccination	O
at	O
early	O
stages	O
of	O
pregnancy	O
induces	O
similar	O
levels	O
of	O
serum	B-COMP
and	O
colostrum	O
antibodies	B-COMP
with	O
those	O
at	O
late	O
stages	O
of	O
pregnancy	O
.	O

Simultaneous	O
implementation	O
of	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
together	O
with	O
surfactant	O
application	O
allowed	O
prolonged	O
disconnection	O
of	O
patient	O
from	O
mechanical	O
ventilation	O
"("""	O
total	O
lung	O
rest	O
""""	O
mode	O
).	O

TITLE	O
:	O
A	O
case	O
of	O
interstitial	O
pneumonia	O
associated	O
with	O
anti	O
-	O
PL	O
-	O
7	O
antibody	B-COMP
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
has	O
increased	O
among	O
patients	O
with	O
severe	O
ARDS	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
rapid	O
immunochromatographic	O
assay	O
for	O
detection	O
of	O
antibodies	B-COMP
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

ABSTRACT	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
female	O
with	O
sickle	O
cell	B-COMP
anemia	O
presented	O
with	O
respiratory	O
failure	O
due	O
to	O
acute	O
chest	O
syndrome	O
(	O
ACS	O
).	O

We	O
report	O
a	O
case	O
of	O
acute	O
hypoxic	O
respiratory	O
failure	O
in	O
an	O
adolescent	O
with	O
blunt	O
chest	O
trauma	O
that	O
was	O
successfully	O
managed	O
with	O
the	O
intraoperative	O
initiation	O
of	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
during	O
the	O
initial	O
damage	O
control	O
surgery	O
.	O

R	O
-	O
848	O
enhanced	O
the	O
antigen	O
specific	O
humoral	O
and	O
cellular	B-COMP
immune	O
responses	O
when	O
co	O
-	O
administered	O
with	O
the	O
vaccines	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
antibody	B-COMP
titre	O
in	O
ELISA	O
and	O
stimulation	O
index	O
in	O
lymphocyte	O
transformation	O
test	O
(	O
LTT	O
)	O
till	O
35	O
dpi	O
and	O
increased	O
proportion	O
of	O
CD4	O

However	O
,	O
treatment	O
with	O
APN	O
-	O
specific	O
antibody	B-COMP
and	O
inhibitors	O
did	O
not	O
completely	O
block	O
PDCoV	O
infection	O
in	O
IPI	O
-	O
2I	O
porcine	O
intestinal	O
epithelial	O
cells	B-COMP
.	O

It	O
inhibits	O
the	O
replication	O
of	O
many	O
viruses	O
and	O
ultimately	O
promotes	O
apoptosis	O
of	O
infected	O
cells	B-COMP
,	O
contributing	O
to	O
the	O
control	O
of	O
virus	O
spread	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
microvascular	O
endothelial	O
cells	B-COMP
(	O
ECs	O
)	O
are	O
integral	O
to	O
the	O
alveoli	O
-	O
capillary	O
barrier	O
of	O
the	O
lung	O
.	O

Despite	O
the	O
significant	O
number	O
of	O
protocols	O
for	O
the	O
culture	O
of	O
various	O
types	O
of	O
murine	O
cells	B-COMP
,	O
the	O
isolation	O
of	O
microvascular	O
endothelial	O
cells	B-COMP
remains	O
a	O
challenging	O
procedure	O
.	O

TITLE	O
:	O
Sero	O
-	O
prevalence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
specific	O
antibodies	B-COMP
in	O
dromedary	O
camels	O
in	O
Tabuk	O
,	O
Saudi	O
Arabia	O
.	O

The	O
construction	O
of	O
mutations	O
in	O
the	O
fusion	O
protein	O
transmembrane	B-COMP
domains	O
(	O
TMDs	O
)	O
or	O
the	O
replacement	O
of	O
these	O
domains	O
with	O
lipid	O
anchors	O
has	O
implicated	O
the	O
TMD	O
in	O
the	O
fusion	O
process	O
.	O

We	O
characterized	O
the	O
growth	O
properties	O
of	O
these	O
recombinant	O
IBVs	O
in	O
Vero	O
cells	B-COMP
and	O
embryonated	O
eggs	O
,	O
and	O
their	O
pathogenicity	O
,	O
tropism	O
,	O
and	O
serotypes	O
in	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
were	O
able	O
to	O
isolate	O
and	O
cultivate	O
a	O
Korean	O
PDCoV	O
strain	O
(	O
KNU16	O
-	O
07	O
)	O
in	O
cell	B-COMP
culture	O
and	O
investigate	O
its	O
pathogenicity	O
.	O

PDCoV	O
-	O
inoculated	O
piglets	O
showed	O
watery	O
diarrhea	O
accompanied	O
by	O
acute	O
enteritis	O
in	O
the	O
natural	O
host	B-COMP
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
to	O
Prolong	O
Pregnancy	O
:	O
A	O
Case	O
Report	O
.	O

PEDV	O
NA	O
,	O
IgG	O
and	O
IgA	O
were	O
detected	O
in	O
the	O
serum	B-COMP
of	O
piglets	O
born	O
to	O
immunized	O
gilts	O
,	O
demonstrating	O
the	O
transfer	O
of	O
antibodies	B-COMP
through	O
colostrum	O
and	O
milk	O
.	O

Furthermore	O
,	O
the	O
vesicle	B-COMP
internalization	O
process	O
requires	O
actin	B-COMP
cytoskeleton	I-COMP
rearrangements	O
.	O

Overall	O
,	O
this	O
study	O
reports	O
marked	O
differences	O
in	O
the	O
activation	O
of	O
early	O
host	B-COMP
responses	O
by	O
pathogenic	O
IBV	O
strains	O
.	O

There	O
are	O
two	O
main	O
ways	O
by	O
which	O
infectious	O
diseases	O
can	O
emerge	O
:	O
by	O
changes	O
in	O
their	O
geographical	O
ranges	O
and	O
by	O
adaptive	O
emergence	O
,	O
a	O
genetic	O
change	O
in	O
a	O
microorganism	O
that	O
results	O
in	O
it	O
becoming	O
capable	O
of	O
invading	O
a	O
new	O
niche	O
,	O
often	O
by	O
jumping	O
to	O
a	O
new	O
host	B-COMP
species	O
such	O
as	O
humans	O
.	O

In	O
addition	O
,	O
one	O
2017	O
PEDV	O
strain	O
,	O
KOR	O
/	O
KNU	O
-	O
1705	O
/	O
2017	O
,	O
was	O
successfully	O
isolated	O
and	O
propagated	O
in	O
Vero	O
cells	B-COMP
.	O

These	O
findings	O
might	O
be	O
associated	O
with	O
improved	O
mucosal	O
immunity	O
,	O
enhanced	O
host	B-COMP
defenses	O
,	O
or	O
reduced	O
susceptibility	O
and	O
warrant	O
further	O
investigation	O
.	O

In	O
this	O
work	O
,	O
a	O
new	O
multiple	O
pathways	O
signal	O
amplification	O
method	O
was	O
proposed	O
to	O
construct	O
a	O
sensitive	O
electrochemiluminescence	O
(	O
ECL	O
)	O
platform	O
for	O
the	O
detection	O
of	O
PEDV	O
antibody	B-COMP
.	O

ABSTRACT	O
:	O
The	O
efficacy	O
of	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
remains	O
controversial	O
.	O

Using	O
the	O
VLP	B-COMP
system	O
,	O
a	O
258	O
-	O
nucleotide	O
RNA	O
fragment	O
,	O
which	O
spans	O
nucleotides	O
19	O
,	O
712	O
to	O
19	O
,	O
969	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
(	O
designated	O
PS258	O
(	O
19712	O
-	O
19969	O
)	O
A	O
MERS	O
-	O
oV	O
RNA	O
packaging	O
signal	O
was	O
identified	O
by	O
the	O
detection	O
of	O
GFP	O
expression	O
following	O
an	O
incubation	O
of	O
MERS	O
VLPs	O
carrying	O
the	O
heterologous	O
mRNA	O
GFP	O
-	O
PS258	O
(	O
19712	O
-	O
19969	O
)	O

Neutralizing	O
antibodies	B-COMP
targeting	O
the	O
spike	O
of	O
MERS	O
-	O
CoV	O
have	O
been	O
shown	O
to	O
be	O
a	O
therapeutic	O
option	O
for	O
treatment	O
of	O
lethal	O
disease	O
.	O

The	O
prevalence	O
of	O
MERS	O
-	O
CoV	O
antibodies	B-COMP
in	O
Israeli	O
camels	O
was	O
examined	O
in	O
71	O
camel	O
sera	B-COMP
collected	O
from	O
four	O
farms	O
across	O
Israel	O
by	O
MERS	O
-	O
CoV	O
-	O
specific	O
microneutralization	O
(	O
Mnt	O
)	O
assay	O
and	O
confirmed	O
by	O
MERS	O
-	O
CoV	O
-	O
specific	O
immunofluorescence	O
assay	O
(	O
IFA	O
).	O

The	O
high	O
rate	O
of	O
MERS	O
-	O
CoV	O
-	O
specific	O
antibody	B-COMP
seropositivity	O
in	O
dromedary	O
camels	O
in	O
the	O
absence	O
of	O
any	O
reported	O
human	O
MERS	O
cases	O
suggests	O
that	O
there	O
is	O
still	O
much	O
to	O
be	O
learned	O
about	O
the	O
dynamics	O
of	O
camel	O
-	O
to	O
-	O
human	O
transmission	O
of	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decade	O
,	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
vvECMO	O
)	O
has	O
been	O
increasingly	O
utilized	O
in	O
respiratory	O
failure	O
in	O
patients	O
.	O

Persistently	O
infected	O
A549	O
cells	B-COMP
were	O
instrumental	O
.	O

A	O
bronchoscopy	O
with	O
BAL	O
and	O
transbronchial	O
biopsies	O
did	O
not	O
show	O
acute	O
cellular	B-COMP
rejection	O
,	O
but	O
the	O
BAL	O
fluid	O
was	O
positive	O
for	O
coronavirus	O
.	O

More	O
importantly	O
,	O
by	O
exploring	O
potential	O
interactions	O
between	O
GRP78	O
and	O
spikes	O
of	O
other	O
coronaviruses	O
,	O
we	O
discovered	O
that	O
the	O
highly	O
conserved	O
human	O
GRP78	O
could	O
interact	O
with	O
the	O
spike	O
protein	O
of	O
bat	O
coronavirus	O
HKU9	O
(	O
bCoV	O
-	O
HKU9	O
)	O
and	O
facilitate	O
its	O
attachment	O
to	O
the	O
host	B-COMP
cell	I-COMP
surface	I-COMP
.	O

After	O
denaturation	O
and	O
renaturation	O
of	O
inclusion	B-COMP
bodies	I-COMP
,	O
the	O
S1	O
protein	O
was	O
obtained	O
by	O
using	O
purified	O
recombinant	O
S1	O
protein	O
in	O
immunized	O
female	O
BALB	O
/	O
c	O
mice	O
.	O

ABSTRACT	O
:	O
Recent	O
reports	O
on	O
the	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
in	O
critically	O
ill	O
burn	O
patients	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
recommended	O
against	O
the	O
use	O
of	O
ECMO	O
.	O

The	O
results	O
showed	O
that	O
TGEV	O
N	O
protein	O
localised	O
in	O
the	O
cytoplasm	B-COMP
,	O
inhibited	O
IEC	O
growth	O
,	O
prolonged	O
the	O
S	O
-	O
phase	O
cell	B-COMP
cycle	O
by	O
down	O
-	O
regulating	O
cell	B-COMP
cycle	O
protein	O
cyclin	O
A	O
,	O
and	O
was	O
mainly	O
degraded	O
through	O
the	O
proteasome	O
pathway	O
.	O

To	O
be	O
specific	O
,	O
in	O
IEC	O
,	O
TGEV	O
N	O
protein	O
induces	O
cell	B-COMP
cycle	O
prolongation	O
at	O
the	O
S	O
-	O
phase	O
,	O
ER	O
stress	O
and	O
up	O
-	O
regulates	O
IL	O
-	O
8	O
expression	O
.	O

TITLE	O
:	O
Establishment	O
and	O
characterization	O
of	O
a	O
cell	B-COMP
line	O
from	O
a	O
feline	O
histiocytic	O
sarcoma	O
.	O

While	O
FHS	O
-	O
1	O
cells	B-COMP
are	O
not	O
suitable	O
for	O
in	O
vitro	O
study	O
of	O
FIP	O
using	O
strain	O
79	O
-	O
1146	O
,	O
they	O
may	O
be	O
applicable	O
for	O
studies	O
aimed	O
at	O
developing	O
new	O
diagnostic	O
and	O
therapeutic	O
strategies	O
for	O
feline	O
HS	O
.	O

Genetically	O
modified	O
new	O
vaccine	O
candidates	O
were	O
able	O
to	O
elicit	O
a	O
strong	O
antibody	B-COMP
(	O
Ab	O
)	O
response	O
to	O
the	O
YSNIGVCK	O
epitope	O
,	O
which	O
correlated	O
with	O
an	O
increased	O
ability	O
to	O
neutralize	O
the	O
CO	O
strain	O
of	O
PEDV	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
previously	O
healthy	O
14	O
-	O
year	O
-	O
old	O
male	O
hospitalized	O
with	O
2009	O
H1N1	O
influenza	O
and	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
coinfection	O
complicated	O
by	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multifocal	O
necrotizing	O
pneumonia	O
,	O
with	O
significant	O
lung	O
tissue	O
damage	O
requiring	O
prolonged	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
support	O
.	O

Our	O
results	O
show	O
that	O
the	O
diverse	O
dimerization	O
forms	O
of	O
coronavirus	O
nsp9	O
proteins	O
enhance	O
their	O
nucleic	B-COMP
acid	O
binding	O
affinity	O
.	O

Tacrolimus	O
was	O
continuously	O
infused	O
to	O
prevent	O
graft	O
-	O
versus	O
-	O
host	B-COMP
disease	O
.	O

As	O
a	O
first	O
step	O
toward	O
understanding	O
the	O
effect	O
of	O
PDCoV	O
on	O
host	B-COMP
cells	B-COMP
,	O
we	O
elucidated	O
mechanisms	O
underlying	O
the	O
process	O
of	O
apoptotic	O
cell	B-COMP
death	O
after	O
PDCoV	O
infection	O
.	O

The	O
use	O
of	O
a	O
pan	B-COMP
-	O
caspase	O
inhibitor	O
resulted	O
in	O
the	O
inhibition	O
of	O
PDCoV	O
-	O
induced	O
apoptosis	O
and	O
reduction	O
of	O
PDCoV	O
replication	O
,	O
suggestive	O
of	O
the	O
association	O
of	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

Tissue	O
damage	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
T	O
cell	B-COMP
produced	O
cytokines	O
and	O
chemokines	O
,	O
which	O
activate	O
microglia	O
and	O
/	O
or	O
BMDM	O
to	O
both	O
strip	O
myelin	B-COMP
and	O
produce	O
toxic	O
factors	O
,	O
ultimately	O
damaging	O
axons	B-COMP
and	O
promoting	O
disability	O
.	O

Although	O
the	O
identified	O
epitopes	O
are	O
identically	O
located	O
as	O
the	O
neutralizing	O
epitope	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
the	O
recombinant	O
protein	O
that	O
includes	O
those	O
epitopes	O
could	O
not	O
elicit	O
neutralizing	O
antibodies	B-COMP
against	O
IBV	O
.	O

However	O
,	O
the	O
vital	O
dynamics	O
of	O
the	O
host	B-COMP
population	O
may	O
occur	O
slowly	O
even	O
when	O
transmission	O
is	O
far	O
from	O
threshold	O
levels	O
.	O

ABSTRACT	O
:	O
Viruses	O
are	O
obligate	O
intracellular	B-COMP
parasites	O
of	O
the	O
host	B-COMP
cells	B-COMP
.	O

Their	O
clinical	O
phenotypes	O
including	O
laboratory	O
test	O
results	O
,	O
high	O
-	O
resolution	O
lung	O
computed	O
tomography	O
data	O
,	O
response	O
to	O
therapy	O
,	O
and	O
prognosis	O
were	O
compared	O
between	O
those	O
who	O
were	O
positive	O
and	O
negative	O
for	O
MAAs	O
,	O
such	O
as	O
antinuclear	O
antibody	B-COMP
(	O
ANA	O
),	O
anti	O
-	O
cyclic	O
citrullinated	O
peptide	O
(	O
CCP	O
),	O
anti	O
-	O
SSA	O
,	O
and	O
anti	O
-	O
SSB	B-COMP
antibodies	B-COMP
.	O

Serum	B-COMP
samples	O
collected	O
between	O
2012	O
and	O
2016	O
were	O
tested	O
.	O

Reasons	O
for	O
the	O
high	O
variance	O
in	O
the	O
results	O
obtained	O
remain	O
unclear	O
;	O
more	O
research	O
is	O
required	O
to	O
ensure	O
higher	O
sensitivity	O
and	O
specificity	O
in	O
terms	O
of	O
PEDV	O
antibody	B-COMP
tests	O
and	O
other	O
PED	O
diagnostic	O
methods	O
.	O

Here	O
,	O
we	O
examined	O
entry	O
of	O
CRCoV	O
into	O
human	O
rectal	O
tumor	O
cells	B-COMP
(	O
HRT	O
-	O
18G	O
cell	B-COMP
line	O
)	O
by	O
analyzing	O
co	O
-	O
localization	O
of	O
single	O
virus	B-COMP
particles	I-COMP
with	O
cellular	B-COMP
markers	O
in	O
the	O
presence	O
or	O
absence	O
of	O
chemical	O
inhibitors	O
of	O
pathways	O
potentially	O
involved	O
in	O
virus	O
entry	O
.	O

Antibody	B-COMP
titers	O
against	O
Newcastle	O
disease	O
and	O
infectious	O
bronchitis	O
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
fed	O
groups	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

Serum	B-COMP
cytokine	O
interleukin	O
(	O
IL	O
)-	O
2	O
and	O
tumor	O
necrosis	O
factor	O
-	O
α	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
both	O
the	O
4	O
%	O
and	O
6	O
%	O
FVW	O
grousp	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
;	O
IL	O
-	O
4	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
groups	O
than	O
in	O
the	O
control	O
group	O
;	O
and	O
IL	O
-	O
6	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
6	O
%	O
FVW	O
group	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

TITLE	O
:	O
Nucleocapsid	B-COMP
protein	O
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
isolates	O
can	O
antagonize	O
interferon	O
-	O
λ	O
production	O
by	O
blocking	O
the	O
nuclear	O
factor	O
-	O
κB	O
nuclear	O
translocation	O
.	O

Cleavage	O
of	O
HA	O
by	O
host	B-COMP
cell	I-COMP
proteases	O
is	O
essential	O
for	O
viral	O
infectivity	O
,	O
and	O
the	O
responsible	O
enzymes	O
are	O
potential	O
targets	O
for	O
antiviral	O
intervention	O
.	O

Moreover	O
,	O
the	O
activity	O
of	O
cellular	B-COMP
serine	O
protease	O
inhibitors	O
against	O
HA	O
-	O
activating	O
TTSPs	O
is	O
poorly	O
understood	O
.	O

Upon	O
serial	O
passages	O
into	O
Vero	O
cells	B-COMP
,	O
PED	O
-	O
CUP	O
-	O
B2014	O
adapted	O
to	O
Vero	O
cells	B-COMP
,	O
which	O
was	O
evidenced	O
as	O
higher	O
virus	O
growth	O
in	O
Vero	O
cells	B-COMP
and	O
confirmed	O
lower	O
virulence	O
in	O
suckling	O
piglets	O
.	O

Higher	O
serum	B-COMP
/	O
colostrum	O
PEDV	O
-	O
specific	O
antibodies	B-COMP
and	O
higher	O
neutralizing	O
titers	O
were	O
shown	O
in	O
sows	O
vaccinated	O
with	O
PED	O
-	O
CUP	O
-	O
B2014	O
compared	O
to	O
unvaccinated	O
sows	O
or	O
sows	O
administered	O
commercial	O
PEDV	O
vaccine	O
.	O

Given	O
that	O
PEDV	O
infection	O
occurs	O
in	O
gut	O
epithelial	O
cells	B-COMP
mainly	O
via	O
the	O
fecal	O
-	O
oral	O
route	O
,	O
induction	O
of	O
PEDV	O
-	O
specific	O
immune	O
responses	O
in	O
the	O
mucosal	O
compartment	O
is	O
required	O
for	O
protective	O
immunity	O
against	O
viral	O
infection	O
.	O

Neurologic	O
signs	O
,	O
petechial	O
hemorrhages	O
and	O
acute	O
respiratory	O
failure	O
constitute	O
the	O
characteristic	O
presenting	O
triad	B-COMP
.	O

ABSTRACT	O
:	O
The	O
major	O
mechanism	O
of	O
antibody	B-COMP
-	O
mediated	O
neutralization	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
involves	O
competition	O
with	O
the	O
cellular	B-COMP
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
for	O
binding	O
to	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
.	O

Here	O
,	O
we	O
report	O
a	O
unique	O
epitope	O
and	O
unusual	O
neutralizing	O
mechanism	O
of	O
the	O
isolated	O
human	O
antibody	B-COMP
MERS	O
-	O
4	O
.	O

TITLE	O
:	O
Heme	O
Oxygenase	O
-	O
1	O
Reduces	O
Sepsis	O
-	O
Induced	O
Endoplasmic	B-COMP
Reticulum	I-COMP
Stress	O
and	O
Acute	O
Lung	O
Injury	O
.	O

However	O
,	O
the	O
role	O
of	O
HO	O
-	O
1	O
activation	O
in	O
the	O
development	O
of	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
stress	O
during	O
sepsis	O
remains	O
unknown	O
.	O

This	O
review	O
summarizes	O
our	O
current	O
understanding	O
of	O
this	O
class	O
of	O
nidovirus	O
-	O
host	B-COMP
interactions	O
,	O
including	O
the	O
potential	O
function	O
of	O
in	O
particular	O
CypA	O
and	O
the	O
inhibitory	O
effect	O
of	O
Cyp	O
inhibitors	O
.	O

In	O
this	O
study	O
,	O
we	O
reexamined	O
furin	O
usage	O
by	O
MERS	O
-	O
CoV	O
using	O
a	O
real	O
-	O
time	O
PCR	O
-	O
based	O
virus	O
cell	B-COMP
entry	O
assay	O
after	O
inhibition	O
of	O
cellular	B-COMP
proteases	O
.	O

Furthermore	O
,	O
a	O
virus	O
cell	B-COMP
entry	O
assay	O
and	O
a	O
cell	B-COMP
-	O
cell	B-COMP
fusion	O
assay	O
provided	O
no	O
evidence	O
that	O
the	O
S	O
protein	O
was	O
activated	O
by	O
exogenous	O
furin	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
and	O
the	O
malaria	O
parasite	O
Plasmodium	O
use	O
the	O
membrane	B-COMP
protein	O
CD81	O
to	O
invade	O
human	O
liver	O
cells	B-COMP
.	O

Here	O
we	O
mapped	O
33	O
host	B-COMP
protein	O
interactions	O
of	O
CD81	O
in	O
primary	O
human	O
liver	O
and	O
hepatoma	O
cells	B-COMP
using	O
high	O
-	O
resolution	O
quantitative	O
proteomics	O
.	O

ABSTRACT	O
:	O
Picornaviruses	O
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
human	O
diseases	O
ranging	O
from	O
the	O
common	O
cold	O
to	O
acute	O
flaccid	O
paralysis	O
,	O
have	O
a	O
short	O
cytosolic	B-COMP
lifecycle	O
that	O
,	O
in	O
cultured	O
cells	B-COMP
,	O
ends	O
in	O
cell	B-COMP
lysis	O
.	O

The	O
transcriptional	O
activity	O
of	O
ISRE	O
,	O
IFN	O
-	O
β	O
promoter	O
,	O
and	O
NF	O
-	O
κB	O
-	O
RE	O
was	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
HCoV	O
-	O
OC43	O
ns2a	O
,	O
ns5a	O
,	O
M	O
,	O
or	O
N	O
protein	O
,	O
following	O
the	O
challenge	O
of	O
cells	B-COMP
with	O
Sendai	O
virus	O
,	O
IFN	O
-	O
α	O
or	O
tumor	O
necrosis	O
factor	O
-	O
α	O
.	O

Both	O
structural	O
and	O
accessory	O
HCoV	O
-	O
OC43	O
proteins	O
are	O
able	O
to	O
inhibit	O
antiviral	O
response	O
elements	O
in	O
HEK	O
-	O
293	O
cells	B-COMP
,	O
and	O
to	O
block	O
the	O
activation	O
of	O
different	O
antiviral	O
signaling	O
pathways	O
.	O

These	O
outbreaks	O
and	O
their	O
socio	O
-	O
economic	O
costs	O
underline	O
the	O
necessity	O
for	O
a	O
precise	O
analysis	O
of	O
virus	O
-	O
host	B-COMP
interactions	O
,	O
which	O
would	O
help	O
to	O
understand	O
disease	O
mechanisms	O
and	O
to	O
develop	O
therapeutic	O
interventions	O
.	O

The	O
combination	O
of	O
quantitative	O
measurements	O
and	O
dynamic	O
mathematical	O
modeling	O
has	O
increased	O
our	O
understanding	O
of	O
the	O
within	O
-	O
host	B-COMP
infection	O
dynamics	O
and	O
has	O
led	O
to	O
important	O
insights	O
into	O
viral	O
pathogenesis	O
,	O
transmission	O
,	O
and	O
disease	O
progression	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
cellular	B-COMP
and	O
/	O
or	O
viral	O
cholesterol	O
levels	O
play	O
a	O
role	O
in	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
replication	O
.	O

Accordingly	O
,	O
surface	O
expression	O
of	O
DC	O
-	O
targeted	O
antigens	O
successfully	O
induced	O
cellular	B-COMP
,	O
mucosal	O
,	O
and	O
humoral	O
immunity	O
in	O
mice	O
and	O
could	O
be	O
used	O
as	O
a	O
vaccine	O
.	O

Here	O
,	O
we	O
constructed	O
expression	O
plasmids	O
as	O
well	O
as	O
recombinant	O
PEDV	O
carrying	O
myc	O
-	O
tagged	O
ORF3	O
to	O
assess	O
their	O
expression	O
and	O
subcellular	O
localization	O
in	O
both	O
transfected	O
and	O
infected	O
cells	B-COMP
.	O

In	O
PEDV	O
-	O
infected	O
cells	B-COMP
,	O
ORF3	O
was	O
predominantly	O
localized	O
in	O
the	O
cytoplasm	B-COMP
,	O
partially	O
in	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)	O
and	O
the	O
Golgi	B-COMP
apparatus	I-COMP
(	O
Golgi	B-COMP
).	O

We	O
also	O
demonstrated	O
that	O
both	O
full	O
-	O
length	O
and	O
naturally	O
truncated	O
ORF3	O
proteins	O
could	O
interact	O
with	O
the	O
S	O
protein	O
but	O
with	O
different	O
binding	O
affinity	O
,	O
which	O
correlate	O
with	O
the	O
ability	O
of	O
the	O
protein	O
to	O
regulate	O
virus	O
replication	O
in	O
cell	B-COMP
culture	O
.	O

In	O
this	O
study	O
,	O
two	O
PEDV	O
isolates	O
with	O
similar	O
growth	O
kinetics	O
were	O
successfully	O
propagated	O
in	O
Vero	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Because	O
membrane	B-COMP
fusion	O
is	O
a	O
crucial	O
step	O
in	O
the	O
process	O
by	O
which	O
enveloped	O
viruses	O
invade	O
host	B-COMP
cells	B-COMP
,	O
membrane	B-COMP
fusion	O
inhibitors	O
can	O
be	O
effective	O
drugs	O
against	O
enveloped	O
viruses	O
.	O

Replication	O
of	O
MERS	O
-	O
CoV	O
lacking	O
the	O
genes	O
for	O
4a	O
and	O
4b	O
(	O
MERS	O
-	O
CoV	O
-	O
Δp4	O
),	O
but	O
not	O
MERS	O
-	O
CoV	O
,	O
induced	O
SG	O
accumulation	O
in	O
MERS	O
-	O
CoV	O
-	O
susceptible	O
HeLa	O
/	O
CD26	O
cells	B-COMP
,	O
while	O
replication	O
of	O
both	O
viruses	O
failed	O
to	O
induce	O
SGs	O
in	O
Vero	O
cells	B-COMP
,	O
demonstrating	O
cell	B-COMP
type	I-COMP
-	O
specific	O
differences	O
in	O
MERS	O
-	O
CoV	O
-	O
Δp4	O
-	O
induced	O
SG	O
formation	O
.	O

Differential	O
mRNA	O
expression	O
analysis	O
identified	O
5621	O
genes	O
as	O
deregulated	O
in	O
peritoneal	O
cells	B-COMP
from	O
FIPV	O
infected	O
versus	O
normal	O
cats	O
;	O
956	O
genes	O
showed	O
>	O
2	O
.	O
0	O
Log	O

Immunization	O
of	O
4	O
-	O
week	O
-	O
old	O
SPF	O
chickens	O
with	O
the	O
rNDV	O
expressing	O
S	O
protein	O
elicited	O
IBV	O
-	O
specific	O
neutralizing	O
antibodies	B-COMP
and	O
provided	O
complete	O
protection	O
against	O
virulent	O
IBV	O
and	O
virulent	O
NDV	O
challenges	O
.	O

TITLE	O
:	O
Chimeric	O
camel	O
/	O
human	O
heavy	O
-	O
chain	O
antibodies	B-COMP
protect	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

These	O
strong	O
antibody	B-COMP
responses	O
may	O
be	O
caused	O
by	O
affinity	O
maturation	O
as	O
a	O
result	O
of	O
repeated	O
exposure	O
to	O
the	O
virus	O
or	O
by	O
the	O
fact	O
that	O
dromedaries	O
-	O
apart	O
from	O
conventional	O
antibodies	B-COMP
-	O
have	O
relatively	O
unique	O
,	O
heavy	O
chain	O
-	O
only	O
antibodies	B-COMP
(	O
HCAbs	O
).	O

Virus	O
-	O
specific	O
T	O
cells	B-COMP
are	O
recruited	O
to	O
the	O
CNS	O
,	O
and	O
control	O
viral	O
replication	O
through	O
release	O
of	O
antiviral	O
cytokines	O
and	O
cytolytic	O
activity	O
.	O

The	O
T	O
cell	B-COMP
chemoattractant	O
chemokine	O
CXCL10	O
(	O
interferon	O
-	O
inducible	O
protein	O
10	O
kDa	O
,	O
IP	O
-	O
10	O
)	O
is	O
prominently	O
expressed	O
in	O
both	O
stages	O
of	O
disease	O
,	O
and	O
serves	O
to	O
attract	O
activated	O
T	O
and	O
B	O
lymphocytes	O
expressing	O
CXC	O
chemokine	O
receptor	O
3	O
(	O
CXCR3	O
),	O
the	O
receptor	O
for	O
CXCL10	O
.	O

Functional	O
studies	O
that	O
have	O
blocked	O
expression	O
of	O
either	O
CXCL10	O
or	O
CXCR3	O
illuminate	O
the	O
important	O
role	O
of	O
this	O
signaling	O
pathway	O
in	O
host	B-COMP
defense	O
and	O
neurodegeneration	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
neurologic	O
disease	O
.	O

In	O
Vero	O
cells	B-COMP
,	O
all	O
three	O
viruses	O
replicated	O
efficiently	O
with	O
similar	O
replication	O
kinetics	O
,	O
while	O
wild	O
-	O
type	O
virus	O
induced	O
stronger	O
host	B-COMP
translational	O
suppression	O
and	O
host	B-COMP
mRNA	O
degradation	O
than	O
the	O
mutants	O
,	O
demonstrating	O
that	O
nsp1	O
suppressed	O
host	B-COMP
gene	O
expression	O
in	O
infected	O
cells	B-COMP
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
may	O
serve	O
as	O
a	O
rescue	O
therapy	O
in	O
refractory	O
ARDS	O
but	O
has	O
still	O
not	O
been	O
studied	O
in	O
predominantly	O
leuco	O
-	O
and	O
thrombocytopenic	O
cancer	O
patients	O
.	O

25	O
patients	O
,	O
11	O
of	O
whom	O
underwent	O
haematopoietic	O
stem	O
cell	B-COMP
transplantation	O
(	O
SCT	O
),	O
were	O
analysed	O
.	O

RESULTS	O
:	O
25	O
patients	O
,	O
11	O
of	O
whom	O
underwent	O
haematopoietic	O
stem	O
cell	B-COMP
transplantation	O
(	O
SCT	O
),	O
were	O
analysed	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
diagnostic	O
system	O
for	O
detection	O
of	O
specific	O
antibodies	B-COMP
and	O
antigens	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
the	O
aim	O
was	O
to	O
establish	O
two	O
ELISA	O
systems	O
for	O
detecting	O
antigens	O
and	O
antibodies	B-COMP
against	O
MERS	O
-	O
CoV	O
.	O
Using	O
a	O
recombinant	O
full	O
-	O
length	O
S	O
protein	O
,	O
an	O
indirect	O
ELISA	O
was	O
developed	O
and	O
found	O
to	O
detect	O
MERS	O
-	O
CoV	O
-	O
specific	O
antibodies	B-COMP
in	O
animal	O
sera	B-COMP
and	O
sera	B-COMP
of	O
patient	O
with	O
MERS	O
.	O

Injury	O
characteristics	O
included	O
firearm	O
injuries	O
(	O
relative	O
risk	O
1	O
.	O
93	O
;	O
1	O
.	O
50	O
-	O
2	O
.	O
48	O
)	O
and	O
motor	O
vehicle	O
crashes	O
(	O
relative	O
risk	O
,	O
1	O
.	O
91	O
;	O
1	O
.	O
57	O
-	O
2	O
.	O
31	O
)	O
relative	O
to	O
falls	O
;	O
spine	B-COMP
(	O
relative	O
risk	O
,	O
1	O
.	O
39	O
;	O
1	O
.	O
20	O
-	O
1	O
.	O
60	O
),	O
chest	O
(	O
relative	O
risk	O
,	O
1	O
.	O
36	O
;	O
1	O
.	O
22	O
-	O
1	O
.	O
52	O
),	O
or	O
lower	O
extremity	O
injuries	O
(	O
relative	O
risk	O
,	O
1	O
.	O
26	O
;	O
1	O
.	O
10	O
-	O
1	O
.	O
44	O
);	O
amputations	O
(	O
relative	O
risk	O
,	O
2	O
.	O
10	O
;	O
1	O
.	O
51	O
-	O
2	O
.	O
91	O
);	O
and	O
more	O
severe	O
injury	O
(	O
relative	O
risk	O
,	O
3	O
.	O
69	O
for	O
Injury	O
Severity	O
Score	O
40	O
-	O
75	O
vs	O
1	O
-	O
8	O
;	O
2	O
.	O
50	O
-	O
5	O
.	O
44	O
).	O

This	O
indirect	O
ELISA	O
was	O
compared	O
to	O
indirect	O
immunoinfluscent	O
assay	O
(	O
IFA	O
),	O
and	O
the	O
overall	O
coincidence	O
rate	O
was	O
96	O
.	O
74	O
%	O
based	O
on	O
testing	O
368	O
clinical	O
serum	B-COMP
samples	O
with	O
different	O
PEDV	O
antibody	B-COMP
levels	O
.	O

This	O
established	O
S1	O
indirect	O
ELISA	O
is	O
capable	O
of	O
detecting	O
serum	B-COMP
antibodies	B-COMP
against	O
PEDV	O
,	O
and	O
due	O
to	O
its	O
high	O
sensitivity	O
and	O
specificity	O
,	O
it	O
could	O
be	O
applied	O
for	O
serological	O
evaluation	O
and	O
indirect	O
diagnosis	O
of	O
PEDV	O
infection	O
.	O

The	O
survival	O
days	O
of	O
mice	O
,	O
and	O
the	O
serum	B-COMP
levels	O
of	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
were	O
examined	O
.	O

ABSTRACT	O
:	O
The	O
one	O
-	O
step	O
polymerase	O
chain	O
reaction	O
(	O
one	O
-	O
step	O
PCR	O
)	O
detection	O
assay	O
is	O
an	O
innovative	O
PCR	O
detection	O
method	O
,	O
eliminating	O
nucleic	B-COMP
acid	O
extraction	O
steps	O
,	O
in	O
which	O
samples	O
can	O
be	O
directly	O
added	O
to	O
PCR	O
reagents	O
for	O
testing	O
.	O

For	O
further	O
application	O
,	O
sdAb	O
-	O
Mc37	O
was	O
conjugated	O
with	O
quantum	O
dots	O
to	O
synthesize	O
a	O
nanoprobe	O
for	O
imaging	O
PEDV	O
in	O
vero	O
cells	B-COMP
.	O

The	O
exact	O
origin	O
of	O
MERS	O
-	O
CoV	O
remains	O
unknown	O
,	O
but	O
the	O
transmission	O
pattern	O
and	O
evidence	O
from	O
virological	O
studies	O
suggest	O
that	O
dromedary	O
camels	O
are	O
the	O
major	O
reservoir	O
host	B-COMP
,	O
from	O
which	O
human	O
infections	O
may	O
sporadically	O
occur	O
through	O
the	O
zoonotic	O
transmission	O
.	O

ABSTRACT	O
:	O
Modified	O
vaccinia	O
virus	O
Ankara	O
(	O
MVA	O
)	O
is	O
a	O
replication	O
-	O
deficient	O
poxvirus	O
,	O
attenuated	O
in	O
chick	O
embryo	O
fibroblast	O
primary	O
cells	B-COMP
.	O

Nucleic	B-COMP
acid	O
of	O
at	O
least	O
one	O
respiratory	O
virus	O
was	O
detected	O
in	O
9	O
out	O
of	O
90	O
(	O
10	O
%)	O
surface	O
samples	O
,	O
including	O
:	O
a	O
plastic	O
toy	O
dog	O
in	O
the	O
children	O
'	O
s	O
playground	O
(	O
2	O
/	O
3	O
swabs	O
,	O
67	O
%);	O
hand	O
-	O
carried	O
luggage	O
trays	O
at	O
the	O
security	O
check	O
area	O
(	O
4	O
/	O
8	O
,	O
50	O
%);	O
the	O
buttons	O
of	O
the	O
payment	O
terminal	O
at	O
the	O
pharmacy	O
(	O
1	O
/	O
2	O
,	O
50	O
%);	O
the	O
handrails	O
of	O
stairs	O
(	O
1	O
/	O
7	O
,	O
14	O
%);	O
and	O
the	O
passenger	O
side	O
desk	O
and	O
divider	O
glass	O
at	O
a	O
passport	O
control	O
point	O
(	O
1	O
/	O
3	O
,	O
33	O
%).	O

Detection	O
of	O
pathogen	O
viral	O
nucleic	B-COMP
acids	O
indicates	O
respiratory	O
viral	O
surface	O
contamination	O
at	O
multiple	O
sites	O
associated	O
with	O
high	O
touch	O
rates	O
,	O
and	O
suggests	O
a	O
potential	O
risk	O
in	O
the	O
identified	O
airport	O
sites	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
suggested	O
that	O
PEDV	O
neutralizing	O
antibody	B-COMP
inhibited	O
virus	O
infection	O
by	O
binding	O
to	O
infectious	O
virions	B-COMP
,	O
which	O
could	O
work	O
as	O
a	O
tool	O
to	O
find	O
the	O
receptor	O
-	O
binding	O
domains	O
.	O

Patients	O
with	O
influenza	O
infection	O
were	O
likely	O
to	O
be	O
taken	O
to	O
emergency	O
rooms	O
and	O
have	O
respiratory	O
failure	O
with	O
higher	O
creatinine	O
kinase	O
levels	O
and	O
lower	O
white	O
blood	O
cell	B-COMP
counts	O
.	O

However	O
,	O
the	O
details	O
of	O
how	O
sialic	O
acid	O
and	O
low	O
pH	O
affect	O
virus	O
binding	O
to	O
the	O
host	B-COMP
cell	I-COMP
are	O
not	O
determined	O
,	O
and	O
the	O
functions	O
of	O
the	O
proteases	O
are	O
unknown	O
.	O

TITLE	O
:	O
SARS	O
-	O
Coronavirus	O
Open	O
Reading	O
Frame	O
-	O
3a	O
drives	O
multimodal	O
necrotic	O
cell	B-COMP
death	O
.	O

Pulmonary	O
vascular	O
endothelial	O
cells	B-COMP
(	O
PVECs	O
)	O
function	O
as	O
an	O
important	O
pro	O
-	O
inflammatory	O
source	O
in	O
ARDS	O
,	O
suggesting	O
that	O
modulation	O
of	O
inflammatory	O
events	O
at	O
the	O
endothelial	O
level	O
may	O
have	O
a	O
therapeutic	O
benefit	O
.	O

TITLE	O
:	O
Infectious	O
Bronchitis	O
Virus	O
Nonstructural	O
Protein	O
4	O
Alone	O
Induces	O
Membrane	B-COMP
Pairing	O
.	O

This	O
has	O
been	O
a	O
perennial	O
challenge	O
as	O
type	O
I	O
FCoV	O
strains	O
do	O
not	O
easily	O
adapt	O
to	O
cell	B-COMP
culture	O
.	O

TITLE	O
:	O
Interplay	O
between	O
the	O
Poly	O
(	O
A	O
)	O
Tail	O
,	O
Poly	O
(	O
A	O
)-	O
Binding	O
Protein	O
,	O
and	O
Coronavirus	O
Nucleocapsid	B-COMP
Protein	O
Regulates	O
Gene	O
Expression	O
of	O
Coronavirus	O
and	O
the	O
Host	B-COMP
Cell	I-COMP
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
can	O
improve	O
oxygenation	O
and	O
remove	O
carbon	O
dioxide	O
by	O
extracorporeal	O
circuit	O
,	O
and	O
can	O
partially	O
or	O
completely	O
take	O
over	O
cardiopulmonary	O
function	O
.	O

Current	O
ongoing	O
trials	O
include	O
the	O
use	O
of	O
mesenchymal	O
stem	O
cells	B-COMP
,	O
vitamin	O
C	O
,	O
re	O
-	O
evaluation	O
of	O
neuromuscular	O
blockade	O
,	O
and	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
.	O

Four	O
cases	O
of	O
acute	O
myelogenous	O
leukemia	O
with	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
treated	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
while	O
undergoing	O
induction	O
chemotherapy	O
were	O
identified	O
.	O

Currently	O
,	O
the	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
patients	O
with	O
hematologic	O
malignancies	O
who	O
develop	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
remains	O
controversial	O
.	O

No	O
cross	O
-	O
reaction	O
was	O
detected	O
with	O
antibodies	B-COMP
against	O
avian	O
influenza	O
virus	O
subtypes	O
(	O
H5	O
,	O
H7	O
,	O
and	O
H9	O
),	O
Newcastle	O
disease	O
virus	O
,	O
Marek	O
'	O
s	O
disease	O
virus	O
,	O
infectious	O
bursal	O
disease	O
virus	O
,	O
and	O
chicken	O
anemia	O
virus	O
.	O

ABSTRACT	O
:	O
Influenza	O
viruses	O
and	O
rhinoviruses	O
are	O
responsible	O
for	O
a	O
large	O
number	O
of	O
acute	O
respiratory	O
viral	O
infections	O
in	O
human	O
populations	O
and	O
are	O
detected	O
as	O
copathogens	O
within	O
hosts	B-COMP
.	O

The	O
following	O
data	O
were	O
collected	O
:	O
demographic	O
data	O
,	O
primary	O
diagnosis	O
,	O
ventilation	O
settings	O
,	O
and	O
use	O
of	O
supportive	O
treatment	O
,	O
in	O
addition	O
to	O
mechanical	O
ventilation	O
(	O
inhaled	O
nitric	O
oxide	O
,	O
surfactant	O
,	O
corticosteroids	O
,	O
prone	O
positioning	O
,	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
).	O

ABSTRACT	O
:	O
A	O
serological	O
method	O
to	O
simultaneously	O
detect	O
antibodies	B-COMP
against	O
infectious	O
laryngotracheitis	O
virus	O
(	O
ILTV	O
)	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
imperative	O
for	O
the	O
differential	O
diagnosis	O
and	O
evaluation	O
of	O
antibodies	B-COMP
titers	O
after	O
vaccination	O
.	O

The	O
simultaneous	O
quantification	O
of	O
ILTV	O
and	O
IBV	O
antibodies	B-COMP
were	O
achieved	O
through	O
the	O
interrogation	O
of	O
microspheres	O
by	O
Luminex	O
200	O
detection	O
system	O
.	O
.	O

In	O
both	O
preventive	O
and	O
therapeutic	O
approaches	O
,	O
TA	O
attenuated	O
LPS	O
-	O
induced	O
histopathological	O
alterations	O
,	O
lipid	O
peroxidation	O
,	O
lung	O
permeability	O
,	O
infiltration	O
of	O
inflammatory	O
cells	B-COMP
,	O
and	O
the	O
expression	O
of	O
proinflammatory	O
mediators	O
.	O

Furthermore	O
,	O
cells	B-COMP
treated	O
with	O
the	O
inhibitors	O
of	O
ERK1	O
/	O
2	O
(	O
PD98059	O
)	O
and	O
p38	O
(	O
SB203580	O
)	O
mitigated	O
the	O
expression	O
of	O
cytokines	O
induced	O
by	O
LPS	O
,	O
thus	O
suggesting	O
that	O
ERK1	O
/	O
2	O
and	O
p38	O
activity	O
are	O
required	O
for	O
the	O
inflammatory	O
response	O
.	O

And	O
the	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
scavenger	O
,	O
pyrrolidinedithiocarbamic	O
(	O
PDTC	O
),	O
redistributed	O
AIF	O
in	O
the	O
mitochondria	B-COMP
and	O
nucleus	B-COMP
in	O
TGEV	O
-	O
infected	O
cells	B-COMP
.	O

TITLE	O
:	O
Cellular	B-COMP
localisation	O
of	O
the	O
proteins	O
of	O
region	O
3	O
of	O
feline	O
enteric	O
coronavirus	O
.	O

All	O
three	O
ORFs	O
were	O
expressed	O
with	O
C	O
-	O
terminal	O
eGFP	O
and	O
3xFLAG	O
tags	O
in	O
different	O
cell	B-COMP
lines	O
and	O
their	O
localisation	O
was	O
determined	O
.	O

In	O
addition	O
,	O
when	O
fcwf	O
-	O
4	O
cells	B-COMP
were	O
adsorbed	O
by	O
FIPV	O
and	O
then	O
stimulated	O
with	O
Poly	O
(	O
I	O
:	O
C	O
),	O
type	O
II	O
FCoV	O
infection	O
inhibited	O
Poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
IFNβ	O
gene	O
expression	O
.	O

TITLE	O
:	O
Detection	O
of	O
neutralizing	O
antibody	B-COMP
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
subclinically	O
infected	O
finishing	O
pigs	O
.	O

Blood	O
samples	O
were	O
centrifuged	O
to	O
obtain	O
sera	B-COMP
.	O

This	O
review	O
will	O
discuss	O
viral	O
vector	O
and	O
nucleic	B-COMP
acid	O
-	O
based	O
vaccines	O
(	O
DNA	O
and	O
mRNA	O
vaccines	O
)	O
as	O
new	O
approaches	O
that	O
might	O
be	O
able	O
to	O
tackle	O
these	O
challenges	O
to	O
global	O
health	O
.	O

We	O
examined	O
the	O
progression	O
of	O
these	O
two	O
types	O
of	O
hepatitis	O
by	O
measuring	O
hepatic	O
transaminase	O
levels	O
in	O
the	O
serum	B-COMP
and	O
inflammatory	O
cells	B-COMP
in	O
the	O
liver	O
,	O
liver	O
histological	O
studies	O
.	O

In	O
early	O
2016	O
,	O
sera	B-COMP
and	O
standardized	O
interviews	O
were	O
obtained	O
from	O
MERS	O
-	O
CoV	O
cases	O
and	O
their	O
contacts	O
.	O

Our	O
study	O
presents	O
clear	O
evidence	O
for	O
the	O
biological	O
importance	O
of	O
the	O
NMD	O
pathway	O
in	O
controlling	O
the	O
stability	O
of	O
mRNAs	O
and	O
the	O
efficiency	O
of	O
replication	O
of	O
a	O
cytoplasmic	B-COMP
RNA	O
virus	O
.	O

Cells	B-COMP
from	O
cotton	O
rat	O
,	O
goat	O
,	O
and	O
sheep	O
provided	O
control	O
scenarios	O
that	O
represent	O
host	B-COMP
systems	O
in	O
which	O
SARS	O
-	O
CoV	O
is	O
neither	O
endemic	O
nor	O
epidemic	O
.	O

Through	O
surveillance	O
in	O
Pakistan	O
,	O
nasal	O
(	O
n	O
=	O
776	O
)	O
and	O
serum	B-COMP
(	O
n	O
=	O
1050	O
)	O
samples	O
were	O
collected	O
from	O
camels	O
between	O
November	O
2015	O
and	O
February	O
2018	O
.	O

In	O
our	O
model	O
,	O
the	O
use	O
of	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
compared	O
with	O
lung	O
protective	O
ventilation	O
resulted	O
in	O
a	O
gain	O
of	O
5	O
.	O
2	O
life	O
years	O
and	O
4	O
.	O
05	O
quality	O
-	O
adjusted	O
life	O
years	O
,	O
at	O
an	O
additional	O
lifetime	O
cost	O
of	O
$	O
145	O
,	O
697	O
Canadian	O
dollars	O
.	O

Non	O
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
are	O
not	O
translated	O
into	O
proteins	O
and	O
play	O
an	O
important	O
role	O
in	O
many	O
biological	O
and	O
pathological	O
processes	O
such	O
as	O
inflammation	O
,	O
viral	O
infection	O
,	O
and	O
mitochondrial	B-COMP
damage	O
.	O

Progressive	O
hypoxemia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
developed	O
and	O
he	O
was	O
transferred	O
to	O
our	O
institution	O
for	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
).	O

As	O
subepithelial	O
myofibroblasts	O
secrete	O
extracellular	B-COMP
matrix	I-COMP
and	O
growth	O
factors	O
contributing	O
to	O
the	O
attachment	O
,	O
proliferation	O
and	O
differentiation	O
of	O
epithelial	O
cells	B-COMP
,	O
co	O
-	O
cultures	O
of	O
primary	O
porcine	O
enterocytes	O
(	O
ileocytes	O
and	O
colonocytes	O
)	O
with	O
myofibroblasts	O
were	O
developed	O
and	O
evaluated	O
for	O
their	O
susceptibility	O
to	O
enteric	O
viruses	O
.	O

TITLE	O
:	O
Early	O
initiation	O
of	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
a	O
mechanically	O
ventilated	O
patient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Our	O
results	O
show	O
that	O
NF	O
-	O
κB	O
was	O
activated	O
in	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	B-COMP
and	O
intestinal	O
epithelial	O
cell	B-COMP
lines	O
J2	O
(	O
IPEC	O
-	O
J2	O
)	O
cells	B-COMP
infected	O
with	O
TGEV	O
,	O
which	O
is	O
consistent	O
with	O
the	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Treatment	O
of	O
TGEV	O
-	O
infected	O
ST	O
cells	B-COMP
and	O
IPEC	O
-	O
J2	O
cells	B-COMP
with	O
the	O
NF	O
-	O
κB	O
-	O
specific	O
inhibitor	O
caused	O
the	O
down	O
-	O
regulation	O
of	O
pro	O
-	O
inflammatory	O
cytokine	O
expression	O
,	O
but	O
did	O
not	O
significantly	O
affect	O
TGEV	O
replication	O
.	O

Herein	O
,	O
we	O
show	O
that	O
distinct	O
IAV	O
strains	O
reduced	O
the	O
functions	O
of	O
the	O
epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
and	O
the	O
cystic	O
fibrosis	O
transmembrane	B-COMP
regulator	O
(	O
CFTR	O
)	O
in	O
murine	O
respiratory	O
and	O
alveolar	O
epithelia	O
in	O
vivo	O
,	O
as	O
assessed	O
by	O
measurements	O
of	O
nasal	O
potential	O
differences	O
and	O
single	O
-	O
cell	B-COMP
electrophysiology	O
.	O

On	O
ICU	O
day	O
14	O
,	O
a	O
vancomycin	O
trough	O
serum	B-COMP
concentration	O
of	O
17	O
mg	O
/	O
L	O
was	O
obtained	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
patient	O
with	O
AIDS	O
successfully	O
treated	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
Chinese	O
virulent	O
genotype	O
GIIb	O
PEDV	O
strain	O
,	O
CH	O
/	O
HNPJ	O
/	O
2017	O
,	O
was	O
serially	O
propagated	O
in	O
Vero	O
cells	B-COMP
for	O
up	O
to	O
90	O
passages	O
.	O

Intestinal	O
epithelial	O
cells	B-COMP
are	O
the	O
primary	O
target	O
cells	B-COMP
of	O
TGEV	O
.	O

Finally	O
,	O
we	O
used	O
this	O
method	O
to	O
refine	O
carbohydrates	O
of	O
the	O
human	O
coronavirus	O
NL63	O
spike	O
glycoprotein	O
and	O
of	O
an	O
HIV	O
envelope	B-COMP
glycoprotein	O
,	O
demonstrating	O
its	O
usefulness	O
for	O
cryoEM	O
refinement	O
.	O

Two	O
recombinant	O
infectious	O
bronchitis	O
viruses	O
(	O
rIBVs	O
)	O
have	O
been	O
generated	O
;	O
the	O
immunogenic	O
S1	O
subunit	O
is	O
derived	O
from	O
the	O
IBV	O
vaccine	O
strain	O
,	O
H120	O
,	O
or	O
the	O
virulent	O
field	O
strain	O
,	O
QX	O
,	O
within	O
the	O
genetic	O
background	O
of	O
Beau	O
-	O
R	O
.	O
The	O
rIBVs	O
BeauR	O
-	O
H120	O
(	O
S1	O
)	O
and	O
BeauR	O
-	O
QX	O
(	O
S1	O
)	O
are	O
capable	O
of	O
replicating	O
in	O
primary	O
chicken	O
kidney	O
cell	B-COMP
cultures	O
and	O
in	O
Vero	O
cells	B-COMP
.	O

Interestingly	O
,	O
high	O
titers	O
of	O
virus	O
-	O
neutralizing	O
antibodies	B-COMP
in	O
sera	B-COMP
were	O
detected	O
at	O
21	O
DPI	O
.	O

In	O
this	O
investigation	O
,	O
a	O
monoclonal	O
antibodies	B-COMP
(	O
MAbs	O
)-	O
based	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detecting	O
antibodies	B-COMP
against	O
PEDV	O
was	O
developed	O
and	O
validated	O
.	O

TITLE	O
:	O
Incidence	O
,	O
significance	O
,	O
and	O
persistence	O
of	O
human	O
coronavirus	O
infection	O
in	O
hematopoietic	O
stem	O
cell	B-COMP
transplant	O
recipients	O
.	O

We	O
also	O
reviewed	O
new	O
treatments	O
(	O
modes	O
of	O
mechanical	O
ventilation	O
,	O
neuromuscular	O
blocker	O
use	O
,	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
)	O
that	O
could	O
be	O
considered	O
in	O
weaning	O
ARDS	O
patients	O
from	O
MV	O
.	O

The	O
increased	O
concentration	O
of	O
IL	O
-	O
1β	O
in	O
the	O
immunized	O
animals	O
directly	O
correlated	O
with	O
the	O
activity	O
of	O
macrophages	O
and	O
stimulated	O
B	O
cells	B-COMP
,	O
which	O
produce	O
this	O
cytokine	O
when	O
activated	O
.	O

PEDV	O
could	O
infect	O
various	O
host	B-COMP
cells	B-COMP
including	O
Vero	O
,	O
Vero	O
-	O
E6	O
and	O
Marc	O
-	O
145	O
and	O
cause	O
obvious	O
cytopathic	O
effects	O
,	O
including	O
roundup	O
,	O
cell	B-COMP
fusion	O
,	O
cell	B-COMP
membrane	I-COMP
vacuolation	O
,	O
syncytium	O
formation	O
and	O
cause	O
apparent	O
apoptosis	O
.	O

TITLE	O
:	O
Deletion	O
of	O
both	O
the	O
Tyrosine	O
-	O
Based	O
Endocytosis	O
Signal	O
and	O
the	O
Endoplasmic	B-COMP
Reticulum	I-COMP
Retrieval	O
Signal	O
in	O
the	O
Cytoplasmic	B-COMP
Tail	O
of	O
Spike	O
Protein	O
Attenuates	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
in	O
Pigs	O
.	O

The	O
PEDV	O
spike	O
(	O
S	O
)	O
protein	O
contains	O
two	O
intracellular	B-COMP
sorting	O
motifs	O
,	O
YxxΦ	O
(	O
tyrosine	O
-	O
based	O
motif	O
YEVF	O
or	O
YEAF	O
)	O
and	O
KVHVQ	O
at	O
the	O
cytoplasmic	B-COMP
tail	O
,	O
yet	O
their	O
functions	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

By	O
transiently	O
expressing	O
PEDV	O
S	O
proteins	O
with	O
mutations	O
in	O
the	O
motifs	O
,	O
we	O
confirmed	O
that	O
the	O
motif	O
KVHVQ	O
is	O
involved	O
in	O
retention	O
of	O
the	O
S	O
proteins	O
in	O
the	O
endoplasmic	B-COMP
reticulum	I-COMP
(	O
ER	O
)-	O
Golgi	B-COMP
intermediate	O
compartment	O
(	O
ERGIC	B-COMP
).	O

ATD	O
is	O
an	O
autosomal	B-COMP
recessive	O
genetic	O
disorder	O
.	O

The	O
wet	O
/	O
dry	O
ratios	O
of	O
lung	O
tissues	O
were	O
measured	O
,	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
was	O
collected	O
to	O
test	O
protein	O
concentrations	O
,	O
total	O
cell	B-COMP
/	O
macrophage	O
numbers	O
,	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
levels	O
.	O

We	O
found	O
that	O
an	O
intact	O
S1	O
/	O
S2	O
site	O
was	O
only	O
required	O
for	O
efficient	O
entry	O
into	O
cells	B-COMP
expressing	O
endogenous	O
TMPRSS2	O
.	O

The	O
patient	O
rapidly	O
developed	O
a	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
requiring	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
for	O
nearly	O
2	O
months	O
.	O

The	O
differences	O
of	O
demographic	O
indexes	O
(	O
gender	O
,	O
age	O
),	O
time	O
of	O
admission	O
,	O
type	O
of	O
injury	O
,	O
atrial	O
fibrillation	O
,	O
trachea	O
cannula	O
,	O
multiple	O
injury	O
,	O
open	O
injury	O
,	O
shock	O
,	O
surgery	O
,	O
blood	O
transfusion	O
,	O
central	O
venous	O
indwelling	O
catheter	O
,	O
infection	O
,	O
and	O
blood	O
routine	O
indexes	O
[	O
white	O
blood	O
cell	B-COMP
count	O
(	O
WBC	O
),	O
red	O
blood	O
cell	B-COMP
count	O
(	O
RBC	O
),	O
platelet	O
count	O
(	O
PLT	O
),	O
plateletcytocrit	O
(	O
PCT	O
),	O
hematocrit	O
(	O
Hct	O
)],	O
biochemical	O
indexes	O
[	O
total	O
bilirubin	O
(	O
TBil	O
),	O
albumin	O
(	O
Alb	O
),	O
serum	B-COMP
creatinine	O
(	O
SCr	O
),	O
blood	O
sodium	O
,	O
blood	O
calcium	O
,	O
blood	O
potassium	O
,	O
blood	O
glucose	O
],	O
arterial	O
blood	O
gas	O
analysis	O
indexes	O
[	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO	O
A	O
total	O
of	O
303	O
patients	O
with	O
severe	O
trauma	O
,	O
including	O
223	O
males	O
and	O
80	O
females	O
,	O
were	O
enrolled	O
.	O

TITLE	O
:	O
Initiation	O
of	O
LPS	O
-	O
induced	O
pulmonary	O
dysfunction	O
and	O
its	O
recovery	O
occur	O
independent	O
of	O
T	O
cells	B-COMP
.	O

This	O
response	O
is	O
not	O
altered	O
by	O
the	O
lack	O
of	O
T	O
lymphocytes	O
suggesting	O
that	O
T	O
cells	B-COMP
play	O
only	O
a	O
minor	O
role	O
for	O
the	O
initiation	O
,	O
propagation	O
or	O
recovery	O
of	O
LPS	O
-	O
induced	O
lung	O
dysfunctions	O
or	O
function	O
of	O
T	O
lymphocytes	O
can	O
be	O
compensated	O
by	O
other	O
immune	O
cells	B-COMP
,	O
such	O
as	O
alveolar	O
macrophages	O
.	O

The	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
of	O
our	O
cell	B-COMP
-	O
based	O
assay	O
was	O
<	O
10	O
%.	O

Several	O
of	O
the	O
investigated	O
compounds	O
inhibited	O
various	O
PKs	B-COMP
with	O
IC	O

Our	O
previous	O
studies	O
showed	O
that	O
TGEV	O
infection	O
activated	O
p53	O
signaling	O
to	O
induce	O
host	B-COMP
cell	I-COMP
apoptosis	O
,	O
which	O
might	O
influence	O
virus	O
replication	O
.	O

And	O
viral	O
titers	O
were	O
observably	O
enhanced	O
in	O
p53	O
-/-	O
PK	O
-	O
15	O
cells	B-COMP
.	O

Stem	O
cells	B-COMP
have	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunomodulatory	O
properties	O
through	O
local	O
paracrine	O
mechanisms	O
.	O

There	O
is	O
no	O
specific	O
treatment	O
for	O
the	O
MERS	O
-	O
CoV	O
till	O
now	O
,	O
but	O
drugs	O
are	O
in	O
pipeline	O
which	O
bind	O
with	O
the	O
spike	O
glycoprotein	O
and	O
inhibit	O
its	O
entrance	O
host	B-COMP
cells	B-COMP
.	O

TITLE	O
:	O
Impact	O
of	O
cannula	O
design	O
on	O
packed	O
red	O
blood	O
cell	B-COMP
transfusions	O
:	O
technical	O
advancement	O
to	O
improve	O
outcomes	O
in	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

Total	O
nucleic	B-COMP
acid	O
was	O
extracted	O
using	O
Pure	O
Link	O
viral	O
RNA	O
/	O
DNA	O
mini	O
kit	O
(	O
Invitrogen	O
),	O
and	O
multiplex	O
RT	O
-	O
PCR	O
assays	O
were	O
performed	O
.	O

However	O
,	O
a	O
significantly	O
increased	O
level	O
of	O
protection	O
was	O
seen	O
in	O
the	O
lower	O
percentage	O
of	O
hens	O
with	O
free	O
yolk	B-COMP
in	O
the	O
abdomen	O
and	O
/	O
or	O
peritonitis	O
post	O
challenge	O
with	O
IBV	O
variants	O
,	O
D388	O
,	O
Q1	O
and	O
Var	O
2	O
not	O
included	O
in	O
the	O
vaccination	O
programme	O
.	O

Recently	O
,	O
biallelic	O
mutations	O
of	O
the	O
EIF2AK4	O
gene	O
have	O
been	O
discovered	O
as	O
a	O
cause	O
for	O
an	O
autosomal	B-COMP
recessive	O
form	O
of	O
PVOD	O
in	O
humans	O
.	O

MERS	O
-	O
CoV	O
viral	B-COMP
nucleocapsid	I-COMP
was	O
mainly	O
detected	O
in	O
upper	O
respiratory	O
tract	O
sites	O
on	O
days	O
2	O
and	O
4	O
p	O
.	O
i	O
.	O

Obtained	O
data	O
confirm	O
the	O
role	O
of	O
DPP4	O
for	O
MERS	O
-	O
CoV	O
entry	O
in	O
respiratory	O
epithelial	O
cells	B-COMP
of	O
llamas	O
.	O

Notably	O
,	O
several	O
nasal	O
epithelial	O
cells	B-COMP
in	O
pigs	O
were	O
found	O
to	O
express	O
viral	O
antigen	O
but	O
not	O
DPP4	O
,	O
suggesting	O
the	O
possible	O
existence	O
of	O
other	O
molecule	O
/	O
s	O
facilitating	O
virus	O
entry	O
or	O
down	O
regulation	O
of	O
DPP4	O
upon	O
infection	O
.	O

The	O
average	O
particle	O
size	O
of	O
the	O
gold	O
nanoparticle	O
-	O
serum	B-COMP
mixture	O
,	O
measured	O
by	O
dynamic	O
light	O
scattering	O
,	O
corresponds	O
positively	O
to	O
the	O
immune	O
status	O
and	O
activity	O
of	O
the	O
subject	O
.	O

The	O
in	O
vitro	O
results	O
indicated	O
that	O
LPS	O
time	O
-	O
dependently	O
enhanced	O
TRIM8	O
expression	O
in	O
lung	O
epithelial	O
cells	B-COMP
.	O

The	O
broad	O
cellular	B-COMP
tropism	O
of	O
MERS	O
-	O
CoV	O
should	O
prompt	O
further	O
exploration	O
of	O
host	B-COMP
diversity	O
of	O
related	O
viruses	O
to	O
identify	O
its	O
ancestral	O
origin	O
.	O

While	O
TAT	O
peptides	O
facilitate	O
active	O
endocytosis	O
of	O
the	O
carriers	O
,	O
we	O
observed	O
that	O
these	O
peptides	O
did	O
not	O
promote	O
endosomal	O
escape	O
or	O
enhanced	O
intracellular	B-COMP
availability	O
of	O
doxorubicin	O
.	O

This	O
study	O
examined	O
the	O
combined	O
use	O
of	O
an	O
ELISA	O
and	O
Western	O
blot	O
(	O
WB	O
)	O
to	O
detect	O
antibodies	B-COMP
against	O
the	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
)	O
of	O
IBV	O
.	O

WB	O
confirmed	O
all	O
false	O
negative	O
sera	B-COMP
in	O
ELISA	O
-	O
rN	O
or	O
IDEXX	O
test	O
as	O
truly	O
positive	O
.	O

A	O
total	O
of	O
389	O
serum	B-COMP
samples	O
from	O
chickens	O
were	O
used	O
to	O
develop	O
and	O
evaluate	O
the	O
ELISA	O
-	O
rN	O
test	O
.	O

To	O
standardize	O
the	O
indirect	O
ELISA	O
development	O
,	O
serum	B-COMP
dilutions	O
(	O
1	O
:	O
100	O
,	O
1	O
:	O
200	O
and	O
1	O
:	O
400	O
)	O
and	O
different	O
concentrations	O
of	O
purified	O
rN	O
antigen	O
(	O
50	O
,	O
100	O
and	O
200	O
ng	O
/	O
well	O
)	O
were	O
tested	O
.	O

Sera	B-COMP
that	O
tested	O
negative	O
in	O
the	O
ELISA	O
-	O
rN	O
and	O
positive	O
in	O
the	O
commercial	O
test	O
also	O
reacted	O
with	O
the	O
rN	O
protein	O
in	O
Western	O
blot	O
.	O

ABSTRACT	O
:	O
Host	B-COMP
factors	O
render	O
cells	B-COMP
susceptible	O
to	O
viral	O
infection	O
.	O

They	O
also	O
facilitate	O
viral	O
egress	O
from	O
infected	O
cells	B-COMP
.	O

ABSTRACT	O
:	O
Several	O
viruses	O
cause	O
pulmonary	O
infections	O
due	O
to	O
their	O
shared	O
tropism	O
with	O
cells	B-COMP
of	O
the	O
respiratory	O
tract	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
summarized	O
some	O
of	O
the	O
recent	O
advancements	O
made	O
in	O
the	O
area	O
of	O
nucleic	B-COMP
acid	O
based	O
therapeutics	O
and	O
highlighted	O
the	O
emerging	O
roles	O
of	O
nucleic	B-COMP
acids	O
in	O
the	O
management	O
of	O
some	O
of	O
the	O
severe	O
respiratory	O
viral	O
infections	O
.	O

The	O
TGEV	O
membrane	B-COMP
(	O
M	O
)	O
protein	O
is	O
a	O
decisive	O
protein	O
for	O
the	O
proliferation	O
of	O
viral	O
proteins	O
,	O
and	O
is	O
associated	O
with	O
virus	O
assembly	O
and	O
budding	O
.	O

To	O
identify	O
the	O
cellular	B-COMP
proteins	O
that	O
interact	O
with	O
the	O
TGEV	O
M	O
protein	O
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
employed	O
,	O
and	O
seven	O
cellular	B-COMP
proteins	O
were	O
identified	O
M	O
-	O
binding	O
partners	O
.	O

Additionally	O
,	O
confocal	O
microscopy	O
revealed	O
that	O
EIF4A2	O
and	O
M	O
were	O
colocalized	O
in	O
the	O
cytoplasm	B-COMP
.	O

TITLE	O
:	O
A	O
24	O
-	O
hour	O
perioperative	O
case	O
study	O
on	O
argatroban	O
use	O
for	O
left	O
ventricle	O
assist	O
device	O
insertion	O
during	O
cardiopulmonary	O
bypass	O
and	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
.	O

The	O
methods	O
adopted	O
in	O
monitoring	O
studies	O
of	O
CoVs	O
in	O
different	O
avian	O
species	O
are	O
mainly	O
based	O
on	O
detection	O
of	O
conservative	O
regions	O
within	O
the	O
viral	O
replicase	O
,	O
nucleocapsid	B-COMP
genes	O
,	O
and	O
3	O
'	O
UTR	O
or	O
5	O
'	O
UTR	O
.	O

In	O
Vero	O
and	O
IPEC	O
-	O
DQ	O
cells	B-COMP
,	O
certain	O
concentrations	O
of	O
BM	O
,	O
PGM	O
,	O
bile	O
and	O
bile	O
acids	O
increased	O
significantly	O
the	O
infectivity	O
of	O
icPC22A	O
but	O
had	O
no	O
or	O
negative	O
effects	O
on	O
icPC22A	O
-	O
S1Δ197	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
7	O
,	O
14	O
,	O
21	O
days	O
post	O
infection	O
(	O
dpi	O
)	O
and	O
subjected	O
for	O
the	O
analyses	O
of	O
serum	B-COMP
antibody	B-COMP
production	O
,	O
T	O
cell	B-COMP
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	B-COMP
frequencies	O
,	O
NK	O
cytotoxicity	O
and	O
serum	B-COMP
cytokine	O
levels	O
.	O

PEDV	O
-	O
infected	O
and	O
control	O
pigs	O
had	O
low	O
,	O
but	O
detectable	O
NK	O
cell	B-COMP
activities	O
at	O
14	O
and	O
21	O
dpi	O
,	O
however	O
,	O
NK	O
cell	B-COMP
activities	O
were	O
barely	O
detectable	O
at	O
7	O
dpi	O
whether	O
the	O
pigs	O
were	O
infected	O
or	O
not	O
.	O

Serum	B-COMP
IL	O
-	O
10	O
levels	O
were	O
induced	O
drastically	O
in	O
orally	O
infected	O
pigs	O
at	O
7	O
dpi	O
and	O
then	O
gradually	O
declined	O
.	O

He	O
was	O
confirmed	O
to	O
have	O
spotted	O
fever	O
rickettsial	O
infection	O
with	O
rising	O
titre	O
of	O
indirect	O
immunofluorescence	O
antibodies	B-COMP
to	O
Ricketssia	O
conorii	O
and	O
made	O
a	O
complete	O
recovery	O
with	O
appropriate	O
antibiotic	O
therapy	O
and	O
supportive	O
care	O
.	O

Although	O
the	O
structure	O
of	O
the	O
sialoglycoconjugate	O
recognized	O
by	O
TER	B-COMP
-	O
119	O
was	O
not	O
chemically	O
demonstrated	O
,	O
its	O
selective	O
binding	O
to	O
virolectins	O
suggests	O
that	O
it	O
may	O
be	O
comprised	O
of	O
a	O
7	O
,	O
9	O
-	O
di	O
-	O
O	O
-	O
acetyl	O
form	O
of	O
sialic	O
acid	O
.	O

By	O
using	O
chemical	O
inhibitors	O
,	O
RNA	O
interference	O
,	O
and	O
dominant	O
negative	O
mutants	O
,	O
we	O
observed	O
that	O
lipid	B-COMP
rafts	I-COMP
and	O
low	O
pH	O
was	O
indeed	O
required	O
for	O
virus	O
entry	O
;	O
IBV	O
mainly	O
utilized	O
the	O
clathrin	O
mediated	O
endocytosis	O
(	O
CME	O
)	O
for	O
entry	O
;	O
GTPase	O
dynamin	O
1	O
was	O
involved	O
in	O
virus	O
containing	O
vesicle	B-COMP
scission	O
;	O
and	O
the	O
penetration	O
of	O
IBV	O
into	O
cells	B-COMP
led	O
to	O
active	O
cytoskeleton	B-COMP
rearrangement	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
describe	O
recent	O
evidence	O
regarding	O
the	O
use	O
of	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
as	O
salvage	O
therapy	O
for	O
severe	O
cardiac	O
or	O
respiratory	O
failure	O
in	O
patients	O
with	O
trauma	O
.	O

ABSTRACT	O
:	O
The	O
protein	O
kinase	O
RIPK1	O
plays	O
a	O
crucial	O
role	O
at	O
the	O
crossroad	O
of	O
stress	O
-	O
induced	O
signaling	O
pathways	O
that	O
affects	O
cell	B-COMP
'	O
s	O
decision	O
to	O
live	O
or	O
die	O
.	O

Taupapillomavirus	O
were	O
the	O
only	O
mammalian	O
viral	O
nucleic	B-COMP
acids	O
detected	O
in	O
two	O
affected	O
dogs	O
,	O
while	O
a	O
third	O
dog	O
was	O
coinfected	O
with	O
low	O
levels	O
of	O
canine	O
parainfluenza	O
5	O
.	O

Compared	O
with	O
the	O
P120	O
group	O
,	O
P3	O
-	O
and	O
P100C4	O
-	O
inoculated	O
pigs	O
had	O
higher	O
serum	B-COMP
PEDV	O
-	O
specific	O
IgG	O
and	O
viral	O
neutralizing	O
(	O
VN	O
)	O
antibody	B-COMP
(	O
Ab	O
)	O
titers	O
at	O
14	O
dpi	O
.	O

P100C4	O
induced	O
higher	O
PEDV	O
-	O
specific	O
antibody	B-COMP
responses	O
than	O
P120	O
post	O
inoculation	O
resulting	O
in	O
a	O
greater	O
anamnestic	O
response	O
post	O
challenge	O
.	O

Point	O
mutations	O
observed	O
in	O
the	O
receptor	O
-	O
binding	O
domain	O
and	O
hypervariable	O
region	O
of	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
protein	O
likely	O
have	O
an	O
effect	O
on	O
these	O
differences	O
in	O
biological	O
characteristics	O
,	O
although	O
the	O
influence	O
of	O
other	O
factors	O
-	O
such	O
as	O
host	B-COMP
innate	O
-	O
immune	O
responses	O
and	O
changes	O
in	O
genomic	O
regions	O
beyond	O
the	O
S1	O
protein	O
-	O
might	O
also	O
be	O
responsible	O
for	O
such	O
changes	O
.	O

Both	O
patients	O
were	O
diagnosed	O
with	O
AE	O
-	O
IPF	O
accompanying	O
acute	O
pertussis	O
infection	O
based	O
on	O
chest	O
computed	O
tomography	O
and	O
serum	B-COMP
pertussis	O
toxin	O
antibody	B-COMP
>	O
100	O
EU	O
/	O
mL	O
.	O
Both	O
patients	O
were	O
treated	O
with	O
macrolide	O
antibiotics	O
and	O
systemic	O
corticosteroids	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
relevant	O
features	O
of	O
the	O
MERS	O
-	O
CoV	O
S	O
-	O
protein	O
RBD	O
,	O
summarize	O
recent	O
advances	O
in	O
the	O
development	O
of	O
MERS	O
-	O
CoV	O
RBD	O
-	O
based	O
vaccines	O
and	O
therapeutic	O
antibodies	B-COMP
,	O
and	O
illustrate	O
potential	O
challenges	O
and	O
strategies	O
to	O
further	O
improve	O
their	O
efficacy	O
.	O

Together	O
with	O
the	O
spike	O
(	O
S	O
)	O
protein	O
,	O
the	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
is	O
one	O
of	O
the	O
immunodominant	O
regions	O
among	O
coronaviruses	O
.	O

The	O
optimal	O
mAb	O
4A11	O
was	O
coated	O
on	O
NC	O
membrane	B-COMP
as	O
the	O
capturing	O
reagent	O
and	O
the	O
mAb	O
A11H7	O
was	O
coupled	O
to	O
gold	O
nanoparticles	O
(	O
AuNPs	O
)	O
as	O
detection	O
reagent	O
for	O
the	O
new	O
ICA	O
.	O

ABSTRACT	O
:	O
Vascular	O
endothelial	O
cadherin	O
(	O
VE	O
-	O
cadherin	O
)	O
is	O
a	O
membrane	B-COMP
protein	O
that	O
is	O
the	O
major	O
component	O
of	O
adherens	B-COMP
junctions	I-COMP
between	O
endothelial	O
cells	B-COMP
.	O

The	O
developed	O
ELISAs	O
were	O
evaluated	O
using	O
large	O
number	O
of	O
confirmed	O
seropositive	O
(	O
79	O
samples	O
)	O
and	O
seronegative	O
(	O
274	O
samples	O
)	O
MERS	O
-	O
CoV	O
human	O
serum	B-COMP
samples	O
.	O

Serum	B-COMP
ASC	O
levels	O
were	O
analyzed	O
from	O
EV	O
obtained	O
from	O
patients	O
that	O
presented	O
lung	O
injury	O
after	O
TBI	O
and	O
compared	O
them	O
to	O
EV	O
obtained	O
from	O
patients	O
that	O
did	O
not	O
show	O
any	O
signs	O
of	O
lung	O
injury	O
.	O

We	O
identified	O
407	O
relevant	O
,	O
peer	O
-	O
reviewed	O
publications	O
and	O
selected	O
208	O
of	O
these	O
based	O
on	O
their	O
contributions	O
to	O
four	O
key	O
areas	O
:	O
virology	O
;	O
clinical	O
characteristics	O
,	O
outcomes	O
,	O
therapeutic	O
and	O
preventive	O
options	O
;	O
epidemiology	O
and	O
transmission	O
;	O
and	O
animal	O
interface	O
and	O
the	O
search	O
for	O
natural	O
hosts	B-COMP
of	O
MERS	O
-	O
CoV	O
.	O
Dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
/	O
CD26	O
)	O
was	O
identified	O
as	O
the	O
human	O
receptor	O
for	O
MERS	O
-	O
CoV	O
,	O
and	O
a	O
variety	O
of	O
molecular	O
and	O
serological	O
assays	O
developed	O
.	O

These	O
results	O
provide	O
a	O
structural	O
framework	O
for	O
understanding	O
coronavirus	O
neutralization	O
by	O
human	O
antibodies	B-COMP
and	O
shed	O
light	O
on	O
activation	O
of	O
coronavirus	O
membrane	B-COMP
fusion	O
,	O
which	O
takes	O
place	O
through	O
a	O
receptor	O
-	O
driven	O
ratcheting	O
mechanism	O
.	O

The	O
present	O
study	O
describes	O
development	O
and	O
evaluation	O
of	O
a	O
multiplexed	O
magnetic	O
microsphere	O
immunoassay	O
(	O
MMIA	O
)	O
to	O
simultaneously	O
detect	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
antibodies	B-COMP
specific	O
for	O
recombinant	O
nucleocapsid	B-COMP
proteins	O
(	O
recN	O
)	O
from	O
hCoVs	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
MERS	O
-	O
CoV	O
.	O
We	O
used	O
paired	O
human	O
sera	B-COMP
to	O
screen	O
for	O
IgG	O
with	O
reactivity	O
against	O
six	O
hCoVs	O
to	O
determine	O
assay	O
sensitivity	O
,	O
specificity	O
and	O
reproducibility	O
.	O

Only	O
isolates	O
(	O
30	O
%-	O
9	O
/	O
30	O
)	O
from	O
diarrheic	O
calves	O
were	O
also	O
positive	O
for	O
fimbriae	B-COMP
,	O
specifically	O
16	O
.	O
7	O
%	O
(	O
5	O
/	O
30	O
)	O
for	O
F5	O
and	O
13	O
.	O
3	O
%	O
(	O
4	O
/	O
30	O
)	O
for	O
F18	O
.	O

TITLE	O
:	O
Severe	O
thoracic	O
trauma	O
caused	O
left	O
pneumonectomy	O
complicated	O
by	O
right	O
traumatic	O
wet	O
lung	O
,	O
reversed	O
by	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
support	O
-	O
a	O
case	O
report	O
.	O

We	O
found	O
that	O
both	O
icPEDV	O
-	O
wt	O
and	O
icPEDV	O
-	O
EnUmt	O
propagated	O
efficiently	O
in	O
interferon	O
(	O
IFN	O
)-	O
deficient	O
Vero	O
cells	B-COMP
.	O

TITLE	O
:	O
Construction	O
and	O
characterization	O
of	O
porcine	O
single	O
-	O
chain	O
fragment	O
variable	O
antibodies	B-COMP
that	O
neutralize	O
transmissible	O
gastroenteritis	O
virus	O
in	O
vitro	O
.	O

Single	O
-	O
chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
antibodies	B-COMP
effectively	O
inhibit	O
virus	O
infection	O
and	O
could	O
be	O
a	O
potential	O
therapeutic	O
reagent	O
for	O
preventing	O
disease	O
.	O

An	O
immunofluorescence	O
assay	O
and	O
western	O
blot	O
analysis	O
demonstrated	O
that	O
two	O
scFv	O
antibodies	B-COMP
reacted	O
with	O
the	O
spike	O
protein	O
of	O
TGEV	O
.	O

ABSTRACT	O
:	O
Sarcoidosis	O
is	O
a	O
T	O
-	O
cell	B-COMP
driven	O
inflammatory	O
disease	O
characterized	O
by	O
granuloma	O
formation	O
.	O

Total	O
nucleic	B-COMP
acid	O
was	O
extracted	O
from	O
specimens	O
followed	O
by	O
the	O
real	O
-	O
time	O
PCR	O
analysis	O
targeting	O
14	O
respiratory	O
viruses	O
to	O
estimate	O
the	O
frequency	O
of	O
infections	O
.	O

Therapeutic	O
antibodies	B-COMP
are	O
key	O
tools	O
for	O
preventing	O
and	O
treating	O
MERS	O
-	O
CoV	O
infection	O
,	O
but	O
to	O
date	O
no	O
such	O
agents	O
have	O
been	O
approved	O
for	O
treatment	O
of	O
this	O
virus	O
.	O

While	O
highly	O
efficacious	O
,	O
post	O
-	O
infusion	O
T	O
cell	B-COMP
activity	O
often	O
results	O
in	O
massive	O
cytokine	O
release	O
precipitating	O
cytokine	O
release	O
syndrome	O
(	O
CRS	O
),	O
the	O
signature	O
toxicity	O
of	O
CAR	B-COMP
T	O
cells	B-COMP
.	O

A	O
probe	O
-	O
based	O
reverse	O
transcription	O
RPA	B-COMP
(	O
RT	O
-	O
RPA	B-COMP
)	O
assay	O
was	O
developed	O
for	O
real	O
-	O
time	O
detection	O
of	O
PDCoV	O
.	O
The	O
amplification	O
can	O
be	O
finished	O
in	O
20	O
min	O
and	O
fluorescence	O
monitoring	O
was	O
performed	O
by	O
a	O
portable	O
device	O
.	O

The	O
clinical	O
performance	O
of	O
the	O
RT	O
-	O
RPA	B-COMP
assay	O
was	O
evaluated	O
using	O
108	O
clinical	O
samples	O
(	O
54	O
intestine	O
specimens	O
and	O
54	O
faecal	O
swab	O
specimens	O
).	O

Additionally	O
,	O
during	O
times	O
of	O
physiologic	O
stress	O
,	O
nearly	O
all	O
cells	B-COMP
,	O
including	O
fibroblasts	O
and	O
epithelial	O
cells	B-COMP
,	O
require	O
glutamine	O
metabolism	O
.	O

The	O
results	O
showed	O
that	O
both	O
vaccine	O
candidates	O
induced	O
high	O
levels	O
of	O
PEDV	O
-	O
specific	O
IgG	O
antibodies	B-COMP
and	O
IFN	O
-	O
γ	O
and	O
reduced	O
the	O
levels	O
of	O
neutralizing	O
antibodies	B-COMP
at	O
21	O
dpv	O
in	O
suckling	O
piglets	O
.	O

Their	O
sera	B-COMP
enhanced	O
SARS	O
-	O
CoV	O
-	O
induced	O
MCP1	O
and	O
IL	O
-	O
8	O
production	O
by	O
human	O
monocyte	O
-	O
derived	O
wound	O
-	O
healing	O
macrophages	O
,	O
whereas	O
blockade	O
of	O
FcγR	O
reduced	O
such	O
effects	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
known	O
to	O
harbor	O
and	O
transmit	O
many	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
,	O
many	O
of	O
which	O
are	O
extremely	O
pathogenic	O
in	O
humans	O
but	O
do	O
not	O
cause	O
overt	O
pathology	O
in	O
their	O
bat	O
reservoir	O
hosts	B-COMP
:	O
henipaviruses	O
(	O
Nipah	O
and	O
Hendra	O
),	O
filoviruses	O
(	O
Ebola	O
and	O
Marburg	O
),	O
and	O
coronaviruses	O
(	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
).	O

We	O
demonstrated	O
that	O
PEDV	O
N	O
expression	O
positively	O
affected	O
both	O
recovery	O
of	O
PEDV	O
from	O
infectious	O
clones	O
and	O
PEDV	O
propagation	O
in	O
cell	B-COMP
culture	O
.	O

TITLE	O
:	O
Extended	O
Use	O
of	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
A	O
Retrospective	O
Multicenter	O
Study	O
.	O

However	O
,	O
activation	O
of	O
the	O
ER	O
stress	O
response	O
was	O
significantly	O
reduced	O
in	O
cells	B-COMP
infected	O
with	O
rN3D	O
/	O
N6D	O
,	O
correlated	O
with	O
a	O
lower	O
level	O
of	O
apoptosis	O
and	O
reduced	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Unfortunately	O
,	O
we	O
have	O
only	O
started	O
to	O
unravel	O
the	O
underlying	O
viral	O
mechanisms	O
used	O
to	O
manipulate	O
host	B-COMP
innate	O
immune	O
responses	O
.	O

Finally	O
,	O
we	O
provide	O
some	O
perspectives	O
on	O
the	O
advantages	O
gained	O
from	O
a	O
better	O
understanding	O
of	O
host	B-COMP
-	O
pathogen	O
interactions	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
is	O
indicated	O
in	O
patients	O
with	O
severe	O
refractory	O
acute	O
respiratory	O
failure	O
.	O

The	O
incidence	O
of	O
cannula	O
-	O
related	O
venous	O
thrombosis	O
after	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
is	O
high	O
.	O

A	O
total	O
of	O
820	O
sera	B-COMP
and	O
823	O
nasal	O
swabs	O
from	O
cattle	O
,	O
sheep	O
,	O
goats	O
,	O
donkeys	O
,	O
buffaloes	O
,	O
mules	O
,	O
and	O
horses	O
were	O
collected	O
.	O

Sera	B-COMP
were	O
screened	O
using	O
virus	O
microneutralization	O
tests	O
and	O
positive	O
sera	B-COMP
(	O
where	O
available	O
)	O
were	O
confirmed	O
using	O
plaque	O
reduction	O
neutralization	O
tests	O
(	O
PRNT	O
).	O

The	O
following	O
parameters	O
were	O
associated	O
with	O
increased	O
mortality	O
,	O
age	O
,	O
WBC	O
,	O
neutrophil	O
count	O
,	O
serum	B-COMP
albumin	O
level	O
,	O
use	O
of	O
a	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
and	O
corticosteroid	O
use	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
six	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
targeting	O
N	O
protein	O
of	O
PEDV	O
and	O
analyzed	O
their	O
applications	O
on	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
western	O
blot	O
assay	O
,	O
and	O
flow	O
cytometry	O
assay	O
.	O

Obtaining	O
virus	O
genome	O
sequence	O
directly	O
from	O
clinical	O
samples	O
is	O
still	O
a	O
challenging	O
task	O
due	O
to	O
the	O
low	O
load	O
of	O
virus	O
genetic	O
material	O
compared	O
to	O
the	O
host	B-COMP
DNA	O
,	O
and	O
to	O
the	O
difficulty	O
to	O
get	O
an	O
accurate	O
genome	O
assembly	O
.	O

In	O
this	O
paper	O
,	O
the	O
linear	O
epitope	O
of	O
the	O
3F10	O
non	O
-	O
neutralizing	O
monoclonal	O
antibody	B-COMP
that	O
was	O
previously	O
prepared	O
in	O
our	O
laboratory	O
was	O
identified	O
.	O

ABSTRACT	O
:	O
The	O
protocol	O
aims	O
to	O
generate	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
fusion	O
protein	O
pseudotyped	O
particles	O
with	O
a	O
murine	O
leukemia	O
virus	O
(	O
MLV	O
)	O
core	O
and	O
luciferase	O
reporter	O
,	O
using	O
a	O
simple	O
transfection	O
procedure	O
of	O
the	O
widely	O
available	O
HEK	O
-	O
293T	O
cell	B-COMP
line	O
.	O

Once	O
formed	O
and	O
released	O
from	O
producer	O
cells	B-COMP
,	O
these	O
pseudovirions	O
incorporate	O
a	O
luciferase	O
reporter	O
gene	O
.	O

Successful	O
Resuscitation	O
Using	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
of	O
2	O
Patients	O
With	O
Severe	O
Liver	O
Rupture	O
:	O
A	O
Case	O
Report	O
.	O

TITLE	O
:	O
A	O
Single	O
V672F	O
Substitution	O
in	O
the	O
Spike	O
Protein	O
of	O
Field	O
-	O
Isolated	O
PEDV	O
Promotes	O
Cell	B-COMP
⁻	I-COMP
Cell	I-COMP
Fusion	O
and	O
Replication	O
in	O
VeroE6	O
Cells	B-COMP
.	O

Moreover	O
,	O
recombinant	O
PEDV	O
viruses	O
bearing	O
S	O
of	O
the	O
G2	O
strain	O
with	O
the	O
single	O
V672F	O
substitution	O
could	O
induce	O
extensive	O
syncytium	O
formation	O
and	O
replicate	O
efficiently	O
in	O
VeroE6	O
cells	B-COMP
stably	O
expressing	O
porcine	O
aminopeptidase	O
N	O
(	O
VeroE6	O
-	O
APN	O
).	O

Brain	O
and	O
spine	B-COMP
magnetic	O
resonance	O
imaging	O
scans	O
showed	O
enhancement	O
of	O
the	O
left	O
bulbar	O
nerve	O
complex	O
and	O
anterior	O
and	O
posterior	O
cervical	O
nerve	O
roots	O
with	O
gadolinium	O
.	O

However	O
,	O
genomic	O
data	O
can	O
be	O
poorly	O
informative	O
of	O
transmission	O
events	O
if	O
mutations	O
accumulate	O
too	O
slowly	O
to	O
resolve	O
individual	O
transmission	O
pairs	O
or	O
if	O
there	O
exist	O
multiple	O
pathogens	O
lineages	O
within	O
-	O
host	B-COMP
,	O
and	O
there	O
has	O
been	O
little	O
focus	O
on	O
incorporating	O
other	O
types	O
of	O
outbreak	O
data	O
.	O

Approximately	O
69	O
.	O
05	O
%	O
(	O
232	O
/	O
336	O
)	O
of	O
the	O
diarrhoeic	O
samples	O
were	O
assessed	O
as	O
bovine	O
coronavirus	O
(	O
BCoV	O
)-	O
positive	O
by	O
RT	O
-	O
PCR	O
assay	O
,	O
and	O
most	O
of	O
the	O
detected	O
strains	O
showed	O
a	O
unique	O
evolution	O
based	O
on	O
40	O
spike	O
(	O
S	O
),	O
nucleocapsid	B-COMP
(	O
N	O
)	O
and	O
haemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
gene	O
fragments	O
.	O

We	O
also	O
found	O
that	O
PDCoV	O
could	O
be	O
detected	O
in	O
sows	O
faeces	O
and	O
sera	B-COMP
while	O
the	O
sows	O
showed	O
mild	O
,	O
self	O
-	O
limited	O
diarrhea	O
in	O
clinic	O
.	O

TITLE	O
:	O
Respiratory	O
Virus	O
Infections	O
of	O
the	O
Stem	O
Cell	B-COMP
Transplant	O
Recipient	O
and	O
the	O
Hematologic	O
Malignancy	O
Patient	O
.	O

For	O
years	O
it	O
was	O
believed	O
that	O
they	O
share	O
receptor	O
specificity	O
,	O
utilizing	O
sialic	O
acids	O
for	O
cell	B-COMP
surface	I-COMP
attachment	O
,	O
internalization	O
,	O
and	O
entry	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
immunized	O
BALB	O
/	O
c	O
mice	O
with	O
recombinant	O
truncated	O
PEDV	O
COE	O
protein	O
and	O
obtained	O
14	O
COE	O
-	O
specific	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
).	O

ABSTRACT	O
:	O
Surfactin	O
has	O
antiviral	O
activity	O
against	O
various	O
enveloped	O
viruses	O
by	O
inhibiting	O
viral	B-COMP
membrane	I-COMP
fusion	O
.	O

For	O
comparative	O
analyses	O
,	O
two	O
eS770	O
proteins	O
lacking	O
the	O
IgG4	B-COMP
Fc	O
domain	O
were	O
generated	O
using	O
the	O
IdeS	O
protease	O
(	O
eS770	O
-	O
ΔFc	O
)	O
or	O
His	O
tag	O
attachment	O
(	O
eS770	O
-	O
His	O
)	O
and	O
the	O
immunogenicity	O
of	O
the	O
above	O
constructs	O
were	O
examined	O
following	O
intramuscular	O
immunization	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Antibody	B-COMP
phage	O
display	O
has	O
been	O
pivotal	O
in	O
the	O
quest	O
to	O
generate	O
human	O
monoclonal	O
antibodies	B-COMP
for	O
biomedical	O
and	O
research	O
applications	O
.	O

High	O
-	O
dose	O
intravenous	O
steroids	O
were	O
started	O
as	O
adjuvant	O
therapy	O
due	O
to	O
the	O
rapid	O
decline	O
,	O
presumably	O
due	O
to	O
a	O
dysregulated	O
host	B-COMP
immune	O
response	O
.	O

EK1	O
,	O
the	O
optimized	O
form	O
of	O
OC43	O
-	O
HR2P	O
,	O
showed	O
substantially	O
improved	O
pan	B-COMP
-	O
CoV	O
fusion	O
inhibitory	O
activity	O
and	O
pharmaceutical	O
properties	O
.	O

The	O
H3K4me3	O
mark	O
of	O
open	O
chromatin	B-COMP
was	O
measured	O
at	O
the	O
promoter	O
regions	O
of	O
cytokines	O
and	O
chemokines	O
that	O
differed	O
significantly	O
from	O
healthy	O
controls	O
.	O

TITLE	O
:	O
[	O
Severe	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
Implication	O
of	O
unconventional	O
T	O
cells	B-COMP
].	O

Thus	O
,	O
using	O
an	O
experimental	O
and	O
translational	O
approach	O
,	O
we	O
test	O
the	O
hypothesis	O
that	O
a	O
tight	O
regulation	O
of	O
UTC	O
is	O
mandatory	O
to	O
fine	O
-	O
tune	O
host	B-COMP
response	O
,	O
and	O
,	O
subsequently	O
to	O
prevent	O
emergence	O
of	O
an	O
aberrant	O
response	O
leading	O
to	O
excessive	O
tissue	O
damages	O
,	O
and	O
eventually	O
,	O
ARDS	O
.	O

The	O
most	O
significant	O
cellular	B-COMP
immune	O
response	O
was	O
induced	O
after	O
vaccination	O
of	O
the	O
animals	O
with	O
the	O
full	O
-	O
length	O
S	O
(	O
rAd5	O
-	O
S	O
).	O

In	O
vitro	O
,	O
LPS	O
activated	O
NIH3T3	O
cells	B-COMP
,	O
which	O
was	O
suppressed	O
by	O
VIP	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
detail	O
,	O
VIP	O
reduced	O
the	O
hydroxyproline	O
content	O
and	O
col3a1	O
messenger	O
RNA	O
induced	O
by	O
LPS	O
in	O
NIH3T3	O
cells	B-COMP
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
α	O
-	O
smooth	O
muscle	O
actin	O
.	O

Most	O
of	O
these	O
unigenes	O
are	O
annotated	O
in	O
cellular	B-COMP
processes	O
,	O
the	O
cell	B-COMP
and	O
binding	O
.	O

Inhibition	O
of	O
UBXN1	O
in	O
IPEC	O
-	O
J2	O
cells	B-COMP
via	O
siRNA	O
interference	O
significantly	O
decreased	O
the	O
viral	O
titer	O
and	O
downregulated	O
the	O
expression	O
of	O
S1	O
.	O

TITLE	O
:	O
Severe	O
Complications	O
in	O
Testicular	O
Germ	O
Cell	B-COMP
Tumors	O
:	O
The	O
Choriocarcinoma	O
Syndrome	O
.	O

ORF3a	O
interacted	O
with	O
TRAF3	O
and	O
ASC	O
,	O
colocalized	O
with	O
them	O
in	O
discrete	O
punctate	O
structures	O
in	O
the	O
cytoplasm	B-COMP
,	O
and	O
facilitated	O
ASC	O
speck	O
formation	O
.	O

To	O
understand	O
whether	O
10d	O
interfered	O
with	O
virus	O
attachment	O
to	O
target	O
cells	B-COMP
or	O
virus	O
-	O
cell	B-COMP
fusion	O
events	O
,	O
inhibitory	O
activity	O
tests	O
against	O
the	O
RSV	O
mutant	O
strain	O
B1	O
cp	O
-	O
52	O
-	O
expressing	O
only	O
the	O
F	O
envelope	B-COMP
glycoprotein	O
-	O
and	O
a	O
plasmid	O
-	O
based	O
reporter	O
assay	O
that	O
quantifies	O
the	O
bioactivity	O
of	O
viral	O
entry	O
were	O
also	O
performed	O
.	O

RESULTS	O
:	O
In	O
the	O
shell	O
gland	O
,	O
the	O
mitochondrial	B-COMP
count	O
was	O
significantly	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
challenged	O
group	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

Overlapping	O
12	O
-	O
mer	O
peptides	O
(	O
n	O
=	O
28	O
,	O
426	O
)	O
across	O
the	O
entire	O
Pp1ab	O
were	O
arrayed	O
on	O
peptide	O
chips	O
and	O
reacted	O
with	O
pooled	O
sera	B-COMP
from	O
coronavirus	O
seropositive	O
cats	O
and	O
from	O
one	O
seronegative	O
cat	O
.	O

We	O
highlight	O
this	O
case	O
to	O
discuss	O
the	O
importance	O
of	O
maintaining	O
a	O
broad	O
differential	O
and	O
pursuing	O
complete	O
work	O
-	O
up	O
when	O
treating	O
younger	O
patients	O
with	O
chest	O
pain	O
and	O
elevated	O
serum	B-COMP
troponin	O
who	O
lack	O
typical	O
risk	O
factors	O
for	O
CAD	O
.	O

VV	O
-	O
ECLS	O
can	O
be	O
configured	O
as	O
a	O
system	O
that	O
uses	O
higher	O
blood	O
flows	O
with	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
or	O
as	O
one	O
that	O
uses	O
lower	O
blood	O
flows	O
for	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
VV	O
-	O
ECCO	O

ABSTRACT	O
:	O
Coronavirus	O
infection	O
induces	O
the	O
generation	O
of	O
autophagosomes	O
,	O
and	O
certain	O
host	B-COMP
proteins	O
regulating	O
cellular	B-COMP
autophagy	O
are	O
hijacked	O
by	O
some	O
coronaviruses	O
to	O
facilitate	O
the	O
formation	O
of	O
double	O
membrane	B-COMP
vesicles	B-COMP
.	O

Using	O
potent	O
antigens	O
in	O
combination	O
with	O
strong	O
adjuvants	O
may	O
effectively	O
trigger	O
the	O
activation	O
of	O
specific	O
MERS	O
-	O
CoV	O
cellular	B-COMP
responses	O
as	O
well	O
as	O
the	O
production	O
of	O
neutralizing	O
antibodies	B-COMP
.	O

Here	O
we	O
show	O
that	O
pan	B-COMP
-	O
PARP	O
inhibition	O
enhanced	O
replication	O
and	O
inhibited	O
interferon	O
production	O
in	O
primary	O
macrophages	O
infected	O
with	O
macrodomain	O
-	O
mutant	O
but	O
not	O
wild	O
-	O
type	O
coronavirus	O
.	O

A	O
probable	O
mechanism	O
is	O
the	O
activation	O
of	O
free	O
radical	O
oxidation	O
processes	O
with	O
the	O
damage	O
of	O
cell	B-COMP
membranes	I-COMP
.	O

Antiviral	O
T	O
cell	B-COMP
responses	O
during	O
early	O
primary	O
infection	O
were	O
also	O
similar	O
between	O
cats	O
that	O
developed	O
FIP	O
and	O
cats	O
remaining	O
healthy	O
.	O

Recovery	O
of	O
antiviral	O
T	O
cell	B-COMP
responses	O
during	O
the	O
later	O
phase	O
of	O
acute	O
infection	O
was	O
observed	O
in	O
a	O
subset	O
of	O
cats	O
that	O
survived	O
longer	O
or	O
resisted	O
disease	O
compared	O
to	O
cats	O
showing	O
rapid	O
disease	O
progression	O
.	O

However	O
emergence	O
of	O
antiviral	O
T	O
cell	B-COMP
responses	O
after	O
a	O
second	O
exposure	O
to	O
FIPV	O
,	O
implicated	O
cellular	B-COMP
immunity	O
in	O
the	O
control	O
of	O
FIPV	O
infection	O
and	O
disease	O
progression	O
.	O

Viral	B-COMP
envelope	I-COMP
proteins	O
from	O
a	O
variety	O
of	O
human	O
pathogens	O
including	O
HIV	O
-	O
1	O
,	O
influenza	O
virus	O
,	O
Lassa	O
virus	O
,	O
SARS	O
,	O
Zika	O
virus	O
,	O
dengue	O
virus	O
,	O
and	O
Ebola	O
virus	O
have	O
evolved	O
to	O
be	O
extensively	O
glycosylated	O
.	O

These	O
host	B-COMP
-	O
cell	B-COMP
derived	O
glycans	O
facilitate	O
diverse	O
structural	O
and	O
functional	O
roles	O
during	O
the	O
viral	O
life	O
-	O
cycle	O
,	O
ranging	O
from	O
immune	O
evasion	O
by	O
glycan	O
shielding	O
to	O
enhancement	O
of	O
immune	O
cell	B-COMP
infection	O
.	O

ABSTRACT	O
:	O
Beta	O
-	O
defensins	O
contribute	O
to	O
host	B-COMP
innate	O
defense	O
against	O
various	O
pathogens	O
,	O
including	O
viruses	O
,	O
although	O
the	O
details	O
of	O
their	O
roles	O
in	O
innate	O
immune	O
cells	B-COMP
are	O
unclear	O
.	O

The	O
CoV	O
envelope	B-COMP
(	O
E	O
)	O
protein	O
is	O
a	O
small	O
,	O
integral	O
membrane	B-COMP
protein	O
involved	O
in	O
several	O
aspects	O
of	O
the	O
virus	O
'	O
life	O
cycle	O
,	O
such	O
as	O
assembly	O
,	O
budding	O
,	O
envelope	B-COMP
formation	O
,	O
and	O
pathogenesis	O
.	O

Upon	O
infecting	O
host	B-COMP
cells	B-COMP
,	O
coronaviruses	O
assemble	O
a	O
multi	O
-	O
subunit	O
RNA	O
-	O
synthesis	O
complex	O
of	O
viral	O
non	O
-	O
structural	O
proteins	O
(	O
nsp	O
)	O
responsible	O
for	O
the	O
replication	O
and	O
transcription	O
of	O
the	O
viral	B-COMP
genome	I-COMP
.	O

He	O
was	O
referred	O
for	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
due	O
to	O
severe	O
hypoxia	O
and	O
pulmonary	O
haemorrhage	O
.	O

The	O
most	O
notable	O
studies	O
include	O
the	O
recent	O
discoveries	O
of	O
monoclonal	O
antibodies	B-COMP
and	O
development	O
of	O
candidate	O
vaccines	O
against	O
the	O
S	O
glycoprotein	O
.	O

TITLE	O
:	O
Susceptibility	O
of	O
porcine	O
IPI	O
-	O
2I	O
intestinal	O
epithelial	O
cells	B-COMP
to	O
infection	O
with	O
swine	O
enteric	O
coronaviruses	O
.	O

We	O
previously	O
reported	O
that	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
infection	O
can	O
alleviate	O
the	O
BST2	O
tethering	O
of	O
HIV	O
-	O
1	O
virions	B-COMP
by	O
downregulating	O
cell	B-COMP
surface	I-COMP
BST2	O
,	O
suggesting	O
that	O
coronaviruses	O
are	O
capable	O
of	O
encoding	O
anti	O
-	O
BST2	O
factors	O
.	O

ABSTRACT	O
:	O
Prader	O
-	O
Willi	O
syndrome	O
(	O
PWS	O
)	O
is	O
generally	O
due	O
to	O
sporadic	O
paternal	O
deletions	O
of	O
the	O
chromosome	B-COMP
15q11	O
-	O
q13	O
region	O
followed	O
by	O
maternal	O
disomy	O
15	O
.	O

Here	O
,	O
we	O
identify	O
several	O
mechanisms	O
by	O
which	O
a	O
SARS	O
-	O
CoV	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
activates	O
intracellular	B-COMP
stress	O
pathways	O
and	O
targets	O
the	O
innate	O
immune	O
response	O
.	O

While	O
in	O
those	O
cells	B-COMP
lacking	O
NLRP3	O
accumulating	O
ORF8b	O
cytosolic	B-COMP
aggregates	O
cause	O
ER	O
stress	O
,	O
mitochondrial	B-COMP
dysfunction	O
,	O
and	O
caspase	O
-	O
independent	O
cell	B-COMP
death	O
.	O

TITLE	O
:	O
[	O
Porcine	O
deltacoronavirus	O
induces	O
mitochondrial	B-COMP
apoptosis	O
in	O
ST	O
cells	B-COMP
].	O

Compared	O
with	O
normal	O
cells	B-COMP
,	O
the	O
amount	O
of	O
cytochrome	O
C	O
released	O
from	O
mitochondria	B-COMP
to	O
cytoplasm	B-COMP
increased	O
significantly	O
in	O
PDCoV	O
-	O
infected	O
cells	B-COMP
,	O
and	O
the	O
release	O
increased	O
with	O
the	O
prolongation	O
of	O
infection	O
,	O
while	O
the	O
apoptosis	O
-	O
inducing	O
factor	O
was	O
always	O
localized	O
to	O
mitochondria	B-COMP
,	O
suggesting	O
that	O
PDCoV	O
induced	O
apoptosis	O
was	O
initiated	O
through	O
caspase	O
-	O
dependent	O
mitochondrial	B-COMP
apoptosis	O
pathway	O
by	O
promoting	O
cytochrome	O
C	O
in	O
the	O
mitochondrial	B-COMP
membrane	I-COMP
gap	O
into	O
the	O
cytosol	B-COMP
.	O

In	O
the	O
spleen	O
(	O
associated	O
with	O
circulation	O
),	O
the	O
EACs	O
producing	O
MBL	O
and	O
expressing	O
CD83	O
are	O
a	O
common	O
precursor	O
of	O
both	O
follicular	O
(	O
FDC	O
)	O
and	O
interdigitating	O
dendritic	B-COMP
cells	B-COMP
(	O
IDC	O
).	O

A	O
fully	O
human	O
polyclonal	O
IgG	B-COMP
antibody	I-COMP
(	O
SAB	O
-	O
301	O
)	O
was	O
safe	O
and	O
well	O
tolerated	O
in	O
healthy	O
individuals	O
and	O
this	O
agent	O
may	O
deserve	O
further	O
testing	O
for	O
efficacy	O
.	O

The	O
expression	O
of	O
six	O
tight	B-COMP
junction	I-COMP
protein	O
genes	O
was	O
lower	O
in	O
PEDV	O
-	O
infected	O
piglets	O
than	O
in	O
the	O
normal	O
animals	O
.	O

These	O
data	O
suggest	O
that	O
the	O
expression	O
of	O
these	O
six	O
tight	B-COMP
junction	I-COMP
proteins	O
,	O
especially	O
Occludin	O
and	O
Claudin	O
-	O
4	O
,	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
intestinal	O
mucosal	O
barrier	O
and	O
resistance	O
to	O
PEDV	O
infection	O
in	O
piglets	O
.	O

Fraxin	O
was	O
also	O
related	O
to	O
the	O
inhibition	O
of	O
the	O
increase	O
in	O
matrix	O
metalloproteinase	O
-	O
9	O
,	O
which	O
is	O
a	O
glycocalyx	B-COMP
-	O
degrading	O
enzyme	O
,	O
and	O
the	O
relief	O
of	O
damages	O
to	O
the	O
endothelial	O
glycocalyx	B-COMP
.	O

Recombinant	O
EMC	B-COMP
isolates	O
of	O
MERS	O
-	O
CoV	O
,	O
in	O
which	O
the	O
S	O
protein	O
is	O
replaced	O
with	O
those	O
of	O
Amibara	O
isolates	O
,	O
were	O
then	O
generated	O
to	O
test	O
the	O
roles	O
of	O
these	O
proteins	O
in	O
viral	O
properties	O
.	O

TITLE	O
:	O
High	O
Hemoglobin	O
Level	O
As	O
a	O
Limiting	O
Factor	O
for	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
seven	O
human	O
cell	B-COMP
lines	O
and	O
found	O
that	O
the	O
human	O
monocytic	O
cell	B-COMP
U937	O
supports	O
the	O
replication	O
of	O
different	O
subtypes	O
of	O
influenza	O
viruses	O
as	O
well	O
as	O
the	O
production	O
of	O
the	O
important	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
was	O
selected	O
to	O
develop	O
the	O
cell	B-COMP
-	O
based	O
model	O
.	O

Gene	O
Ontology	O
analysis	O
suggested	O
that	O
cellular	B-COMP
macromolecule	O
and	O
protein	O
location	O
(	O
GO	O
-	O
BP	O
)	O
and	O
transcription	O
factor	O
binding	O
(	O
GO	O
-	O
MF	O
)	O
were	O
abundant	O
in	O
IBV	O
-	O
stimulated	O
avian	O
DCs	O
.	O

Here	O
,	O
we	O
showed	O
that	O
recombinant	O
staphylococcal	O
PI	O
-	O
PLC	O
possesses	O
enzyme	O
activity	O
that	O
causes	O
shedding	O
of	O
glycosylphosphatidylinositol	O
-	O
anchored	O
CD55	O
and	O
CD59	O
from	O
human	O
umbilical	O
vein	O
endothelial	O
cell	B-COMP
surfaces	O
and	O
triggers	O
cell	B-COMP
lysis	O
via	O
complement	O
activity	O
.	O

In	O
adults	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
higher	O
serum	B-COMP
levels	O
of	O
surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
)	O
are	O
linked	O
to	O
lung	O
injury	O
and	O
worse	O
outcomes	O
.	O

ABSTRACT	O
:	O
The	O
interaction	O
between	O
a	O
low	O
pathogenic	O
avian	O
influenza	O
virus	O
(	O
A	O
/	O
CK	O
/	O
TUN	O
/	O
145	O
/	O
2012	O
),	O
a	O
H9N2	O
Tunisian	O
isolate	O
,	O
and	O
a	O
vaccine	O
strain	O
(	O
H120	O
)	O
of	O
avian	O
infectious	O
bronchitis	O
,	O
administered	O
simultaneously	O
or	O
sequentially	O
three	O
days	O
apart	O
to	O
chicks	O
during	O
20	O
days	O
,	O
was	O
evaluated	O
using	O
ELISA	O
antibody	B-COMP
levels	O
,	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
analyses	O
and	O
histopathology	O
examination	O
.	O

Antiviral	O
therapy	O
within	O
48	O
h	O
after	O
onset	O
,	O
avoidance	O
of	O
corticosteroids	O
and	O
rescue	O
therapies	O
for	O
ARF	O
or	O
myocarditis	O
,	O
such	O
as	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
,	O
improve	O
survival	O
.	O

Electromyography	O
showed	O
peripheral	O
nerve	O
injury	O
(	O
mainly	O
in	O
axon	B-COMP
).	O

In	O
humans	O
,	O
the	O
respiratory	O
epithelium	O
is	O
the	O
only	O
site	O
where	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
molecule	O
is	O
effectively	O
cleaved	O
,	O
generating	O
infectious	O
virus	B-COMP
particles	I-COMP
.	O

Fibrinogen	B-COMP
and	O
antithrombin	O
activity	O
have	O
been	O
reported	O
as	O
biomarkers	O
of	O
coagulopathy	O
;	O
however	O
,	O
the	O
utility	O
of	O
these	O
two	O
markers	O
has	O
not	O
been	O
well	O
established	O
.	O

Especially	O
,	O
rAd	O
/	O
Spike	O
induced	O
the	O
highest	O
neutralizing	O
antibody	B-COMP
titer	O
and	O
the	O
strongest	O
cytokine	O
-	O
induced	O
T	O
cell	B-COMP
responses	O
among	O
the	O
three	O
candidate	O
vaccines	O
.	O

The	O
current	O
study	O
employs	O
a	O
variety	O
of	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
activators	O
and	O
inhibitors	O
to	O
investigate	O
the	O
regulation	O
of	O
P53	O
by	O
UPR	O
in	O
lung	O
cells	B-COMP
.	O

Using	O
a	O
reverse	O
-	O
genetics	O
system	O
based	O
on	O
CRISPR	O
/	O
Cas9	O
technology	O
to	O
construct	O
a	O
recombinant	O
TGEV	O
in	O
which	O
this	O
specific	O
nsp1	O
motif	O
was	O
altered	O
,	O
we	O
found	O
that	O
this	O
mutation	O
does	O
not	O
affect	O
virus	O
replication	O
in	O
cell	B-COMP
culture	O
but	O
significantly	O
reduces	O
TGEV	O
pathogenicity	O
in	O
pigs	O
.	O

This	O
study	O
provides	O
important	O
information	O
about	O
the	O
antigenic	O
diversity	O
of	O
PEDV	O
circulating	O
in	O
the	O
endemic	O
areas	O
,	O
which	O
arises	O
from	O
continuous	O
non	O
-	O
lethal	O
mutations	O
to	O
ensure	O
viral	O
fitness	O
in	O
the	O
host	B-COMP
environment	O
.	O

Furthermore	O
,	O
strong	O
antibody	B-COMP
responses	O
to	O
PEDV	O
were	O
detected	O
in	O
the	O
sera	B-COMP
and	O
colostrum	O
of	O
immunized	O
sows	O
and	O
in	O
the	O
sera	B-COMP
of	O
their	O
offspring	O
.	O

TITLE	O
:	O
Cricket	O
paralysis	O
virus	O
internal	O
ribosome	B-COMP
entry	O
site	O
-	O
derived	O
RNA	O
promotes	O
conventional	O
vaccine	O
efficacy	O
by	O
enhancing	O
a	O
balanced	O
Th1	O
/	O
Th2	O
response	O
.	O

Application	O
of	O
the	O
RNA	O
adjuvant	O
in	O
mouse	O
enhanced	O
the	O
efficacy	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
spike	O
protein	O
,	O
a	O
protein	O
-	O
subunit	O
vaccine	O
and	O
human	O
papillomavirus	O
L1	O
protein	O
,	O
a	O
virus	B-COMP
-	I-COMP
like	I-COMP
particle	I-COMP
vaccine	O
,	O
by	O
activating	O
innate	O
immune	O
response	O
through	O
TLR7	O
and	O
enhancing	O
pAPC	O
chemotaxis	O
,	O
leading	O
to	O
a	O
balanced	O
Th1	O
/	O
Th2	O
responses	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
polymorphisms	O
in	O
inflammatory	O
mediator	O
and	O
cellular	B-COMP
adhesion	O
genes	O
as	O
risk	O
factors	O
for	O
feline	O
infectious	O
peritonitis	O
.	O

TITLE	O
:	O
Glycine	O
29	O
Is	O
Critical	O
for	O
Conformational	O
Changes	O
of	O
the	O
Spike	O
Glycoprotein	O
of	O
Mouse	O
Hepatitis	O
Virus	O
A59	O
Triggered	O
by	O
either	O
Receptor	O
Binding	O
or	O
High	O
pH	O
.	O
ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
uses	O
its	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
to	O
bind	O
the	O
host	B-COMP
receptor	O
mouse	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-COMP
adhesion	O
molecule	O
1a	O
(	O
mCEACAM1a	O
)	O
and	O
mediate	O
virus	O
entry	O
.	O

Surprisingly	O
,	O
we	O
uncovered	O
aberrant	O
viral	O
RNA	O
transcription	O
of	O
rC3663	O
in	O
A72	O
cells	B-COMP
.	O

However	O
,	O
the	O
ability	O
of	O
TGEV	O
to	O
inhibit	O
the	O
host	B-COMP
innate	O
immune	O
response	O
by	O
modulating	O
the	O
NF	O
-	O
κB	O
signaling	O
pathway	O
is	O
not	O
clear	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
PEDV	O
ORF3	O
has	O
expression	O
characteristic	O
of	O
aggregation	O
in	O
cytoplasm	B-COMP
,	O
but	O
its	O
biological	O
function	O
remains	O
elusive	O
.	O

Moreover	O
,	O
IFN	O
-	O
γ	O
suppressed	O
TGEV	O
infection	O
in	O
ST	O
cells	B-COMP
more	O
efficiently	O
than	O
did	O
IFN	O
-	O
α	O
,	O
and	O
the	O
combination	O
of	O
IFN	O
-	O
γ	O
and	O
IFN	O
-	O
α	O
displayed	O
a	O
synergistic	O
effect	O
against	O
TGEV	O
.	O

ABSTRACT	O
:	O
Ventilator	O
settings	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
supported	O
by	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
are	O
currently	O
set	O
arbitrarily	O
.	O

TITLE	O
:	O
The	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
MERS	O
coronavirus	O
M	O
protein	O
contains	O
a	O
ABSTRACT	O
:	O
Coronavirus	O
M	O
proteins	O
represent	O
the	O
major	O
protein	O
component	O
of	O
the	O
viral	B-COMP
envelope	I-COMP
.	O

In	O
addition	O
,	O
HY	O
treatment	O
could	O
decrease	O
IBV	O
-	O
induced	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
in	O
CEK	O
cells	B-COMP
.	O

The	O
availability	O
of	O
the	O
SeACoV	O
infectious	O
clone	O
and	O
a	O
panel	O
of	O
antibodies	B-COMP
against	O
different	O
viral	O
proteins	O
will	O
facilitate	O
further	O
studies	O
on	O
understanding	O
the	O
molecular	O
mechanisms	O
of	O
SeACoV	O
replication	O
and	O
pathogenesis	O
.	O

The	O
diagnostic	O
criteria	O
of	O
AMAN	O
refer	O
to	O
AIDP	O
,	O
of	O
which	O
the	O
feature	O
of	O
AMAN	O
suggests	O
a	O
pure	O
motor	O
nerve	O
dysfunction	O
and	O
significant	O
damage	O
on	O
motor	O
axon	B-COMP
.	O

For	O
9	O
women	O
from	O
whom	O
a	O
second	O
serum	B-COMP
sample	O
was	O
collected	O
,	O
antibodies	B-COMP
remained	O
detectable	O
at	O
titers	O
>	O
1	O
:	O
20	O
by	O
pseudoparticle	O
neutralization	O
tests	O
(	O
n	O
=	O
8	O
)	O
and	O
90	O
%	O
plaque	O
-	O
reduction	O
neutralization	O
tests	O
(	O
n	O
=	O
2	O
).	O

The	O
full	O
-	O
length	O
genomic	O
cDNA	O
was	O
transcribed	O
in	O
vitro	O
,	O
and	O
its	O
transcript	O
was	O
transfected	O
into	O
BHK	O
-	O
21	O
/	O
N	O
cells	B-COMP
that	O
could	O
stably	O
express	O
IBV	O
N	O
protein	O
.	O

Acute	O
renal	O
injury	O
with	O
hypoperfusion	O
state	O
due	O
to	O
toxicity	O
at	O
cellular	B-COMP
level	O
,	O
redox	O
cycling	O
and	O
intracellular	B-COMP
reactive	O
oxidative	O
stress	O
generation	O
may	O
also	O
cause	O
death	O
in	O
early	O
stages	O
in	O
paraquat	O
poisoning	O
despite	O
optimal	O
management	O
.	O

Steroids	O
and	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
have	O
been	O
discussed	O
in	O
a	O
previous	O
article	O
.	O

ABSTRACT	O
:	O
A	O
major	O
limitation	O
of	O
current	O
humanized	O
mouse	O
models	O
is	O
that	O
they	O
primarily	O
enable	O
the	O
analysis	O
of	O
human	O
-	O
specific	O
pathogens	O
that	O
infect	O
hematopoietic	O
cells	B-COMP
.	O

Here	O
,	O
we	O
show	O
that	O
implantation	O
of	O
human	O
lung	O
tissue	O
,	O
which	O
contains	O
up	O
to	O
40	O
cell	B-COMP
types	O
,	O
including	O
nonhematopoietic	O
cells	B-COMP
,	O
into	O
immunodeficient	O
mice	O
(	O
lung	O
-	O
only	O
mice	O
)	O
resulted	O
in	O
the	O
development	O
of	O
a	O
highly	O
vascularized	O
lung	O
implant	O
.	O

Real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
also	O
confirmed	O
that	O
the	O
amount	O
of	O
viral	O
RNA	O
in	O
cell	B-COMP
cultures	O
pre	O
-	O
transfected	O
with	O
pGenesil	O
-	O
M	O
and	O
pGenesil	O
-	O
N	O
was	O
reduced	O
by	O
45	O
.	O
8	O
and	O
56	O
.	O
1	O
%,	O
respectively	O
.	O

TITLE	O
:	O
Porcine	O
IL	O
-	O
12	O
plasmid	O
as	O
an	O
adjuvant	O
improves	O
the	O
cellular	B-COMP
and	O
humoral	O
immune	O
responses	O
of	O
DNA	O
vaccine	O
targeting	O
transmissible	O
gastroenteritis	O
virus	O
spike	O
gene	O
in	O
a	O
mouse	O
model	O
.	O

Transfection	O
of	O
different	O
cell	B-COMP
types	O
with	O
FCoV	O
3b	O
fused	O
to	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
or	O
3	O
×	O
FLAG	O
confirmed	O
localization	O
of	O
FCoV	O
3b	O
in	O
the	O
mitochondria	B-COMP
and	O
nucleoli	O
.	O

Mutational	O
analysis	O
also	O
revealed	O
that	O
mitochondrial	B-COMP
translocation	O
is	O
mediated	O
by	O
N	O
-	O
terminal	O
residues	O
10	O
-	O
35	O
,	O
in	O
which	O
a	O
Tom20	O
recognition	O
motif	O
(	O
residues	O
13	O
-	O
17	O
)	O
and	O
two	O
other	O
overlapping	O
hexamers	O
(	O
residues	O
24	O
-	O
30	O
)	O
associated	O
with	O
mitochondrial	B-COMP
targeting	O
were	O
identified	O
.	O

Assessing	O
the	O
spatiotemporal	O
distribution	O
of	O
FCoV	O
3b	O
did	O
not	O
provide	O
convincing	O
evidence	O
of	O
dynamic	O
shuttling	O
behaviour	O
between	O
the	O
nucleoli	O
and	O
the	O
mitochondria	B-COMP
.	O

TITLE	O
:	O
Venovenous	O
extra	O
-	O
corporeal	O
membrane	B-COMP
oxygenation	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
matched	O
cohort	O
study	O
.	O

TITLE	O
:	O
Epitope	O
mapping	O
and	O
cellular	B-COMP
localization	O
of	O
swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
nucleocapsid	B-COMP
protein	O
using	O
a	O
novel	O
monoclonal	O
antibody	B-COMP
.	O

We	O
generated	O
and	O
characterized	O
an	O
N	O
-	O
reactive	O
monoclonal	O
antibody	B-COMP
(	O
mAb	O
)	O
3E9	O
from	O
mice	O
immunized	O
with	O
recombinant	O
N	O
protein	O
.	O

The	O
most	O
intense	O
immunoreaction	O
was	O
detected	O
using	O
a	O
neutralizing	O
antibody	B-COMP
directed	O
against	O
the	O
receptor	O
binding	O
domain	O
S1B	O
of	O
the	O
MERS	O
-	O
S	O
protein	O
,	O
which	O
produced	O
an	O
immunosignal	O
in	O
the	O
cytoplasm	B-COMP
of	O
ciliated	O
respiratory	O
epithelium	O
and	O
along	O
the	O
apical	O
membranous	O
region	O
.	O

TITLE	O
:	O
Right	O
Ventricular	O
Hypertrophy	O
in	O
Refractory	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Treated	O
With	O
Venovenous	O
Extracorporeal	O
Membrane	B-COMP
Oxygenation	O
Support	O
.	O

A	O
substantial	O
down	O
-	O
regulation	O
of	O
α	O
-	O
actinin	O
-	O
4	O
was	O
confirmed	O
in	O
NS7	O
-	O
expressing	O
and	O
PDCoV	O
-	O
infected	O
cells	B-COMP
.	O

The	O
role	O
of	O
Mincle	O
for	O
MERS	O
-	O
CoV	O
-	O
triggered	O
cytokine	O
/	O
chemokine	O
induction	O
was	O
established	O
based	O
on	O
the	O
results	O
of	O
antibody	B-COMP
blockage	O
,	O
siRNA	O
depletion	O
of	O
Mincle	O
and	O
its	O
adaptor	O
spleen	O
tyrosine	O
kinase	O
(	O
Syk	O
),	O
and	O
Syk	O
pharmacological	O
inhibition	O
.	O

TITLE	O
:	O
Transcriptome	O
analysis	O
of	O
PK	O
-	O
15	O
cells	B-COMP
in	O
innate	O
immune	O
response	O
to	O
porcine	O
deltacoronavirus	O
infection	O
.	O

GHRH	O
antagonists	O
suppressed	O
the	O
activation	O
of	O
MLC2	O
,	O
ERK1	O
/	O
2	O
,	O
JAK2	O
/	O
STAT3	O
pathway	O
and	O
increased	O
the	O
intracellular	B-COMP
P53	O
and	O
pAMPK	O
levels	O
.	O

Here	O
,	O
we	O
propagated	O
a	O
virulent	O
strain	O
SADS	O
-	O
CoV	O
/	O
CN	O
/	O
GDWT	O
/	O
2017	O
in	O
Vero	O
cells	B-COMP
for	O
up	O
to	O
83	O
passages	O
.	O

Sequence	O
alignments	O
showed	O
that	O
these	O
four	O
novel	O
strains	O
exhibited	O
16	O
nucleotide	O
mutations	O
and	O
resultant	O
10	O
amino	O
acid	O
substitutions	O
in	O
open	O
reading	O
frame	O
1a	O
/	O
1b	O
,	O
spike	O
,	O
NS3a	O
,	O
envelope	B-COMP
,	O
membrane	B-COMP
and	O
nucleocapsid	B-COMP
proteins	O
.	O

Evidence	O
that	O
IPA	O
can	O
occur	O
in	O
nonimmunocompromised	O
hosts	B-COMP
is	O
increasing	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
effect	O
of	O
overexpression	O
,	O
silencing	O
,	O
antibody	B-COMP
inhibition	O
,	O
and	O
co	O
-	O
expression	O
with	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
of	O
integrin	O
αvβ3	O
on	O
PEDV	O
infection	O
was	O
investigated	O
and	O
analyzed	O
in	O
African	O
green	O
monkey	O
Vero	O
E6	O
cells	B-COMP
and	O
porcine	O
intestinal	O
epithelial	O
cells	B-COMP
(	O
IECs	O
)	O
using	O
the	O
classical	O
strain	O
CV777	O
and	O
variant	O
strain	O
HM2017	O
of	O
PEDV	O
.	O

TITLE	O
:	O
Circular	O
RNA	O
CircEZH2	O
Suppresses	O
Transmissible	O
Gastroenteritis	O
Coronavirus	O
-	O
induced	O
Opening	O
of	O
Mitochondrial	B-COMP
Permeability	O
Transition	O
Pore	B-COMP
via	O
Targeting	O
MiR	O
-	O
22	O
in	O
IPEC	O
-	O
J2	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
circular	O
RNA	O
circEZH2	O
was	O
down	O
-	O
regulated	O
during	O
TGEV	O
infection	O
and	O
promoted	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
-	O
light	O
-	O
chain	O
-	O
enhancer	O
of	O
activated	O
B	O
cells	B-COMP
(	O
NF	O
-	O
κB	O
)	O
via	O
targeting	O
miR	O
-	O
22	O
in	O
porcine	O
intestinal	O
epithelial	O
cell	B-COMP
line	O
(	O
IPEC	O
-	O
J2	O
).	O

We	O
compared	O
vaccination	O
status	O
of	O
2880	O
people	O
with	O
non	O
-	O
influenza	O
respiratory	O
viruses	O
to	O
3240	O
people	O
with	O
pan	B-COMP
-	O
negative	O
results	O
.	O

As	O
limited	O
therapeutic	O
antibody	B-COMP
is	O
accumulated	O
in	O
lung	O
tissue	O
following	O
systemic	O
administration	O
,	O
inhalation	O
is	O
newly	O
recognized	O
as	O
an	O
alternative	O
,	O
possibly	O
better	O
,	O
route	O
of	O
therapeutic	O
antibody	B-COMP
for	O
pulmonary	O
diseases	O
.	O

Nucleocapsid	B-COMP
,	O
spike	O
and	O
the	O
region	O
from	O
the	O
p4	O
.	O
7	O
to	O
p12	O
.	O
7	O
genes	O
of	O
positive	O
samples	O
were	O
sequenced	O
,	O
and	O
sequence	O
and	O
phylogenetic	O
analyses	O
were	O
conducted	O
.	O

TITLE	O
:	O
Peripheral	O
blood	O
leukocyte	O
telomere	B-COMP
length	O
is	O
associated	O
with	O
survival	O
of	O
sepsis	O
patients	O
.	O

TITLE	O
:	O
GILT	O
restricts	O
the	O
cellular	B-COMP
entry	O
mediated	O
by	O
the	O
envelope	B-COMP
glycoproteins	O
of	O
SARS	O
-	O
CoV	O
,	O
Ebola	O
virus	O
and	O
Lassa	O
fever	O
virus	O
.	O

While	O
overexpression	O
of	O
GILT	O
inhibited	O
the	O
entry	O
mediated	O
by	O
envelope	B-COMP
glycoproteins	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
and	O
Lassa	O
fever	O
virus	O
(	O
LASV	O
),	O
depletion	O
of	O
GILT	O
enhanced	O
the	O
entry	O
mediated	O
by	O
these	O
viral	B-COMP
envelope	I-COMP
glycoproteins	O
.	O

TITLE	O
:	O
Influences	O
of	O
cyclosporin	O
A	O
and	O
non	O
-	O
immunosuppressive	O
derivatives	O
on	O
cellular	B-COMP
cyclophilins	O
and	O
viral	B-COMP
nucleocapsid	I-COMP
protein	O
during	O
human	O
coronavirus	O
229E	O
replication	O
.	O

ABSTRACT	O
:	O
Midaortic	O
syndrome	O
(	O
MAS	B-COMP
)	O
is	O
characterized	O
by	O
a	O
diffuse	O
narrowing	O
of	O
the	O
distal	O
thoracic	O
or	O
abdominal	O
aorta	O
and	O
is	O
concomitant	O
with	O
various	O
etiologies	O
.	O

The	O
common	O
symptoms	O
of	O
MAS	B-COMP
include	O
severe	O
hypertension	O
or	O
arterial	O
insufficiency	O
distal	O
to	O
the	O
stenosis	O
.	O

Three	O
cases	O
of	O
enteritis	O
caused	O
by	O
BRoV	O
showed	O
the	O
hallmark	O
lesions	O
of	O
the	O
shortening	O
and	O
fusion	O
of	O
villi	O
,	O
denudation	O
and	O
infiltration	O
of	O
mononuclear	O
cells	B-COMP
in	O
the	O
lamina	O
propria	O
.	O

Engagement	O
of	O
the	O
opiate	O
receptors	O
generates	O
a	O
series	O
of	O
intracellular	B-COMP
signals	O
,	O
including	O
inhibition	O
of	O
adenylate	O
cyclase	O
,	O
decreased	O
opening	O
of	O
calcium	O
channels	O
,	O
increased	O
potassium	O
currents	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
).	O

ABSTRACT	O
:	O
The	O
coronavirus	O
S	O
-	O
protein	O
mediates	O
receptor	O
binding	O
and	O
fusion	O
of	O
the	O
viral	O
and	O
host	O
cell	B-COMP
membranes	I-COMP
.	O

The	O
results	O
of	O
a	O
neutralization	O
test	O
and	O
immunoprotection	O
experiment	O
show	O
that	O
an	O
original	O
serum	B-COMP
and	O
vaccine	O
can	O
still	O
provide	O
effective	O
protection	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

However	O
,	O
whether	O
lncRNAs	O
participate	O
in	O
TGEV	O
-	O
induced	O
inflammation	O
in	O
porcine	O
intestinal	O
epithelial	O
cells	B-COMP
(	O
IPECs	O
)	O
is	O
largely	O
unknown	O
.	O

The	O
results	O
were	O
similar	O
to	O
those	O
obtained	O
from	O
the	O
VN	O
test	O
using	O
live	O
MERS	O
-	O
CoV	O
and	O
were	O
more	O
sensitive	O
than	O
the	O
ELISA	O
performed	O
using	O
synthetic	O
MERS	O
S1	O
fragment	O
as	O
the	O
antigen	O
as	O
well	O
as	O
the	O
competitive	O
ELISA	O
performed	O
using	O
a	O
monoclonal	O
antibody	B-COMP
against	O
MERS	O
-	O
CoV	O
.	O
According	O
to	O
the	O
comprehensive	O
results	O
of	O
the	O
four	O
types	O
of	O
serodiagnosis	O
methods	O
,	O
positive	O
antibodies	B-COMP
were	O
detected	O
only	O
in	O
dromedary	O
camels	O
and	O
the	O
remaining	O
herbivorous	O
animals	O
were	O
not	O
infected	O
with	O
the	O
virus	O
.	O

TITLE	O
:	O
Engineering	O
a	O
Novel	O
Antibody	B-COMP
-	O
Peptide	O
Bispecific	O
Fusion	O
Protein	O
Against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
tremendous	O
efforts	O
have	O
been	O
made	O
in	O
the	O
engineering	O
of	O
bispecific	O
or	O
multi	O
-	O
specific	O
antibody	B-COMP
-	O
based	O
therapeutics	O
by	O
combining	O
two	O
or	O
more	O
functional	O
antigen	O
-	O
recognizing	O
elements	O
into	O
a	O
single	O
construct	O
.	O

We	O
previously	O
developed	O
potent	O
fully	O
human	O
monoclonal	O
antibodies	B-COMP
and	O
inhibitory	O
peptides	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
a	O
novel	O
coronavirus	O
that	O
causes	O
severe	O
acute	O
respiratory	O
illness	O
with	O
high	O
mortality	O
.	O

TITLE	O
:	O
Gold	O
nanoparticle	O
-	O
adjuvanted	O
S	O
protein	O
induces	O
a	O
strong	O
antigen	O
-	O
specific	O
IgG	O
response	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
related	O
coronavirus	O
infection	O
,	O
but	O
fails	O
to	O
induce	O
protective	O
antibodies	B-COMP
and	O
limit	O
eosinophilic	O
infiltration	O
in	O
lungs	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
TLR	O
agonist	O
-	O
adjuvanted	O
vaccine	O
induced	O
highly	O
protective	O
antibodies	B-COMP
without	O
eosinophilic	O
infiltrations	O
,	O
as	O
well	O
as	O
Th1	O
/	O
17	O
cytokine	O
responses	O
.	O

TITLE	O
:	O
The	O
Porcine	O
Deltacoronavirus	O
Replication	O
Organelle	B-COMP
Comprises	O
Double	O
-	O
Membrane	B-COMP
Vesicles	B-COMP
and	O
Zippered	O
Endoplasmic	B-COMP
Reticulum	I-COMP
with	O
Double	O
-	O
Membrane	B-COMP
Spherules	O
.	O

Replication	O
organelles	B-COMP
for	O
the	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
infects	O
ciliated	O
epithelial	O
cells	B-COMP
in	O
the	O
chicken	O
respiratory	O
tract	O
.	O

To	O
combine	O
the	O
safety	O
and	O
efficacy	O
advantages	O
of	O
inactivated	O
and	O
attenuated	O
PEDV	O
vaccines	O
,	O
respectively	O
,	O
in	O
this	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
subjecting	O
PEDV	O
virions	B-COMP
to	O
heat	O
treatment	O
at	O
44	O
°	O
C	O
for	O
10	O
min	O
to	O
reversibly	O
unfold	O
structural	O
proteins	O
,	O
followed	O
by	O
exposure	O
to	O
RNAse	O
to	O
fragment	O
the	O
genome	O
,	O
would	O
result	O
in	O
a	O
vaccine	O
preparation	O
with	O
intact	O
viral	O
structure	O
/	O
antigenicity	O
but	O
highly	O
diminished	O
replicative	O
abilities	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
burn	O
patients	O
:	O
a	O
case	O
series	O
and	O
literature	O
update	O
.	O

Older	O
seronegative	O
camels	O
responded	O
more	O
strongly	O
to	O
vaccination	O
than	O
younger	O
animals	O
;	O
and	O
neutralising	O
antibodies	B-COMP
were	O
detected	O
in	O
nasal	O
swabs	O
.	O

Further	O
,	O
tests	O
for	O
anti	O
-	O
glomerular	O
basement	B-COMP
membrane	I-COMP
antibody	B-COMP
,	O
myeloperoxidase	O
-	O
ANCA	O
,	O
and	O
proteinase	O
3	O
-	O
ANCA	O
revealed	O
negative	O
results	O
.	O

Our	O
data	O
provide	O
further	O
evidence	O
that	O
vaccination	O
of	O
the	O
reservoir	O
host	B-COMP
may	O
impede	O
MERS	O
-	O
CoV	O
zoonotic	O
transmission	O
to	O
humans	O
.	O

Male	O
patients	O
with	O
higher	O
ISS	O
,	O
lactate	O
level	O
,	O
and	O
red	O
blood	O
cell	B-COMP
transfusion	O
should	O
be	O
cared	O
for	O
with	O
caution	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
modified	O
form	O
of	O
cardiopulmonary	O
bypass	O
which	O
may	O
provide	O
support	O
for	O
severe	O
cardiorespiratory	O
failure	O
including	O
paediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PARDS	O
).	O

Generally	O
,	O
the	O
effect	O
of	O
the	O
fusion	O
peptide	O
on	O
the	O
membrane	B-COMP
is	O
sensitive	O
to	O
the	O
lipid	O
composition	O
of	O
target	O
membranes	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
utilized	O
steady	O
-	O
state	O
and	O
time	O
-	O
resolved	O
fluorescence	O
spectroscopy	O
in	O
tandem	O
with	O
circular	O
dichroism	O
spectroscopy	O
to	O
elucidate	O
the	O
binding	O
,	O
oligomeric	O
status	O
,	O
and	O
secondary	O
structure	O
of	O
the	O
fusion	O
peptide	O
and	O
its	O
impact	O
on	O
the	O
depth	O
-	O
dependent	O
membrane	B-COMP
organization	O
and	O
dynamics	O
.	O

While	O
PDCoV	O
N	O
significantly	O
suppresses	O
PEDV	O
replication	O
,	O
overexpression	O
of	O
TGEV	O
N	O
,	O
like	O
that	O
of	O
PEDV	O
N	O
,	O
increases	O
production	O
of	O
PEDV	O
RNA	O
and	O
virions	B-COMP
.	O

PLpro	O
also	O
functions	O
as	O
both	O
a	O
deubiquitinating	O
(	O
DUB	O
)	O
and	O
deISGylating	O
(	O
deISG	O
)	O
enzyme	O
and	O
removes	O
ubiquitin	O
(	O
Ub	O
)	O
and	O
interferon	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
from	O
cellular	B-COMP
proteins	O
.	O

These	O
mutant	O
enzymes	O
will	O
provide	O
new	O
functional	O
tools	O
for	O
delineating	O
the	O
importance	O
of	O
DUB	O
versus	O
deISG	O
activity	O
in	O
virus	O
-	O
infected	O
cells	B-COMP
and	O
may	O
serve	O
as	O
potential	O
candidates	O
for	O
attenuating	O
the	O
MERS	O
virus	O
in	O
vivo	O
for	O
modified	O
vaccine	O
design	O
efforts	O
.	O

The	O
virus	O
titers	O
and	O
sizes	O
of	O
syncytia	O
increased	O
gradually	O
with	O
the	O
cell	B-COMP
passages	O
.	O

In	O
addition	O
,	O
artificial	O
changes	O
in	O
mortalin	O
expression	O
affected	O
the	O
cell	B-COMP
entry	O
of	O
transferrin	O
,	O
further	O
confirming	O
the	O
above	O
results	O
.	O

Investigations	O
revealed	O
an	O
extremely	O
high	O
serum	B-COMP
myogenic	O
enzyme	O
levels	O
and	O
impaired	O
renal	O
function	O
with	O
serum	B-COMP
creatinine	O
level	O
of	O
510	O
μmol	O
/	O
L	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
rhabdomyolysis	O
,	O
AKI	O
stage	O
3	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Development	O
and	O
comparison	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
based	O
on	O
recombinant	O
trimeric	O
full	O
-	O
length	O
and	O
truncated	O
spike	O
proteins	O
for	O
detecting	O
antibodies	B-COMP
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
used	O
to	O
rescue	O
patients	O
with	O
severe	O
hypoxemic	O
and	O
hypercapnic	O
respiratory	O
failure	O
refractory	O
to	O
optimal	O
therapy	O
and	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
ECCO2R	O
)	O
supports	O
hypercapnic	O
respiratory	O
failure	O
and	O
allows	O
very	O
low	O
tidal	O
volume	O
ventilation	O
to	O
minimize	O
the	O
risk	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

In	O
this	O
study	O
,	O
an	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
utilizing	O
ECoV	O
spike	O
S1	O
protein	O
was	O
developed	O
in	O
two	O
formats	O
,	O
and	O
further	O
validated	O
by	O
analyzing	O
27	O
paired	O
serum	B-COMP
samples	O
(	O
acute	O
and	O
convalescent	O
sera	B-COMP
)	O
from	O
horses	O
involved	O
in	O
an	O
ECoV	O
outbreak	O
and	O
1084	O
sera	B-COMP
of	O
horses	O
with	O
unknown	O
ECoV	O
exposure	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
coronavirus	O
is	O
the	O
major	O
target	O
of	O
host	B-COMP
neutralizing	O
antibodies	B-COMP
,	O
however	O
the	O
immunodominant	O
neutralizing	O
region	O
in	O
the	O
S	O
protein	O
of	O
PDCoV	O
has	O
not	O
been	O
defined	O
.	O

The	O
vaccine	O
elicited	O
a	O
specific	O
S1	O
-	O
immunoglobulin	O
G	O
antibody	B-COMP
response	O
,	O
which	O
was	O
detected	O
in	O
the	O
sera	B-COMP
of	O
the	O
vaccinated	O
mice	O
at	O
weeks	O
4	O
and	O
6	O
from	O
the	O
onset	O
of	O
the	O
first	O
immunization	O
.	O

TITLE	O
:	O
Bacterial	O
Artificial	O
Chromosome	B-COMP
-	O
Based	O
Lambda	O
Red	O
Recombination	O
with	O
the	O
I	O
-	O
SceI	O
Homing	O
Endonuclease	O
for	O
Genetic	O
Alteration	O
of	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Over	O
the	O
past	O
two	O
decades	O
,	O
several	O
coronavirus	O
(	O
CoV	O
)	O
infectious	O
clones	O
have	O
been	O
engineered	O
,	O
allowing	O
for	O
the	O
manipulation	O
of	O
their	O
large	O
viral	O
genomes	O
(~	O
30	O
kb	O
)	O
using	O
unique	O
reverse	O
genetic	O
systems	O
.	O

Tracking	O
and	O
quantifying	O
viral	O
infection	O
,	O
among	O
others	O
,	O
in	O
permissive	O
hosts	B-COMP
is	O
a	O
key	O
endpoint	O
for	O
studying	O
MERS	O
pathogenesis	O
and	O
evaluating	O
the	O
efficacy	O
of	O
selected	O
MCMs	O
developed	O
for	O
MERS	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
MERS	O
-	O
CoV	O
Neutralizing	O
Antibodies	B-COMP
in	O
Sera	B-COMP
Using	O
Live	O
Virus	O
Microneutralization	O
Assay	O
.	O

ABSTRACT	O
:	O
Pseudotyped	O
viral	B-COMP
particle	I-COMP
production	O
has	O
been	O
used	O
extensively	O
and	O
broadly	O
for	O
many	O
viruses	O
to	O
evaluate	O
levels	O
of	O
neutralizing	O
antibodies	B-COMP
,	O
viral	O
entry	O
inhibitors	O
and	O
vaccine	O
immunogenicity	O
.	O

ABSTRACT	O
:	O
Innate	O
immune	O
cells	B-COMP
play	O
a	O
vital	O
role	O
in	O
mounting	O
an	O
effective	O
host	B-COMP
response	O
to	O
a	O
variety	O
of	O
pathogen	O
challenges	O
.	O

Myeloid	O
cells	B-COMP
such	O
as	O
neutrophils	O
and	O
monocyte	O
-	O
macrophages	O
are	O
major	O
innate	O
leukocytes	O
that	O
orchestrate	O
protective	O
immunity	O
to	O
viral	O
lung	O
infections	O
.	O

A	O
majority	O
of	O
studies	O
use	O
the	O
total	O
number	O
of	O
infiltrating	O
cells	B-COMP
and	O
their	O
activation	O
status	O
as	O
measures	O
to	O
demonstrate	O
their	O
role	O
during	O
an	O
infection	O
.	O

Interactions	O
between	O
SADS	O
-	O
CoV	O
and	O
the	O
host	B-COMP
innate	O
immune	O
response	O
is	O
unclear	O
yet	O
.	O

TITLE	O
:	O
Endocytic	O
Pathway	O
of	O
Feline	O
Coronavirus	O
for	O
Cell	B-COMP
Entry	O
:	O
Differences	O
in	O
Serotype	O
-	O
Dependent	O
Viral	O
Entry	O
Pathway	O
.	O

According	O
to	O
our	O
previous	O
study	O
,	O
type	O
I	O
FCoV	O
infection	O
is	O
inhibited	O
by	O
compounds	O
inducing	O
intracellular	B-COMP
cholesterol	O
accumulation	O
,	O
whereas	O
type	O
II	O
FCoV	O
infection	O
is	O
not	O
inhibited	O
.	O

Intracellular	B-COMP
cholesterol	O
accumulation	O
was	O
reported	O
to	O
disrupt	O
late	B-COMP
endosome	I-COMP
function	O
.	O

We	O
investigated	O
whether	O
the	O
antiviral	O
activities	O
of	O
a	O
late	B-COMP
endosome	I-COMP
trafficking	O
inhibitor	O
and	O
cholesterol	O
-	O
accumulating	O
agents	O
are	O
different	O
between	O
the	O
FCoV	O
serotypes	O
.	O

We	O
examined	O
the	O
pathogenic	O
effects	O
of	O
the	O
viruses	O
in	O
chicken	O
embryos	O
and	O
the	O
size	O
and	O
morphology	O
of	O
the	O
virus	B-COMP
particles	I-COMP
,	O
performed	O
phylogenetic	O
analysis	O
based	O
on	O
the	O
S1	O
gene	O
and	O
complete	O
genomic	O
sequences	O
,	O
and	O
examined	O
the	O
antibody	B-COMP
responses	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

The	O
type	O
I	O
interferon	O
(	O
type	O
I	O
IFN	O
)-	O
mediated	O
immune	O
responses	O
provide	O
host	B-COMP
protection	O
from	O
infectious	O
diseases	O
.	O

Our	O
research	O
provides	O
new	O
insights	O
into	O
the	O
mechanism	O
for	O
FIPV	O
to	O
counteract	O
host	B-COMP
innate	O
immune	O
response	O
.	O

In	O
this	O
work	O
,	O
we	O
aimed	O
to	O
target	O
the	O
liver	O
macrophages	O
with	O
lipid	O
polymer	O
hybrid	O
nanoparticles	O
(	O
LPH	O
),	O
combining	O
the	O
merit	O
of	O
polymeric	O
nanoparticles	O
and	O
lipid	O
vesicles	B-COMP
.	O

With	O
the	O
development	O
of	O
modern	O
technologies	O
,	O
new	O
diagnostic	O
strategies	O
,	O
including	O
multiplex	O
nucleic	B-COMP
acid	O
amplification	O
and	O
microarray	O
-	O
based	O
assays	O
,	O
are	O
emerging	O
.	O

TITLE	O
:	O
Characterization	O
of	O
novel	O
monoclonal	O
antibodies	B-COMP
against	O
MERS	O
-	O
coronavirus	O
spike	O
protein	O
.	O

A	O
random	O
intercept	O
model	O
was	O
used	O
to	O
fit	O
a	O
curve	O
to	O
HAI	O
antibody	B-COMP
responses	O
over	O
time	O
.	O

The	O
nucleocapsid	B-COMP
(	O
N	O
)	O
protein	O
,	O
a	O
core	O
component	O
of	O
PDCoV	O
,	O
is	O
essential	O
for	O
virus	O
replication	O
and	O
is	O
a	O
significant	O
candidate	O
in	O
the	O
development	O
of	O
diagnostics	O
for	O
PDCoV	O
.	O
In	O
this	O
study	O
,	O
monoclonal	O
antibodies	B-COMP
(	O
mAbs	O
)	O
were	O
generated	O
and	O
tested	O
for	O
reactivity	O
with	O
three	O
truncations	O
of	O
the	O
full	O
protein	O
(	O
N1	O
,	O
N2	O
,	O
N3	O
)	O
that	O
contained	O
partial	O
overlaps	O
;	O
of	O
the	O
five	O
monoclonals	O
chosen	O
tested	O
,	O
each	O
reacted	O
with	O
only	O
the	O
N3	O
truncation	O
.	O

TITLE	O
:	O
Polymorphisms	O
in	O
dipeptidyl	O
peptidase	O
4	O
reduce	O
host	B-COMP
cell	I-COMP
entry	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Extracorporeal	O
membrane	B-COMP
oxygenation	O
reduced	O
the	O
need	O
for	O
renal	O
replacement	O
therapy	O
,	O
with	O
a	O
RR	O
of	O
0	O
.	O
88	O
(	O
95	O
%	O
CI	O
0	O
.	O
77	O
-	O
0	O
.	O
99	O
).	O

In	O
addition	O
,	O
G	O
-	O
2	O
also	O
consistently	O
had	O
markedly	O
higher	O
mean	O
serum	B-COMP
concentrations	O
of	O
I	O
-	O
FAB	O
and	O
ACTG2	O
and	O
lower	O
mean	O
serum	B-COMP
concentrations	O
of	O
CLDN	O
-	O
3	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

In	O
severe	O
forms	O
of	O
ARDS	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
ECMO	O
)	O
is	O
often	O
the	O
last	O
option	O
for	O
life	O
support	O
.	O

Pseudotyped	O
virus	O
bearing	O
the	O
I507	O
L	O
mutation	O
in	O
RBD	O
showed	O
enhanced	O
entry	O
into	O
host	B-COMP
cells	B-COMP
as	O
compared	O
to	O
the	O
prototype	O
virus	O
.	O

TITLE	O
:	O
Heparin	O
-	O
free	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
in	O
a	O
multiple	O
trauma	O
patient	O
:	O
A	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Bats	O
host	B-COMP
virulent	O
zoonotic	O
viruses	O
without	O
experiencing	O
disease	O
.	O

The	O
identified	O
camel	O
IFN	O
-	O
α	O
protein	O
and	O
the	O
subtypes	O
will	O
facilitate	O
a	O
better	O
understanding	O
of	O
the	O
host	B-COMP
immune	O
response	O
to	O
viral	O
infections	O
in	O
camel	O
and	O
the	O
development	O
of	O
potential	O
antiviral	O
biologicals	O
for	O
zoonotic	O
diseases	O
for	O
which	O
camel	O
act	O
as	O
a	O
reservoir	O
.	O

This	O
study	O
took	O
an	O
immunoinformatics	O
approach	O
to	O
identify	O
significant	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
and	O
B	O
cell	B-COMP
epitopes	O
in	O
the	O
2019	O
-	O
nCoV	O
surface	O
glycoprotein	O
.	O

We	O
identified	O
five	O
CTL	O
epitopes	O
,	O
three	O
sequential	O
B	O
cell	B-COMP
epitopes	O
and	O
five	O
discontinuous	O
B	O
cell	B-COMP
epitopes	O
in	O
the	O
viral	O
surface	O
glycoprotein	O
.	O

This	O
is	O
the	O
first	O
study	O
that	O
describes	O
the	O
modulation	O
of	O
miRNAs	O
and	O
the	O
related	O
host	B-COMP
immune	O
factors	O
by	O
IBV	O
in	O
chicken	O
embryos	O
.	O

Anticardiolipin	O
antibodies	B-COMP
were	O
negative	O
:	O
anticardiolipin	O
β2GPI	O
antibody	B-COMP
≤	O
1	O
.	O
2	O
U	O
/	O
mL	O
(<	O
3	O
.	O
5	O
),	O
anticardiolipin	O
immunoglobulin	O
G	O
antibody	B-COMP
≤	O
8	O
U	O
/	O
mL	O
(<	O
10	O
),	O
and	O
anticardiolipin	O
immunoglobulin	O
M	O
antibody	B-COMP
≤	O
5	O
U	O
/	O
mL	O
(<	O
8	O
).	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
underlying	O
mechanism	O
in	O
which	O
RUS	O
attenuates	O
LPS	O
-	O
induced	O
pulmonary	O
endothelial	O
cell	B-COMP
apoptosis	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
the	O
well	O
-	O
known	O
cause	O
of	O
severe	O
respiratory	O
,	O
enteric	O
and	O
systemic	O
infections	O
in	O
a	O
wide	O
range	O
of	O
hosts	B-COMP
including	O
man	O
,	O
mammals	O
,	O
fish	O
,	O
and	O
avian	O
.	O

Our	O
results	O
showed	O
that	O
the	O
IBV	O
EIC	O
contributed	O
to	O
the	O
induction	O
of	O
ER	O
stress	O
response	O
,	O
as	O
up	O
-	O
regulation	O
of	O
ER	O
stress	O
-	O
related	O
genes	O
was	O
markedly	O
reduced	O
in	O
cells	B-COMP
infected	O
with	O
the	O
EIC	O
-	O
defective	O
mutants	O
.	O

EIC	O
-	O
defective	O
mutants	O
also	O
formed	O
smaller	O
plaques	O
,	O
released	O
significantly	O
less	O
infectious	O
virions	B-COMP
into	O
the	O
culture	O
supernatant	O
,	O
and	O
had	O
lower	O
levels	O
of	O
viral	O
fitness	O
in	O
cell	B-COMP
culture	O
.	O

TITLE	O
:	O
Transmissible	O
Gastroenteritis	O
Virus	O
Infection	O
Up	O
-	O
Regulates	O
FcRn	O
Expression	O
via	O
Nucleocapsid	B-COMP
Protein	O
and	O
Secretion	O
of	O
TGF	O
-	O
β	O
in	O
Porcine	O
Intestinal	O
Epithelial	O
Cells	B-COMP
.	O

TITLE	O
:	O
Host	B-COMP
factor	O
prioritization	O
for	O
pan	B-COMP
-	O
viral	O
genetic	O
perturbation	O
screens	O
using	O
random	O
intercept	O
models	O
and	O
network	O
propagation	O
.	O

So	O
far	O
,	O
most	O
published	O
studies	O
identified	O
host	B-COMP
factors	O
primarily	O
for	O
single	O
pathogens	O
.	O

Here	O
,	O
we	O
present	O
a	O
novel	O
two	O
-	O
stage	O
procedure	O
for	O
the	O
identification	O
of	O
host	B-COMP
factors	O
involved	O
in	O
the	O
replication	O
of	O
different	O
viruses	O
using	O
a	O
combination	O
of	O
random	O
effects	O
models	O
and	O
Markov	O
random	O
walks	O
on	O
a	O
functional	O
interaction	O
network	O
.	O

Subsequently	O
the	O
inferred	O
estimates	O
are	O
spread	O
across	O
a	O
network	O
of	O
functional	O
interactions	O
thereby	O
allowing	O
for	O
the	O
analysis	O
of	O
missing	O
genes	O
in	O
the	O
biological	O
studies	O
,	O
smoothing	O
the	O
effect	O
sizes	O
of	O
previously	O
found	O
host	B-COMP
factors	O
,	O
and	O
considering	O
a	O
priori	O
pathway	O
information	O
defined	O
over	O
edges	O
of	O
the	O
network	O
.	O

We	O
validated	O
the	O
detected	O
host	B-COMP
factors	O
experimentally	O
using	O
pharmacological	O
inhibition	O
and	O
an	O
additional	O
siRNA	O
screen	O
and	O
found	O
that	O
some	O
of	O
the	O
predicted	O
host	B-COMP
factors	O
indeed	O
influence	O
the	O
replication	O
of	O
these	O
pathogens	O
.	O

The	O
initial	O
source	O
of	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
was	O
the	O
Huanan	O
seafood	O
market	O
in	O
Wuhan	O
,	O
Hubei	O
province	O
,	O
China	O
,	O
with	O
pangolins	O
as	O
a	O
potential	O
animal	O
host	B-COMP
.	O

CDV	O
RNA	O
was	O
mainly	O
detected	O
in	O
the	O
Canidae	O
family	O
,	O
with	O
viral	O
nucleic	B-COMP
acid	O
recorded	O
between	O
2005	O
and	O
2008	O
with	O
a	O
peak	O
prevalence	O
of	O
67	O
%	O
among	O
the	O
wolf	O
population	O
,	O
followed	O
by	O
a	O
sharp	O
decline	O
,	O
suggesting	O
an	O
epizootic	O
behaviour	O
of	O
the	O
virus	O
.	O

We	O
have	O
tested	O
the	O
ability	O
of	O
magnetic	O
Nanotrap	O
®	O
(	O
NT	O
)	O
particles	O
to	O
improve	O
stability	O
and	O
detection	O
of	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEEV	O
),	O
viral	B-COMP
capsid	I-COMP
protein	O
,	O
and	O
viral	O
genomic	O
RNA	O
in	O
whole	O
human	O
blood	O
at	O
elevated	O
temperature	O
and	O
prolonged	O
storage	O
conditions	O
.	O

Except	O
for	O
the	O
discharged	O
cases	O
,	O
5	O
cases	O
were	O
positive	O
for	O
COVID	O
-	O
19	O
specific	O
IgM	B-COMP
antibody	I-COMP
and	O
1	O
case	O
was	O
negative	O
.	O

TITLE	O
:	O
Detection	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
-	O
neutralizing	O
antibody	B-COMP
using	O
high	O
-	O
throughput	O
imaging	O
cytometry	O
.	O

Finally	O
,	O
antibodies	B-COMP
and	O
small	O
molecular	O
inhibitors	O
that	O
can	O
block	O
the	O
interaction	O
of	O
ACE2	O
with	O
RBD	O
should	O
be	O
developed	O
to	O
combat	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
next	O
decade	O
is	O
likely	O
to	O
produce	O
any	O
number	O
of	O
global	O
challenges	O
that	O
will	O
affect	O
health	O
and	O
health	O
care	O
,	O
including	O
pan	B-COMP
-	O
national	O
infections	O
such	O
as	O
the	O
new	O
coronavirus	O
COVID	O
-	O
19	O
and	O
others	O
that	O
will	O
be	O
related	O
to	O
global	O
warming	O
.	O

Furthermore	O
,	O
unlike	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
in	O
which	O
trypsin	O
is	O
important	O
for	O
the	O
release	O
of	O
virus	O
from	O
infected	O
cells	B-COMP
,	O
PDCoV	O
release	O
was	O
not	O
affected	O
by	O
trypsin	O
.	O

We	O
also	O
demonstrated	O
that	O
trypsin	O
promotes	O
PDCoV	O
replication	O
by	O
enhancing	O
cell	B-COMP
-	O
to	O
-	O
cell	B-COMP
membrane	I-COMP
fusion	O
.	O

Treatment	O
of	O
the	O
cells	B-COMP
with	O
the	O
CD13	O
inhibitor	O
2	O
'	O
2	O
'-	O
dipyridyl	O
decreased	O
viral	O
titers	O
.	O

Here	O
,	O
we	O
co	O
-	O
expressed	O
the	O
MERS	O
-	O
CoV	O
nonstructural	O
proteins	O
nsp5	O
,	O
nsp7	O
,	O
nsp8	O
,	O
and	O
nsp12	O
(	O
RdRp	O
)	O
in	O
insect	O
cells	B-COMP
as	O
a	O
part	O
a	O
polyprotein	O
to	O
study	O
the	O
mechanism	O
of	O
inhibition	O
of	O
MERS	O
-	O
CoV	O
RdRp	O
by	O
RDV	O
.	O

Finding	O
the	O
possible	O
intermediate	O
host	B-COMP
of	O
SARS	O
-	O
CoV	O
-	O
2	O
is	O
imperative	O
to	O
prevent	O
further	O
spread	O
of	O
the	O
epidemic	O
.	O

Furthermore	O
,	O
some	O
coronaviruses	O
have	O
been	O
demonstrated	O
able	O
to	O
spread	O
via	O
a	O
synapse	B-COMP
-	O
connected	O
route	O
to	O
the	O
medullary	O
cardiorespiratory	O
center	O
from	O
the	O
mechanoreceptors	O
and	O
chemoreceptors	O
in	O
the	O
lung	O
and	O
lower	O
respiratory	O
airways	O
.	O

TITLE	O
:	O
Development	O
and	O
Clinical	O
Application	O
of	O
A	O
Rapid	O
IgM	O
-	O
IgG	O
Combined	O
Antibody	B-COMP
Test	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
Infection	O
Diagnosis	O
.	O

The	O
results	O
indicated	O
great	O
detection	O
consistency	O
among	O
samples	O
from	O
fingerstick	O
blood	O
,	O
serum	B-COMP
and	O
plasma	O
of	O
venous	O
blood	O
.	O

9	O
patients	O
were	O
unconfirmed	O
until	O
a	O
third	O
-	O
time	O
nucleic	B-COMP
acid	O
test	O
.	O

Notably	O
,	O
infected	O
patients	O
may	O
be	O
falsely	O
excluded	O
based	O
on	O
two	O
consecutively	O
negative	O
respiratory	O
pathogenic	O
nucleic	B-COMP
acid	O
test	O
results	O
.	O

These	O
three	O
different	O
kits	O
got	O
the	O
same	O
result	O
for	O
each	O
sample	O
and	O
the	O
positive	O
ratio	O
of	O
nucleic	B-COMP
acid	O
detection	O
for	O
2019	O
-	O
nCoV	O
was	O
only	O
47	O
.	O
4	O
%	O
in	O
the	O
suspect	O
patients	O
.	O

It	O
might	O
be	O
better	O
to	O
make	O
a	O
diagnosis	O
combining	O
the	O
computed	O
tomography	O
scans	O
and	O
nucleic	B-COMP
acid	O
detection	O
.	O

ABSTRACT	O
:	O
With	O
a	O
large	O
number	O
of	O
COVID	O
-	O
19	O
patients	O
discharging	O
from	O
hospital	O
,	O
some	O
had	O
showed	O
re	O
-	O
fever	O
and	O
positive	O
nucleic	B-COMP
acid	O
test	O
after	O
discharge	O
from	O
hospital	O
.	O

The	O
effects	O
of	O
cluster	O
of	O
differentiation	O
4	O
(	O
CD4	O
)+	O
T	O
lymphocytes	O
,	O
inflammatory	O
indicators	O
,	O
and	O
glucocorticoid	O
treatment	O
on	O
viral	O
nucleic	B-COMP
acid	O
clearance	O
were	O
analyzed	O
.	O

Results	O
for	O
only	O
four	O
(	O
6	O
.	O
9	O
%)	O
urine	O
samples	O
were	O
positive	O
for	O
viral	O
nucleic	B-COMP
acid	O
out	O
of	O
58	O
cases	O
;	O
viral	O
RNA	O
was	O
still	O
present	O
in	O
three	O
patients	O
'	O
urine	O
specimens	O
after	O
throat	O
swabs	O
were	O
negative	O
.	O

The	O
duration	O
of	O
RNA	O
detection	O
may	O
relate	O
to	O
host	B-COMP
cell	I-COMP
immunity	O
.	O

However	O
,	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
is	O
associated	O
with	O
a	O
coagulopathy	O
characterized	O
by	O
thromboembolic	O
and	O
hemorrhagic	O
complications	O
.	O

Patients	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
n	O
=	O
10	O
)	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
patients	O
treated	O
with	O
venoarterial	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
(	O
n	O
=	O
8	O
)	O
due	O
to	O
cardiocirculatory	O
failure	O
.	O

In	O
-	O
hospital	O
mortality	O
was	O
30	O
%	O
for	O
venovenous	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
and	O
37	O
.	O
5	O
%	O
for	O
venoarterial	O
extracorporeal	O
membrane	B-COMP
oxygenation	O
patients	O
.	O

We	O
found	O
that	O
compared	O
to	O
pharyngeal	O
swab	O
specimens	O
,	O
nucleic	B-COMP
acid	O
detection	O
of	O
COVID	O
-	O
19	O
in	O
fecal	O
specimens	O
was	O
equally	O
accurate	O
.	O

Results	O
from	O
the	O
current	O
study	O
showed	O
that	O
pretreatment	O
with	O
nafithromycin	O
significantly	O
reduced	O
the	O
total	O
cell	B-COMP
count	O
,	O
total	O
protein	O
,	O
MPO	O
,	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
levels	O
in	O
BAL	O
fluid	O
compared	O
to	O
LPS	O
control	O
group	O
.	O

ABSTRACT	O
:	O
A	O
better	O
understanding	O
of	O
the	O
complex	O
interactions	O
between	O
the	O
immune	O
system	O
and	O
tumour	O
cells	B-COMP
from	O
different	O
origins	O
has	O
opened	O
the	O
possibility	O
to	O
design	O
novel	O
procedures	O
of	O
antitumoral	O
immunotherapy	O
.	O

TITLE	O
:	O
Perspectives	O
on	O
monoclonal	O
antibody	B-COMP
therapy	O
as	O
potential	O
therapeutic	O
intervention	O
for	O
Coronavirus	O
disease	O
-	O
19	O
(	O
COVID	O
-	O
19	O
).	O

Finally	O
,	O
we	O
show	O
that	O
the	O
sera	B-COMP
from	O
convalescent	O
SARS	O
patients	O
cross	O
-	O
neutralized	O
SARS	O
-	O
2	O
-	O
S	O
-	O
driven	O
entry	O
.	O

Clade	O
1	O
consisted	O
of	O
a	O
group	O
of	O
conserved	O
proteins	O
in	O
Orthocoronavirinae	O
comprising	O
Orf1ab	O
polyprotein	O
,	O
Nucleocapsid	B-COMP
protein	O
,	O
Spike	O
glycoprotein	O
,	O
and	O
Membrane	B-COMP
protein	O
.	O

In	O
addition	O
,	O
there	O
are	O
many	O
significantly	O
important	O
trials	O
with	O
positive	O
results	O
:	O
high	O
dose	O
vitamin	O
C	O
for	O
septic	O
shock	O
,	O
weaning	O
strategy	O
with	O
pressure	O
support	O
ventilation	O
(	O
PSV	O
)	O
mode	O
,	O
tranexamic	O
acid	O
for	O
patients	O
with	O
acute	O
traumatic	O
brain	O
injury	O
,	O
and	O
new	O
monoclonal	O
antibody	B-COMP
for	O
Ebola	O
virus	O
disease	O
.	O

The	O
virus	O
replicated	O
in	O
Vero	O
cells	B-COMP
and	O
cytopathic	O
effects	O
were	O
observed	O
.	O

The	O
spike	O
protein	O
of	O
coronavirus	O
GX_P2V	O
shares	O
92	O
.	O
2	O
%	O
amino	O
acid	O
identity	O
with	O
that	O
of	O
2019	O
-	O
nCoV	O
isolate	O
Wuhan	O
-	O
hu	O
-	O
1	O
,	O
and	O
uses	O
ACE2	O
as	O
the	O
receptor	O
for	O
infection	O
just	O
like	O
2019	O
-	O
nCoV	O
.	O
Three	O
drugs	O
-	O
cepharanthine	O
(	O
CEP	O
),	O
selamectin	O
and	O
mefloquine	O
hydrochloride	O
exhibited	O
complete	O
inhibition	O
of	O
cytopathic	O
effects	O
in	O
cell	B-COMP
culture	O
at	O
10	O
μmol	O
/	O
L	O
.	O
CEP	O
demonstrated	O
the	O
most	O
potent	O
inhibition	O
of	O
GX_P2V	O
infection	O
,	O
with	O
a	O
concentration	O
for	O
50	O
%	O
of	O
maximal	O
effect	O
[	O
EC50	O
]	O
of	O
0	O
.	O
98	O
μmol	O
/	O
L	O
.	O
The	O
viral	O
RNA	O
yield	O
in	O
cells	B-COMP
treated	O
with	O
10	O
μmol	O
/	O
L	O
CEP	O
was	O
15	O
,	O
393	O
-	O
fold	O
lower	O
than	O
in	O
cells	B-COMP
without	O
CEP	O
treatment	O
([	O
6	O
.	O
48	O
±	O
0	O
.	O
02	O
]	O
×	O
10vs	O
.	O

TITLE	O
:	O
Serologic	O
Detection	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Functional	O
Antibodies	B-COMP
.	O

Antibody	B-COMP
levels	O
measured	O
in	O
both	O
assays	O
correlated	O
strongly	O
with	O
virus	O
-	O
neutralizing	O
antibody	B-COMP
titers	O
,	O
proving	O
their	O
use	O
for	O
serologic	O
confirmatory	O
diagnosis	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
.	O

Here	O
,	O
we	O
discovered	O
that	O
the	O
expression	O
of	O
miR	O
-	O
10a	O
-	O
5p	O
was	O
constitutively	O
up	O
-	O
regulated	O
by	O
PHEV	O
in	O
both	O
the	O
N2a	O
cells	B-COMP

The	O
novel	O
coronavirus	O
nucleic	B-COMP
acid	O
test	O
was	O
negative	O
.	O

The	O
first	O
pool	O
was	O
from	O
a	O
Carassius	O
auratus	O
(	O
crusian	O
carp	O
)	O
cell	B-COMP
line	O
and	O
the	O
second	O
was	O
from	O
Ctenopharyngodon	O
idella	O
(	O
grass	O
carp	O
)	O
head	O
kidney	O
tissue	O
.	O

Drugs	O
are	O
possibly	O
effective	O
for	O
2019	O
-	O
nCoV	O
include	O
:	O
remdesivir	O
,	O
lopinavir	O
/	O
ritonavir	O
,	O
lopinavir	O
/	O
ritonavir	O
combined	O
with	O
interferon	O
-	O
β	O
,	O
convalescent	O
plasma	O
,	O
and	O
monoclonal	O
antibodies	B-COMP
.	O

The	O
S1	O
domain	O
of	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
attaches	O
the	O
virus	O
to	O
its	O
cellular	B-COMP
receptor	O
ACE2	O
on	O
the	O
host	B-COMP
cells	B-COMP
.	O

TITLE	O
:	O
Evidence	O
of	O
the	O
COVID	O
-	O
19	O
Virus	O
Targeting	O
the	O
CNS	O
:	O
Tissue	O
Distribution	O
,	O
Host	B-COMP
-	O
Virus	O
Interaction	O
,	O
and	O
Proposed	O
Neurotropic	O
Mechanisms	O
.	O

Meanwhile	O
,	O
several	O
independent	O
research	O
groups	O
have	O
identified	O
that	O
SARS	O
-	O
CoV	O
-	O
2	O
belongs	O
to	O
β	O
-	O
coronavirus	O
,	O
with	O
highly	O
identical	O
genome	O
to	O
bat	O
coronavirus	O
,	O
pointing	O
to	O
bat	O
as	O
the	O
natural	O
host	B-COMP
.	O

The	O
docking	O
pose	O
revealed	O
the	O
involvement	O
of	O
the	O
SBDβ	O
of	O
GRP78	O
and	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
the	O
coronavirus	O
spike	O
protein	O
in	O
recognition	O
of	O
the	O
host	B-COMP
cell	I-COMP
receptor	O
.	O

TITLE	O
:	O
Consensus	O
of	O
Chinese	O
experts	O
on	O
protection	O
of	O
skin	O
and	O
mucous	O
membrane	B-COMP
barrier	O
for	O
healthcare	O
workers	O
fighting	O
against	O
coronavirus	O
disease	O
2019	O
.	O

Important	O
questions	O
concerning	O
the	O
interaction	O
between	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
host	B-COMP
antiviral	O
defence	O
,	O
including	O
asymptomatic	O
and	O
presymptomatic	O
virus	O
shedding	O
,	O
are	O
also	O
discussed	O
.	O

Among	O
the	O
structural	O
proteins	O
,	O
the	O
spike	O
protein	O
(	O
S	O
-	O
protein	O
),	O
the	O
envelope	B-COMP
protein	O
(	O
E	O
-	O
protein	O
),	O
and	O
the	O
nucleocapsid	B-COMP
protein	O
(	O
N	O
-	O
protein	O
)	O
can	O
be	O
constructed	O
based	O
on	O
the	O
crystal	O
structures	O
of	O
the	O
proteins	O
from	O
SARS	O
-	O
CoV	O
.	O
It	O
is	O
known	O
that	O
PL	O
-	O
Pro	O
,	O
3CL	O
-	O
Pro	O
,	O
and	O
RdRp	O
are	O
important	O
targets	O
for	O
design	O
antiviral	O
drugs	O
against	O
2019	O
-	O
nCoV	O
.	O
And	O
S	O
protein	O
is	O
critical	O
target	O
candidate	O
for	O
inhibitor	O
screening	O
or	O
vaccine	O
design	O
against	O
2019	O
-	O
nCoV	O
because	O
coronavirus	O
replication	O
is	O
initiated	O
by	O
the	O
binding	O
of	O
S	O
protein	O
to	O
cell	B-COMP
surface	I-COMP
receptors	O
.	O

NETs	O
include	O
a	O
DNA	O
backbone	O
coated	O
with	O
cytoplasmic	B-COMP
proteins	O
,	O
which	O
drive	O
pulmonary	O
cytotoxic	O
effects	O
.	O

Dornase	O
alfa	O
is	O
a	O
US	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
recombinant	O
DNase	O
,	O
which	O
cleaves	O
extracellular	B-COMP
DNA	O
and	O
may	O
therefore	O
break	O
up	O
the	O
backbone	O
of	O
NETs	O
and	O
DAMPs	O
.	O

No	O
serious	O
prespecified	O
cell	B-COMP
infusion	O
-	O
associated	O
or	O
treatment	O
-	O
related	O
adverse	O
events	O
was	O
identified	O
in	O
any	O
patient	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
encode	O
multiple	O
interferon	O
antagonists	O
that	O
modulate	O
the	O
host	B-COMP
response	O
to	O
virus	O
replication	O
.	O

We	O
herein	O
report	O
the	O
case	O
of	O
a	O
previously	O
healthy	O
38	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
hyperleukocytosis	O
with	O
dysplastic	O
myeloid	O
precursor	O
cells	B-COMP
and	O
severe	O
disseminated	O
intravascular	O
coagulation	O
.	O

TITLE	O
:	O
Natural	O
small	O
molecules	O
as	O
inhibitors	O
of	O
coronavirus	O
lipid	O
-	O
dependent	O
attachment	O
to	O
host	B-COMP
cells	B-COMP
:	O
a	O
possible	O
strategy	O
for	O
reducing	O
SARS	O
-	O
COV	O
-	O
2	O
infectivity	O
?	O

Here	O
,	O
we	O
describe	O
the	O
development	O
of	O
PRESCIENT	O
(	O
Platform	O
for	O
the	O
Rapid	O
Evaluation	O
of	O
antibody	B-COMP
SucCess	O
using	O
Integrated	O
microfluidics	O
ENabled	O
Technology	O
),	O
a	O
droplet	O
microfluidic	O
system	O
that	O
can	O
enable	O
high	O
-	O
throughput	O
single	O
-	O
cell	B-COMP
resolution	O
identification	O
of	O
nAb	O
repertoires	O
elicited	O
in	O
response	O
to	O
viral	O
infection	O
.	O

TITLE	O
:	O
Coronavirus	O
endoribonuclease	O
targets	O
viral	O
polyuridine	O
sequences	O
to	O
evade	O
activating	O
host	B-COMP
sensors	O
.	O

CoVs	O
encode	O
an	O
endoribonuclease	O
designated	O
EndoU	O
that	O
facilitates	O
evasion	O
of	O
host	B-COMP
pattern	O
recognition	O
receptor	O
MDA5	O
,	O
but	O
the	O
target	O
of	O
EndoU	O
activity	O
was	O
not	O
known	O
.	O

TITLE	O
:	O
Single	O
cell	B-COMP
RNA	O
sequencing	O
of	O
13	O
human	O
tissues	O
identify	O
cell	B-COMP
types	O
and	O
receptors	O
of	O
human	O
coronaviruses	O
.	O

TITLE	O
:	O
Protein	O
Structure	O
and	O
Sequence	O
Reanalysis	O
of	O
2019	O
-	O
nCoV	O
Genome	O
Refutes	O
Snakes	O
as	O
Its	O
Intermediate	O
Host	B-COMP
and	O
the	O
Unique	O
Similarity	O
between	O
Its	O
Spike	O
Protein	O
Insertions	O
and	O
HIV	O
-	O
1	O
.	O

ACE2	O
is	O
the	O
receptor	O
for	O
both	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
SARS	O
-	O
CoV	O
.	O
To	O
predict	O
the	O
potential	O
host	B-COMP
range	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
we	O
analyzed	O
the	O
key	O
residues	O
of	O
ACE2	O
for	O
recognizing	O
S	O
protein	O
.	O

Many	O
CoV	O
proteins	O
are	O
modified	O
by	O
PTMs	O
,	O
including	O
glycosylation	O
and	O
palmitoylation	O
of	O
the	O
spike	O
and	O
envelope	B-COMP
protein	O
,	O
N	O
-	O
or	O
O	O
-	O
linked	O
glycosylation	O
of	O
the	O
membrane	B-COMP
protein	O
,	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
of	O
the	O
nucleocapsid	B-COMP
protein	O
,	O
and	O
other	O
PTMs	O
on	O
nonstructural	O
and	O
accessory	O
proteins	O
.	O

TITLE	O
:	O
Membrane	B-COMP
binding	O
proteins	O
of	O
coronaviruses	O
.	O

SARS	O
-	O
CoV	O
-	O
2	O
RBD	O
exhibited	O
significantly	O
higher	O
binding	O
affinity	O
to	O
ACE2	O
receptor	O
than	O
SARS	O
-	O
CoV	O
RBD	O
and	O
could	O
block	O
the	O
binding	O
and	O
,	O
hence	O
,	O
attachment	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
RBD	O
and	O
SARS	O
-	O
CoV	O
RBD	O
to	O
ACE2	O
-	O
expressing	O
cells	B-COMP
,	O
thus	O
inhibiting	O
their	O
infection	O
to	O
host	B-COMP
cells	B-COMP
.	O

A	O
retrospective	O
analysis	O
was	O
performed	O
for	O
the	O
clinical	O
data	O
and	O
chest	O
CT	O
images	O
of	O
9	O
children	O
,	O
aged	O
0	O
to	O
3	O
years	O
,	O
who	O
were	O
diagnosed	O
with	O
COVID	O
-	O
19	O
by	O
nucleic	B-COMP
acid	O
detection	O
between	O
January	O
20	O
and	O
February	O
10	O
,	O
2020	O
.	O

A	O
total	O
of	O
82	O
patients	O
(	O
19	O
.	O
7	O
%)	O
had	O
cardiac	O
injury	O
,	O
and	O
compared	O
with	O
patients	O
without	O
cardiac	O
injury	O
,	O
these	O
patients	O
were	O
older	O
(	O
median	O
[	O
range	O
]	O
age	O
,	O
74	O
[	O
34	O
-	O
95	O
]	O
vs	O
60	O
[	O
21	O
-	O
90	O
]	O
years	O
;	O
P	O
<	O
.	O
001	O
);	O
had	O
more	O
comorbidities	O
(	O
eg	O
,	O
hypertension	O
in	O
49	O
of	O
82	O
[	O
59	O
.	O
8	O
%]	O
vs	O
78	O
of	O
334	O
[	O
23	O
.	O
4	O
%];	O
P	O
<	O
.	O
001	O
);	O
had	O
higher	O
leukocyte	O
counts	O
(	O
median	O
[	O
interquartile	O
range	O
(	O
IQR	O
)],	O
9400	O
[	O
6900	O
-	O
13	O
800	O
]	O
vs	O
5500	O
[	O
4200	O
-	O
7400	O
]	O
cells	B-COMP
/	O
μL	O
)	O
and	O
levels	O
of	O
C	O
-	O
reactive	O
protein	O
(	O
median	O
[	O
IQR	O
],	O
10	O
.	O
2	O
[	O
6	O
.	O
4	O
-	O
17	O
.	O
0	O
]	O
vs	O
3	O
.	O
7	O
[	O
1	O
.	O
0	O
-	O
7	O
.	O
3	O
]	O
mg	O
/	O
dL	O
),	O
procalcitonin	O
(	O
median	O
[	O
IQR	O
],	O
0	O
.	O
27	O
[	O
0	O
.	O
10	O
-	O
1	O
.	O
22	O
]	O
vs	O
0	O
.	O
06	O
[	O
0	O
.	O
03	O
-	O
0	O
.	O
10	O
]	O
ng	O
/	O
mL	O
),	O
creatinine	O
kinase	O
-	O
myocardial	O
band	O
(	O
median	O
[	O
IQR	O
],	O
3	O
.	O
2	O
[	O
1	O
.	O
8	O
-	O
6	O
.	O
2	O
]	O
vs	O
0	O
.	O
9	O
[	O
0	O
.	O
6	O
-	O
1	O
.	O
3	O
]	O
ng	O
/	O
mL	O
),	O
myohemoglobin	O
(	O
median	O
[	O
IQR	O
],	O
128	O
[	O
68	O
-	O
305	O
]	O
vs	O
39	O
[	O
27	O
-	O
65	O
]	O
μg	O
/	O
L	O
),	O
high	O
-	O
sensitivity	O
troponin	O
I	O
(	O
median	O
[	O
IQR	O
],	O
0	O
.	O
19	O
[	O
0	O
.	O
08	O
-	O
1	O
.	O
12	O
]	O
vs	O
<	O
0	O
.	O
006	O
[<	O
0	O
.	O
006	O
-	O
0	O
.	O
009	O
]	O
μg	O
/	O
L	O
),	O
N	O
-	O
terminal	O
pro	O
-	O
B	O
-	O
type	O
natriuretic	O
peptide	O
(	O
median	O
[	O
IQR	O
],	O
1689	O
[	O
698	O
-	O
3327	O
]	O
vs	O
139	O
[	O
51	O
-	O
335	O
]	O
pg	O
/	O
mL	O
),	O
aspartate	O
aminotransferase	O
(	O
median	O
[	O
IQR	O
],	O
40	O
[	O
27	O
-	O
60	O
]	O
vs	O
29	O
[	O
21	O
-	O
40	O
]	O
U	O
/	O
L	O
),	O
and	O
creatinine	O
(	O
median	O
[	O
IQR	O
],	O
1	O
.	O
15	O
[	O
0	O
.	O
72	O
-	O
1	O
.	O
92	O
]	O
vs	O
0	O
.	O
64	O
[	O
0	O
.	O
54	O
-	O
0	O
.	O
78	O
]	O
mg	O
/	O
dL	O
);	O
and	O
had	O
a	O
higher	O
proportion	O
of	O
multiple	O
mottling	O
and	O
ground	O
-	O
glass	O
opacity	O
in	O
radiographic	O
findings	O
(	O
53	O
of	O
82	O
patients	O
[	O
64	O
.	O
6	O
%]	O
vs	O
15	O
of	O
334	O
patients	O
[	O
4	O
.	O
5	O
%]).	O

